<SEC-DOCUMENT>0001564590-15-001840.txt : 20150319
<SEC-HEADER>0001564590-15-001840.hdr.sgml : 20150319
<ACCEPTANCE-DATETIME>20150319165330
ACCESSION NUMBER:		0001564590-15-001840
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150319
DATE AS OF CHANGE:		20150319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		15713393

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>abio-10k_20141231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="margin-top:1pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#254;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December&#160;31, 2014 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: 000-22873 </p>
<p style="margin-top:2pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Its Charter) </p>
<p style="margin-top:1pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation or Organization)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">80020</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(720) 940-2200 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Exchange Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of Each Class</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Each Exchange on Which Registered</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock $0.001 par value</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Exchange Act: None </p>
<p style="margin-top:1pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 and Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;small reporting company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:16.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font></p></td>
<td valign="bottom"  style="width:1.16%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:20.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="top"  style="width:2.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:16.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font> (Do not check if a smaller reporting company)</p></td>
<td valign="bottom"  style="width:1.16%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:20.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:2.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:9pt;font-family:'Wingdings'">&#254;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the common stock held by non-affiliates of the Registrant on June&#160;30, 2014, the last business day of the most recently completed second fiscal quarter, was $30,003,945 based on the last sale price of the common stock as reported on that day by the Nasdaq Capital Market. </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;17, 2015, the Registrant had 21,198,411 shares of common stock outstanding. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s Definitive Proxy Statement, which will be filed with the Commission pursuant to Section&#160;14A in connection with the 2015 annual meeting of stockholders, are incorporated by reference into Part III of this Form 10-K. </p>
<p style="margin-top:4pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:none;">PART I</font></a></p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_1_Business"><font style="text-decoration:none;">Business</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_1A_Risk_Factors"><font style="text-decoration:none;">Risk Factors</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_1B_Unresolved_Staff_Comments"><font style="text-decoration:none;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_2_Properties"><font style="text-decoration:none;">Properties</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_3_Legal_Proceedings"><font style="text-decoration:none;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4_Mine_Safety_Disclosures"><font style="text-decoration:none;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:none;">PART II</font></a></p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5_Market_for_Registrant"><font style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6_Selected_Financial_Data"><font style="text-decoration:none;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_7_Management"><font style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_7A_Quantitative"><font style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_8_Financial"><font style="text-decoration:none;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Report_of_Independent_Registered_Public"><font style="text-decoration:none;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, KPMG LLP</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:none;">BALANCE SHEETS</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_OPERATIONS"><font style="text-decoration:none;">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_PREFERRED"><font style="text-decoration:none;">STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS"><font style="text-decoration:none;">STATEMENTS OF CASH FLOWS</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL"><font style="text-decoration:none;">NOTES TO FINANCIAL STATEMENTS</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9_Changes_in_and_Disagreements"><font style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9A_Controls"><font style="text-decoration:none;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9B_Other_Information"><font style="text-decoration:none;">Other Information</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:none;">PART&#160;III</font></a></p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_10_Directors"><font style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_11_Executive_Compensation"><font style="text-decoration:none;">Executive Compensation</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_12_Security_Ownership"><font style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_13_Certain"><font style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_14_Principal"><font style="text-decoration:none;">Principal Accountant Fees and Services</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:none;">PART&#160;IV</font></a></p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-12pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_15_Exhibits"><font style="text-decoration:none;">Exhibits and Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:none;">SIGNATURES</font></a></p></td>
<td valign="bottom"  style="width:0.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:78.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PART I </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_1_Business"></a>Item&#160;1. <font style="font-style:italic;">Business</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Some of the statements under &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report constitute forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of these statements include, but are not limited to, statements regarding the following: the timing and results of any clinical trials, including GENETIC-AF, the ongoing Gencaro trial for the prevention of atrial fibrillation, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment,<font style="font-style:normal;"> </font>the potential for rNAPc2 to be developed for, or to effectively treat hemorrhagic fever viruses, including the Ebola virus, our ability to obtain additional funding or enter into a strategic or other transaction, the extent to which our issued and pending patents may protect our products and technology, the potential of such product candidates to lead to the development of safe or effective therapies, our ability to enter into collaborations, our ability to maintain listing of our common stock on a national exchange, our future operating expenses, our future losses, our future expenditures, and the sufficiency of our cash resources to maintain operations. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In addition, you should refer to the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms &#8220;ARCA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to ARCA biopharma, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. Our lead product candidate, Gencaro&#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that we are evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular systolic dysfunction, or HFREF. We have identified common genetic variations in receptors in the cardiovascular system that we believe interact with Gencaro&#8217;s pharmacology and may predict patient response to the drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. We are pursuing this indication for Gencaro because data from the previously conducted Phase 3 HF trial of Gencaro in 2,708 heart failure, or HF, patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AF is a disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AF is considered an epidemic cardiovascular disease. The estimated number of individuals with AF globally in 2010 was 33.5 million.&nbsp;&nbsp;According to the 2015 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the United States in 2010 ranged from 2.7 million to 6.1 million people.&nbsp;&nbsp;AF increases the risk of stroke and may also contribute to worsening heart failure.  The approved therapies for the treatment or prevention AF have certain disadvantages in HFREF patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENETIC-AF is a Phase 2B/3 multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to an active comparator, the beta-blocker Toprol XL (metoprolol succinate), in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent  AF who have a beta-1 389 arginine homozygous genotype, the genotype we believe responds most favorably to Gencaro.&nbsp;&nbsp;The primary endpoint of GENETIC-AF, time to recurrent symptomatic AF/atrial flutter, or AFL, or all-cause mortality, will be measured over a twenty-four week period after a patient has established a normal heart rhythm. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe data from the BEST trial indicate that Gencaro may have a genetically regulated effect in reducing or preventing AF, whereas we believe the therapeutic benefit of Toprol XL does not appear to be enhanced in patients with this genotype. A retrospective analysis of data from the BEST trial shows that the entire cohort of patients in the BEST trial treated with Gencaro had a 41% reduction in the risk of new onset AF (time-to-event) compared to placebo (p = 0.0004).  In the BEST DNA substudy, patients with the beta-1 389 arginine homozygous genotype experienced a 74% (p = 0.0003) reduction in risk of AF when receiving Gencaro, based on the same analysis.  The beta-1 389 arginine homozygous genotype was present in about 47% of the patients in the BEST pharmacogenetic substudy, and we estimate it is present in about 50% of the U.S. general population.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have created an adaptive design for GENETIC-AF. We are seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study who have recently experienced at least one episode of paroxysmal or persistent AF and who have the beta-1 389 arginine homozygous genotype that we believe responds most favorably to Gencaro.  In addition to measuring the primary endpoint of recurrent symptomatic AF/AFL or all-cause mortality, an additional efficacy measure in the Phase 2B portion of GENETIC-AF will be AF burden, defined as a patient&#8217;s percentage of time in AF per day, regardless of symptoms. At least 150 patients in the Phase 2B portion of the trial will have either a newly or previously implanted Medtronic device that measures and records AF burden. The GENETIC-AF Data Safety Monitoring Board, or DSMB, will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to our pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.&nbsp;&nbsp;The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&#8217;s primary end-point.&nbsp;&nbsp;The DSMB interim analysis will focus on available data regarding the primary end point, AF/AFL event rates, AF burden, and safety.  Should the DSMB interim analysis conclude that the interim data is consistent with pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3.&#160; The DSMB may also recommend changes to the study design before the trial proceeds to Phase 3, or it may recommend that the study not proceed to Phase 3. Based on the DSMB recommendation, and other factors, including input from the trial&#8217;s Steering Committee, the Company will make the final determination on the trial&#8217;s development steps.&nbsp;&nbsp;The full Phase 2B/3 trial is designed for 90 percent power at a p-value of less than 0.01 significance level to detect a 25 percent reduction in the risk of AF recurrence or death in patients in the Gencaro arm compared to patients in the Toprol XL arm.&nbsp;&nbsp;In consultation with the GENETIC-AF Steering Committee, we implemented amendments to the trial protocol in March 2015 which we believe may expand the eligible target population, increase the patient screening and enrollment rate, and simplify trial procedures.&nbsp;&nbsp;We have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections.&nbsp;&nbsp;Under the revised protocol, patients in sinus rhythm who have experienced symptomatic AF in the past 120 days are now eligible for inclusion in the trial, as are patients with AF episodes lasting 7 days or less, or paroxysmal AF.&nbsp;&nbsp;Previously, these patients were not eligible to be enrolled in the trial. We believe this expanded target population has the potential to improve trial screening and enrollment rates and could broaden the potential commercial market for Gencaro, should it achieve regulatory approval in the future.&nbsp;&nbsp;The amendments to the protocol do not fundamentally alter or impact the original endpoints of the clinical trial.&nbsp;&nbsp;&nbsp;&nbsp;Based on the projected impact of the expanded patient population and the current enrollment rate, we now project that the enrollment of 200 patients for the Phase 2B portion of the trial may be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017. We do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate.&nbsp;&nbsp; We met with the FDA, prior to implementation, to confirm the acceptability of the amendments to the protocol and received no objections. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our GENETIC-AF clinical trial of Gencaro requires a companion diagnostic test to identify the patient&#8217;s receptor genotype.&nbsp;&nbsp;&nbsp;&nbsp;We have an agreement with Laboratory Corporation of America, or LabCorp, to provide the companion diagnostic test and services to support our GENETIC-AF trial.&nbsp;&nbsp;LabCorp has developed the genetic test and obtained an Investigational Device Exemption, or IDE, from the United States Food and Drug Administration, or the FDA, for the companion diagnostic test which is being used in our GENETIC-AF clinical trial.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic, Inc., or Medtronic, a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, is collaborating with us on the GENETIC-AF trial. Under the collaboration with Medtronic, ARCA is conducting a substudy that includes continuous monitoring of the cardiac rhythms of at least 150 patients enrolled during the Phase 2B portion of the trial.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;color:#;">The collaboration is administered by a joint ARCA-Medtronic committee. Medtronic uses its proprietary CareLink System to collect and analyze the cardiac rhythm data from the implanted Medtronic devices and the data will be used by the DSMB as part of the interim analysis. Medtronic will support the reimbursement process for U.S. patients enrolled in the Phase 2B portion, and will provide financial support of unreimbursed costs for a certain number of U.S. patients in the Phase 2B portion up to a certain maximum amount per patient. If GENETIC-AF proceeds to Phase 3, we will seek to enroll an additional 100 patients, with Medtronic devices for </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#;">monitoring and recording AF burden, in the substudy.&nbsp;&nbsp;Medtronic will provide the agreed upon CareLink System cardiac rhythm data collection and analysis for the Phase 3 portion of the substudy and support the reimbursement process.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted patents in the United States, Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which, if we are granted patent term extension, may provide market exclusivity for these uses of Gencaro into approximately 2030 in the United States and Europe.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To support the continued development of Gencaro, we completed public equity offerings during 2013 that raised approximately $19.3 million of net proceeds.&nbsp;&nbsp;In February 2014, we completed a public equity offering that raised approximately $7.9 million of net proceeds as additional funds for the Phase 2B portion of the GENETIC-AF trial and to support our ongoing operations.&nbsp;&nbsp;In light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, we will need to raise a significant amount of additional capital to finance the completion of GENETIC-AF and our ongoing operations.&#160; We are seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the GENETIC-AF trial, and we anticipate that our current cash and cash equivalents, will be sufficient to fund our operations, at our projected cost structure, through the end of 2015.  However, changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate.  We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate.  We will be required to raise additional funds prior to completion of the Phase 2B portion of GENETIC-AF.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4, 2013, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, to implement a six-for-one reverse split of our common stock, as previously authorized and approved at our special meeting of stockholders on February&#160;25, 2013. On March 5, 2013, our common stock began trading on The NASDAQ Capital Market on a post-split basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reverse split effected a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options and warrants to purchase shares of our common stock, and the number of shares reserved for issuance pursuant to our existing stock option plans were reduced proportionately. No fractional shares were issued as a result of the reverse split, and stockholders who otherwise would have been entitled to a fractional share received in lieu thereof, a cash payment based on the closing sale price of our common stock as reported on The NASDAQ Capital Market on March&#160;4, 2013. The reverse split did not alter the par value of our common stock or modify any voting rights or other terms of the common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to become a leading biopharmaceutical company developing cardiovascular therapies with an emphasis on genetically-targeted therapies. To achieve this goal, we are pursuing the following strategies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Advance the development of Gencaro.</font><font style="font-family:Times New Roman;"> We plan to focus our efforts on completing the GENETIC-AF clinical trial. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Raise additional funding or complete a strategic transaction.</font><font style="font-family:Times New Roman;"> To support the continued clinical development of Gencaro, including the GENETIC-AF clinical trial, we expect to seek additional funding, through the sale of public or private equity or debt securities, or the completion of a strategic transaction. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Build a cardiovascular pipeline.</font><font style="font-family:Times New Roman;"> Our management and employees, including our chief executive officer, have extensive experience in cardiovascular research, molecular genetics and clinical development of cardiovascular therapies. We are seeking to leverage this expertise to identify, acquire and develop other cardiovascular products or candidates, with an emphasis on pharmacogenetic applications. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Leverage our existing assets.&#160;</font><font style="font-family:Times New Roman;">We are pursuing opportunities to leverage certain of our development-stage product candidates. These opportunities include collaborations with institutions conducting proof of concept studies and government funded development. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Atrial Fibrillation Market Background and Opportunity<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AF is a disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the heart&#8217;s atria, predisposing to the formation of clots. These clots may travel from the heart and become lodged in the arteries leading to the brain and other organs, thereby blocking necessary blood flow and potentially resulting in stroke. In addition, we also believe that the development of AF in a HFREF patient can be associated with increased risk of death and other heart failure related adverse outcomes. AF is considered an epidemic cardiovascular disease.&nbsp;&nbsp;The estimated number of individuals with AF globally in 2010 was 33.5 million.&nbsp;&nbsp;According to the 2015 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the United States in 2010 ranged from 2.7 million to 6.1 million.  The approved therapies for the treatment or prevention AF have certain disadvantages in HFREF patients, such as toxic or cardiovascular adverse effects, and most of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goals of current medical therapy for AF are to maintain sinus rhythm or to control ventricular rate response in patients who cannot maintain sinus rhythm, in an effort to minimize patient symptoms and avoid the risk of complications such as stroke. Current treatments include pharmaceutical intervention and device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF. However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with HFREF. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current device interventions for the treatment of AF include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Electrical cardioversion which is used to restore normal heart rhythm with administration of a direct current shock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Radiofrequency ablation which is effective in some patients for whom medications are ineffective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Atrial pacemakers which are implanted under the skin and then intravenously into the heart to regulate heart rhythm. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gencaro </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of AF. Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine, or NE, which activate these receptors. We believe that Gencaro is well-tolerated in cardiovascular patients because of its mild vasodilator effects. Originally developed by Bristol-Myers Squibb, or BMS, the active pharmaceutical ingredient, or API, in Gencaro, bucindolol hydrochloride, has been tested clinically in approximately 4,500 patients. Gencaro was the subject of a Phase 3 HF mortality trial in 2,708 patients, mostly in the United States, or the BEST trial. The BEST trial included a DNA bank of over 1,000 patients, which was used to evaluate the effect of genetic variation on patients&#8217; response to Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of the BEST trial, our scientific co-founders, Dr.&#160;Michael Bristow and Dr.&#160;Stephen Liggett, hypothesized that the unique pharmacologic properties of Gencaro would interact with common genetic variations of beta-1, beta-2 and alpha-2C, adrenergic receptors, which are important receptors that regulate cardiac or adrenergic (sympathetic) nerve function. They tested this hypothesis prospectively in a substudy conducted using data from the BEST DNA bank. On the basis of this study, Drs. Bristow and Liggett have determined that patients with certain variations in these receptors had substantially improved outcomes on primary and certain secondary clinical endpoints in the trial, such as mortality, HF progression, hospitalization and prevention of arrhythmias, relative to the counterpart genotype groups and the general patient population of the BEST trial. We believe that these genetically determined receptor variations, which are detectable using standard DNA testing technology, can serve as diagnostic markers for predicting enhanced therapeutic response to Gencaro, and potentially avoiding adverse events, in individual patients. We have patented our methods for treating AF and HF patients with Gencaro in the United States and Europe based on genetic testing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pharmacology and Pharmacogenetics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro&#8217;s pharmacology appears to be different from other compounds in the beta-blocker class in two fundamental respects. First, the National Heart, Lung and Blood Institute of the National Institutes of Health, or NHLBI, and the Cooperative Studies Program of the Department of Veterans Affairs sponsored studies conducted by Drs. Bristow and Liggett indicated that in human myocardial preparations, Gencaro leads to inactivation of constitutively active (i.e. functional in the absence of bound agonist) beta-1 receptors through a mechanism separate from beta-blockade, in addition to inhibiting the binding activity of the beta-1 receptor like a typical beta-blocker. Second, other studies, including BEST, indicated that Gencaro lowers the systemic levels of the neurotransmitter NE, released by cardiac and other adrenergic nerves. These two properties interact with common genetic variations in two cardiac receptors, the beta-1 and alpha-2C receptors, to produce the unique pharmacogenetic profile of Gencaro. We believe that these two properties, and their pharmacogenetic implications, are unique to Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro has an important interaction with the beta-1 receptor found on muscle cells, or cardiac myocytes, of the heart. The general role of the beta-1 receptor and its downstream signaling cascades is to regulate the strength and rate of the heart&#8217;s contractions. NE serves as an activator of the beta-1 receptor, causing the receptor to initiate signaling to the cardiac myocyte. Although this signaling may be beneficial to the failing heart in the short term, in chronic HFREF patients the beta-1 receptor also initiates harmful, or cardiomyopathic, signaling which, over time, exacerbates the heart&#8217;s structural and functional decline. Beta-blockers counteract this destructive process by reducing beta-1 receptor signaling. They do this by binding to the receptor and blocking NE molecules from binding and activating the signaling activity and, in Gencaro&#8217;s case, by also inactivating certain beta-1 receptors that are constitutively active (active in the absence of NE stimulation) as well as by lowering NE levels. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are two common genetic variations of the beta-1 receptor, each of which we estimate is present in approximately 50% of the U.S. population. One of these variations is known as the beta-1 389 arginine receptor variant, exclusively present in the beta-1&#160;389 arginine homozygous or, genotype. Laboratory studies indicate that this variation results in a higher functioning beta-1 receptor, which has a greater ability to mediate the stimulatory effects of NE than the counterpart &#8220;beta-1&#160;389 glycine or &#8220;beta-1&#160;389 Gly&#8221; version of the beta-1 receptor. In addition, the beta-1 389 arginine variant is also more likely to be constitutively active and signal the cardiac myocyte to contract in the absence of NE. The beta-1 389 arginine receptor also has much higher affinity for NE as compared to the beta-1&#160;389 glycine version, present in patients with either one or two copies of the beta-1&#160;389 glycine gene allele, or Gly carriers. Patients with the beta-1&#160;389 glycine version, also present in approximately 50% of the U.S. population who are Gly carriers, results in a beta-1 receptor that is much lower functioning and, according to laboratory studies, has less probability of being in a constitutively active state and has lower NE affinity compared to the beta-1&#160;389 arginine receptor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Gencaro has a powerful interaction with the higher-function beta-1&#160;389 arginine variation of the beta-1 receptor. Laboratory studies show that constitutively active receptors will continue to signal in the presence of standard beta-blockade with neutral antagonists. Laboratory studies in isolated human heart preparations also show that Gencaro has the novel ability of being able to reduce the signaling of constitutively active receptors. We believe that this property contributes to the enhanced lowering of heart failure and arrhythmia event rates in HFREF patients who are beta-1&#160;389 arginine homozygous genotype relative to individuals who are beta-1&#160;389 Gly carriers or to the general population. In addition, we believe the unique NE lowering properties of Gencaro have a selectively beneficial effect in patients who have only beta-1&#160;389 arginine receptors, because of the high affinity of these receptors for NE. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The efficacy of Gencaro also appears to be influenced by the alpha-2C receptor, located on the terminus of cardiac adrenergic nerves, at the neuromuscular junction with the cardiac myocyte. The role of this receptor is to modulate the release of NE at this junction, which in turn affects the activation of beta-1 receptors and the heart&#8217;s activity. There are two important genetic variations of this receptor that appear to affect the effects of Gencaro; the &#8220;alpha-2C -wild type&#8221;, which is the normal functioning version of the receptor (approximately 87-90% of the U.S. general population), and the &#8220;deletion variant&#8221;, a version of the receptor that functions poorly (present in at least one copy in approximately 10-13% of the U.S. general population). The DNA substudy of patients from the BEST trial, conducted by Drs. Bristow and Liggett, indicated that these two variations of the alpha-2C receptor appear to affect Gencaro&#8217;s heart failure and arrhythmia responses in HFREF patients only if the 389 Gly variant of the beta-1 receptor is also present; in patients with the beta-1&#160;389 Gly variant, the wild type version of the alpha-2C receptor enhances clinical response, whereas the alpha-2C deletion variant reduces efficacy. When only the arginine version of the beta-1 receptor is present (beta-1&#160;389 arginine homozygous genotype), the efficacy of Gencaro does not appear to depend on which version of the alpha-2C receptor is present. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DNA substudy from the BEST HFREF trial indicated that the combinations of these receptor variations in individual patients appear to influence the response to Gencaro with respect to significant clinical endpoints. However, the beta-1 389 Arg/Arg variant appeared to have the most powerful beneficial effect on Gencaro heart failure and arrhythmia responses. While we believe that the beta-1&#160;389 Gly carrier patients who also are alpha-2C wild type homozygotes may respond favorably to Gencaro, we believe that patients who possess only the beta-1&#160;389 arginine variant (beta-1&#160;389 arginine homozygous genotype) exhibit enhanced clinical responses to Gencaro, and should be the primary targeted population. The beta-1&#160;389 arginine homozygous genotype constitutes an estimated 47-50% of the U.S. population. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The BEST trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NHLBI and Veterans Affairs Cooperative Studies funded BEST trial began in 1995. It was a double-blind, placebo-controlled, multi-center study of bucindolol&#8217;s effect on reduction of mortality and morbidity in an advanced chronic HFREF population. The primary endpoint of the BEST trial was all cause mortality, or ACM, and the pre-specified main secondary endpoint was progression of HF, defined as death from HF, cardiac transplant, HF hospitalization, or emergency room visit for the treatment of worsening HF not requiring hospitalization. The trial was planned to run four and one-half years, and enroll 2,800 patients. The trial enrolled a total of 2,708 chronic HF patients, who were mostly from the United States. Under the umbrella of the BEST trial substudies program, a DNA bank and substudy was created, and 1,040 of the BEST patients participated by providing blood for DNA analysis. The DNA bank provided data for the DNA substudy of BEST patients conducted by Drs. Bristow and Liggett. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1999, the BEST trial was terminated prior to the completion of follow-up, in response to a recommendation of the BEST trial DSMB. The primary reason for termination was loss of investigator equipoise; in other words, the fact that the BEST investigators were no longer uncertain regarding the comparative therapeutic merits of giving a placebo versus giving a beta-blocker to a HFREF patient. Positive mortality results from two other HF trials involving other beta-blockers had been reported, and a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. As a result, some investigators began to prescribe these other beta-blockers to patients in the trial, which threatened to destroy the trial&#8217;s integrity; therefore the trial was terminated early. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Results and the DNA Substudy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following termination, the preliminary results of the study were analyzed and published. The preliminary determination and general perception were that the BEST trial had failed on the basis of not meeting its primary endpoint of ACM. The published values were a 10% risk reduction in mortality with a p-value of 0.10. Subsequently, we reanalyzed the results from BEST, in accordance with the FDA approved, pre-specified statistical analysis plans, which had not been performed by the sponsors of BEST when the trial was terminated. Our reanalysis appeared to show a 13% risk reduction on the primary endpoint of all-cause mortality in the BEST trial with a p-value of 0.053. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2003 and 2004, the results of the DNA substudy conducted by Drs. Bristow and Liggett began to be analyzed and released. The DNA substudy results indicated a significant enhancement of response on the major heart failure clinical endpoints from the BEST trial in patients with the beta-1&#160;389 arginine homozygous genotype. The risk reduction on HF clinical efficacy endpoints such as mortality and hospitalization ranged from 34% to 48% in this genotype. In addition, in arrhythmia endpoints of atrial fibrillation or ventricular fibrillation/ventricular tachycardia, or VT/VF, tracked by adverse events, or AEs, and surveillance electrocardiograms, or ECGs, the risk reduction by bucindolol in the beta-1&#160;389 arginine homozygous genotype appeared to be even greater, with risk reductions of 74% for both endpoints. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shown below are certain of the primary and secondary endpoint data from the BEST HF DNA substudy results, by genotype: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BEST Trial Clinical Responses<font style="font-size:11pt;"><sup style="font-size:85%; vertical-align:top">1</sup></font> by Genotype Groups </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom"  style="width:51%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Endpoint</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{beta-1&#160;389&#160;Arg/<br>Arg&#160;+&#160;any&#160; alpha-2C}<br>&#8220;Very&#160;Favorable&#8221;<br>Patient Type<br>(47%)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{beta-1&#160;389&#160;Gly<br>carrier+&#160;alpha-2C<br>Wt/Wt}&#160; &#8220;Favorable&#8221;<br>Patient&#160;Type<br>(40%)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{beta-1&#160;389&#160;Gly<br>carrier&#160;+&#160;alpha-2C<br>Del&#160; carrier}<br>&#8220;Unfavorable&#8221;<br>Patient&#160;Type<br>(13%)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:51%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Cause Mortality (ACM), TTE</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 38%*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 25%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8593; &#160;&#160;<font style="font-style:normal;">4%</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cardiovascular Mortality (CVM), TTE</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 48%*</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 40%*</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8593; <font style="font-style:normal;">11%</font></p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACM + transplantation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 43%*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 24%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8593; &#160;&#160;<font style="font-style:normal;">4%</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HF (HF) Progression</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 34%**</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 20%</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; &#160;&#160;1%</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HF Hosp days/patient</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 48%**</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 17%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8593; <font style="font-style:normal;">19%</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AF prevention (from AE and ECG db)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 74%**</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; &#160;&#160;6%</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8593; <font style="font-style:normal;">33%</font></p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VT/VF prevention (from AE db)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 74%**</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:15.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 49%*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:17.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8595; 24%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:3pt;line-height:6pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Covariate adjusted, transplant censored analysis with 1 &#8211; hazard ratio estimates presented </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">p&lt;0.05; **p <font style="font-family:'Symbol';"><font style="font-size:10pt;font-family:'Symbol'">&#163;</font></font> 0.007; TTE: Time To Event </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Analysis of BEST trial for AF </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BEST study data were further analyzed focusing on AF prevention, rate control in patients with established AF, and on clinical outcomes of patients with AF. Although there was no pre-determined AF endpoint, including reduction in risk of AF, in the BEST trial, according to our analysis of adverse events and surveillance ECG&#8217;s during the trial, 7.9% of patients developed new onset AF, with a greater incidence observed in the placebo group (9.7%)&#160;compared to the bucindolol group (6.2%). This corresponded to a 36% reduction in the incidence of new onset AF (based on crude event rates) for patients receiving bucindolol (p = 0.002). In a time to event analysis, the risk of new onset AF was reduced by 41% (p = 0.0004) with bucindolol treatment. Patients in the BEST study with the beta-1 389 Arg/Arg genotype who received Gencaro had a 74% reduction in the risk of developing new onset AF (p = 0.0003). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further published analyses of the data from BEST suggest that Gencaro may also have potential efficacy for other clinical endpoints and outcomes related to AF. A published analysis of the BEST data revealed that of the 303 patients in the BEST trial with established AF, 67% of those who received Gencaro achieved ventricular response rate control, defined as a resting heart rate of less than or equal to 80 beats per minute without symptomatic bradycardia (p &lt; 0.005). In AF patients who achieved ventricular response rate control, Gencaro produced a 39% reduction (p = 0.025) in cardiovascular mortality/cardiovascular hospitalizations. In addition, Gencaro also improved cardiovascular clinical endpoints for those AF patients possessing the beta-1&#160;389 arginine genotype that ARCA believes is most favorable for Gencaro response. In a substudy of 1,040 patients in BEST in which patient genotypes were analyzed, Gencaro was associated with a 72% decrease (p = 0.039) in cardiovascular mortality/cardiovascular hospitalizations in those 52 AF patients in the substudy with the beta-1 389 arginine homozygous genotype. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analysis of the BEST Study data also shows that Gencaro has potential efficacy against the serious arrhythmias of VT/VF, which also appears to be genetically regulated. A published report demonstrated that patients in the BEST Trial who received Gencaro experienced a 58% reduction in the incidence of VT/VF (p = 0.00006), adjusted for the competing risk of mortality. In addition, the authors of this report determined that Gencaro reduced the incidence of VT/VF by 74% (p = 0.00005) in patients with the beta-1 389 arginine homozygous genotype. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with the overall study cohort, most patients (89%)&#160;in the 1,040 patient DNA substudy were free of AF (91% sinus rhythm, 9% other non-AF rhythms) at baseline. The proportion of patients free of AF at baseline was also similar in the two treatment groups for the overall DNA substudy cohort, as well as in the beta-1 389 genotype subgroups. In the BEST DNA substudy, the proportion of patients who developed new onset AF was similar compared to the overall study cohort for both the placebo group (11% and 10%, respectively) and the Gencaro group in the DNA substudy population compared to the overall study cohort (7% and 6%, respectively). Also, there was a similar reduction in new onset AF observed in the bucindolol group compared to placebo (43% and 41%, respectively, by time to event analysis). Therefore, the overall results from the genetic substudy population are consistent with the results from the overall study population. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In patients with all genotypes, the AF risk reduction of 41-43% by Gencaro in BEST is based on an analysis of adverse events and surveillance ECG&#8217;s which was similar to AF risk reductions observed in a meta-analysis of data regarding seven placebo-controlled beta-blocker trials in HFREF patients. In the meta-analysis, beta-blockers appeared to reduce the incidence of new onset AF in all but one trial, with an overall relative risk reduction of 27%.&#160;Despite what we believe to be potential evidence for the prevention of AF in HFREF trials, no beta-blocker has FDA approval for use in this indication.&#160;However, the evidence of modest efficacy by beta-blockers approved for other indications will require that any Phase 3 trials with Gencaro will have an active beta-blocker comparator instead of a comparison against placebo.&#160;The Phase 2B/3 trial GENETIC-AF trial will only enroll patients with the beta-1 389 arginine homozygous genotype. In the BEST trial, the post hoc analysis of patients with the beta-1 389 arginine homozygous genotype who received Gencaro had a 74% reduction in the risk of developing AF.&#160;In another trial, the active comparator we are using in GENETIC-AF, metoprolol CR/Toprol XL, reduced the risk of developing AF by 48% in all genotypes. Because these are not the same trials, the results should not be relied on as direct comparisons. However, we believe that these two data points indicate that Gencaro may have an advantage in preventing AF when compared to metoprolol in GENETIC-AF, in part due to our plan to only enroll beta-1 389 arginine homozygous genotype patients who appear to respond best to Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical and Regulatory Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory strategy for Gencaro is to conduct our adaptive design Phase 2B/3 clinical trial, GENETIC-AF, to obtain an AF approval in a genotype specific HFREF population. We are enrolling certain patients with the beta-1 389 arginine homozygous genotype in our AF clinical trial because our analysis of the BEST DNA substudy indicated this group had a 74% reduction in risk for new AF events. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have created an adaptive design for GENETIC-AF.&nbsp;&nbsp;We are seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study.&nbsp;&nbsp;The GENETIC-AF DSMB will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to our pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. In addition to measuring the primary endpoint of recurrent symptomatic AF/AFL or all-cause mortality,  an additional efficacy measure in the Phase 2B portion of GENETIC-AF will be AF burden, defined as a patient&#8217;s percentage of time in AF per day, regardless of symptoms. Under our trial design, at least 150 patients in the Phase 2B portion of the trial will have AF burden measured by continuous monitoring, either by previously implanted cardiac resynchronization or defibrillation devices, or newly or previously inserted implantable loop recorders. When the first 200 patients have completed 24 weeks of follow-up, certain data related to the primary endpoint of recurrent symptomatic AF/AFL or all-cause mortality, AF/AFL event rates and certain data related to AF burden will be evaluated by the trial&#8217;s DSMB to determine if the interim data is consistent with pre-trial assumptions and if it indicates potential for achieving statistical significance for the Phase 3 endpoint.  If the interim evaluation confirms our assumptions and acceptable safety is observed, the trial would then proceed to the Phase 3 portion and full enrollment, subject to obtaining sufficient financing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received guidance from the FDA regarding our Phase 2B/3 clinical study comparing Gencaro to Toprol XL for the prevention of AF in approximately 620 patients. Based on this FDA guidance, we believe that a successful GENETIC-AF Phase 3 clinical trial, with a p-value of less than 0.01, could be sufficient evidence of efficacy upon which to base a New Drug Application, or NDA, for the approval of Gencaro for an AF indication in HFREF patients. Our Investigational New Drug, or IND, application for atrial fibrillation, under which our GENETIC-AF trial is performed, has been accepted by FDA and is active. We implemented amendments to the GENETIC-AF trial protocol in March 2015 which we believe may expand the eligible target population, increase the patient screening and enrollment rate, and simplify trial procedures.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Gencaro Test </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved, we believe that Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic to predict enhanced efficacy. We believe the drug label we will propose for Gencaro would identify the patient receptor genotype studied in the trial that can expect enhanced efficacy and, and that the label would recommend receptor genotype testing prior to initiation of therapy.  Therefore, the commercialization of Gencaro may require an FDA approved diagnostic test for this genotype be available, or the Gencaro Test.&nbsp;&nbsp;We believe the Genaro Test could be developed and commercialized through a preferred diagnostic provider, by the company marketing Gencaro, or a combination of approaches.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our GENETIC-AF clinical trial, we have an agreement with LabCorp to provide the companion diagnostic test and services to support the trial.&nbsp;&nbsp;To provide those services, LabCorp has developed the genetic test and obtained from the FDA an Investigational Device Exemption, or IDE, for the companion diagnostic test we use in our GENETIC-AF clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Licensing and Royalty Obligations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed worldwide rights to Gencaro, including all preclinical and clinical data from Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC, who has licensed rights in Gencaro from BMS. In addition, we have sublicensed CPEC&#8217;s rights from BMS. CPEC is a licensing entity which holds the rights of the biotechnology companies that were the commercial sponsors of the BEST trial. If the FDA grants marketing approval for Gencaro, the license agreements state that we are required to make a milestone payment of $8.0 million within six months after FDA approval. The license agreements also state that we are required to make milestone payments of up to $5.0 million in the aggregate upon regulatory marketing approval in Europe and Japan. The licenses state that our royalty obligations range from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels including a 5% royalty that CPEC is obligated to pay BMS. The agreements state that we have the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. &nbsp;&nbsp;We also have licensed worldwide rights to intellectual property covering the pharmacogenetic response of Gencaro based on the cardiac receptor polymorphisms, which is owned by the University of Colorado. We have no material future financial obligations under this license. We also have licensed exclusive, worldwide rights to develop and commercialize diagnostics for these receptor polymorphisms, for the purpose of prescribing Gencaro, from the licensee of these rights, the University of Cincinnati. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Development Pipeline </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development activities are substantially focused on our lead product candidate, Gencaro, for the treatment of AF. We also believe, based upon data from the BEST trial, that Gencaro may have additional potential for the treatment of AF rate control, VT/VF and prevention of heart failure endpoints in HFREF patients. We do not expect to pursue development of Gencaro for disease indications beyond AF without entering into a strategic partnership or collaboration. We believe Gencaro has potential to address these additional indications, and that the clinical response of patients with these diseases may be genetically influenced, based on the same genetic markers we have identified for our proposed treatment of AF with Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have exclusive pharmacogenetic and other patent rights to drug candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas, in both early and later stages of development. We may seek partners to assist us in the development of these candidates or who may license them. We may also seek funds to advance the development of the compounds on our own.&nbsp;&nbsp;We are currently exploring options to develop one of these candidates, recombinant Nematode Anticoagulation Protein c2, or rNAPc2, as a potential therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens, including seeking development partners, out-licensing the compound and applying for grant or government funding.&nbsp;&nbsp;In February 2015, the World Health Organization prioritized rNAPc2 for testing in human efficacy trials in patients infected with the Ebola virus.&nbsp;&nbsp;The U.S. FDA Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.&nbsp;&nbsp;Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 individuals in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon marketing approval, as well as certain financial incentives that can help support development of the drug.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current AF treatments include pharmaceutical intervention and device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF. However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with heart failure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Considering that most of the approved drugs and device interventions for the treatment or prevention of AF have notable risks or adverse side effects, we believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in patients with HF where the approved drugs are contra-indicated or have </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warnings regarding their prescribing information. We believe that Gencaro&#8217;s prevention of AF in HF patients would provide this patient population a safer treatment option than other treatments currently approved by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical industry is highly competitive. We face significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Most of these companies have significantly greater financial, product development, manufacturing, and commercial resources than we have. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our proposed prescribing information for Gencaro includes a recommendation for genetic testing, which will add additional cost and procedures to the process of prescribing Gencaro, and which could make it more difficult for us to compete against existing or future therapies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing and Product Supply </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the API and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. We outsource all manufacturing and analytical testing of the Gencaro API and drug product. We have selected third party contract manufacturing organizations on the basis of their technical and regulatory expertise. Our approach with our contract manufacturing partners has been to replicate the manufacturing processes that were used to support the prior pivotal clinical trial with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk. We contracted with Groupe Novasep to complete the drug substance registration batches required for the Gencaro NDA. These batches were successful, and the resulting drug substance was used to supply the drug product registration campaign. Remaining inventory was placed in current Good Manufacturing Practice, or cGMP, storage to provide a backup supply for the GENETIC-AF trial, and for use as an initial source of drug substance to support eventual product launch, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For drug product production, we have contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths are manufactured, with the maximum recommended dose of 50mg twice daily for patients weighing 75kg or less and 100mg twice daily for patients weighing more than 75kg. Registration batches were successfully completed by Patheon, Inc. and tablets from these runs have been placed in cGMP storage to supply the GENETIC-AF trial. In addition, we have contracted with a separate service provider for packaging and distribution of our clinical trial materials.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing focus for 2015 is to supply the blinded clinical trial materials for Gencaro and the comparator compound, and to manage the clinical distribution channels necessary for the successful execution of the GENETIC-AF trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses totaled $5.6 million for the year ended December&#160;31, 2014 as compared to $2.9 million for 2013, an increase of approximately $2.7 million. R&amp;D expense in 2015 is expected to be higher than 2014 as we continue to enroll patients in our GENETIC-AF clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governmental authorities in the United States at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products. In the United States, the FDA regulates these activities at the federal level pursuant to the Federal Food Drug and Cosmetic Act, or the FDCA, and the regulations promulgated thereunder. We anticipate that all of our products will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and our products may be subject to new legislation or regulations.&nbsp;&nbsp; Both before and after approval or clearance, failure to comply with the requirements of the FDA and other state and federal statutes can lead to significant penalties or could disrupt our ability to manufacture and sell these products. In addition, the FDA could refuse to provide certificates needed to export our products if the agency determines that we are not in compliance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Premarket Approval of Drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval is required for marketing of any new drug, dosage form, indication, or strength. The steps required before new human therapeutic drug products are marketed in the United States and foreign countries include rigorous preclinical and clinical testing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries. There is no guarantee that products will be approved in a specific timeframe or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Phase<font style="font-style:normal;">. Preclinical studies are generally conducted in the laboratory to identify potential drug candidates and to evaluate their potential efficacy and safety. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate short and long-term toxicity in animals. Preclinical studies are governed by numerous regulations, including but not limited to FDA&#8217;s Good Laboratory Practices. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Phase<font style="font-style:normal;">. Before human clinical trials can commence, an Investigational New Drug, or IND, application, submitted to FDA must become effective. For an IND to become effective, the applicant must submit, among other things, information on design of the proposed investigation, reports necessary to assess the safety of the drug for use in clinical investigation, and information on the chemistry and manufacturing of the drug, controls available for the drug, and primary data tabulations from animal or human studies. The clinical phase of development involves the performance of human studies, including adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase 1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. Phase 2 trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase 3, larger-scale, multi- center trials are conducted with patients afflicted with a specific target disease over a longer term to confirm Phase 2 results and provide reliable and conclusive data supporting efficacy and safety of a drug as required by regulatory agencies for drug approval. The conduct of clinical trials is subject to extensive regulation. FDA may delay or suspend clinical trials through clinical holds. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">NDA Submission.<font style="font-style:normal;"> In the United States, the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of an NDA. Under the current Prescription Drug User Fee Act, or PDUFA, after submission of an NDA and payment, or waiver, of the required fee, the FDA&#8217;s goal is to review most standard NDAs within 10 months from the time that a sponsor&#8217;s application is accepted as filed by FDA, which can occur within a 60-day window following the initial submission of the application. At the end of the 10 months, the FDA&#8217;s goal is to issue a &#8220;complete response,&#8221; or approve the NDA. While FDA&#8217;s goal is to issue a complete response within 10 months, the process may take longer than 10 months, particularly if multiple review cycles are required. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy the statutory and regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase 3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than we interpret data. Under the Food and Drug Modernization Act of 1997, the FDA is authorized to approve a drug based on a single adequate and well-controlled study if such study and other confirmatory data are sufficient to establish the drug&#8217;s effectiveness. However, it has long been the FDA&#8217;s general position that the standard of proof of a drug&#8217;s effectiveness generally requires at least two well-controlled and adequate Phase 3 clinical studies demonstrating statistically significant results as compared to a placebo or active control (with p-values of less than 0.05) with respect to the primary endpoint or endpoints of the trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in accordance with current FDA law and regulations, the FDA may refer a drug to an advisory committee for review prior to approval. Most new compounds are referred to an FDA advisory committee, which could add additional time to the review process. There is no guarantee that the advisory committee will recommend approval of a drug candidate. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase 4 clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post-marketing programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice, or cGMP, requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves the NDA, the sponsor is authorized to begin commercialization of the drug in accordance with the approval. Even if the FDA approves the NDA, the FDA may decide later to suspend or withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require additional clinical studies, to require changes in labeling or to prevent further marketing of a product based on the results of these post-marketing programs. The FDA also has authority to request implementation of a risk evaluation and mitigation strategy, or REMS that could restrict distribution of Gencaro or require us to provide additional risk information to prescribers. Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-approval Compliance.<font style="font-style:normal;"> If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including compliance with cGMP, as well as labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse events. In addition, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for labeling, promotion to health care professionals, direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Companies are responsible for compliance with such requirements and would be responsible to ensure that all contract manufacturing organizations who perform work for them also comply with such requirements. Similarly, if a drug manufacturer hires contract sales representatives or consultants to promote its products, such organizations or individuals must comply with all of the same requirements applicable to the drug manufacturer. The FDA regularly inspects companies to determine compliance with cGMPs and other post-market requirements. Failure to comply with statutory requirements and the FDA&#8217;s regulations can result in a variety of administrative or enforcement actions, including but not limited to an FDA Form 483 (which is issued by FDA at the conclusions of an inspection when an investigator has observed any conditions that may constitute violations), a public warning letter, suspension or withdrawal of regulatory approvals, product recalls, product detentions, refusal to provide export certificates, seizure of products and criminal prosecution. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Drug Price Competition and Patent Term Restoration Act of 1984.<font style="font-style:normal;"> Under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch-Waxman Act also provides for patent term restoration and the award, in certain circumstances, of non-patent marketing exclusivities. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Generic Drug Approval<font style="font-style:normal;">. The Hatch-Waxman Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA. Generic drug applications are &#8220;abbreviated&#8221; because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book must certify to the FDA&nbsp;&nbsp;that (i)&#160;no patent information on the drug has been listed in the Orange Book; (ii)&#160;that each patent listed in the Orange Book for that approved drug has expired; (iii)&#160;FDA should approve the product on the date on which a listed patent expires; or (iv)&#160;that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a certification pursuant to (iv)&#160;above, or a Paragraph IV certification, and the NDA holder files an infringement suit against the ANDA applicant within 45 days of receiving the Paragraph IV notification, the NDA owner is entitled to an automatic 30-month stay of FDA&#8217;s ability to approve the ANDA. This 30-month stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Extension<font style="font-style:normal;">. While the term of a U.S. patent is generally 20 years from the earliest priority date of a patent application (excluding a provisional patent application), a U.S. patent that covers subject matter requiring regulatory approval to market is eligible for an extension of that patent term. The Hatch-Waxman Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. Patent Term Extension, or PTE, extends the term of an issued patent for generally 1) the length of the FDA approval process, i.e., the complete period of NDA review, and 2) half of the time spent in clinical trials, i.e., the investigational new drug (IND) period. However, the maximum period of restoration cannot exceed five years, or restore the total remaining term of the patent to greater than 14 years from the date of FDA approval of the product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under 35 U.S.C. &#167; 156(a), a patent covering a method of using a product is eligible for PTE if the following conditions are met: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patent has not yet expired; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patent was not previously extended; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patent owner submits an application for PTE that includes all necessary supporting information within 60 days of FDA approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4)</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the product was subject to regulatory review before its commercial marketing or use; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the drug application is for the first permitted commercial marketing of the product. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained four U.S. patents (U.S. Patent Nos. 7,678,824; 8,080,578; 8,093,286; 8,946,284). We believe that, if approved by the FDA, any one of the U.S. patents may be eligible for PTE, which could provide approximately 5 years of additional patent life based on our current clinical trial plans. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Supplementary Protection Certificate, or SPC, is a form of patent term extension that is available for pharmaceutical products approved for marketing in the European Union. We obtained a patent in Europe on methods for using Gencaro that is similar to the &#8216;824 patent (EP 1802775); this patent is in force in certain countries in Europe, including the United Kingdom, France, Germany, Italy and Spain. We believe that this patent may be eligible for an SPC, if Gencaro is approved for marketing in any European country in which the patent is in force, which could provide up to five years of additional patent life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Patent Marketing Exclusivities.<font style="font-style:normal;"> Separate and apart from patent protection, the Hatch-Waxman Act entitles approved drugs to various periods of non-patent statutory protection, known as marketing exclusivity. The Hatch-Waxman Act provides five years of &#8220;new chemical entity&#8221; marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2) NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand-alone NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph IV certification. Four years into the five-year exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Hatch-Waxman Act also provides three years of &#8220;new use&#8221; marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA&#8217;s approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA&#8217;s approval or were conducted by or for the applicant, this three-year exclusivity prohibits the final approval of ANDAs or 505(b)(2) NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for other products containing the same active ingredient, without those changes. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FDA Premarket Review of Medical Devices </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless an exemption applies, each medical device that a company wishes to market in the United States requires either approval of a premarket approval application, or PMA, or clearance of a premarket notification, commonly known as a &#8220;510(k)&#8221; from the FDA. The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class I or II, which may require the manufacturer to submit to the FDA a 510(k) requesting permission to commercially distribute the device. Clearance of a 510(k) usually requires between three months and one year from the time of submission of the 510(k), although the process may take longer. The FDA&#8217;s 510(k) clearance procedure is less rigorous than the PMA approval procedure, but is available only to companies who can establish that their device is substantially equivalent to a legally-marketed &#8220;predicate&#8221; device that was (i)&#160;on the market prior to the enactment of the Medical Device Amendments of 1976, (ii)&#160;reclassified from Class III to Class II, or (iii)&#160;has been cleared through the 510(k) procedure. 510(k)s must typically be supported by performance data, including preclinical data, bench testing, and in some cases, clinical data. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class III, and require a PMA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PMA Pathway<font style="font-style:normal;">. Generally, a PMA must be supported by extensive data and valid scientific evidence, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in-depth review of the submitted information and will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with FDA&#8217;s Quality System Regulations, or QSR. By statute, the FDA has 180 days to review the &#8220;accepted application&#8221;, although, generally, review of the application can take between one and three years, and it may take significantly longer. The PMA application process can be expensive, and there is a substantial &#8220;user fee&#8221; that must be paid to FDA in connection with the submission of a PMA application. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several years. In addition, if FDA discovers that an applicant has submitted false or misleading information, FDA may refuse to review submissions until certain requirements are met pursuant to its Application Integrity Policy, or AIP. If the FDA approves the PMA, it may place restrictions on the device.&nbsp;&nbsp;After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval. PMA supplements often must be approved by FDA before the modification to the device, the labeling, or the manufacturing process may be implemented.&nbsp;&nbsp;Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on our business, financial condition and results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials.<font style="font-style:normal;"> Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance. These trials generally require an Investigational Device Exemption, or IDE, application approved in advance by the FDA for a specified number of patients, unless the proposed study is deemed a non-significant risk study, which is eligible for an exemption from </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">the IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin if the IDE application is approved by the FDA and the appropriate institutional review boards or IRBs at the clinical trial sites. Submission of an IDE application does not give assurance that the FDA will issue the IDE. If the IDE application is approved, there can be no assurance the FDA will determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that may affect its scientific soundness, study indication or the rights, safety or welfare of human subjects. The trial must also comply with the FDA&#8217;s regulations, including the requirement that informed consent be obtained from each subject. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance to market the product in the United States.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In Vitro Diagnostic Companion Diagnostic Devices.<font style="font-style:normal;"> FDA has described IVD companion diagnostic devices as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic product. An IVD companion diagnostic device could be used to (i)&#160;identify patients who are most likely to benefit from a particular therapeutic product; (ii)&#160;identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product; or (iii)&#160;monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, dose, discontinuation) to achieve improved safety or effectiveness. Although FDA&#8217;s regulation of IVD companion diagnostic devices is evolving and implemented on a case-by-case basis, FDA&#8217;s stated policy for a novel therapeutic product is that an IVD companion diagnostic device should be developed and approved or cleared contemporaneously to support the therapeutic product&#8217;s safe and effective use. The clinical performance and clinical significance of the IVD companion diagnostic device is to be established using data from the clinical development program of the corresponding therapeutic product. FDA recognizes, however, that there may be cases where contemporaneous development may not be possible. With respect to the Gencaro Test, there is no assurance that we will be able to develop and obtain approval or clearance contemporaneously with Gencaro. Failure to develop the Gencaro Test or obtain clearance or approval could delay approval of Gencaro, if FDA regards the Gencaro Test as an IVD companion diagnostic test that is essential to the safe and effective use of Gencaro. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Continuing Regulation.<font style="font-style:normal;"> After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a PMA approval. Unless subject to an exemption, medical devices distributed in the United States must be manufactured in compliance with the FDA&#8217;s Quality System Regulations, or QSRs, and current good manufacturing practices. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing, as well as complaint handling, corrective and preventative actions and internal auditing. In complying with the QSRs, manufacturers must expend significant time, money and effort. Companies are also subject to other post-market and general requirements, including but not limited to product listing and establishment registration, post-market surveillance requirements, limitations on promotion, and requirements for recordkeeping and reporting of certain adverse events, malfunctions, corrections and removals. &nbsp;&nbsp;As discussed above, FDA regularly inspects companies to assess compliance with the QSRs and other post-market requirements.&nbsp;&nbsp;Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, and potential civil and criminal penalties.&nbsp;&nbsp;With respect to the Gencaro Test, we intend to seek a new or amended collaborative arrangement with a diagnostic company in which we could license them certain rights to perform the diagnostic test for patients with AF. As part of such arrangement, we will seek to have the diagnostic company take responsibility for compliance with the FDA&#8217;s device approval and on-going regulatory requirements. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">International Marketing Approvals.<font style="font-style:normal;"> International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Regulatory Requirements.<font style="font-style:normal;"> We are also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Medical Device Tax</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the U.S. Congress adopted and President Obama signed into law comprehensive health care reform legislation. Among other initiatives, these laws impose significant new taxes on medical device makers in the form of a 2.3% excise tax on U.S. medical device sales, with certain exemptions, beginning on January 1, 2013. The Gencaro Test is likely to be subject to this tax.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The future success of our business will partly depend on our ability to maintain market exclusivity for Gencaro in the United&#160;States and important international markets, and for other products or product candidates that we may acquire or develop. We will rely on statutory protection, patent protection, trade secrets, know-how, and in-licensing of technology rights to maintain protection for our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that both patent protection and data exclusivity statutes will give Gencaro market exclusivity in the United States and in major international markets. If approved by the FDA or international regulatory agencies, Gencaro will qualify as a New Chemical Entity, or NCE, as it has never received regulatory approval in any jurisdiction. As an NCE, Gencaro will enjoy market exclusivity in the United States and most international markets under data exclusivity statutes. These laws provide for an exclusivity period beginning from regulatory approval, during which any generic competitor is barred from submitting an application that relies on the data that has been submitted in connection with the approval of the NCE. In the United States, the Hatch-Waxman Act provides for an initial period of up to five years from approval of the NCE, during which a generic application attempting to rely on the data submitted for the NCE cannot be filed with the FDA. This period can be effectively extended to seven and one-half years from FDA approval because a provision of the Hatch-Waxman Act provides for an automatic 30-month extension of the exclusivity period if we promptly pursue litigation against a company attempting to enter the market with a generic for a drug that is covered by a composition of matter or method of use patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many international markets have data exclusivity statutes that are analogous to Hatch-Waxman and often more protective. The analogous statute in the European Medicines Evaluation Agency will, in general, provide Gencaro with a minimum of ten years of protection before such a generic application may be approved. Protection under Hatch-Waxman and other data exclusivity statutes is sometimes considered superior to patent protection, as the generic cannot be marketed during the period of exclusivity, thus eliminating the need to initiate patent infringement litigation with its accompanying risks and costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to protection under data exclusivity statutes, we believe that Gencaro&#8217;s patent portfolio will also provide market exclusivity. We have been granted patents in the United States and Europe that claim the use of Gencaro in patients predicted to have a favorable response to the drug based on genetic polymorphisms in the genes encoding the beta-1 and/or alpha-2C receptors. We believe that this patent strategy may deter generic competition because of the threat of patent litigation or may exclude generic competition from the market until the patents expire if we are successful in litigation. Consequently, if our patent strategy is successful, we believe we may avoid generic competition with Gencaro in the United States or certain countries in Europe until at least the expiration of these patents, which would be no earlier than 2026 in the United States and into 2025 in Europe. In addition, we believe that if Gencaro is approved, any one of our U.S. patents may be entitled to an extension of its term and the European patent may be entitled to an extension through a supplemental protection certificate in one or more countries in Europe. The length of any such extension may vary by country. We cannot predict whether any such extensions will be granted, but if they are, they may provide market exclusivity for Gencaro into approximately 2030 in the United States and Europe.&nbsp;&nbsp;In addition, we were granted a patent on the S-isomer formulation of Gencaro, which we believe could be important in Gencaro&#8217;s future development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have patent rights relating to rNAPc2, as well as other patent rights in additional pharmacogenetic drug candidates having possible indications in cardiovascular disease, oncology, and other therapeutic areas; these are in both early and later stages of development. We may seek collaborators to assist us in the development of these candidates or we may seek to raise funds to advance the development of the compounds on our own.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2014, we had 16 full-time employees.&nbsp;&nbsp;None of our employees are represented by any collective bargaining unit. We believe that we maintain good relations with our employees. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Corporate Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;27, 2009, we completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, and amended on October&#160;28, 2008 in which a wholly-owned subsidiary of Nuvelo, Inc. merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo, Inc. Immediately following the Merger, we changed our name from Nuvelo, Inc. to ARCA biopharma, Inc. Nuvelo was originally incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January&#160;31, 2003, Nuvelo merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March&#160;25, 2004, Nuvelo was reincorporated from Nevada to Delaware. On December 28, 2009, we merged ARCA Colorado with and into us via a short form merger pursuant to which we were the surviving corporation.&nbsp;&nbsp;On January&#160;27, 2009, in connection with the Merger with ARCA Colorado described above, Nuvelo changed its name to ARCA biopharma, Inc. Our principal offices are located in Westminster, Colorado. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4, 2013, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, to implement a six-for-one reverse split of our common stock, as previously authorized and approved at our special meeting of stockholders on February&#160;25, 2013. On March 5, 2013, our common stock began trading on The NASDAQ Capital Market on a post-split basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reverse split effected a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options and warrants to purchase shares of our common stock, and the number of shares reserved for issuance pursuant to our existing stock option plans were reduced proportionately. No fractional shares were issued as a result of the reverse split, and stockholders who otherwise would have been entitled to a fractional share received in lieu thereof, a cash payment based on the closing sale price of our common stock as reported on The NASDAQ Capital Market on March&#160;4, 2013. The reverse split did not alter the par value of our common stock or modify any voting rights or other terms of the common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 electronically with the SEC. The public may read or copy any materials that have been filed with the SEC at the SEC&#8217;s Public Reference Rooms at 100 F Street, N.E., Washington, D.C. 20549 on official business days during the hours of 10:00 a.m. and 3:00&#160;p.m. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports on our website at http://www.arcabiopharma.com on the earliest practicable date following the filing with the SEC or by contacting the Investor Relations Department at our corporate office by calling (720)&#160;940-2200. Information found on our website is not incorporated by reference into this report. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_1A_Risk_Factors"></a>Item&#160;1A.<font style="font-style:italic;"> Risk Factors </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">An investment in ARCA&#8217;s securities involves certain risks, including those set forth below and elsewhere in this report. In addition to the risks set forth below and elsewhere in this report, other risks and uncertainties not known to ARCA, that are beyond its control or that ARCA deems to be immaterial may also materially adversely affect ARCA&#8217;s business operations. You should carefully consider the risks described below as well as other information and data included in this report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business and Financial Condition </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our management and our independent registered public accountant, in their report on our financial statements as of and for the year ended December&#160;31, 2014, have concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, substantial doubt exists as to our ability to continue as a going concern. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audited financial statements for the fiscal year ended December&#160;31, 2014 were prepared assuming that we will continue as a going concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. Our management and our independent registered public accountants concluded as of December&#160;31, 2014 that due to our need for additional capital and the uncertainties surrounding our ability to raise such funding, substantial doubt exists as to our ability to continue as a going concern.&nbsp;&nbsp;We believe our cash and cash equivalents balance as of December&#160;31, 2014 will be sufficient to fund our operations, at our projected cost structure, through the end of 2015. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate.&nbsp;&nbsp;We will be required to raise additional funds prior to completion of the Phase 2B portion of GENETIC-AF.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings. However, we cannot guarantee that will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on terms satisfactory to us. If we are unable to raise sufficient additional capital or complete a strategic transaction, we may be unable to continue to fund our operations, develop Gencaro or our other product candidates, or realize value from our assets and discharge our liabilities in the normal course of business. If we cannot raise sufficient funds, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our clinical trials, our trials could be delayed or otherwise adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GENETIC-AF clinical trial requires that we identify and enroll a large number of patients with the condition under investigation and the trial will enroll only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AF burden data. Because of the rigorous enrollment criteria, we may not be able to enroll a sufficient number of patients to complete our clinical trial in a timely manner. To date, we have enrolled fewer patients in the trial than we had originally projected to enroll at this point.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is affected by factors including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">design of the protocol or amendments made to the protocol; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the size of the patient population; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eligibility criteria for the study in question; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perceived risks and benefits of the drug under study; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">availability of competing therapies, including the off-label use of therapies approved for related indications; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts to facilitate timely enrollment in clinical trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the success of our personnel in making the arrangements with potential clinical trial sites necessary for those sites to begin enrolling patients; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient referral practices of physicians; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">availability of clinical trial sites;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of clinical trial sites outside the United States and regulatory compliance within other countries;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other clinical trials seeking to enroll subjects with similar profiles;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number of patients having the specific genotype needed for our trial; and</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number of patients having, or willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we continue to have difficulty enrolling a sufficient number of patients in our GENETIC-AF trial, we may need to delay or terminate our GENETIC-AF trial, which would have a negative impact on our business. Our projected clinical trial timeline assumes that we significantly increase the rate of patient enrollment from the current rate.&nbsp;&nbsp;If our projections are inaccurate, the trial will take significantly longer than we project.&nbsp;&nbsp;For instance, in the second quarter of 2014, and in the first quarter of 2015, we have made material modifications to certain entry criteria and policies for the GENETIC-AF trial that we believe may increase the rate of patient screening and enrollment.&nbsp;&nbsp;We do not yet know how these protocol changes will impact the enrollment rate or if our new enrollment projections will prove to be accurate. Delays in enrolling patients in our clinical trials would also adversely affect our ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on us or on any future collaborators. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to raise substantial additional funds through public or private equity transactions and/or complete one or more strategic transactions, to continue development of Gencaro. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the expected development timeline to potentially obtain FDA approval for Gencaro, if at all, the substantial additional costs associated with the development of Gencaro, including the costs associated with the GENETIC-AF clinical trial, and the substantial cost of commercializing Gencaro, if it is approved, we will need to raise substantial additional funding through public or private equity transactions or a strategic combination or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may discontinue our development activities on Gencaro or discontinue our operations. Even if we are able to fund continued development and Gencaro is approved, we expect that we will need to complete a strategic transaction or raise substantial additional funding through public or private debt or equity securities to successfully commercialize Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our cash and cash equivalents balance as of December&#160;31, 2014 will be sufficient to fund our operations, at our projected cost structure, through the end of 2015. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our liquidity, and our ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> progress of GENETIC-AF, including enrollment and any data that may become available; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for Gencaro;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to retain the listing of our common stock on the Nasdaq Capital Market; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general economic and industry conditions affecting the availability and cost of capital; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to control costs associated with our operations; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms and conditions of our existing collaborative and licensing agreements. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to our stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to us, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational activities to conserve our cash resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro in a timely manner, we may not be able to continue our business operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. We are screening and enrolling patients in our Phase 2B clinical study of Gencaro in 200 HFREF patients with AF, and the trial could expand to a Phase 3 clinical study of approximately 420 HFREF additional patients with AF.&#160;&#160;We began screening patients for the Phase 2B portion of GENETIC-AF in April 2014 and enrolled our first patient in June 2014.&#160;&#160; We implemented amendments to the trial protocol in March 2015 which we believe may expand the eligible target population, increase the patient screening and enrollment rate, and simplify trial procedures.&nbsp;&nbsp;We do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate.&#160;&#160;The complex nature of the disease indication and the genotype required for the trial result in stringent enrollment criteria, which may cause GENETIC-AF to enroll more slowly and take longer than we currently project.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to demonstrate that a product candidate, including Gencaro, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect our business. Failure to obtain marketing approval of Gencaro from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect our business and could, among other things, preclude us from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. We do not currently have the capital resources or management expertise to commercialize Gencaro and, as a result, will need to complete a strategic transaction, or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, if it is approved. Failure to successfully provide for the commercialization of Gencaro, if it is approved, would damage our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our clinical trials for our product candidates may not yield results that will enable us to further develop our products and obtain the regulatory approvals necessary to sell them. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will receive regulatory approval for our product candidates only if we can demonstrate in carefully designed and conducted clinical trials that the product candidate is safe and effective. We do not know whether any current or future clinical trials, including the GENETIC-AF clinical trial for Gencaro, will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, GENETIC-AF is designed as an adaptive trial. The DSMB will analyze certain trial data from the Phase 2B portion and recommend whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.&nbsp;&nbsp;The DSMB interim analysis will focus on data regarding the trial&#8217;s primary end point, AF/AFL event rates, AF burden, and safety.&#160; Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and that the data indicates potential for achieving statistical significance for the Phase 3 endpoint, then the DSMB may recommend that the study proceed to Phase 3.&#160; The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&#8217;s Steering Committee and the DSMB, will make the final determination on the trial&#8217;s next development steps. If we do not see sufficient efficacy and safety in the Phase 2B portion of the trial, we will not initiate the Phase 3 portion of the trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are lengthy, complex and expensive processes with uncertain results. We have spent, and expect to continue to spend, significant amounts of time and money in the clinical development of our product candidates. We have never conducted a Phase 2 or Phase 3 clinical trial and have limited staff with the requisite experience to do so. We therefore rely on contract research organizations, or CROs, to conduct certain aspects of our clinical trial. During the third quarter of 2014 we reduced the scope of our primary CRO&#8217;s work and we have assumed those responsibilities for our GENETIC-AF clinical trial. While certain of our employees have experience in designing and administering clinical trials, these employees have no such experience as employees of ARCA.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results we obtain in preclinical testing and early clinical trials may not be predictive of results that are obtained in later studies. We may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates. If we fail to adequately demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals to commercialize our product candidates, and our business, results of operations and financial condition would be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administering our product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying approval of our product candidates for any or all targeted indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If clinical trials for a product candidate are unsuccessful, we will be unable to commercialize the product candidate. If one or more of our clinical trials are delayed, we will be unable to meet our anticipated development timelines. Either circumstance could cause the market price of our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are relying on contract research organizations to conduct substantial portions of our GENETIC&#8211;AF clinical trial, and as a result, we will be unable to directly control the timing, conduct and expense of all aspects of the clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have sufficient staff with the requisite experience to conduct our clinical trial and are therefore relying on third parties to conduct certain aspects of our clinical trial. We have contracted with Duke University, as our CRO to conduct&nbsp;&nbsp;components of our GENETIC-AF trial. As a result of this contract, we have less control over many details and steps of the trial, the timing and completion of the trial, the required reporting of adverse events and the management of data developed through the trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trial. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay ongoing trials, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we are using a CRO to conduct components of our clinical trial, we have to devote substantial resources and rely on the expertise of our employees to manage the work being done by the CRO. We have never conducted a clinical trial and the inability of our current staff to adequately manage any CRO that we engage may exacerbate the risks associated with relying on a CRO. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not achieve our projected development goals in the time frames we announce and expect. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as, the commencement and completion of clinical trials, particularly with respect to steps for commencing and continuing GENETIC-AF, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug product, which we sometimes refer to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale-up and delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products. FDA approval of Gencaro, if it occurs, is expected to require years of additional clinical development, including the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completion of genetic trials. There can be no assurance that our GENETIC-AF trial will fully enroll or be completed, or that we will make regulatory submissions or receive regulatory approvals as planned. If we fail to achieve one or more of these milestones as planned, our business will be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market we are required to meet certain listing requirements, including, among others, (i) a minimum closing bid price of $1.00 per share, (ii) a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and (iii) either: (x)&#160; stockholders&#8217; equity of at least $2.5 million; or (y)&#160; a total market value of listed securities of at least $35 million. </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2012 our stock price fell below the Nasdaq Capital Market&#8217;s minimum bid price requirements and we became subject to delisting from the exchange. On March&#160;4, 2013 we executed a 1 for 6 reverse split of our common stock and have subsequently regained compliance with the minimum bid price requirements. On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&nbsp;&nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.&nbsp;&nbsp;If our stock does not trade above these levels, we may seek to execute a reverse split of our common stock in 2015 in order to regain compliance.&nbsp;&nbsp;The delisting of our common stock from a national exchange could impair the liquidity and market price of the common stock.&nbsp;&nbsp;It could also materially, adversely affect our access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect our ability to raise capital on terms acceptable to us, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In future periods, if we do not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, we would be subject to delisting from the Nasdaq Capital Market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 17, 2015, the closing price of our common stock was $0.77&#160;per share, and the total market value of our listed securities was approximately $16.3&#160;million. As of December 31, 2014, we had stockholders&#8217; equity of $14.7 million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful, we may not be able to complete the development of these product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have a collaboration agreement with Medtronic, Inc., or Medtronic, for the support of our GENETIC-AF trial. Medtronic can terminate its collaboration with us for various reasons including uncured material breach of the collaboration by us, an ARCA bankruptcy, if, after FDA communication, it is reasonably concluded that the FDA will not allow GENETIC-AF to enroll or proceed, or if Medtronic&#8217;s obligations under the collaboration agreement are unilaterally expanded. We may seek additional third party collaborators for the development of Gencaro or other product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our current arrangement with Medtronic, as amended, we have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties. Our ability to benefit from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our product candidates pose the following risks to us: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may elect to take over manufacturing rather than retain us as manufacturers and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may be required to issue equity securities to collaborators that would dilute our existing stockholders&#8217; percentage ownership; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may be required to assume substantial actual or contingent liabilities; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators may experience financial difficulties. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of our clinical trials, the potential market for our product candidates, the costs and complexities of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine that additional collaborations for our Gencaro development is necessary and were unable to enter into such collaborations on acceptable terms, we might elect to delay or scale back the development or commercialization of Gencaro in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our GENETIC-AF clinical trial requires the use of a third-party diagnostic services provider to administer the genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, we will be unable to directly control the timing, conduct and expense of the genetic test. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our GENETIC-AF clinical trial of Gencaro requires a companion diagnostic test that identifies the patient&#8217;s receptor genotype.&nbsp;&nbsp;The trial will only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta-1 389 Arg receptor as detected by a beta-1 389 Arg/Arg genotype. Accordingly, the GENETIC-AF trial requires the use of a third-party diagnostic service to perform the genetic testing. There has been limited experience in our industry in prospective development of companion diagnostics required to perform the required molecular profiling. We entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support our GENETIC-AF trial. To provide those services, LabCorp obtained from the FDA an Investigational Device Exemption, or IDE, for the companion diagnostic test being used in our GENETIC-AF clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and similar regulatory authorities outside the United States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization.&#160;Changes to regulatory advice could delay our development programs or delay or prevent eventual marketing approval for our product candidates that may otherwise be approvable. In July 2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <font style="font-style:italic;">in vitro</font> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<font style="font-style:italic;">in vitro</font> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices.&nbsp;&nbsp; It is difficult to predict how FDA will implement the guidance. For example, the guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion will be applied by the agency. The FDA&#8217;s evolving position on the topic of companion diagnostics could affect our clinical development programs that utilize companion diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make us repeat aspects of a trial or initiate new trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given our limited experience in developing diagnostics, we expect to rely primarily on third parties for the design and manufacture of the companion diagnostics for our product candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our product candidates that require such diagnostics, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not receive marketing approval and we may not realize the full commercial potential of any products that receive marketing approval. As a result, our business could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug label we intend to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, we believe developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro and also to the ability to conduct our GENETIC-AF clinical trial. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third-party diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regulatory approval is required for the genetic test to be used in the GENETIC-AF trial and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect our business, operating results and prospects. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third-party diagnostics provider must obtain FDA Premarket Approval, or PMA, for such test. The FDA may require additional validation of the genetic test we are using in GENETIC-AF prior to any approval of Gencaro or the genetic test. We anticipate the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect our business, operating results and prospects for commercializing the genetic test.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If a third-party diagnostics provider responsible for the genetic test or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any diagnostic for which a third-party diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third-party diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System Regulation, or QSR, and International Standards Organization, or ISO, requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third-party diagnostics provider, or certain of its third-party manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm our reputation and cause product sales and profitability of Gencaro to suffer and may prevent us from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for our GENETIC-AF trial. We believe that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although we anticipate that Gencaro, if approved in a timely manner, would be the first genetically-targeted cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta-blocker class currently on the market. Prescribers may be more familiar with these other beta-blockers, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our failure to raise substantial additional funding or enter into a strategic transaction may materially and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we are able to raise substantial additional funding for the development of Gencaro through other means, we will need to complete a strategic transaction to continue the development of Gencaro through the clinical development and commercialization phases, and to continue our other operations.&nbsp;&nbsp;The strategic transactions that we may consider include a potential combination or partnership. Our board of directors and management team have and will continue to devote substantial time and resources to obtaining additional capital or the consideration and implementation of any such strategic transaction. In addition, conditions in the financial markets may lead to an increased number of biotechnology companies that are also seeking to enter into strategic transactions, which may limit our ability to negotiate favorable terms for any such transaction. Further, our current employees do not have experience in the strategic transaction process, and our previous efforts to enter into a strategic transaction have not been successful. As a result of these and other factors, there is substantial risk that we may not be able to complete a strategic transaction on favorable terms, or at all. The failure to complete such a strategic transaction may materially and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be limited in our ability to access sufficient funding through a private equity or convertible debt offering. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq rules impose restrictions on our ability to raise funds through a private offering of our common stock, convertible debt or similar instruments without obtaining stockholder approval. Under Nasdaq rules, an offering of more than 20% of our total shares outstanding for less than the greater of book or market value requires stockholder approval unless the offering qualifies as a &#8220;public&#160;offering&#8221; for purposes of the Nasdaq rules. As of February 27, 2015 we had approximately 21.2&#160;million shares of common stock outstanding, 20% of which is approximately 4.2&#160;million shares. To the extent we seek to raise funds through a private offering of stock, convertible debt or similar instruments, we are limited in how much funding we could raise privately without requiring a stockholder vote.&nbsp;&nbsp;SEC rules impose restrictions on our ability to raise funds through the registered offering of our securities pursuant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our &#8220;shelf&#8221; registration statement on Form S-3. Under SEC rules, we are prohibited from selling securities under such registration statement if the aggregate market value of the securities sold thereunder in any twelve-month period exceeds one-third of the market value of our outstanding common stock held by non-affiliates. In addition, we are currently subject to certain contractual rights of investors arising from our public and private equity financing transactions that limit the nature and price of future public and private financing transactions that we may effect. For example, in January 2013, we entered into separate subscription agreements with certain institutional investors in connection with a private investment in public equity, pursuant to which we sold shares of our common stock and warrants to purchase shares of our common stock to the investors. In connection with this transaction, we agreed that, subject to certain exceptions, we would not, while the warrants issued in such financing are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#8220;variable rate transaction,&#8221; which means a transaction in which we issue or sell any convertible securities either (A)&#160;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)&#160;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. The restrictions imposed by the terms of our previous offerings, and that could be imposed in future offerings, may limit our access to capital on agreeable terms and delay or make impossible certain otherwise available equity financing opportunities and could severely restrict our access to the capital necessary to conduct our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unless we are able to generate sufficient product revenue, we will continue to incur losses from operations and will not achieve or maintain profitability. We are years away from commercializing a product and generating product revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our historical losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital, among other things. We are years away from commercializing a product and generating any product revenue. As a result, we expect to continue to incur significant operating losses for the foreseeable future. Even if we ultimately receive regulatory approval for Gencaro or our other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, we may experience larger than expected future losses and may never reach profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of our product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA for such drug. We have not received an NDA approval from the FDA for Gencaro or any of our other product candidates. There can be no guarantees with respect to our product candidates that clinical studies will adequately support a NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To receive regulatory approval for the commercial sale of any product candidates, we must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well-controlled clinical trials of the product candidates. This process is expensive and can take many years, and failure can occur at any stage of the testing. Our failure to adequately demonstrate the safety and efficacy of our product candidates will prevent regulatory approval and commercialization of such products. In 2008, we submitted and the FDA accepted our NDA filing for Gencaro for the treatment of chronic HF. In 2009, the FDA issued a Complete Response Letter, or CRL, in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase 3 clinical trial of Gencaro in patients with HF. We have initiated a clinical study of Gencaro in HFREF patients to assess its efficacy in reducing or preventing AF. This trial has been initiated as a Phase 2B study in approximately 200 patients and, depending on the outcome of the Phase 2B portion, may be expanded to a Phase 3 study with up to an estimated additional 420 patients. We believe the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017. This product candidate will require years of clinical development. Even if we conduct additional studies in accordance with further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that we or our collaborators conduct preclinical studies that do not comply with Good Laboratory Practices or GLP or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices, or GCP, or those clinical trials fail to demonstrate clinical significance, it is unlikely that we will be able to obtain FDA approval for product development candidates. Our inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm our business. Significant delays in clinical development could materially increase product development costs or allow our competitors to bring products to market before we do, impairing our ability to effectively commercialize any future product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in reaching agreement on acceptable terms with prospective study sites; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining approval of our clinical trial protocol from an IRB to conduct a clinical trial at a prospective study site; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other clinical trials seeking to enroll subjects with similar profile; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of our clinical trials and clinical investigators to be in compliance with the FDA&#8217;s Good Clinical Practices; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unforeseen safety issues, including negative results from ongoing preclinical studies; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inability to monitor patients adequately during or after treatment; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficulty recruiting and monitoring multiple study sites;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100.26%;">
<tr style="height:7.2pt;">
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of our third-party contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any approvals we may obtain may not cover all of the clinical indications for which we seek approval or permit us to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, we may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on our commitment to conduct further clinical trials, which we may not have the resources to conduct or which may negatively impact our financial situation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture and tableting of Gencaro is done by third party suppliers, who must also meet current Good Manufacturing Practices, or cGMP, requirements and pass a pre-approval inspection of their facilities before we can obtain marketing approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">side effects; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety and efficacy; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defects in the design of clinical trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fact that the FDA or other regulatory officials may not approve our or our third party manufacturer&#8217;s processes or facilities; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In pursuing clinical development of Gencaro for an AF indication, we will be required to amend the Gencaro HF NDA or prepare a new NDA. The FDA could approve Gencaro, but without including some or all of the prescribing information that we have requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact our ability to successfully commercialize Gencaro and effectively protect our intellectual property rights in Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our product candidates receive regulatory approval, we would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit our ability to develop and commercialize other potential products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product candidate of ours is approved by the FDA or by another regulatory authority, we would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our third-party manufacturers and the manufacturing facilities that they use to make our product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our third-party manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post-market information. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketing and advertising of our drug products by our collaborators or us will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of our products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S. Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize our ability to market the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the FDA, state or foreign regulations, the marketing of our drug products by us or our collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far-reaching nature of these laws, we may be required to discontinue one or more of our practices to be in compliance with these laws. Health care fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against us for violations of these laws, even if we successfully defend against it, could have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. We may become subject to such litigation and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial condition and results of operations. We could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of our product candidates or limit our ability to commercialize our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, our collaborators or our third-party manufacturers fail to comply with applicable continuing regulatory requirements, our business could be seriously harmed because a regulatory agency may: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue untitled or warning letters; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspend or withdraw our regulatory approval for approved products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refuse to approve pending applications or supplements to approved applications filed by us; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspend our ongoing clinical trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict our operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of our products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek an injunction; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue criminal prosecutions; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">close the facilities of our contract manufacturers; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impose civil or criminal penalties. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reliance on third parties to commercialize Gencaro could negatively impact our business. If we are required to establish a direct sales force in the United States and are unable to do so, our business may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization of Gencaro, particularly the establishment of a sales organization, will require substantial additional capital resources. We currently intend to pursue a strategic partnership alternative for the commercialization of Gencaro, if it is approved, and we have suspended our efforts to build internal sales, marketing and distribution capabilities. If we elect to rely on third parties to sell Gencaro and any other products, then we may receive less revenue than if we sold such products directly. In addition, we may have little or no control over the sales efforts of those third parties.&nbsp;&nbsp;If we are unable to complete a strategic transaction, we would be unable to commercialize Gencaro or any other product candidate without substantial additional capital. Even if such capital were secured, we would be required to build internal sales, marketing and distribution capabilities to market Gencaro in the United States. None of our current employees have experience in establishing and managing a sales force. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we are unable to sell Gencaro and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro, if it is approved, may be delayed indefinitely. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are dependent on our key personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business is highly dependent on the principal members of our board of directors and executive management, including our President and Chief Executive Officer, Michael R. Bristow. The loss of the services of any such individual might seriously harm our product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and we compete for talent with companies that are larger and have more financial resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently operate manufacturing facilities for clinical or commercial production of our product candidates, including their active pharmaceutical ingredients, or API. We have no experience in drug formulation or manufacturing, and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We do not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. We have contracted with Groupe Novasep to manufacture commercial quantities of the API for Gencaro. For drug production, we have contracted with Patheon, Inc. to manufacture the Gencaro tablets. In addition, we have contracted with a separate service provider for packaging and distribution of our clinical trial materials.&nbsp;&nbsp;These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. In addition, these manufacturers may have staffing difficulties, may not be able to manufacture our products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock-outs or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, we may be unable to find an alternative third-party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional costs, which could impact our ability to commercialize and sell our product candidates. We or our contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt our business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, our contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S. Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If our contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, we may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize our regulatory approval for Gencaro and other product candidates, and we may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number of potential manufacturers is limited and we may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long lead times are often needed to manufacture drugs; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the manufacturing process is complex and may require a significant learning curve; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of our control and, consequently, we can provide no assurance of our successful and timely transition from a clinical development stage company. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical development stage biopharmaceutical company with a limited operating history. To date we have not generated any product revenue and have historically funded our operations through investment capital. Our future growth depends on our ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of Gencaro and our other product candidates which in turn, will depend, among other things, on our ability to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct an additional clinical trial and develop and obtain regulatory approval for Gencaro or other product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully partner a companion genetic test with the commercial launch of Gencaro; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enter into a strategic transaction enabling the continued development and commercialization of Gencaro, or alternatively, raise significant additional capital to enable these activities; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue additional indications for Gencaro and develop other product candidates, including other cardiovascular therapies; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain commercial quantities of Gencaro or other product candidates at acceptable cost levels. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any one of these factors or other factors discussed in this report could affect our ability to successfully commercialize Gencaro and other product candidates, which could impact our ability to earn sufficient revenues to transition from a clinical development stage company and continue our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If approved by the FDA, Gencaro will be entering a competitive marketplace and may not succeed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro is a new type of beta-blocker and vasodilator being developed for AF. While we anticipate that this drug, if approved, would be the first genetically-targeted cardiovascular drug, and potentially the only beta-blocker approved for AF, Gencaro will be one of a number of accepted treatments for AF. In addition, our proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that we believe responds most favorably to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of our common stock and the value of our assets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales of our products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro or our other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro or our other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. Also, prevalence and severity of side-effects could negatively affect market acceptance of Gencaro or our other product candidates. Failure to achieve market acceptance of Gencaro would significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain acceptable prices or adequate reimbursement from third-party payors for Gencaro, or any other product candidates that we may seek to commercialize, then our revenues and prospects for profitability will suffer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or any strategic partner&#8217;s ability to commercialize Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental payors, such as Medicare and Medicaid; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private health insurers, including managed-care organizations; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other third-party payors. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many patients will not be capable of paying for our potential products themselves and will rely on third-party payors to pay for their medical needs. A primary current trend in the U.S. health care industry is toward cost containment. Large private payors, managed-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly approved health care products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues lower than anticipated. If the prices for our product candidates decrease, or if governmental and other third-party payors do not provide adequate coverage and reimbursement levels, then our revenue and prospects for profitability will suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Health care reform measures could materially and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health-related industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on our business. We or any strategic partner&#8217;s ability to commercialize Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third-party payors, and any change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to obtain strategic partnerships or licenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our competitors may be better positioned in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing approved products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than us. Other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to our programs or advantageous to our business. We expect that our ability to compete effectively will depend upon our ability to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost-effective manner; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of our products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop competitive formulations of our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attract and retain key personnel; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identify and obtain other product candidates on commercially reasonable terms. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to identify and license or acquire other products or product candidates, then we may be unable to expand our business, and the acquisition or licensing of other products or product candidates may put a strain on our operations and will likely require us to seek additional financing. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our strategies is to license or acquire clinical-stage products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of our competitors may have greater resources than we do. If we undertake any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into our business may put a strain on our operations, divert personnel, financial resources and management&#8217;s attention. In 2015, we expect our research and development activities will be dedicated to Gencaro. If we are not able to substantially expand our research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then we will likely be unable expand our pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require us to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating results. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We would be subject to applicable regulatory approval requirements of the foreign countries in which we market our products, which are costly and may prevent or delay us from marketing our products in those countries. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulatory requirements in the United States, we would be subject to the regulatory approval requirements in each foreign country where we market our products. In addition, we might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture our products and any companion genetic test for Gencaro. If we decide to pursue regulatory approvals and commercialization of our product candidates internationally, we may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our internal control over financial reporting is not considered effective, our business and stock price could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal control over financial reporting in our annual report on Form 10-K for that fiscal year. Our management, including our chief executive officer and principal financial officer, does not expect that our internal control over financial reporting will prevent all error and all fraud.&nbsp;&nbsp;We continue to operate with a small staff for financial reporting. Though the process and design of our internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit our ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in our internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the&#160;likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal control over financial reporting in the future. A material weakness in our internal control over financial reporting would require management to consider our internal control over financial reporting as ineffective. If our internal control over financial reporting is not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property and Other Legal Matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If product liability lawsuits are successfully brought against us, then we will incur substantial liabilities and may be required to limit commercialization of Gencaro or other product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face product liability exposure related to the testing of our product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once we begin marketing and distributing our products commercially. If we cannot successfully defend against product liability claims, then we will incur substantial liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or eventual outcome, liability claims may result in: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreased demand for our products and product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">injury to our reputation; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">withdrawal of clinical trial participants; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs of related litigation; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantial monetary awards to patients and others; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss of revenues; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the inability to commercialize our products and product candidates. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient amounts or at an acceptable cost, or at all. We may not be able to obtain commercially reasonable product liability insurance for any product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued or be required to pay fines for any injury or contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The loss of any rights to market key products would significantly impair our operating results. </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed from CPEC, who has licensed rights in Gencaro from Bristol Meyers Squibb (BMS), the exclusive rights to Gencaro for all therapeutic and diagnostic uses in any country until the later of (i)&#160;10&#160;years from the first commercial sale of Gencaro in such country, or (ii)&#160;the termination of our commercial exclusivity in such country. This license includes a sublicense to us from BMS. We are obligated to use commercially reasonable efforts to develop and commercialize Gencaro, including obtaining regulatory approvals. Our ability to develop and commercialize Gencaro is dependent on numerous factors, including some factors that are outside of our control. CPEC has the right to terminate our license if we materially breach our obligations under the license agreement and we fail to cure any such breach within the terms of the license. If our license agreement with CPEC is terminated for reasons related to non-payment of fees, or for any other breach, then we would have no further rights to develop and commercialize Gencaro for any indication. The termination of this license, or of any other agreement which enables us to market a key product or product candidate, could significantly and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain intellectual property licensed by us is the subject of additional licensing arrangements to which the party that has licensed rights to us is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, our and our partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and our business would be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may own or control patents or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation that would be costly and time consuming. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or any strategic partner&#8217;s ability to commercialize Gencaro and other product candidates depends upon our ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to us. We may choose to seek, or be required to seek, licenses under third party patents, which would likely require the payment of license fees or royalties or both. We may also be unaware of existing patents that may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringed by Gencaro, the genetic testing we intend to use in connection with Gencaro or our other product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro or our other product candidates. Moreover, a license may not be available to us on commercially reasonable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we are infringing on its technology, then our business and results of operations could be harmed by a number of factors, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement and other intellectual property claims, even if without merit, are expensive and time-consuming to litigate and can divert management&#8217;s attention from our core business; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monetary damage awards for past infringement can be substantial; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a court may prohibit us from selling or licensing product candidates unless the patent holder chooses to license the patent to us; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if a license is available from a patent holder, we may have to pay substantial royalties. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be forced to bring an infringement action if we believe that a competitor is infringing our protected intellectual property. Any such litigation will be costly, time-consuming and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our intellectual property rights may not preclude competitors from developing competing products and our business may suffer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitive success will depend, in part, on our ability to obtain and maintain patent protection for our inventions, technologies and discoveries, including intellectual property that we license. The patent positions of biotechnology companies involve complex legal and factual questions, and we cannot be certain that our patents and licenses will successfully preclude others from using our technology. Consequently, we cannot be certain that any of our patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention or in opposition proceedings in a foreign patent office, any of which could result in substantial cost to us, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology. Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. We may have to defend against such claims and possible associated antitrust issues. We could also incur substantial costs in seeking to enforce our proprietary rights against infringement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the composition of matter patents on the compound that comprises Gencaro have expired, we hold the intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta-1 and alpha-2C receptors. We have obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. Our NDA requested a label that will include a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. We believe that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and our business may suffer. The approved label may not contain language covered by the patents, or we may be unsuccessful in enforcing them. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to effectively protect our intellectual property rights in some foreign countries, as our patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We require our employees, consultants, business partners and members of our scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for us, utilizing the property or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may breach these and other agreements with us regarding our intellectual property and we may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect our licensed intellectual property, which could seriously harm our intellectual property position. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to protect our proprietary technology, trade secrets and know-how, then our competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with us. Further, we have trade secrets relating to Gencaro, and such trade secrets may become known or independently discovered. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of our product candidates. All of these factors may affect our competitive position. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the manufacture, use or sale of our products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial damages or licensing fees and limit our ability to sell some or all of our products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination) in the United States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or outcome, our involvement in any litigation, interference or other administrative proceedings could cause us to incur substantial expense and could significantly divert the efforts of our technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our stock price to decline. Adverse outcomes in patent litigation may potentially subject us to antitrust litigation which, regardless of the outcome, would adversely affect our business. An adverse determination may subject us to the loss of our proprietary position or to significant liabilities, or require us to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent us from manufacturing and selling our products, if any. These outcomes could materially harm our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Stock Price Volatility </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our stock price is expected to be volatile. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory status of Gencaro and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progress of GENETIC-AF and enrollment and any data that may become available;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of our future clinical trials and any future NDAs of our current and future product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the entry into, or termination of, key agreements, including key strategic alliance agreements; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results and timing of regulatory reviews relating to our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of any of our product candidates, if approved, to achieve commercial success; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general and industry-specific economic conditions that may affect our research and development expenditures; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of clinical trials conducted by others on drugs that would compete with our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issues in manufacturing our product candidates or any approved products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the initiation of or material developments in or the conclusion of litigation to enforce or defend any of our intellectual property rights; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the loss of key employees; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the introduction of technological innovations or new commercial products by our competitors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes in estimates or recommendations by securities analysts, if any, who cover our common stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future sales of our common stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes in the structure of health care payment systems; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period-to-period fluctuations in our financial results; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to retain the listing of our common stock on the Nasdaq Capital Market. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales or the possibility of future sales of our common stock may depress the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales in the public market of substantial amounts of our common stock could depress prevailing market prices of our common stock. As of December&#160;31, 2014, approximately 21.2&#160;million shares of common stock were outstanding.&nbsp;&nbsp;All of these shares are freely transferable without restriction or further registration under the Securities Act, except for shares held by our directors, officers and other affiliates and unregistered shares held by non-affiliates. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2014 approximately 9.4&#160;million shares of our common stock were issuable upon the exercise of outstanding warrants. Once a warrant is exercised, if the shares of our common stock issued upon the exercise of any such warrant are not available for sale in the open market without further registration under the Securities Act, then the holder can arrange for the resale of shares either by invoking any applicable registration rights, causing the shares to be registered under the Securities Act and thus freely transferable, or by relying on an exemption to the Securities Act. If these registration rights, or similar registration rights that may apply to securities we may issue in the future, are exercised, it could result in additional sales of our common stock in the market, which may have an adverse effect on our stock price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2014, there were approximately 1.5&#160;million shares of our common stock which may be issued upon the exercise of outstanding stock options and the vesting of restricted stock units, and we anticipate that we will continue to issue stock option and restricted stock unit awards to our employees and consultants in the fiscal year ended December 31, 2015 and thereafter. If and when these options are exercised and these restricted stock units are vested, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options and restricted stock units may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options and vesting of the restricted stock units, and the prompt resale of shares of our common stock received, may also result in downward pressure on the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the absence of a significant strategic transaction, we will need to raise significant additional capital to finance the research, development and commercialization of Gencaro. If future securities offerings occur, they would dilute our current stockholders&#8217; equity interests and could reduce the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish a classified board of directors so that not all members of our board may be elected at one time; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit who may call a special meeting of stockholders; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our certificate of incorporation provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The bylaws provide, however, that our stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of our outstanding common stock. These provisions of our certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. We designed these provisions to reduce our vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for our shares. As a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are permitted to issue shares of our preferred stock without stockholder approval upon such terms as our board of directors determines. Therefore, the rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of our preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of our current stockholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of our governing documents and current Delaware law may, collectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lengthen the time required for a person or entity to acquire control of us through a proxy contest for the election of a majority of our board of directors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discourage bids for our common stock at a premium over market price; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally deter efforts to obtain control of us. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_1B_Unresolved_Staff_Comments"></a>Item&#160;1B.<font style="font-style:italic;"> Unresolved Staff Comments</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_2_Properties"></a>Item&#160;2.<font style="font-style:italic;"> Properties</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters facility consists of approximately 5,300 square feet of office space in Westminster, Colorado, which is leased until September 2016. We believe that this facility is adequate to meet our current needs. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_3_Legal_Proceedings"></a>Item&#160;3.&#160;<font style="font-style:italic;">Legal Proceedings</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_4_Mine_Safety_Disclosures"></a>Item&#160;4.&#160;<font style="font-style:italic;">Mine Safety Disclosures</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART II </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_5_Market_for_Registrant"></a>Item&#160;5. <font style="font-style:italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;7, 2011, our common stock began trading on the Nasdaq Capital Market under the symbol &#8220;ABIO&#8221;, and was previously traded under the same symbol on the Nasdaq Global Market. Prior to completion of the merger with Nuvelo, Nuvelo&#8217;s common stock traded under the symbol &#8220;NUVO&#8221; on the Nasdaq Global Market from January&#160;31, 2003 to January&#160;27, 2009 (except for the period between June&#160;19, 2003 and March&#160;19, 2004, where it temporarily traded under the symbol &#8220;NUVOD&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth, for the periods indicated, the high and low sales prices for our common stock, as reported by the Nasdaq Capital Market in 2014 and 2013 (adjusted for the one-for-six reverse stock split effective March&#160;4, 2013): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2014</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">High</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Low</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second quarter</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.00</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth quarter</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.70</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2013</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">High</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Low</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second quarter</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.58</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth quarter</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholders </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;17, 2015, we had approximately 91 stockholders of record of our common stock, and the last sale price reported on the Nasdaq Capital Market for our common stock was $0.77 per share. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividend Policy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to dividends in such amounts and at such times, if any, as may be declared by our Board of Directors out of legally available funds. We have not paid any dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information relating to our equity compensation plans as of December&#160;31, 2014, under which our equity securities were authorized for issuance, is included in Item&#160;12 of Part III of this Annual Report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities and Use of Proceeds </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_6_Selected_Financial_Data"></a>Item&#160;6. <font style="font-style:italic;">Selected Financial Data </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_7_Management"></a>Item&#160;7. <font style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have included or incorporated by reference into this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Annual Report on Form 10-K, and from time to time our management may make, statements that constitute &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Forward-looking statements may be identified by words including &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;potential&#8221; and similar expressions. These statements involve known and unknown risks, uncertainties and other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our website. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. Our lead product candidate, Gencaro&#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that we are evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular systolic dysfunction, or HFREF. We have identified common genetic variations in receptors in the cardiovascular system that we believe interact with Gencaro&#8217;s pharmacology and may predict patient response to the drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. We are pursuing this indication for Gencaro because data from the previously conducted Phase 3 HF trial of Gencaro in 2,708 heart failure, or HF, patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AF is a disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENETIC-AF is a Phase 2B/3 multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to an active comparator, the beta-blocker Toprol XL (metoprolol succinate), in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF who have a beta-1 389 arginine homozygous genotype, the genotype we believe responds most favorably to Gencaro.&nbsp;&nbsp; The primary endpoint of GENETIC-AF, time to recurrent symptomatic AF/atrial flutter, or AFL, or all-cause mortality, will be measured over a twenty-four week period after a patient has established a normal heart rhythm. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe data from the BEST trial indicate that Gencaro may have a genetically regulated effect in reducing or preventing AF, whereas we believe the therapeutic benefit of Toprol XL does not appear to be enhanced in patients with this genotype. A retrospective analysis of data from the BEST trial shows that the entire cohort of patients in the BEST trial treated with Gencaro had a 41% reduction in the risk of new onset AF (time-to-event) compared to placebo (p = 0.0004).  In the BEST DNA substudy, patients with the beta-1 389 arginine homozygous genotype experienced a 74% (p = 0.0003) reduction in risk of AF when receiving Gencaro, based on the same analysis.  The beta-1 389 arginine homozygous genotype was present in about 47% of the patients in the BEST pharmacogenetic substudy, and we estimate it is present in about 50% of the U.S. general population.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have created an adaptive design for GENETIC-AF. We are seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study who have recently experienced at least one episode of paroxysmal or persistent AF and who have the beta-1 389 arginine homozygous genotype that we believe responds most favorably to Gencaro.  In addition to measuring the primary endpoint of recurrent symptomatic AF/AFL or all-cause mortality, an additional efficacy measure in the Phase 2B portion of GENETIC-AF will be AF burden, defined as a patient&#8217;s percentage of time in AF per day, regardless of symptoms. At least 150 patients in the Phase 2B portion of the trial will have either a newly or previously implanted Medtronic device that measures and records AF burden. The GENETIC-AF Data Safety Monitoring Board, or DSMB, will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to our pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.&nbsp;&nbsp;The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&#8217;s primary end-point.&nbsp;&nbsp;The DSMB interim analysis will focus on available data regarding the primary end point, AF/AFL event rates, AF burden, and safety.  Should the DSMB interim analysis conclude that the interim data is consistent with pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3.&#160; The DSMB may also recommend changes to the study design before the trial proceeds to Phase 3, or it may recommend that the study not proceed to Phase 3. Based on the DSMB recommendation, and other factors, including input from the trial&#8217;s Steering Committee, the Company will make the final determination on the trial&#8217;s development steps.&nbsp;&nbsp;The full Phase 2B/3 trial is designed for 90 percent power at a p-value of less than 0.01 significance level to detect a 25 percent reduction in the risk of AF recurrence or death in patients in the Gencaro arm compared to patients in the Toprol XL arm.&nbsp;&nbsp;In consultation with the GENETIC-AF Steering Committee, we implemented amendments to the trial protocol in March 2015 which we believe may expand the eligible target population, increase the patient screening and enrollment rate, and simplify trial procedures.&nbsp;&nbsp;We have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections.&nbsp;&nbsp;Under the revised protocol, patients in sinus rhythm who have experienced </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">symptomatic AF in the past 120 days are now eligible for inclusion in the trial, as are patients with AF episodes lasting 7 days or less, or paroxysmal AF.&nbsp;&nbsp;Previously, these patients were not eligible to be enrolled in the trial. We believe this expanded target population has the potential to improve trial screening and enrollment rates and could broaden the potential commercial market for Gencaro, should it achieve regulatory approval in the future.&nbsp;&nbsp;The amendments to the protocol do not fundamentally alter or impact the original endpoints of the clinical trial.&nbsp;&nbsp;&nbsp;&nbsp;Based on the projected impact of the expanded patient population and the current enrollment rate, we now project that the enrollment of 200 patients for the Phase 2B portion of the trial may be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017. We do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate.  We met with the FDA, prior to implementation, to confirm the acceptability of the amendments to the protocol and received no objections.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted patents in the United States, Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which, if we are granted patent term extension, may provide market exclusivity for these uses of Gencaro into approximately 2030 in the United States and Europe.&nbsp;&nbsp;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To support the continued development of Gencaro, we completed public equity offerings during 2013 that raised approximately $19.3 million in net proceeds.&nbsp;&nbsp;In February 2014, we completed a public equity offering of approximately $7.9 million in net proceeds as additional funds for the Phase 2B portion of the trial and to support our ongoing operations.&nbsp;&nbsp;In light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, we will need to raise a significant amount of additional capital to finance the completion of GENETIC-AF and our ongoing operations.&#160; We are seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the GENETIC-AF trial, and we anticipate that our current cash and cash equivalents will be sufficient to fund our operations, at our projected cost structure, through the end of 2015. However, changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate.  We will be required to raise additional funds prior to completion of the Phase 2B portion of GENETIC-AF.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development, or R&amp;D, expense is comprised of clinical, regulatory, and manufacturing process development activities and costs. Our research and development expenses totaled $5.6 million for the year ended December&#160;31, 2014 as compared to $2.9 million for 2013.  The $2.7 million increase in research and development expenses in 2014 as compared to 2013 was primarily due to a $2.1 million increase in costs related to our GENETIC-AF clinical trial, including CRO costs, clinical site initiation and monitoring activities, which began patient screening and enrollment during 2014; and a $0.6 million increase in personnel costs.&nbsp;&nbsp;During 2013, we had minimal clinical development activities and costs as our GENETIC-AF clinical trial was being initiated.&#160;&#160;During the third quarter of 2014, we&#160;reduced the scope of work of our primary contract research organization, or CRO, hired additional clinical personnel, and assumed greater managerial responsibility for certain aspects of the GENETIC-AF clinical trial.&#160;&#160; These changes will reduce the anticipated amounts paid to our primary CRO, but will increase our personnel and other costs as we perform those project responsibilities.&#160;&#160;We do not expect this reorganization of responsibilities to materially change the overall projected cost of the clinical trial.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect R&amp;D expense in 2015 to be higher than 2014 as we activate new clinical sites and enroll additional patients in our GENETIC-AF clinical trial and incur incremental costs associated with transitioning to the protocol amended in the first quarter of 2015. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses, or G&amp;A, primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A expenses were $4.1 million for the year ended December&#160;31, 2014, compared to $4.0 million for 2013, an increase of approximately $56,000. The increase in expenses during 2014 is comprised of increased non-cash, stock-based compensation expense of $283,000, related to restricted stock units granted during the third quarter of 2013 and the first quarter of 2014 and increased personnel, travel costs, board advisory fees, occupancy and insurance costs, which are primarily attributable to personnel returned from furlough, salary changes for executives and other administrative employees, and incremental corporate activities undertaken to support our clinical trial.&#160;&#160;During the first half of 2013, employees were working at reduced levels, reduced salaries or were furloughed.&#160;&#160;In the latter part of 2013 we returned personnel to work to support initiating our GENETIC-AF clinical trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost increases noted above were partially offset by decreases in consulting and legal fees. During the first half of 2013, we incurred additional costs for our special proxy solicitation and shareholder meeting as part of our financing completed in June 2013.&#160;&#160;These activities and related costs were not recurring in&#160;2014.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A expenses in 2015 are expected to be higher than in 2014 as we increase administrative activities to support our GENETIC-AF clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest and Other Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income was $7,000 for the year ended December&#160;31, 2014 as compared to $5,000 for 2013, resulting in an increase of $2,000.&nbsp;&nbsp;This is due to the increase in cash balances resulting from our February 2014 sale of equity securities.&nbsp;&nbsp;Interest income was nominal in both years due to low investment yields. We expect interest income to continue to be nominal in 2015. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest and Other Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other expense was $3,000 for the year ended December&#160;31, 2014, as compared to $4,000 for 2013. The amounts and related change between years are nominal to our overall operations. Based on our current capital structure, interest expense for 2015 is expected to be comparable to 2014. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,756</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows from Operating, Investing and Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,156</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2014 increased nearly $4.1 million compared with the 2013 period due to increased R&amp;D and SG&amp;A expenses discussed above. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities of approximately $8.0 million for the year ended December&#160;31, 2014 is comprised of approximately $7.9 million of net proceeds from the sales of our preferred and common stock and $0.3 million of proceeds from the exercise of warrants for cash, less $179,000 in payments made on a vendor financing arrangement. Net cash provided by financing activities of approximately $19.2 million for the year ended December&#160;31, 2013 is comprised of approximately $19.3 million of net proceeds from the sales of our preferred and common stock, less $174,000 in payments made on a vendor financing arrangement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sources and Uses of Capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary sources of liquidity to date have been capital raised from issuances of shares of our preferred and common stock and funds provided by the merger with Nuvelo. The primary uses of our capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2014, we agreed to sell to certain investors an aggregate of 5,116,228 shares of our common stock and warrants to purchase an aggregate of 1,279,057 shares of our common stock at a purchase price of $1.70 per share of common stock, for aggregate </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gross proceeds of approximately $8.7 million, before deducting placement agent fees and other offering related expenses. The offering closed on February&#160;7, 2014, and the net proceeds to us were approximately $7.9 million.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock.&nbsp;&nbsp;The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $2.125 per share, equal to 125% of the closing bid price of our common stock on the Nasdaq Capital Market on February 3, 2014. The offering was effected as a takedown off our Registration Statement on Form S-3, as amended, which became effective on April&#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;4, 2014. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold pursuant to a placement agency agreement dated January 21, 2014, as amended.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the cash compensation paid to the placement agent in conjunction with the transaction, and pursuant to the placement agency agreement, we issued warrants to the placement agent to purchase 153,486 shares of our common stock, which have not been registered under the Securities Act of 1933, as amended.&nbsp;&nbsp;The warrants issued to the placement agent have substantially the same terms as the warrants issued to the purchasers in the offering, except that such warrants expire on April 4, 2016, and were restricted from transfer for a period of 180 days from the date of commencement of sales in connection with the offering.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed three equity-financing transactions in 2013 and raised approximately $19.3 million, net of offering costs. On January&#160;22, 2013, we sold approximately $1 million of our common stock and warrants for common stock in a private placement transaction with accredited investors including our Chief Executive Officer. We issued 356,430 shares of common stock together with warrants to purchase 249,501 shares of common stock. The net proceeds, after deducting placement agent fees and other offering expenses, were approximately $805,000.&nbsp;&nbsp;Each unit, consisting of a share of common stock and a warrant to purchase 0.70 shares of common stock, was sold at a purchase price of $2.81 per unit. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share. Pursuant to the terms of the Registration Rights Agreements (the Rights Agreements) entered into as part of this and prior Private Placement transactions, we filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February&#160;14, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;31, 2013, we sold approximately $730,000 of common stock and warrants for common stock in a Registered Direct Offering in which we issued 164,636 shares of common stock and warrants to purchase 65,855 shares of common stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by us, was approximately $616,000.&nbsp;&nbsp;Each unit, consisting of a share of common stock and a warrant to purchase 0.40 shares of common stock, was sold at a purchase price of $4.43 per unit. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share. The Registered Direct Offering was effected pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;1, 2013. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 4, 2013, we sold shares of our Series A Convertible Preferred Stock, or Preferred Stock, and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20 million.&nbsp;&nbsp;We issued 125,000 shares of Preferred Stock and warrants to up to purchase 6,250,000 shares of common stock at a <font style="color:#;">at a purchase price of $160 per share of Preferred Stock.&nbsp;&nbsp;The net proceeds, after deducting placement agent fees and other offering expenses payable by us, were approximately $17.9 million.&nbsp;&nbsp;Each share of Preferred Stock is convertible into 100 shares of common stock at any time at the option of the holder.&nbsp;&nbsp;As of December 31, 2013, no shares of the Preferred Stock remained outstanding as all shares of the Preferred Stock had been converted into 12,500,000 shares of common stock.&nbsp;&nbsp;The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance. </font>Our Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the our Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May&#160;29, 2013, and the Preferred Stock and warrants were offered and sold pursuant to a prospectus dated May&#160;30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company&#8217;s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since we have an accumulated deficit, the deemed dividend is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company&#8217;s statement of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financings positioned us to initiate our GENETIC-AF Phase 2B/3 clinical trial during 2014.&nbsp;&nbsp;Our ability to execute our GENETIC-AF Phase 2B trial in accordance with our projected time line depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">recruitment of sufficient clinical trial sites, enrollment of patients and enrollment at a rate consistent with our projected timeline;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">effects of protocol amendments and their projected impact on enrollment;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to control costs associated with the clinical trial and our operations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to retain the listing of our common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic and industry conditions affecting the availability and cost of capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms and conditions of our existing collaborative and licensing agreements.  </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to increase the pool of patients eligible for enrollment in GENETIC-AF, consistent with the adaptive design nature of the trial, we consulted with the GENETIC-AF Steering Committee and implemented amendments to the trial protocol in March 2015.&nbsp;&nbsp;We have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections.&nbsp;&nbsp;Under the revised protocol, patients in sinus rhythm who have experienced symptomatic AF in the past 120 days are now eligible for inclusion in the trial, as are patients with paroxysmal AF.&nbsp;&nbsp;Previously, these patients were not eligible to be enrolled in the trial.&nbsp;&nbsp;Based on the projected impact of this expanded patient population and the current enrollment rate, we now anticipate that the enrollment of 200 patients for the Phase 2B portion of the trial may be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.&nbsp;&nbsp;We do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities will be necessary for us to complete both Phase 2B and Phase 3 of the GENETIC-AF clinical trial and submit for FDA approval of Gencaro.&nbsp;&nbsp;Such financing would likely result in additional dilution to our existing stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations.&nbsp;&nbsp;We anticipate that our current cash and cash equivalents will be sufficient to fund our operations, at our projected cost structure, through the end of 2015<font style="font-style:italic;font-size:12pt;">. </font>However, our forecast of the period of time through which our financial resources will be adequate to support our current and forecasted operations could vary materially.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While our significant accounting policies are described in Note 1 of &#8220;Notes to Financial Statements&#8221; included within Item&#160;8 in this report, we believe the following critical accounting policy affected our most significant judgments, assumptions, and estimates used in the preparation of our financial statements and, therefore, is important in understanding our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to our drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. We develop estimates of liabilities using our judgment based upon the facts and circumstances known at the time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not participated in any transactions with unconsolidated entities, such as special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnifications </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify certain parties from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. We have entered into indemnity agreements with each of our directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. We also maintain an insurance policy for our directors and executive officers insuring against certain liabilities arising in their capacities as such. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_7A_Quantitative"></a>Item&#160;7A. <font style="font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_8_Financial"></a>Item&#160;8. <font style="font-style:italic;">Financial Statements and Supplementary Data</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:90.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Report_of_Independent_Registered_Public"><font style="text-decoration:none;">Report of Independent Registered Public Accounting Firm, KPMG LLP</font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:none;">Balance Sheets as of December&#160;31, 2014 and 2013</font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_OPERATIONS"><font style="text-decoration:none;">Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2014 and 2013</font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_PREFERRED"><font style="text-decoration:none;">Statements of Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2014 and 2013 </font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS"><font style="text-decoration:none;">Statements of Cash Flows for the years ended December&#160;31, 2014 and 2013</font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:90.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL"><font style="text-decoration:none;">Notes to Financial Statements</font></a></p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Report_of_Independent_Registered_Public"></a>Report of Independent Registered Public Accounting Firm </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors and Stockholders </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of ARCA biopharma, Inc. (the Company) as of December&#160;31, 2014 and 2013, and the related statements of operations and comprehensive loss, preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December&#160;31, 2014. These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ARCA biopharma, Inc. as of December&#160;31, 2014 and 2013, and the results of its operations and its cash flows for each of the years in the two-year period ended December&#160;31, 2014, in conformity with U.S. generally accepted accounting principles. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in note 1 to the financial statements, the Company has suffered recurring losses from operations and is dependent upon raising additional funds from strategic transactions, sales of equity, and/or issuance of debt. The Company&#8217;s ability to consummate such transactions is uncertain. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:61.19%;text-indent:-2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denver, Colorado </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a>BALANCE SHEETS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,756</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,488</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,502</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,391</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,503</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value; 5 million shares authorized;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; no shares issued or outstanding.&nbsp;&nbsp;Series A convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock, $0.001 par value; 135,000 shares designated from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized preferred stock; no shares issued or outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2014 and 2013</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 100 million shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; at December 31, 2014 and 2013; 21,150,486 and 15,685,562</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares issued and outstanding at December 31, 2014 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2013, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,342</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OF_OPERATIONS"></a>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,625</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,068</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,940</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,693</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,940</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp;Deemed preferred stock dividend</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common stockholders per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.04</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,629,479</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OF_PREFERRED"></a>STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="26" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series A Convertible</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="26" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,660,315</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">70,898</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(67,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,907</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;net of offering costs</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">521,066</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for fractional shares</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercise of warrants for cash</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of offering costs</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed preferred stock dividend for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; beneficial conversion feature</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of deemed preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividend for beneficial conversion</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; feature on common stockholders</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2013</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15,685,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">90,498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(74,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,116,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,861</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,866</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercise of warrants for cash</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon vesting</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of Restricted Stock Awards</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">21,150,486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">99,342</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(84,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OF_CASH_FLOWS"></a>STATEMENTS OF CASH FLOWS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of deferred charges</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">356</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,038</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(836</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of principal on vendor finance agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,156</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,756</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,756</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL"></a>NOTES TO FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) The Company and Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January&#160;27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, and amended on October&#160;28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidate, Gencaro&#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro&#8217;s pharmacology and may predict patient response to the drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA has created an adaptive design for GENETIC-AF.&nbsp;&nbsp;The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&#8217;s primary end-point.&#160; The DSMB interim analysis will focus on available data regarding the&nbsp;&nbsp;primary endpoint, AF/AFL event rates, AF burden, and safety.&#160;Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&#8217;s&nbsp;&nbsp;Steering Committee and the DSMB, will make the final determination on the trial&#8217;s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants.&nbsp;&nbsp;In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company&#8217;s ongoing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations.&nbsp;&nbsp;&#160; The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents  will be sufficient to fund its operations, at its projected cost structure, through the end of 2015.  However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company&#8217;s ongoing operations.&nbsp;&nbsp;If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> progress of GENETIC-AF, including enrollment and any data that may become available; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic and industry conditions affecting the availability and cost of capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Company&#8217;s ability to control costs associated with its operations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&nbsp;&nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented.&nbsp;&nbsp;Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font> which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities.&#160;&#160;The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued.&#160;&#160;The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In August 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU No. 2014-15&#8221;), <font style="font-style:italic;">Presentation of Financial Statements &#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-style:italic;text-decoration:underline;">.</font>&#160;&#160;ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued.&#160;&#160;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Estimates in the Preparation of Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation cost recognized&nbsp;&nbsp;is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company&#8217;s history of operating losses. The Company has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic earnings per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted earnings per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#8217;s potentially dilutive shares include stock options, restricted stock units and warrants for common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except shares and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp;Series A Preferred Stock deemed dividend</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,631,668</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares of unvested common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,188</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total weighted-average shares used in computing net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share attributed to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,629,480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.04</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&nbsp;&nbsp;As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,371,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147,484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,910,546</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,409,926</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Unobservable inputs for the asset or liability </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets include $15.3 million at December&#160;31, 2014 and $16.5 million at December&#160;31, 2013, in money market funds, classified as cash equivalents, which are measured at fair value based on Level 1 inputs on a recurring basis. The Company has the ability to liquidate these investments without restriction.&nbsp;&nbsp;The Company determines fair value for these money market funds and equity securities with Level 1 inputs through quoted market prices.&nbsp;&nbsp;We have no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December 31, 2014.&nbsp;&nbsp;There were no transfers between any fair value hierarchy levels in 2014 or 2013. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Other Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of other financial instruments, including cash, and accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2014 and 2013, the Company did not have any debt outstanding. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(4) Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or life of the lease</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2014 and 2013, depreciation and amortization expense was $12,000 and $26,000 , respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5) Related Party Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transactions with the Company&#8217;s President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado, or the Lab. Funding of any unrestricted research grants is contingent upon the Company&#8217;s financial condition, and can be deferred or terminated at the Company&#8217;s discretion. Total expense under these arrangements for the years ended December&#160;31, 2014 and 2013 was $350,000 and $297,000 respectively.   </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6) Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has or is subject to the following commitments and contingencies: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which has served as the Company&#8217;s primary business office since October&#160;1, 2013. The lease has a three year term and expires on September 30, 2016.&nbsp;&nbsp;Below is a summary of the future minimum lease payments committed for the Company&#8217;s facility in Westminster, Colorado as of December&#160;31, 2014 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense under these leases for the years ended December&#160;31, 2014 and 2013 was $78,000 and $63,000, respectively . </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Duke University </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2013, the Company entered into a clinical research agreement with Duke University (Duke) to serve as the clinical research organization for the Company&#8217;s GENETIC-AF clinical study.&nbsp;&nbsp;Under the agreement the Company is responsible to pay Duke for their work managing certain aspects of the clinical study.&nbsp;&nbsp;Upon completion of the clinical study, the agreement will terminate.&nbsp;&nbsp;The agreement can be terminated earlier by the Company for any reason with 90 days written notice to Duke.&nbsp;&nbsp;In the event of an early termination, the Company and Duke would coordinate efforts for an orderly wind-down of the study, and the Company would be responsible to pay Duke for time and effort incurred through the date of termination and through the wind-down period.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">University of Cincinnati </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2011, the Company entered into a license agreement with the University of Cincinnati to license exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain U.S. and international diagnostic patents covering genetic markers for ARCA&#8217;s lead drug candidate, Gencaro. These patents provide the basis for exclusive worldwide development, use and commercialization of the genetic test which may indicate a patient&#8217;s likely response to Gencaro as a treatment for chronic HF, AF, and other indications. Under the terms of the agreement, ARCA agreed to pay the University of Cincinnati annual license fees and is obligated to future milestone payments for each United States patent issued subsequent to the date of the agreement. The agreement also requires royalty payments on net sales from genetic testing performed expressly for the purpose of prescribing bucindolol.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA has licensed worldwide rights to Gencaro, including all preclinical and clinical data from Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC, who has licensed rights in Gencaro from BMS. CPEC is a licensing subsidiary of Indevus Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of Gencaro.&nbsp;&nbsp;Under the terms of its license agreement with CPEC, the Company will incur milestone and royalty obligations upon the occurrence of certain events.&nbsp;&nbsp;If the FDA grants marketing approval for Gencaro, the license agreement states that the Company will owe CPEC a milestone payment of $8.0 million within six months after FDA approval. The license agreement states that a milestone payment of up to $5.0 million in the aggregate shall be paid upon regulatory marketing approval in Europe and Japan. The license agreement also states that the Company&#8217;s royalty obligation ranges from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels, including a 5% royalty that CPEC is obligated to pay under its original license agreement for Gencaro. The agreement states that the Company has the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(7) Equity Financings and Warrants </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2013 Equity Financings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Private Investment in Public Equity (PIPE) Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;22, 2013, the Company entered into a Subscription Agreement (the &#8220;January 2013 Purchase Agreement&#8221;) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the January 2013 Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January&#160;25, 2013. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on January&#160;22, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company filed a registration statement for the resale of the shares underlying the units sold in the private placement. That registration statement was declared effective by the Securities and Exchange Commission on February&#160;14, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#8220;variable rate transaction,&#8221; which means a transaction in which the Company issues or sells any convertible securities either (A)&#160;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)&#160;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Offering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &#8220;Investors&#8221;) in connection with its Registered Direct public offering,&nbsp;&nbsp;pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fees and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the offering closed on February&#160;4, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on January&#160;31, 2013.  The Offering was effected as a takedown of the Company&#8217;s Registration Statement on Form S-3, as amended, which became effective on April&#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;1, 2013.&nbsp;&nbsp;The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offering&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;4, 2013, the Company sold shares of its Series A Convertible Preferred Stock (Preferred Stock) and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20.0 million. The Company issued 125,000 shares of Preferred Stock and warrants to purchase up to 6,250,000 shares of common stock at a purchase price of $160 per share of Preferred Stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by the Company, were approximately $17.9 million. ARCA&#8217;s Director and Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Preferred Stock was convertible into 100 shares of the Company&#8217;s common stock at any time at the option of the holder.&nbsp;&nbsp;Each share of Preferred Stock had a liquidation preference of $.001 per share. The shares of Preferred Stock had no preferential dividends or redemption rights, and no voting rights except as required by law. During 2013, all 125,000 of the shares of the Preferred Stock were converted into 12,500,000 shares of ARCA common stock.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each purchaser in the offering was issued a warrant to purchase 50 shares of the Company&#8217;s common stock for each share of Preferred Stock purchased. The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance, provided that the holder will be prohibited from exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the Company&#8217;s Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May&#160;29, 2013, and the Preferred Stock and Warrants were offered and sold pursuant to a prospectus dated May&#160;30, 2013. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company&#8217;s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since ARCA has an accumulated deficit, the deemed dividend is recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company&#8217;s statement of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2014 Equity Financing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Offering</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2014, the Company agreed to sell to certain investors an aggregate of 5,116,228 shares of the Company&#8217;s common stock and warrants to purchase an aggregate of 1,279,057 shares of the Company&#8217;s common stock at a purchase price of $1.70 per share of Common Stock, for aggregate gross proceeds of approximately $8.7 million, before deducting placement agent fees and other offering related expenses. The offering closed on February&#160;7, 2014, and the net proceeds to the Company were approximately $7.9 million.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $2.125 per share, equal to 125% of the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on February 3, 2014. The offering was effected as a takedown off the Company&#8217;s Registration Statement on Form S-3, as amended, which became effective on April&#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;4, 2014. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2014, warrants to purchase 9,371,002 shares of common stock were outstanding at exercise prices ranging from $1.60 to $116.89, with a weighted average exercise price per share of $2.31. These warrants, which were granted as part of various financing and business agreements, expire at various times between April 2016 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(8) Share-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s equity incentive plan, <font style="font-style:italic;">the 2013 Equity Incentive Plan </font>(the Equity Plan),<font style="font-style:italic;"> </font>was approved by stockholders on September 17, 2013.&nbsp;&nbsp;The maximum number of shares issuable under this plan is 2,250,000 shares.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2014, options and awards for 1,437,477 shares were outstanding under the Equity Plan, and 672,852 shares were reserved for future awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of three to four years from the date of grant and have a maximum term of ten years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the adoption of the Equity Plan, the Company discontinued grants under its previous plan, the <font style="font-style:italic;">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan </font>(the 2004 Plan), effective September 17, 2013. The 2004 Plan expired in 2014; however, options outstanding under the 2004 plan will continue to vest according to the original terms of each grant.&nbsp;&nbsp;As of December&#160;31, 2014, options to purchase 59,776 shares with a weighted average exercise price of $15.10 per share were outstanding under this plan. Other stock plans that were assumed by ARCA in the Merger still have options outstanding that will continue to vest according to the original terms of each grant, but no new options can be granted under these plans, as the plans have expired.&nbsp;&nbsp;As of December 31, 2014, options to purchase 42,291 shares with a weighted average exercise price of $17.78 were outstanding under these plans.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December&#160;31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December&#160;31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of ARCA&#8217;s stock option and stock award activities for the years ended December&#160;31, 2014 and 2013, and related information as of December&#160;31, 2014, is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, beginning of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.67</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066,712</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised for the years ended December&#160;31, 2014 and 2013 was $0 and $0, respectively. As of December&#160;31, 2014, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $633,000 which is expected to be recognized over a weighted average period of 2.2 years. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding and exercisable as of December&#160;31, 2014:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,933</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727,869</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.47</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329,189</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,495</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.11</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,410</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.98</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,300</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.44</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.68</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,070</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.55</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.99</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.42</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.74</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began granting restricted stock units (RSUs) to employees during 2013 in conjunction with the adoption of its 2013 Equity Incentive Plan.&nbsp;&nbsp;The fair value of RSU awards is the closing price of the Company&#8217;s common stock on the date of grant and is recognized as compensation expense on a straight-line basis over the respective vesting period. The stock awards granted have a requisite service period of three or four years with annual vesting on the grant anniversary date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and released</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2014, the total unrecognized compensation cost related to unvested stock awards was approximately $629,000.&nbsp;&nbsp;This cost will be recognized on a straight-line basis over the next 2.4 years and will be adjusted for estimated forfeitures.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-cash Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to non-employees was negligible in 2014 and 2013. ARCA did not recognize any tax benefit related to employee stock-based compensation cost as a result of the full valuation allowance on its net deferred tax assets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;line-height:11pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(9) Employee Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. The Company adopted the plan in 2006 and contributed $108,000 and $70,000 for the years ended December&#160;31, 2014 and 2013, respectively . </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-weight:bold;">10) Income Taxes </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective June&#160;1, 2005, the Company changed from an S-Corporation to a C-Corporation. As an S-Corporation, the net operating loss carryforwards were distributed to the Company&#8217;s stockholders; such amounts were not significant. Since June 2005 through December&#160;31, 2014, for federal income tax purposes, the Company has net operating loss carryforwards of approximately $113.7 million, and approximately $991,000 of research and development credits that may be used to offset future taxable income. The net operating loss carryforwards will expire beginning 2025 through 2034. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section&#160;382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#8217;s net operating loss carryforwards may be limited. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to the Company&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that the Company will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax asset of approximately $44.5 million at December&#160;31, 2014, reflecting a decrease of approximately $0.4  million from December&#160;31, 2013. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2014 the Company has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal income tax benefit at statutory rates</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax benefit, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(296</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,041</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset adjustment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,907</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(365</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without regard to the deferred tax liability on the impaired IPR&amp;D, the Company has had no provision for income taxes since inception due to its S-corporation status and its subsequent net operating losses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company&#8217;s net deferred tax assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacation accrual</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net current deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,799</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contribution carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized intangibles</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,437</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. Thus, the Company&#8217;s open tax years extend back to 2009. The Company believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on the Company&#8217;s financial condition, result of operations, or cash flow. For the years ended December&#160;31, 2014 and 2013, the Company has no reserve for uncertain tax positions. The Company does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve months. In the event the Company concludes it is subject to interest or penalties arising from uncertain tax positions, the Company will record interest and penalties as a component of other income and expense. No material amounts of interest or penalties were recognized in the financial statements for the years ended December&#160;31, 2014 and 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_9_Changes_in_and_Disagreements"></a>Item&#160;9. <font style="font-style:italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.  </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_9A_Controls"></a>Item&#160;9A. <font style="font-style:italic;">Controls and Procedures </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of management, including our Chief Executive Officer and our Principal Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this annual report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act). Our internal control system was designed to provide reasonable assurance to management and our board of directors regarding the preparation and fair presentation of published financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of management, including our Chief Executive Officer and Principal Financial Officer, we have assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2014. In making our assessment of internal control over financial reporting, we used the criteria issued in the report Internal Control-Integrated Framework (2013) by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). We have concluded that our internal control over financial reporting was effective as of December&#160;31, 2014 based on these criteria. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant to the exemption from Section&#160;404(b) of the Sarbanes-Oxley Act for non-accelerated filers provided by the Dodd-Frank Wall Street Reform and Consumer Protection Act. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2014, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. On May 14, 2013, the Committee of Sponsoring Organizations of the Treadway Commission (COSO) published an updated Internal Control - Integrated Framework (2013) and related illustrative documents. The Company adopted the new framework in 2014.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations on the Effectiveness of Controls </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including the Chief Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_9B_Other_Information"></a>Item&#160;9B. <font style="font-style:italic;">Other Information </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART III</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_10_Directors"></a>Item 10. <font style="font-style:italic;">Directors, Executive Officers and Corporate Governance </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to &#8220;Election of Board of Directors,&#8221; &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; and &#8220;Executive Officers&#8221; in our Definitive Proxy Statement to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, relating to our 2015 Annual Meeting of Stockholders. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_11_Executive_Compensation"></a>Item&#160;11. <font style="font-style:italic;">Executive Compensation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this item is incorporated by reference to &#8220;Executive Compensation&#8221; in our Definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act, relating to our 2015 Annual Meeting of Stockholders. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_12_Security_Ownership"></a>Item&#160;12. <font style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this item is incorporated by reference to &#8220;Equity Compensation Plan Information&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act, relating to our 2015 Annual Meeting of Stockholders. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_13_Certain"></a>Item&#160;13. <font style="font-style:italic;">Certain Relationships and Related Transactions, and Director Independence </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this item is incorporated by reference to &#8220;Certain Relationships and Related Transactions&#8221; in our Definitive Proxy Statement to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, relating to our 2015 Annual Meeting of Stockholders. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.53%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_14_Principal"></a>Item&#160;14. <font style="font-style:italic;">Principal Accountant Fees and Services </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this item is incorporated by reference to &#8220;Ratification of Selection of Independent Auditors&#8221; in our Definitive Proxy Statement to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, relating to our 2015 Annual Meeting of Stockholders. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART IV </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_15_Exhibits"></a>Item&#160;15. <font style="font-style:italic;">Exhibits and Financial Statement Schedules </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following documents are filed as part of this Report: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial statements filed as part of this Report are listed under Part II, Item&#160;8, page 43 of this Form 10-K. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">No schedules are required because either the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements or the notes thereto. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this annual report on Form 10-K. We will furnish a copy of any exhibit listed to requesting stockholders upon payment of our reasonable expenses in furnishing those materials. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K*</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/25/2008</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October&#160;28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K*</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/29/2008</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation of the Registrant, as amended.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1(a)</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of Amendment to Restated Certificate of Incorporation.</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/5/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Amended and Restated Bylaws of the Registrant, as amended.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/16/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Certificate.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated July&#160;17, 2007, by and between ARCA Discovery, Inc. and Silicon Valley Bank.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February&#160;19, 2009, by and between ARCA biopharma, Inc. and SVB Financial Group.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated August&#160;19, 2008, by and between ARCA biopharma, Inc. and Silicon Valley Bank.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February&#160;19, 2009, by and between ARCA biopharma, Inc. and SVB Financial Group.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated October&#160;18, 2009, by and between ARCA biopharma, Inc. and BioMed Realty, L.P.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/4/2010</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.19</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/18/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrant to Purchase Common Stock.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/3/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock, dated </p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 22, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock, dated December 20, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/1/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrant Agency Agreement by and between ARCA biopharma, Inc. and Computershare Trust Company, N.A. dated May 31, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">S-1/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant. </p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">S-1/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant Agency Agreement by and among ARCA biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A. dated February 3, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.18</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to Exhibits 3.1, 3.1(a), 3.1(b) and 3.2</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC L.L.C.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing Agreement, dated September&#160;11, 2006, by and between ARCA Discovery, Inc. and Patheon, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.10</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 2 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 3 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 4 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 5 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 6 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.7</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Executive Incentive Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.8</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Non-Executive Incentive Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.9</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Nonqualified Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.10</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Partial Acceleration Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.34</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of No Acceleration Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.35</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Director Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.36</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Notice of Grant of Stock Option.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.37</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Notice of Director Grant of Stock Option.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.38</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R. Bristow.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.43</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.46</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment Agreement, dated June&#160;12, 2008, by and between ARCA biopharma, Inc. and Christopher D. Ozeroff.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.45</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.48</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/21/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Option Amendment pursuant to ARCA biopharma, Inc. 2004 Equity Incentive Plan and ARCA biopharma, Inc. 2004 Stock Option Plan (change of control).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/10/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Option Agreement and Grant Notice pursuant to ARCA biopharma, Inc. 2004 Equity Incentive Plan (NDA/change of control acceleration).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/10/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated February&#160;11, 2009, by and between ARCA biopharma, Inc. and Patrick Wheeler. </p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/4/2010</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.53</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.52</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/18/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License Agreement, dated April&#160;15, 2011, by and between ARCA biopharma and the University of Cincinnati.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/16/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/15/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>8-K</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Michael Bristow.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Patrick Wheeler.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Christopher Ozeroff.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/3/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated October 22, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated December 18, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.40</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Amendment to the Registration Rights Agreement, dated December 18, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated January 22, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.43</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.44</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/1/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of April 18, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/22/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 21, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46(a)</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 31, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Letter Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of July 26, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.48</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office Lease Agreement by and between ARCA biopharma, Inc. and Circle Point Properties, LLC, effective August 1, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/6/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.49&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R. Bristow, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Patrick M. Wheeler, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.7</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.51&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Christopher Ozeroff, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.8</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2013 Equity Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.53&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.54&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.55&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.56&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.57&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Research Agreement by and between ARCA biopharma, Inc. and Duke University, dated November 5, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/20/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.65</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.59&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change Order No. 1 to Clinical Research Agreement between ARCA biopharma, Inc. and Duke University, dated November 12, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/12/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.60&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Amendment to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated July 28, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.61&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Amendment to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated September 9, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/12/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.62&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated December 29, 2014, by and between ARCA biopharma, Inc. and Brian Selby.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/30/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.63&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment Agreement, dated December 29, 2014, by and between ARCA biopharma, Inc. and Thomas A. Keuer.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/30/2014</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.64&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canadian Addendum to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated February 4, 2015.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/16/2009</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">14.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Power of Attorney (included in the signature page hereto).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.95%;"></td>
<td style="width:1.36%;"></td>
<td style="width:48.5%;"></td>
<td style="width:0.78%;"></td>
<td style="width:6.9%;"></td>
<td style="width:0.5%;"></td>
<td style="width:12.44%;"></td>
<td style="width:0.5%;"></td>
<td style="width:0.65%;"></td>
<td style="width:7.68%;"></td>
<td style="width:0.78%;"></td>
<td style="width:8.23%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted </p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#8217;s Form 8-K, File No. 000-22873. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Indicates management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item&#160;15(b) of Form&#160;10-K. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#167;</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been requested for portions of this document, which are omitted and filed separately with the SEC. Omitted portions have been filed with the Securities and Exchange Commission pursuant to Rule&#160;24b-2 of the Securities Exchange Act of 1934, as amended. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:54.16%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:94.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<font style="font-size:7.5pt;">S</font>/ B<font style="font-size:7.5pt;">RIAN </font>L<font style="font-size:7.5pt;">. </font>S<font style="font-size:7.5pt;">ELBY</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:94.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;19, 2015</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael R. Bristow and Brian L. Selby, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of ARCA biopharma, Inc., in the capacities and on the dates indicated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<font style="font-size:7.5pt;">S</font>/&#160;Michael R. Bristow</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive</p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael R. Bristow</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Officer and Director<br> (Principal Executive Officer)</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<font style="font-size:7.5pt;">S</font>/&#160;Brian L. Selby</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance </p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<font style="font-size:7.5pt;">S</font>/&#160;Linda Grais</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Linda Grais</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Raymond Woosley</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Raymond Woosley</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert Conway</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert Conway</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Daniel Mitchell</p></td>
<td valign="bottom"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:0.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Daniel Mitchell</p></td>
<td valign="bottom"  style="width:1.04%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:13.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K*</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/25/2008</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated October&#160;28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K*</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/29/2008</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation of the Registrant, as amended.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1(a)</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of Amendment to Restated Certificate of Incorporation.</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/5/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Amended and Restated Bylaws of the Registrant, as amended.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/16/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Certificate.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated July&#160;17, 2007, by and between ARCA Discovery, Inc. and Silicon Valley Bank.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February&#160;19, 2009, by and between ARCA biopharma, Inc. and SVB Financial Group.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated August&#160;19, 2008, by and between ARCA biopharma, Inc. and Silicon Valley Bank.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February&#160;19, 2009, by and between ARCA biopharma, Inc. and SVB Financial Group.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to Purchase Stock Agreement, dated October&#160;18, 2009, by and between ARCA biopharma, Inc. and BioMed Realty, L.P.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/4/2010</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.19</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/18/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrant to Purchase Common Stock.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/3/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock, dated October 22, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock, dated December 20, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrants to Purchase Shares of Common Stock.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/1/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Warrant Agency Agreement by and between ARCA biopharma, Inc. and Computershare Trust Company, N.A. dated May 31, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">S-1/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant. </p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">S-1/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Common Stock Purchase Warrant.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant Agency Agreement by and among ARCA biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A. dated February 3, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>8-K</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.18</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to Exhibits 3.1, 3.1(a), 3.1(b) and 3.2</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC L.L.C.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing Agreement, dated September&#160;11, 2006, by and between ARCA Discovery, Inc. and Patheon, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/15/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.10</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 2 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 3 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 4 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 5 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 6 to the ARCA Discovery, Inc. 2004 Stock Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.7</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Executive Incentive Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.8</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Non-Executive Incentive Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.9</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Stock Incentive Plan, Form of Nonqualified Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/28/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.10</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Partial Acceleration Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.34</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of No Acceleration Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.35</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Director Stock Option Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.36</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Notice of Grant of Stock Option.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.37</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2004 Equity Incentive Plan (f/k/a Nuvelo, Inc. 2004 Equity Incentive Plan), Form of Notice of Director Grant of Stock Option.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.38</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R. Bristow.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.43</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.46</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment Agreement, dated June&#160;12, 2008, by and between ARCA biopharma, Inc. and Christopher D. Ozeroff.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.45</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.48</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/21/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Option Amendment pursuant to ARCA biopharma, Inc. 2004 Equity Incentive Plan and ARCA biopharma, Inc. 2004 Stock Option Plan (change of control).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/10/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Option Agreement and Grant Notice pursuant to ARCA biopharma, Inc. 2004 Equity Incentive Plan (NDA/change of control acceleration).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/10/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated February&#160;11, 2009, by and between ARCA biopharma, Inc. and Patrick Wheeler. </p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/4/2010</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.53</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.52</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/18/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License Agreement, dated April&#160;15, 2011, by and between ARCA biopharma and the University of Cincinnati.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/16/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/15/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/22/2011</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Michael </p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristow.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Patrick Wheeler.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Amendment Agreement, dated March 30, 2012, by and between ARCA biopharma, Inc. and Christopher Ozeroff.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">5/14/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/3/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated October 22, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10/23/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated December 18, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.40</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Amendment to the Registration Rights Agreement, dated December 18, 2012.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/19/2012</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated January 22, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.43</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Registration Rights Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.44</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subscription Agreement.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/1/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of April 18, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">4/22/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 21, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46(a)</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment No. 1 Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 31, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">2/4/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">1.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Letter Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of July 26, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.48</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office Lease Agreement by and between ARCA biopharma, Inc. and Circle Point Properties, LLC, effective August 1, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/6/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.49&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R. Bristow, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Patrick M. Wheeler, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.7</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.51&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Agreement by and between ARCA biopharma, Inc. and Christopher Ozeroff, effective as of June 13, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.8</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. 2013 Equity Incentive Plan.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.53&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.54&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.3</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.55&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.4</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.56&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.5</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.57&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">9/23/2013</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.6</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Research Agreement by and between ARCA biopharma, Inc. and Duke University, dated November 5, 2013.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">3/20/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.65</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.59&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change Order No. 1 to Clinical Research Agreement between ARCA biopharma, Inc. and Duke University, dated November 12, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/12/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.60&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Amendment to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated July 28, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8/13/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.61&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Amendment to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated September 9, 2014.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/12/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.2</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.62&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated December 29, 2014, by and between ARCA biopharma, Inc. and Brian Selby.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/30/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.63&#8224;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment Agreement, dated December 29, 2014, by and between ARCA biopharma, Inc. and Thomas A. Keuer.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">8-K/A</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">12/30/2014</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.64&#167;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canadian Addendum to Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated February 4, 2015.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">11/16/2009</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">14.1</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Power of Attorney (included in the signature page hereto).</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br>Date</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br>Herewith </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith)</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br>&#160;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#8217;s Form 8-K, File No. 000-22873. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Indicates management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item&#160;15(b) of Form&#160;10-K. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#167;</p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been requested for portions of this document, which are omitted and filed separately with the SEC. Omitted portions have been filed with the Securities and Exchange Commission pursuant to Rule&#160;24b-2 of the Securities Exchange Act of 1934, as amended. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.33%;text-indent:-5.33%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.33%;text-indent:-5.33%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.64
<SEQUENCE>2
<FILENAME>abio-ex1064_20141231390.htm
<DESCRIPTION>EX-10.64
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#222222;font-size:9.5pt;font-family:Arial;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="Background-color:#FFFFFF;">E</font><font style="Background-color:#FFFFFF;text-transform:none;">xhibit</font><font style="Background-color:#FFFFFF;"> 10.64</font></p>
<p style="margin-top:10pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-size:8pt;font-family:Arial;text-transform:none;font-style:normal;font-variant: normal;"><a name="Text11"></a>User SAP Number:<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Region<font style="text-transform:uppercase;">:</font><font style="text-decoration:underline;text-transform:uppercase;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">CANADIAN ADDENDUM</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">TO THE CLINICAL TRIAL COLLABORATION AGREEMENT <br>BETWEEN MEDTRONIC AND ARCA </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This addendum (&#8220;<font style="font-weight:bold;">Addendum</font>&#8221;) is to the Clinical Trial Collaboration Agreement (the &#8220;<font style="font-weight:bold;">Collaboration Agreement</font>&#8221;) made and entered into as of April 18, 2013 between ARCA biopharma, Inc., a Delaware corporation (hereinafter &#8220;<font style="font-weight:bold;">ARCA</font>&#8221;) and Medtronic, Inc., a Minnesota corporation (hereinafter &#8220;<font style="font-weight:bold;">Medtronic</font>&#8221;), as amended by the Second Amendment to the Collaboration Agreement entered as of August 28, 2014. This Addendum is for the purpose of supply and distribution of Medtronic devices and CareLink services within Canada under the Collaboration Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Addendum is made as of Feb. 4<sup style="font-size:85%; vertical-align:top">th</sup>, 2015 by and between:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.18%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-variant: small-caps;letter-spacing:-0.15pt;font-style:normal;text-transform:none;">Medtronic of Canada Ltd.<font style="font-weight:normal;font-variant: normal;">, a corporation organized under the laws of Canada having its principal place of business at 99 Hereford Street, Brampton, Ontario L6Y 0R3 (&#8220;</font><font style="font-variant: normal;">Medtronic Canada</font><font style="font-weight:normal;font-variant: normal;">&#8221;);</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.18%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.18%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA<font style="font-weight:normal;">; and </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.18%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.18%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">Medtronic</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, ARCA and Medtronic have entered into the Collaboration Agreement with respect to GENETIC-AF and the Phase 2B Study;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, ARCA wishes to select and activate approximately </font>[*]<font style="font-weight:normal;"> investigational sites in the Phase 2B Study, and approximately </font>[*]<font style="font-weight:normal;"> additional centres will be added&nbsp;&nbsp;for the Phase 3 component (as applicable if ARCA carries out the Phase 3 component), for a total of </font>[*]<font style="font-weight:normal;"> sites, located primarily in the United States and Canada. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties wish to arrange for the supply and distribution of Medtronic Reveal devices and Medtronic CareLink services to investigational sites within Canada under the Collaboration Agreement; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Medtronic Canada is engaged in the business of selling and distributing Medtronic Devices and CareLink services in Canada;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE<font style="font-weight:normal;">, for good and valuable consideration the Parties agree to supplement and modify the terms and conditions of the Collaboration Agreement as follows with respect to investigational sites in Canada:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Definitions</font>: Except as otherwise defined in this Addendum, all other capitalized terms shall have the meaning ascribed to them in the Collaboration Agreement. For the purpose of this Addendum, the following capitalized terms have the following respective meaning:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">CareLink</font>&#8221; or the &#8220;<font style="font-weight:bold;">CareLink System</font>&#8221; means Medtronic&#8217;s proprietary remote monitoring service that provides secure access to data from patients who have certain Medtronic cardiac medical device implants, including Reveal, that is currently marketed by Medtronic in Canada under the &#8220;Medtronic CareLink&#8221;&#174; trademark.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">De-identify</font>&#8221; and &#8220;<font style="font-weight:bold;">De-identification</font>&#8221; mean removal of information that identifies individuals in a manner that conforms with Canadian Privacy Laws.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Effective Date</font>&#8221; means the date when this Addendum is executed by all Parties;&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Eligible Patient</font>&#8221; means, for the purpose of this Addendum, any patient selected who (i) meets the criteria for participating in Phase 2B Study, the AF Burden Substudy, or the Phase 3 Portion, as the case may be, (ii) who has signed the corresponding REB approved patient informed consent form, and (iii)&#160;who has signed the </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap"></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Medtronic CareLink network enrolment consent form in accordance with the terms of use between Medtronic Canada and investigational sites in Canada using CareLink network services for the commercial use of Medtronic Devices, in a form substantially similar to <font style="text-decoration:underline;">Addendum Exhibit B</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Governmental Authority</font>&#8221; means any applicable federal, provincial, local or other governmental body with jurisdiction over the applicable subject matter.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Health Canada</font>&#8221; means the Therapeutic Products Division of Health Canada.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Party</font>&#8221; means ARCA or Medtronic or Medtronic Canada or either one of them, and &#8220;Parties&#8221; mean all of them.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Privacy Laws</font>&#8221; means Canadian federal and provincial legislation and regulations with respect to the protection of personal information in Canada and in the relevant province, as applicable, where the Canadian investigational site is located that is transmitting a study subject&#8217;s CareLink Data, including the federal <font style="font-style:italic;">Personal Information Protection and Electronic Documents Act </font>(Canada), the British Columbia <font style="font-style:italic;">Freedom of Information and Protection of Privacy Act</font>, the Alberta <font style="font-style:italic;">Health Information Act</font>, the Ontario <font style="font-style:italic;">Personal Health Information Protection Act</font> and the Quebec <font style="font-style:italic;">Act respecting the Protection of Personal Information in the Private Sector</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Regulatory Authority</font>&#8221; means, for purposes of this Addendum when used herein or in the Collaboration Agreement, any Governmental Authority with jurisdiction over drug products or medical devices intended for human use in Canada, including the Therapeutic Products Division of Health Canada.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.96%;margin-left:7.04%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</p></td>
<td valign="top" style="width:92.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&#8220;<font style="font-weight:bold;">Reveal LINQ System</font>&#8221; means the Reveal LINQ insertable cardiac monitor, patient assistant device and MyCareLink&#8482; patient monitor.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Adherence to Obligations in the Collaboration Agreement</font>. This Addendum is intended to supplement the Collaboration Agreement with respect to the <font style="font-size:10pt;">supply and distribution of Medtronic Reveal devices and CareLink services to investigational sites within Canada. For greater clarity, this means that this addendum does not modify the Collaboration Agreement with respect to the conduct of the study anywhere outside Canada. This Addendum shall only be read into the Collaboration Agreement with respect to the conduct of the study within Canada at Canadian participating sites or dealings with Governmental Authorities in Canada.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Product Supply and Distribution</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font>As between the Parties, Medtronic Canada is responsible for the distribution, shipment and supply of the Reveal LINQ Systems to the investigational sites in Canada under the Collaboration Agreement. <font style="font-weight:bold;">[*]</font>, the Reveal LINQ insertable cardiac monitors and patient assistant devices intended to be distributed to investigational sites in Canada under the Collaboration Agreement, and Medtronic Canada shall provide the use of a MyCareLink patient home monitor with each Reveal LINQ insertable cardiac monitor, <font style="font-weight:bold;">[*]</font> per Reveal LINQ System in accordance with Section 5.2(a) of the Collaboration Agreement, <font style="font-weight:bold;">[*]</font>. Medtronic Canada shall ship such Reveal LINQ Systems to the investigational sites in Canada as directed from time to time by ARCA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;">ARCA</font> will issue a purchase order request to Medtronic Canada specifying the location where Reveal LINQ Systems are to be delivered (&#8220;Bill To: ARCA / Ship to: [specified investigational site(s) in Canada]&#8221;) in order to supply and resupply each investigational site with the number of products needed in Canada. ARCA will provide Medtronic Canada with the following information that Medtronic Canada will include as notes in the shipping documents with each product shipment to help ensure that Reveal devices are used only in the relevant study: Study Name, Study Coordinator, Room Number of Study Coordinator, Phone Number of Study Coordinator.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase Orders to be sent to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic of Canada Customer Service</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel# <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax# <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms Kathy Schreiber</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing Manager of Cardiac Diagnostics and Monitoring</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax# <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font>Medtronic Canada shall ship the requested number of Reveal LINQ Systems to the designated participating sites in Canada so that the devices are received no more than 2 working days after Medtronic Canada&#8217;s receipt of ARCA&#8217;s purchase order.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font>Upon shipment, Medtronic Canada shall invoice to ARCA directly such Reveal LINQ Systems ordered by it from time to time under this Addendum, and ARCA shall pay such invoices to Medtronic Canada directly. Medtronic Canada shall provide ARCA with an invoice along with accompanying documentation, in a form satisfactory to ARCA. <font style="font-weight:bold;">[*]</font> Unless the Parties agree to use different terms, all invoices by Medtronic Canada to ARCA shall be addressed to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Rd., Suite 140</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Westminster, Colorado 80020</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the attention of:&#160;&#160;<font style="text-decoration:underline;">Accounts Payable</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">[</font><font style="font-weight:bold;text-decoration:underline;">*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">[</font><font style="font-weight:bold;text-decoration:underline;">*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:36pt;"></font>Medtronic Canada will pay the shipping costs incurred to deliver the Reveal LINQ Systems to investigational sites in Canada. Risk of loss of the Reveal LINQ Systems passes to ARCA upon shipment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6<font style="margin-left:36pt;"></font>Title to the Reveal <font style="letter-spacing:-0.15pt;">LINQ insertable cardiac monitor</font> devices and to the corresponding patient assistant devices shall transfer from Medtronic Canada to the investigational site at the same time as the transfer of risk of loss.&nbsp;&nbsp;There is no title transfer for the CareLink Service, or the MyCareLink patient home monitors provided as part of a Reveal LINQ System.&nbsp;&nbsp;Medtronic Canada retains title to the MyCareLink patient home monitor and patient receives a license to use them.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7<font style="margin-left:36pt;"></font>Payment of the service fees and reimbursable expenses set out in Section 7.2 of this Addendum will be made in Canadian dollars (CAD). Any and all training services performed and expenses incurred by Medtronic Canada under this Addendum shall be invoiced to ARCA within a reasonable time after their performance or being incurred.&nbsp;&nbsp;ARCA reserves the right not to pay invoices received more than one year after the date of performance of the corresponding service.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8<font style="margin-left:36pt;">Payments </font>under this Addendum will be subject to Goods and Services Tax, Harmonized Sales Tax and/or Provincial Sales Tax, as applicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9<font style="margin-left:36pt;"></font>ARCA shall send payments to Medtronic Canada by electronic funds transfer to the follow address, unless the Parties agree to use a different address for payment:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="margin-left:36pt;"></font><font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.04%;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address: <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phone: <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic of Canada contact for payment questions: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louise Thurston</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phone: <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic GST #: <font style="font-weight:bold;">[*]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.87%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:13.87%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All payments shall be made by bank transfer to the account number provided by Medtronic Canada in writing at least thirty (30) days before payment is due. Any and all costs related to the bank transfer in Canada shall be borne by Medtronic Canada.&nbsp;&nbsp;ARCA is not responsible for additional expenses and commissions charged by the bank(s) of the recipient.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10<font style="margin-left:36pt;"></font>ARCA shall provide Medtronic Canada with a complete list of the Canadian investigational sites and investigators and their addresses, including telephone numbers, which shall be annexed to this Addendum as <font style="text-decoration:underline;">Addendum </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit&#160;A</font> as the information becomes available.&nbsp;&nbsp;The Parties will date and initial the <font style="text-decoration:underline;">Addendum Exhibit&#160;A</font> as it is added to this Addendum, and ARCA may update Exhibit A from time to time as new sites are added or new information becomes available.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.11<font style="margin-left:36pt;">ARCA shall only order from Medtronic Canada such devices for investigational study sites in Canada that require them for the Phase 2B Study</font>, including the AF Burden Substudy, or the Phase 3 Study.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12<font style="margin-left:36pt;">ARCA&#8217;s obligation to pay to Medtronic Canada </font>purchase price or services fees and expenses due under this Addendum survives termination and expiration of this Addendum. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13<font style="margin-left:36pt;"></font>Each of ARCA and Medtronic Canada shall designate at least one person to act as the primary contact for the Party for this Addendum and shall direct their communications relating to this Addendum through that person.&nbsp;&nbsp;Medtronic Canada designates <font style="text-decoration:underline;">Kathy Schreiber, Marketing Manager of Cardiac Diagnostics and Monitoring</font>, and ARCA designates <font style="text-decoration:underline;">Laura Emery, Senior Director, Clinical Operations</font>.&nbsp;&nbsp;A Party can change its designation by notifying the other party in writing. To support adequate product supply, ARCA shall provide Medtronic Canada with a provision/distribution plan per Canadian investigational site approximately one month prior to study start, and shall provide an updated version promptly after changes in the enrolment forecast.&nbsp;&nbsp;Such plans and forecasts are not binding on ARCA, who is not obligated to purchase the number of Reveal LINQ Systems forecasted. ARCA will collaborate with Medtronic Canada and mutually agree on the amount of product to be stocked at individual Canadian participating sites to minimize product waste and inventory costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">CRMA Services</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font>As between the Parties, Medtronic Canada shall not be providing CRMA Services, which shall be performed solely by Medtronic. Medtronic Canada does not have the ability to provide the collection and analysis services contemplated by the CRMA Services with respect to study subjects enrolled by investigational sites in Canada, though Medtronic does have that ability per the Collaboration Agreement, including with respect to study subjects enrolled by Canadian investigational sites. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">[*]</font> Medtronic Canada is not obligated to provide CareLink Services to an investigational site that does not have a current CareLink Network Services Agreement in place.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font>If the CareLink Primary User for an Eligible Patient is not the investigator selected by ARCA prior to the Eligible Patient starting his or her participation in the study, ARCA shall arrange for the existing CareLink Primary User to adjust the CareLink settings so that ARCA&#8217;s selected investigator becomes the CareLink Primary User. ARCA acknowledges that Medtronic Canada does not change CareLink settings for physician users and ARCA&#8217;s failure to arrange for the investigator to be the CareLink Primary User for the Eligible Patient means Medtronic Canada cannot provide CareLink Services for the study for that patient.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Conduct of GENETIC-AF</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font>A new section 2.2(a)(1) is added to  the Collaboration Agreement  as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.31%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(a)</font> ARCA shall conduct GENETIC-AF at no cost to Medtronic Canada. GENETIC-AF shall be conducted in accordance with the requisite approvals of the FDA and Health Canada and according to the Protocol, provided that the Protocol may be revised based on the determination of the Steering Committee as a result of Regulatory Authority guidance or other factors.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;">Section 2.2(b) </font>of the Collaboration Agreement is replaced for the purposes of this Addendum by the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(b)</font> The sponsors of GENETIC-AF shall comply with all applicable laws and regulations governing sponsors of clinical trials and shall be responsible for complying with agreements with the institutions representing the investigational sites, and providing appropriate information to and monitoring of the investigators so that GENETIC-AF is performed by those investigators in conformance with generally accepted standards of good clinical practice, with the protocol and with all applicable local, state, provincial and federal laws and regulations governing the performance of clinical investigations, including, but not limited to, the United States <font style="font-style:italic;">Food, Drug and Cosmetics Act </font>and the regulations of the FDA, the Canada <font style="font-style:italic;">Food and Drugs Act</font> and its regulations, and guidances issued by Health Canada. ARCA shall be responsible for and have the sole responsibility to conduct all regulatory activities to secure FDA Approval, and Health Canada authorization, of GENETIC-AF.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font>An additional sentence of Section 2.2(c) of the Collaboration Agreement is added as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Additional support from Medtronic Canada for investigational sites in Canada requires prior mutual agreement of ARCA and Medtronic Canada.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font>An additional sentence of Section 2.2(c) of the Collaboration Agreement is added as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Medtronic Canada shall not be responsible for the payment of any costs relating to the conduct of GENETIC-AF at Canadian investigational sites, whether direct or indirect.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font>A new Section 2.2(d)(1) of the Collaboration Agreement is added as  follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(d)</font> ARCA shall include in the informed consent and research authorizations required to be signed by GENETIC-AF participants the appropriate language to permit the Parties to have access to and utilize the data as provided in this Agreement, in particular the right to use the De-identified Study Data, the CareLink Data and the Combined Study Data for research and commercial purposes pursuant to Sections 3.1, 3.2 and 3.3, respectively, and in compliance with federal and provincial Privacy Laws applicable in Canada.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">General; CRMA Committee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;">Section 4.3(c) </font>of the Collaboration Agreement is amended for the purposes of this Addendum by adding the following sentence at the end:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;In addition, in connection with any such regulatory submissions to Health Canada regarding the Drug Product, the Parties agree that the CRMA Committee or ARCA, as the case may be, shall also consult with Medtronic Canada concerning such filings and coordinate any input from Medtronic Canada in the filings as necessary or advisable.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;">If the Parties fail to reach agreement on a matter related to Section 6.1 of this Addendum (including the substantive elements of Section 4.3(c) of the Collaboration Agreement</font>, as amended by this Addendum with respect to regulatory submissions to Health Canada), then any Party may by written notice to the other Parties invoke the dispute resolution procedure set forth in <font style="font-weight:bold;">Article X</font>, unless otherwise indicated in the Collaboration Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Phase 2B Study; CRMA Services.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1<font style="margin-left:36pt;"></font>An additional sentence of Section 5.1(a) of the Collaboration Agreement is added as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The AF Burden Substudy Protocol will also require that all patients be enrolled in CareLink and have consented prior to their CareLink Data transmission to the standard CareLink Network Services Agreement consent form reproduced in <font style="text-decoration:underline;">Addendum Exhibit B</font>.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;"></font>A new Section 5.1(b) (1) of the Collaboration Agreement is added, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(b)</font> The investigator nomination criteria for investigational sites in Canada will (i) require that all candidates are at an investigational site that has an active existing CareLink Network Services Agreement in force, and (ii) either require that all candidates are CareLink users or attempt to determine which investigators are not CareLink users. Medtronic Canada shall provide training to investigators on the implantation of the Reveal device prior to performing this procedure if they are not already trained, at no charge to ARCA. Upon request, Medtronic Canada will provide documentation to ARCA attesting the training provided to clinical Investigators on the implantation of the Reveal device. In the case of investigators that are not CareLink services users, upon prior written request by ARCA to Medtronic Canada specifying the name(s) and institution of study personnel to be trained, Medtronic Canada shall provide additional training services for investigators who are not CareLink users on the use of the CareLink network,&nbsp;&nbsp;the MyCareLink patient home monitors or the CareLink website, and Medtronic Canada shall charge service fees for such training at Medtronic&#8217;s standard rate of <font style="font-weight:bold;">[*]</font> plus applicable taxes, and reimbursement of expenses incurred by Medtronic Canada if training is requested to be provided on site. If a CareLink trainer must provide the training on site, all reasonable travel, lodging and meal expenses incurred by the trainer to deliver such CareLink training shall be reimbursed by ARCA to Medtronic. An estimate of airfare expenses must be approved in advance by ARCA in writing. All such expenses shall be duly justified by Medtronic Canada with the corresponding receipts or invoices in order to be reimbursed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with Medtronic Canada&#8217;s own travel and expense policy:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.16%;margin-left:11.84%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.48%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:9pt;"><font style="font-family:Arial;">Airfare shall be reimbursed for economy class (coach) fare only. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.16%;margin-left:11.84%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:9pt;"><font style="font-family:Arial;">Mileage will be reimbursed at the rate of $ 0.50/ kilometer. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.16%;margin-left:11.84%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:9pt;"><font style="font-family:Arial;">Medtronic Canada may not submit gasoline bills in addition to the per kilometer rate.&#8221;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3<font style="margin-left:36pt;"></font>An additional paragraph shall be added to Section 5.2 of the Collaboration Agreement as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Medtronic and ARCA shall agree on an enrollment plan for the Phase 2B Study to ensure that all patients eligible for the study are actively enrolled, including those with existing Medtronic Devices and those willing to have a Reveal device implanted. Eligible patients without a Medtronic Device, who agree to have a new device implanted, will be implanted with a Reveal without unreasonable delay. Medtronic Canada shall ensure that sufficient Reveal devices and MyCareLink patient monitors are reasonably available to ARCA&#8217;s Phase 2B Study investigational sites in Canada in order to avoid unreasonable delay in the enrollment process, and Medtronic Canada shall be responsible for distributing Reveals to the Study sites in Canada that require them based on device orders from ARCA. Medtronic Canada shall provide training and technical support for Medtronic Devices, including training relating to insertion and use of Reveals. Medtronic Canada shall provide training on CareLink services to investigators at Canadian investigational sites who are not pre-existing CareLink users upon prior written request by ARCA to Medtronic Canada at its standard service fees set out in Section 5.1(b) above. <font style="font-weight:bold;">[*]</font>, given that there are no approved fee codes in Canada for the reimbursement of the Reveal devices or MyCareLink patient monitors, and most provinces do not have codes for Reveal insertion or explantation procedures and related physician fees. As between the Parties, <font style="font-weight:bold;">[*]</font> The Parties agree that Medtronic Canada shall not owe compensation to ARCA for the work performed by Medtronic Canada under this Agreement and Medtronic Canada shall not be liable to the other Parties or to any third party for any other payments which may be associated with the Collaboration Agreement, including this Addendum, or with any of the services provided hereunder.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4<font style="margin-left:36pt;"></font>An additional sentence shall be added to the end of Section 5.2(b) of the Collaboration Agreement as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;ARCA agrees to engage Medtronic Canada&#8217;s CRHF Patient Management Services to assist ARCA in support of Phase 2B Study and Phase 3 Portion site identification, as applicable.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5<font style="margin-left:36pt;">As between the Parties, with respect to Section 5.3(e) </font>and Section 5.4 of the Collaboration Agreement and consistent with Section 4 of this Addendum, Medtronic shall provide the mutually agreed analysis assistance to ARCA on the CareLink Data, and the CRMA Services, rather than Medtronic Canada.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6<font style="margin-left:36pt;">The following sentence </font>shall be added to Section 5.4 of the Collaboration Agreement: &#8220;Medtronic support for the reimbursement process for Reveal and the MyCareLink patient monitors shall not apply to Genetic AF Canadian sites.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7<font style="margin-left:36pt;"></font>A new Section 5.5(a)(1) of the Collaboration Agreement shall be added  as follow:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(a)</font> ARCA will, through the CRMA Committee, involve Medtronic in all regulatory communications and actions that implicate Medtronic&#8217;s rights and duties under this Agreement, or that implicate the use of Medtronic Devices, and shall provide a copy to and involve Medtronic Canada where those regulatory communications concern a Regulatory Authority as defined under this Addendum. Medtronic will consult on the regulatory process related to conducting GENETIC-AF, as reasonably requested by ARCA. The Parties do not believe that an Investigational Device Exemption (&#8220;IDE&#8221;) or an Investigational Testing Authorization under the Food and Drugs Act (Canada) will be necessary in order to use Reveal in the Phase 2B Study, and the Protocol shall not be amended in a way that will require use of Reveal in a manner inconsistent with FDA approval of Reveal, or Health Canada licenses pertaining to the Reveal devices, the MyCareLink patient home monitor, or the CareLink network system. Medtronic, however, agrees to file and prosecute any regulatory application or submission that in Medtronic&#8217;s sole judgment is required by any Regulatory Authority in order for Medtronic to perform the CRMA Services required by this Agreement.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8<font style="margin-left:36pt;"></font>A new Section 5.5(b)(1) of the Collaboration Agreement shall be added as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">(b)</font> ARCA will consult with, and allow participation by Medtronic on a reasonable basis regarding the content of any submissions to Regulatory Authorities (as defined in this Addendum) related to the GENETIC-AF trial or any Drug Product Application to the extent it involves the CRMA Services, Medtronic Devices, or the Medtronic Field of Use; <font style="font-style:italic;">provided that</font>, as between the Parties, Medtronic Canada shall file with Health Canada all required Medical Device Problem Reports (initial and final reports) regarding Medtronic Devices that arise in the course of conducting Phase&#160;2B Study or the Phase 3 Portion, and shall file with Health Canada any required notice of field corrective </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.32%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action (&#8220;recall&#8221;) that affects Medtronic Devices used in the study, should such a field action occur. ARCA will provide Medtronic with the opportunity to attend or participate in all substantial contacts, including meetings and conference calls between ARCA and the FDA, and ARCA and Health Canada, and any other Regulatory Authority regarding the CRMA Services, Medtronic Devices, or the Medtronic Field of Use. Medtronic will consult with, and allow participation by ARCA on a reasonable basis regarding the content of any submissions to the FDA related to the CRMA Services, and will provide ARCA with the opportunity to attend or participate in all substantial contacts, including meetings and conference calls, between Medtronic and the FDA or Health Canada related to the CRMA Services. Medtronic is responsible for submitting reportable events relating to Medtronic Devices to the relevant regulatory agencies. At Medtronic&#8217;s request and as further specified in Section 12.7 of the Collaboration Agreement (as amended for the purposes of this Addendum), ARCA shall cooperate diligently with Medtronic in the investigation of medical device complaints, and Medtronic shall determine their reportability under Medtronic&#8217;s regulatory obligations as the device manufacturer. Notwithstanding the foregoing, each Party shall notify the other Parties of any oral or written communications to or from the FDA, or to or from Health Canada, on matters relating to the CRMA Services or the Medtronic Devices used in the study(ies), and shall provide the other Parties with copies of such communications reasonably promptly and give the other Party the right to review and participate in any response to any such communications.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Inventions; Confidentiality; Publicity</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;">Section 6.1 of the Collaboration Agreement is amended for the purposes of this Addendum by adding the following sentence at the end of the Section:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.31%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;For greater certainty, it is understood by the Parties that this joint ownership means that each Party shall be free to do the following without consent of the other joint owner(s), but subject to Section 6.2 : (i) utilize the Joint Inventions as provided in this Agreement, (ii)&#160;assign all or any part of its interest in a Joint Invention to an Affiliate or to a third party, or (iii) license such Joint Inventions to any third party in their respective fields of use in accordance with the Collaboration Agreement without having to account to the other joint owner(s) for profits earned from licensing.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Representations, Warranties and Covenants</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.93%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="margin-left:36pt;"></font>ARCA represents and warrants that all material consents, approvals and authorizations of all Governmental Authorities and other persons required to be obtained by ARCA, including any required Clinical Trial Authorization in connection with the conduct of the GENETIC-AF trial, as applicable, have been and shall be obtained by ARCA prior to initiating the Phase 2B Study, the AF Burden Substudy or the Phase 3 Portion at a Canadian investigational site.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.93%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2<font style="margin-left:36pt;"></font>The following sentence is added to Subsection 7.1(g) of the Collaboration Agreement:&nbsp;&nbsp;With respect to Medtronic&#8217;s activities with respect to any Canadian site of Genetic-AF, 7.1(g) shall be read without including the word  &#8220;immunizations&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Term and Termination</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.91%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1<font style="margin-left:36pt;">This Addendum shall remain in force for the term of the Collaboration Agreement, </font>and expires upon expiration or earlier termination of the Collaboration Agreement for any reason, <font style="font-style:italic;">provided</font> that Medtronic Canada may terminate this Addendum in whole or in part as provided below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.07%;margin-left:6.93%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:96.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">upon at least sixty (60) days written notice to the other Parties after Health Canada advises any Party, or issues any written decision, pronouncement, or other communication, including but not limited to letters, emails, website information, final guidance documents, or final rulemaking, either to the Parties or to Third Parties, which provides a reasonable basis for concluding that Health Canada will not allow the GENETIC-AF study to enroll or proceed at investigational sites in Canada; or</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.46%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.07%;margin-left:6.93%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:96.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">upon at least ten (10) days written notice given within thirty days after an action, authorized or unauthorized, is taken by the Steering Committee, (e.g. an amendment that (i)&#160;materially expands Medtronic Canada&#8217;s obligations hereunder beyond those Medtronic Canada voluntarily undertakes by entering into this Addendum, or (ii)&#160;causes the proposed use of the Medtronic Devices, the MyCareLink patient home monitors or the CareLink network services to become outside the scope of their respective licensed indications in Canada.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11. <font style="margin-left:36pt;"></font><font style="font-weight:bold;">Notices</font>. All notices to Medtronic Canada under this Addendum shall be in writing and shall be deemed given and delivered, as and when provided in Section 11.12 of the Collaboration Agreement, if addressed to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.1%;width:67.83%;">
<tr>
<td style="width:15.85%;"></td>
<td style="width:51.99%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic Canada</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99 Hereford Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brampton, Ontario </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L6Y 0R3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canada</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contact Person:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms Kathy Schreiber, <br>Marketing Manager of Cardiac Diagnostics and Monitoring</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phone:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reveal Sale and Distribution.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1<font style="margin-left:36pt;">Section 12.1 of the Collaboration Agreement</font> shall not apply to the activities of Medtronic Canada.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2<font style="margin-left:36pt;"></font>An additional sentence shall be added to Section 12.2 of the Collaboration Agreement as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;ARCA shall return to Medtronic Canada all Reveal devices unused by Canadian investigational sites as soon as practicable after the completion of each phase of the GENETIC-AF study, unless ARCA and Medtronic Canada agree in writing to maintain the devices at a different location for use in the Phase 3 Portion. Medtronic Canada shall credit up to two (2) Reveal devices per site provided that (i)&#160;they are returned with at least 90 days remaining prior to their Use Before Date shown on the Reveal device package, (ii)&#160;are in their original packaging, unopened and undamaged and (iii)&#160;the seal of all implantable products is not damaged or broken.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3<font style="margin-left:36pt;"></font>An additional sentence shall be added to Section 12.7 of the Collaboration Agreement as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;ARCA shall assist and cooperate with Medtronic Canada with respect to fulfillment of Medtronic Canada&#8217;s legal and regulatory obligations applicable to Reveal devices and Reveal LINQ Systems provided hereunder, such as Health Canada complaint reporting, complaint investigation, medical device problem reporting, device tracking pursuant to the provisions of the <font style="font-style:italic;">Food and Drugs Act</font> (Canada) and its regulations, and carrying out any field corrective actions (recalls)  that may affect Reveal devices and Reveal LINQ Systems sold to ARCA hereunder by Medtronic Canada and shipped to Canadian investigational sites.&nbsp;&nbsp;In particular, in order to meet timelines for reporting to Health Canada, ARCA shall notify Medtronic Canada as soon as possible, but in any event within 48 hours of becoming aware of any reported any incident that comes to their attention involving a device that is sold by Medtronic Canada under this Addendum and that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) is related to a failure of the device or a deterioration in its effectiveness, or any inadequacy in its labelling or in its the directions for use; and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) has led to the death or a serious deterioration in the state of health of a patient, user or other person, or could do so were it to recur.</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:14.08%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic Canada shall report these to Health Canada as and when required under the post-market vigilance provisions of the <font style="font-style:italic;">Medical Devices Regulations</font>. ARCA, as sponsor, and/or ARCA&#8217;s clinical investigators shall report them to Research Ethics Boards / Ethics Committees / Institutional Review Boards or other recipients if and as required.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.08%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic Canada shall maintain complete and accurate records concerning the post-market traceability of the Medtronic Devices purchased by ARCA. Medtronic Canada shall maintain records concerning traceability for a minimum period corresponding to the forecasted lifetime of the Medtronic Devices required to be so registered. The device tracking system shall record or allow retrieval of product information as needed to comply with all legal requirements applicable to Medtronic in Canada, including information on all parties involved in the product&#8217;s chain of distribution and its end user, as well as information on product performance and safety record.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13<font style="margin-left:36pt;"></font><font style="font-weight:bold;">General Provisions.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1<font style="margin-left:36pt;">The Parties are independent contractors, p</font>ersonnel of each Party shall be employees or agents of such Party and under no circumstances are such personnel to be considered employees or agents of another Party. Each Party shall have the sole responsibility for the conduct of its employees or agents, and for the payment of their entire compensation, including salary, withholding of income and social security taxes, workers&#8217; compensation, employee and disability benefits, unemployment insurance and the like.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2<font style="margin-left:36pt;">This Addendum may be executed in three (3) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3<font style="margin-left:36pt;">Except as expressly and specifically amended herein, all other provisions of the Collaboration Agreement continue in full force and effect, including as to the performance of the Collaboration Agreement at Canadian investigational sites.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4<font style="margin-left:36pt;"></font>This Addendum forms part of the Collaboration Agreement and is appended thereto as its <font style="text-decoration:underline;">Appendix B</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the Parties hereto have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">MEDTRONIC:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">MEDTRONIC, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8200 Coral Sea St NE(MVS23)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mounds View, MN 55112</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Rd, Suite 140</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Westminster, Colorado 80020</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:</p></td>
</tr>
<tr style="height:73.5pt;">
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Richard Clark&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;Richard Clark&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Title<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;Sr. Director&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;2/4/15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Michael Bristow&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name<font style="text-decoration:underline;">&#160;&#160;&#160;Michael Bristow&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Title<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;President/CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;2/4/15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:252pt;;">
<tr>
<td style="width:252pt;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">MEDTRONIC CANADA:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-weight:bold;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">Medtronic of Canada Ltd.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99 Hereford Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brampton, Ontario<br>L6Y 0R3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canada</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Genevi&#232;ve Lavertu </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sr Director, Legal, Scientific Affairs &amp; Business Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email&#160;: <font style="font-weight:bold;">[*]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: <font style="font-weight:bold;">[*]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:73.5pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Genevi&#232;ve Lavertu&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genevi&#232;ve Lavertu </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-size:9pt;font-family:Arial;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sr Director, Legal, Scientific Affairs &amp; Business Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;February 3, 2015&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0.9pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CANADIAN ADDENDUM EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic Canada Initials  ____<font style="margin-left:340pt;"></font>ARCA Initials  ____</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Note: attach an Excel Spreadsheet here with at least the following information for each Canadian participating site]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Site name:Address: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Investigator name: Address including telephone number:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CANADIAN ADDENDUM EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">[Canadian CareLink services standard patient consent form]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">INFORMED CONSENT</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Collection, Use and Disclosure of Personal Health Information Relating to the Medtronic CareLink Services and Monitors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Client shall obtain and maintain the required consent from all patients enrolled in the Medtronic CareLink Services.&nbsp;&nbsp;Said consent shall contain the following information:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medtronic intends to use the data collected through the Services for the following purposes:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>make any and all uses and disclosures of PHI necessary to provide the Services to Client;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>use the PHI in its possession for its proper management and administration and to fulfill any legal responsibilities of Medtronic;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>disclose the PHI in its possession to a third party for the purpose of Medtronic&#8217;s proper management and administration or to fulfill any legal responsibilities of Medtronic; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that the disclosures are required by law or Medtronic has received from the third party written assurances that (i) the information will be held confidentially and used or further disclosed only as required by law or for the purpose for which it was disclosed to the third party; and (ii) the third party will notify Medtronic of any instances of which it becomes aware in which the confidentiality of the information has been breached;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>perform Data Aggregation for the Health Care Operations of Client;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>development of systems to enable physicians to deliver better services and to enhance the performance of medical devices, utilizing only de-identified data;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>develop tools to improve medical devices, or to enhance the performance of existing medical devices, utilizing only de-identified data;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>other research and public health initiatives analogous to those above, using only de-identified data;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-right:7.04%;text-indent:3.52%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>patient information collected through the Medtronic CareLink Services may be transferred and stored outside of Canada, including the United States.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:7.04%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In no case will Medtronic use the data collected through the Services to identify or contact individuals who provided the data, or provide data to anyone in a form which would enable them to identify or contact such individuals.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>abio-ex231_201412318.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (Nos. 333-161485, 333-146078, 333-134981, 333-126590, 333-115747, 333-108563, 333-103055, 333-101276, 333-96313, 333-68172, 333-68170, 333-53089, 333-53087, 333-41663, 333-39194, 333-91471, 333-08978, 333-154839, and 333-191295) on Form S-8, the registration statements (Nos. 333-195054, 333-186584, 333-172686, and 333-178984) on Form S-3 and the registration statement (No. 333-187508) on Form S-1 and the related prospectuses of ARCA biopharma, Inc. (the Company) of our report dated March&#160;19, 2015, with respect to the balance sheets of ARCA biopharma, Inc. as of December&#160;31, 2014 and 2013, and the related statements of operations and comprehensive loss, preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December&#160;31, 2014, which report appears in the December&#160;31, 2014 annual report on Form 10-K of ARCA biopharma, Inc. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our report dated March&#160;19, 2015 contains an explanatory paragraph that states that the Company&#8217;s recurring losses from operations and its dependence upon raising additional funds from strategic transactions, sales of equity, and/or issuance of debt raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denver, Colorado </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;19, 2015 </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>abio-ex311_201412316.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Michael R. Bristow, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form 10-K of ARCA biopharma, Inc.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;19, 2015 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael R. Bristow</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael R. Bristow</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>abio-ex312_201412317.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Brian L. Selby, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#49;<font style="font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#46;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">I have reviewed this annual report on Form 10-K of ARCA biopharma, Inc.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#50;<font style="font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#46;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#51;<font style="font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#46;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#52;<font style="font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#46;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#53;<font style="font-size:10pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#46;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;19, 2015 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Vice President, Finance</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>abio-ex321_201412319.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SEC. 1350 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Michael R. Bristow, Chief Executive Officer of ARCA biopharma, Inc. (the &#8220;Company&#8221;), and Brian L. Selby, Vice President, Finance of the Company, each hereby certifies that, to the best of his knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s Annual Report on Form 10-K for the period ended December&#160;31, 2014, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act, and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Witness Whereof<font style="font-weight:normal;">, the undersigned have set their hands hereto as of the 19th day of March, 2015. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael R. Bristow</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 1pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:49%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael R. Bristow</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer<br>(Principal Executive Officer)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Vice President, Finance<br>(Principal Financial Officer and Principal<br>Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by Section&#160;906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. &#167; 1350, as adopted) has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Annual Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of ARCA biopharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report), irrespective of any general incorporation language contained in such filing. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>abio-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Instance Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:abio="http://www.arcabiopharma.com/20141231" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="abio-20141231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD_abioshares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_abioPatients">
    <measure>abio:Patients</measure>
  </unit>
  <unit id="U_abioSegment">
    <measure>abio:Segment</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <context id="C_0000907654_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000907654_20150317">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2015-03-17</instant>
    </period>
  </context>
  <context id="C_0000907654_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesAPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesAPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ConvertiblePreferredStockMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapBusinessAcquisitionAxis_abioOriginalMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:OriginalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapBusinessAcquisitionAxis_abioAmendmentMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:AmendmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseThreeHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioBestTrialMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="abio:ClinicalTrialsByPhaseAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PhaseThreeHeartFailureMember</explicitMember>
        <explicitMember dimension="us-gaap:HealthCareTrustFundAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:BestTrialMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseTwoBHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioGENETICAFTrialMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="abio:ClinicalTrialsByPhaseAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PhaseTwoBHeartFailureMember</explicitMember>
        <explicitMember dimension="us-gaap:HealthCareTrustFundAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:GENETICAFTrialMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseThreeHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioGENETICAFTrialMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="abio:ClinicalTrialsByPhaseAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PhaseThreeHeartFailureMember</explicitMember>
        <explicitMember dimension="us-gaap:HealthCareTrustFundAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:GENETICAFTrialMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140201_20140228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20150218_20150218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsequentEventTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SubsequentEventMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-02-18</startDate>
      <endDate>2015-02-18</endDate>
    </period>
  </context>
  <context id="C_0000907654_20130304_20130304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2013-03-04</startDate>
      <endDate>2013-03-04</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:StockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:StockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ComputerEquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FurnitureAndFixturesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LeaseholdImprovementsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ComputerEquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ComputerEquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EquipmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FurnitureAndFixturesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FurnitureAndFixturesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LeaseholdImprovementsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LeaseholdImprovementsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapChiefExecutiveOfficerMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ChiefExecutiveOfficerMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapChiefExecutiveOfficerMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ChiefExecutiveOfficerMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementGeographicalAxis_abioWestminsterMember_20130801">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementGeographicalAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:WestminsterMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-08-01</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementGeographicalAxis_abioWestminsterMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementGeographicalAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:WestminsterMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PrivatePlacementMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-01-22</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130121_20130122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PrivatePlacementMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-21</startDate>
      <endDate>2013-01-22</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PrivatePlacementMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-01-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130130_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-30</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130204_20130204">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-02-04</startDate>
      <endDate>2013-02-04</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PublicOfferingMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ConvertiblePreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-06-02</startDate>
      <endDate>2013-06-04</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PublicOfferingMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ConvertiblePreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-06-04</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapTitleOfIndividualAxis_abioDirectorAndChiefExecutiveOfficerMember_20130604">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PublicOfferingMember</explicitMember>
        <explicitMember dimension="us-gaap:TitleOfIndividualAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:DirectorAndChiefExecutiveOfficerMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-06-04</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PublicOfferingMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:PublicOfferingMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-02-03</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140202_20140203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-02-02</startDate>
      <endDate>2014-02-03</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140206_20140207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-02-06</startDate>
      <endDate>2014-02-07</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:RegisteredDirectOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapWeightedAverageMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WeightedAverageMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20130917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:TwoThousandAndThirteenPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-17</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:TwoThousandAndThirteenPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_abioIncentiveStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:IncentiveStockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_abioIncentiveStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapPrincipalOwnerMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:IncentiveStockOptionMember</explicitMember>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PrincipalOwnerMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndFourStockOptionPlanMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:TwoThousandAndFourStockOptionPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioOtherStockOptionPlanMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:OtherStockOptionPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:TwoThousandAndThirteenPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:TwoThousandAndThirteenPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EmployeeStockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EmployeeStockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeOneMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeTwoMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeThreeMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeFourMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeFiveMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeOneMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeTwoMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeThreeMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeFourMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:ExercisePriceRangeFiveMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRangeAxis_us-gaapMaximumMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20130101_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioFirstThreePercentPayContributionMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:DefinedContributionPlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:FirstThreePercentPayContributionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioNextTwoPercentPayContributionMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:DefinedContributionPlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:NextTwoPercentPayContributionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:TaxPeriodAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:EarliestTaxYearMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:TaxPeriodAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LatestTaxYearMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementScenarioAxis_abioWithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns="http://xbrl.org/2006/xbrldi">abio:WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <dei:EntityRegistrantName id="F_000000" contextRef="C_0000907654_20140101_20141231">ARCA Biopharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000001" contextRef="C_0000907654_20140101_20141231">0000907654</dei:EntityCentralIndexKey>
  <dei:DocumentType id="F_000002" contextRef="C_0000907654_20140101_20141231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000003" contextRef="C_0000907654_20140101_20141231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000004" contextRef="C_0000907654_20140101_20141231">2014-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000005" contextRef="C_0000907654_20140101_20141231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="F_000006" contextRef="C_0000907654_20140101_20141231">2014</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000007" contextRef="C_0000907654_20140101_20141231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000008" contextRef="C_0000907654_20140101_20141231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000009" contextRef="C_0000907654_20140101_20141231">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="F_000010" contextRef="C_0000907654_20140101_20141231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0000907654_20140101_20141231">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityPublicFloat id="F_000012" contextRef="C_0000907654_20140630" decimals="0" unitRef="U_iso4217USD">30003945</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="F_000013" contextRef="C_0000907654_20150317" decimals="INF" unitRef="U_shares">21198411</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000014" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">15354000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000015" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">16756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsCurrent id="F_000016" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000017" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">169000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000018" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">15488000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000019" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">16925000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000020" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000021" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000022" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">608000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000023" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000024" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">16132000</us-gaap:Assets>
  <us-gaap:Assets id="F_000025" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">17084000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000026" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">795000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000027" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">597000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000028" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">329000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000029" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">459000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000030" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">264000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000031" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">446000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000032" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">1388000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000033" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">1502000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000034" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000035" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:Liabilities id="F_000036" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">1391000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000037" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">1503000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000038" xsi:nil="true" contextRef="C_0000907654_20141231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000039" xsi:nil="true" contextRef="C_0000907654_20131231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000040" xsi:nil="true" contextRef="C_0000907654_20141231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000041" xsi:nil="true" contextRef="C_0000907654_20131231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000042" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000043" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000044" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">99342000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000045" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">90498000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000046" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">-84622000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000047" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">-74933000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000048" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">14741000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000049" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">15581000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000050" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">16132000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000051" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">17084000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000052" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000053" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000054" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000055" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000056" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000057" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000058" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000059" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000060" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000061" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20131231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000062" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20141231" decimals="INF" unitRef="U_shares">135000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000063" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20131231" decimals="INF" unitRef="U_shares">135000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000064" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000065" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20131231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000066" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000067" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20131231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000068" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000069" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000070" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000071" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000072" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">21150486</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000073" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">15685562</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000074" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">21150486</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000075" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">15685562</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000076" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">5625000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000077" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2928000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000078" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">4068000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000079" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">4012000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses id="F_000080" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">9693000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="F_000081" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">6940000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000082" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-9693000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000083" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-6940000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestAndOtherIncome id="F_000084" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000085" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense id="F_000086" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000087" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:InterestExpense>
  <us-gaap:NetIncomeLoss id="F_000088" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-9689000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000089" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-6939000</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000090" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2026000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000091" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-9689000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000092" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-8965000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000093" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000094" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">-1.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000095" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_shares">20501224</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000096" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_shares">8629479</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding id="F_000097" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231" decimals="INF" unitRef="U_shares">2660315</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000098" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000099" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20121231" decimals="-3" unitRef="U_iso4217USD">70898000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000100" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20121231" decimals="-3" unitRef="U_iso4217USD">-67994000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000101" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">2907000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000102" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">521066</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000103" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">1421000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000104" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">1421000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits id="F_000105" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">64</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares id="F_000106" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">4245</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue id="F_000107" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">12000</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue id="F_000108" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">12000</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue>
  <abio:PreferredStockIssuedDuringPeriodSharesNewIssues id="F_000109" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">125000</abio:PreferredStockIssuedDuringPeriodSharesNewIssues>
  <abio:PreferredStockIssuedDuringPeriodValueNewIssues id="F_000110" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">17917000</abio:PreferredStockIssuedDuringPeriodValueNewIssues>
  <abio:PreferredStockIssuedDuringPeriodValueNewIssues id="F_000111" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">17917000</abio:PreferredStockIssuedDuringPeriodValueNewIssues>
  <abio:DeemedDividendBeneficialConversionPreferredStock id="F_000112" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2026000</abio:DeemedDividendBeneficialConversionPreferredStock>
  <abio:DeemedDividendBeneficialConversionPreferredStock id="F_000113" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2026000</abio:DeemedDividendBeneficialConversionPreferredStock>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000114" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2026000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000115" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">-125000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000116" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">12500000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000117" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000118" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-33000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000119" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000120" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000121" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000122" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-6939000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000123" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131231" decimals="INF" unitRef="U_shares">15685562</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000124" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000125" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131231" decimals="-3" unitRef="U_iso4217USD">90498000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000126" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20131231" decimals="-3" unitRef="U_iso4217USD">-74933000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000127" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231" decimals="INF" unitRef="U_shares">5116228</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000128" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000129" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">7861000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000130" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">7866000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares id="F_000131" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231" decimals="INF" unitRef="U_shares">209025</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue id="F_000132" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">338000</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue>
  <abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue id="F_000133" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">338000</abio:IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="F_000134" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231" decimals="INF" unitRef="U_shares">139671</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="F_000135" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="F_000136" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000137" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000138" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000139" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-9689000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000140" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="INF" unitRef="U_shares">21150486</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000141" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000142" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231" decimals="-3" unitRef="U_iso4217USD">99342000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000143" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20141231" decimals="-3" unitRef="U_iso4217USD">-84622000</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationAndAmortization id="F_000144" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000145" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:DepreciationAndAmortization>
  <us-gaap:AmortizationOfDeferredCharges id="F_000146" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">67000</us-gaap:AmortizationOfDeferredCharges>
  <us-gaap:ShareBasedCompensation id="F_000147" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">647000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000148" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">283000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000149" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-214000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000150" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-130000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000151" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">545000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000152" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-14000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000153" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">198000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000154" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">532000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000155" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-130000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000156" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">356000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000157" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-182000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000158" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet id="F_000159" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet id="F_000160" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000161" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-9406000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000162" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-5288000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000163" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000164" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000165" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-19000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000166" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-32000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000167" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000168" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2083000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000169" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">9038000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000170" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">1741000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000171" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">836000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000172" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">328000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths id="F_000173" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths>
  <us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths id="F_000174" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">174000</us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000175" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">8023000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000176" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">19156000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000177" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-1402000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000178" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">13836000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000179" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">2920000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid id="F_000180" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="F_000181" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:InterestPaid>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000182" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) The Company and Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January&amp;#160;27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&amp;#160;24, 2008, and amended on October&amp;#160;28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidate, Gencaro&amp;#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro&amp;#8217;s pharmacology and may predict patient response to the drug. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA has created an adaptive design for GENETIC-AF.&amp;nbsp;&amp;nbsp;The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&amp;#8217;s primary end-point.&amp;#160; The DSMB interim analysis will focus on available data regarding the  primary endpoint, AF/AFL event rates, AF burden, and safety.&amp;#160;Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&amp;#8217;s  Steering Committee and the DSMB, will make the final determination on the trial&amp;#8217;s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&amp;nbsp;&amp;nbsp;The Company has historically funded its operations through issuances of common and preferred stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants.&amp;nbsp;&amp;nbsp;In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company&amp;#8217;s ongoing operations.&amp;nbsp;&amp;nbsp;&amp;#160; The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents  will be sufficient to fund its operations, at its projected cost structure, through the end of 2015.  However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company&amp;#8217;s ongoing operations.&amp;nbsp;&amp;nbsp;If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; progress of GENETIC-AF, including enrollment and any data that may become available; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;general economic and industry conditions affecting the availability and cost of capital; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to control costs associated with its operations; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a reasonable period of time.&amp;nbsp;&amp;nbsp;These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&amp;nbsp;&amp;nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&amp;#160;4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented.&amp;nbsp;&amp;nbsp;Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2014, the FASB issued FASB Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-10, &lt;font style="font-style:italic;"&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/font&gt; which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities.&amp;#160;&amp;#160;The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued.&amp;#160;&amp;#160;The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; In August 2014, the FASB issued FASB Accounting Standards Update (&amp;#8220;ASU No. 2014-15&amp;#8221;), &lt;font style="font-style:italic;"&gt;Presentation of Financial Statements &amp;#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-style:italic;text-decoration:underline;"&gt;.&lt;/font&gt;&amp;#160;&amp;#160;ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity&amp;#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued.&amp;#160;&amp;#160;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a reasonable period of time.&amp;nbsp;&amp;nbsp;The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting Estimates in the Preparation of Financial Statements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&amp;#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s stock-based compensation cost recognized  is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company&amp;#8217;s history of operating losses. The Company has not performed an Internal Revenue Code Section&amp;#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. &lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000183" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company calculates basic earnings per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted earnings per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&amp;#8217;s potentially dilutive shares include stock options, restricted stock units and warrants for common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands, except shares and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&amp;nbsp;&amp;nbsp;Series A Preferred Stock deemed dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss available to common shareholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares of common stock outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,501,224&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,631,668&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Weighted-average shares of unvested common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total weighted-average shares used in computing net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; loss per share attributed to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,501,224&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,629,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&amp;nbsp;&amp;nbsp;As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;Such potentially dilutive shares of common stock consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities, excluded:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;471,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,371,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,910,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,409,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000184" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs for the asset or liability &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial assets include $15.3 million at December&amp;#160;31, 2014 and $16.5 million at December&amp;#160;31, 2013, in money market funds, classified as cash equivalents, which are measured at fair value based on Level 1 inputs on a recurring basis. The Company has the ability to liquidate these investments without restriction.&amp;nbsp;&amp;nbsp;The Company determines fair value for these money market funds and equity securities with Level 1 inputs through quoted market prices.&amp;nbsp;&amp;nbsp;We have no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December 31, 2014.&amp;nbsp;&amp;nbsp;There were no transfers between any fair value hierarchy levels in 2014 or 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Other Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of other financial instruments, including cash, and accounts payable, approximated fair value due to their short maturities. As of December&amp;#160;31, 2014 and 2013, the Company did not have any debt outstanding. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000185" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4) Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser of useful life or life of the lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&amp;#160;31, 2014 and 2013, depreciation and amortization expense was $12,000 and $26,000 , respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000186" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5) Related Party Arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Transactions with the Company&amp;#8217;s President and Chief Executive Officer &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into unrestricted research grants with its President and Chief Executive Officer&amp;#8217;s academic research laboratory at the University of Colorado, or the Lab. Funding of any unrestricted research grants is contingent upon the Company&amp;#8217;s financial condition, and can be deferred or terminated at the Company&amp;#8217;s discretion. Total expense under these arrangements for the years ended December&amp;#160;31, 2014 and 2013 was $350,000 and $297,000 respectively.   &lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000187" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6) Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has or is subject to the following commitments and contingencies: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employment Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Operating Lease  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;August 1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which has served as the Company&amp;#8217;s primary business office since October&amp;#160;1, 2013. The lease has a three year term and expires on September 30, 2016.&amp;nbsp;&amp;nbsp;Below is a summary of the future minimum lease payments committed for the Company&amp;#8217;s facility in Westminster, Colorado as of December&amp;#160;31, 2014 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense under these leases for the years ended December&amp;#160;31, 2014 and 2013 was $78,000 and $63,000, respectively . &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Duke University &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2013, the Company entered into a clinical research agreement with Duke University (Duke) to serve as the clinical research organization for the Company&amp;#8217;s GENETIC-AF clinical study.&amp;nbsp;&amp;nbsp;Under the agreement the Company is responsible to pay Duke for their work managing certain aspects of the clinical study.&amp;nbsp;&amp;nbsp;Upon completion of the clinical study, the agreement will terminate.&amp;nbsp;&amp;nbsp;The agreement can be terminated earlier by the Company for any reason with 90 days written notice to Duke.&amp;nbsp;&amp;nbsp;In the event of an early termination, the Company and Duke would coordinate efforts for an orderly wind-down of the study, and the Company would be responsible to pay Duke for time and effort incurred through the date of termination and through the wind-down period.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;University of Cincinnati &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2011, the Company entered into a license agreement with the University of Cincinnati to license exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain U.S. and international diagnostic patents covering genetic markers for ARCA&amp;#8217;s lead drug candidate, Gencaro. These patents provide the basis for exclusive worldwide development, use and commercialization of the genetic test which may indicate a patient&amp;#8217;s likely response to Gencaro as a treatment for chronic HF, AF, and other indications. Under the terms of the agreement, ARCA agreed to pay the University of Cincinnati annual license fees and is obligated to future milestone payments for each United States patent issued subsequent to the date of the agreement. The agreement also requires royalty payments on net sales from genetic testing performed expressly for the purpose of prescribing bucindolol.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA has licensed worldwide rights to Gencaro, including all preclinical and clinical data from Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC, who has licensed rights in Gencaro from BMS. CPEC is a licensing subsidiary of Indevus Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of Gencaro.&amp;nbsp;&amp;nbsp;Under the terms of its license agreement with CPEC, the Company will incur milestone and royalty obligations upon the occurrence of certain events.  If the FDA grants marketing approval for Gencaro, the license agreement states that the Company will owe CPEC a milestone payment of $8.0 million within six months after FDA approval. The license agreement states that a milestone payment of up to $5.0 million in the aggregate shall be paid upon regulatory marketing approval in Europe and Japan. The license agreement also states that the Company&amp;#8217;s royalty obligation ranges from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels, including a 5% royalty that CPEC is obligated to pay under its original license agreement for Gencaro. The agreement states that the Company has the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <abio:EquityFinancingsAndWarrantsDisclosureTextBlock id="F_000188" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7) Equity Financings and Warrants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2013 Equity Financings &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Private Investment in Public Equity (PIPE) Transactions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;22, 2013, the Company entered into a Subscription Agreement (the &amp;#8220;January 2013 Purchase Agreement&amp;#8221;) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the January 2013 Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January&amp;#160;25, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA&amp;#8217;s common stock on the Nasdaq Capital Market on January&amp;#160;22, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company filed a registration statement for the resale of the shares underlying the units sold in the private placement. That registration statement was declared effective by the Securities and Exchange Commission on February&amp;#160;14, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &amp;#8220;variable rate transaction,&amp;#8221; which means a transaction in which the Company issues or sells any convertible securities either (A)&amp;#160;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)&amp;#160;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Registered Direct Offering &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &amp;#8220;Investors&amp;#8221;) in connection with its Registered Direct public offering,&amp;nbsp;&amp;nbsp;pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fees and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the offering closed on February&amp;#160;4, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA&amp;#8217;s common stock on the Nasdaq Capital Market on January&amp;#160;31, 2013.  The Offering was effected as a takedown of the Company&amp;#8217;s Registration Statement on Form S-3, as amended, which became effective on April&amp;#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&amp;#160;1, 2013.&amp;nbsp;&amp;nbsp;The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Public Offering&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June&amp;#160;4, 2013, the Company sold shares of its Series A Convertible Preferred Stock (Preferred Stock) and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20.0 million. The Company issued 125,000 shares of Preferred Stock and warrants to purchase up to 6,250,000 shares of common stock at a purchase price of $160 per share of Preferred Stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by the Company, were approximately $17.9 million. ARCA&amp;#8217;s Director and Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each share of Preferred Stock was convertible into 100 shares of the Company&amp;#8217;s common stock at any time at the option of the holder.&amp;nbsp;&amp;nbsp;Each share of Preferred Stock had a liquidation preference of $.001 per share. The shares of Preferred Stock had no preferential dividends or redemption rights, and no voting rights except as required by law. During 2013, all 125,000 of the shares of the Preferred Stock were converted into 12,500,000 shares of ARCA common stock.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each purchaser in the offering was issued a warrant to purchase 50 shares of the Company&amp;#8217;s common stock for each share of Preferred Stock purchased. The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance, provided that the holder will be prohibited from exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the Company&amp;#8217;s Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May&amp;#160;29, 2013, and the Preferred Stock and Warrants were offered and sold pursuant to a prospectus dated May&amp;#160;30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company&amp;#8217;s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since ARCA has an accumulated deficit, the deemed dividend is recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company&amp;#8217;s statement of stockholders&amp;#8217; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2014 Equity Financing &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Registered Direct Offering&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&amp;#160;3, 2014, the Company agreed to sell to certain investors an aggregate of 5,116,228 shares of the Company&amp;#8217;s common stock and warrants to purchase an aggregate of 1,279,057 shares of the Company&amp;#8217;s common stock at a purchase price of $1.70 per share of Common Stock, for aggregate gross proceeds of approximately $8.7 million, before deducting placement agent fees and other offering related expenses. The offering closed on February&amp;#160;7, 2014, and the net proceeds to the Company were approximately $7.9 million.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $2.125 per share, equal to 125% of the closing bid price of ARCA&amp;#8217;s common stock on the Nasdaq Capital Market on February 3, 2014. The offering was effected as a takedown off the Company&amp;#8217;s Registration Statement on Form S-3, as amended, which became effective on April&amp;#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&amp;#160;4, 2014. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Warrants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2014, warrants to purchase 9,371,002 shares of common stock were outstanding at exercise prices ranging from $1.60 to $116.89, with a weighted average exercise price per share of $2.31. These warrants, which were granted as part of various financing and business agreements, expire at various times between April 2016 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. &lt;/p&gt;&lt;/div&gt;</abio:EquityFinancingsAndWarrantsDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000189" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8) Share-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s equity incentive plan, &lt;font style="font-style:italic;"&gt;the 2013 Equity Incentive Plan &lt;/font&gt;(the Equity Plan),&lt;font style="font-style:italic;"&gt; &lt;/font&gt;was approved by stockholders on September 17, 2013.&amp;nbsp;&amp;nbsp;The maximum number of shares issuable under this plan is 2,250,000 shares.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&amp;#160;31, 2014, options and awards for 1,437,477 shares were outstanding under the Equity Plan, and 672,852 shares were reserved for future awards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of three to four years from the date of grant and have a maximum term of ten years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In conjunction with the adoption of the Equity Plan, the Company discontinued grants under its previous plan, the &lt;font style="font-style:italic;"&gt;Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan &lt;/font&gt;(the 2004 Plan), effective September 17, 2013. The 2004 Plan expired in 2014; however, options outstanding under the 2004 plan will continue to vest according to the original terms of each grant.&amp;nbsp;&amp;nbsp;As of December&amp;#160;31, 2014, options to purchase 59,776 shares with a weighted average exercise price of $15.10 per share were outstanding under this plan. Other stock plans that were assumed by ARCA in the Merger still have options outstanding that will continue to vest according to the original terms of each grant, but no new options can be granted under these plans, as the plans have expired.&amp;nbsp;&amp;nbsp;As of December 31, 2014, options to purchase 42,291 shares with a weighted average exercise price of $17.78 were outstanding under these plans.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December&amp;#160;31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December&amp;#160;31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of ARCA&amp;#8217;s stock option and stock award activities for the years ended December&amp;#160;31, 2014 and 2013, and related information as of December&amp;#160;31, 2014, is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding, beginning of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total intrinsic value of options exercised for the years ended December&amp;#160;31, 2014 and 2013 was $0 and $0, respectively. As of December&amp;#160;31, 2014, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $633,000 which is expected to be recognized over a weighted average period of 2.2 years. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options outstanding and exercisable as of December&amp;#160;31, 2014:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Remaining Contractual Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,933&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;727,869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.55&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company began granting restricted stock units (RSUs) to employees during 2013 in conjunction with the adoption of its 2013 Equity Incentive Plan.&amp;nbsp;&amp;nbsp;The fair value of RSU awards is the closing price of the Company&amp;#8217;s common stock on the date of grant and is recognized as compensation expense on a straight-line basis over the respective vesting period. The stock awards granted have a requisite service period of three or four years with annual vesting on the grant anniversary date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units outstanding,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;191,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(139,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units outstanding,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;471,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2014, the total unrecognized compensation cost related to unvested stock awards was approximately $629,000.&amp;nbsp;&amp;nbsp;This cost will be recognized on a straight-line basis over the next 2.4 years and will be adjusted for estimated forfeitures.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Non-cash Stock-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&amp;#160;31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense related to non-employees was negligible in 2014 and 2013. ARCA did not recognize any tax benefit related to employee stock-based compensation cost as a result of the full valuation allowance on its net deferred tax assets. &lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000190" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9) Employee Benefit Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a 401(k) plan and makes a matching contribution equal to 100% of the employee&amp;#8217;s first 3% of the employee&amp;#8217;s contributions and 50% of the employee&amp;#8217;s next 2% of contributions. The Company adopted the plan in 2006 and contributed $108,000 and $70,000 for the years ended December&amp;#160;31, 2014 and 2013, respectively . &lt;/p&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000191" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;font style="font-weight:bold;"&gt;10) Income Taxes &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective June&amp;#160;1, 2005, the Company changed from an S-Corporation to a C-Corporation. As an S-Corporation, the net operating loss carryforwards were distributed to the Company&amp;#8217;s stockholders; such amounts were not significant. Since June 2005 through December&amp;#160;31, 2014, for federal income tax purposes, the Company has net operating loss carryforwards of approximately $113.7 million, and approximately $991,000 of research and development credits that may be used to offset future taxable income. The net operating loss carryforwards will expire beginning 2025 through 2034. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section&amp;#160;382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&amp;#8217;s net operating loss carryforwards may be limited. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to the Company&amp;#8217;s history of operating losses, management is unable to conclude that it is more likely than not that the Company will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax asset of approximately $44.5 million at December&amp;#160;31, 2014, reflecting a decrease of approximately $0.4  million from December&amp;#160;31, 2013. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&amp;#160;31, 2014 the Company has not performed an Internal Revenue Code Section&amp;#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal income tax benefit at statutory rates&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,294&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and experimentation credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(171&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax asset adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,907&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Without regard to the deferred tax liability on the impaired IPR&amp;amp;D, the Company has had no provision for income taxes since inception due to its S-corporation status and its subsequent net operating losses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company&amp;#8217;s net deferred tax assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vacation accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net current deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charitable contribution carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and experimentation credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. Thus, the Company&amp;#8217;s open tax years extend back to 2009. The Company believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on the Company&amp;#8217;s financial condition, result of operations, or cash flow. For the years ended December&amp;#160;31, 2014 and 2013, the Company has no reserve for uncertain tax positions. The Company does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve months. In the event the Company concludes it is subject to interest or penalties arising from uncertain tax positions, the Company will record interest and penalties as a component of other income and expense. No material amounts of interest or penalties were recognized in the financial statements for the years ended December&amp;#160;31, 2014 and 2013. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock id="F_000192" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January&amp;#160;27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&amp;#160;24, 2008, and amended on October&amp;#160;28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidate, Gencaro&amp;#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro&amp;#8217;s pharmacology and may predict patient response to the drug. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA has created an adaptive design for GENETIC-AF.&amp;nbsp;&amp;nbsp;The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&amp;#8217;s primary end-point.&amp;#160; The DSMB interim analysis will focus on available data regarding the  primary endpoint, AF/AFL event rates, AF burden, and safety.&amp;#160;Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&amp;#8217;s  Steering Committee and the DSMB, will make the final determination on the trial&amp;#8217;s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. &lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:LiquidityDisclosureTextBlock id="F_000193" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&amp;nbsp;&amp;nbsp;The Company has historically funded its operations through issuances of common and preferred stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants.&amp;nbsp;&amp;nbsp;In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company&amp;#8217;s ongoing operations.&amp;nbsp;&amp;nbsp;&amp;#160; The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents  will be sufficient to fund its operations, at its projected cost structure, through the end of 2015.  However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company&amp;#8217;s ongoing operations.&amp;nbsp;&amp;nbsp;If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; progress of GENETIC-AF, including enrollment and any data that may become available; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;general economic and industry conditions affecting the availability and cost of capital; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to control costs associated with its operations; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a reasonable period of time.&amp;nbsp;&amp;nbsp;These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&amp;nbsp;&amp;nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.&lt;/p&gt;&lt;/div&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <abio:ReverseStockSplitPolicyTextBlock id="F_000194" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&amp;#160;4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. &lt;/p&gt;&lt;/div&gt;</abio:ReverseStockSplitPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000195" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented.&amp;nbsp;&amp;nbsp;Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.  &lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000196" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2014, the FASB issued FASB Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-10, &lt;font style="font-style:italic;"&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/font&gt; which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities.&amp;#160;&amp;#160;The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued.&amp;#160;&amp;#160;The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; In August 2014, the FASB issued FASB Accounting Standards Update (&amp;#8220;ASU No. 2014-15&amp;#8221;), &lt;font style="font-style:italic;"&gt;Presentation of Financial Statements &amp;#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-style:italic;text-decoration:underline;"&gt;.&lt;/font&gt;&amp;#160;&amp;#160;ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity&amp;#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued.&amp;#160;&amp;#160;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a reasonable period of time.&amp;nbsp;&amp;nbsp;The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000197" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting Estimates in the Preparation of Financial Statements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&amp;#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates. &lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000198" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.  &lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000199" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000200" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <abio:AccruedExpensesPolicyTextBlock id="F_000201" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/p&gt;&lt;/div&gt;</abio:AccruedExpensesPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000202" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting. &lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000203" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000204" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s stock-based compensation cost recognized  is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.  &lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000205" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company&amp;#8217;s history of operating losses. The Company has not performed an Internal Revenue Code Section&amp;#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000206" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands, except shares and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&amp;nbsp;&amp;nbsp;Series A Preferred Stock deemed dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss available to common shareholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares of common stock outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,501,224&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,631,668&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Weighted-average shares of unvested common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total weighted-average shares used in computing net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; loss per share attributed to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,501,224&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,629,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000207" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&amp;nbsp;&amp;nbsp;As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;Such potentially dilutive shares of common stock consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities, excluded:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;471,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,371,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,910,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,409,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000208" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser of useful life or life of the lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000209" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Below is a summary of the future minimum lease payments committed for the Company&amp;#8217;s facility in Westminster, Colorado as of December&amp;#160;31, 2014 (in thousands):&lt;/p&gt;&lt;/div&gt;&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000210" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December&amp;#160;31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December&amp;#160;31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock id="F_000211" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of ARCA&amp;#8217;s stock option and stock award activities for the years ended December&amp;#160;31, 2014 and 2013, and related information as of December&amp;#160;31, 2014, is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding, beginning of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="F_000212" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options outstanding and exercisable as of December&amp;#160;31, 2014:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Remaining Contractual Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,933&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;727,869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.55&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,515&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;494,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="F_000213" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units outstanding,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;191,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(139,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units outstanding,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;471,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000214" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&amp;#160;31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000215" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal income tax benefit at statutory rates&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,294&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and experimentation credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(171&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax asset adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,907&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000216" contextRef="C_0000907654_20140101_20141231">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company&amp;#8217;s net deferred tax assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vacation accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net current deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charitable contribution carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and experimentation credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net noncurrent deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 id="F_000217" contextRef="C_0000907654_20140101_20141231">2009-01-27</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
  <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 id="F_000218" contextRef="C_0000907654_us-gaapBusinessAcquisitionAxis_abioOriginalMember_20140101_20141231">2008-09-24</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
  <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 id="F_000219" contextRef="C_0000907654_us-gaapBusinessAcquisitionAxis_abioAmendmentMember_20140101_20141231">2008-10-28</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
  <abio:NumberOfPatients id="F_000220" contextRef="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseThreeHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioBestTrialMember_20140101_20141231" decimals="INF" unitRef="U_abioPatients">2708</abio:NumberOfPatients>
  <abio:NumberOfPatientsCompanyPlansToEnroll id="F_000221" contextRef="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseTwoBHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioGENETICAFTrialMember_20140101_20141231" decimals="INF" unitRef="U_abioPatients">200</abio:NumberOfPatientsCompanyPlansToEnroll>
  <abio:NumberOfPatientsCompanyPlansToEnroll id="F_000222" contextRef="C_0000907654_abioClinicalTrialsByPhaseAxis_abioPhaseThreeHeartFailureMember_us-gaapHealthCareTrustFundAxis_abioGENETICAFTrialMember_20140101_20141231" decimals="INF" unitRef="U_abioPatients">420</abio:NumberOfPatientsCompanyPlansToEnroll>
  <us-gaap:Revenues id="F_000223" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:Revenues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000224" contextRef="C_0000907654_20130101_20131231" decimals="-5" unitRef="U_iso4217USD">19300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000225" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140201_20140228" decimals="-5" unitRef="U_iso4217USD">7900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:ClosingBidPriceOfCommonStock id="F_000226" contextRef="C_0000907654_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20150218_20150218" decimals="INF" unitRef="U_iso4217USD_abioshares">1.00</abio:ClosingBidPriceOfCommonStock>
  <abio:NotificationForDelistingOfSharesDescription id="F_000227" contextRef="C_0000907654_20140101_20141231">On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.  NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.</abio:NotificationForDelistingOfSharesDescription>
  <abio:GracePeriodProvidedToMeetContinuedListingStandard id="F_000228" contextRef="C_0000907654_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20150218_20150218">P180D</abio:GracePeriodProvidedToMeetContinuedListingStandard>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000229" contextRef="C_0000907654_20130304_20130304">1-for-6 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure id="F_000230" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
  <us-gaap:NumberOfOperatingSegments id="F_000231" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_abioSegment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000232" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_shares">20501224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000233" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_shares">8631668</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="F_000234" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_shares">2188</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000235" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_shares">20501224</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000236" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_shares">8629480</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <abio:SecuritiesInMoney id="F_000237" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20140101_20141231" decimals="-3" unitRef="U_shares">0</abio:SecuritiesInMoney>
  <abio:SecuritiesInMoney id="F_000238" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20140101_20141231" decimals="0" unitRef="U_shares">0</abio:SecuritiesInMoney>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000239" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20140101_20141231" decimals="INF" unitRef="U_shares">1068515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000240" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20130101_20131231" decimals="INF" unitRef="U_shares">843442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000241" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20140101_20141231" decimals="INF" unitRef="U_shares">471029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000242" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">419000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000243" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20140101_20141231" decimals="INF" unitRef="U_shares">9371002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000244" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20130101_20131231" decimals="INF" unitRef="U_shares">8147484</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000245" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_shares">10910546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000246" contextRef="C_0000907654_20130101_20131231" decimals="INF" unitRef="U_shares">9409926</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000247" contextRef="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="-5" unitRef="U_iso4217USD">15300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000248" contextRef="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20131231" decimals="-5" unitRef="U_iso4217USD">16500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount id="F_000249" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount>
  <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount id="F_000250" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_iso4217USD">0</abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount>
  <us-gaap:AssetsFairValueDisclosure id="F_000251" contextRef="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000252" contextRef="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000253" contextRef="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000254" contextRef="C_0000907654_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000255" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20140101_20141231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000256" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20140101_20141231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000257" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20140101_20141231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000258" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20140101_20141231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000259" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20140101_20141231">Lesser of useful life or life of the lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000260" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20141231" decimals="-3" unitRef="U_iso4217USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000261" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20131231" decimals="-3" unitRef="U_iso4217USD">99000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000262" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20141231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000263" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20131231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000264" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20141231" decimals="-3" unitRef="U_iso4217USD">89000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000265" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20131231" decimals="-3" unitRef="U_iso4217USD">89000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000266" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20141231" decimals="-3" unitRef="U_iso4217USD">82000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000267" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20131231" decimals="-3" unitRef="U_iso4217USD">176000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000268" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20141231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000269" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20131231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000270" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">418000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000271" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">514000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000272" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">382000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000273" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">485000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000274" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapChiefExecutiveOfficerMember_20140101_20141231" decimals="0" unitRef="U_iso4217USD">350000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000275" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapChiefExecutiveOfficerMember_20130101_20131231" decimals="0" unitRef="U_iso4217USD">297000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:AreaOfRealEstateProperty id="F_000276" contextRef="C_0000907654_us-gaapStatementGeographicalAxis_abioWestminsterMember_20130801" decimals="0" unitRef="U_utrsqft">5300</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000277" contextRef="C_0000907654_us-gaapStatementGeographicalAxis_abioWestminsterMember_20140101_20141231">P3Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:LeaseExpirationDate1 id="F_000278" contextRef="C_0000907654_us-gaapStatementGeographicalAxis_abioWestminsterMember_20140101_20141231">2016-09-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000279" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">80000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000280" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">62000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000281" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000282" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">78000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000283" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">63000</us-gaap:OperatingLeasesRentExpenseNet>
  <abio:AgreementTerminationNoticePeriod id="F_000284" contextRef="C_0000907654_20140101_20141231">P90D</abio:AgreementTerminationNoticePeriod>
  <abio:ExpectedMilestonePaymentsUponApproval id="F_000285" contextRef="C_0000907654_20141231" decimals="-5" unitRef="U_iso4217USD">8000000</abio:ExpectedMilestonePaymentsUponApproval>
  <abio:AnotherExpectedMilestonePaymentsUponApproval id="F_000286" contextRef="C_0000907654_20141231" decimals="-5" unitRef="U_iso4217USD">5000000</abio:AnotherExpectedMilestonePaymentsUponApproval>
  <abio:MinimumPercentageOfRoyaltyObligation id="F_000287" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.125</abio:MinimumPercentageOfRoyaltyObligation>
  <abio:MaximumPercentageOfRoyaltyObligation id="F_000288" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.25</abio:MaximumPercentageOfRoyaltyObligation>
  <abio:PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement id="F_000289" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.05</abio:PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement>
  <abio:MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown id="F_000290" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.125</abio:MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown>
  <abio:MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown id="F_000291" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.17</abio:MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown>
  <abio:RoyaltyBuyDownDuePeriod id="F_000292" contextRef="C_0000907654_20140101_20141231">P6M</abio:RoyaltyBuyDownDuePeriod>
  <us-gaap:CommonStockSharesIssued id="F_000293" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_shares">356430</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000294" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_shares">249501</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="F_000295" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130121_20130122" decimals="-6" unitRef="U_iso4217USD">1000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <abio:NetProceedsFromIssuanceOfPrivatePlacement id="F_000296" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130121_20130122" decimals="-3" unitRef="U_iso4217USD">805000</abio:NetProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:EquityIssuanceDates id="F_000297" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20140101_20141231">2013-01-25</us-gaap:EquityIssuanceDates>
  <abio:PrivatePlacementSubscriptionDate id="F_000298" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20140101_20141231">2013-01-22</abio:PrivatePlacementSubscriptionDate>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000299" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_shares">0.70</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:SharesIssuedPricePerShare id="F_000300" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_iso4217USD_abioshares">2.81</us-gaap:SharesIssuedPricePerShare>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000301" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130121_20130122">P7Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000302" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_iso4217USD_abioshares">2.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares id="F_000303" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20130122" decimals="INF" unitRef="U_pure">1.00</abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares>
  <abio:ClosingBidPriceDate id="F_000304" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20140101_20141231">2013-01-22</abio:ClosingBidPriceDate>
  <us-gaap:CommonStockSharesIssued id="F_000305" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_shares">164636</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000306" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_shares">65855</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000307" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130130_20130131" decimals="-4" unitRef="U_iso4217USD">730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:NetProceedsFromIssuanceOfCommonStock id="F_000308" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130204_20130204" decimals="-3" unitRef="U_iso4217USD">616000</abio:NetProceedsFromIssuanceOfCommonStock>
  <us-gaap:EquityIssuanceDates id="F_000309" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130130_20130131">2013-02-04</us-gaap:EquityIssuanceDates>
  <abio:RegisteredDirectSubscriptionDate id="F_000310" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130130_20130131">2013-01-31</abio:RegisteredDirectSubscriptionDate>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000311" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_shares">0.40</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:SharesIssuedPricePerShare id="F_000312" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_iso4217USD_abioshares">4.43</us-gaap:SharesIssuedPricePerShare>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000313" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130130_20130131">P5Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000314" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_iso4217USD_abioshares">4.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abio:ClosingBidPriceDate id="F_000315" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20130101_20131231">2013-01-31</abio:ClosingBidPriceDate>
  <abio:PreferredStockIssuedDuringPeriodSharesNewIssues id="F_000316" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604" decimals="INF" unitRef="U_shares">125000</abio:PreferredStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000317" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_shares">6250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000318" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604" decimals="0" unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:SharesIssuedPricePerShare id="F_000319" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_iso4217USD_abioshares">160</us-gaap:SharesIssuedPricePerShare>
  <abio:NetProceedsFromIssuanceOfCommonStock id="F_000320" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604" decimals="-5" unitRef="U_iso4217USD">17900000</abio:NetProceedsFromIssuanceOfCommonStock>
  <abio:PreferredStockPurchasedByOfficer id="F_000321" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapTitleOfIndividualAxis_abioDirectorAndChiefExecutiveOfficerMember_20130604" decimals="INF" unitRef="U_shares">781</abio:PreferredStockPurchasedByOfficer>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000322" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapTitleOfIndividualAxis_abioDirectorAndChiefExecutiveOfficerMember_20130604" decimals="INF" unitRef="U_shares">39050</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000323" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_shares">100</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockLiquidationPreference id="F_000324" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="3" unitRef="U_iso4217USD_abioshares">0.001</us-gaap:PreferredStockLiquidationPreference>
  <abio:PreferredStockConvertedInToCommonStock id="F_000325" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">125000</abio:PreferredStockConvertedInToCommonStock>
  <us-gaap:ConversionOfStockSharesConverted1 id="F_000326" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20131231" decimals="INF" unitRef="U_shares">12500000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000327" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_shares">50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000328" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_iso4217USD_abioshares">1.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000329" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604">P5Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <abio:PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership id="F_000330" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130604" decimals="INF" unitRef="U_pure">0.0999</abio:PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership>
  <abio:IntrinsicValueOfEmbeddedBeneficialConversionFeature id="F_000331" contextRef="C_0000907654_us-gaapSecuritiesFinancingTransactionAxis_abioPublicOfferingMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20130602_20130604" decimals="-5" unitRef="U_iso4217USD">2000000</abio:IntrinsicValueOfEmbeddedBeneficialConversionFeature>
  <us-gaap:CommonStockSharesIssued id="F_000332" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_shares">5116228</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000333" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_shares">1279057</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharesIssuedPricePerShare id="F_000334" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_iso4217USD_abioshares">1.70</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000335" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140202_20140203" decimals="-3" unitRef="U_iso4217USD">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:NetProceedsFromIssuanceOfCommonStock id="F_000336" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140206_20140207" decimals="-5" unitRef="U_iso4217USD">7900000</abio:NetProceedsFromIssuanceOfCommonStock>
  <abio:ClosingBidPriceDate id="F_000337" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140101_20141231">2014-02-03</abio:ClosingBidPriceDate>
  <us-gaap:EquityIssuanceDates id="F_000338" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140101_20141231">2014-02-07</us-gaap:EquityIssuanceDates>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000339" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_shares">0.25</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000340" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140202_20140203">P5Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000341" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_iso4217USD_abioshares">2.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares id="F_000342" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioRegisteredDirectOfferingMember_20140203" decimals="INF" unitRef="U_pure">1.25</abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000343" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">9371002</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000344" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000345" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">116.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000346" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapWeightedAverageMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">2.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abio:ClassOfWarrantOrRightsExpirationDateEarliest id="F_000347" contextRef="C_0000907654_20140101_20141231">2016-04</abio:ClassOfWarrantOrRightsExpirationDateEarliest>
  <abio:ClassOfWarrantOrRightsExpirationDateLatest id="F_000348" contextRef="C_0000907654_20140101_20141231">2020-01</abio:ClassOfWarrantOrRightsExpirationDateLatest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000349" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20130917" decimals="INF" unitRef="U_shares">2250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000350" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20141231" decimals="INF" unitRef="U_shares">1437477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000351" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20141231" decimals="INF" unitRef="U_shares">672852</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000352" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000353" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20140101_20141231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000354" contextRef="C_0000907654_20140101_20141231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000355" contextRef="C_0000907654_us-gaapAwardTypeAxis_abioIncentiveStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231" decimals="INF" unitRef="U_pure">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000356" contextRef="C_0000907654_us-gaapAwardTypeAxis_abioIncentiveStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapPrincipalOwnerMember_20140101_20141231" decimals="INF" unitRef="U_pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <abio:PercentageHoldingForStockOptionsExercisePrice id="F_000357" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231" decimals="INF" unitRef="U_pure">0.10</abio:PercentageHoldingForStockOptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000358" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndFourStockOptionPlanMember_20141231" decimals="INF" unitRef="U_shares">59776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000359" contextRef="C_0000907654_us-gaapPlanNameAxis_abioOtherStockOptionPlanMember_20141231" decimals="INF" unitRef="U_shares">42291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000360" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndFourStockOptionPlanMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">15.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000361" contextRef="C_0000907654_us-gaapPlanNameAxis_abioOtherStockOptionPlanMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">17.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="F_000362" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20140101_20141231" decimals="INF" unitRef="U_shares">420279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="F_000363" contextRef="C_0000907654_us-gaapPlanNameAxis_abioTwoThousandAndThirteenPlanMember_20130101_20131231" decimals="INF" unitRef="U_shares">1160535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000364" contextRef="C_0000907654_20140101_20141231">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000365" contextRef="C_0000907654_20130101_20131231">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000366" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000367" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_pure">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000368" contextRef="C_0000907654_20140101_20141231" decimals="4" unitRef="U_pure">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000369" contextRef="C_0000907654_20130101_20131231" decimals="4" unitRef="U_pure">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000370" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000371" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000372" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000373" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000374" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">843442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000375" contextRef="C_0000907654_20121231" decimals="INF" unitRef="U_shares">144019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000376" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_shares">228579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000377" contextRef="C_0000907654_20130101_20131231" decimals="INF" unitRef="U_shares">741535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000378" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_shares">3506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000379" contextRef="C_0000907654_20130101_20131231" decimals="INF" unitRef="U_shares">42112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000380" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">1068515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000381" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">494291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000382" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">194550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000383" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">1066712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000384" contextRef="C_0000907654_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000385" contextRef="C_0000907654_20121231" decimals="2" unitRef="U_iso4217USD_abioshares">18.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000386" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000387" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">1.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000388" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">140.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000389" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000390" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">2.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000391" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000392" contextRef="C_0000907654_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000393" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">2.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000394" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000395" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000396" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20141231" decimals="0" unitRef="U_iso4217USD">633000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000397" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20140101_20141231">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000398" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">0.36</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000399" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000400" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000401" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000402" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">22.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000403" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.33</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000404" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000405" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">1.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000406" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">22.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000407" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20140101_20141231" decimals="INF" unitRef="U_iso4217USD_abioshares">33.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000408" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20141231" decimals="INF" unitRef="U_shares">29933</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000409" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20141231" decimals="INF" unitRef="U_shares">727869</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000410" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20141231" decimals="INF" unitRef="U_shares">212495</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000411" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20141231" decimals="INF" unitRef="U_shares">82300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000412" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20141231" decimals="INF" unitRef="U_shares">15918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000413" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">1068515</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000414" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20140101_20141231">P9Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000415" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20140101_20141231">P8Y5M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000416" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20140101_20141231">P9Y1M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000417" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20140101_20141231">P4Y5M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000418" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20140101_20141231">P3Y8M27D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000419" contextRef="C_0000907654_20140101_20141231">P8Y3M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000420" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.05</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000421" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000422" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000423" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">13.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000424" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">32.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="F_000425" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">2.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000426" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20141231" decimals="INF" unitRef="U_shares">704</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000427" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20141231" decimals="INF" unitRef="U_shares">329189</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000428" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20141231" decimals="INF" unitRef="U_shares">70410</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000429" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20141231" decimals="INF" unitRef="U_shares">78070</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000430" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20141231" decimals="INF" unitRef="U_shares">15918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000431" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">494291</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000432" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeOneMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000433" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeTwoMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000434" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeThreeMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000435" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFourMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">13.55</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000436" contextRef="C_0000907654_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abioExercisePriceRangeFiveMember_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">32.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000437" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">4.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="F_000438" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRangeAxis_us-gaapMinimumMember_20140101_20141231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="F_000439" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRangeAxis_us-gaapMaximumMember_20140101_20141231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000440" contextRef="C_0000907654_20131231" decimals="INF" unitRef="U_shares">419000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000441" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_shares">191700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000442" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_shares">139671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000443" contextRef="C_0000907654_20141231" decimals="INF" unitRef="U_shares">471029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000444" contextRef="C_0000907654_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000445" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000446" contextRef="C_0000907654_20140101_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000447" contextRef="C_0000907654_20141231" decimals="2" unitRef="U_iso4217USD_abioshares">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000448" contextRef="C_0000907654_20130101_20131231" decimals="2" unitRef="U_iso4217USD_abioshares">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000449" contextRef="C_0000907654_20130101_20131231" decimals="INF" unitRef="U_shares">419000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_000450" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20141231" decimals="0" unitRef="U_iso4217USD">629000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000451" contextRef="C_0000907654_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140101_20141231">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000452" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">158000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000453" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">77000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000454" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">489000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000455" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">206000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000456" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">647000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000457" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">283000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans id="F_000458" contextRef="C_0000907654_20140101_20141231">matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000459" contextRef="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioFirstThreePercentPayContributionMember_20140101_20141231" decimals="INF" unitRef="U_pure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000460" contextRef="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioFirstThreePercentPayContributionMember_20140101_20141231" decimals="2" unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000461" contextRef="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioNextTwoPercentPayContributionMember_20140101_20141231" decimals="2" unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000462" contextRef="C_0000907654_20140101_20141231" decimals="0" unitRef="U_iso4217USD">108000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000463" contextRef="C_0000907654_20130101_20131231" decimals="0" unitRef="U_iso4217USD">70000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000464" contextRef="C_0000907654_us-gaapDefinedContributionPlanNameAxis_abioNextTwoPercentPayContributionMember_20140101_20141231" decimals="2" unitRef="U_pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:OperatingLossCarryforwards id="F_000465" contextRef="C_0000907654_20141231" decimals="-5" unitRef="U_iso4217USD">113700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000466" contextRef="C_0000907654_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20141231" decimals="-3" unitRef="U_iso4217USD">991000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardDescription id="F_000467" contextRef="C_0000907654_20140101_20141231">The net operating loss carryforwards will expire beginning 2025 through 2034.</us-gaap:TaxCreditCarryforwardDescription>
  <abio:OperatingLossCarryforwardsExpirationYear id="F_000468" contextRef="C_0000907654_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20140101_20141231">2025</abio:OperatingLossCarryforwardsExpirationYear>
  <abio:OperatingLossCarryforwardsExpirationYear id="F_000469" contextRef="C_0000907654_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20140101_20141231">2034</abio:OperatingLossCarryforwardsExpirationYear>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="F_000470" contextRef="C_0000907654_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20140101_20141231">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#8217;s net operating loss carryforwards may be limited</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <us-gaap:TaxCreditCarryforwardLimitationsOnUse id="F_000471" contextRef="C_0000907654_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20140101_20141231">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#8217;s net operating loss carryforwards may be limited</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000472" contextRef="C_0000907654_20141231" decimals="-5" unitRef="U_iso4217USD">44500000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000473" contextRef="C_0000907654_20140101_20141231" decimals="-5" unitRef="U_iso4217USD">-400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000474" contextRef="C_0000907654_20140101_20141231" decimals="INF" unitRef="U_pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000475" contextRef="C_0000907654_20130101_20131231" decimals="INF" unitRef="U_pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000476" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-3294000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000477" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-2429000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000478" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-296000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000479" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">-209000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000480" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">171000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000481" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">133000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate id="F_000482" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">1041000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset id="F_000483" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">2907000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000484" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">178000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000485" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">184000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000486" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">-365000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000487" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">2587000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000488" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000489" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000490" contextRef="C_0000907654_us-gaapStatementScenarioAxis_abioWithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences id="F_000491" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences id="F_000492" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsGrossCurrent id="F_000493" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:DeferredTaxAssetsGrossCurrent id="F_000494" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent id="F_000495" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent id="F_000496" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent id="F_000497" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent id="F_000498" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration id="F_000499" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">42135000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration id="F_000500" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">39799000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000501" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">410000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000502" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">371000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000503" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">991000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000504" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">820000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000505" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">741000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000506" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">3351000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000507" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">158000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000508" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">454000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="F_000509" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="F_000510" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsGrossNoncurrent id="F_000511" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">44437000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
  <us-gaap:DeferredTaxAssetsGrossNoncurrent id="F_000512" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">44800000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent id="F_000513" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">44437000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent id="F_000514" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">44800000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="F_000515" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="F_000516" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000517" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000518" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued id="F_000519" contextRef="C_0000907654_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued id="F_000520" contextRef="C_0000907654_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense id="F_000521" contextRef="C_0000907654_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense id="F_000522" contextRef="C_0000907654_20130101_20131231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:OpenTaxYear id="F_000523" contextRef="C_0000907654_20140101_20141231">2009</us-gaap:OpenTaxYear>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abio-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Schema Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20141231" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arcabiopharma.com/20141231" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" namespace="http://fasb.org/us-types/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" namespace="http://fasb.org/us-gaap/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" namespace="http://xbrl.sec.gov/country/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arcabiopharma.com/20141231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS" id="Role_StatementBALANCESHEETS">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical" id="Role_StatementBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" id="Role_StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>100040 - Statement - STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&apos; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" id="Role_StatementSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100070 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100080 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100090 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangements" id="Role_DisclosureRelatedPartyArrangements">
        <link:definition>100100 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrants" id="Role_DisclosureEquityFinancingsAndWarrants">
        <link:definition>100120 - Disclosure - Equity Financings and Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100130 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>100140 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100170 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100180 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100190 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100200 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100210 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>100220 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails" id="Role_DisclosureSummaryOfBasicAndDilutedLossPerShareDetails">
        <link:definition>100230 - Disclosure - Summary of Basic and Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual" id="Role_DisclosureNetLossPerShareDetailsTextual">
        <link:definition>100240 - Disclosure - Net Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1" id="Role_DisclosureNetLossPerShareDetails1">
        <link:definition>100250 - Disclosure - Net Loss Per Share (Details 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails" id="Role_DisclosureFinancialInstrumentsDetails">
        <link:definition>100260 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100270 - Disclosure - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" id="Role_DisclosurePropertyAndEquipmentDetailsTextual">
        <link:definition>100280 - Disclosure - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails" id="Role_DisclosureRelatedPartyArrangementsDetails">
        <link:definition>100290 - Disclosure - Related Party Arrangements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" id="Role_DisclosureCommitmentsAndContingenciesDetailsTextual">
        <link:definition>100300 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails" id="Role_DisclosureFutureMinimumLeasePaymentsDetails">
        <link:definition>100310 - Disclosure - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" id="Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual">
        <link:definition>100320 - Disclosure - Equity Financings and Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual" id="Role_DisclosureShareBasedCompensationDetailsTextual">
        <link:definition>100330 - Disclosure - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails" id="Role_DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails">
        <link:definition>100340 - Disclosure - Estimated Weighted Average Grant Date Fair Value Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails" id="Role_DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails">
        <link:definition>100350 - Disclosure - Summary of Stock Option and Stock Award Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails" id="Role_DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails">
        <link:definition>100360 - Disclosure - Summary of Stock Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfRSUActivityDetails" id="Role_DisclosureSummaryOfRSUActivityDetails">
        <link:definition>100370 - Disclosure - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails" id="Role_DisclosureNonCashShareBasedCompensationExpenseDetails">
        <link:definition>100380 - Disclosure - Non-Cash, Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails" id="Role_DisclosureEmployeeBenefitPlansDetails">
        <link:definition>100390 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual" id="Role_DisclosureIncomeTaxesDetailsTextual">
        <link:definition>100400 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails" id="Role_DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails">
        <link:definition>100410 - Disclosure - Income Taxes - Income Tax Benefit Attributable to Our Loss from Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>100420 - Disclosure - Income Taxes - Net deferred tax assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="abio_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" name="IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" name="IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" name="PreferredStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PreferredStockIssuedDuringPeriodValueNewIssues" name="PreferredStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_DeemedDividendBeneficialConversionPreferredStock" name="DeemedDividendBeneficialConversionPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_FinancialInstrumentsAbstract" name="FinancialInstrumentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" name="EquityFinancingsAndWarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_CompanyBasisOfPresentationTextualAbstract" name="CompanyBasisOfPresentationTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" name="CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" name="CompanyAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_OriginalMember" name="OriginalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_AmendmentMember" name="AmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ClinicalTrialsByPhaseAxis" name="ClinicalTrialsByPhaseAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ClinicalTrialsByPhaseDomain" name="ClinicalTrialsByPhaseDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PhaseThreeHeartFailureMember" name="PhaseThreeHeartFailureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_BestTrialMember" name="BestTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_GENETICAFTrialMember" name="GENETICAFTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PhaseTwoBHeartFailureMember" name="PhaseTwoBHeartFailureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_NumberOfPatients" name="NumberOfPatients" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_NumberOfPatientsCompanyPlansToEnroll" name="NumberOfPatientsCompanyPlansToEnroll" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ClosingBidPriceOfCommonStock" name="ClosingBidPriceOfCommonStock" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_NotificationForDelistingOfSharesDescription" name="NotificationForDelistingOfSharesDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_GracePeriodProvidedToMeetContinuedListingStandard" name="GracePeriodProvidedToMeetContinuedListingStandard" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_SecuritiesInMoney" name="SecuritiesInMoney" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FairValueDisclosuresAdditionalTextualAbstract" name="FairValueDisclosuresAdditionalTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_WestminsterMember" name="WestminsterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ExpectedMilestonePaymentsUponApproval" name="ExpectedMilestonePaymentsUponApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_AnotherExpectedMilestonePaymentsUponApproval" name="AnotherExpectedMilestonePaymentsUponApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_MinimumPercentageOfRoyaltyObligation" name="MinimumPercentageOfRoyaltyObligation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MaximumPercentageOfRoyaltyObligation" name="MaximumPercentageOfRoyaltyObligation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" name="PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" name="MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" name="MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_RoyaltyBuyDownDuePeriod" name="RoyaltyBuyDownDuePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_EquityFinancingsAndWarrantsTextualAbstract" name="EquityFinancingsAndWarrantsTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_NetProceedsFromIssuanceOfPrivatePlacement" name="NetProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_PrivatePlacementSubscriptionDate" name="PrivatePlacementSubscriptionDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_DirectorAndChiefExecutiveOfficerMember" name="DirectorAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PublicOfferingMember" name="PublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" name="ClassOfWarrantOrRightExercisableExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" name="ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_ClosingBidPriceDate" name="ClosingBidPriceDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_RegisteredDirectSubscriptionDate" name="RegisteredDirectSubscriptionDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PreferredStockPurchasedByOfficer" name="PreferredStockPurchasedByOfficer" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_PreferredStockConvertedInToCommonStock" name="PreferredStockConvertedInToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" name="PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" name="IntrinsicValueOfEmbeddedBeneficialConversionFeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_ClassOfWarrantOrRightsExpirationDateEarliest" name="ClassOfWarrantOrRightsExpirationDateEarliest" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ClassOfWarrantOrRightsExpirationDateLatest" name="ClassOfWarrantOrRightsExpirationDateLatest" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_TwoThousandAndThirteenPlanMember" name="TwoThousandAndThirteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IncentiveStockOptionMember" name="IncentiveStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_TwoThousandAndFourStockOptionPlanMember" name="TwoThousandAndFourStockOptionPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_OtherStockOptionPlanMember" name="OtherStockOptionPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PercentageHoldingForStockOptionsExercisePrice" name="PercentageHoldingForStockOptionsExercisePrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FirstThreePercentPayContributionMember" name="FirstThreePercentPayContributionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_NextTwoPercentPayContributionMember" name="NextTwoPercentPayContributionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" name="WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" name="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>abio-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20141231.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20141231/role/TemplateLink" />
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS" xlink:href="abio-20141231.xsd#Role_StatementBALANCESHEETS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" order="10190.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10830.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10840.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="10150.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>abio-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="abio-20141231.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20141231/role/TemplateLink" />
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical" xlink:href="abio-20141231.xsd#Role_StatementBALANCESHEETSParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11050.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="abio-20141231.xsd#abio_DeemedDividendBeneficialConversionPreferredStock" xlink:type="locator" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" />
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" order="11800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_PreferredStockIssuedDuringPeriodValueNewIssues" order="12000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_DeemedDividendBeneficialConversionPreferredStock" order="12220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="12440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="14820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="15020.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="11620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" order="11980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="12400.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="abio-20141231.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="abio-20141231.xsd#abio_GracePeriodProvidedToMeetContinuedListingStandard" xlink:type="locator" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard" />
    <loc xlink:href="abio-20141231.xsd#abio_NotificationForDelistingOfSharesDescription" xlink:type="locator" xlink:label="abio_NotificationForDelistingOfSharesDescription" />
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceOfCommonStock" xlink:type="locator" xlink:label="abio_ClosingBidPriceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatients" xlink:type="locator" xlink:label="abio_NumberOfPatients" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PhaseTwoBHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseTwoBHeartFailureMember" />
    <loc xlink:href="abio-20141231.xsd#abio_GENETICAFTrialMember" xlink:type="locator" xlink:label="abio_GENETICAFTrialMember" />
    <loc xlink:href="abio-20141231.xsd#abio_BestTrialMember" xlink:type="locator" xlink:label="abio_BestTrialMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PhaseThreeHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseThreeHeartFailureMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseDomain" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseDomain_2" />
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseDomain" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseDomain" />
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseAxis" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_AmendmentMember" xlink:type="locator" xlink:label="abio_AmendmentMember" />
    <loc xlink:href="abio-20141231.xsd#abio_OriginalMember" xlink:type="locator" xlink:label="abio_OriginalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="abio_OriginalMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="abio_AmendmentMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_ClinicalTrialsByPhaseAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abio_ClinicalTrialsByPhaseAxis" xlink:to="abio_ClinicalTrialsByPhaseDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abio_ClinicalTrialsByPhaseAxis" xlink:to="abio_ClinicalTrialsByPhaseDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ClinicalTrialsByPhaseDomain" xlink:to="abio_PhaseThreeHeartFailureMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_HealthCareTrustFundAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareTrustFundAxis" xlink:to="us-gaap_HealthCareTrustFundNameDomain_2" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareTrustFundAxis" xlink:to="us-gaap_HealthCareTrustFundNameDomain" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareTrustFundNameDomain" xlink:to="abio_BestTrialMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareTrustFundNameDomain" xlink:to="abio_GENETICAFTrialMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ClinicalTrialsByPhaseDomain" xlink:to="abio_PhaseTwoBHeartFailureMember" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyBasisOfPresentationTextualAbstract" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatients" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_Revenues" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_ClosingBidPriceOfCommonStock" order="11400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NotificationForDelistingOfSharesDescription" order="11480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_GracePeriodProvidedToMeetContinuedListingStandard" order="11560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" order="11820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="11930.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShareDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_SecuritiesInMoney" xlink:type="locator" xlink:label="abio_SecuritiesInMoney" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_SecuritiesInMoney" order="10130.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShareDetails1" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureFinancialInstrumentsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsTextualAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FinancialInstrumentsTextualAbstract" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FinancialInstrumentsTextualAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11030.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11450.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureRelatedPartyArrangementsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_RoyaltyBuyDownDuePeriod" xlink:type="locator" xlink:label="abio_RoyaltyBuyDownDuePeriod" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20141231.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20141231.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20141231.xsd#abio_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="abio_AgreementTerminationNoticePeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <loc xlink:href="abio-20141231.xsd#abio_WestminsterMember" xlink:type="locator" xlink:label="abio_WestminsterMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="abio_WestminsterMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AgreementTerminationNoticePeriod" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExpectedMilestonePaymentsUponApproval" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRoyaltyObligation" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRoyaltyObligation" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="10860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_RoyaltyBuyDownDuePeriod" order="10900.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateLatest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateEarliest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="abio-20141231.xsd#abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" xlink:type="locator" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" xlink:type="locator" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockConvertedInToCommonStock" xlink:type="locator" xlink:label="abio_PreferredStockConvertedInToCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockPurchasedByOfficer" xlink:type="locator" xlink:label="abio_PreferredStockPurchasedByOfficer" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectSubscriptionDate" xlink:type="locator" xlink:label="abio_RegisteredDirectSubscriptionDate" />
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceDate" xlink:type="locator" xlink:label="abio_ClosingBidPriceDate" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <loc xlink:href="abio-20141231.xsd#abio_PrivatePlacementSubscriptionDate" xlink:type="locator" xlink:label="abio_PrivatePlacementSubscriptionDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuanceDates" xlink:type="locator" xlink:label="us-gaap_EquityIssuanceDates" />
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="abio-20141231.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:type="locator" xlink:label="us-gaap_WeightedAverageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PublicOfferingMember" xlink:type="locator" xlink:label="abio_PublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_DirectorAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_DirectorAndChiefExecutiveOfficerMember" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_2" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="abio_PublicOfferingMember" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="11520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="11560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_WeightedAverageMember" order="11600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract" order="11630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_NetProceedsFromIssuanceOfPrivatePlacement" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_EquityIssuanceDates" order="11950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PrivatePlacementSubscriptionDate" order="12010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="12180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" order="12420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClosingBidPriceDate" order="12480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock" order="12830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_RegisteredDirectSubscriptionDate" order="12950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" order="13530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="13650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockPurchasedByOfficer" order="13830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="14120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockConvertedInToCommonStock" order="14180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="14240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" order="14590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" order="14720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateEarliest" order="15990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateLatest" order="16050.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureShareBasedCompensationDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageHoldingForStockOptionsExercisePrice" xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="abio-20141231.xsd#abio_OtherStockOptionPlanMember" xlink:type="locator" xlink:label="abio_OtherStockOptionPlanMember" />
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndFourStockOptionPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_IncentiveStockOptionMember" xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndThirteenPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndFourStockOptionPlanMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_OtherStockOptionPlanMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="11810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11920.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFiveMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFourMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeThreeMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeTwoMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeOneMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeTwoMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeThreeMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeFourMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeFiveMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11830.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails" xlink:href="abio-20141231.xsd#Role_DisclosureNonCashShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails" xlink:href="abio-20141231.xsd#Role_DisclosureEmployeeBenefitPlansDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <loc xlink:href="abio-20141231.xsd#abio_NextTwoPercentPayContributionMember" xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" />
    <loc xlink:href="abio-20141231.xsd#abio_FirstThreePercentPayContributionMember" xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DefinedContributionPlanNameAxis" xlink:to="us-gaap_DefinedContributionPlanNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DefinedContributionPlanNameAxis" xlink:to="us-gaap_DefinedContributionPlanNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10410.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <loc xlink:href="abio-20141231.xsd#abio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <loc xlink:href="abio-20141231.xsd#abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_StatementScenarioAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="abio_IncomeTaxesTextualAbstract" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OpenTaxYear" order="11550.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>abio-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="abio_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="abio_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="abio_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding. Series A convertible preferred stock, $0.001 par value; 135,000 shares designated from authorized preferred stock; no shares issued or outstanding at December 31, 2014 and 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100 million shares authorized at December 31, 2014 and 2013; 21,150,486 and 15,685,562 shares issued and outstanding at December 31, 2014 and 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Deemed preferred stock dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends And Other Adjustments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss available to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss available to common stockholders per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of warrants for cash, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of warrants for cash, value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issued during period value new issues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:to="abio_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issued during period value, new issues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:to="abio_PreferredStockIssuedDuringPeriodValueNewIssues_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_DeemedDividendBeneficialConversionPreferredStock" xlink:type="locator" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock" />
    <label xml:lang="en-US" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend beneficial conversion preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeemedDividendBeneficialConversionPreferredStock" xlink:to="abio_DeemedDividendBeneficialConversionPreferredStock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:to="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Deficit During Development Stage [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash, net of offering costs, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment for fractional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Reverse Stock Splits</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants for cash, shares</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Warrants For Cash Shares</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants for cash, value</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Warrants For Cash Value</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock, net of offering costs, shares</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issued During Period Shares New Issues</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock, net of offering costs</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issued During Period Value New Issues</label>
    <label xml:lang="en-US" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed preferred stock dividend for beneficial conversion feature</label>
    <label xml:lang="en-US" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend Beneficial Conversion Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of Restricted Stock Awards, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of Restricted Stock Awards, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of deferred charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Deferred Charges</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets And Liabilities Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of principal on vendor finance agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:to="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Short Term Debt Maturing In More Than Three Months</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsAbstract" />
    <label xml:lang="en-US" xlink:label="abio_FinancialInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FinancialInstrumentsAbstract" xlink:to="abio_FinancialInstrumentsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FinancialInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="abio-20141231.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financings and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financings and Warrants</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings And Warrants Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks, Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Disclosure [Text Block]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="abio_ReverseStockSplitPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ReverseStockSplitPolicyTextBlock" xlink:to="abio_ReverseStockSplitPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</label>
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</label>
    <loc xlink:href="abio-20141231.xsd#abio_AccruedExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedExpensesPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for estimating costs incurred that have not yet been billed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedExpensesPolicyTextBlock" xlink:to="abio_AccruedExpensesPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</label>
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Potentially Dilutive Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Weighted Average Grant Date Fair Value per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option and Stock Award Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding and Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Cash, Share-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Benefit Attributable to Our Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <loc xlink:href="abio-20141231.xsd#abio_CompanyBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company basis of presentation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_CompanyBasisOfPresentationTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company and summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company and summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company And Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company And Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_OriginalMember" xlink:type="locator" xlink:label="abio_OriginalMember" />
    <label xml:lang="en-US" xlink:label="abio_OriginalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OriginalMember" xlink:to="abio_OriginalMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_OriginalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original</label>
    <label xml:lang="en-US" xlink:label="abio_OriginalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_AmendmentMember" xlink:type="locator" xlink:label="abio_AmendmentMember" />
    <label xml:lang="en-US" xlink:label="abio_AmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AmendmentMember" xlink:to="abio_AmendmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</label>
    <label xml:lang="en-US" xlink:label="abio_AmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseAxis" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseAxis" />
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials by Phase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalTrialsByPhaseAxis" xlink:to="abio_ClinicalTrialsByPhaseAxis_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trials By Phase</label>
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials By Phase [Axis]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseDomain" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseDomain" />
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials by Phase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalTrialsByPhaseDomain" xlink:to="abio_ClinicalTrialsByPhaseDomain_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trials By Phase</label>
    <label xml:lang="en-US" xlink:label="abio_ClinicalTrialsByPhaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials By Phase [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_PhaseThreeHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseThreeHeartFailureMember" />
    <label xml:lang="en-US" xlink:label="abio_PhaseThreeHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase three heart failure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PhaseThreeHeartFailureMember" xlink:to="abio_PhaseThreeHeartFailureMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PhaseThreeHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 heart failure (HF) trial of Gencaro</label>
    <label xml:lang="en-US" xlink:label="abio_PhaseThreeHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Three Heart Failure [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_HealthCareTrustFundAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Trust Fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareTrustFundAxis" xlink:to="us-gaap_HealthCareTrustFundAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_HealthCareTrustFundAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Trust Fund [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_HealthCareTrustFundNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Trust Fund, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareTrustFundNameDomain" xlink:to="us-gaap_HealthCareTrustFundNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_HealthCareTrustFundNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Trust Fund Name [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_BestTrialMember" xlink:type="locator" xlink:label="abio_BestTrialMember" />
    <label xml:lang="en-US" xlink:label="abio_BestTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Best trial.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_BestTrialMember" xlink:to="abio_BestTrialMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_BestTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BEST Trial</label>
    <label xml:lang="en-US" xlink:label="abio_BestTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Best Trial [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_GENETICAFTrialMember" xlink:type="locator" xlink:label="abio_GENETICAFTrialMember" />
    <label xml:lang="en-US" xlink:label="abio_GENETICAFTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GENETIC-AF trial.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_GENETICAFTrialMember" xlink:to="abio_GENETICAFTrialMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_GENETICAFTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GENETIC-AF Trial</label>
    <label xml:lang="en-US" xlink:label="abio_GENETICAFTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G E N E T I C A F Trial [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_PhaseTwoBHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseTwoBHeartFailureMember" />
    <label xml:lang="en-US" xlink:label="abio_PhaseTwoBHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase two b heart failure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PhaseTwoBHeartFailureMember" xlink:to="abio_PhaseTwoBHeartFailureMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PhaseTwoBHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase Two B Heart Failure</label>
    <label xml:lang="en-US" xlink:label="abio_PhaseTwoBHeartFailureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Two B Heart Failure [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Registered direct offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RegisteredDirectOfferingMember" xlink:to="abio_RegisteredDirectOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registered Direct Offering</label>
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Offering [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company And Summary Of Significant Accounting Policies Table [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company And Summary Of Significant Accounting Policies Table [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Basis of Presentation (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company Basis Of Presentation Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of completion of business combination with Nuvelo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Effective Date Of Acquisition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination with Nuvelo, date of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Date Of Acquisition Agreement1</label>
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatients" xlink:type="locator" xlink:label="abio_NumberOfPatients" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of patients.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfPatients" xlink:to="abio_NumberOfPatients_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of patients</label>
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Patients</label>
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of patients company plans to enroll.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfPatientsCompanyPlansToEnroll" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of patients company plans to enroll</label>
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Patients Company Plans To Enroll</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fund raised through sale of convertible preferred and common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</label>
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceOfCommonStock" xlink:type="locator" xlink:label="abio_ClosingBidPriceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing bid price of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClosingBidPriceOfCommonStock" xlink:to="abio_ClosingBidPriceOfCommonStock_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_NotificationForDelistingOfSharesDescription" xlink:type="locator" xlink:label="abio_NotificationForDelistingOfSharesDescription" />
    <label xml:lang="en-US" xlink:label="abio_NotificationForDelistingOfSharesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Notification for delisting of shares description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NotificationForDelistingOfSharesDescription" xlink:to="abio_NotificationForDelistingOfSharesDescription_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_GracePeriodProvidedToMeetContinuedListingStandard" xlink:type="locator" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard" />
    <label xml:lang="en-US" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grace period provided to meet continued listing standard.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_GracePeriodProvidedToMeetContinuedListingStandard" xlink:to="abio_GracePeriodProvidedToMeetContinuedListingStandard_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum closing bid price of common stock</label>
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Closing Bid Price Of Common Stock</label>
    <label xml:lang="en-US" xlink:label="abio_NotificationForDelistingOfSharesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notification for delisting of shares</label>
    <label xml:lang="en-US" xlink:label="abio_NotificationForDelistingOfSharesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notification For Delisting Of Shares Description</label>
    <label xml:lang="en-US" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of grace days provided by NASDAQ to meet continued listing standard</label>
    <label xml:lang="en-US" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grace Period Provided To Meet Continued Listing Standard</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Financial Instrument Maximum Exposure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Weighted-average shares of unvested common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total weighted-average shares used in computing net loss per share attributed to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Issued Basic</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic and diluted loss per share</label>
    <loc xlink:href="abio-20141231.xsd#abio_SecuritiesInMoney" xlink:type="locator" xlink:label="abio_SecuritiesInMoney" />
    <label xml:lang="en-US" xlink:label="abio_SecuritiesInMoney_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">This represents the number of securities that are "in-the-money" as of the end of the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecuritiesInMoney" xlink:to="abio_SecuritiesInMoney_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_SecuritiesInMoney_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Securities in-the-money</label>
    <label xml:lang="en-US" xlink:label="abio_SecuritiesInMoney_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities In Money</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic By Common Class [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsTextualAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_FinancialInstrumentsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FinancialInstrumentsTextualAbstract" xlink:to="abio_FinancialInstrumentsTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Disclosures (Additional Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_FinancialInstrumentsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_FinancialInstrumentsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents consisting of money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments (Additional Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures Additional Textual [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets between fair value hierarchy levels</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</label>
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesLineItems_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="abio_CommitmentsAndContingenciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_WestminsterMember" xlink:type="locator" xlink:label="abio_WestminsterMember" />
    <label xml:lang="en-US" xlink:label="abio_WestminsterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Westminster.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WestminsterMember" xlink:to="abio_WestminsterMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_WestminsterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Westminster, Colorado</label>
    <label xml:lang="en-US" xlink:label="abio_WestminsterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Westminster [Member]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office facilities taken on lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiry date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</label>
    <loc xlink:href="abio-20141231.xsd#abio_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="abio_AgreementTerminationNoticePeriod" />
    <label xml:lang="en-US" xlink:label="abio_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AgreementTerminationNoticePeriod" xlink:to="abio_AgreementTerminationNoticePeriod_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical research agreement with Duke University, termination notice period</label>
    <label xml:lang="en-US" xlink:label="abio_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected milestone payments due upon approval.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExpectedMilestonePaymentsUponApproval" xlink:to="abio_ExpectedMilestonePaymentsUponApproval_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Another expected milestone payment due upon approval.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of royalty obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfRoyaltyObligation" xlink:to="abio_MinimumPercentageOfRoyaltyObligation_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of royalty obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MaximumPercentageOfRoyaltyObligation" xlink:to="abio_MaximumPercentageOfRoyaltyObligation_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty obligated to pay under its original license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of range of royalties that can be bought down.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of range of royalties that can be bought down.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_RoyaltyBuyDownDuePeriod" xlink:type="locator" xlink:label="abio_RoyaltyBuyDownDuePeriod" />
    <label xml:lang="en-US" xlink:label="abio_RoyaltyBuyDownDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty buy down due period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RoyaltyBuyDownDuePeriod" xlink:to="abio_RoyaltyBuyDownDuePeriod_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected milestone payments due upon approval</label>
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Milestone Payments Upon Approval</label>
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another expected milestone payments due upon approval</label>
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Another Expected Milestone Payments Upon Approval</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of royalty obligation</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Royalty Obligation</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of royalty obligation</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Royalty Obligation</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product sales levels royalty</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Obligated To Pay Under Its Original License Agreement</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of range of royalties that can be bought down</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Range Of Royalties That Can Be Buy Down</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of range of royalties that can be bought down</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Range Of Royalties That Can Be Buy Down</label>
    <label xml:lang="en-US" xlink:label="abio_RoyaltyBuyDownDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty buy down due period</label>
    <label xml:lang="en-US" xlink:label="abio_RoyaltyBuyDownDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Buy Down Due Period</label>
    <loc xlink:href="abio-20141231.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financings and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement" />
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity&apos;s raising of capital via private rather than public placement, net of related financing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NetProceedsFromIssuanceOfPrivatePlacement" xlink:to="abio_NetProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_PrivatePlacementSubscriptionDate" xlink:type="locator" xlink:label="abio_PrivatePlacementSubscriptionDate" />
    <label xml:lang="en-US" xlink:label="abio_PrivatePlacementSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Date of private placement subscription agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PrivatePlacementSubscriptionDate" xlink:to="abio_PrivatePlacementSubscriptionDate_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_DirectorAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember" />
    <label xml:lang="en-US" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Director and chief executive officer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DirectorAndChiefExecutiveOfficerMember" xlink:to="abio_DirectorAndChiefExecutiveOfficerMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director and Chief Executive Officer</label>
    <label xml:lang="en-US" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director And Chief Executive Officer [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Convertible Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Financing Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Financing Transaction [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Financing Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Financing Transaction Type [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_PublicOfferingMember" xlink:type="locator" xlink:label="abio_PublicOfferingMember" />
    <label xml:lang="en-US" xlink:label="abio_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PublicOfferingMember" xlink:to="abio_PublicOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</label>
    <label xml:lang="en-US" xlink:label="abio_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:type="locator" xlink:label="us-gaap_WeightedAverageMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity financings and warrants (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings And Warrants Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants available to purchase additional commons shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Private Placement</label>
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of private placement</label>
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Private Placement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuanceDates" xlink:type="locator" xlink:label="us-gaap_EquityIssuanceDates" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityIssuanceDates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Equity Offering Close Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuanceDates" xlink:to="us-gaap_EquityIssuanceDates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityIssuanceDates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuance Dates</label>
    <label xml:lang="en-US" xlink:label="abio_PrivatePlacementSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription agreement date</label>
    <label xml:lang="en-US" xlink:label="abio_PrivatePlacementSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Subscription Date</label>
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercisable expiration period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercise price of share percentage of closing bid price of common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceDate" xlink:type="locator" xlink:label="abio_ClosingBidPriceDate" />
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Date of closing bid price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClosingBidPriceDate" xlink:to="abio_ClosingBidPriceDate_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant coverage ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price for common stock unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants were exercisable upon issuance, expiry year</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercisable Expiration Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing bid price of the common stock</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Share Percentage Of Closing Bid Price Of Common Shares</label>
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing bid price date</label>
    <label xml:lang="en-US" xlink:label="abio_ClosingBidPriceDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Closing Bid Price Date</label>
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity&apos;s raising of capital via registered direct offering, net of related financing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NetProceedsFromIssuanceOfCommonStock" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectSubscriptionDate" xlink:type="locator" xlink:label="abio_RegisteredDirectSubscriptionDate" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Date of registered direct offering subscription agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RegisteredDirectSubscriptionDate" xlink:to="abio_RegisteredDirectSubscriptionDate_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</label>
    <label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</label>
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription agreement date</label>
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectSubscriptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Subscription Date</label>
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockPurchasedByOfficer" xlink:type="locator" xlink:label="abio_PreferredStockPurchasedByOfficer" />
    <label xml:lang="en-US" xlink:label="abio_PreferredStockPurchasedByOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock purchased by officer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PreferredStockPurchasedByOfficer" xlink:to="abio_PreferredStockPurchasedByOfficer_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PreferredStockPurchasedByOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Purchased by Officer</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockPurchasedByOfficer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Purchased By Officer</label>
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockConvertedInToCommonStock" xlink:type="locator" xlink:label="abio_PreferredStockConvertedInToCommonStock" />
    <label xml:lang="en-US" xlink:label="abio_PreferredStockConvertedInToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock converted in to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PreferredStockConvertedInToCommonStock" xlink:to="abio_PreferredStockConvertedInToCommonStock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued upon conversion of each share of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock liquidation preference per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Liquidation Preference</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockConvertedInToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of preferred stock converted in to common stock</label>
    <label xml:lang="en-US" xlink:label="abio_PreferredStockConvertedInToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Converted In To Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issued in conversion of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</label>
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" xlink:type="locator" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" />
    <label xml:lang="en-US" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of total number of shares of common stock then issued and outstanding limit on beneficial ownership.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" xlink:to="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total number of shares of common stock then issued and outstanding limit on beneficial ownership</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Common Stock Then Issued And Outstanding Limit On Beneficial Ownership</label>
    <loc xlink:href="abio-20141231.xsd#abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" xlink:type="locator" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" />
    <label xml:lang="en-US" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrinsic value of embedded beneficial conversion feature.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" xlink:to="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature_lbl" />
    <label xml:lang="en-US" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of embedded beneficial conversion feature</label>
    <label xml:lang="en-US" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intrinsic Value Of Embedded Beneficial Conversion Feature</label>
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateEarliest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights expiration date earliest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightsExpirationDateEarliest" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateEarliest_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateLatest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights expiration date latest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightsExpirationDateLatest" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateLatest_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or rights expiration date earliest</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration Date Earliest</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or rights expiration date latest</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration Date Latest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndThirteenPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" />
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and thirteen plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Plan</label>
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Thirteen Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_IncentiveStockOptionMember" xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" />
    <label xml:lang="en-US" xlink:label="abio_IncentiveStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_IncentiveStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Stock Option</label>
    <label xml:lang="en-US" xlink:label="abio_IncentiveStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Principal Owner [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndFourStockOptionPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember" />
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2004 Stock Option Plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndFourStockOptionPlanMember" xlink:to="abio_TwoThousandAndFourStockOptionPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand And Four Stock Option Plan</label>
    <label xml:lang="en-US" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Four Stock Option Plan [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_OtherStockOptionPlanMember" xlink:type="locator" xlink:label="abio_OtherStockOptionPlanMember" />
    <label xml:lang="en-US" xlink:label="abio_OtherStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OtherStockOptionPlanMember" xlink:to="abio_OtherStockOptionPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_OtherStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Stock Option Plan</label>
    <label xml:lang="en-US" xlink:label="abio_OtherStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Stock Option Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding under Equity plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="abio-20141231.xsd#abio_PercentageHoldingForStockOptionsExercisePrice" xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" />
    <label xml:lang="en-US" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum ownership percentage for 110% fair market value on the grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options award, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options award, expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage holding for stock options exercise price</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Holding For Stock Options Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average exercise Price of Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and awards granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted average grant date fair value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding beginning of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding end of the period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average exercise Price, Options Outstanding, Beginning of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average exercise Price, Options Outstanding, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average exercise Price, Options vested and expected to vest, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense related to unvested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period of weighted average period of compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeOneMember" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Range One.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExercisePriceRangeOneMember" xlink:to="abio_ExercisePriceRangeOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$0.36-$1.33</label>
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range One [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeTwoMember" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Range Two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExercisePriceRangeTwoMember" xlink:to="abio_ExercisePriceRangeTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$1.38-$1.38</label>
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Two [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeThreeMember" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Range Three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExercisePriceRangeThreeMember" xlink:to="abio_ExercisePriceRangeThreeMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$1.40-$1.95</label>
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Three [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFourMember" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Range Four.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExercisePriceRangeFourMember" xlink:to="abio_ExercisePriceRangeFourMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$1.96-$22.98</label>
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Four [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFiveMember" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Range Five.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExercisePriceRangeFiveMember" xlink:to="abio_ExercisePriceRangeFiveMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$22.99-$33.42</label>
    <label xml:lang="en-US" xlink:label="abio_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Five [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price Range, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price Range, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Average Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units award, requisite service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted stock units outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted stock units outstanding, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted stock units outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted stock units outstanding, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanNameAxis" xlink:to="us-gaap_DefinedContributionPlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanNameDomain" xlink:to="us-gaap_DefinedContributionPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_FirstThreePercentPayContributionMember" xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" />
    <label xml:lang="en-US" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First three percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First 3% of pay contributed</label>
    <label xml:lang="en-US" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Three Percent Pay Contribution [Member]</label>
    <loc xlink:href="abio-20141231.xsd#abio_NextTwoPercentPayContributionMember" xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" />
    <label xml:lang="en-US" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Next two percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Next 2% of pay contributed</label>
    <label xml:lang="en-US" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Next Two Percent Pay Contribution [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Defined Contribution Pension And Other Postretirement Plans</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plan, Percentage of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company&apos;s contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</label>
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes (Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="abio_IncomeTaxesTextualAbstract_lbl" />
    <loc xlink:href="abio-20141231.xsd#abio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" />
    <label xml:lang="en-US" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario, Unspecified</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</label>
    <loc xlink:href="abio-20141231.xsd#abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" />
    <label xml:lang="en-US" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Without deferred tax liability on impaired in process research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" xlink:to="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Without Deferred Tax Liability On Impaired In Process Research And Development</label>
    <label xml:lang="en-US" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Without Deferred Tax Liability On Impaired In Process Research And Development [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Description</label>
    <label xml:lang="en-US" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</label>
    <label xml:lang="en-US" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Limitations On Use</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" />
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment of the carrying value of deferred tax assets during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal income tax benefit at statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Enacted Tax Rate</label>
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset adjustment</label>
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Adjustment To Deferred Tax Asset</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetClassificationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetClassificationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Classification [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Current Classification [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vacation accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net current deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Noncurrent Classification [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charitable contribution carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Charitable Contribution Carryforwards</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total noncurrent deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net noncurrent deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncurrent deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net noncurrent deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Accrued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>abio-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-03-19T17:58:48.7449948+00:00 -->
<!-- Version            : 2.0.3.5 -->
<!-- Package ID         : B476788B1303AFAB1C13F837836AB6DC-0000907654-001501 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/role/TemplateLink" xlink:href="abio-20141231.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abio-20141231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="abio-20141231.xsd#abio_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="abio_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS" xlink:href="abio-20141231.xsd#Role_StatementBALANCESHEETS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical" xlink:href="abio-20141231.xsd#Role_StatementBALANCESHEETSParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="abio-20141231.xsd#abio_DeemedDividendBeneficialConversionPreferredStock" xlink:type="locator" xlink:label="abio_DeemedDividendBeneficialConversionPreferredStock" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" />
    <loc xlink:href="abio-20141231.xsd#abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_PreferredStockIssuedDuringPeriodValueNewIssues" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_DeemedDividendBeneficialConversionPreferredStock" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="13710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="14810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="15010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="abio-20141231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="abio-20141231.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="abio-20141231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstruments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FinancialInstrumentsAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="abio-20141231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipment">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangements" xlink:href="abio-20141231.xsd#Role_DisclosureRelatedPartyArrangements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="abio-20141231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrants" xlink:href="abio-20141231.xsd#Role_DisclosureEquityFinancingsAndWarrants" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrants">
    <loc xlink:href="abio-20141231.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="abio-20141231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:href="abio-20141231.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlans">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abio-20141231.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <loc xlink:href="abio-20141231.xsd#abio_AccruedExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedExpensesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="abio-20141231.xsd#abio_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="abio_ReverseStockSplitPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ReverseStockSplitPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedExpensesPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="abio-20141231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="abio-20141231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="abio-20141231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="abio-20141231.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="abio-20141231.xsd#abio_GracePeriodProvidedToMeetContinuedListingStandard" xlink:type="locator" xlink:label="abio_GracePeriodProvidedToMeetContinuedListingStandard" />
    <loc xlink:href="abio-20141231.xsd#abio_NotificationForDelistingOfSharesDescription" xlink:type="locator" xlink:label="abio_NotificationForDelistingOfSharesDescription" />
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceOfCommonStock" xlink:type="locator" xlink:label="abio_ClosingBidPriceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <loc xlink:href="abio-20141231.xsd#abio_NumberOfPatients" xlink:type="locator" xlink:label="abio_NumberOfPatients" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyBasisOfPresentationTextualAbstract" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PhaseTwoBHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseTwoBHeartFailureMember" />
    <loc xlink:href="abio-20141231.xsd#abio_GENETICAFTrialMember" xlink:type="locator" xlink:label="abio_GENETICAFTrialMember" />
    <loc xlink:href="abio-20141231.xsd#abio_BestTrialMember" xlink:type="locator" xlink:label="abio_BestTrialMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:type="locator" xlink:label="us-gaap_HealthCareTrustFundAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PhaseThreeHeartFailureMember" xlink:type="locator" xlink:label="abio_PhaseThreeHeartFailureMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseDomain" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseDomain" />
    <loc xlink:href="abio-20141231.xsd#abio_ClinicalTrialsByPhaseAxis" xlink:type="locator" xlink:label="abio_ClinicalTrialsByPhaseAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_AmendmentMember" xlink:type="locator" xlink:label="abio_AmendmentMember" />
    <loc xlink:href="abio-20141231.xsd#abio_OriginalMember" xlink:type="locator" xlink:label="abio_OriginalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="abio_OriginalMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="abio_AmendmentMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_ClinicalTrialsByPhaseAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ClinicalTrialsByPhaseAxis" xlink:to="abio_ClinicalTrialsByPhaseDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ClinicalTrialsByPhaseDomain" xlink:to="abio_PhaseThreeHeartFailureMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_HealthCareTrustFundAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareTrustFundAxis" xlink:to="us-gaap_HealthCareTrustFundNameDomain" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareTrustFundNameDomain" xlink:to="abio_BestTrialMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareTrustFundNameDomain" xlink:to="abio_GENETICAFTrialMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ClinicalTrialsByPhaseDomain" xlink:to="abio_PhaseTwoBHeartFailureMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyBasisOfPresentationTextualAbstract" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatients" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_Revenues" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_ClosingBidPriceOfCommonStock" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_NotificationForDelistingOfSharesDescription" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="abio_GracePeriodProvidedToMeetContinuedListingStandard" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyBasisOfPresentationTextualAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShareDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_SecuritiesInMoney" xlink:type="locator" xlink:label="abio_SecuritiesInMoney" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_SecuritiesInMoney" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1" xlink:href="abio-20141231.xsd#Role_DisclosureNetLossPerShareDetails1" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureFinancialInstrumentsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <loc xlink:href="abio-20141231.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsTextualAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="abio-20141231.xsd#abio_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="abio_FinancialInstrumentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FinancialInstrumentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FinancialInstrumentsTextualAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FinancialInstrumentsTextualAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosurePropertyAndEquipmentDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureRelatedPartyArrangementsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_RoyaltyBuyDownDuePeriod" xlink:type="locator" xlink:label="abio_RoyaltyBuyDownDuePeriod" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <loc xlink:href="abio-20141231.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20141231.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20141231.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20141231.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20141231.xsd#abio_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="abio_AgreementTerminationNoticePeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <loc xlink:href="abio-20141231.xsd#abio_WestminsterMember" xlink:type="locator" xlink:label="abio_WestminsterMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="abio_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="abio_WestminsterMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="abio_CommitmentsAndContingenciesLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AgreementTerminationNoticePeriod" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExpectedMilestonePaymentsUponApproval" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRoyaltyObligation" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRoyaltyObligation" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_RoyaltyBuyDownDuePeriod" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual">
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateLatest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateLatest" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightsExpirationDateEarliest" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightsExpirationDateEarliest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="abio-20141231.xsd#abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" xlink:type="locator" xlink:label="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" xlink:type="locator" xlink:label="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockConvertedInToCommonStock" xlink:type="locator" xlink:label="abio_PreferredStockConvertedInToCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockPurchasedByOfficer" xlink:type="locator" xlink:label="abio_PreferredStockPurchasedByOfficer" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="abio-20141231.xsd#abio_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectSubscriptionDate" xlink:type="locator" xlink:label="abio_RegisteredDirectSubscriptionDate" />
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="abio-20141231.xsd#abio_ClosingBidPriceDate" xlink:type="locator" xlink:label="abio_ClosingBidPriceDate" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="abio-20141231.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <loc xlink:href="abio-20141231.xsd#abio_PrivatePlacementSubscriptionDate" xlink:type="locator" xlink:label="abio_PrivatePlacementSubscriptionDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuanceDates" xlink:type="locator" xlink:label="us-gaap_EquityIssuanceDates" />
    <loc xlink:href="abio-20141231.xsd#abio_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfPrivatePlacement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="abio-20141231.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:type="locator" xlink:label="us-gaap_WeightedAverageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_PublicOfferingMember" xlink:type="locator" xlink:label="abio_PublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:type="locator" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_DirectorAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="abio_DirectorAndChiefExecutiveOfficerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_DirectorAndChiefExecutiveOfficerMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="abio_PublicOfferingMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_WeightedAverageMember" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_NetProceedsFromIssuanceOfPrivatePlacement" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_EquityIssuanceDates" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PrivatePlacementSubscriptionDate" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClosingBidPriceDate" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_RegisteredDirectSubscriptionDate" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockIssuedDuringPeriodSharesNewIssues" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockPurchasedByOfficer" order="13820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="14110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PreferredStockConvertedInToCommonStock" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="14230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership" order="14580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature" order="14710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateEarliest" order="15980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightsExpirationDateLatest" order="16040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureShareBasedCompensationDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="abio-20141231.xsd#abio_PercentageHoldingForStockOptionsExercisePrice" xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="abio-20141231.xsd#abio_OtherStockOptionPlanMember" xlink:type="locator" xlink:label="abio_OtherStockOptionPlanMember" />
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndFourStockOptionPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndFourStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_IncentiveStockOptionMember" xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="abio-20141231.xsd#abio_TwoThousandAndThirteenPlanMember" xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndFourStockOptionPlanMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_OtherStockOptionPlanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails" xlink:href="abio-20141231.xsd#Role_DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFiveMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeFourMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeThreeMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeTwoMember" />
    <loc xlink:href="abio-20141231.xsd#abio_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="abio_ExercisePriceRangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeOneMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeTwoMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeThreeMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeFourMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="abio_ExercisePriceRangeFiveMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfRSUActivityDetails" xlink:href="abio-20141231.xsd#Role_DisclosureSummaryOfRSUActivityDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfRSUActivityDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails" xlink:href="abio-20141231.xsd#Role_DisclosureNonCashShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails" xlink:href="abio-20141231.xsd#Role_DisclosureEmployeeBenefitPlansDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <loc xlink:href="abio-20141231.xsd#abio_NextTwoPercentPayContributionMember" xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" />
    <loc xlink:href="abio-20141231.xsd#abio_FirstThreePercentPayContributionMember" xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanNameAxis" xlink:to="us-gaap_DefinedContributionPlanNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <loc xlink:href="abio-20141231.xsd#abio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <loc xlink:href="abio-20141231.xsd#abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="abio_IncomeTaxesTextualAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_OpenTaxYear" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <loc xlink:href="abio-20141231.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:href="abio-20141231.xsd#Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNetClassificationAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetClassificationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetClassificationAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Non-Cash, Share-Based Compensation Expense (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 283</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">77</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 489</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 206</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"$YM"'"`(``((;```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F=%NVC`8A>\G[1TBWT[$
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MF%6AF%6AF%6AF%6AF%6AF%6AF+5`,6N!8M8"Q:S%_S)K3`T#\?'SW_^4<<R1
M5]PA;CH*9WXMM1UZ++G1GNJ?T:<NYNP`;V<?X:AT5]TTJ90X\R'LYA[*3TW)
MO;<NI,[(T^D`KZ70L'OBTB#RL:5=+;2O7MDEIK[I],!W_0X-C59-]9YL/C9H
M\S\```#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O
M+G)E;',@H@0"**```@``````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ
M;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].
MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4
M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>4"T\U<%J"`=[!ZH^^CSY
MLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++28,5\YS3$<G[(F,#GB;:
M7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]47P``
M`/__`P!02P,$%``&``@````A``IZ.`0S`@``J1H``!H`"`%X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````+R9S6[;,!"$[P7Z#@+O-<U=QDF*R#FT*)!KFSX`(=&6$)D2
M1/;';U_"-6@':*8782\&1,'DAZ5F9BD]//X^#-5//\=^#+4RJ[6J?&C&M@_[
M6GU__O+A3E4QN="Z80R^5D<?U>/V_;N'KWYP*?\I=OT4JSQ+B+7J4IH^:AV;
MSA]<7(V3#_G.;IP/+N7+>:\GU[RXO=>T7F_T?#V'VKZ:LWIJ:S4_M895]7R<
M\M+_GWS<[?K&?QZ;'P<?TC_6T+_&^25VWJ<\J9OW/M6J#$5]NF-XE9F5?@,G
MUT,6YP[AT$88AS8(A^^%<?@>X9`1QB&#<-@*X[!%.):$<2Q!G-LE<1HW-)\Z
MUX<\Z5GH90A1+`I1K.4"48;.;G.+8*0W".Z/D;8:`ZV&I*V&H-5(.PTT&NF=
M@AMEQ$L#:T/2)DS0A%E:XPQ%SM+^Q]``;6Y'1;LMNT9^;&^6Q(GI..1NNN33
MWVNT_J++ER2Z$)2A<SC=(!@C36,@#DF?$PB>$TCZG$#PG,#2D<`X$Z1U;:"N
MC70O86`OP=*)R3`Q[:*)F?*K`7^QG-.E/OUBB"6=M_C<A:,,G:T/AK;TXP*?
M%K/H]I0ZO%T:`VM#T@T-P8:&I!L:@@T-2QL?0^-CZ0QGF.%6.L,MS'#I",<)
M+FR`L#)&6N0&BMQ(B]Q`D9.TJ@BJBJ55Q?#986E9,=257;0SCIV;??LMS?G[
MR?71[GH8':I(.A\(YH.5[D1M:0+UJP],VS\```#__P,`4$L#!!0`!@`(````
M(0"'2L(+100``(8-```/````>&PO=V]R:V)O;VLN>&ULE)=1<]HX$,??;^:^
M`^/W%FP#;3(A'0+FDCD*#';+HT:Q!6ABRSY)+O#M;VV"65O4DSZ!,/OGOZO?
MKL3#MV,2=WXQJ7@J1I;]N6=UF`C3B(O=R/H1S#Y]M3I*4Q'1.!5L9)V8LKX]
M_OW7PR&5;Z]I^M8!`:%&UE[K[+[;5>&>)51]3C,FX,DVE0G5L)2[KLHDHY':
M,Z:3N.OT>L-N0KFPS@KW\B,:Z7;+0S9-PSQA0I]%)(NI!OMJSS-E/3YL><Q^
MGC/JT"Q;T`1\'V.K$U.EO8AK%HVL`2S3`ZM](//L*><Q/+US>Z[5?:R27,E.
MQ+8TCW4`Z5W4H5Y.WW&&Q3>+4OSD[*"N0<6R<]QP$:6'XJM0VE.U<L'`H7RT
MX9'>P_->KU=]]LSX;J\O'X)\%^F7%83?*5\[HDSO4A$".T4\H;D^D1=QKCY/
M80N+JK]`9K;5D?<<WLB7R"Z,8Y6G\7R\F'C$?_:\P$=1_3X*<]K#R(I*V)L]
MTSRD4/7JIUVD4587_[0?C`/ON[<(?+*<D>7*6X^#E^7")^/%E$R0"G;2;SJI
MJZS6WLQ;K[TI\8/EY%^"5:#451T&[3*3L?],9O/E!E=DB.)+`'`R``F9I$E&
MQ:G<$#]/$BI/)-T2G^^P#2SSI6ECP329ITJ1%9/$WT-9<>@7Y.!K,W3&!14A
MIS%0H+0LNT7A:&CK*O^[9O1*0OM*0*BDZ;^<9T6WX?`[%&[WFO'KHB-95)``
M(F,IJ=A!VPB-+0R@'RH+ML$BU"_AN@PJ;4Q2H!ID("L805>J!C6B#38]<`\>
MWNLA=JH4V]#"4]V.@^V8?!;E?Z4*LBIVE@E5SAQLQ,4"!II>DL7IB3'RQ`3;
M<DU6,16U1##9ML'D"TSEA)&`'NOI8Y#M/R012E=UYP"C:'^`1;#R&M>]8"1M
M@\G;5-V0P6S:!IRM8.`>'V!(8?HVAEW94.:.FGZ&&%3'`!5OS(U@C*=CX-D^
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MI_8QT;!HU+DV3-'@T7GM*MD'E*J[`RS:5*Z2[T<ORJJ/ARHLVG2*B09_`IB4
M4"1-C_BH&6)Z^B7-W7*.P34=+L$A_'\H7LH+>'\P/!\BW<M?J,?_`0``__\#
M`%!+`P04``8`"````"$`IDAH9<\#``"A#```&````'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;)17T6ZC.!1]7VG_`?$>P(1`B)*,)E3='6E'6JUV9YX=<!*K
M@!%VFO;O]]HF8#MMIWE)BWTX/O?<ZYN;]9>7IO:>2<\I:S<^"B+?(VW)*MH>
M-_Y__S[.EK['!6XK7+.6;/Q7POTOV]]_6U]8_\1/A`@/&%J^\4]"=*LPY.6)
M-)@'K",M[!Q8WV`!C_TQY%U/<*5>:NHPCJ(T;#!M?<VPZC_#P0X'6I('5IX;
MT@I-TI,:"]#/3[3C5[:F_`Q=@_NG<S<K6=,!Q9[65+PJ4M]KRM6W8\MZO*\A
M[A>4X/+*K1YNZ!M:]HRS@PB`+M1";V/.PSP$INVZHA"!M-WKR6'C?T6K`J5^
MN%TK@WY0<N'&_QX_L<L?/:W^HBT!MR%/,@-[QIXD]%LEE^#E\.;M1Y6!OWNO
M(@=\KL4_[/(GH<>3@'0O("(9V*IZ?2"\!$>!)H@7DJED-0B`3Z^ALC3`$?RB
M_EYH)4X;?YX&BRR:(X![>\+%(Y64OE>>N6#-3PU"`Y4FB0>2.:@?]N,@7B[0
M(OTU2Z@5J0`?L,#;=<\N'E0-G,D[+&L0K8#Y&IG6,<;Z7J@0HR3Y*ED4%T3!
M(3_/VS1>A\]@:3E`=AH"-V*$(!M17!$R$Z!NE`B!NQ+GD,*WS;\JDB\YBN;V
M>;M;B*.Y>`.Q'$DLC6"=J?%C;1(,)6!8D28CK3)TIR&)*@#I<&$L6`<G]QPL
MP1L?HAISD"Z<@S4D53F4A65O%^9VG,?ON`%%_7DW)-@1E=JG[C0D4Z*2*)U.
M5685]C::LF@YE=XC2H(=49DC2D.TJ#S-G>HJS.TT3Z+Q;4M4=H\H"79$.5;L
M-$2+FKVARMI_7Y;\XC*ZPL?E+,&.K'R,5I>SAB0J@8Z/A;DWE9OE4GZ/'`FV
MY623^5J.AF@Y,S=QUN9T+RU!"/K/YPU2:$>2T_QV`V;,W-*QL+`!4&\3P);F
M=/2/<X=TTS5;0C;='^W6@#&:T;`RB(VC>+JPMA;90(TZDM\NOV[=2+==2Y.3
MI-V`T7T*"OW6+DTR`):YT>ALB;*QWB]1MV/X'#MI-I7*8)O1LM5*@8P56\1=
M71S=MO%LNCC#X1J3JQLWBX+$O74#R0"`V762;TN[JY?+H0@NG^7+5!N#-(TQ
MR\E8L0^_JV?#!'AS\V]\,=MR'"TB%,=3Y$.:3,PRC?,D<^^:GA3U(-60_D@*
M4M?<*]E93H$(7!]7]82ZDQ.JFC''#1@0.WPDWW%_I"WW:G*`5Z,@`S-Z/6+J
M!\$Z-<CLF8#14/U[@I\"!*:"*`#P@3%Q?9"CT_CC8OL_````__\#`%!+`P04
M``8`"````"$`&!.:E-@#``"H#```&0```'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6R<EUUOJS@0AN]7VO^`N"]@/D.4Y*BDZNZ1]DBKU7Y<$W`25,`1=IKV
MW^\,0P"['Z=M+]*`7P_/O&,/SNK;4U-;C[R3E6C7-G,\V^)M(<JJ/:SM?_Z^
MOUG8EE1Y6^:U:/G:?N;2_K;Y]9?5170/\LBYLB!"*]?V4:G3TG5E<>1-+AUQ
MXBV,[$77Y`HNNX,K3QW/RWY24[N^Y\5NDU>M31&6W4=BB/V^*OB=*,X-;Q4%
MZ7B=*^"7Q^HDK]&:XB/AFKQ[.)]N"M&<(,2NJBOUW`>UK:98?C^THLMW->3]
MQ,*\N,;N+UZ$;ZJB$U+LE0/A7`)]F7/JIBY$VJS*"C)`VZV.[]?V+5MN662[
MFU5OT+\5O\C9=TL>Q>6WKBK_J%H.;D.=L`([(1Y0^KW$6S#9?3'[OJ_`GYU5
M\GU^KM5?XO([KPY'!>6.("-,;%D^WW%9@*,0QO%[C$+4``"?5E/AT@!'\J?^
M_Z4JU7%M![$3)5[`0&[MN%3W%8:TK>(LE6C^(Q%#J#&(/P0)@'X8]QU_$;$H
M_GD4EXCZ!.]RE6]6G;A8L&K@F?*4XQID2XA\S8PXQES?2A7P,,@M1EG;L-PA
M"PGU>=Q$\6+E/H*GQ:#)7FJ8KMA>%5@*P!L9(?,YX^NN7U%0C"AH';)E=`-B
MCVR^\=Q7%!.\1@(.S4G0K0!6T_M$.`ET,X#0,U+/2!..U-O9#8T@_`H!3EK;
MD.9H012GN@D9:9*^>(LP"$/3I;F`A9#"%$$CA!4]]^A];U!LD"6>048:(O-A
MP2?3@_L*;^>")&11$(T1-+)8)_M8]7"226A6CS1$>!-$7CP^GP"U\=!G;/)6
M`TQTP/>M0[$)-L6EM4\:`F->C,W"0)LKC+)K:/@J,_K$SU<^3C(1`QT@(PTA
MAFGHIX:YV[F`I6$43>M#(TR_0HB33,+0("3-:&*<S,I']25%OWLU)`:]P70M
MA-7Z?F'[62:44;=L$*7]?@V<Q%QRVCA;P(MBS$I'Q*;[Z<(R:M5:1S$1LD%$
MB,Q9F(4UQH.W"+$]?YZ0FKI.F(P>T/9@)!H(0\^)XW3VIZNWNIHY\;3;=$NQ
M=W\>F#J^#CQ9,@"3B(!]9V%V0C8?UU:%3OBEMPA[Y35B]N)L$!%AZ,R*2EM%
M&V?,8=-NTQ&QJ1LF?F#KT*M`,W$Q]8O!1!*];2*-S[8S'0SIW-3P[L"WO*ZE
M58@S'OI\V(/CW?%`>NOCR]RXG^%!%>^[XP"<$T_Y@?_(NT/52JOF>PCI.0E`
M='32I`LE3OUI;2<4G!#[KT?X1<#AB.,Y(-X+H:X7^(#Q-\;F?P```/__`P!0
M2P,$%``&``@````A`!G#@`X#`P``AP@``!D```!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&ULE)9=;YLP%(;O)^T_6+XO7PFD1"%5FZY;I4Z:IGU<.\:`5<#(
M=IKVW^\8!P*D[=)>!+#?\_+XG(/=U=5S5:(G)A47=8)]Q\.(U52DO,X3_/O7
MW<4E1DJ3.B6EJ%F"7YC"5^O/GU9[(1]5P9A&X%"K!!=:-TO75;1@%5&.:%@-
M,YF0%='P*'-7-9*1M`VJ2C?PO,BM"*^Q=5C*<SQ$EG'*;@7=5:S6UD2RDFC@
M5P5O5.=6T7/L*B(?=\T%%54#%EM><OW2FF)4T>5]7@M)MB6L^]F?$]IYMP\G
M]A6G4BB1:0?L7`MZNN;8C5UP6J]2#BLP:4>290F^]I>;2^RN5VU^_G"V5X-[
MI`JQ_RIY^L!K!LF&,ID";(5X--+[U`Q!L'L2?=<6X(=$*<O(KM0_Q?X;XWFA
MH=HA+,BL:YF^W#)%(:%@XP2A<:*B!`#X114WG0$)(<_M=<]3721X%CGAPIOY
M($=;IO0=-Y88T9W2HOIK1?[!RIH$!Q.X'DR"^=G!LT,P7+M@N'W_S:Y=19N4
M6Z+)>B7%'D&C`:=JB&E;?PDN738L>Y^?M](#>3$FU\8EP?"%P,H5E/1I'4;S
ME?L$=:`'S<VIQA\K-IW"E`_P>D;(TI#Q]4IU*$9L4$SE#-N-'0#OGBV8O/<5
MQ64O&9%`AH8D)ELSZ,#WB4P0Z`8`813V_A;2:N8]]68P,"*`-AD2O/]F(TXP
M+.^X]-B;O-EJX+?7A%$TUFQ>TRQZS8@/OH'S^8QXRC?K?6UFK,:?^VU;>4X\
MZ:O-B>!(/R*+/D)FQ%.R:<VLIB/SG3"(1W]?+J:--HV(_%%`/(P8L2\^PF[$
M4_9C3FQ6K:9CG_3$YJW9$9,Y#R<[Q_^_!1,T93MVDF6SFKBMM^_,)M-P-AB+
M;MH[5L72V8W?[G$5DSG;L+)4B(J=V=0#<.U'^_/F.C`?WF3\!LZA=M=V^PDX
M!QJ2L^]$YKQ6J&096'K.`EI0VI/$/FC1M#OK5F@X`=K;`@Y\!MN1YX`X$T)W
M#V:SZ_^%6/\#``#__P,`4$L#!!0`!@`(````(0#]AIBDVP<``"HE```9````
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M$?Z4;\NB*O;UU(2;@5"9\VJVFIE(ST^[W&1@RSXIL_W:^^`_ZNC!FST_-07Z
M-\_>*_3[I#H4[[^4^>[W_)R9:IM]LCOP4A2?+/6WG87,XIE8_;'9@3_+R2[;
MIV_'^J_B_=<L?SW49KMCDY%-[''W5675UE34A)D&L8VT+8Y&@/DY.>6V-4Q%
MTB_-_^_YKCZLO7`QC9?ST#?TR4M6U1]S&]*;;-^JNCC]!R3?A8(@@0MB_G=!
M@G#T8L-L%)BW<XO]8!H\Q'Z\&)8P@W2:ZJBT3I^?RN)]8EK."*XNJ6U@_]%$
M;LL"272%^E:=3(%LD`\VRMHSUXHI064V]_-S'$9/L\]F0[:.LY$<GS*2EF&K
M;\,J`*"&%M`(F)D$NBQ,07$6US>U%6O)5FS[-AL`3.Q.?<"476$\4(J2E#B,
M*4=?XRPZ#LG([#;.R.Y+],UV;3.SBTQCHD3B<-G%;VJZ`4[499]P0'%`(X!H
MC*3&T%R8MZMO%ZT]4XFNV''(:KD!SK)I)'^^L#U.LT@PXR$*HXCMF,($/XKF
M_HI&T$!HZD"2,D7&A;^=C"7S9-@;;8!CWJY/.)I3,4G+:5M2<4`C@,A=4+FV
M3X;WP"YBLB-V,6Z`LVKV()@^L*P2_'(X7?9=#%<N?ME_,&.*)JSA=5G]Y?>D
M8Q?Q=%@_;("S:-+AU;_QFH+7^LM%(X!LA#THH$%ZNV\LF2L.:8DVP.G?.>&`
MXH!&`-&VHMK&#1.[:&B8``=IY(#B@$8`T>B;R8$+.*Z3FU6\DL)Y;.BU!_-D
M$8;S.>\`%Z9/1`E$8X0JMZZ$MGZD<O`R,@@C-N8V/I#H\&#76M*1NNDA$(T1
M*MYZ$A)_NV]]<#`JFCN,(_7%3`2B!*(Q0A5:^T$*QW6O#Z9E?O9C5WBA(V&E
MR.O<&80C&J^B2JVG,*7#P]@')Z(U%8T`)-H(;*@F+E*?CA*(Q@@5;QWF?O'@
M2U0\\XJ-/6>;ZP^&[R)87;G^D+VYLG-$NRA-=E2Y-1.D?*"%P7J(XKEH8>1/
MC9[$YX@2B,8(56A-`RD<V<)@-0,MC/S(*>6(\CFB,4*56@M!2@=J"89#:AFS
MV;KQ6U?JK\0@$#.L)?4SC".Z"V0X5+3U%"1ZY``&)Z+B^2G(!Y(?^7!RF#)"
MX@CXFD,.U^R(QAPB/&">=[O:#9MY7<S/.8[4ZTD$H@2B,4(57O&VX<\A`=C6
M[<YU)*RT=;NN"01'8X0J-1MY?Q,$=A6O*3^).5+;!+P%W,M](DH@&B-4MK67
MNWO7WC80LOFQQY%Z78E`E$`T1JC2*^XVHA7`N`9:H76W=N.3@"-*(!HC5*GU
MCOMK"HY#YX%H!2!UK3#UC9FA?Z(WN(TI>Z_&;%V_*QHC-`]F;./F6G#%X&)^
MGG"D7D4B$"40C1&JU#H,J_B(W@!?&N@-;EY)P!$E$(T1JM3:"E,Z?$8+P(QH
M;S`/VSB2Z=SNR"F-KB.UK:X$HC%"Q3.C&_"+*P8WYV>S@+M5(A`E$(T1HM"6
MDI=WN!&:54.?-1T)M:Q`E$`T1JA2YFRW:QF"-=$&X"<=1\(-$,?L:)ETI*X!
M!*(Q0D5;N[J[>T.[BIL<^_"P<21<7EC6(TIP-$:HTBN^-J(1P-=N3X002+VN
M1"!*(!HC5*FUFOMK"@9%&X)/A!!(`PW1DOJ&X(CN`AD.%6_=!(D?Z&+P'BJ:
M3X20&U0B$"40C1&J\(J)C6@$,+&!1@`2;@2.J)`C&B-4*3.Q@5J""Y%:+L1$
MX%:5A!Q1`M$.@?M501#;\T5W<Y!*_BXW"Z^XF;@'[TCN)GP4+J.E&&40IZ^_
M<HMZ1&.$2K_+R\(K7B:K#21WGV]IOAMCGXX2%Z;7IP2B,4(41\S;;O='PV9#
M=\&.AQM'`L51,`^6[&I,",/W%W/QK9)RE#XIC1&:`C.]<2=*\^%7^,>"E7;C
M2+V*1"!*(!HC5*DU'S38QMTRB>RJH8.$(V&EL*Q'E.!HC%"EUHZ84GOJ&&@/
M,#$R/L0U&`$)VB->+?G7+(DC8.&PI$<TYE#AUF;N%P[F1(2++X\B(,&W1WXL
M[IJXUWN52B`:(U3W79YGO88??A;\8YTC]7H2@2B!:(Q0A=9T6&4M>:`EP*K,
M!G:?'^37MQ'WLT0@2B`:(U0I\[R1`^&*]\GF!5([VX(5&WY))*Q0(!HC5/AW
M.9]YPD0T@VQ>(+GF74Z7[*B<N"A]MRB!V&=9[#LU'!`.CZ;`PQ>GK'S-DNQX
MK";;XLT^=A*8^XL=VCT2\R&PW],S?.,_)LTS$;/N!?.DRB5]S?Y(R]?\7$V.
MV=Z$G$^7IN=*>-8%_JB+2_/(QTM1FV=4FE\/YIFDS#Q;,9\:\KXHZO8/>]3L
MGG)Z_A\``/__`P!02P,$%``&``@````A`#4_!*1!#@``O5(``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&ULG)Q+;^,X%H7W`\Q_"+POQY(M.0XJ-6B+
M;\P`@\$\UB['28Q.XL!V=77_^R%-6KJ\1QT_LJBJ?#F7$8](ZHA6Z>O??G][
MO?EMM=VM-^\/@V(X&MRLWI>;Q_7[\\/@/_]67^X&-[O]XOUQ\;IY7ST,_ECM
M!G_[]M>_?/VYV?ZZ>UFM]C>^A??=P^!EO_^XO[W=+5]6;XO=</.Q>O<_>=IL
MWQ9[_^WV^7;WL5TM'@]%;Z^WY6A4W[XMUN^#V,+]]IPV-D]/Z^5*;)8_WE;O
M^]C(=O6ZV/OCW[VL/W;'UMZ6YS3WMMC^^N/CRW+S]N&;^+Y^7>__.#0ZN'E;
MWMOG]\UV\?W5]_OW8K)8'ML^?`/-OZV7V\UN\[0?^N9NXX%BGV>WLUO?TK>O
MCVO?@V#[S7;U]##XI;AWT_'@]MO7@T'_7:]^[LB_;W8OFY]ZNW[\^_I]Y=WV
MYRF<@>^;S:]!:A\#\L6W4*T.9^"?VYO'U=/BQ^O^7YN?9K5^?MG[TUWY'H6.
MW3_^(5:[I7?4-S,LJ]#2<O/J#\#_>?.V#D/#.[+X_?#WS_7C_N5A,*Z'U70T
M+KS\YOMJMU?KT.3@9OECM]^\_2^*BM14;*1,C8S]T:>?E\/RKBJJ^H)6)JD5
M_W?;RMF'X`_VT`__][&X&-Y5U:2^FY[?D3JUXF?'L94K.C)+K?B_CZU<<2R%
M'POQU(1!D6RMAI.RFMZ=<7)NXXD^C!NQV"^^?=UN?M[XR>A/Y>YC$:9V<1]^
MQW'$Q//;CJ$_&T)^[(16?@G-/`R\47YT[/RX_^W;9%9_O?W-C]5ETLQ14^2*
MYJ@(`S,T*XZ`-%NP(GG4'(L4!YH#PX'EP$7@_^SZ4Y3MT=YZ\UH'_7#/'.R?
M:T>C@CH8=3S:>03T-W6_YV!"TZ.X:P\E^H22R6R::V2?AK6C^C2SO!W=HRG8
MJ3:HJ4:CO!V+FDG!CMGU:;ICSDZ#7VVRTQ`&\M@/Z,]/1ZCR.G*>JQ$;8/.H
MF;2GK.%`<"`Y4!QH#@P'E@-'0-9SOT)F/?^\QT'],/#&MB.[8F=X'B73PS0N
MBZ(:3>[8"6ZHQ*_K?FFMV;`54=+9)CE0'&@.#`>6`T=`9HI?Y3-3SAL.H2HW
MIRBX.U%3']R9C<9W(SZR&ZHHII,"%"(JB#<<*`XT!X8#RX$C(//&7]>N\"94
M<6^ZN7A8A^91T_6KB2`-)>]#^,K7`<%K)`>*`\V!X<!RX`C(O)@R+SZ?/$&=
M>U"-V+B?1TWL\FP\]6>?*9JHZ%P2'$@.%`>:`\.!Y<`1D%D0PC^/`*=7SE#%
MK1CGIW8>-7Z*=FO-:))KFJ/F>$$4'$@.%`>:`\.!Y<`1D)GA4]H59H0J;D:5
M=W0>-;D9?%D]:EHS.)`<*`XT!X8#RX$C(#,C!,+,C<]GQT'.;6"7]'D2=:._
M`2*`2"`*B`9B@%@@CI*\\R$#7CXOBA@=_<6:#'H>*9*(FA#+.B)`(X$H(!J(
M`6*!.$IR$T("HR:<&`$QL&7I8L0O$D44S0Y7T&+(YT#Z,74B%G1$@D8!T4`,
M$`O$49([$>+7!4[$M)8[P:-$02)=S/I`!!`)1`'10`P0"\11DG<^Q"S:^?/B
M5!'3V8FY$$7=V6U264<$$`E$`=%`#!`+Q%&2FQ#R%#7AQ%R(\2L?`3`7HBC-
MA:(>WK$QTH3M&W]MH69P(D&C@&@@!H@%XBC)S0B!Z@(S8OZB9HSA1JL@(2U-
M!TX$:"00!40#,4`L$$=)WOD0I6CGSYP.,8&=F`XDIB43.!$%)Q*(`J*!&"`6
MB*,D-R%$*&K"B>D0$Q<=`15>&J(H3H=R.&;7S:8@L>U@C@`B@2@@&H@!8H$X
M2G(K0H"ZP(J8MS(K"G9;-"](*$OC@!,!&@E$`=%`#!`+Q%&2=;[D(?&\R7`H
M.[7UDD3=XM<`$4`D$`5$`S%`+!!'26["=6&QC*DO'PELT,^3B)H0R^(]IM_]
MQ9MJJ)%`%!`-Q`"Q0!PEN2F^7Q=,BS+(V>T#V70]3()Y$E$S8EE'!&@D$`5$
M`S%`+!!'2=[YD.WHFG#FM(B1\/-K1!E%79<;(`*(!**`:"`&B`7B*,E-N"XW
MEC$2YM.";RXD$34AEM%I`;M-4"6!*"`:B`%B@3A*<EM"@KMB;,3@E]O"]E/F
MX2.V+"\V0`00"40!T4`,$`O$49*;P!/DF1,D1L(3$X3GQJ;D1`"10!00#<0`
ML4`<);D)(<GQD3#QI_#S,%7&`$A'P@SF!P^)3:JB\R/?HQ))T<TI"40!T4`,
M$`O$49)[PH/EF0.C)V`6?!.NY`&R`2*`2"`*B`9B@%@@CI+<!!XISS0A9L03
MLX,'R:;D1`"10!00#<0`L4`<)9D)81<:9L?IK>E#&0\2;)MIGD3=4&^`B$3B
MA/$/+^"G%Q**%!`-Q`"Q0!PEN2L\:WZ^5HS[,B;?E4TBZD8LZXAH->'C_8K=
MK\CVI\>]:P5$`S%`+!!'26Y$2'YT\3QA1)#S8<$W9,91U'6[`2(2B1\!%C4X
MP9M0T(0&8H!8((Z2W(D0"*D3YZT6XY@C_?%V>]7P>6<244=B64=$J^D:*DMF
MK6Q%W0CA#6G0&"`6B*,D]X7GSQ,CI"=WPA[%.(JZWC=`1")_LL4MH4`!T4`,
M$`O$49([<5WD'&/DQ$_$DX@ZPD.H2)J4/::SL)3"Q.%5"EK60`P0"\11DMO2
M%T)/YZ]Q3)-TXD#^2AKJ"F30I/GS1":A%05$`S%`+!!'2>Y)7R8-5Z,3DP<S
M:5&P-6`^AE`*1"023?$/D!Z^\J`JH4H!T4`,$`O$49+;TA=+SQ@J/;&T9"-_
M/H98"D2T)%Q^_5,%W!'>A&H+CNNM!F*`6"".DMR1ZS+J.(9-.GFJDF]Z)1&=
M/9!1DR:MLO(+NP.2T(8"HH$8(!:(HR2S9-*76.N3<^=0QJ))R1X;F2<1L02(
M2*28%/'YI.$LKK1I%HW&\@MK5D(C"H@&8H!8((Z2W"6>8,^+*[Y3$.!*=M+G
M241=@B2;--D*PZ83-*.`:"`&B`7B*,E=";GQ\A`W"65\[/!=H22BKL2RC@C0
M2"`*B`9B@%@@CI+<A.N2["0F2?]GEV3A\\4DZKK<`!%`)!`%1`,Q0"P01TEN
M`H^M9\Z/GOC*'\V=3R"^`A&)Q/DQGHW@9@]*%!`-Q`"Q0!PEN2<\P'Z>1L*%
M&68%WPU*(CH@>`05K29<=OVS]GR=X`6J+6@ONT`,$`O$49([P3/K"2<PJU8E
MWPV9\&C:`!%`)!`%1`,Q0"P01TG>^>O"Z23FSA/K`X335-8-$`%$`E%`-!`#
MQ`)QE.0F\"AZ8@3T1%#VF,E\PN-C`T0`D8FDA:*J)V,62Q74:"`&B`7B*,F]
MN"Z$3GI"**Z5/'(VJ8P."*Z129/2Q60&_Z-`02L:B`%B@3A*,E,J'D,_'R`'
M.8\0?(LPB;JN-T`$$)E(-",\">^_\B5409$&8H!8((Z2W(WKXF;5%S?Y#6T2
M45<@;H)&)A)=N?/75S2%MZ*A%0/$`G&4Y*;PM'EBB/2E3+Z(5%%4'>X])D4Y
M8X(F"3JW!!`)1`'10`P0"\11DGO!0^<)+V+8])WMPB9?^.95%'5>L$MNDP34
MBUC2$0D:!40#,4`L$$=)[@7/GB>\Z,N<L'1`YJPX$4!D2T+R&@U9HZK]<9NS
M@!@@%HBC)'?BLL19]21.V/]*HNX4-T`$$)G(\;$X'D(55&@@!H@%XBC)K>"1
M\[P;DJHG>L+G"TE$+>%A5(!&MH3.01;.52OJA@AOVH#&`G&4Y+[P-'IBLL2`
MF2T<\/E"!2D4B``B$SD.D7(ZHU_LJJ6@7@,Q0"P01TENS&4)M>I)J&.V435/
M(CI0>&@5H)&)''?$8(CP)C0T88!8((Z2W`F>3T\,D9Y<.N9[7%44?7)MX:%4
MI)+./`E$`=%`#!`+Q%&2>1$V0K,=KL^].,CS6%K6[#(P3Z*N8PT0`40"44`T
M$`/$`G&4Y)V_+H76,0CZ:-"%#=C92B)J`L^/`C02B`*B@1@@%HBC)#<A)$2Z
MQWEB!,1`F2V8+%/.ZZBA?>=$@$8"44!T(C&E5T51PV?:!HIL5E34DWK,@I^C
M-;DY(?]1<\Z[RM8Q-F8FP:UL$E&7>-H4H)%`%!"=2+K#\Q>>4<7FJ($BFQ75
ME?__X_E-H:,EN4F7Y=.Z)Y^6,(2BZ+B>UE/6@2:UTKDG@$@@"H@&8H#81(X'
M,QZQHW6T)+?FLL!:]P56UO-Y$G4];X`((!*(`J);$N-]R4:`:7]^#&^V);&"
M?<;AVA_[@MP7GEY/+#I]J94EJ'G-@V0#1`"10!00G<CQV1%V0@P4V*Q@,IRP
MM.!H1>X+3Z]GKC<]*192?0TI%H@`(H$H(+HEW06Q9UWFO]Z>4^9:$0RAR_)L
MW9-G(>@G$9U:/(P*T$@@"HA.Y'@SX/^'2+ZZ&BBQ6<ED6,`@(H>6#Z++\FW=
MEV]YTD\BZ@P$6M!((`J(3J2]&_"OP>+6\-]DH15'26;&]+*`>Y#G`;>"L)]$
MQ^M!/66GIF&"\8AU221!9Z<$HH!H(`:(!>(HR:VY+OY.8XZEX08?0$NBKH,-
M$`%$`E%`=")IHW;:LWUMH,AF1=,Q;GF[7,$>ALMM"UGV\DPXC1'XA&U11&WC
M1*2&.HT$HA*)S\/V/MJGH<AD1;5_BI9O@5NH<93D+O'D_/D5WK^"#SX<A@W<
M).IZW@`10"00!40#,4!L(L=9#Y,ZO$8P].%P>-&+^%;`^':WM]7V>=6L7E]W
M-\O-C_#&O['?E&]I^S;"7\KP6BO&Y\5]<WBE'^.BN/=O2@N7QO8'_N6!'XOG
MU3\6V^?U^^[F=?7D?Y7?J_71<AM?/QB_V6\^#N^:^[[9^]<&'O[YXE\3N?(O
M>1L-O?AIL]D?OPF_H'WQY+?_`P``__\#`%!+`P04``8`"````"$`GN/U>H("
M```<!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R<5%UOFS`4?9^T
M_V#YO1@(D#0*J9I5W2JMTC3MX]DQ!JQBC&SGZ]_OVDY9VFQ=NQ?`^-QS[CW7
MUXNKO>S0EFLC5%_B)(HQXCU3E>B;$G__=GLQP\A8VE>T4STO\8$;?+5\_VZQ
M4_K!M)Q;!`R]*7%K[3`GQ+"62VHB-?`>=FJE);6PU`TQ@^:T\D&R(VD<%T12
MT>/`,->OX5!U+1B_46PC>6\#B>8=M9"_:<5@'MDD>PV=I/IA,UPP)0>@6(M.
MV(,GQ4BR^5W3*TW7'=2]3S+*'KG]XHQ>"J:54;6-@(Z$1,]KOB27!)B6BTI`
M!<YVI'E=XNMDOBHP62Z\/S\$WYF3;V1:M?NH1?59]!S,AC:Y!JR5>G#0N\K]
M@F!R%GWK&_!%HXK7=-/9KVKWB8NFM=#M'`IR=<VKPPTW#`P%FBC-'1-3'20`
M3R2%.QE@"-W[]TY4MBWQI(CR:3Q)`([6W-A;X2@Q8AMCE?P90,F1*I"D1Q)X
M'TF2-$IG>9(7_V8A(2-?X`VU=+G0:H?@T("F&:@[@LD<F%UE$_#GSY5!22[F
MV@7Y4$`;Z,9VF5WF"[(%"]D1LPH8&(`1DXX(`N)C!J#Z]@Q<T-,,TNE([Y-<
M!<C,-_94;_(_>BX(G#FM)IL\$PR8[$PP>RKXLK4.7.+4FYK&R7-7PW;AMV?Q
MF,`30^%(G1KZLIX#G^@5(V4P,6QG7J_X2P.+M^@YL-,[.1;Y[SJ":,"$(I/L
MN6J8TG"()=<-_\"[SB"F-FX"$TAU_!LNAQ5<#JGORK@!PSG0AM]3W8C>H([7
M$!I'4RA7A_$."ZL&?\K6RL)8^L\6;F$.0Q!'`*Z5LH\+=X&,]_KR%P```/__
M`P!02P,$%``&``@````A`$:*XH5>!```\@\``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&ULG)?;CN(X$(;O1]IWB'(_)`Z$0P2,.HEZ9Z19:;7:PW4(
M!J).XB@.3??;3U4J!]NPW73W10/%[Y_/578Y7G][*7+KF=<R$^7&9A/7MGB9
MBGU6'C?V/W\_?EW:EFR2<I_DHN0;^Y5+^]OVMR_KBZB?Y(GSQ@*'4F[L4]-4
M@>/(],2+1$Y$Q4OXYB#J(FG@8WUT9%7S9-\.*G+'<]VY4R19:9-#4-_C(0Z'
M+.6Q2,\%+QLRJ7F>-,`O3UDE>[<BO<>N2.JG<_4U%44%%KLLSYK7UM2VBC3X
M<2Q%G>QRF/<+FR5I[]U^N+(OLK064AR:"=@Y!'H]YY6S<L!IN]YG,`-,NU7S
MP\9^8$',5K:S7;<)^C?C%ZF\M^1)7'ZOL_W/K.20;:@35F`GQ!-*?^PQ!(.=
MJ]&/;07^K*T]/R3GO/E+7+[S['AJH-P^S`@G%NQ?8RY3R"C83#P?G5*1`P#\
MMXH,EP9D)'EI7R_9OCEM[.E\XB_<*0.YM>.R><S0TK;2LVQ$\1^)6&=%)EYG
M,@7Z[GMOXBU]YL\_X#+K7.!U=)EY_F)Y!XM#\VK3%"=-LEW7XF+!V@-R626X
MDED`SGU^:#9#QOXO89`I-'E`EXT-FP9R(:'*S]O9PE\[SU"9M-.$UQJF*Z)>
M@65`VY@";3(=X!V@(:$J].UB]FPH1K;>->P#(ZQG@-Q0+'5)3!(`5&8\'S0:
M+93]?EH4:[1F(#(#,05TE,5M%*BPBH+5GL*>>CN!.`ATVE2-=(2DF0U)CLQ`
MK`2T[,`V^C@2#MK84`,E^ZMARNWB"4D#/SMJEJZNB7I-OS9B):!1SC]#B8,,
MRJ6QYD/2S-L]LW3;/X.1%&-J8R6@,2X^PXB#3$9C.X2D6;2,_DU&4BB,2D!C
MQ'/5:#?O+T`<9#).]2R%I&$SUE*Z$^B)NB(BA<*H!#3&U6<8<9#).-,)0M*,
MC%>()%`0E8"&R&#3JGE\>P.W:A/.2$_8B48ZUU!$G4+!4R,Z'W;N#]>94;_7
MMO5R;*JTK3O1R'E=Z4ZB@I)S&]%!L8]_')2ZOPXZMMP.E$0*J*&(&"E43B6B
M<V*35SC?*3@="3J?V;(9B?0&:331:!`-'5*-Z(C8X>]'I/-`0UP9[3ED)*+N
MN,#VJ.^H2!/,IU>"N!/<*#QV^OMIZ5S0:<U6CL^5T`/&<D97D5B-Z-G#KJ[P
MW'<T,SH+WCZ;.Y'*I1PAW9.6$M&YL),K7.\L/.K[>I[,XX0IAT/[Z]%5).XB
MW9D#A1T*K]-A#[^?CCJ^3F<>)*P_%L;G!L\SFE`TB,9MT0^#B(Z(/?Q^1.KX
M.J)YCL"%"1>:3P_:WGQFS"'J!&/%\8XUK$W"HRL3W04*7A]YQ/-<6JDXXW5H
M!MY#=+BJ/4SQ`<^(ARR`)_<;<2\(;^DC+X!G6$S38`0WKBHY\C^2^IB5TLKY
M`1#<R0(V5$UW-OK0B*J]L>Q$`W>M]NT)[M8<[@KN!,0'(9K^`_[`<%O?_@(`
M`/__`P!02P,$%``&``@````A`/]D:Q>8`@``/P8``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S`N>&ULC%3+;MLP$+P7Z#\0O$>4Y%=B6`YB!VD#-$!1]'&F
MJ95$1!0%DHZ3O^]2C`7)3M/X((O4<'9V=I>KZV=5DR<P5NHFHTD44P*-T+EL
MRHS^^GEW<4F)=;S)>:T;R.@+6'J]_OQI==#FT58`CB!#8S-:.=<N&;.B`L5M
MI%MH\$NAC>(.EZ9DMC7`\^Z0JED:QW.FN&QH8%B:CW#HHI`";K78*VA<(#%0
M<X?Z;25;>V13XB-TBIO'?7LAM&J18B=KZ5XZ4DJ46-Z7C39\5V/>S\F4BR-W
MMSBC5U(8;77A(J1C0>AYSE?LBB'3>I5+S,#;3@P4&;U)EML99>M5Y\]O"0<[
M>">VTH<O1N;?9`-H-I;)%V"G]:.'WN=^"P^SL]-W70&^&Y)#P?>U^Z$/7T&6
ME<-JSS`AG]<R?[D%*]!0I(G23H;0-0K`)U'2=P8:PI^[_X/,7971R3R:+>))
M@G"R`^ONI*>D1.RMT^I/`"5>5$^2OI),4/WK]S1*+V?);/Y_%A84=0G><L?7
M*Z,/!)L&8]J6^Q9,ELCL,YN@/T%'G^N_4D5YGN3&LV04NQV/6RS/TWJZ2%;L
M"3T5KYC-.>8$L3TB?"E07J\1,Q]J?-OUHQ0/]E*\=5[;)FP@=Z\M'2O;OH&X
M["$C)>C04,G1K?<5^4,9Q2"]@.GB1,(F8*:]ZNU@8Z1@.E;P?F0/QGJ.(D_Z
MS((]`3.(/-@81<9.'>;^?F0//LUY>A(Y8.9=NTQF,?[&`)QH3Q(`Z=5B"`C*
MPL"&?E9@2MA"75LB]-X/8XK,_6Y_3]RDWN23_0W>']VTL?X#SF_+2WC@II2-
M)3442!E'"Q1EP@T0%DZWW13MM,/)[5XKO*@!6R^.$%QH[8X+W]C]U;_^"P``
M__\#`%!+`P04``8`"````"$`&R^4I'8"``#'!0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6R<E%U/VS`4AN\G[3]8OB=.TB^HFB):Q(8TI&G:Q[7K
MG"06<1S9+H5_OV.[C0@PC>VFC>W73][SE=7EHVK)`Q@K=5?0+$DI@4[H4G9U
M07]\OSD[I\0ZWI6\U1T4]`DLO5Q__+`Z:'-O&P!'D-#9@C;.]4O&K&A`<9OH
M'CH\J;11W.'2U,SV!G@9+JF6Y6DZ9XK+CD;"TKR'H:M*"KC68J^@<Q%BH.4.
M_=M&]O9$4^(].,7-_;X_$UKUB-C)5KJG`*5$B>5MW6G#=RW&_9A-N3BQP^(5
M7DEAM-652Q#'HM'7,5^P"X:D]:J4&(%/.S%0%?0J6VZGE*U7(3\_)1SLLV=B
M&WWX9&3Y17:`R<8R^0+LM+[WTMO2;^%E]NKV32C`5T-*J/B^==_TX3/(NG%8
M[1D&Y.-:ED_78`4F%#%)/O,DH5LT@+]$2=\9F!#^&/X/LG1-02?S9+9()QG*
MR0ZLNY$>28G86Z?5KRC*CJ@(R8^0";H_GN=)?C[+9O._4UAT%`*\YHZO5T8?
M"#8-OM/VW+=@MD3R*;+H8XCU3Z%BC!YRY2F!A5%8+,_#>CJ_6+$'S*DX:C91
M@Q,Q:+*Q8GM2^%*@O<$C1O[2XP1K^';V3Y;\I;&E?#%^W^8-R5BQ?4-Q/DA&
M'C%W_^[17\)>>):2/$\'?DCM)FI"<X>-[;.-D8/I_SCPEPJ*80Y%F2Y>.HB:
M>2AKEH_MX=1Y0#S,Y\-A=!8'*O:;`E/#%MK6$J'W?E@R)`Z[<8XW.,>AZ]EP
M@'/4\QKNN*EE9TD+%5Y-DP4.CHF3&!=.]Z'<.^UP@L)C@Q],P/9,$Q176KO3
MPC?8\`E>_P8``/__`P!02P,$%``&``@````A`)'(1R)`!```NPX``!@```!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6R4EUV/JS80AN\K]3\@[A,P^=I$28X6
MT+9':J6JG]>$F`0MX!0[F]U_?V8P-K9SNB4W^1A>7C^>P8.]_?)>5]X;;7G)
MFIU/IJ'OT29GQ[(Y[?R__GR9//D>%UESS"K6T)W_0;G_9?_C#]L;:U_YF5+A
M@4/#=_Y9B,LF"'A^IG7&I^Q"&[A2L+;.!/QM3P&_M#0[=C?551"%X3*HL[+Q
MI<.F'>/!BJ+,:<KR:TT;(4U:6F4"^/FYO'#E5N=C[.JL?;U>)CFK+V!Q**M2
M?'2FOE?GFZ^GAK79H8)YOY-YEBOO[L^=?5WF+>.L$%.P"R3H_9S7P3H`I_WV
M6,(,,.U>2XN=_TPV*5GYP7[;)>CODMZX\=OC9W;[J2V/OY0-A6Q#G41V^(-6
M-!?T")7S/:S(@;%7O/4KA$(8A'<"'(3_JX9YCG"40`]C_E9#OG1E^ZWUCK3(
MKI7XG=U^IN7I+&"D!:0!L[$Y?J24YU`&&&L:+=`U9Q58P*=7E_@\01JS=TE7
M'L5YY\^6T\4JG!&0>P?*Q4N)EKZ77[E@]3]21'HK:1+U)O!]D]>CY93,P^4#
M'K/>`[Y[#Q(]##+O3>!;F_S?+`*9D2[9:2:R_;9E-P\>=9@SOV2X<,@&#%5F
M91YTKO\KU9!C-'E&EYT/:Q2RR*'>;_MP&[Q!1?->$4L%?&H%L16)4F#YT#0U
M`@'0:F0H@(G\_8=`D:$8R91K+`,F2.2`W"MFMB*]5\RUPD*%.INHF-T9+)G/
MD?$FT!FI6FCW+C.Q5,SUI!(WD!H!"PA*;`)]#H+BG0^3U35;.B!2`9]:L;(5
MB5*H_*=&P"*#A3B>#,4VV9,];BP5\^Y97(>KY6*H4)?#1`DTF!&PP):/@*'8
M!EL[8%)AIHPX:R51$HUF!"RTU2-H*+;1B+,$8RF1;(?O+>-$*32:$;#0\'UM
M])7/'S04.VC.HHRE9-%!S>&=[9937A^61&H$++#U(V`H=L"<7A!+B55/ETU)
M=-*,@,5&H#>,SUJG=NC<3M%KY#J(0N*BZ>N:S8S8<-B/1Y>4R.YM-@_B=H]>
M@W#%?C(AT60&3V2!KX\)<=9-HL4#J1RBJ[E-BOUY/*GLYA:IT\5B(C56E9V.
MDVC-`*CN@H@-B.UY/*!LYA:@DYV8J(8_=&)R!Z@T`Z`1L0%AI@\`HMI^$".G
MI\5$:LP,1D[[2;1F`%1WW640N_7X#,K>;F8P<AL,[B=A$A:@L]83K1D`U5UW
M@-BSQP/*#F\!.DLU)L9;0+["[B)I'UEV;7(6AN%L/1]:@EUB[-P&X+B]"1P-
M[DH]#"!W)[UFZ,5)'UEU6!$AZZ>Y^^[!0X?,O\ZD/!K(W6I-VQ--:%5Q+V=7
MW.H3,--1?7;I#Q7Z`IP"+MF)_IJUI[+A7D4+N#6<KJ!LK3Q'R#^"7;J]\($)
MV/]W/\]P2*2P#PVG("X8$^H/`NICY_X;````__\#`%!+`P04``8`"````"$`
M]6:L2A<&``"B'```&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R4F=MN
MHT@0AN]7VG=`W`]G;(CBC#([FMV1=J75:@_7!+=M%&,L().9M]_JKC)-%V`@
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M5EG(UH"*9-_5S_=BWYYV=KAQXJT7^B"W7D33?BED2-O*WYJV*O]#D4^A,$A`
M0>`G!0G"N<$N3D3E]3EKLZ?'NGJWH%G`JKEFLO7\!PAX2PCMNQ2G,H349)!G
M&65G0Y?#Y!M8EF]/<>(_NM^@E#EI/J$&OG<:K7!A-MV48!K]*8W7]N8LQ=)9
MUEI.Y1/^H6\3=!,Q;*!F?1N9>32YE#<[.0@6K9=$G.CX.`/41*J1^GE%IN']
MO*1X9T,R7;7B).P202/4;%6]?6^3Q'[<*8Q4(:U^JO>=I9@[1UU<=$8-^/=F
M-^&]6>,MQ=Q[P[Q1DZJL`R=)N[>-E+=K;*68VVZ[N)@R:K#841H%Z43W2M2S
M#14"9^[77`[B$TC8!%"#>4=.J-\V\DY-^_NV4LQM=3TQ;]0,N]F'I'BB\_M'
MC9K;0"0:\90,Z17W?G8^$L?80ZG'JDHB+*OGA+K;C++Z$BO+G1%"IK/N%RRL
M"KFST=EW0KV[36?&J9F<$3Z&\X`;/HJPEX,TG;1>12Q_#%D<'"0RR)%J@)J9
MK\*6?`P/FEFO)M4<1;>:>Q/,\E=!2ZGY-N+X(%&DL+7U=%W,E!FVY$-IGA[^
M&+\T'RAU%'6IZ_?-&3!^S;3;"+A2W<CDC**1[<Q@M>P1[".1H(=[#Q_=0N0Y
MA:V`8>M^?DK-EG:`$!+=*CM%YF`5O)2:.W.$D&C6>16\@A%X#1!"(D3(-M@F
M&_W<,/I)'DV7@U.I6=:)WBNXMB0R&:)%IOTJA`5C".,,(=%LT5?12Q[_!_3B
M#"$1%CV$$\C4X2=@_%J&$36*%U]C@HK?/W[!4TN_;]:=@6QFFXT`+-5L)F<4
M#3$2,&0MPX@:-7<2(=&()T/73'Y((^.I/,0(BFY]-='0\FFP?#\I-5O2WL$5
M"TNBFW&O\,:2AJOXI=3,>4`1$M%!Q`^B2>]5!`O'"*;K25FCR*2(WNMFZJL@
M%N+QRECM1$<F>Q3=BCZUD\-5_%)J7G1.$1(1NKW(UT=B,VD&L&40"<=`IB%!
MR:.H2UZOC3D#AK'[FRQ$,AEE3P?)HVBXH4,&K&404:/F($*B$4\&KIG\QLY:
M>NVHLBBZ53;5;6=6=A6^PC%\\;,(B=`Y")Q4+[IA':T"F%+SCN8'3!)A1R=!
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M5(&KH<'63O0:TQ10M+`4>%6$5RJEJ(_B%W$^-U9>O<EK(!\^[NG^VEU1/0?J
M;J![`VZ(KME1_)'5Q^+26&=Q@*&>LP7&U'C'A"_:ZJHN;%ZJ%NZ&U*\GN`L4
M<.WA.2`^5%5[>R%OL;K;Q:?_`0``__\#`%!+`P04``8`"````"$`<K2S7F$#
M``!?"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R<EEUOHS@4AN]7
MVO^`N"]@2$B)0D8-57='VI%&H]V9:P><Q"I@9#M-^^_W'!P0-IVV,S=)L%^_
M/.<CMC>?GIO:>V)2<='F/@DBWV-M*2K>'G/_OW\?;FY]3VG:5K06+<O]%Z;\
M3]L__]A<A'Q4)\:T!PZMROV3UMTZ#%5Y8@U5@>A8"S,'(1NJX5$>0]5)1JM^
M45.'<12E84-YZQN'M?R(AS@<>,GN17EN6*N-B60UU<"O3KQ3@UM3?L2NH?+Q
MW-V4HNG`8L]KKE]Z4]]KRO7G8RLDW=<0]S-9T'+P[A]F]@TOI5#BH`.P"PWH
M/.8LS$)PVFXJ#A%@VCW)#KE_1]8%B?UPN^D3])VSBYK\]M1)7/Z2O/J'MPRR
M#77""NR%>$3IYPJ'8'$X6_W05^"K]"IVH.=:?Q.7OQD_GC24>PD186#KZN6>
MJ1(R"C9!O$2G4M0``)]>P[$U("/TN?^^\$J?<C])@^4J2@C(O3U3^H&CI>^5
M9Z5%\\.(R-7*F,17DP3HK_-Q$-\NR3)]WR4T1'V`]U33[4:*BP==`^]4'<4>
M)&MP'B(S'&.L/PL58D23.W3)?6AWB$)!?9ZV:40VX1/DM+QJ=G.-HR@&!98"
M\$9&B'S*^'K6!Q04(PI6`=EV9@"\1[;8)BM>4=R.$HL$,C0EP6PET$UO$^$B
MT$T`TLA!V!G-8J0N)@,6P>)W"'!1[D.88PK2*!DC-&DRFE5?O`7)HBBR!841
M](@6$73P-"=OYP+%-DD2I?:+=D9C2$A&5C.2J<!!M<C27R%#L4.6+!PRHS%D
M-R3)TI7;PD8Q3]+*1OE8X^`B&RF-7"2CN99M1:(XLYD+2V#7U4H6GE7.1O!^
M:^,BM[67-L#.:":M/1FP"++?(<!%;H[<UC::K&]M$B1NALSTO&8$_MG3E+S=
MV;W:)IFW]E4TH&1.K@IG?H)J98K@3CDIUCMD9E^=_OV366OWEKD_D$W>W&\/
MQ77^E2SA[CEA^5AKPVD]KYO;VU?1P)0ZFR8>^6@RS$^83;;,>6Z.NX;)(RM8
M72NO%&<\JV/HAW%TO$?<]=<(9WR']PO<F\-Q`H[WCA[9%RJ/O%5>S0Y@&04K
MV)NDN2"8!RVZ_I#="PT'>__S!!<Y!B=3%(#X((0>'O`%X]5P^S\```#__P,`
M4$L#!!0`!@`(````(0#.$#:*"@,``.,(```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;)166V^;,!A]G[3_@'@OMQ!R44C5I.I6:9.F:9=G!PQ8!8QL
MIVG__3[;@=HD3;J7)-C'AW.^8_O+ZO:EJ9UGS#BA;>J&7N`ZN,UH3MHR=7__
M>KB9NPX7J,U135N<NJ^8N[?KSY]6!\J>>(6Q<("AY:E;"=$M?9]G%6X0]VB'
M6Y@I*&N0@$=6^KQC&.5J45/[41`D?H-(ZVJ&)?L(!RT*DN%[FNT;W`I-PG"-
M!.CG%>EXS]9D'Z%K$'O:=S<9;3J@V)&:B%=%ZCI-MGPL6\K0K@;?+V&,LIY;
M/9S0-R1CE--">$#G:Z&GGA?^P@>F]2HGX$"6W6&X2-V[<+D-`]=?KU2!_A!\
MX,9OAU?T\(61_!MI,50;<I()["A]DM#'7`[!8O]D]8-*X`=S<ER@?2U^TL-7
M3,I*0-Q3<"2-+?/7>\PSJ"C0>-%4,F6T!@'PZ31$;@VH"'I1WP>2BRIU)XDW
MG063$.#.#G/Q0"2EZV1[+FCS5X/"(Y4FB8XD$U!_G(^\:#X-I\EU%E\K4@;O
MD4#K%:,'!W8-O)-W2.[!<`G,O3.M8_#ZGE7P*$GN)(OB`A<<\GE>)T&R\I^A
MIMD1L]$8.!(#)K01VQXAHP!Y@T9P/M8X@0S/5[^7)!?9DJ*9_;[-&8B-V)Y!
MS`>(I1%J-]88O[M#>HUR$>P%HR1),!:I,;':"K+66V/`4A#;"BY71X)3%^P-
M823!FS,5ZD9C$AUG/-*U-6>C^>1\5:`"9E4N:Y+@D:;I0*LE:8A1#&/`*D9B
MOUANZ^MQR$77XM`80X$Q8"F8V0HN6Y?@D?63.#0F5G&$TU%86W-V]I:5)4FV
M(^.L7Y8DP2-)XQ.M(48MC`'KQ0O[Q1]+0RZZEH;&&`J,`4L!=(?_\*[0(_,G
M>1Q!^GS$\X6]564_DOKU=&3<AEJ7[C7Z*FXP*_$6US5W,KJ7?22$E(=1W>,V
MLL>I+C5,0(OI4(F_(U:2ECLU+F!IX,W@4##=I/2#H)VZ"7=40'-1/ROX,X'A
M-@D\`!>4BOY!WKW#WY/U/P```/__`P!02P,$%``&``@````A`%DJZOF=!```
M>!$``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R46-MNZC@4?1]I_B'*
M>TF<*T'`T2%59XXT1QJ-YO(<@H&H28SBM+1_/]O>!L=.2\D+$._E[;4O7K%9
M?GMK:N>5=KQB[<HE,]]U:%NR7=4>5NX_?S\]S%V']T6[*VK6TI7[3KG[;?WK
M+\LSZY[YD=+>`0\M7[G'OC\M/(^71]H4?,9.M`7+GG5-T<-C=_#XJ:/%3DYJ
M:B_P_<1KBJIUT<.BN\<'V^^KDCZR\J6A;8]..EH7/?#GQ^K$+]Z:\AYW3=$]
MOYP>2M:<P,6VJJO^73IUG:9<_#BTK"NV-<3]1J*BO/B6#R/W355VC+-]/P-W
M'A(=QYQYF0>>ULM=!1&(M#L=W:_<[V21!Y'KK9<R0?]6],P'OQU^9.??NFKW
M1]52R#;4251@R]BS@/[8B2&8[(UF/\D*_-DY.[HO7NK^+W;^G5:'8P_ECB$B
M$=AB]_Y(>0D9!3>S(!:>2E8#`?ATFDJT!F2D>)/?YVK7'U=NF,SBU`\)P)TM
MY?U3)5RZ3OG">];\AR"B7*&30#D)@;VR![-@'I,X^=J+AXQD@(]%7ZR7'3L[
MT#6P)C\5H@?)`CQ_'!&$(K#?!5A.`;(<RO"Z#I*E]PJ9*Q5D@Q!H?`TQ$?D'
MB/D5X@&M*S>(>,A-9#V$VMWF*"99'-.K>QG&!B%SF5T15SX8,`A`0H8$;B\L
MP$!P&'EF+8P0V:B223X8,!:.IBPLP"L78KBF//2MA1&2R)*1.(PCTYX;]B2-
M=54-6M"L]^=#@"U:Q%QV@Y`(:84V*<.:Z%P:E)(IE`38HA18E!"2JDQ%<]V:
M6#'#GF1!?)UOT$JGT!)@BU9X=8LMBQ#,5*BK@YR&QN"3/(E7T=W[7(`M0E9Q
M-@A!0HEO9VEH)8-N-'*43:$DP!8EG7K,$4)4Z1(26J7-#7OJSW5(!BT"$G-_
MJB3:W/9V?38*,]CWPQ%S\6EZC%IJ;'U;[`ABL%)I9B4M-\QQIF>;M(1"#MKG
M/BDFJ*L&/:M3-@JC.GO0O=C:ACF*/VEN(G1T0.^V4$NTU4O:,?:2PB"M(-&M
MHFA=A%N\`Z-(;T@S:Y-DG(QU/+)U7&%4CX<C=3+ML:^W@$ELDI"+DXZU]R);
MR15&E=$4K]PPZIDFI4E"3L9*'NE850D-J0XSO;"JH6&/?2VY)K%)4D[&6AYI
MQXK81:_U"SL:-=A-C$EPDK03E&;HW^MI(;(T8:,P0[VZ"+HX)0^/:,02<7DR
M#KX\I,EIYA8<;"*5)M1KV!6:Z2A--S$&4T%JJ!&":?8E43G+(JHU$HDJC-(*
MN\T,*_E$*8))LB_1%BE;5Q4&E2++0GM[Y";`CS+MP<R;)?VWM3482WYD:ZO"
M(+6'>90$UM;-340:9:'>0R:Y2<(?H&H/WT>QK;`*HQ0V2FVERTU`',]UP4UJ
MEOC?]\J$6ZRMM;%>0/4;8M1I_H.#CG*B`!^<=/"BB_?`AG8'FM.ZYD[)7L0E
M-H##[W44+]@;LM@$XKYDC>?BXBW&O:L![KVGXD!_%MVA:KE3TSVX]&<IO$0Z
MO#GC0\].\IJV93W<>.7/(_S#0>$^YL\`O&>LOSR(!:[_F:S_!P``__\#`%!+
M`P04``8`"````"$`0FDCIC<#``!B"P``&````'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;)2676^;,!2&[R?M/R#N"S@)^5*2JJ'K5JF3IFD?UPZ88!4PLIVF
M_?<[MFD:.X0EO:`A?OWRG./#R5G<OE:E]T*XH*Q>^BB(?(_4*<MHO5WZOW\]
MW$Q]3TA<9[AD-5GZ;T3XMZO/GQ9[QI]%08CTP*$62[^0LIF'H4@+4F$1L(;4
ML)(S7F$)MWP;BH83G.E-51D.HF@<5IC6OG&8\TL\6)[3E-RS=%>16AH33DHL
M@5\4M!'O;E5ZB5V%^?.NN4E9U8#%AI94OFE3WZO2^>.V9AQO2HC[%8UP^NZM
M;T[L*YIR)E@N`[`+#>AIS+-P%H+3:I%1B$"EW>,D7_IW:)Z@D1^N%CI!?RC9
MBZ//GBC8_BNGV1.M"60;SDF=P(:Q9R5]S-17L#D\V?V@3^`']S*2XUTI?[+]
M-T*WA83CCB$B%=@\>[LG(H6,@DTPB)53RDH`@*M7454:D!'\JO_O:2:+I3\<
M!_$D&B*0>QLBY`-5EKZ7[H1DU5\C0JV5,1FT)D.@;]<'P6`:HWC\?Y?0$.D`
M[['$JP5G>P^J!IXI&JQJ$,W!644VA/QT1P8AJ3UW:I/>"FH!Q_&RB@>+\`4R
MF+:2]:G$420=BNG!)`2\`R-$?LS8SZ;$2Q^N'VS#@ZW&7QO)3(.C+S?.<G)V
MV8*"9%T.I<0.U,B!,I*)R6:D_VQ%TJ>PT$;7H"FQ@Q;;#UX;R4BC1?9:TKUF
MX4")7YXI)79PQO8CUT;2C=.]9N&,K\%18@=GXN`8R=EJ.KML04VN@5)B!^KC
MS3$E;B2FFI"IIL@]NGZ-A:=^R(ZZ1/\;J,0.WLS)F9$8O`%"<32:.J><'$N@
MQ4UC:','%PMN=@V<$MMP8R<O:R/IA3N6],,A:*:7ITZK'3QTB-H<;:O1/W?Z
MF^3X&RLSR.GN_>>FU?;#8Z<WKEO-V6H_OVZ#J1Y[<4$ATY'A^M'3W?;9:MJ*
M'\90\W;>DCZ%#7=5:T<=O=UMH*VFNV6=6;21KFKI,`JY11X[K]>ZU9Q!ZNOJ
M9DHR0T2#M^0[YEM:"Z\D.1Q/%$R@!W,S(YD;R1H]+&R8A-E&?RQ@EB4P240!
MB'/&Y/N-FL(.T_'J'P```/__`P!02P,$%``&``@````A`-2%[/5X7@``\BX!
M`!0```!X;"]S:&%R9613=')I;F=S+GAM;.2=WVX<1[+F[Q?8=R@(.E@2("F2
M$F7)]OB`HDB;,[+$(])C#!9[4>PNDCUN=O=T=4OB7!D'^P:[-POL`L9<[U-X
MW\1/LK\O(C,KJZJ;TG@\>[/`.6.1K,J,C(SXXF]F??FO'V['Q;MJ7H^FD]\]
MV-O9?5!4D\%T.)I<_^[!=Q<GV\\>%/6BG`S+\712_>[!754_^->O_N-_^+*N
M%P7O3NK?/;A9+&:?/WI4#VZJV[+>F<ZJ"7^YFLYORP4_SJ\?U;-Y50[KFZI:
MW(X?[>_N/GUT6XXF#XK!=#E9,._!XZ</BN5D])=E=>2_>OKX^8.OOJQ'7WVY
M^.KE=+"\K2:+`CJ*X\EBM+@K3B<^`707&]^=ORP>;G[Y:/'5EX_TBK^VMU]\
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MK.KBS7)A`,$*NJ^].'QU^/KHN#C_YOCXXGR=FIY.BHN;Z;)&N>LM0&!<U74Q
M7=Q4\_>CNBKJ634878WNU]_'W:DC=\NZKA;UY[T_E_6-H<E`_ZC^LAR]*\?5
M9-%C]1O140R"(/EHW<$NI@N$^/YGSN;`XAS<$H1IOIFT:*N85#UF^Y3W3;7Z
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MHD+?/0QQTS8B5NJ[Z.G!L-#N9*^K13'6A**?`6;SZ@:C"?GVZ^[CKW"(/@='
MJUL@F6=S/"^&HW>C(4YY]Z5FCG?E:"Q;7RRFFBR)>X"17_UB`:,</'O[^**L
M<26UNN%HO,22="?YOAI=W\C"E!BJ\AHOS^U=)OB]0=L2C?R>'+]]>_RR.+]X
M<_0'$VO[US=O7KT\?GO^GXKC?_ON].)/Q<;+XY/3H].+M8C5]C][(MXEW22J
M^TL%H!O]"#17[NXKF74X"];AZ./6`3]HE75(J'#4F/[NA!\!C!>$G9.)XI`7
MY;B<#*HM]TJ"!4RA\GYWW!4O1H`TZ[_^S5/\&,UDKEPFF06A/::RODF.WO0*
MH1=M`VGR5A"7+B6_=KSN.(?#/R]K<PN-DBM%ZV['?6'=Y]?.NYQA6ZH/U7R@
M2`:']7TY5V`/U*05_A.&-&_R/B*3N-SK*1*;B.:_G_?_P/!=JC^">L9'#TD&
M(P5A)OY*9A57%='TO&<07$'L"=;60=-U@G7O2UV2SP5EVY=E#;P)W&,<U7TN
M(G3W]V0H/JZ%/>>Y^]9J%>R]=K_HOL/:B18XA6E>S$<#8;;Y&\4ALJR`_=?(
M[Z>,NU*(NZNTA[H(]>1C'%W-F]YK;8-S='C^37'RZLWW:WVE(^42KL;3]VU/
M`OX)/]ZMB<@3UM0RT/,*$1Z0-U)FP)T$?JM_6Z9B*:$BC@A.ROU#OZP0;]1"
MV-5ER>&MDDY_]0"?[27J\/AZ@/1>]X/?HYN2N+@SM>56S,QG84;/;EL^HSN_
MA/^C*^J^U&7PB##7!?0>!I\M<2A11@GQ;&46ICM-C[95\W1?ZM)V-9I@VJ0\
M]]$VGPZJ:ACDA=BJ&&4FL0-.W1E)*=WS<N[I==\D)5C>61;7>((3.YH!GH#F
M.SQ)+),37Q7E]5Q>YV31'2&Q"([*_QP6EW?AK?:25[VX,:P&U`/J:A-Y\G])
ML$P<S"/^2$[.6+WJP2VR4]&)T<HL"]VEX)ZW6;Q)R<KWSI>SV=B8(3L351W"
M4QVB)_DI#E#XWZ7C3<NEZ?[U`EG`>YR1KS4%.U_>WBJES++.R<Z0$!VH0!#R
M>>+YV93T[8JTU8I'BO4UB(V]3;*QO]7<+ZMZ,!_-+(L(Y2^6]6A",--=K)4T
M+MLEC2VEMZ01D0O\J.>VBI)0:%QB?2K,ZYS4GX'8%JI3W%!E^LNRG"M.,YS\
M'GP@/*SYQ18CC7EX.-TIWDR*WY<3'KS[^:=]*_+L/M]JS2;#/:XL0BDN`]FR
MYI>HM9:3R/NV`BX9_/UH<6,$IFDDTR7YUOG0?%Q[0`N"EEL2W%?,1WKL,*J8
M;?,9GK?^Y*/:K]Y65-#*2<#J+87=LL'$X9968P%/5(C:?09G%`ZCKM)'E/G-
M8#$E\<83_,V?@*3W-R,%V/QW.A[?;5/IX.EZ>5F/AJ,@8:^7BKR]M%1L^$^;
MQ:U6.O2%:J;1!,MD6Q<9NY(+V#-\B*7!PA5K-S;']6'SX$B]G+_#/B+$V8;Z
M:CY.YDYQ>DM@C)DC!8<_.,8`:R@-'#<GER.,`98,\O'")W#+H_[6DN.Z.B)I
MBK%*&'#K60B09O)"6(\9)Z[%YAC/P%.$5Z*PM/1R,5LBMN3(?<=:+/2A(#U[
MO!Q0+YA+R,1VK05$5@U4R%/-6;47K""BM0RCRH:R]]T;!5!ZY<(+'HIJAA:5
M15KXH%I:NL\<66'1C"C,K(7QFGJ=BUK(U8CO9,\]18AP406[-B6"Z#G!+=EI
M#WSFP]'T75D/R'G.R1&0]8$=.SGR_/+C_ZB+,?HLHSU<#N0NX!A+^K<*\C^#
M<CY5LGWC<HF5':+:X^+F;HA-O$'+,4F;A@AEX772`0]<*W$)W5YGQE8LRNW+
M,;DSA%*<);<\).:MJ7Z3BC7XD8*JW@I7*OF:Z#Y+E&(7@S%I)U4O<8OY7ZU+
M6V-B$&UK&?XVNIR3UV^`X_`$XB9DA2G2*!HT;`"\YHOBBFP-88L1-*ZN%C+)
M<KR=4W?UU7)BP:@!T#<G9$%:;"MP=0HEA!96,].^*>$3-H750:SPBX<F<C:!
MD>G<?A#Q,#7?F/H.X+QE6;!AM(!AXQ%RK:?18]P:ISMNAC8L8[;;K=M2,H-Z
M\G18+M/6Q,5H!WJF68?SY?7'9'(1'+W%#5MQ<S=3^JWFG[859^;?[;]X]+B[
M*T!I(&^K49*OCU\?7YP>;1\&UAV>,`P4&F-L(\,[IHR#&U1U4G@\!RO1`+8Z
M[;ZRH`XA6@I+?3>BEHF4@7L26_3#R7LLZY1M\,8W)YM!=AHJM9[]K<]VGQ7?
MG$1^`1-!MEX<GU_X*R"MP7B]O,99UR2V29%N<?U2N#H88&ZOEF.-RRY(58CF
MYD:G9(2?Q(6&(Y+TLJ`6L1AM#WA"J$/&8CB]51$*ZS.E3$QTB_"#)VT5\,*1
M:+%$(\ETMABFU.55%2N?5W)<!N;'1&)Y&J-G7K(L.CX/%AT:(=GD._$AF)Y4
M]>,923!N$$+!&S8J;T\_W-44OXL--K::C=!G9'9<>J3P&0;T#O,[!USJ>M.8
MH?87F"A_ZL04[Z8T:P00"B/VBL?/GA=`&0H_J8J;Z>WTKW?7[++4:KJ@=<)]
MA_B3+3KB:5(:EWI\_5M26*CY.WR12^2$Y0=.N"(C7^;I8<9G4S1-[D![?Q8C
MK!:OL?A0EZ[O;F>+*>TV9%T/3QY%V"'U*H,+'U[90D&_[4$)9D/#G#(4-J2G
M=P9W`A$YYF;/V)MAB0]'=MIWV%6D42(51B_8Y[AD1*BNJA\D7%!93>;8Y**<
M@>,?6)J9:;R1[N:RW1*6J,O%3`$J^L;R38@6R^&=<RCCQDMIW[G+U[?3R0@I
MT+0OI@`9F=_S;U]L(C6:GBK<W5^1+^JB=!Y9\:)1VW63.GS+-L!KD%0!0@("
M3(`)*P(&Z0YE,S(__A(]$0N$RBP$]?HE&R38E>)6K"<:"YF.FNX'+`_\43RG
MH2)B:.;(/VU#JB<^V=]-:N%,T5I]J;?E#Z9W(U,/I]JAK2%=W!!\PMS($2?;
MX*PT/TU[E"P4&N'*Z4[Q_I/B/5ML`[C+M;V<N19XU&4R<HM97]J&:`=M`C/K
MF8AOFXSO_/R3V7Y;A%F7$77G2*1MX)6:@^35EJF>8;3.JVL9+<D:<V0CV\!;
M4@?$'^LM]098Y'6AY9?+.4;2/2K')V@X]XW00*LI46YFO!PZK-GT\)!?1OA(
M/OY'Y<!@)E@=T`E[!GW1CR@'-QA:K2F7(E7E/>X;X+0"8*(S2DI$"]\#HUY&
MH!%;LP]ZHY8BK1"V3(ST9CFN/1OE4N]>LZ6HFD$"'%Q64`/OXQH`M2#+`0("
MD6;'\"/N)0Q`C6]GFN#$!8`QWTE<QTJY8">^-S)VOJB\8L!+]'CPD[$\[JU"
M%6`AZHKE+L;@&WA)O.BC2JUA6#-F5I&$C=6L[;$V_I'>2I#B^AL]PI92$1"@
M]QAJ`8DK%FD4O2V@03?IDG@:@JI(.&81&G/U(%DSJF_$Z@"A5Z,Y%N:F'"MW
MKS$^ZZ'\A5MHS5E<XDO)<5/33@#;#&$[-EZ(1+`(1TT$3UX>.K+C'+OHA3UR
M]DX"GLU+U3\R_`I]$,1NCN[Q+=1I.8G%RNFE077V&LZOJ;J\@_S)R#]<%W5.
MTA"'(50+92VW0M%Z$#N#,0"6D`,!PO]9RJBE.K-[(9:H%=1$#X7I\A<4.395
MXAYO7]'%2BP=/)ZOL>'7F$;*7/-)-_%QP5;'I4,&"H3I)!2GX59@@"+Q/]H4
M35E=H6;\=S&US'OA[-'H8*":1^0!F9EE,TS8Q7;]/7";-++<007YL$"\M'&;
MI3@HX>L;%7^FKT4/EL5D:0T\T#$?U8`^]FRJO#+&RC0OR0@^#CYNOWXOC15P
MBIAA-4.Z">#(R$Z*'ZH[_F9%["60XS*4[PB3NOWM+Y$_L?%$P"K]P*MW-+Y9
MQY/%BV&LK@C2>P?AN2RB/R%3V^>/M"ZG1J0T<V;Y<VU0"%29.#PV(Q`V'\8:
M"PAUR129KI/.Z82[J"OI"+`/)U+]![!6.03)I\352&9N/04KY?9YTB9(BE4*
M$!Y-/,$BFK>6DI1UM[.A0"S@OXC6/\PUP?[]W'+C-)<[UG)BX*\DAFG;X@]<
MS:?+ZQN$QHNY!B+BD6PUY&`*0VD!'WWP0T]=7KJ'H(:P-H(8:)#0FN6.X\.]
MYSN/8Q?8VO)PI*FFJ=/H$<TH/$F9E5UQ<<-2;X3]`C6S8JUQYG12G%27<^4,
M!:GDW"0;47E9;TH7SKR15DV>8$"JGD9E[*SGLYWG<3GLA55Z@O$T8\N_E5]O
MR2O;P(ZV'`"+?3/4=F=.[,^H--]K.KDV1&JTWI87'+"X'A#`[98T-CF!P;Z<
MR584^R^Z+GIW?M>#C`"XBD-,K4$X%[(*[$L(8DQ<37,Z^7^W)1;/*GQ4RF0-
M@#&C,A6FBH(OI%4-`S(*A.*D5;1K+JXB"QP*%O)@I_AF^AZ%(]QEE6-UIT1C
MV/A="XQ3<)?572O<#;YG0L`<+!2G$2$'M;3.!=NV\(R!(:D/@:T@LX[VIBU:
MZB$:L"1@H(ME*1R(`"]8-S1S#S5(98BBLNWY.P2C;Z"'9-_OA`.4;%SLM9+U
M)KF)6J+Y9OI'/+_66.<B(V>Q:WQS)C?5-9&02?4]MM9SB]%,NYA*:KQOVJSC
M.H]%DT1E1YSOUOD;;N7`'D`PLY]7D$N^+;.'U*R6"T/^\0BO"KXNR+R+`RF5
MW:LK_?+CW[JK`R<H)*AQ/L\69/,$?38_5-LOVBV",3T4ER\5XH(T,;[ZHCN'
MB'(I-OF!7/8]XM",RH4J"9F4):5P-$)>J(4H\IT6UXK!R8'7UJ.<>Y$V8'"\
M5E)`<N0'BL=$>O(@6NZC[:M9&<-OT1M6HWYXG"/6;7@@IZ(1RX#408E63GJD
M2']R9Q/D4D)ZB(5HHK&"?>F!.VNPLC$F"($>>5W6P_(O'-B8J0>XX(@1"^E-
MYP[`N%`C`%FW@5&-B[0$Q#RK:#X%TDH!$>^6.>]=Z*]8EEQCDC9QLSO>7MO^
M]^@7,2XEL.(*QD^NM^0:U62K1"TY1!P"]^.U(94*J):7M/H"M@%X'XS+$44R
M_3TV6I(W&K->O$2-1I:!#9T+I^LO]-PJ854PYX.P(@=+4Q"1F.]H]2%L'E4"
M6B6MHDBZ0[-34U5G)DQ.M?"ZY\)<,)Y<#6U^7ZX,,1K78UA=8I"4NO,XX[T%
M@>/1#RI?H<($M8+6+`S(Q[1^2@$Z2M1=ADE^Z.KL158&:#"C$7NAL<QP8P^#
M9VFN.6*,MW<)(*EBZX@T)>TKWY+0&TJ).`RMW'SE3Q>^)EGL:J)L.<3Z5HE#
M@<)5NAOM6*/#'B)+(*5H@RDNL?7/&6KY-/`,@%&LTMG6S!CDE25/;5!-FEBJ
MP6L3[U7C8!JJH'*_Q>%;<P)81$)$X%31R!W<:''?C!_V(]\`\R,8D)C"1K-`
M21*^,D#E\(;GGIJ_EF/$5YD(55S@8;9SD4U:0$Y?ARS+M_2>D46B+#!;>)@M
M%6D['&X+LCB<1/"8[']H![58QJQET_XC`VU]0^9\9<U`DF1MRT2'004H2U5%
M$8)41O4Z!G-BAD%,`)3G66VV^BT"6"6ML_W52J^6<WO4_!'ZT%IQLQ4[F*D=
MN2>)@);,<6`P;7TU1^FU,O-$$2NH)6!>K>XI&==U"LEXHE&.;Z(X6<'<:UGE
M&@IN]$+'RR-6BWF_A5BT]))`E(&@U]GJK4;#HY<T4^<\ZQHO*94E0/`\R\*C
M`GZG/(49856Q=0+2@VIR3ISH9.=$>HP5V900/<-0Y2JM/X:P4=GBRXJRV6Q.
MKY&"U92B:Y+A$(?2Y;MJ.;G[Z!*/["&)?>AIC^+YV\FD9AGB;J->0*(E?*6Y
M9;=5[TH&R1:07)FKI<(,Y6KXD[E_6I_2L,06T7/0^%@XO!]5PPP>9#E<GP27
MO.([':Q7[]E<Q9(#%XR'*:B&(!*P@X!6%\O9[/*^;O-;N59+UD8,B0RW;%Z]
M3,%8E,65T"+H0AK'R@^:GOF\N3:P^"S5QE.&`7;Z,PE#4EUGB4"J0Q9]UG@8
M,MOK0/;+S@'Q-UE,OV<],AP+H["A_:K`77(I4]718V58I^%>'YZ_//PW*4+*
M=^/09-X?H!%/,Z2=""\=M3P_.=P)UP:<!Y&7<3E2QB2XMAJJY4C>T`ZA5=_B
M`&M#=?+E=GF+,*UX^R&G^:G@`*:U.I*+H2=:]!Y:.<#N,=_C7:N'FD('*N=+
M)4U"XF%8+(4.>\]V045.R`[5KP'OKZG_,XZC0EJGY:F$$<SQ&M;Q"+NI,-F,
M-SF2D?5"7=ZQ!))C$*!'XR;+W7(O6AE0IAJZ+*[_>^-IB"58YQ4L$_WW,@KQ
MI-&$-$&78XIMFG=9UQY<D*&0)RN$BXUA5E+.^'LONWKVY*WR#D#IN?)CQ3E,
MZO5;(JF$"X.;GW^R9J]NJ@PA2>FGO6W(WGX*UWW46N-)7LVR96')3G%(<CG*
MET3$54L2D_\V05&PY2L17Y!V-9TND$Z&:?#?,1--FE>$%&9SY>>:5#3PF>!2
MHD/N2<]-)SU&O>!8D3GP9]!*F&#0^65'J2\0*#5/6<`F"5M);T/A+%HHEJ?W
M\G:][W;.=T)&UI+QYC>QF*PY"V550Y149L,>__KP\&S38H=D.V!S;CN:-',,
MGFGZL9Z,M"CMET2YH1T+8W&?'3DE1C`^=$`Q3_@&,^(:*G4VCE5#T_0W#'U+
M??7:[+74&$ITNHQ&C-CG!)@'(G)/*8L6HK)[C*>';>\.)S16C@N_=D#YCQ.&
M1G.V_^")%A3(3.J0Q]W\@TW")YUOQH<C&E<$J.2W3OJ$\UB14\B74,40)^"5
MG$_P#^K905"G*O8D7P`+.M4PL'%/>G+UUKM(#IL.O;,YP;>2?<J7=/I5YUQ)
MHJM//J]G8.#O'AAK<1T??'5*6^F2#I$F/WQR>/[",N-09__.YC@/&%<7W\V,
MEQN__/@_#\^_^^7'_[7).G9LF.T]KAEQ$6=>_=\9_S-ZQ!TG?Y5#SMTINP_X
M2?UMYCC<0M&>?C,_P;_S1RYPV>@-K-X7;VD2F>BO5R7=;I1,;`3]XI$-S%TK
M,#Z<N@20D!"_<$7ISHV+Z8Q\Q/.]@\W/BV.EJV*A]*HX"GT5)UY,20(@!7RK
M!,O<66E-I:$2A+`=JJ7"<E+LV!_5G"8?XS0>M#S&0[5,Z]=4U,QRL,5.Q3,Q
MY@@PINT9[@$7/2[]<SBT>NM#/Q:KQ-&K`XUPJNDQ6;_]1S0<)B=#0!I',2D7
MGDB897D4MDG1RE91"LEFFQ!4RW%Q3\]UR]N.I3K@R#>!S6G4`O13HPWOS+-M
ML@`@=]&R.52ZBK4BQ%750L=OF43IZ97?ZG)'*;#&R8D=^=Y5DJX#D*OEBF*A
M`0\CCW1G6S&*UT02P&2U>]D63+$C"_^*-?"(;OJK!Y+-PJ"X%8Z`'!Z2J%`5
M<%"VXL@MA4^-FAJ(74=Y(S:"WZ;5\<(?PW:+F=SA%B)KU[5O5S2>LTN6K?<E
MW+=5;#6;XN6W[<5TVU#`!PTENX^"&&"0;CSBW^N!Z7!Y30;Q'X2F#)8.!%/_
M;Z'I++/ZVI4&:P"JN->__/C?BE;-O=@X7UXN#+GV=P^VG^P"7B_=9"A28YSO
MV`/K"C.H\;@9;#+P\93O88BC`"D@QP,8DX#63#T`$DPO^?]_#A!]%>R8C$*P
M"_^DB:3MTO3&*!VD*/P>U1>4=345N)=BK\:"V.ORZ5BP:HI?`P:%EB<TV@:R
M`Q"&$F7F)P77"'<%_X0FK8A(.14-GCHXY?U^B)N<VSQ5U4K6R/LR%/][4C5"
M3ZPB-U450EP)M*R%84GTL#*\SV!13E<'#/-<4[O6^?]36BO9A.$4*)?A\"*L
MMBY+QHT(,<C_X.**X8WE^9BKCK$*/BL`1!O3C!&2X;/M0TJB!3)3FY`E8?WB
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MTK]MY`7=\3UD2H0OAK,R.LR^5*@5Z"0\3/P,@RX$T"F9&^$S?]`-G[?#:BU:
M;TCZHM?V!J"@"#@Z<DI5XN#C&J9@(!\P6/%&$X_4_G*,(A"<(8:=Z'/QE?U=
MBA+^GB4H6+A:D27'U%)HK0O%<B_UF;!WJX\ZM@AVD!LT[X<WGWM*4+43'9&0
ML=,BE??7P!Q>8_5UU987/R*-5)"84,C.>Y:-@$-YK5.S4>)2B")XFM#\(JK4
M:L96$/S1R8I("?Q"ZXS5&159(,>T">JH1BM6"K0'*!*ATTNU_N@5L8',HTJ'
MVO)P#D5KB*?8;/9Q[`3I;<4%P\7X(";LT4($RU>7[X+\P=@Z82DXJP@WBW<)
M(_%*ALFTAP5;=D$,M@00^[FL>C0<*>S3/9Z*<0TMCZBGD-)[2R]F%\4;I->A
MU_G2)S"I3.EJE((\BW=W9NN#O[FN(TJ=:8D>-:U:0*5A)F@P$A%3)@&NVH9K
M.^T?&6_:HJ+-)M=#8QS*;3?-;-O-L!IT_90J\'F7%+:'VX-TKTK00MZ#/91;
M*'AZ])C_QDY?V@O>:,;A(T2,H!1`4'^?Y\`Z\!?%)DCQBD5Q#L1H3S97)E%<
MN"PG/Q">8\$P+037I.U<R'L:&=.(X?Q?8T2T=Z,%.69MN&U>9@_3@2*Y;[XG
M[XG@;S@<<RX.);J$.])=2_Y()U$LZ0>CXW=$Z]B3-U)?>*ZA6T8P-),0=06M
M]92VVIZR/)XY"PRO>CI8Y!C2NN!NAA;X,433/\QTNHMB!WWCI9`Z%9;,%#*H
MJ.8]CVFN+48&AM1-4.")T2<9,TP8TC&9.9/]J'63ZCT62(9"$8D:?E4H4LC.
MV7S2%,9,*V&;Q0SV&=,J4JS==J?XGDNZDE,`\TD]<2*.Q#;)+?X!7C9U*YP*
MMAXN3Z^\NFZ\T(Q8P^RNOYP5#!DS":FB$GPKER!5MMRJ2'JMJ"*0UDUBF"VR
M#ZI',B>@VV2&7?EL>D.^;'<3+_4ZLNK;P@"J:[@I5S^"^B"VU<BHNM.-JL#`
ML(E2-)]ZH](QPS&P:Q@E08LM(NY[[12O5NZ7L3Z(@/@5Q^94E,[Q2Z4TV'AT
M98!N_]9`XK=^6$%#\V2<>IVX^LEJXYC&^M8.\U,!M*T04D-1L'_-/`U82SX"
M?;D[Z,.XZ$FPFK0V0/F/\1D!"=;L$SC>5=K#X&8=ASM:>W_']]$1U;`D=,H,
MN8F-`@H)A="L02K3]:!H8F`TEB:.H()P!L,2>2?AM_MEH_\KX93'%68*/B7B
MS`$!*J]WFE%]&>3\`Q(2['*T3V0J)6UE'.!*X"OA<7\L4&%1]&5E!V&D>8&*
M*-IC9;JUUC!!JPSB4(GXQ.RI*5#$`DM'LEZD,%'7B$)`8,JNU#@M$-\ICC^4
M*M&9N$1N&!:TV!%QSSQ8.V$=:;NJ='`MF4!^@@=VA:_X&^T=[LYDJ1Y3X-)/
M=?.75@>2-@ENZV0RUD6K5^!(WGW<:NG*]M*XJ"/:\3V7:P:YPLMC$%S=U526
M"WI=\4(A'#+LM):5=+07J2L&/"-K@=W*;[GH6..0B&Z%/U>M.,X!2[*98A0_
M[&C!M58CKCB*MJ*>>"I\85@B6]DSB.>5!3T]/_PBDW>'6S9%T`M0UOY.*S!!
M8=E^0U$=BS0T$Q=I!@WI13$FI1S"$*9PJ=",G#.%-88IP)AYZKY'\MO(5(V8
M572Z"M]Z+D_W2]K=*`9-159S4\C:D7WMJL*-EA>(VPM22%J35$8=<<FI=9&.
MB@A=:HYLTF@U)-:=.%+LD2`V4BY=9F/#Y5IF2K)]CXJ60#H2`NM"@X<8%&>,
MH"0M]!,V]"FD1:P65#/[1V_?:+F1VMI.6.+WB0D=@E%+,2:UF:*#PC+._/#[
MT'O*&>;`OD9G<N=BIW@;FB\C<;5R`;CU37(*0X,H$C]>+[A%T30N'C:4#'%E
MP>B#;)OUD_&`)1.L^.:_RHXY>S3K$A$YPQHXQ^+&D7/0H?AG'>S&$9^#"/TR
MJQ&BA@A-Y9<HH>*'OG%WD`D2N[CA).L0M\Q&*#4SR"TW=G@/3G"5I=#4AX?M
M5GI,*Z'>F'=E1\QD:.&+T@(6ZY`0YNF*ANJ]F-(<@DY;7\JK0J0O2778S27.
M#C9'0\TXWIU.V(&=<L@\"#'-YTSA+#DI2=80Y$MKE7$CA8<;V)5M5UP-HHW3
MKJ.W((,?_$G9%1NYO0WI[$!8L%E`KCRQMAQ*M>C""$8?QSO9HZ1#DE@HN779
MR$77A`]M?T_#M;0^"ME*499[TZB_ZYYD.AY'N"UU>"DP-5WEKQ-/*"=@B&KB
MQMDU,<9"2ZL[_3U\..TW:$3)2\JI7<J!K.G:ML8ND1NZF"5B(;481UG.\+M)
M_(7;T4)JUOO*@K44V]*8A`3R<N4GBI\(=V\$^(?0Z/XO'EQ].-)C'(P#%/K=
M3!")HJGOT#S3-XQ-2TXX)N4NK=CFOP\_H^U&6][Y\L)#5'J+<420`XL/T^+$
M"R?>6?$Q^B0+2:AMWZ/?97Q(Q1&VORS"+5S`D,E@JH)X6X<+79Y]=$]N2FQD
M1QM#T.MG0U%]&$*R?823Q_:@>(T;_,G<[8F3M5MMOR"4&)K?NNZ>SHO&SILO
MM"XOB:(`'.(H_;I<EJ*@*BF$]B::(_);.E?H)9HFF&AG2=(X4L#F$E&;Q"-A
M>3NUVK9"CE17H@WE8:A,T0K;?`M29&59=IFGN)T!,*)7:T4HA,,&!/C`".M\
M94G"=6&EA9G\<%5Y:-YC[JE=C%U<*#W;M?-B:)1FO[N5!!@#(_,II0L?V5GU
M0S&[6R!-35Y$_FHT7(T3S!^)?TEMFPV#!R2&^0V.,"D4.I1XA4<<BOU'0QI5
MS';PD$C.FLWAI:!/`I(L'6VN1=H39T1[3T,26/."F-[&I*@%+W@^XHR7$08!
MG@KV+@&NE^$:C9!$3ITS*:C"R,[G%@,%*R313X=5UA$JDW=3V>T?\=L$Q@W)
MHL-]2`[@.UGNP(TD9,,"$GPV*?MAXN1"Z45>B5:Z)U3K7$.!#&,PBW)";">L
MTF-18:,>OFX'>T@FS@ZHIU`/=9FP\:;PBJV=$,FP95_3=:2?0I"$2R.&J?Q:
M$GBAW[7>#VZ`1"47S.9=IR(,$,&H-43@B>SXI?"52`O9PY&4BV47B$E!=4F=
M=\(:_/"K&+>4LKEL5!U'3TEE2AD*BP=@H>YK);_%E66Z>".<'8*#G!^F6&FL
MK*5*K$/<8D-Z2PUT6C.]7C)B[9Q'I_"D=&TR$ZL7$>U[F$O`M((GAB19(E,#
MHREY,R#2AXRL7Y16P>UR*T;WLDQG(:S:#S<UNFE:Z$##R4MC?N.^"#:8X<@[
M@@SL_0"\I;?;6M,MF'E6&]\A&D5L7'$:0S6U^.HL/ZU>]/FJ/#&=_/S3XV?[
M;!Z%5*_46MP@-+*4)]H9Z.$<AP$CV^@)`."=.UP\KWC-R3JT.IT+$7NZE-K^
MR2B%U<>"E333=4([$>XB"<=0>XBN*U]?::XSG)%SV9TNKA^7<]59LB?NNVAT
MGR;'CPYYT6P'N#0>Z)H+%%<&;4`+1IB/-80>=_2,(A&W;R1LZZ`OC"3$\-IB
M/(C&2]KV]]UO$L1GO34Z^S1!7K5U_EF?:FAKC*]9-W>JM$QQ\;%>T&6>O1(G
M>&0O_?,(JY:"(C#2C!,-!A^_W;*:VSPBI9^P0$&S:L@0@PT+.&WGX?Q$XCL[
M6H]VIJM"\O-J@>D^C\&3']UKNK!S[@)OVH]4L!(?;-/\?1V"L+-%H7<E/]MG
M.IM>5+95#%8MT#PE2V'8>1YSXD*Y",<;5\/.$+(\_PL1ISP/;&F\!<)<E$C)
MRILL#DW/Z`;';XC9-2T$GNA,H<#8HA,=ZZ5SEI^7XF?PW*-XAT##1=Q>"#)B
MMKH1=3\>WO_$E[YR%[YX")0TWU[J:NL&X139_/C=M=!G'=BD>9NIL+_E9O?]
MA]U?;#SGDTK/N[_MO;?Q=.OYX]YCK[!XGZO/[)S8%0T_5`]+\,K,48\6S_2`
MT+\[SR\__O?NKS;VMW;WGW9_*]!QMR=6:SV#VHA8P(7NBQO/MIX_/>C^=NV7
M3/QRFH@U^9>ZND/8V@DE56>IAMO=3Z)<<113V(&HY.+7'875[CU[UOVM?_\F
M0EMW["A_C`O0")PP']TAM"O.L48BHE/K<)"3M89Y+PRQUXMS=]*-W9TGG_5^
MR8FF)^U?JN?UJQ?A()6=W)JI;$2`8(Z";71T_[PA&=GAS[EF6..?Z28=@(]Q
M4W"9[L,0['"^XNRT"TKD47NJWSEG6W"0(`E>=_DJ4FUZR^!8[D`Q4&A7/K1$
M9H]TKL%16CEX>3F2)NRRBM9HL@T<;7L=6EM!%3YF_W/Y#!#HM73E@?`Q\W>_
M$#RCG?B>YH/0>V'.0X/F;3[H($M/`HT+;,0*(YXA8?!"5K6X[O^FQQXDY"Y9
MJ^;Z;8]8>!HFNRTO241`WZZ`*9X,;3VR)]V+0:`XZPL\6SEPNF\@>BK5L'>M
MR)OLLW<M^]A6N<57WT4\6FTVNX]_'S]Z@^<0NX=:&M1]H>EB.6VZ6#[IH?L<
MSL>;6<?X?0/K,);UXGA9G&JG\,3#18(%`K#,A;&X*1036%]M25,B/!WF5?QE
MJ3_^0$)F4F/0`*:85K`4/5&"RLPZ_&"/J)J!T8B9@=#`9?5.W9QD^1"%>"K&
M6QDI1<C%!JD!`A!1N,G]#Q,@G11F<-G"TUFGD:4T4E>3_!"1F<L7UW_AN%"<
MZW_,\I453_>PNM]-4G;H+TMD#\=!%%@V5XO!]_)%A*R55791<6>1Y7\C0S#\
MW5WV>?;__GEJXBI=+A[B7'8BF^4+W6X0<UIMJH7`7GT6C?QP[T!RWN+J3"B4
M%YT03OO*O]``(]\([W3DH0G)T9Q/Z;TIA]_F[RQ&BR8KB5$D_FXU@QX;@[(!
MPJ2?/LX%&W^4!;Y-C3]P,/C\')(]:&Y@4W-$M$?$L^%CVF9+'^X]W3E0HM^^
M9[KJ.4RMV(?M:C<JJI3&I/3YN=YUV\GR/'D0:_0S;Z)K\JY!3M,F*#E*-H,L
ML[P=.=E$8=G:K1512A!KLNB$]P<2>$H[2/)[KZ/TSLM16-P40*"[Z7!48">>
M*P5;7'YTHLGV6CCAX_4Y8`Q4=PYM6$T'H7=;=U844QQ!IB)>F`H:)90HS#!C
M[%?J0@`S&?G$3"^GM\54HM31!?D043#EM-L3S645RTE?(#>"0ML*_=^/(UV=
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M\G+].P>KWSFADF&U%A,'JO?6$MF=,)%43Z\6>/^]]:SNP>L.HXB4=2&HN`_>
MUZ>>.MG0IK?.VB^[;])BMJ:[44*<-7IV7]P@&=K[W9-GO7C[!"HDH*N"N972
MG/KMY%:9*F54Q-JK?>GAX1X)`Z[,T$,/]Y_:O]L@U!/VV(AQ1@_'77&8]1-W
MU])^\D+>H+MZ]7T^Z\%FT7[QOBE:@Z;[=G*C3DY%%URAEEKC$3!X17-`O,Z"
M+U+AN,V[E`O"HBE3EEOQJ(IEYB\N)UD,P#\)Y^CELOIFZ-50'NV3YK7<73DH
MZ9TFN9O&2DTQWLT,,9P?H@Q$`=/2\D?AJT[6=R+)>%5>[A0GE`*%H(BP4.M>
M,BW3FD[]I(ZQG'$-4@,S%,F0)<=EKA%3Z225.R2=9NQQ%\PIR<#4%JC31M0E
MY2=P2ESW`,:B$Q2C<SR/BV$14^A,CY["IXJ\R_)C/G;>"//SS^P'F)H,:D^6
M62^E"'=K3#SB2:A57Q7+'SZ4+.4/Y^=K[T'\IYN2JT^?LRN(\)JMRS+LXG4*
MCBW"S-?#SBG%104-7Z5O!N@/FMY9,)4^R=4#[IR"YHA`U;R:6D."\->$210L
M[9KKT$="/.0OT,/IKF?V4B@;MD5(`JS.1%41M<0@F.X.P@2INGQ0OTW(Y/<]
MYGY!87F2+N'1BW%>%UWT>+3@MH7\+TJ%ON<V`8O>:-);2H'"('(`,<^<3(MG
M(G6DP)2,[!/1$IDU`BX!LQ]T2BW102$$P&U:&3&L*9)FPGX]I<G<3ZPUW5(0
M`J72C?C%-/+S>:>4T>??-216MZ8KZSYRO0+8PA6"07];_:YYO5IRHMLO?<+(
M[9ZZO($7Y/7`&+.I7=0,Y^T](GK<VK<6@)(.L&[VM"KC0.;<D1@XV'J,6:K5
M4X.`JZD8VC@_HU0$?:VZW%3N-W[.RN_=A;8B8;<"3`^J,D'RHDGX[$QJ-0WC
M<Q*`6=*GY,)Z7'"=<HU;LD`^%>F;+^DU`P.RT0&.PSFAYAF^5\>-4W;OPU/S
MVU]PU\A[:;$.1:<O'(JV4+*-%S?Y5*EW:6"X(8C5KG?7$GAB^975'(%D6!B=
MN\QO^(BSZ(A]+VU=07@K<[L*XVU)GA31`C[1H7%T_^Q9`^Y/'^O?;4>EZ(GK
MRR5?A6DL9Y?*4UV=PPD:OA=H$9`7ER/2="0V=;HF(]U(K_D=G<GX$@^S;THI
M30`5RFG)_7'R)O"56[OJ>F&OFRN#^UTTH0U(Y,(A09,)5#HUW&6'1!5&;9`C
M8B9.4_U`R,3M2%+NB!NE64X3FQ;IV>2,*Z,SXZL:@KJ`'VF16=$^9Q?%A@3W
M,9;-R`\.1GK$,N8@<T+.N$=:@"R%XZ8;AWB4LV\.M&:;C8W7>JPO3R3CSP#@
MRD8VJ-T6!OD&QC+/^@^FY"]5SV20\(4*)X5X86AYS??<#;L]Y$.3D26!$QI(
M<\<5^'AX4_?ND0RAWO3)%"S'EL'F(MM5EL=G:YYIJ'*C9MSHJD6C,*+]B,E&
M$UUZU'T.+AZ2]AQ+=X#(?%4=W?$+A3,KYCNE-]9-)KV)KUEEI592%3$=#]_C
MS1?A:EV>HO67ZA<NT$CG*PN[CTSK#D<&))8X(S/VR@YB>+NIIQN`Z2CJ:U[C
M$YO7$UH<<<[#"$@[[HVT1(?]]0=+/U%^E@3H2V)F6@"ZT+C?_X2C&1*,>AS1
MFB-8D_AAV3D;:M6JLR[?+86I)A2H'[5V?0\D^S:'QHH$TCVR"/90OA:2J<YR
M7A8%^K*`4YQN8Q960$WZ1IN@"V.'DGEKFA8ZH,N(!G4^:*9/2[ESY0F>,#QL
MQ]5KP$FJE9`D80$OZU.3]K-U60B;[I6+<"%2E`V=$3(N`'.M)N=DKT+3-6LU
M3]?WR1HAD3U9TW-:D1C$=P.XU$U)\K#CK6PP0A0E_>+?B?Z.,^O.6;K183Z]
MXTY?O@P5IP8A50"M\1NA0U=KYGLDH4(O8:_:W#"?8(*^JBA^BX+P"55)N?[$
M5X8Y:4!"-WT,M&<`C_2IAN:CHV<TD]R6G,287A-8HB/'$_`^?3,J.Z[TZM61
MQ99'9\='7;U/7\L+>T"[R`JU_)J8@\\2YID]*_*2B(Z-]Z(@_0![PS<E?Q.B
ME2^?6F([41D@`X\QT.8[\.+;<QQNUNDNF3\NODH$FN\#GV)FWRT)ZYV'X1NQ
M-26GP4ZQ$3\M7*SZM/`QAS:Z[W&-E+H&-(]>F?,QJUD&:A&6$GO\<P+&)+8_
M+,#@>X6**?T0%22)JF.N%MK&:NN&-(O2G%`PX8C2F]^`GA(%H6M=?C+T1'+-
MHJ+VI][-I&\<A+2(Y^BUW'261&*=I$3RW2?9NH+E-U'IT!/):NH[9GR[Q/=-
MUY5VM%Q$/7RVLYMJ,7+1V/EZ]$'%E\4-H&$?_,L_PQ`<?"(,X5_#N)R*-7,M
M9\++AP?9C,PFDLMK0C<ND+=N+*C&U%MYU#C)7]3=IX]8K6`0(QPOE1ZV[?A]
M.2N5/UG)*`L*<SHS;AFZ]S=3GSA5T&LPM+>_<_`O6L(^_X%WNDA5O9NIIV,>
M3E]AJW2.LBDV^7?[[."Y7FR.N\0G'>S&#*C;4-SPFAP43!7)LAV.2MC"<1F$
MI;FXDFJ.B8%8V/.^K&3BU$7E-8PQ>!"C#!FT^LLER7XY;?9;0V\%F?R%"IK8
MI24F7NU]]B\*Y;FIQ]<38%Z/VU+Z,F><35L>-:$'VZH=8#9"L25>&!);"KIX
M')Z^)^GTV::5(SY]2-5$^J]T)SZ;<QT+@GUJK1&61D)DS_Q34(&JC;/3L^/-
M(D_3=H=YDW^8?M\"Y<=MB.JXD^<`,\;/K[TXC)F18D.;QG6BX2OW%M)!C=_<
MTGQSWJX:M8@MW27$`6V=`L#H>IE37X<V%Q*)6Y,PYDD\P?8Y8_RIP)%T%X/D
M17(K'PWC[QTF&CIV*>V(0GU$#(!S/^,CY+<YH^L8(#5#&29\?/!TZPF77#>=
M-?>2H(E3BXH#V?Z3YUL'NWN<@?&\+PIWSV#2O`;FO#D;[5>FS#R^=F+GX5X$
M99K1_2N:0YT8L+02GFHH3)&*<3<[I!&:8R_MC*#KNKRJ-&5@9#(6*O-V:'BV
M>^`)!.V%Y*:_<^%^778M[,C//^W[]9W]4ND%(ZS=8B_1VDXA-$MKLD5TU-UD
MYI^TEDY/J]%7XM(;!]_"FXE:&[6[\UF^P_E;SI*TI2P-*ZU-,J]7!'A"97_G
MV9X_&Z71225I2SA16U.&F2GYQ#JYH3XJ9;?(:&`>0O8FF8CH(#=/B[FAB,J;
M-JAQVIV&A_L[^\^:CEL&)]DWUB+W=G?-"FEC5E[SGL*L?-FPT;9RY2>'],=F
M'P/*](!7^WCD#2'A`)4Z)Z[9*;^*"`4&\`SIQ$_1AR..-Z^-TT]!2\Q@C>T4
MDW[K>QXE0+_IB9OV`2=GS62Z>VR(XXR(6!)`ARD(AX,F<+8BE+H-M8[C'4&L
MY);-L+Q,<^O_SS_I0WXK*_ZG?4S#:\+^-96[-OR8CR0%*A>ZJ"%<L,0A]I!X
M)H;UFUYK+#]29RV3DRD/$X:'-'R2/9/_IAT/>;`/2J@$:P8`R$4V#.Q(N]HF
M\'-X2%F@*'@]+6*$K*,$W2."]V\B:DA)=2/PVE?-&)B8.I-:DH8>ES(ULB#V
M!.)!Q)RQ"2L30^Z*LJ?%SZG\*>/A>0C)0A0XD8^S8<2.=32<)>6T9DO@!"+=
MJ'SD?//GGY`:?95;:[*M-G5/:TKZUBS)O@BM:3Q>=W@P!XRM)O^`B)G6H[WZ
M8IW6"%EF,44NJ[2PQ=X3OEN@J+X9Z_BU^-JEI#$9+>:)X%C=<2=<PW)=F7T+
M.M]$._FSF@4VZ<8+UF^$Y1S(UIYMI%0.W(GKS(35[RQ&C[$AT%;K$%G('ABD
MW4^C:%]-HEB\)E[22XVGS'.,(&.`G(=+X&E"(5)>$/WS5Z54PD_1#T?RU6+<
M5"X<C4(KE`DQ?\[YW@.[MP9L5M9^:<,7%,/-YM[GH85^M_L]-(7._Y>]<^N)
M*\ON^%<I1>X$2\!0!1C()"UAC&<<N6UBZ&F-HCQ@#&VZ;2`4=+='_13E2^1U
MGO.>]^2;S"?)[[_6OIV]SSE5;L^E1XJ4B[O89U_67GO=+TE"RXJ4756D#0K_
M"06_H/I9\(IBG$N5B&(FL/%B@%&GK(N$FO8,H1-I%!]692*'%281JWUWO3+4
M]-'6ZJ/-1Y&@+Q+C.JS99:A'VZN[V]M+BE!<IW`BG=G8]4?(5#MXF,PATDA4
M613%Q0EZ)8.9O_X_E\#UB*;>ML$H<,4+,@8/R8$_QUZSJ>%'@[(G]M@&1.D_
ME9RU]:ERUM;ZUN9/D[,NQ.7=2?;3Q:RM=90Y[(J.RU#'*&89Z2);1%)HIP?/
M)XI7D43XF2-1,9G3N377[2;ETV_/2Q])X(1FL/"7'<2NXR1V"4U4=/!X#0JD
M29`#4!]B>.QKLF(@W[Z,@,=X<U)$G,)145(#J6S7YN6Z5U0%17J"=&?9\XGG
M?;2$%00L$1_A;))Q6,TJG(A`*]`1LY7J_0716&\#+D2`0E2F%<,C\=.H=."G
MGBJ(%`Z[)O`SG]6'-I)JG(%K-JZI:R].+=9S:N'^_($JDU<^+[SP.PK+1/G'
M.7K)G#7-`(>OQ-]T>KBKOK*X#BAJ/'?SS(,)(6*.H-C'DF@[$J^U8D=&TO/F
MQ"F.X6R(,?N(6UG\.ZKR[5:J'PC`+73U#I$O6:OD.3#)#1^)L.F.QTCX@]E&
M-A?Z6PD/P"19'LD4A5/Q3/DDU?Z&MQ=XT.HLA$3E*3H;-^&QTA2Y&>+8RRY:
M_%(M[-LMM6Y>HQE4LRZ_@/,D."U0\'G:/0K\M.@A3H!O=+NY("/`<V]#IIN4
M6.(6'\/)N!LC#V>$=X@H[NQ.?PKL-_=6-[;+6RM!WB#[(1947T5Z2P5G(YJ\
MT(["(OVXV)>>5$`<HYSE:A)HL[#MSR_4BV4Q?>FYB^9)&-^)4I"5QX-M$K%8
M2N6-O1ZKSB"<H?/:-/,9QY",=O7!O*U;FL-D_YCG:DH0JBX!4K:0>V[<R0C%
M^XX`+VXG^'-<QQ0O"'XW2QU_=_H]F>:HQ0ST"&]YG^*#"F?/NQ,DZAT:V@78
M\QA-^R1:=INXD^ZC-(=8"?5>M[I!-SXUR?0=O+.+-@U04`X4LT-P.A@U>N<B
M/&;JL?/U857<1BA[D0CTB+%FNEZ2!!ZE7##!'`0N:$-)6@'E/%Q5!=H"K$V5
MXM^1A?AM&HQ+]?L27S9.=QH?8_:_8>(\/O!.-S<4N.M;>6U,[2TN4;UJDY;"
MO$(!;2^=\A*5U>0/=#YU'F97IFE&?N2\SA\&_[ZF*)JT;9,&Q$HHNV_I[E:]
M*I20N#HG,@T7O!0V_`=6S@-=\VJRM[ZWEXQ9=Q;\FNL%9`0LT4>[]8-+4(*0
MC:4>G'"RPC)@`#7V5XDYL3HP+"E:3S2UW;A5%HAB`FNZOT4P*P2??;P^0&JZ
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M-.A^FD@E;^?KDU_C;88)<W)V=>Y1*Q8$RFDZZ1\B`]@W!=<:.LCKZ3Z,20DL
MS2X+GTM]4J-J[2G<03D,((X^?+3XX&1]96HB2K@)0%K@H-U2MGPSG<''08AY
MYC\ML>?N0R/:P'BW&C=BCR2?%7_D>'W4?0+1RAPRC;FM;$-2D0AWUQ6R-CO<
M7IUB<9CA8,@TMCY2A*05K1'.)0[!$O'RA8A9BF?FZ>IL1P+>SM(SWX'P:3HW
M0S(/C5?QX"2]7&_YP+V$Q]K0ZL>:@';7=T8<:\L*X]&^&(5R%^.B=-QKK-F)
M=Q8);*D6B`@5<.^5Y4M1OD_7.^$M#=]5YGBB"47U542W3_:QS;:+6R[WX'!)
M"-/(,97L$@2E)"&%L`M!IE\P&I'$9NN(L1EQ"H,.OR=1XX_H-XO/<Q)>9X43
M8M6#=AWG,"!V(O<+Y8.?LV$'RB3Z5-W^_UMUP..%5ITH8]4,8-^"!-J\!#A3
ME,I*>KRWNKDS10.;#;S,(,)E1Z)TX"C:PPCQ`L&'">:17F`<%4J,;L,:#^`9
MZ[L(C,&G%`NX8`HC[X7HG^XT^0V*>./.WG1W^CSK&I&[&GVP4#@7B&2"T$<Q
M!"4)?[`;1`/EHLLRF&3UN9Q:YGKG,/$C03RG>^]SM'?"SD<V1PXCP<Q4R;=)
MIH1B5N+&FHAH:-G.4A`HL@.RD\!RKH.3R65('Y2HF%=Y]5SZT\ECM(YOUX[/
M$!78J1L>UG0%@OU[Z@*^:V2&8TEGH;JKR,9@A=KS'^Z87]W#1R*?=A]ZV;XE
M)C2N.SDB@;M*@5.YI?X&N&),)6G#LJZX+4F(N/.P/L-UK_ZL_4+[]RDV`V*D
MD*YG:8,Z;MMJ^4_44M,\>R$N3`L_7'524%0?^M,U>>Z'S)_M[&*2IJHI%8VX
MC5*"EI,BYXI-79[:-".2,.S]*14/[M\790:#2&NF$>7T1'T=!4,8)P/^K++\
MVFQ9N.J63](JQ;U`),U+8:Y\D][L5>O-0K)LY[&*H`H-Q,(->*FACU@KS&@W
M1Y7'OM)381`=RB7N&[22V!,IFOB:3Y+@/#CB]?45J1!0R!`[;S5F'43=WSP,
M1P0VI2[[3NP/9;)"`0R,%;`A`ME"FFHDXK"+F+_)TNZ?CW&#DCPQ+%GA(B`F
M^Z#HMV)A3*K/!*(#S,@LJI6NKS`JE<L-%[3`O^/`-Q80-BYSX)2`P)W5K9VD
MM+B=HV"2$8<ZF.!&ND<[,US9B=_:IPJ7L+1*S1ZB)7R]AJ(_NXK=^ERM*X`[
M.;TGC?>6RN$*\B9C!;YL?+$#%_XDK@<RB94KU$9)G7<Q_.GQ-?<CS(S&?S,?
M:[J2?YARI01AQ8!@Y+F^6%?TN3*5S:!A*!FA%R^9AVK&W0R<\SX2+R9\IK"1
M(!_$D"#^OV=OH/_A?E(7*<G#2AKE/B\4P#'@W'5`"%5=$4A$0&DT-DN,OW-1
MM"N8F$#5!>&"$\0;8K_OE6LKZ!59Y616L__3O[??NVMI,P/X/'E_SY5A#>+6
ME/AYUPGL:T6)8$;VLYM:)`"TR]6W!"RG&Y]-5L!$;)N@Q^W#+GUM]Z'Q=A<<
M4V5D.B)-LX\>>_ZP4`"Z\_Z_N;]R<U?R(7>[W5;/+&*K?#6JEF#A0,I#,F!0
MT2Q%P$,SO[,.J"Y;Z,._.!>EE:V<\$9T7O%,S2AJ#^?UY?6-)<RL>J+,;&,C
M683^DE*([<-ED,*!WL.$+=\BC0Y"N!G(I`?^$O=9L`M&I"QL]8DO2_KBW,:;
MS6\2[U=DP.D:+2R448JGPNTE*=%!#][>LWET#!T,'8>UIK@39DK,<WMO=6<G
M13,MJ=[P0%3X;%I:J0;Y1I`]UD.A**<^.K$H.P3`/J08U[T,QI&NHFP(@4,+
M.N+!\"D9P8MG**'ITVC(IX&/L//[.T5.T!\Q\<N0<FSP98.)7*++V2',9Z&]
M^I%LDZZ1O>FYCE2H*S/D\C:VD,[VDFOY8VYC9WUGMU5PF]T&'MQ*>4%;<;+"
M.2.<16@+<6%KMB$KISWHZ2K!`*O;FT.6L&@L7C*7OYNS[]S+2+"IDX;I`O/[
MTV]X`BA3(&&4LRK1,]Y50*(EUW?H0:1B4PUG=M$*9Y.26FM/D7UT-5A36=TZ
MH$UF#FF(78A>\FYW1^05&ZN"KVD[R)#(QH6V;$ML1B+:4%M3MM?W7*AH_[#;
M_X?#.-UWU^]P[%-8HRFX^%D]F?KPKEU(D,&GA#0%;Y=<5@]+4R</T8?+\W=-
M'>NOZC+0"R!2+[./_S85TA#?"1X+&0<<PPV3G289FGNM2B\A(@E6=[4D`KE,
M'.WDE]86WN,A4/'`UCY#%L21/SJZM&5X7EC]^/I03/72,:K^2P379-_-4O7?
M#T,\6?W[D6Q?]8]AC=+'K+P<K&/6/_KZHOY`2F009^L__4KB^WESO7$_S1^>
M>C.=(#E`@L^H)-M^O[))T$53TWP%*CJ=-O73>L^#>**K<2&\WG7\(@B:$M[1
MUI;Y(E0H=RDU-`@*'+U>Y`0$<^]_CQ/V.E".*.KF"B]+XB26TOGD0:CB5I5%
M&=,6A?8*,4S]:=!BDL5-PHYEPD9<YVBI*GO8LJFUH7!CIG"\J-@D249<MO9H
MTPJV!.<^ST%S6T,E)D5#*+9@+9L(@:D[4V0-BKPA?ZS./2)/2W-X$XEH.$1:
M4%]'O7(%;YAAX.?8/4H8DAF*MTYRLF;J<8?0O%;IJZZ"5TI*A=IDJN@086HX
M2WP*+[-AH$;D."0\:LU?#WD5,V7CPR?D0E;W>IS3O<G(8C6E(]X_M@(^0$52
MMUBEC)WT\$$5-;+7\[!>MIFTN\UZ>-CEV'G!?`ZH2)!C,R-\J1R_>A[=;T15
MZ"MF.N-R$C0:HY=;JE9>'7\YMPI"40(B"RR'M$GP0A(>US2%\L.F7Q-=#?%R
M+57H).M&:9"G*B(1O8FRW2L^QGX,IS%F"^'(":Y!@>[*5$)*9DNO%(&S>JB1
MWO`YI;&XW=R$V\NB&&G0=@!8J.F7.\R8@<4I0L'HYTG4#8:4P49P=BA)-#)H
M9=.,2^=75\(ST7NS@KK:XE)*&>NF$S?VKXYT8J#%,O"=9-LQR2.I$":ZV!4"
MO1M.CF\!3'NM*F+-`^80YD!IL"\B?8V5`R*$<?+)DQZ1[FFJ"EQ/]2H_`[\`
MQ^*",`5[__SR\W_0_]Y];K)$*6P,L.C?,'60$F!&UI*G7GUE2MCMHYUI_;LM
M,<K-]SMB6X*[&RN=9P_SR-#_$,&9_94,LH.#R?KOM8NQLCUX1&`:8:3A!7*U
M-I-9!RI^N/`U7,D5-EO?"A*L'EJ<)Q5\%ZH)>[WJ;\&@;0,UT%[$2#.C9TLX
MSYY^K`RM5QRI84$2]'-F@C'@#8]!X16$U+0RRH(:=N4Y>K\O9!RMF@FNKN[J
M_.MWU)V0JP6:*\-/>I0>>X[-SDM&IZ,P`*,]O<9B3[UB@3BY<_``W<ZN#!=8
M6`%B,4350'./]4.*<E`X4DL]2*8HO2)ODF\C=RML2-*A5>^$UCVVB+^[/K?G
MW>>ZGR1%[8-5KZAW11=2I9$]P4A)ZA!Q@6/NUST*3RRUU$F!#EY;<6MCNO+M
M0[>9":.ILH'9G_(KIW=G5'*A2)T$`#695%`A9GGH,^^O3!V/<#8&=7%YBY*Z
MF<R^G3^6<[$(RVUG`W%GI+\UFZ7S45<4-5NO"`+',JN?H<V&>^;3=PQX,-TH
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M[DM,Q*=GN`55FZ&'9KMQ6S%%T&Y8>Y%Y#I:E<G:I(V;H99"K@CD"DWD3AT@,
M-`>]&=*?O3I0F+[((,1A=^8`:N<5C`,W@1H)#Y"W+\,SX.3Z9?#TX>3L'PS#
M9I"!9L]%Z1/8Q:P2H\AQF"X\04/[=NKJ[00<&&K%^0Q868_8:)G%TZ>+>VT&
M2ZW8P_A681?4-'66!=U5(7AJ^WS_UC,Z%K5>G>O]A"!RJ06XBN/1>A;S&];S
MY99]=_0P,P<2P0`F>86?$[;US8(H2/E^)%:QV50_@-QM*[WLP.U]&5$WU$4&
M8PD7'?/=A::4+A'A(RFGVY#9Z,0;C]!'R%DGH:$':IIW?O:68>HLK0IAMY0^
M:2!?-$<A_.+V^ANW\_1O.;XL,4FS-TKMN\/ZR*MC\Z&TEA4A\=N7\*'$+HYH
MQ9LOD:6AX=I;B6TC+6P[.`&PZ8HDP8Y)0!!K9<=L.*P6(4>QI-]\N'+;2Y#Z
MHCL#V&?PEL!W8[(:G9CWC\.(**?G/=YZ6#L`'!">`<%/=U.1YJVM!0V*B'`E
M#>*="`I"UBG[YNV?<H!V+MH5QHAS#Z1L.-*FHW\?FBO?(%\A&,A_B/RSS$)2
M(:SI,!99#D`'@.%/R\E5E\`,VT%+['&FR!MF0DB=G)50Z6=R<JCLW%]A3V-2
MGC/KT*,2VE1BBR6QI9M.`PP#4I=E_5QW7M9OBZY+K._N+:@$DG-K)/69HSLM
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MXGB-5YPT+L,@EZGU1Y4*0GN7L-,2$KJ%U*=.\.RL'EB6T39-(V![3HJSX`'!
MQQNE]=`[^\INRW<:@2:YQ'0LBI!2%QV.0*:CL@S%*Z4E0`\C23!M1H/S3A60
M$Q0Q@/J]]<UD*7@-?(LIC`Y%F:B?B9VP0C'APD-JMBZU-^GF:VG-XKC"D4+=
MC.)NE%PZ4I4@V\&E`"&3K,U"RZL5")8F3.DVT^MHW>,'JG4/>O2LW-B_?T,O
M)3,((5+=8A*JL<=[65CU_/X9ZP]^TQK;ZB$KL^WVIZ:/\PM@]Q'K8H$=&=V<
M6[-7:-2Y]'J#$!JB:XP%)G.4%+?QCSPO!'>D`N`(;S:3:$,[S=8:"LF)+483
M8KV')^<W\/?0-EYH.M8JS2\.T^P(5.H%5K:V%/;<]_/NQD;]LT#X<?-WD+>@
M$,WM'/1A</%!LY6!8XY]4C_-D;%N4-([/0@V,M0@I#"J>UR3=%3B`.2`GF-@
M1I<E,-X54M4[*`P:'0%"5RIBWZ57/YS2WL;>*!*6F\A#$+CU\Q&]E)KM@0_Z
M+U=@^_;&+E*-(BD:]UAFBE.9V8%'`9>#&X1(BA]H`X'9A+0D$3ZLA7NNHD1(
MX%:[1+,-=BDQ*'VL>@^0YP@,YPE!HY.H6!CW-=RU;^-MTGZUTGD^=V$)`CR6
M;VUJ_BG]+Q$.V-Z;:S9PI8ZZ:'?J@`P,9<K,@D/4.,TY8%<GQPXAVN\8),4<
MS3!4SW0F'\X73.&1>?'VO<"OV9!#+8PL`A.]Z&6J)A<X&VDPQW\*P`&6'7FR
MUS!=W$90K$QO(W'`N"@QTJ%0J$$MH-J\>R,)&!+=!$PIYYK877.1V\)Y.EXZ
MS1@$1Q6O!*4*+@?6PD.#7GN;=5PI*D$=*>02I(1W[-CKQJO)M"VO$KB^D8@[
MT7[`8\)\T+G^%"4'!,%(ND)(DH`&6Z"A92$.`*.#TO':I16)!'ODG5"FF)1Y
M4;6P]%QI@\`E]N7@1^&10NI%E+'SO+B6/R7@C2EZQO?3S)W=FG4Z.;BTOL$A
MMPFTQRXEW&6DC\"41LH[*8B3=GR<X_N.+W.W73IO7M];Y<S)$0U@U.1NLA+_
MU01^*&@1$O'<2AC)_ZZ9?W6MEWT`Q47#KPGQ__QW_8NXQ'-1R2,JPAS+*SE9
M.1$?G3?+%7M^3#VI,UONR>4[4Q.[<]2KQ$]?4A"J:&UO'TMPLX7GU.L4!5?<
MA?'<>I:CWM:RR^RW_\MZ?JU=-AL$B))B*0AE]S``EJ?WJB8R^8*"K\IJ>V[&
MI:/0(:5>XO%?6:\TNY@>?_D@T`N/G-^F7J:+L*]"RX4#BU^SF;TZ;P36B.?U
M,+GZ8^!'#!:=Y-".28[E$,MRK*IO(*(B=,0%.P\`,V3V'_;E^YI0'DA!+=S\
MDC.`OCG*S*8;";$J=E%&T-1+(36O'9RJ?[1?!.\.614\S5`]=-I7?_FL]#4.
MO>@\*#G.]^_<UQ>M22^Q)MG;-IK^TC4[1(1Z/=&1)#^>P*OV91IHAGT*'7RB
MNCKO""!;^?+XR>1!0Y\V)E_P8.F$<BA&7F]P.OK7+TYOUR<;7@UAL_[T^/QK
M<8'Z9\I(K$^FNU9!H=&8[(\;FUY>H?Z27/;U&)?3K&9?SGS:QO*DJY?D)`)L
MK.U(=N-H)EXY(7(&+?'AR$MZ(N$+Y#]CIMSD+F7H\S,E<_S!FIGSQ3V-3J[K
M$P2[<7._:MF+V<@LW]$O&>O)(TX@R7F=<C2EBW/48)0D/F#1%&Q7K_2"XGC4
M(/(=27XFR3YW&IB+8S6[>)EK[Z8+PFIK8;GG\!N+;2EFE:'TQ?[QD_U_%F1N
M(H?J+B6[JB^7N\B$CPY"@0&PZ%O>P6N*MF(L,6DB!AIVZM%JJO+,P1QU1ZZB
M2V"Q8V;OUY1WP!<M`F?;Z;C)$&>\G2OM,MZ<?D#T#%N\Q<E5.&+N)51-=S=0
MCD++5T8KM!";%S,KM=,>O&2>-P%C]&_=!D-0`&210V(R-+JT%&6T'^5:2OS0
M4*Z;?ROG+]X7\I2ZRP8?XO#?<]DMP8/RL#WPTOY'H91R-&MPF4:6ON6^R0=C
M+ZHY9S4.TE,0_$K@CH*KD?CT0J2VS"V"=GY#&DJ-VM,U]K+V"%"&H7V##B3)
M*3186JL]^6!'0];^MIXQQ/9RJ+G3K.9I'&?SY*$$_GJ&*,;T8EZ)L_6'>6G'
M(H-><OR!&P$101W+R!V^_GIFP5VSU;\?8<@]GVQ.WN(,(+@"WB`Y;.773PDQ
M-LT1,)`1C?I_/?EQ\OCP^(2V/6B4]3QYYRBF:A_XB2L5[4V77,]>D<BZ)^-)
MO;ZB>W&S4S_QR??7D\>37]NID7CLU#].%JWZDGH#ZC15G_YQK,W"Y?91?FH!
MA/>?BK?44UBZ;!^'+*2<11H#[647L'>WF'U?IU8%DFS&Z4"/>,?0H"MHA]E_
M,J6,KC)H$C`NL3G$+]4GZ]..PCXGD=?6WX1R`"Y6UG_<AR:^D<ID6D_N<W+X
M@WGJWTR>BA<=P)OOL33)@OGR8G(8ZP@>0?./34?[E^?862;/"("8_VN]1E'C
M\O)J#5*\!G,]_U`/^\J+$=4_CQUYVLA</5OSFQ[;X$(@&.LI@<!+;E>BUZ:I
M^/4)0ILQ3$?/<+'>DJ`K#7XA?@U\MI_K$,8;'Y&N3L@8FR/9&*$.WH37Y^Z6
M@4*I^\@['$EOZ?VK*+(/U!%0'[GF""DHG5SBTSETS0ZQBK]>]F*A]X]HFGPZ
MF?(OY-[S#P2YF/0A$:R=,/EW.C!9XD12/ZP>(CLW0(I79@',4`NCBRU]T;OT
M,F?)FIL2ZT%^V37L?$U"G`UU,((6#N->^/F8$;MQ7G0$RGE0O;/->M6"W/4;
M'!8C8?KNB`"BN\D^PK'HR8VN?S+VIM*'DJ?3)ZMHQQAWZHWZTX*8I('UB.>G
MKX?_^/2>NJ9F]-!B3R_1.7J$\+3(\?7%'2IUXTDV2XD([^09P3)J7-[+>P>,
M/C49'M(*1[TRT7)8'S^:*HZ0+"B9<LNK]J"[#AT9J,>N5QJ"1,TV`2KW*ZP#
MW_.@JPG&MV<TA\PQ<8LQ%'$&&FRE]93<UICM:UEH[]]_C1YM<<O3YGW,_^VB
MD3<7K+L,@8KM=\%!9"**SR=!!?,R@3K6YYP4-@G96$DQ0)->%W7<*U=H7.>I
M@1):K]<_R^1BV7%-FU;I"T238JH.Q;%:>6N?%55]6_?PDR>)4CK;EG*@4G[0
MPMA\-#>XK7?^12B]];'?05VL2ZI4>5KQ&L^*RS5K!$-HM4;,H?1-RJ!JCH]0
MIX($T*_?XA(G2KB9KW_//WF^5Z&)=>J-JBOKO_]'P4=2;^F5J/'`0_J*K"2P
MB^@!BBL?T)J:]F*-^60?5XUY,JB\CCI]<7JFJ%\#"FDAQ!M?68&A?I)I^%MO
MR<W.[.E2T;!([/6`43/U8L84I-H@)-4M7-/W22H>(L<D-@P;VLPN-@O-#)L#
MR-RV$8KS]O]QP'X7]AX<.W'OL"2E]T/1ER`R64=,GQ5Y@/5N#MXAENA^PV"Y
M'5-WAQ2C;GH5%`L'[;RAB\3(/5K;V/J$F=^!!'WSSC;6-IJLPD!0ZN6^<A@I
ML!4TY9&XR:D>%LA*_7/5]@:^AK42X5AFOUX'3X9RT.H`8;84NB4%\1-"?L<4
M\M=UM;C%&Q"[X7'95/7HOM7/BO'6NL'7]4UX)\IFB_6\Q]C3('?CG7H6PF;9
M6;QIS\N!SG?A0K&>?1>;(0'#5%:I*)[J)\?IVVMAC8AQIA1FL1^S3]4G/[H/
MS8H=?V1YZP!4";7U-VF'YIX]]](?YHTPMIK;9P1:)]]]/4=YR]%FJP^Y/)ND
M>WW=UB(!ORPYLL*]>IF,S8Z:`[UD!I_-48=[N_O_RFJGB';D)]"!&<*#"F+:
M821^%V3(XZ+%/#Q0P.+Y4MY-O?MG;?.$Y1HGU!/%,H5FRA^6:2MJ4,^2@6FD
M(36ZMIP@T!D"U-RS>G&7K;CK.?=3K_IN$^=ZG&P>:"#>X-F,#Q'-=!$@K[4%
MQSAW9CI*_7DX66`S\>E-#K`^G??FG,L(V]-.LH]M[WAP2KVDYI85X#5YNOZX
MV*A;W8<)7/M1WXIF8.IU^2ZK!!"2G=Q;C?I.33J\9J$F;'TL6UO.+5XJCSA[
M.0L5;/+X0S""^;C@/9ZXVW9,`6H)?.&PQ701%&(T/MEAF[UU*FI:U:50Q-H,
M=?5PO`H65E3_WOBO`XE3'Q<Q6>XQEB0I_,GU+*[+$=>"+:C3_^2Z+KU3?WD8
M\Y?]F?6;*;_\E!HZ]8I?J-V*PE-<R#:Y:+@8#L0N7WN0L1L#1JB7,YD%`9U&
M6+TN`O1H(&1JEA\7-5`2'S[W-KXE3DH2D/N19UN]DPX#9ZGB"35X?&/QW@)>
MQ<H<#K+ZDX)QR'XB0B#>.N]@:,(KHP_U%%&#_!%SFU1(LT?;]_T842P)AG;G
M-FY5K/VQ:R$8&A`&C/!YJQ]UG0.#`X"'RJ;4>P]%*.J?HR)MIIJ/0#$5+9=I
MKY[/")_B+N=U%>)ZI%\/`AR\W\Z2*L+4(^4G.GE[?3_7T'U9ZN1'=73S67JW
M\M+,$PN''7YL1`X8%.CV0E-\GCNZ>U+'`IR+Z-ZF.EUD>SK/I%\SV0ZQG5#C
M\4<=!^[%<=/=WL=?V'@[(!*,_8?][[OA0TDW'@Q<B5=:BG(YQUL2B'GDZ_O-
M["Q,(&LOT&EC7WI&/EVN5%W?ULXY:I`V^C<6/RJ$]ZH`W>JDV5)]NCB)*"'2
M@.`K;F"T')5%/R\QRP)NN]K':U<)ALKE`@>`GR;N;Z4Q>!4+OUOR8M(\H>!1
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M9:89)3+%!`63YP`-1AL'-J6_B$:NC[5\6.]BV&9]#LE1"N0@Z=JGNE:(HWQ)
M3<1<)/7(`_X\+GN,0'4\B(U2EG;RN"S"M?@$A`U;TM`!6E<J@"42VBGO-!+P
M@H+9EM"J84Y>2#MHO,[6__[^#__^7W_XC]^3_C%0;"N/P&R8-N_">4_%K3Q\
ML.Q6O6U908@,^SO5T\LKU*.>%ON[(9`SC6UEP?)R5I7U43@0#9#UW.%:U5.B
M#X+($F&&^L,75L;O,\F*"_:4X]"QDT?M8*$KJ?O5$DX<A:4?X'P@F^D`QT8L
M<[5*X'HRQ]6'."&259%D8\FHGL5D]NCS@ARUQ9GJR3&4><Z65FC3@>OA3T,A
M+.4E]59=J#_`;3N0WEZ/A,!)\1S+8JL_P7Y\?HL4+N<6%IN0`D8`LC?H?5./
M)W<`APU7T&>Q_RKD^7=2")Y?QFI(+RE9DK+ZKQ"HL-7B8=.NS>,O[?:)O-+7
M%BE3+YW&#6!`/3ZD.6!6L0#",H$4FI^KC^#CNZ*V?B-S?9G+20G[6_P!S:70
M"!H>S<NTEZGQU,^J!M?D9UF"JZ2D"QYGMPY7?=7"B!!075[S,K=\&%RW5HGP
MMSUNJ#$TDC(;BY7U/8CGYKT=G+I#^]9DPPN5!3\ZD2?1VT'S1*Y*6"SSBOV9
M#$%R'"%VGE+M\9@CX9%Y`E[`VD1^EY;L91;0LZ5?S.=WG_^?`````/__`P!0
M2P,$%``&``@````A`.*F)6P4#P``@9L```T```!X;"]S='EL97,N>&UL[%U[
M;^/&$?^_0+\#H6N+!JBMMVTYEH.SSFP#7*]![HH6:(J"DBB;.3Y4DKK8*?K=
M.[-\[8BO76I)*D!CY"11XLQOWK,/DG??O#BV]L7T`\MSEX/QY6B@F>[&VUKN
MTW+PUT_ZQ<U`"T+#W1JVYYK+P:L9#+ZY__6O[H+PU38_/IMFJ`$)-U@.GL-P
M?SL<!IMGTS&"2V]ONO#-SO,=(X2/_M,PV/NFL0WP),<>3D:CJZ%C6.X@HG#K
M;$2(.(;_^;"_V'C.W@BMM65;X2NC-="<S>VW3Z[G&VL;H+Z,9\8FH<T^Y,@[
MUL;W`F\77@*YH;?;61LSCW(Q7`R!TOV=>W!T)PRTC7=PP^5@DA[2HF^^W2X'
M5P,M$GGE;0'$[_Y]\,*O?Q.]O/G#FS>C?WWU]3^^-[?__.'W^>]^^&HP3-AP
M-,$&U30O1Y5DX>N(\C"6X/YNY[F9(%.P.E/0[6?7^\G5\3MP!A`/?W9_%_RL
M?3%L.#)&>!O/]GPM!"N#?.R(:SAF](N585MKW\*?[0S'LE^CPQ,\P!PC_IUC
M@9GPX##BT"V?-:))9+I!&$2F*1[A97)`)`,/5LMD_%@@$^$UK^=UBOX(+R9%
MM5S*>.7](J?#4WBEMN+X^$_KY4#7(8>,1R-4*V^PEI@M5B/@UQFSJWEGDDWU
MJ7ZM5#+BBWF[(<.IKE*5-0SUM]?O.E.G>F9ETL5IN*L(P(!3JT4+0K<BOJ]U
M_.O"3SHN:.U8C%$E29^%GJK<2+RPEM<GRS$#[8/YD_:]YQ@N&I$OH`P9J?](
MGOB#>A:IJZDGW3)R)'_@@T6]!*ER6+]6Y4:-3)N0SW=<1TXJ33VA/*X%?EJ#
M*N?_I_%*9&)5N<H6:MB,:]WIXZNS]NS"*-X\&WX`(T$V2F`VB..:O000]Y9M
MI^.FZ16.+.#(_1T,X4+3=W7XH,7O/[WN85SAPF@360VCW]7\^LDW7L<3UEV+
MG1!XMK5%%$\K-IJ)N\G5U:.^>F1\.62B*$J(ZOKJN@6BCP^+E7JDJ\5"-=&)
M#G^*B;Z=XY]BHCK\MU*FT[B?F*D"F=+30@MG'T:7UXO%XF9\=7-SLYA-Q[,9
M4_(Z]FC+W9HO)DY(*%-3'L$<$"RF-XNK"0`9S6X8JTX13`'`]7Q^,Q\O)C/X
MGU62]A&HUNE\T+=5.00]695#T)-56:D=*LC\<:3`7&#/L<HAZ,FJ'(*>K'JM
M.`-?]VY5#D%/5N40]&15-HA0&*LPQ]YSK'((>K(JAZ`GJRIK/N,,O.C=JAR"
MGJS*(>C:JO&P"AMKG4WBY3LS9?UQ,H2#*4J=-?$=\%H]KN3E8B-4&!.O/7\+
M"Z_):N+X&L:CT;'[.]O<A3#Z]:VG9WP-O3W\N_;"$)8I[^^VEO'DN88-;X?)
M&<EKQ9FPD`MKMLM!^&QM/@,S,JD0V2%BT1:'-,/.<.0RNYZ-KF?SR54T.%3$
MVC&WUL')2Y?R+HP!4"/JMEYP3H=NRB1VO6RN>HA6B,TG>`8S-;.TX`G@$XE+
M")ZA0L9LW4941NX,,1FY$P1EY,X0E1%"IRBX$DUNO0/L(3@VL*[?C$;1M+4H
MGVJ"'/`"CRD&P9V3UV?M*04:K3U'5E;(+[G8>)C@'^O$"R2M.2,O9\T)!5+6
MG"$J(_6;Q+J$>#I-@NFY`,F1OLG/F\$`1M&)A7CB[(0+=]'2G7"R$Q`V3[Q`
M8J*>_!G-A!:4E8,#XLA53GD6R1E'-E8M<RUY3NHSA"1MB)R#URJ@RJ?BG@E:
ML(UIVQ^Q*?K[+NW#8!KU_NYEQVV_@MU1N#\)=W?A6UBKB-]&/5?T`2"6G30I
M/4DS]GO[]</!69N^SC;*,1;L**Z)9)\>6+.8?7YK6T^N8[*)X$%$YCO?"\U-
MR#;RL<6<,CS3$CSCF)`(GE/XSTKX@YZ$]7$*?YAH+#0BZ*57_N!<POQ5^@-N
M68R=&DS`.W45'I4(8#HI00!&Z`,!;K&,=0#NV0<"&*8G",!!,P0`I\(K3HD#
M6/)-68(/9"R!?ULL(<<D4A*6+4I9EGZ!?X64.DF_)ZF9R[?@Z)F:X4,%@)-8
MEJ78OE(,9W:(M$P%\*%"!3I4734E;UR6\WM3")=T`4.F$4@#51I1YY5<S@6>
M&8!JC3PH[$,XI\!4U#<$@-,+!,X0L'^I?PP]56#>&WHJP3P$4H,[C`G>&TB%
M[`D#X.DE*K(^84PJ1H=JX"#TE2$Y;YCTE2)Y#'WER,P4D[Y2)`>AKPS)6Z*O
M%,ECZ"M'<J;H*T5R$$`CO61(WA)]I4@>0U\Y,C,%7L?8BRDX"'UE2,X2TY93
MY)"?-HTF4;GYTW'#"53M95<[DSHN&S6!X9/3H^%3-'0$8[#!%#>6QJM:C63R
M5'OV?.MG&&7BU:T;F$TU_0%>#1U:&_[(3[ZQ_V2^P%@T6OQ[V95/]@*29(+C
MV!LIPE),&7^8Q1]H,LR5Z^<$+*<KHE9R-JJOG9D_\@PZNUWK(;4@T"7[QH`S
M3'UC0'O'&)2[H:(PA2J90!3V3M7NPJL)*J98KM!!L9A\:K)9K:]RS'$XT1]S
M$*4WYL*""V9H6/D;5E6$B6IASSLI<SZF6M-RM1"C/5[2`2"D+Z25N(7H&O\_
MM*/5\F[5SH?:]'B47F5TG<VK*TVPO`LTPE*QHZ"<-LX@BPOZ$,_F*Q4<KL-,
M`Z^1X"JK')=[*9:FBJJP2KGW-656HPF^+6)[Y-C^.M%:1/4!*5+$;T3%/YZ>
M$J%=(ZU4=\/;O0F6'N54:55<5Q-7?98.1,4G.;8ILQJ[GZ@/8GVX@U6K^E#"
M3(T^N#&A3&(J'N_0%HE6R\QKU`#'KC$>2!+@5+<M.[829FKT(63(G#KD[5@Z
MW%$:@"!-FPF)VJTA,S5VX_RXHE_+&4YYJ"7SFC+ULP)PPPPJH=,F@$FF`+-G
MXXZFO5>G)?"8F5#,YR63#WK5R5L,>,[I^P?.16NY+^5P%P?KL355TJZ)(YD@
M+Y<S[UG%@D9@A'U(!AS)0"2K"QJA+441+$T5)>HA2IC5:$*PO)=%-H&8LXU\
M8)_:A@CA',.O:!LB#U38[045S&<)4.I9S%TVFB.H\3>9+$!2%/&TII%7`XZW
ME=H^)!<:52E5*`C.'5^#*2EBXG/76#Z)5)DT2Q>BR1]RU)I-T.*^B*;,)/Q=
MS%ZD,!.(YV&OMO')I*^3L52YBNJ],#*"X2[,W@K4A-OK!#Z7Q4B-`Y8F52G)
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M?CJYT]XO\^UV$9(&.N=85<U`:=H1Z/C*3-HZ&JDYC?+"UH:BI*"59]"6`N$$
MHY+VMR5X^3@5:3B%LFT><:?I5D2.#L-)K:*KXUU>SZ4YJ1GL,KT2CU:3"YH!
M%'+@',!?AEX+!D[D*CHZ5R)<+P42F9!6\_#DU2H,NIEW"+EO7HZJHM\=XFZ+
M;V$S7J8_DK5:6M<]P4UKX/UBW+1&CO-P4]*($<2YM%L%N+1P43]HWB,2:/F6
MI@J;<,RW@E5*C5U`+4],YZ?6<JSGIU9^Y;"%!JOQ9-CQ39)$UDA$IS":T%8^
M'X!EKG#J.N\C9.:Z-&?)J/JL%HS/U05I\LZ;145?7-!BRMB1U$$2OG@S$9&8
MB?PZR^#',01*V!6M7=<PZ[3=D6HC:X`K*<EYJ]9"Y((`/&V=;F"L<3LEV8!X
M$?7ZW&2]<OT(;]D0\\2<OL[7$XFF<[BK%%UJ==[QHOU:?#8YTWUO%4"C1]^T
M>FF^1&&O`#J5VYM`3-_VU=5*F$FHJ=,5FU-#X13#=1JSDJ%`RERG0.MO]C=1
M?9L?.@0NK+4XX98T,O@V;KWA;46M+:X=I2['Y]H$!+OK(]SGD7MJ#GUF3GI7
M2,TU''C,X&3T6^U">[O!NIA>-(PCRO7!LN%9JWA5`]ZQ<W,(X-%[#]'!^!:+
M5;322C[!?,#1`D^1I044HMX2]Y3SM*"+D:4%["-:4Y"6HP7WPY2FE>ZEF^(0
M+Y-Q!LVP+*ZT?YY2W<\%=3\KLB.[&W6&"T46P<73RNR((<[1`I%E:65V!,/Q
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ME,($/HH`^I-I;"WW20.]Q$6<*`@GCF3(I+%`U0//998B`V=':*C_X42E#!HX
M.R)#DRKV3R)DOG7WA]1"-)=BZ18A\=YR/YM;ZCDT2TP`I`BE#^8A](W4_VA(
M3005\P&?CYC2H"F"/>[PN&?\`(]#3)2(^]2YV,$>6@3X7PXAIT8\BR."DTTB
M1#Y9(3Q*.+8FC6&$)43"@SN4IR2.,HH@C;\9OHO10D+WR$=+),IN^`[=__8E
M>U8FTWMHP*.2V5,TT_$`*&IK[HR#'7Y*OUP.LO=_9@_I!F>*?_6=]<4+&8GE
M('O_'I]^#E$,(Q!(-^\#>*(VO&H'WUH._O/X<+UX]ZA/+FY&#S<7LZDYOUC,
M']Y=S&>KAW?O],5H,EK]%U3FV&YP^S*>+0?/8;B_'0Z#S;/I&,&E8VU\+_!V
MX>4&'JKN[7;6QAP&>Q^22O!LFJ%C#R>CT6*X&#H&>YXQ$+D-;/B5'PL;@_^8
M'5L.N`\1?#:=`K#A\LQ$B&&`CQS]B$SN_P<``/__`P!02P,$%``&``@````A
M`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/
MV'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP
M;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E
M<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^
MEINX[85*)9N5BO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC
M('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^
M-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;
M5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]
M]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_
M2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP
M?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0
M$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_
MGG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7X
MD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`
M\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&
MNXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H
M'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8
M\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]
M*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T
M._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_
M7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?
MH5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^
M$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^
MRIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"
MG9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51
MYA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKL
MZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,
M8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU
M)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$
MXR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=
MHEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@
MI#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!
M#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA
M;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]
M6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#
M8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.
MVF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2
MU.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-
MTJV_````__\#`%!+`P04``8`"````"$`GD$U3=L#``#-#0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6R45UN/ZC80?J_4_Q#E?0G.%1!P=,AJVR.U
M4E7U\FP2`]$F<12;9???=^P))';8+7D!XOG\^9N+)\/ZVWM5.F^L%06O-RZ9
MS5V'U1G/B_JX<?_^Z^5IX3I"TCJG):_9QOU@POVV_?FG]86WK^+$F'2`H18;
M]R1EL_(\D9U81<6,-ZP&RX&W%97PV!X]T;2,YGI357K^?!Y[%2UJ%QE6[2,<
M_'`H,O;,LW/%:HDD+2NI!/WB5#3BRE9EC]!5M'T]-T\9KQJ@V!=E(3\TJ>M4
MV>K'L>8MW9?@]SL):7;EU@\C^JK(6B[X0<Z`SD.A8Y^7WM(#INTZ+\`#%7:G
M98>-^YVL4K)PO>U:!^B?@EW$X+<C3OSR2UODOQ4U@VA#GE0&]IR_*NB/7"W!
M9F^T^T5GX(_6R=F!GDOY)[_\RHKC24*Z(_!(.;;*/YZ9R""B0#/S(\64\1($
MP*=3%:HT("+T77]?BER>-FX0SZ)D'A"`.WLFY$NA*%TG.PO)JW\11#HJ)/$[
MD@#4=W9_YB\B$L7_S^*A(NW@,Y5TNV[YQ8&J@3-%0U4-DA4P*\\"B,]]S\`E
MM>>[VJ2W`EI`.MZV<;!8>V\0PJS#[!`#-^"&\4U$>@?1DWB@[R827)\N4FTR
M1?J)J6"'$%TXVK%TL&`(@,@,!7P='06&*`X\#V+[9,2$.L$JI.E@P3@YG'*R
M`F]<<.(6\R#N0ZI=W"$FUEGS(S,@J6'L-1N*H&(?CX4"VXJ6YJ$[Q(3W%1G&
M3Q3%4Q0IL*4HF5N*$(.*GD9!,JV?:$JF:%)@6U-@:4(,:K+TIO=M1M;4JVAP
MS[^N8`6V*C@)+3V(&53P8,$X>3GE9`6V(V$5Z0XQB:Z7T">!94^']F"9+/MZ
M,W01:'./AT2C;66Q%9,.A$D*B9TFPQPDY+;;U&6UY*]31;"+&G<^ZFL2[WP'
M0EW+97\P=CW#O/![V:8NU1P?+B&"K=30E8QT(0AU)>%(%YHQTT$0]793F.J=
MCPO#3FL*LYLDN;9C]6XCD65.#7,8]5?#U#6I=Y,[S3OI2[=+)((P8*/WZ=#8
M7PI3TZ3NK68<^SHN^O+H-"&HNX]A&%A93CN6*V`Q[QE,;9/Z.'FDD7<@//HI
MO"<.:6Z(S]5-ZNCD3DM?V"V]`V$V^Z!TE_*!I@XS[Y3*QPYM5/Y8$X)P/AAI
MNF_$+.+TC,-EQ=HC2UE9"B?C9S49^]"N;ZLXM>_("B8PF):M]12F>;WNW0PP
M3#?TR'ZG[;&HA5.R`U#.9PF47HOC.#Y(WNB1;\\EC-'ZYPG^-C&8L.8S`!\X
ME]<'-?#?_HAM_P,``/__`P!02P,$%``&``@````A`)P%E7D_`P``TPD``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG%9=;YLP%'V?M/^`>"^?`9(H
M2=50=9NT2=.TCV<'3+`*&-E.T_[[7=N$Q$[:-7M)@'M\./?<:U\6M\]MXSQA
MQ@GMEF[H!:Z#NX*6I-LNW5\_'VZFKL,%ZDK4T`XOW1?,W=O5QP^+/66/O,98
M.,#0\:5;"]'/?9\7-6X1]VB/.XA4E+5(P"W;^KQG&)5J4=OX41"D?HM(YVJ&
M.7L/!ZTJ4N![6NQ:W`E-PG"#!.CG->GY@:TMWD/7(O:XZV\*VO9`L2$-$2^*
MU'7:8OYEVU&&-@WD_1Q.4''@5C=G]"TI&.6T$A[0^5KH><XS?^8#TVI1$LA`
MVNXP7"W=NW">AZ'KKQ;*H-\$[_G)M<-KNO_$2/F5=!C<ACK)"FPH?930+Z5\
M!(O]L]4/J@+?F5/B"NT:\8/N/V.RK064.X&,9&+S\N4>\P(<!1HO2B1301L0
M`+].2V1K@"/H6?WO22GJI1NG7I(%<0AP9X.Y>""2TG6*'1>T_:-!*J.1)!I(
M8E`_Q",OFB9ADOZ;Q=>*5(+W2*#5@M&]`UT#[^0]DCT8SH'YD)G6,>;Z6JJ0
MHR2YDRR*"[+@4)^G51JG"_\)/"T&S%IC8$N,F-!$Y`>$+`7(&S5"YK;&&&IX
MV?V#)+G(E!1EYOO6%R`F(K^`F(X00R-X=[U&N0AZX<22-+9%:LQ$=97T.C]Y
M8"B8_(\"N6CI0IIC4>+$*LM:8U)5UILXFDU&!U3Q<R,>3:+9&#?T0:=?[Y!<
M9.NSWK_6F(G6%\VLOLO-</"*NM14]W9O2;"MRJZ;Q@RJPLPR-3?#<7S9L^P:
M51)LJ4J#D5?5:JTQF?(J#":V*AU6S6;43@ZRDU/B;7<DV-9AO6BM,5I'-`LL
M\W(=/M<QNT:'!)LZPC"R_-`87:4P.^YMW=E&='KL.\.;$(ZB]YNCT*:J.+55
M#:"A>>(T,57G0WRP+YD>[3.568?[VV6#`6K[E1TWBVZ?`://`JNWY`26!'90
M2]*S58^>%K,MSG'3<*>@.SDW0VC(\:F>Z6LYT]54'@,P4GNTQ=\0VY*..PVN
M8&G@9;##F1[*^D;07IW\&RI@F*K+&CZ>,)R>@0?@BE)QN)&S9OP<6_T%``#_
M_P,`4$L#!!0`!@`(````(0#)*BK`B`0``*41```9````>&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;)18;8^J.!3^OLG^!\+W*[8HCD:]&9S,[DWV)IO-OGQ&
MJ$H&J*$XSOS[/:<%;`N.,!\<:9^>\YR7/J6NOW_DF?/.2I'R8N.2R=1U6!'S
M)"V.&_>?OU^_/;F.J*(BB3)>L(W[R83[??OK+^LK+]_$B;'*`0N%V+BGJCJO
M/$_$)Y9'8L+/K("9`R_SJ(+'\NB)<\FB1"[*,X].IX&71VGA*@NK<H@-?CBD
M,7OA\25G1:6,E"R+*N`O3NE9--;R>(BY/"K?+N=O,<_/8&*?9FGU*8VZ3AZO
M?AP+7D;[#.+^(+,H;FS+AX[Y/(U++OBAFH`Y3Q'MQKSTEAY8VJZ3%"+`M#LE
M.VS<9[+:T<#UMFN9H']3=A7:=T><^/6W,DW^2`L&V88Z807VG+\A]$>"0[#8
MZZQ^E17XLW02=H@N6?47O_[.TN.I@G+/(2(,;)5\OC`10T;!S(3.T5+,,R``
MGTZ>8FM`1J*/C4O!<9I4IXWK!Y/Y8NH3@#M[)JK7%$VZ3GP1%<__4R!2FU)&
M_-H(_*^-$#JA3W,R#QY;\10C&>!+5$7;=<FO#G0-^!3G"'N0K,!R$YGBT<9Z
M+U2($8T\HY6-"^T.40BHS_LV($]K[QUR&M>8L(LA)F+7(+`40*_E"&G3.?9G
MO:&"8*2"54!NH1H`VRTW:OGM0=S(&TP@0\.9(!@JK3D.R-)T'2K,K&6[TP8,
MS[,QGA$LNZT-V5_,+<\*$\AB$>(OIOAG8G8*(]D99*!I]31@T\SN;H>F,+C(
M)!50RV&H,."V)1Y0NTL:C-TE@4GJZRY!L$D&,F!&'RK,0F9H-IOW)4A!N@E:
MC.&"8)-+0*T6#16FYM+'1`&Z3/`(TO;WUUE!L,W$M[*B,&1&9%ZF$W]F`G8=
MP*WSC"9:CF&&8)N9Y3A4F)GB99'JGS/X$#@6AJ=*HFU&MTB5]-2@?DIW)DU.
M*(F#RT>4@(*<:=LG,#,1UJ`[G)0%>]+DA'(YG),25Y/3PN:D0,HMO-M8*KDC
MS;R]YPG*I<9EF!+)57;M;HI?UTY38CFRJY=U]QA!G=18?+W))/K1N5"#I*_:
M^STQQA>1$=[[9-C>2=(D:'KO5FHG.\48I<"D*\$!M0H?UB`]#?<DEXS27(E^
M6`1-5.LB:"/FIABELZ0KM/Z\LRD42)W0RR7I'L^UF9Z&M+15OM4%4/D'G=FC
MLKY]*I)&2C61\>TSN@79/4(MD1W(3"ZS=JQOGY$UR'A[Z#!K01UFHZ26]DBM
M;Q^5-4CK7GW$Z!^*"C=80B3Z4??6(-W[/1FE/3+J0Z6^;A>YRBZ*+24UJ)%V
M:AV1NW:^4X]1HDJ5.D*`MZ//MWR%-4C/R#U1Q1O5B'HH484LWKQW7O6E2115
MB%2IB3YB=H.EI+A+!M2C1U'MM[,0KLGX)M74PY[':[2:;^NA;L7JTIBS\LAV
M+,N$$_,+WG@IG!'M:'L;?Z88I34>PBU=7FF]=@(NR>?HR'Y&Y3$MA).Q`YB<
M3A:0SU)=L]5#Q<_RJKKG%5R/Y=<3_!S"X'XWG0#XP'G5/"#Q]@>6[?\```#_
M_P,`4$L#!!0`!@`(````(0#LZU5U50,``)8*```9````>&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;)16VVZC,!!]7VG_`?%>P"0A%R6IFE3=76E76JWV\NR`
M2:P"1K;3M'^_,QBH<7I)7TBPCX_/G!G&7EX_EH7WP*3BHEKY)(A\CU6IR'BU
M7_E_?M]=S7Q/:5IEM!`56_E/3/G7Z\^?EB<A[]6!,>T!0Z56_D'K>A&&*CVP
MDJI`U*R"F5S(DFIXE?M0U9+1K%E4%F$<14E84E[YAF$A+^$0><Y3=BO28\DJ
M;4@D*Z@&_>K`:]6QE>DE="65]\?Z*A5E#10[7G#]U)#Z7IDNONTK(>FN@+@?
MR9BF'7?S<D9?\E0*)7(=`%UHA)['/`_G(3"MEQF'"-!V3[)\Y=^0Q9:,_'"]
M;`SZR]E)6?\]=1"G+Y)GWWG%P&W($V9@)\0]0K]E.`2+P[/5=TT&?DHO8SD]
M%OJ7.'UE?'_0D.X)1(2!+;*G6Z92<!1H@GB"3*DH0``\O9)C:8`C]''EQ[`Q
MS_1AY8^28#*-1@3@WHXI?<>1TO?2H]*B_&=`I*4R)*.6!'Y;$A('\6Q")LG[
M+*%1U`1X2S5=+Z4X>5`UL*>J*=8@60!S%YG1T<?Z6J@0(Y+<(,O*AW*'*!3D
MYV&=1/-E^`">IBUF<XXA0\2V0V`J0%ZO$6RS-;[L>B<%P2@%LX#:-F8`N'MM
ML;/O"XA9#QDH`8=L)>C6"*KI;46X"'"6@(1$/;\1:3#C7O76&A@H&)\KF+Y:
MB9TGN*BIOMZ"A#CF;PP&GA;&-:K#N`D"`;8M;]N!8%?,R+'#8)*FDD@TBR+'
MKZT-F,+T\_S`K>0CPA#L"AL[P@S&RI,U,-AY.MSYLDK!1>]5BL%8"JR!@0(\
M?*PO^^VD(-B-?>+$;C!D3$Q:AK-;,]OH&LB8#V5<9@0N<N4DPPTW!M/)B8+(
M*:*M`9PK(O#%7NY,@W:U3!TM+<C*BCTR\(-@E[/R<IDAS:KW2J,%V2I,2WW!
M@P_U5&(Z)#RMYN"61PMZ3H@#V+:`%\1@L_NX):9%#D6Y10*W`JRD9U&1V]-:
MA*7*7`/,*5DRN6=;5A3*2\41C_@8JK\?[:\?-S&V;F=\@]<2'`_[";@5U'3/
M?E"YYY7R"I8#911@"Y?F7F%>M*B;LWDG--P'FK\'N/\Q.-"B`,"Y$+I[P0WZ
M&^7Z/P```/__`P!02P,$%``&``@````A`!)8DV-U`P``H@L``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&ULG)9;;]HP%,??)^T[1'EO+D"@($)54G6K
MM$G3M,NS21RPFL21;4K[[7=.#)EM:&GI`R7VWX??N?CDS&^>Z\I[HD(RWJ1^
M'$2^1YN<%ZQ9I_[O7_=7U[XG%6D*4O&&IOX+E?[-XO.G^8Z+1[FA5'E@H9&I
MOU&JG86AS#>T)C+@+6U@I^2B)@H>Q3J4K:"DZ`[553B(HG%8$];XVL),O,<&
M+TN6TSN>;VO:*&U$T(HHX)<;ULJ#M3I_C[F:B,=M>Y7SN@43*U8Q]=(9];TZ
MGSVL&R[(J@*_G^,1R0^VNX<C\S7+!9>\5`&8"S7HL<_3<!J"I<6\8.`!AMT3
MM$S]VWB6Q8D?+N9=@/XPNI/&=T]N^.Z+8,4WUE"(-N0),[#B_!&E#P4NP>'P
MZ/1]EX$?PBMH2;:5^LEW7RE;;Q2D.P&/T+%9\7)'90X1!3/!H,/(>04`\.G5
M#$L#(D*>N_\[5JA-Z@_'03*)AC'(O165ZIZA2=_+MU+Q^J\6Q0C5&QGLC0R!
M?K\_"`;729R,SUL)-5'GX!U19#$7?.=!U<!ORI9@#<8SL'SP3'/TOK[F*N"A
MD5NTDOI0[N"%A/P\+49)/`^?(*;Y7K,\UCB*[*#`5`!>SPB>FXRGHWY`03&B
M8.B0;:D7P';/-K#)LA.*ZUYBD4"$3!*,UA"JZ6TB/`0Z`V"4.`A+K1GUU)FQ
M8!&,+B'`0ZD/;O8A&"7#WD,=)JT9=\F+[+WL])[%!77\\<C@(9=K9/_V4FN,
MR!@+%L'X$@(\Y.8F<0BTQB`P%BR"R24$>,B-P=@AT)I)EYLX&4;X9TLR2S).
M;(E%B2\EY\:?KV$\Y%).;(2EUAAQ,A8L@NDE!'C(S91[B[3&(#`6+((8+JT9
MA+<O<*=VO?_?(?3]V8M&)R]0O^FVMAA[GI&-,R"Z0]H7>>JDH3.9^J^`:`M=
MB.R(8!,T0-[7VF+=.BV@L5.:R[W(2(NY8E-@V_LXA6Z6\&GT-[<V8J.C=AG+
MS!6;PFFR9Y)RJKL>58<6O9*4P^91=3A=]0S(J79Z5!U:=+K/XTP#E\RH#CT2
MZ8FAIF)-,UI5TLOY%L>=`11[O]J/8K<#?(TYZTL<T7`][#=@0FK)FGXG8LT:
MZ56T!)-1,`$(H6<L_:!XV\TI*ZY@-NJ^;F`6IO!RCP(0EYRKPP/^0#]=+_X!
M``#__P,`4$L#!!0`!@`(````(0`9TWGR7P0``+81```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;)18VV[J.!1]'VG^(<I["79"N`@X.E!UYDASI-%H
M+L\A,1`UB:/8+>W?S[:=!%\H(2^EV,N;Y;67%S'K;Q]EX;V3AN6TVOAH,O4]
M4J4TRZO3QO_G[Y>GA>\QGE194M"*;/Q/POQOVU]_65]H\\K.A'`/*E1LXY\Y
MKU=!P-(S*1,VH36I8.9(FS+A\+8Y!:QN2)+)1641X.DT#LHDKWQ58=4\4H,>
MCWE*GFGZ5I**JR(-*1(._-DYKUE7K4P?*5<FS>M;_932LH82A[S(^:<LZGME
MNOIQJFB3'`K8]P>*DK2K+=\XY<L\;2BC1SZ!<H$BZNYY&2P#J+1=9SGL0,CN
M->2X\;^CU1['?K!=2X'^S<F%:?][[$POOS5Y]D=>$5`;^B0Z<*#T54!_9&((
M%@?.ZA?9@3\;+R/'Y*W@?]'+[R0_G3FT>P8[$AM;99_/A*6@*)29X)FHE-("
M",!?K\R%-4"1Y$.^7O*,GS=^&$]F\VF(`.X=".,ON2CI>^D;X[3\3X%06TH5
MP6T1>.V*S"9S-%V&\\>+A&T1>&V+(#S!BQF:Q<-4`K4MJ=)SPI/MNJ$7#ZP'
MQ%F="".C%506\H0@\FUY0!>QYKM8))<"FD%/W[=1C-;!._0A;3$[%V,A]AU"
MM`_8])1`I?&4Q"*3$IY;C&Y`3,3^!F+10PR.(-5XCF(1R.M[FFRXKR^EW2E,
M).TCM-YK`P:#R&1POV$"O/%A>]HGA]8G*TRLVHFN^Y:\]OKL#$7]6H,3F'F\
M*F*1R0V'-C>%B22WIW!AB;8WIJ/%[#:[V&1W7S$!-EDYI!1$D0KC_C.57OHD
M7O:3AESS,80$V"04Q=<V*/,HC&8>;<#X9/'M-OK4BT5#]E48C8$V8#!8F@SN
M-T.`S;UC;%M$8<"FO<4QMIO28>S$09!XNA[WV4BT22>*;3HM2+EC:471WIS]
MPA[(RN8!5BI.S3-^/0G*(++DQM?ZHX\8#4(B#$=[1*X:,DD+TEFHY)4C)@L1
M?QJ+`0U46.H:N$9!7:+J3K'CK@<Y5A%!^#@A%9LZH1M642!E%139X8:^FC:%
MLK)W0"@W=*/8.BT[\9@$QTYODS9B?KJ5K0\^1JB0A'[T9S:*K>WO4)>DXME,
M?B/J(R:+48&*W$2]898N0:\4,7;,TH$<LU@Y.]`4E94#9ND"53QU+:[)T4KS
MQ:PITZCL16[X1K&59[L6I%OEJZS%5M8^9A6Y:BA76I#&0A\Q-,"CLE6BS<1W
MK=*"X+3V;G:_@7J0;14L$O#A7)%HDY";*RU(Y8KSS&3,HOGU\)LZC<I?[.9O
M%%NG9=>"]"YUB>R((J)/$^5!KZC`O!\KN$O5/E;T$5.#4=$J[F*##RLMR/!*
M:"7?O@<YLEAI>S]6X'9M$[KA%0523_]6Q\3]7%2P)Y5(ZN:M[I1U<B(_D^:4
M5\PKR!'.P70B;KB-NG>K-YS6\J)VH!SNR_+?,_P^0N"R,YT`^$@I[]Z(G?>_
MN&S_!P``__\#`%!+`P04``8`"````"$`1CQ%Z)$"``#@!@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6R455UOFS`4?9^T_V#YO1@2DK112-4NRE9I
MDZ9I'\^.N8!5C)'M?/3?[QHGJ$DZC;X`AN-S[CWW^K*X/ZB:[,!8J9N,)E%,
M"31"Y[(I,_KKY_KFEA+K>)/S6C>0T1>P]'[Y\<-BK\VSK0`<08;&9K1RKITS
M9D4%BMM(M]#@ET(;Q1TN3<EL:X#GW295LU$<3YGBLJ&!86Z&<.BBD`)66FP5
M-"Z0&*BYP_AM)5M[8E-B")WBYGG;W@BM6J38R%JZEXZ4$B7F3V6C#=_4F/<A
M2;DX<7>+*WHEA=%6%RY".A8"O<[YCMTQ9%HN<HD9>-N)@2*C#\G\\9:RY:+S
MY[>$O7WU3&RE]Y^-S+_*!M!L+),OP$;K9P]]ROTKW,RN=J^[`GPW)(>";VOW
M0^^_@"PKA]6>8$(^KWG^L@(KT%"DB483SR1TC0'@E2CI.P,-X8?NOI>YJS(Z
MGD:363Q.$$XV8-U:>DI*Q-8ZK?X$4'*D"B2C(PG>CR3)-$I'D]GM`!86(NH2
M7'''EPNC]P2;!C5MRWT+)G-D?CLC3,5C'SPXH]C4&*S%*NR6:3I>L!U:)XZ8
MQX#!:X])>@1#T5X9U88K>[!7]M[Z4![#B]<RH[=EQN^1\>",(G<??)JF/6]0
M#IBT:YC7^:3G0KY'TG_VR,E1OPF[X4QP<B$8,->"2#[<0`^^S&QZ(10P:5?8
MN/]V5K3I>S0]^%)SUO,&-P/F.KG9N=`P-_VF_[D9,->"?E0//@@>?)G9I9L!
M\[:;8=*$@ZC`E/`)ZMH2H;=^BB18@?YM/^`>1EW+]1]PP+2\A&_<E+*QI(8"
MM\;1#*MHPH@*"Z?;[IAOM,/1TCU6^"<!/$5QA.!":W=:^"'8_YN6?P$``/__
M`P!02P,$%``&``@````A`#\N3D5I`P``G@H``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&ULE%9=;]HP%'V?M/\0Y;TD#N8C"*@*5;=)FS1-^W@VB0&K
M21S9IK3_?O?&)-C0M=E+2VZ.SSGW7OO&\]OGL@B>N-)"5HN0#.(PX%4F<U'M
M%N&OGP\WTS#0AE4Y*V3%%^$+U^'M\N.'^5&J1[WGW`3`4.E%N#>FGD61SO:\
M9'H@:U[!FZU4)3/PJ':1KA5G>;.H+*(DCL=1R4056H:9ZL,AMUN1\7N9'4I>
M&4NB>,$,^-=[4>N6K<SZT)5,/1[JFTR6-5!L1"',2T,:!F4V^[*KI&*;`O)^
M)I1E+7?S<$5?BDQ)+;=F`'21-7J=<QJE$3`MY[F`#+#L@>+;17A'9FLR#*/E
MO"G0;\&/VOD=Z+T\?E(B_RHJ#M6&/F$'-E(^(O1+CB%8'%VM?F@Z\%T%.=^R
M0V%^R.-G+G9[`^T>04:8V"Q_N><Z@XH"S2`9(5,F"S``?X-2X-:`BK#GYO]1
MY&:_"(?CP6@2#PG`@PW7YD$@91AD!VUD^<>"R(G*DB0GDB&X/[U/!LET1$;C
M]UDBZZA)\)X9MIPK>0Q@UX"FKAGN03(#YC8SZZ/+]5^I0HY(<H<LBQ"V.V2A
MH3]/2TJG\^@):IJ=,*MK#/$1ZQ:!K0![G4?(W/7X>M5;*PA&*]@%]+:R`>#N
MO"47NJ\@SN8])U"A_DX0#)UVA"E-?>F5Q=#.[=H)>,K45\8^T7_NP+86N&@1
M0GI=ZG047SBPF$G3-!*G)![1L0]9NY"4QFF:G!&>23#4OSP(OC!'J:^\LABG
M/$[`4Q[_CS*"WVN,Q3C*3L!3GOC*_1J#BRYROVJ,Q;2-&>-!]ZNS=A%3.J3T
MO+$]B_@9<L[XV^<'P;ZU)#Z?!GND+,8ICA/PE-/_44;P>VVQ&$?9"7C*!(:\
MFW2_OC2K_.RO3\P)9#M#)R1.+D[UVD>0-([/I\YWB2.O=VN('9#>>:83?U.L
M3B"G1&[$5\?!UU_=CLFWYQFQ(%?=B?CJ..H<]9X=L@,22-^8:7`7P*UD.Y0.
MH47Q^6@T6QBO"V?(E-`)G9Z'C_5IKP/V:UERM>-K7A0ZR.0!/_4)3,PNVEU#
M[A(<Y1?Q%5Y/,!YU+^!V4+,=_\;43E0Z*/@6*./!!.:;LO<+^V!DW7RC-]+`
MO:#YN8=[((</6SP`\%9*TSZ@0'>S7/X%``#__P,`4$L#!!0`!@`(````(0#3
M20)B>@4``),4```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*Q8VV[C
M-A!]+]!_$/2^EBE9OL'V(K:4=H$M4!3;W6=%IFTAEFA(2IS\?6=(BN)%Z[A%
M7Z+X<&9TSG#(H;CZ_%:>O5=:-P6KUCX9C7V/5CG;%]5Q[?_][?'3W/>:-JOV
MV9E5=.V_T\;_O/GUE]65U<_-B=+6@PA5L_9/;7M9!D&3GVB9-2-VH16,'%A=
M9BW\K(]!<ZEIMN=.Y3D(Q^-I4&9%Y8L(R_J>&.QP*'*:L/REI%4K@M3TG+7`
MOSD5EZ:+5N;WA"NS^OGE\BEGY05"/!7GHGWG07VOS)=?CA6KLZ<SZ'XCDRSO
M8O,?3OBRR&O6L$,[@G"!(.IJ7@2+`")M5OL"%&#:O9H>UOX#6:8A\8/-BB?H
M>T&OC?:_UYS8];>ZV'\M*@K9AGG"&7AB[!E-O^P1`N?`\7[D,_!G[>WI(7LY
MMW^QZ^^T.)Y:F.X8%*&PY?X]H4T.&84PHS#&2#D[`P'XZY4%E@9D)'OCSVNQ
M;T]K/YJ.XMDX(F#N/=&F?2PPI._E+TW+RA_"B"M204(9!)X#06XX1M(1GM)Q
M,IJ$\6S.WW[#<2(=X2D=YZ,9&2^B&;"^X0>C7"X\I5\8C<)Y3.(IZG4]`Y$O
MGOXD:[/-JF97#VH:,M)<,EPA9`F>7=Y%!#43/YL(F`$,\H!1UCXL1LAQ`]7S
MN@DGX2IXA1G/I<W6M2&FQ:ZSP.G%L(D-I!H0@`"E`F;L?U"!45!%]_YM!VBR
M+,J=1>>2V$"J`09EJ!6;<@3+9KC@NSRC$Y2VD>?(I+05-K!X.DX[!TD<)-41
M@R>4IL[S-C\TADJ:&@3M0I!&9K5,3!4[9=2I2!PDU1&#,Q3R_9S1F'/NWK05
M2`BSH95S;!%41IU;XB"ICA@$(4'W$T1CDZ!$%@;!J450&2F"#I+JB$%P9A+$
M;6$&&VJWM=R],6`<D[M`K.3.+.[*2'%WD%1'#.YX)M"VM-L5B\8F08F8R9U;
M!)61(N@@J8X8!"&T3A"3.XU&_99_=W8QD$E>(%9V%Q9Y9:3(.TBJ(P9Y`LM"
M9W\[O=S:I-A!LWZ#<J'$A5(#,CEA7[A[RHGH(K!+=?JW$@KGHG>-B;W:.P-(
MB]H3R-RJBD1:P3Z.+7`^-O.>]D'@Q:8`[!+W"Q`]Q1`@H)!T`NS=@`B#2)QX
M1'>54,A]IM8VG4J/D,^3R1:;A<96'!IX`;>G(G_>,L@1)'F@-")XESPRR(ZC
MSX*`8!;Z)(>QE<4=$5;1!U,AK"9B*HA]&DEEE'"!16"JP[9BJ0OCP;V/J_W&
M+C]3"V<Q)5<V*UVN@,S%&CN'(F7556M"'"@U(%,.-B%-SL"DZ#1%RS)*2T)Z
MOL/8JI8='M9Q+^+YE*<W!TH-*Y,FMB*-)J\I,ODONR(>/ZQM44)6JJV3TZZW
MZE,M8H%C!Z6&E:D!6Y*FX8-4BP8&X;K06R(A,]7VT:BWZAP3%TH-R*2)C4FC
MR5,=S@8K_`,)LL7I$@1D9=K93I55+\&!4J)#I@3(D"[A`YIH;34A"9F9=C9-
M9=73=*`4:KXO?8,F9D&GR3.](/@)*[_1[F[U/)2I04)6JNVC5&^E-+A0:D"F
MAG_56Z$!V:F6T+3_KMJY4.)">-^`L82CX"3N#\0';$GK(]W1\[GQ<O:"=P,@
M8K-2L+BXV)+Y$@L)Q#LC"QCA^Y4]$H[AMH,O>6=$W8/8(Q!L,!:!6'!R&7K_
M!$8F@R,QC/`/./LM9`HC?+DY(S,8X;W:&H&KFX=P\"W@,(2'('X(CY;PE>CJ
M>)A`_,%`H&]0'J@;%`?:!J6!LB%A6YA9/K&!4@Q70I?L2/_(ZF-1-=Z9'J`L
MQKR)U.)22?QH9<]^8BU<!O'V?8++/PJ7#F/<!P^,M=T/4!RHZ\3-/P```/__
M`P!02P,$%``&``@````A`+[1&_^+`@``+08``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3$N>&ULE%1=;YLP%'V?M/]@^;T8""$M"JG25=TJ;=(T[>/9,1>P
MBC&RG:;]][O&"4O3:FU?`)OC<^['N5Y>/JB.W(.Q4O<E3:*8$NB%KF3?E/37
MSYNS<TJLXWW%.]U#21_!TLO5QP_+G39WM@5P!!EZ6]+6N:%@S(H6%+>1'J#'
M/[4VBCM<FH;9P0"OQD.J8VD<YTQQV=/`4)BW<.BZE@*NM=@JZ%T@,=!QA_';
M5@[VP*;$6^@4-W?;X4QH-2#%1G;2/8ZDE"A1W#:]-GS38=X/2<;%@7M</*-7
M4AAM=>TBI&,AT.<Y7[`+ADRK924Q`U]V8J`NZ3HIKG+*5LNQ/K\E[.S1-[&M
MWGTVLOHJ>\!B8YM\`S9:WWGH;>6W\#![=OIF;,!W0RJH^;9S/_3N"\BF==CM
M.2;D\RJJQVNP`@N*-%$Z]TQ"=Q@`/HF2WAE8$/XPOG>R<FU)9UF4GL^3>8YX
ML@'K;J3GI$1LK=/J3T`E>Z[`DNY9\'U@R:/Y(IXEKY.P$-&8X#5W?+4T>D?0
M-"AI!^XMF!1(_')&F(K'KCVXI&AJC-5B%^Y7Z6RQ9/=8.K''7`4,/B=,,B$8
MBD[*J/9V90_VRKZV/I2KL'$LD[XL,WN/C`=C<XZ"3V?G$V]0#IAL-,QQ/ME[
MA#P82YX_43HMY1Z$=IUJF<XNIG">5!-M=%Q-[]`T]VY\I:7^W!C(5-FPDR^.
M5;/X956,_U0UR;`I_[>1/_54<[^#3?V7:7;JFS">P;T*3`.?H.LL$7KK1R]%
M/TZ[TZVP3GV?3O>S8CW>%FSZ@=,Z\`:^<=/(WI(.:J2,HP46PX1Y#PNG!XP<
M1U8['-/QL\5K&="2<83@6FMW6*`PFR[ZU5\```#__P,`4$L#!!0`!@`(````
M(0#(/['7VP8``'L;```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*R9
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MT7`'_FQ'NVI??!S[OYK/I*K?#CW<[CG,B$S,W_T(JZX$1T%F[,Z)4MD<X0+@
MW]&I)J4!CA3?A^-GO>L/:VOJC>>+R=2!\-%KU?51322M4?G1]<WI7QKD,"DJ
MXC(1.'*1^=A=SIVY1U1N9$Y9)AQYYF2\G,]GWG)Q.W/&,N'(,E?W#0FRPXSA
MR(>4$[YQJ1[+@R/+6]QWI0N6"$>6Z-PU(#RBPX7"\;$9KE@B'!^:H0/51XN!
ME"&]T7?.T1%U!/^Y9Y8VK<.AK,.B+YZ?VN9S!&L%Y'>7@JP\CD]4>4'3.R-*
M_&<5#J5-5%Z(S-H"ZZ!X.W@LOST[WN+)_@:/4LEB-E=B](B`1Y#GALB&)MB:
M(#)!;(+$!*D),A/D"K#!)V$6/'#_AUE$AIC%I[GA0+KG&L[P")X2FF!K@L@$
ML0D2$Z0FR$R0*T!S!A84Y,P4ROKZNLBKAF3!"JA4C>M.])EO:`RLL7SJ`2(A
M(EM$(D1B1!)$4D0R1'*5:*;`6JF9<ML,$@U/(:QW-YXA%J0^:*[KZ)8%(HA;
M%B*R121")$8D021%)$,D5XEF$+P3'C"(1`\&\6EM*'&ASH1EKFL^.B*(IX6(
M;!&)$(D121!)$<D0R56BN0%W_@$W2+3N!B4SN:X$E'A0H(H_4[U:0A8T$P_8
M]FK:3$^+1!"W-69$/JD)DDY%EGI%AG0F@KATKDIKGL%+_@'/2+3N&26J9XS0
MCFMX"5'B*0:)&/*B<R>.,8%(G.<3B)F&X@U234464S5N5";.<]5<5=5L@?7A
M`5M(M&X+):Z^S,SU"@AHT!PN0JDN3P\*A1*_Z"U+@W>L2'.62STM8D'NT$JL
MC$XB9J(K4;()&B:]9YA,'V:E7T2N#J/9"YW>`_:2:-U>2ES5`M<U)AG0H#E<
MA/#)=0V?0J$D[&5D^`8:FJB(":UH6S8SUL<8)21(-$4QV6W17$W0K"--[P/>
M#>&Z>0P9Q6G<NX!%>?J[P;1/:@G_.)+%%3$$_0QY,I?&4#'.2#B2:W'*D=3-
M;NOF6H9N(FE0U:[]=F=!^GJC`AG22W!J]%X!BS)JT'S$I98TD8[H*E7(M6@9
M+LTJY"(R(^%(+L4I1S(JTW6=A7%UN9:BNTB:V0=<I+TO-&A\FAN'(KT4IV8[
MQJ+T4IP:!H12B\MO&9K*$2..%K04]04KYAJRQA*.U$JD5ZW(9C=E<ZXQR.H6
MDM[W`0M9JRPGM'$H@D+DTPX8@JKC*,116X[D*S7BR!O,F3G&TQ[S\[)Z$H[D
M\"E'4CCCB`K/S?=]SL\/PKI!I/=]P"#6*JL&4634F-$;!`Z-@AJ3GHE$CK8L
M2KGS$4?:6WQJ-#0QBW)A61<O(V=E+!<)CY(W+N7R<D(91_J(1G.1<ZV?C:B[
M3'IJU66ZBS$F>UK]H2[?-PU<-JQ)5];)*10+V\.@G;GV@+-F'5+%O*?(>QJD
MU:O(D]Y3Y*E2N.\A>XFP5'NT\9D:BUG,3BOK:L*16L'W#)7I0[G&6RWGNE=J
MFG3CR&W8QF1F?VTN/S,;MB>%V[2GU]QF;;XLEH!\#A,_)`HQVF(4811CE&"4
M8I1AE&M(KT72E*ON7*DYU082;C0X%.F?M68I!+#+31(ABI=8B-$6HPBC&*,$
MHQ2C#".R^RZOBSI#=]/IMN.I:M^JH#H>NU'9?)"=<H=T!`+3;?S-W(?O9)B8
MR1T/]O>'8D!G%GSGWSB3>'XR%+'!4\^'+TT\1KKPX5,+\QR&OL;A)X<7]TK\
MAOP4<8V[/FRC8?W-U(>M),Q?9OX+F(I/;&8^;*U<X9Z_N18?>'YPC8>>'U[C
M6\^'KWRLOUWX\(6+>>SY\)T+W!9.PT\?E^*M^J-HW^IS-SI6>[CADV%=;NF/
M)_2/GBT9KTT//WH,J\<!?N2J8`]X0M:5?=/T_`\R@/C9[/D_````__\#`%!+
M`P04``8`"````"$`N`E&?V(#``#0"@``&````'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;*Q6VXZ;,!!]K]1_0+QON(3<4,@J8;7M2JU45;T\>\$$:P$CV]GL
M_GUGN!4,3;-57[@,Q\=GS@RVM[<O>68\4R$9+P+3F=FF08N(QZPX!N;W;_<W
M:].0BA0QR7A!`_.52O-V]_[=]LS%DTPI508P%#(P4Z5*W[)DE-*<R!DO:0%?
M$BYRHN!5'"U9"DKB:E">6:YM+ZV<L,*L&7QQ#0=/$A;1.QZ=<EJHFD30C"C0
M+U-6RI8MCZZARXEX.I4W$<]+H'AD&5.O%:EIY)'_<"RX((\9Y/WB>"1JN:N7
M$7W.(L$E3]0,Z*Q:Z#CGC;6Q@&FWC1ED@+8;@B:!N7?\T'%,:[>M#/K!Z%GV
MG@V9\O,'P>)/K*#@-M0)*_#(^1-"'V(,P6!K-/J^JL`78<0T(:=,?>7GCY0=
M4P7E7D!&F)@?O]Y1&8&C0#-S%\@4\0P$P-7(&;8&.$)>JON9Q2H-3'<S6R\6
MWG*]`II'*M4]0T[3B$Y2\?QGC:I2ZEC<A@7N+<M%_+S!P[W!SY>SQ<J>.R#R
M+Y-:=0:5(7=$D=U6\+,!708294FP9QT?B%LG:MF=-W^R!CQ!DCVR!";\'I"T
MA'H^[US'WEK/4(.HP1S&&&>("%L$E@[D=1K!H/^@$5E0(Y8311_:0$^T)JA%
MZ(+`J+Z@Z;9IO4%P8,*UYXV6^:'&0`NVXL)^9&"&]Y:Y$0R570XFUPO3@(;5
M<S4K.I#N!;1>WPMLH!6T9=O)5[<0\E126PL.=<2%O[OGW%S3U8%T79"SKLM=
MH*[+U<)A0QE-I%]`Q],*&#8@<*FGU>NT#BJX&BNK';NL#(<-E361R\H:T%#9
M8EH9[F_:8G"-9SALJ*R)7%;6@(;*EM/*-A/*G.4,5]LW+E7(-!1;1[0^6W4Z
MJL4B[$!ZGSG0GWW3+A>Q0@^G;T,P0Z]WUMK\OU$C`1-+^#_]@;#CZM8T(<V;
MC:ZM'@BH3EN]]=8[34[%D88TRZ01\1-NJY#,;MN%NSU_[R*!%C_@66`J[OKA
M)'[NP^(YYME[_KX^4^@3>'[H30PX+/RP6I!U_,:';AA/<'!L4%IYH(]PNO.,
MU7V"\T1)CO0S$4=62".C"1AC5QTMZA-)_:)X"8;!_LX5'"2JQQ1.CA1V,!N7
MLX1SU;Z@_=U9=/<+``#__P,`4$L#!!0`!@`(````(0#R0*=8`PD``.,E```8
M````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK%I=;^.X#GU?X/Z'(.^;V+*=
MQD;;11-_`KO`XF+O[G.:N*TQ21S$[G3FWR]I2;8H>C*>P7VIFV/R2*1(BK)]
M_]N7TW'VN;PV57U^F+L+9SXKS_OZ4)U?'^;_^RO]=3V?->WN?-@=ZW/Y,/]:
M-O/?'O_SR_U'??W4O)5E.P.&<_,P?VO;2[1<-ONW\K1K%O6E/,.=E_IZVK7P
M\_JZ;"[7<G?HE$['I7"<U?*TJ\YSR1!=IW#4+R_5OHSK_?NI/+>2Y%H>=RW,
MOWFK+HUF.^VGT)UVUT_OEU_W]>D"%,_5L6J_=J3SV6D?%:_G^KI[/H+=7UQ_
MM]?<W0]&?ZKVU[JI7]H%T"WE1+G-X3)<`M/C_:$""]#MLVOY\C!_<J-"A//E
MXWWGH+^K\J,Q_I\U;_5'=JT.OU?G$KP-ZX0K\%S7GU"T."`$RDNFG78K\.=U
M=BA?=N_']K_U1UY6KV\M+'<`%J%AT>%K7#9[\"C0+$2`3/OZ"!.`O[-3A:$!
M'ME]Z:X?U:%]>YB+N_GLN6S:M$*J^6S_WK3UZ1]YTU444EDH9;@J96^U".X<
MSX6QII)XB@2NBF2U$.O`#59(<F-T7RG"58\.[KNA`'2=K7!5"L&TD59*$:YZ
M)'?AB^!NW1EZ8TCP93<D7'_,.,C/3A&N2A'7Y<9(H5*`ZR3CEC(0NKB*=^WN
M\?Y:?\P@66')F\L.4]^-@$P'E!RZ#[%O11B$%I(\(<O#'&8/0=1`6GQ^=-?N
M_?(SA/)>R6Q&9*C$5DM@W")M;`.)#:0VD-E`;@.%`2S!";TG(*S_#YY`%O2$
MMF&C@<$UPC);2VB5V`82&TAM(+.!W`8*`R!F0R*:9H]7$KW.*/PPA[_&.EOF
M;*0,5"5MSY8A,4,2AJ0,R1B2,Z0P$6(GU(WI=J(P9`14`,-0.Z"5$(UZSUK<
M7DA[(V9(PI"4(1E#<H84)D)LAQ)HVHY)'D`:_&"2(TOG%&W*1B("ZK#A)M_R
M0"^DU6*&)`Q)&9(Q)&=(82+$`["2I@=N1SD*4T,E8AD:6(;V0KVA#$D8DC(D
M8TC.D,)$B*&P;9B&RGJ^N`/'W+89]:C-$@F,/&9(S)"$(2E#,H;D#"E,A!@(
MZ68:>-LJ%*96243(S@8WF:U$?,@'(XA7=&WC7DBO;<*0E"$90W*&%!(1`LLE
M,11VX^F&HC`U5"*FH1+Q1;<_"\>U$C7N[_<V*HYN;MV.G"K$ZXM[UFOAK@^L
M5@',^_N:M3!9B<4N%!+39`Q>(1;?C=U.CUJO(`$ET5C5.[JJ6RTUQ'BLH55O
M8:*ANQY*-32$4::A@2O7T,!5:*CCHL9C7V)T8K<#VY5=#.Q0VJT;!0D(J-[D
M,+0MEGIP1AF$W/6:2L6*RJ.%W>)*]("$*W0H5ZJEAI8HTQ!1M">1CTXBM#;A
M8I3+F`3U,39!AH^[`(/SQ_<C3'9/Q-T2@@0S/!E:S=#6E5+>$"BQAN!.OTYN
M:*5-HJ3@&*`7.-70P)5IK@'*-43IK5PO-!>466,2P]I1MV%39;CM.Z&I6C`S
M-"5$0M,-[?W3E5(>7(8YV6$1:RF:V2PVU8@DQ(RPD-5,<<&\M),S37]S$KF6
M(I,(K4VCT/3?F@1U,G9OAI.GQR8J6M5/0E9LLNJGI(:*%;L2\@*U1P2.*X05
M.XD2(J'9#S@XDK'GE'V]\MS5RBH]!2&G#L+F[J<<A(J6@R1D!:0UERT^60%%
M;XCD6$,T;UCR*OKN29`*M7[$P4.,/A^GMX*[4%*TB!O!3=V&K>)/N4WVF*3F
MJ;;3K'GP!)!6_"T>F\!M_M`DQ!JZ'5=*SRQY"C(3E+'GE'V]$J&_MB95:)F1
MC1=;S9]RD.Q1@5DOZ<:5$$D\Z(EL!TDIW^\58Z7H#UR)ADQW*$73'8PKUXH#
M5Z&A$>NQ_[2L=X/NP-"^5?M/FQIJ,:SW2,WWH$ATP?WDRB:6>$+UM68W(ARV
M/4HICU1(7O*EE&^V(\)A2:=&)%Q&5J@\5%*F"Z=,(E<V6I.P:F.AI":F)DR5
M^1X>J<+^AZ[_J[Y\R_70L?2^1Q*KNDG(/+JY#(HYE'`HY5#&H9Q#!8%(1<)C
MM&VV[W9=V`\^D>B8J.T*(D=UX=BMQB"E4S?F4,*AE$,9AW(.%02B[L"6W,C`
MD4PSEAM+B[7<&AH*Q99#,8<2#J4<RCB4<Z@@$+4/6^#I]LF&V2PE<#9&DV$$
MO5A;!7WGT#Y(:<6$0RF',@[E'"H4!!>@IR9C]SG=9-FK$I-5^VJ:+*%O']]%
M+S!8JVB,`[R6&EJ33$/]@P&KLN:#@&8N%#1F._9]TVV772*Q74(!K?96;[W%
MDST$!3S&U'.*-318FRA(OI*3&X"&C`U`*PY<N88&KD(K=IZCRXV-W'239=M'
M3)80YE!_\A&.W:_C,17S8,CS6$'>NNO776>%;])HMY%PM51#@\&9A@;RG)*O
M?<_WK?V[(%K4)]BF3?>);.J(3R1$6G3AV"VZ4%)#.,<*"K`]^?SHW[F.L!KH
MA&NE&C+#@G'G%K<;.G;W6VBBD3#!5FVZ2V1C1UPB(2M,+..V^.;0#A,)J3`)
M/?")W8HE7"W5D!DFC#Q74HI\[?IW_MINBS03[S]Q?4VG&`^LI_>?'8G5![`^
M;ZNDH-D<2H:4"GR5/Z'K!+Y5:A*E1XH(8\\X>ZX@Q1[Z3A@*B[P@Y#2#QKI#
MHS.?UAYB)PK10,)(0M"1:#]LE90!Q1Q*.)1R*.-0SB'\2J*+4OF]0_<>5G[U
M(-].G\KK:[DMC\=FMJ_?\8L&R*O'^QZ6GUML1*B_M[#O!!&\#`+[;'P5P;N3
M$?PN@E<.([@+(T`K.W)'.#!V-WU[#(%?@71)8]V!4RBPC8T#'4V$/08?9RN\
M*(;MEM^!C1MTQN[`9RA/8UP;F-C8O#8")CPRPL:+X(4J'_G)!_Y1I_@1O(7D
M"MMU!*\^1O`P@M<.',_""%X<<!R>+43;40?"(X8(3]%<)X$[>)CF=U*XDX[>
MR>!.-GH''C9$>,(&MF6_NO")S67W6OZQN[Y6YV9V+%\@8)WN$'V5'^G('ZTZ
MT3W7+7QD`UD)'US`QU0EO(9R\-CW4M>M_H$#])]G/?X+``#__P,`4$L#!!0`
M!@`(````(0`Z7%]H]@<``)@G```8````>&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULK%K;;N,V$'TOT'\P_+ZQ=?,-21:)%]LNT`)%T<NS8LNQL+9E2,IF]^][
MAAR)XI"U(R$ON<P,1T=GAH>4Q-N/WX^'T;>LK/+B=#<.;J;C47;:%-O\]'PW
M_ONOSQ\6XU%5IZ=M>BA.V=WX1U:-/][__-/M:U%^K?995H^0X53=C?=U?5Y-
M)M5FGQW3ZJ8X9R=X=D5Y3&O\6SY/JG.9I5LUZ'B8A-/I;'),\]-89UB5;\E1
M[';Y)OM4;%Z.V:G62<KLD-;`7^WS<]5D.V[>DNZ8EE]?SA\VQ?&,%$_Y(:]_
MJ*3CT7&S^O)\*LKTZ8#[_A[$Z:;)K?YQTA_S35E4Q:Z^0;J)!NK>\W*RG"#3
M_>TVQQT0[:,RV]V-'X+5.HG'D_M;1=`_>?9:=?X>5?OB]9<RW_Z6GS*PC3I1
M!9Z*XBN%?MF2"8,GSNC/J@)_E*-MMDM?#O6?Q>NO6?Z\KU'N!'=$-[;:_OB4
M51LPBC0W84*9-L4!`/!S=,RI-<!(^EW]?LVW]?YN',UNDODT"A`^>LJJ^G-.
M*<>CS4M5%\=_=5#`J722D)/@-R?!7Q?B(X['[]X7G>@;4'Q\2NOT_K8L7D=H
M,D"LSBFU;+!"XH8(#:.EYO^8`264Y(&RW(TQ.W#3%<KY[3X(%[>3;RC!AF,>
M/3%VQ+J)H,H!7HL1M+P#1LI"&*F:!/JQ,1C0H0#41$A`(*H+R-\U#3<4C/ZP
MN%G:%WK4,>C`!MRZ:['(B/M<FX)1V9EU<5D8#IJ;BW<MUL71W-T;IVX)DQM8
M>_8+Y5&XFOM]9(O50M'4IFG=!LF"X`:[N"X7A(+MB[-EV:4I"L3%VR!Y\;E]
M<47*;'XS[T\+9;*1:4L(@3,S*Y)MV@9)9+1<R<D]7PRH%R6R@6F+`!8)RMH@
M"0Q,2V!A')+6]NTDRF0CTQ:!+!;(VB")+`#5$EH\Q8WT['"5QP;&)H$L$<A,
ME`/-I]53:%1?:%IGH0JX@I;"0)L$M)F$UD8YT$@I.YUV>0(&6E<M`&Q"73J-
M/I<`VB@'`.EE!X":A.%R0*L'K+Q==K1)L"-D=,T#$>6`$YI-X*(I]*1OX5HY
M-X73)@%-+"_KH(URH)&D"MX2E+DO,E;F+FG:9".+I:+3I@OSUT<:Z:U`%BV4
M1%SI+A;J+A8VH8ZFNV(I\+1,DI:`K$Z4$5MK)0P\JO\V>*[(JURX\!5X/-"&
M9R37AD?2.X@]K=G6W&33%7@<9<,SNFO#(_T=!$\+MP6/35?@<90-SXBO!8^:
M5L+3^YS+K:?&V:+?F"ZC:Z)L=$9_;70DPX*\-Z'3\MWE+F33%70<9:,SXFRC
M$TN!$KNWS-O0714:TQ5X/-"&9^39AH=<DKPWS=N0!HK:LND*/(ZRX1F)MN$A
M2L(+%],!ZUA(F01>;:)F,P*72$GF@8B2BP5MSQQP"8P]5PN51T!KUX$N-*G0
M/-`'S;-:!(.VNJ&[?+!)\&86!K6'6ILHAS>Q5EP1$7>!"-D$#>L4SD@_`VBC
M'`">U6".%Q;]*^>N#J$V"7*,[C.V-LK!1L+<4;,KY+",=Q;WD$TV.4;9&4`;
M)0%$'K$/$DS:GEVM\MA=S2;!C9%U#<U$.="$TE_F)G+UO3'9W!CE9@`\<.G,
M^,@CYN&`&:_R"&ZT:@MNC&HSM#;*X89DM=,W:IT)%D,>NR-6Z$Y3L4F@,Z+-
MZ/1`1#GH?#J.^=FWIUP1C]ADE70F1=Q$.<A\(C[LV3O2HMW=4+#)YFTF==Q$
M.>B$CE_I>%>K(S;9]$BM-E$.`!)1T5;!@(?LB,6XVU/:)+B1*LX#?3WE47'>
MNO1M*U?&HU:@.TO,3,JXB7)X(WWM\':E<!0M](!-=N&DC$=ME`00^V1\E@S1
M`Y7*1L<F43NIY";*0==+R6-7R1N338]4<A/E`'@G)8^U('?G/)L$-U+)390#
M32CYY=:)7;%N3#8W4JQ-E`/`)];!;%#KN((=:Y--SUP*MHERT`G!OD*/J\DQ
MFRQZYE*3390#0&@RK;0#WA'%KEBS25`CQ=I$.<B$6%^AQI7DF$TV-5*2390#
MX-TD.78EF4V"'2G))LH!A[OJ2C+5+5Q&0]ZRQY1***(V"712KWD@HB2ZY/WT
M6J6RT;%)H)-Z;:(<=+WTFF:#H*<QV9TE]=I$.0`\>KU8#JE=XBHVFP0[4K%-
ME`.NEV+3LY1DATTV.U*QFX'N<PG.!CBM/>0KC<HC.L<GUPLIUSRPV]?ZL('^
MN'[,RN=LG1T.U6A3O-!!`DS3^]O6K$\Y/"81CCE$-#4<3]P<@)">>+Y:0Y`\
M8^(%/.K[MC-F"8]B47J2*:ZC)J?CH2,8ZL""XPGA";T(,`9;$!\VC,$.P.<!
M!UB:?1YP@&71YTG@41_+);9X!H_:<TM/A#%X[O!DBS`&#P0^#[C&?MSG`=?8
M#/L\X!J[5(\G!M?8(7H\(<;@-8;'$V$,W@_X/.`:C_<^#[C&`[?/`Z[Q9.OS
M@&L\,WH\`7C3!Q,DHR'&X&6A9TR(,7A7Y_.`:[PH\WG`-=YS^3S@&F^9/![0
MYF4M`&OXCNH9$8`U?.ST><`:/DSZ/&`-WV9\'C"`ST6N!^>7'ORY,,`3_XB+
M>^.I8)[XAWCUH,]'R:+0G/$,>$1%O`5!/;SE0#6\Q4`M5"DF[85Q+NJ</F>_
MI^5S?JI&AVP'N9NJS7.I3U;I?^KB#*7%Z:BBQHDH]><>)^`R',51[[=W15$W
M_X#127NF[OX_````__\#`%!+`P04``8`"````"$`DBA@TY\%``#<%P``&```
M`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)Q8VX[B.!!]7VG_(<H[)'8()`@8
M-;1Z=Z1=:;7:RW,Z&(B:Q"A)7^;OM^PR:9=)0]AYF!F<DZKC4^53X,6WC_+H
MO8FZ*62U]-DX]#U1Y7);5/NE__=?3Z/$]YHVJ[;9459BZ?\0C?]M]?-/BW=9
MOS0'(5H/(E3-TC^T[6D>!$U^$&76C.5)5/!D)^LR:^%CO0^:4RVRK7ZI/`8\
M#*=!F165CQ'F]9`8<K<K<O$H\]=25"T&J<4Q:X%_<RA.S3E:F0\)5V;UR^MI
ME,OR!"&>BV/1_M!!?:_,Y]_WE:RSYR/L^X--LOP<6W^X"%\6>2T;N6O'$"Y`
MHI=[3H,T@$BKQ;:`'2C9O5KLEOX#FV^BV`]6"RW0/X5X;ZS_>\U!OO]2%]O?
MBDJ`VE`G58%G*5\4]/M6+<'+P<7;3[H"?]3>5NRRUV/[IWS_513[0POECF%'
M:F/S[8]'T>2@*(09<TTCET<@`'][9:%:`Q3)/O2_[\6V/2S]:#J.9V'$`.X]
MBZ9]*E1(W\M?FU:6_R*(*5)=$&Z"1,#>/.=CGL0LGMZ.$B`CO<''K,U6BUJ^
M>]`UD+,Y9:H'V1PBGW>&/+J]?K55H*>"/*@H2Q_:'7;10'W>5BR<+H(WT#0W
MF'4/AB(V9X0J!=#K.,+.;8[]JI^I*+"BHJ13W-:X`+$[;MS)VX-(.@AA`@H-
M9Z+`4&DK,0MG75PDAYA)QW9C+9#,DWLR*_#2AVUU6TY3)S%"IKI6HW2:I&$8
M4LB&0*9I1""$'#2Q+8MJH@@.V?5"J9=<>3YE1WD08\EC+1`&4\K@>F8%IO*P
MT-4',3/L9;!;5QS[.9_:SPFOV3V\%-CAQ9R\:\0@K^G,SJL5V^!SK1@AHD:1
M=<ZO"Z3`E$CJ5@8AAL>DAX@-X$ED,R7$4DIL6.^HEYS>88RV[QHQ5N]8"X0!
M@U8=KHU&4W$B-[7!H#J<3>S-8YD(@BEU/@M-R2E3'%PXAA9JG_QHXNAB,$AN
M%$]B.[=AAV$00NE3<LHYAY-#GR7D7#]DB#&9TZ2'FXV((W(T*3EEI1:Y89W%
MT(`)2;?W#<8HZ%3/*(AA$!+%7QL$N\O8-=II/M>Y#.;,+B$*&79H[88=)QU`
M-72<_;IMJ*]$CF\PY@S;M0%A[CYN&.1,_PJWNSR?]9@^B]RC8;OZ*)V$I&Y&
M.X*)>4)ZE*IWE_LSM&YHG&YJ,W9Q>"U_-WRL%9K]+LMGEY[/6.SJ8YOZB)$O
M!(8-05P[G8[OW^@L]&[[5#)V\0430>?.Z6-'$%?8\;M&@D:[X\AU-@.RYI&]
M0BK''<\?YESZ+>H-C+G694`V"]OKU7E4?[JZ4U[*>N]V5(Z&36OGFI8!8>W2
M,"*'"EN+0-ALPK[F^;^<GU\Z/^.?2F@2:P,Z]]BLI\E<")G^5$_'^P?6&<V;
MZ,G=;R#<=O@DY.3[E]'3AK`4?D9^+:@S!@82[1D'W!T'ZJ<KS(RSH).P9R00
M#(N2Z`I39R@,9-HS'+@['+AM_&PZHWH936T,3_5Q^N(L.;-A(%$T>UI[=T9P
M!*&D+(YBTH&&*,&XFZ%=>M<<X3@`R!3C[APQ(-N%\#6]0K/?-2=XSYS@[IPP
M(-2G[V#84X(\)\S4+US;#:]/,(VF[IRXLAB,)8N]0I,[(^)&<O1X4A3F#J@(
M079V:X5F5Y9N#8(;V16:;IWQB^P(LK/CBG$&'E[Y#1DYAG^#SZ71)ZY_ZHA+
MWZ:#;^D5*H;CXC>2H^O>*`6"[.S6"LWN6/.-['V6?%$*!)F[(<=MT3[@LE65
MU$`B3L8U\L/+5+QK+$6]%QMQ/#9>+E_512F'BY5NM;O$?>#J(LQ97\/EKKX)
M#;H'<+=ZRO;B]ZS>%U7C'<4.0H;C&;"J\786/[3RI&\XGV4+MZKZOP>X11=P
M+1B.`;R3LCU_4)>.W;W\ZC\```#__P,`4$L#!!0`!@`(````(0#*QWM<F@8`
M`%<<```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%G;CJ,X$'U?:?\A
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M=O?#,G\JMW755/MV`>9<W*C-.79C%RP]/>Y*8"#=/JN+_<;YR!Z$'SONTV/G
MH'_+XJW1_I\UA^KMM[K<?2[/!7@;XB0C\%Q57R3TTTZ*0-FUM$47@3_KV:[8
MYZ_']J_J[?>B?#FT$.X5,)+$'G;?>=%LP:-@9N&OI*5M=80-P-_9J92I`1[)
MOW77MW+7'C;.,ERL(F_)`#Y[+II6E-*D,]N^-FUU^@]!3)E"([XR`E=E!-)K
MHNY2Z<)5Z;)@P0(OO./^@;(!5V7#AW\G;@!H=AZ`:[^!^-X-A,H&7$<;_GK%
M5A-HN!B2+L(\;_.GQ[IZFT'9@-.;2RZ+D#V`91G:X(>AA9A*G8]2J5,%=`/Y
M^/4IBA[=KY!"6P5)KD!B$Y+:D#4S(?P*Q#<AV17(TH2(*Y!@@+C@B,$;D%RZ
M-ZXG>.\%"29>6`]F.T<E-F3MF9#T-H3?AF2W(>(*9#7LQ?`"E(GN!9D32S@T
MWO>&5-HX<),A)];A8!Z]@9"P2Q@_]DC*I/HR"2'7UR)O'1-'9_KZ/(SB>`QP
M=V^!@*`[Y_2(0PW?SU4J$:Z$3(*0[G[=!E(41$@^#.'P&[W?(3A5R:A`:`(C
M8%"P]Y.02H0$\6J"$(T$"I#$RF=>2$+,J49&!4(3&!S@\+F?@U0B',@IDR`$
MM\P"GYPP*2Z/%/G[^(SBA28P^$0FG_>+1X)-'C$Y)Q*$C!M->X$\?N<AR7?>
MK\IN+,_LC`J$)C`V+J<VTA%N5[]4(@2(IQ.$:`10@)$)_("6`\5G5"`T@<$@
M_AD&4HDP(*TF04C0E3`CBVF_V#N<]P(9'XK.^L4>+32!P87!P4O#,:%!2RW"
MAARI26<9NGTW9<D422T)MR29)1%*HBK,7WG>F+HF%=F'[\XLAMU;;RST<$\4
M1FTABADYC5,%&+GR6RJ9I2)TB4E,MM;[B6%#-HB1&D@88I"8[_GDN$W5NL[K
M?8W,TA"ZQ*0E>Z9&Z_TCC&&'U>E$I$82A4$Z\VM\M#:-3?&62J8`HPN$+C$)
MR?XYG1!V6YU03/R?,*TC8YM7$KT:M'I0G*A69MD1AITY/"C]N*QD1YW."ONO
MP8I42R*?[>#TP(,.PF2.<:FQS,BQPHW5^9(L9\/R</+I$C-<LK5.)X:-V"!&
MYQG6-VMY)OMKLK=T6.[WQ@?)585L6.X5A"XQR<AV.YT,-F>##!UL&&)4,87Q
MD@!2!1@K@UN2[)81H:N8A&3WG4X(>[5.B-&Z2!B"5.VL5O1Q,%4`U8%),7)#
M/?8"ZR'!`,RC(*;9*88;0$!-MK(_3V>+W=QD2^<AIK5\=7:@I.<?KE?P:&\6
M'[>T,DLB=(G!PK\R3-R>[3HM<YA8T\I2F#'74B5!,BO&0M\G2MQ2RBR)T"4F
MEY^:)GQ[FEB3NDD4!G<>K>DS3JK6,0M)Q^94F40]&Y2'(T.7F`PA?_2<F_8<
M[DLM,UHQV42B,'JT4`LY^U[L^18Q1(PZF65%Z!*3"ADE)E*Q1XJ8U$/B]Q.#
M/*&72Y)BZ;#<NYL/DJL*V;#<*PA=8I*Z:YR0;PMI7,AN$X7!S`H#TI?38;G?
M&Q\DDHRED`W+O8+0)2:9NZ8(^=Z4DK'*"#&84O,XI'66*B-C1G%+DBG)#XT(
M7<4D1*:':6\V?7N*8)Z5<_T8T;LU56JX3;:,PXB4'%>(D6QF280N,;F0X6$B
M%WN(8!Z9>1(?0?VL9W:;=%CMF?)!(C-N3CR3#:L]7N@2D]-=\X-_;7X@[SP2
M!<(7C"R(`A*$U`#05T'<6(WC96"QPTV@_?DZ@)9F^DLH$UV43;9WS0_P,8>6
M%_/(@9PHT)A1J9*H0YRQE1?0=[#<TLHLB?R6)&^OL<!/0_CAX)*_%'_D]4MY
M;F;'8@^O>[U%!+5>XX<A_-%6E^[5^'/5P@>=[M\#?,`KX#6#MP#POJK:_@?D
MBCM\$GSZ'P``__\#`%!+`P04``8`"````"$`L%;,780D``"GP0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLG5MSV[BRMN^_JN\_I'R_'>O@DVHR
MNV2>25$B=9;N/(DS<4T2IVS/FK7^_6X(:#:`%U&L77LN1LZ#1@-$-T"P`8*_
M_?>_OWU]]Z^'YY?'I^\?SGKG%V?O'KY_?/KT^/W/#V>K9?I?-V?O7E[OOW^Z
M__KT_>'#V7\>7L[^^_?___]^^^?I^:^7+P\/K^](P_>7#V=?7E]_C-Z_?_GX
MY>';_<OYTX^'[Y3R^>GYV_TK_?/YS_<O/YX?[C\=,GW[^KY_<7'U_MO]X_<S
MK6'T_!8=3Y\_/WY\B)\^_OWMX?NK5O+\\/7^E>K_\N7QQPMK^_;Q+>J^W3__
M]?>/__KX].T'J?CC\>OCZW\.2L_>??LX*O[\_O1\_\=7NNY_]X;W'UGWX1^@
M_MOCQ^>GEZ?/K^>D[KVN*%[S[?O;]Z3I]]\^/=(5J&9_]_SP^</9N#<:Q]>W
M9^]__^W00NO'AW]>K+_?O7QY^B=[?OPT>?S^0,U-AE(F^./IZ2\E6GQ2B#*_
MA]SIP03-\[M/#Y_O__[Z.G_Z)W]X_//+*]G[DBY)7=GHTW_BAY>/U*2DYKQ_
MJ31]?/I*%:#_O_OVJ'R#FN3^WX???QX_O7[Y<-:_/+^YO!Q>W5R3FC\>7E[3
M1Z7S[-W'OU]>G[YMM%3/Z-):^D8+_1HM@ZOSR^N+08\*?:N2@5%"OT9)[_*\
M?W/9N[Q26HX4/S0YZ9=S7IP/^Y?7-X?RC^0DO8?+IU^3L]^W+O](SBN3DWY-
MSIOSWO#B5U6]-MGHUV1[XS52CSW4E'Y/O,9;DY-^.>?UVZZQ1^ZHO4/YI3;\
M]=L:MM<YEOA$_^K\NG=Q.U".=:1E>^P(Z@]3ZENMTF-74'^8O,,WUIA]074?
M+O:--69GZ(DW]"[>X@X]]@?U!Q=Z^\8*LTOTQ+)O;.(^&U;]88JE"APQ2I_M
MJ?[@BEY('S^6M1L=Q"9OK2?;1`T`IM3>[5L:ML\FZ5L-^S9K]KE=U1]O:QSN
M8GW+$F]KG`%;0OW![7JTGN_U"'ZX(<3WK_>___;\],\[NLV285Y^W*N;=F^D
MM/&M0)NFNSG\[-Y`-P6E9:S4?#BC2Z=1_X7N:/_ZO7_3^^W]O^@F]-'(W*&,
M)Q&QA+KC*+6Q#Q(?I#[(?)#[H/!!Z8/*!Q,?U#Z8^F#F@\8'K0_F/ECX8.F#
ME0_6/MCX8.N#G0_V/AAWYF7#C#MC=@2,-[:M]Y[<K?,YZMK_%SZGU"B?XRK<
M,;"<T'7!B"4X2^R#Q`>I#S(?Y#XH?%#ZH/+!Q`>U#Z8^F/F@\4'K@[D/%CY8
M^F#E@[4/-C[8^F#G@[T/QF,@G3'95&,PWMBVGN-@-`5P'"P\K^6Q2TE_.*/_
M6V-7WW6<.RU#-WFN3@0D!I(`28%D0'(@!9`22`5D`J0&,@4R`](`:8',@2R`
M+(&L@*R!;(!L@>R`[(&,QXC0JF,TZ]BQJ^-F-#,YP<V4--UE:8IA^9EW![PS
M0NZ-=.`Z8]0)L3/&0!(@*9`,2`ZD`%("J8!,@-1`ID!F0!H@+9`YD`60)9`5
MD#60#9`MD!V0/9#Q&)$8FFTX1K..';LZKD<SVQ-<3TD?7(\+NS.$9IZ6,PX]
M/^N$.%L,)`&2`LF`Y$`*("60"L@$2`UD"F0&I`'2`ID#60!9`ED!60/9`-D"
MV0'9`QF/$8FAV8;C"*4<NSI^1J/5"7ZFI%T_TT0],%I^=NGY62?$=8R!)$!2
M(!F0'$@!I`12`9D`J8%,@<R`-$!:(',@"R!+("L@:R`;(%L@.R![(.,QHCM$
M$2+'KHZ?T?/V"7ZFI%T_T\3SLRO/SSJASL^`)$!2(!F0'$@!I`12`9D`J8%,
M@<R`-$!:(',@"R!+("L@:R`;(%L@.R![(.,QHCM$$:+81HZ?T<3J!#]3TJZ?
M:>+YV;7G9YU0YV=`$B`ID`Q(#J0`4@*I@$R`U$"F0&9`&B`MD#F0!9`ED!60
M-9`-D"V0'9`]D/$8T1VB"%%L(\?/:&+E^)D*J]$:"=UZ3PRL*46N"VKBN>"-
MYX*=4.>"0!(@*9`,2`ZD`%("J8!,@-1`ID!F0!H@+9`YD`60)9`5D#60#9`M
MD!V0/9#Q&-$=H@A1;"/'!=4Z#/@@+8ZIA93C`9%#3M?I#+JT`B"(8D0)HA11
MABA'5"`J$56()HAJ1%-$,T0-HA;1'-$"T1+1"M$:T0;1%M$.T1X1!7>5HWPX
MLVQ+X5UD48"Y%G?=3T61[96%7_B<#CI3>(1'K#NU&DCU\D:Z6V^D$RG.&"-*
M$*6(,D0YH@)1B:A"-$%4(YHBFB%J$+6(YH@6B):(5HC6B#:(MHAVB/:(R`T[
M<[,AR0V110'F6MQU0Q59/L$-=2#:<4.-R`VY7E$/4(PH090BRA#EB`I$):(*
MT011C6B*:(:H0=0BFB-:(%HB6B%:(]H@VB+:(=HC(I\#0Y+/(0L8G%:W;#G7
MYU2H^02?,Y%I>^C3J*\WS*BET$CM:U"CH:#8H"%UDBZZTKOQGGH3D6+_31%E
MB')$!:+2H'Y?=0^W&538\X1F,%%2NQDTLJXY4ELT_&;0:-C7Z\X7/2^.F9@\
M)"`M8-0(RECJL._JL/R<,^HT>Y'X0@18<VE0J#U4X.V$]C!Q.KL]-+JB.5]G
M\/[MA7]'U%)]61F-U>X4:K5K\B$KH[?XD(@47TUJ$&U18)2QE(R'.2-7O;>&
M5H@4ZRH=]:[SJ.C1"8VE@TW.N*W1M=T[^K>>!2/*`?YDT'5WS8F1NKP]N-BM
MYV`I*Z&P@]6\GE1FI*[%YW+)R$U2>$5YO;F4'.&BW$94<9`3&E&'3:@(KLV=
MVF%$CN-YG!_`-5*.Q^F,EN,D1HIVF:C](;WS2\\6*:MQW1N:46N^MOT/"BO\
MPJX\;RQ_59C;D.I!_X2&U'$!IR$U\KS1LV[4,P$%>Y`WR/9&C8PW>MT_91W4
M)L><T=3'=D8HJ3"ZPB65ORK);4+UH&HWH81$?O%DH)]PG<;4R/-*/PRG=KBI
M6X4]#AI$/UW;]&Z\X$EB,G:..O`TIZS9'A6AL%RDCA16^(5=>)VK%#74*YTF
M54]&3I,>;\B#N/M8S\CJIE&`Q0&6!%@:8%F`Y0%6!%@98%6`30*L#K!I@,T"
MK`FP-L#F`;8(L&6`K0)L'6";`-L&V"[`]@%&>VWTLWW/,OKX+@1#KD";;ISL
MKD.JQS6[C__"(?73G=VS::JG^JQ=MRC`X@!+`BP-L"S`\@`K`JP,L"K`)@%6
M!]@TP&8!U@18&V#S`%L$V#+`5@&V#K!-@&T#;!=@^P`CAT2CDT,&8,@5R"$=
M2=<AU3/:"0ZI'^D<A^R>\F00[]]Z=XR(9ON'6XW,26)$":(4488H1U0@*A%5
MB":(:D131#-$#:(6T1S1`M$2T0K1&M$&T1;1#M$>$;DB&)(\$5G`X.2'MISK
MANK9_00WU(_ZCAL:)+/`J`\H1I0@2A%EB')$!:(2485H@JA&-$4T0]0@:A'-
M$2T0+1&M$*T1;1!M$>T0[1&1SX$AR>>0!0Q./F?+N3ZG(APG^)P.B#@^9V(D
M\C`2]36ZE"?$V*!?!*%$BA\M4T09HAQ1@:A$5"&:(*H131'-$#6(6D1S@VAD
M@+F[BLB<8!X=P'',8V(ZP^YI/5(OO*@PCZ#8H)\'QT1`+*/56/&R#*5R1`6B
MTB#=`H>H6L52\O0T8?2S0%LM`ES+*:(9H@91BVAN4,A.*AAT@IUT[,BQDT97
M8I1(O6>DHBJ"8H-NJ(-U3Z;]6V^Q*Q$I;H:4D73)C)'<+')&MOK!A1<`+$2*
MU9<&7<G";\5HT#G>1#(>J7TM4JQ^RDAJ/V,DM6\8':U]*U*L?FZ0KKT[/*J0
MT0EVU1$FQZX:64:,U&MCOET-HG&ZL^O@PHO9))Q1FC1E)`V?&70C`8V<I5SU
M7JRK$"ENF9*1J*\8224F@H[4OA8I5C]E).IG!EFU;UCJ:.U;D6+U<T8']:Y=
M51#K!+OJF)=C5XT<NP***:JD3'TC%Y@@2@VR>D_&4K81M2[G%CJX\**CA<E(
M4MP,):JO&-E&A*K67`FI_90S"IJQE%2U,>AX55N1XJK.'?6NQ53D[`2+Z4";
M8[$N]F9[J1<WCBC<<;"8W'9B@V[EL2UAI.]$-\/!<.CUII1%9/3.4'?.4A0M
MZ3H^A!H+EKH\Q,0'Y]=>1+AD`2FLPL(F+"474C/2%](;#B]ZWMUDRB*B>X:Z
M&Y8Z>B$M2^D+Z=W0._CNLM2<)0ZE.1Z@WCL]P0,.XFX<TR#E9%UC#_Q(:F2D
M;BP/,.A6.E7"2'I0RD@:*D-=.4N)KH*1W-Y*1J*K0ET3EA)=-2.IUY21Z)JA
MKH:E1%?+2.HU9Q0PCXJOO+V##DPX1G3?&:0"-99Y/%>/1(I'C9B1S`42@P8W
M>K67CGJX]OPZQ5P9(VF#G)'H+@PRRQV]<_\5YA+S5(Q$\X21:*X-,K6^'O8N
M!UZ<?XJY9HQ$=\-(=+<&=;4>^#W/R>/V/!6R.,&T.L)AC[T#$_1P>YZW8!*)
ME)C69)3.F!@IY8F=F_3\%=N4=4G&C)'<J')&(E6\27V)&2M&HG["2-37;U(_
MQ8PS1J*^823JVS>IGSL975.K2,$)IE;BWB"KD=>+/6>+!IV4F%HC<D-&B9%2
MU>U,/;B`CFQTT1RZD^KY^QTR+#%G]5)BP8COAQ?G5U>WUG_NW:IDI=+/*D:B
M=,)*!=6,G"OK>1/^*>LZ>F4SEA+U#:L7U#(R5]8[]]>ZYZSG<#&N5ZB`CNT5
M^OR'PR;AUR^/'_^Z>Z*6IW$[L)(SH!%8G_XP4%H\9]'(O2/WO`?.R&0D*?:,
MV*"!N'YBT.50;QRXN%+'^[CV2EF39,L8B?)<E%L.Y:__%D9JJ#<JT-$^GE^6
MK%D*JQA)81,IC"^N-LA<26AV.65%HGO&2'0WHOO(A;1&REP(SB[GK/E0F.L8
M*@8$CD'G,U%75'ZQ?/IQ\(L3G$1'E9R;AT;NB-+SYMO1H)/B=HP-NI8Y1L+H
M^N`DP]MA_];SMI0529_.&$EWRED1Q6ADT$$?T96ZUM.0X;E_TRU9LQ16,9+"
M)E(87UO-2%]([W9X>0FCAVD1T3U#W0TK.GHA+4OI"^GUZ)P<MVO-675@]%!Q
M+'`2_8J!XR6!T8-";MWPH<-ACF=H1(>@B1$&/>^1.!IH*6?XT.A&GH02(W73
MX^'CZMKWL91E9#M,9I`^ATWO!V0I9X*"KF&JH,9'.@<G,'P8`2FLPL(F4IBX
M!ES<E*5$UPQU-2PEK=(BFC/":/5`1;%L0__"H#KHY1A4([5YH.M5`]_5HD,Y
MARW_?,TQH@11BBA#E",J$)6(*D031#6B*:(9H@91BVB.:(%HB6B%:(UH@VB+
M:(=HCX@.V^C,S88<WP58P.!TWH:=U[TIJ4C6"6ZH`U^.&VKDN:$WF8CH,4W-
M9TB*:Q\C2A"EB#)$.:("48FH0C1!5".:(IHA:A"UB.:(%HB6B%:(UH@VB+:(
M=HCVB,@-P9#DAL@"!B<WM.5<-U21Q!/<4`<>'3<T2&[@$4UX#W-H03&B!%&*
M*$.4(RH0E8@J1!-$-:(IHAFB!E&+:(YH@6B):(5HC6B#:(MHAVB/B'P.#$D^
MARQ@</(Y6\[Q.9K#G^)S!W'WB<R@6W&P"%&,*$&4(LH0Y8@*1"6BBI$\\$P,
M<A<>>EX(L18I'KBGB&:(&D0MHCFB!:(EHA6BM4'6POB&D3P?;"6C/6WRPFL[
MD>++WB.B8XB4#WTXLU:0QG<!QFYAR[%?!%;(E4E.&`T/XIYGZHCQ%45[K+FA
M'U@R&4F*+S)&E"!*$66(<D0%HI*1K))5!O7HQ1^NV,0P9S5_X*^_U"+%&:>,
MY,%VUNF7,AL6<Q;$^]YC8BM2K'_.2/0O.OTR,"Q9S-7O/9BO1(KUKPVR%CPW
MG7YIGZWDM"S>]Q[O=B+%^O>,I/[DUMI]>O0R$<N17VOH6J#O70&=N=6)=5D[
MKSJH<P=A%;-^^XV?-M#X83&#J%@N+T(4(TH0I8@R1#FB`E%ID&6WRB#7K_45
M6=6O4=D4E<TZ96*X1G+:3N`%;5J1XA:;H_Y%IU]N&4O,N4*T1F6;3IGML7#E
M.U2V1V7DGL8+K/D?N2>H(U]$QIX0V,`R5+'Q$WQ1A]*M2MP=--!(?&$_D\,2
M==2)Z?C)Q?G`N^O&1N)&8A")09?BYRDCNLINE(?5G<Q(T6(QFSLWZ!?U+#HQ
M$^<Y'WCC26DDK'I6!EE!GDFG1Y[^ZH[I&#MMS/*53U'Y#)4WG2)1WG9,5_R6
M@N]>!`YU+U#WLM-SU)ZK3HS;R5\G7V-Q&RQNV^F12]EU3.N^OO!BB7M431U$
MNZ9E`^H?QEV/^R;U&9;K+L:;-M`9BEI$6]T=SM4:Q0E=2"]I.%U((V=.;:0N
M=/BO!Y'A>`B9$H-H6Q-[?6H0K>H>[2Y:EY4Q1_6%0;V?UJG$3!4C&5$GC*2:
M=:=:+\Y<]Z]OKKSEDBEFFS$2Y0TC4=YVRG5;WIP/KR_L_[R!:(XJ%HRDH"4C
M*6CE%81&6V.F#2-1O64DJG>=:MU``UJ6\->3]IB->H7Q$M%.O0(\AWJ`9C^W
M+?4`.YO;`]1"P@D]0*\[.#U`(VM,C89&ZL+L!3KW!H'8"%AY$H.L83\UZ/AN
M@`PSYJB^,*C75>G6&V)+S%099(U+$Y2J.]57.MS?ZP]]Y5/,-D/E#4JUG7+=
ME/01`V]Z-,=,"U2]1*F5IYHVNWC==HV9-JAZBU*[3K5N$KH+^.O?>\Q%'J_]
MQFIO\GAP+_)XW[]N/`<CC[>SN1ZOEE!.\'B]XN)XO$;.F&^DNO'UUAN9XB%D
M2@RRAN[4H%^-^5J7E3%']85!/"[0MU#\M]9*S%4QDE%GPDC&M+K3K<>TFS[L
M:)YBKADCT=TP$MUMIUN/^?0=EJ$]Y/LSBCFJ6#"2@I:,I*"55U!O<'[ES1W6
MF&O#2'1O&8GN7:?;W!5O+JZ]A_,]YJ(>8+Q$E%,/`,^A'J`9VY:J?NF-9]0%
M['QN%U#K*R=T`;T<XW0!C:P!/!H:*3/"*G?SQI/8B%BY$H.<85\K^M6PKZ6L
MC#FJ+[Q*#0;TC1QW:EUBKLH@:QR:=(K$QG7'S,KY)=W87>535#Y#Y4VG2)2W
M'=,GCM#6#6^,FZ/N!>I>=GI$]ZIC1C>M4#L[H;SHXAI+VF!)VTZKE+3KV$^;
M:(_*J1MHXUH&H&[`_B7JJ1\P?-N54*?0&;0+NIU"K?;8G>)_M1%JJ->,G+YB
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M.=?BCB]>GK;T>1!W%Y@84;'=`##H>W?42*1XH(X1)8A21!FB'%&!J$14(9H@
MJA%-$<T0-8A:1'-$"T1+1"M$:T0;1%M$.T1[1/09#+W.20<GL2''=P$6,/C8
MM;CKAFJIR!X2CP]]%/KV%W\,<C<?^3>U2*2X]C&B!%&**$.4(RH0E8@J1!-$
M-:(IHAFB!E&+:(YH@6B):(5HC6B#:(MHAVB/B-Q0>X"UBXS<$%G`X.2&MISK
MAFJ5Z`0WU(M*]HST4B//#;V(1212XH9=1D8)2J6(,D0YH@)1B:A"-$%4(YHB
MFB%J$+6(YH@6B):(5HC6B#:(MHAVB/:(R`W!:N2&R`(&)S>TY5PW5*LJ)[BA
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MU*/CM%AL(CE%/U2_%BG..&4DU9\QDNHWC(Y6OQ4I5C\W*+`EZ%)%-T\PK(F>
M2CWO#AH<*T:(8D8TH%LM[X6-$Y'BJJ>,9*->9I!U*DS.4JYZ;S6A$"E67S(2
M]95!KF'U=;O;3?M>]6M6)AXQ923Z9P99U6]8ZFCU6Y'BZL\9X;[#2Q6G.\&P
M)O)G&U8CJWM&!Z6.K6.#>M;0E@18REFE(3*#K(;(6<IIB(&W#E:(%#=$R4C4
M5P:Y=C27:=6V[N1D[)^BNIE!5FT;ECI:VU:DN+9S1@&SJ3#7"68S43';;!HY
M9@,4J_5B&GOMLX@0I099PU[&4A)>S@URYCZ#@;?KH!`I;H82U5<&N4:#NM9&
MS*K^%)7-6$KJVAATO*ZM2'%=YXYZ9XIY=5JL\2#NQAH-<E]\'WC+CI&1LH^B
M,<@^C(B1636@HP_\D\-2%I&MJAGJSEGJZ,[`@J5XW\[`&W-+%I#"*H-HUXO<
M.5E,5KQJ1C0-ZVX9L/ESRE*B:V:0U5`-2QV]F):ECI8X9ZE#B:XGJ`C,VSOO
ME0[8V'$6@SQ/\*:!D9&R+C`VR#Z4B)'<C5)&TE@9ZLI92IYX"D8RSI2,1%=E
MD&M8?9%6Q6K.*<JFC$39S"#K(AN6DHJUC$37G%'`/BHT<8)]="3#L8\);MB/
M>8,+/PYVU4GQ\!$SDME<8A"],WCXML5MCS8JNIL!4LR5,9(VR!F)[L(@&K3T
M=S/\[64EYJD,LIZD)BA5&V1J/0R,+U/,-6,DM6X82:U;@[I:^X/)W,GC=CVZ
M!Y]B6B7N#<(:>5W/7_!1,T#*:!\?P$@>Y!*#G`TI`__TIE0RV@.<YP,92\E-
M+&<D)192HC:XWW0EYJD,ZEF+'A,4JT6U74UO3)IBQADCJ7EC4,\*<+<=LSL5
M#/3S3NQPBW"-K^(Q)_1K';YQ^K5&[JDB%][>G(CF5`?CBQ?'!O74:;`_OTLE
MEA@/"2EKDPZ0,9("<BOGD0(*2XP+*%F;%%`9Y/1QTQK'KZ`.%##%`F:,Y`H:
M*^>1*V@M,;Z".6L[7(%K<A6<.<'D2MSK[QIY_1TF75K*N@O%-!M6NIQ)ET%F
MTG7=N^A[\Z"4<\D=+C/(TIVSU-%Y2L%2/.GR#V\J64`*JPQR[\UP)37G_/GT
M<<HBHGQFD'4E#4L=O9*6I?A*_&%KS@*!F[D?DOI?[;ZZPDB509YCP#U>9[0N
M.69==((P>W#2,>F$J6&WTH"909:VO,LIVHJ.R9!:HK:J$Y,2)AT3=77'I')3
M5#<SR*I<T^44;6W'I')S1YO;@?W`T\%\>%C4\17S*XQ'&42Q3#9"A"A&E"!*
M$66(<D0%HA)1A6B"J$8T131#U"!J$<T1+1`M$:T0K1%M$&T1[1#M$8W'`787
M8`&#CUV+NZYX6JCL"D-E!KG+X_XGP"*18L^,$26(4D09HAQ1@:A$5"&:(*H1
M31'-$#6(6D1S1`M$2T0K1&M$&T1;1#M$>T3DAMH#K$GL^"[``@8G-[3SNFZH
MPEPG3&ET5,R9Q1I$/]U<=.!OX8S4)_#47$B>'F)$":(4488H1U0@*A%5B":(
M:D131#-$#:(6T1S1`M$2T0K1&M$&T1;1#M$>$;DA&)+<$%G`X.2&MISCAO21
MS%/<\"#NSJP-\D9#;T(<B50W&B)*$*6(,D0YH@)1B:A"-$%4(YHBFB%J$+6(
MYH@6B):(5HC6B#:(MHAVB/:(QN,`NPNP@,''L2/GNJ&*&[Y]-%0?2?4>\!C)
MY#9"%"-*$*6(,D0YH@)1B:A"-$%4(YHBFB%J$+6(YH@6B):(5HC6B#:(MHAV
MB/:(R.>,N<6VX[L`"QB<?,[.Z_K<:?%A^BHS^)Q&M-[.@UIDI)P5I[Z_D3P6
M*<Z8($H198AR1(5!@9T=ZOO>I_0S#)P>-'PX<ZY92_UTNTUL\EC;;1*#K)79
MU*!K>93+)*/9R./%(7,1X(8L',VNP57LZX1!QH3*Q+IW%$E3/N`$"ZZ\=XXB
M(Z0VZ';S,C@T)68I'7KI77K1QX2+DGE;:A"-HGRQ&6LY6E;.4KJL:V\C0^$4
MY;:8"AF=T&(ZPF1/4LF:AQ:S*WCE1U>,D/H*P;$6TZKH1'CE#$/_;?2$BY)1
M(C6(^H.TF-%RM*R<:Z3+ZOMK/H53EMMD_R>!*CJW&@8;C1S?\S]L$9E\ZI3`
M8RVI5=');JHEKX:>0R1&B_7N;&J0XWM:R_&R<I/1E-6_\7IPX93EMF0P9G3R
MV='7&#1B9%U@%&!Q@"4!E@98%F!Y@!4!5@98%6"3`*L#;!I@LP!K`JP-L'F`
M+0)L&6"K`%L'V";`M@&V"[!]@-$DPOB!972:101@R!5H'N%(NHYZ6D2)3H2'
MOFV05;>(Q2P6!U@28&F`90&6!U@18&6`50$V";`ZP*8!-@NP)L#:`)L'V"+`
ME@&V"K!U@&T";!M@NP#;!Q@Y)!J='#(`0ZY`#NE(N@ZI'O=/N&V;Z(`]T='(
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M%DTQA>(((_5D'TH9C-0#-:;0TS+E":70<H5J@=`%40A9)04;^EJYAI[Q>PU'
M>Q)&:GD:*T&;$49JD1I3:$_"2*U58\J$4M2*-:;0!H616K?&%-J7,%*KUY@2
M44H43*&]'".U;(]Y$DI1B_>80CLY1FH)'U-H0\=(K>1C"NWK&*D%?4RAS:KD
M/J$N2GM6R7U"*;1/E=PGE$)[4\E]0BFT48FN)]1):(<162Z4,J$4M>\':TU[
M>J@&H13:$$S:0C6@G<#D!Z$4VA!,?A!*F5#*))A"NX.I;J$\M".8_""40CNH
MR0]"*3&EJ"VT>*4)I23!%-I&37X0RD.[J<D/0BFTJ9K\()1"K_N,U'YUK`&]
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M&AW03G>N8!H=C#]2Q]ZC1CIMG%)"^NA,_)$Z4ASST-'X(W6R.*;0`?DC=9@X
MIM`)^"-UICBFJ$M21Z]C"GU58*1.8,<4^KC`2!W$CBGTB8&1.GL=4^@;`B-U
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M6]ZG^T`P3TG:RF!*12E5,&5"*77P>B94@SI8@PG5H`YJB_MT[Z#-VG@]$TII
M@REW5(.[H+:(4J)@2DPI2;#6,=4Z"=8ZIEHG06TI:4N#*1FE9,&4G%**<`UZ
M@U'1"SW8Q#V:Y^K/JG@>DE-*$4R)>S37UU\"@3S4UL&4N$_W=OT"FY?GKG]X
ML@T-F7=]]6RK7QA_WV5[^?VW'_=_/M3WSW\^?G]Y]_7A,X5$+@Z?TWU^_%-M
MB]7_>#6?3_WCZ?7UZ1M%3<[>?7FX__3PK`1H#>OST],K_X.<X_T_3\]_'<(N
MO_^/`````/__`P!02P,$%``&``@````A`"?"9!7R`P``U@X``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULG)=1;Z,X$,??3[KO@'C?@)T$FBC)JMVJ
M>RO=2JO5W>ZS"TZ""AC93M-^^YLQA&(#);V7$(;Q_,;C\1^\^?Q2Y-XSERH3
MY=8GL]#W>)F(-"L/6__??QX^W?B>TJQ,62Y*OO5?N?(_[_[\8W,6\DD=.=<>
M1"C5UC]J7:V#0"5'7C`U$Q4OX<E>R()IN)6'0%62L]0,*O*`AF$4%"PK_3K"
M6EX30^SW6<+O17(J>*GK()+G3$/^ZIA5ZA*M2*X)5S#Y=*H^):*H(,1CEF?Z
MU03UO2)9?SN40K+''.;]0A8LN<0V-[WP199(H<1>SR!<4"?:G_,J6`40:;=)
M,Y@!EMV3?+_U;\GZCB[]8+<Q!?J5\;/J_/?449R_RBS].RLY5!O6"5?@48@G
M=/V6H@D&![W1#V8%?D@OY7MVRO5/<?Z+9X>CAN5>PHQP8NOT]9ZK!"H*869U
M&HG((0'X]8H,6P,JPE[,]9RE^KCUZ6I&%F$$WMXC5_HAPXB^EYR4%L7OVH=@
M3FT,VL2`:Q-C'LV6<3@GTT&".A\SO7NFV6XCQ=F#G@&DJAAV(%E#X.'Y0!+H
M>XO.6Q]Z&G)5L`C/.[J\V03/4+BD\;FK?>"W]2&M1P#0E@RTZ\GHC&2L!Z9R
M5QNZ&#J,F7\$@\Y;'W[;Y.ERU<:MR;7/PK1+=SZ+CX#0&4H>622WE(T3-.M;
M.E'8IF-5$]KH^FJBLZ&WY6PL5CVCD86#I+LHW`HTGFH='&0C&XN-'%E$"-]#
MDG@&6;_?L#C.IC86:)].3>?#-47Q[NP-L^<7D._[3!QE,QN+S5P,,U=]9ARC
MIDQ0<9Q-;2PV=3E,)=!C[E3I"OKO_:F:83;U8K*QT0@6BMG%3M#0VZ$U)KAT
MEC,>H4%.79I9SQ48)[`XS,$V)KATL&_;U]J9Q%$@Q,[#:!9/KJD9Z9!K]2$V
M^4VB;/*')(FTFM2JPL5DE3<>42!\';KEI==L4C/0F2;&`I,US7A$CU!%73"9
MWJ=FF(-M-,G&CF@2&1`E$J^NV*MFI$,>TJ5X1)?(D##1FVO(?7$RP7JE'E$G
M,B!/=&Z^>:9V45^@3+`>>42AJ*-0[^]9XVU7^&*R>WE$F"CJ2D?Z)VCH[=`:
MDT6+1H2)0K]U:4:8(OBVFY(F,]`!8ZQ>4<?``])TA>S31H2BSN?8D"[%(XI(
M/Z1+QMN99"-55G7C$17$=^?_JVXC0MUI#NG2C2N(]2FB_LPNN#SP+SS/E9>(
M$YX0*'PXM];V]')+L9BN?;&^A?3A0=`^@5-%Q0[\.Y.'K%1>SO<0,S1O$UF?
M2^H;+2HH&APNA(8#A?E[A/,CAX_G$#MK+X2^W""@/9'N_@,``/__`P!02P,$
M%``&``@````A`&"M6+*P#```ASL``!D```!X;"]W;W)K<VAE971S+W-H965T
M,38N>&ULK%O;;N-(#GU?8/_!\/O$EB5?D630UAV8!1:+V=UGM^,D1L=Q8+MO
M?[^DBE052<6M#/:EW3DF6<4C%NN49-W^_N/P,OBV.YWWQ]>[870S'@YVK]OC
MP_[UZ6[X[S^+WQ;#P?FR>7W8O!Q?=W?#G[OS\/?[O__M]OOQ].7\O-M=!A#A
M]7PW?+Y<WE:CT7G[O#MLSC?'M]TK?/-X/!TV%_CS]#0ZOYUVFX?&Z?`RFHS'
ML]%ALW\=N@BK4Y\8Q\?'_7:7';=?#[O7BPMRVKUL+C#_\_/^[<S1#ML^X0Z;
MTY>O;[]MCX<W"/%Y_[*__&R"#@>'[:I^>CV>-I]?(.\?4;+9<NSF#Q/^L-^>
MCN?CX^4&PHW<1&W.R]%R!)'N;Q_VD`'2/CCM'N^&GZ)5G2R'H_O;AJ#_['??
MS\'_!^?GX_?RM'_X8_^Z`[;A.N$5^'P\?D'3^@$A<!X9[Z*Y`O\\#1YVCYNO
M+Y=_';]7N_W3\P4N]Q0RPL16#S^SW7D+C$*8F\D4(VV/+S`!^'=PV&-I`".;
M'\WG]_W#Y?EN&(]ODLETOHC`?O!Y=[X4>XPY'&R_GB_'PW^=542Q7)0)18%/
MCC*[F<['\4>"Q!0$/BG(_&:RF$;3&<[DRN@).<(G.4ZF-U$R_I4?1&URAT_R
MF_5QFY$;?'8D>V6><W*$SX\E"(NUF2A\?BC!)?G!9X\$1ZXTFDK+-I?-_>WI
M^'T`RQ>N_?EM@\T@6D$H+C&7:5MT[]4<%!L&^811[H:0`E33&1;*M_MHOKP=
M?8/BWI+-NL-&6J1L@96,83,-Y!HH-%!JH-)`'0`C(*%E`NK[_\`$1D$F.(<U
M`YZ:B4J;+=@ETT"N@4(#I08J#=0!(-*&%1FFW=U;^#JC,721X#K'R52FLW8V
MT*<XG]0@F4%R@Q0&*0U2&:0.$9$G-)#^>:(QK`CH`E<*VAE-H*VW1G$RDVRD
MK1&SD1DD-TAAD-(@E4'J$!&Y0Q,,<\=%/H<>SHVW]S+'.`TMG,S:(8J#N>*@
M-6*WS""Y00J#E`:I#%*'B.``KJ7F((J2FSDX?+#9823)@D,4"PO%0FO4LF"0
MW""%04J#5`:I0T2P`-N39@'VTX]S@'$D!PY1'*@](&V-6@X,DAND,$AID,H@
M=8@(#E`>!UO>]8Z'QC)10N:^OQDD,TAND,(@I4$J@]0A(K*"S;M_5F@LLW+(
MQ$D_W'Q3AR2P7?KV-AW+HLY:([Z@N4$*@Y0&J0Q2.V0R09I%HA$TW/Z9-M8R
M58+"7`E*)HUVF8RC1.7I#=I$.4PSPT:O%`1%<:/K&ZSTGBB+('0L0U?>@$/7
M(K1,'M5+4+S8RB<SE/_OG`IXYXZ<[($MC4=9$S2!D@JN<"2GEY+5-*R#:*&:
M6\96H#*"6$KIY#PB7-O6*EJJFBK8RHNHDL-?G43%5G(2BN^:P[\W"<DWRJ:`
M[^O-(G(B2Y#L("@VGW(\5>65DN/$-Y6,H&DXS7BJQ%;N'7WX#D;;2?#%+[TC
M0U7WB$K0U-ZQ>T1)'\JQ_O21>`MKU$&J1K7`B,BJ.8O3T<%!L!+]-..I*MO<
M.WJK#OK:23!7I7=DJ")(C:AVP-H[=H\HZ4-%UY\^I_]$]9$D%-4W4PLNC<@J
MK#X'Q0MWF!LGJBWDUJ=@R.\A)4,^<D60J.MH:19I."7)"2J\_IR@M6K_#I(E
M-5/YI7B?!1PG84DY:!J[36(Y5F686Y^"H;"7F<@568G2Z>`D=)2<H-[KSXE3
MAZ).2#"&=1)%JGVGX-%PXJ]F1A!<37?H-PO,N!0<)2P38U6IP`O5,6N.TLQ%
MDH'"KS\93B9".%[(ZXB4H]@79X8,9Q5[QXP<8_BFW=[BF2KMG,.'C;VCY[23
MX'F5'-Z/6!$4Q9&KR>E"U63M1X,XDB>4D@%/[M9/<R"Z/.^W7]9'2`(*HF/+
MPQ70M-E/$>E1/Z<U04)>.:N9*"^K(<@*-JN6/K,*<@[OB[!@**RH/B-6Y#B[
M.F+-X3M*#:ZAIO"=XU1#Z9_'M_<H!077<HI15<]RD#Q=S=2:2*/6BFLFLU!N
MH<)"I84J"]4"$M6%4]74Q(M&J'[PN-U$DG00I.A0VBCU5BT=%LHM5%BHM%!E
MH5I`D@XH_9".CD455`"J154!#/FR3RV462BW4&&ATD*5A6H!R?Q080;-Y!?Y
M.3T:-ETXZ#5[BU_#*4&_.(%Z*[[*N84*"Y46JBQ4$P0?NG].4!7V3]EI2)$R
MR<HP90>]?PYM!KT;@H'/EL)XJ&`K+UY*AMH3KMJ6*F_`D6N"NG)'>=8_=R?F
M1.ZD[Z!-M[T^GJFS1CIQ5G#VY#EE%LH)"J1:P5`@NZQC9:&:'1OF9(6C^NJ?
MLM-J(F6"XG"WB6=JPT[Q*(_"TR_TS$*YA0J&/%DE0SY69:%:0#)GU&7]<W8J
M3N1,4`PU&EQGI1+3B3,#+>6M[#T&MIJ3UI$W*G+Z6I2!BPM2G^NGY"!7AZK8
MBH92UZ@60TG&4+;U9\R)/,$803&4?L"8.D:F4!Y-E?BG+!E#LW?H(0]?"P5Y
MS'WG*#F(CULQ1'$-%V%<R05JL/Y<.,4FN"!(5L]<'U_Q)`<K)E3B#,'</(ES
M=<;+R0HJQEM9)4Y6\^">'H?WJK=B2(ZH#@WUKT:4_*&<Z\^?$W^"/X)D+<U5
MYT\Q?U0;,72>EJV.Y<=F8NGHDWM.T:!J>,T5!(DZXV!7QZS:J5T=LQ9C"@[Q
M2-V?P\9:2DV&X%#'^:2$A=N2A7*"8&[L6#`4]"/K6%FH9D>[+<')[R,)6F'9
M!(#]!KYI+WX\UT<+MO(L9!;*+50P%.Q*#/E8E85J`<EK^B&MB=NMTM(,J;ZB
MSP]DAL75,F.7!5G17:%D`LM(;4P^CB\$-ZFPIWBK*Z-5<K1X.5^JG:'V<6`T
MR1L*Q=[]!,G1O!$$=P7]'..Y5FWD&72`C""Z391$JH7GUJ4@*&P:UJJ2@6/=
MXFOA(ME`;=F?#:=$P^Z*7;5IFT+;3-7^F))9T`8R@F!1XTVSY5+O2]:E($@4
MC!L_"%S)P(N)HKD6@24;J#K[L^$TJF"#(%4;A@UG)FK#050;<W.G&;<EX#EP
M*0@2M6&L*K*B>]AQ/%4\UR*RI`.%8W\ZT%IM&P1A_;7-(YYKX8N*%W/S>T1&
M$!5'9!Y96)>"(%$<)G`E`R?Z&50M`DLV4.+U9\,)0E$<!*GB4*TKQ1NG\DIG
M!%%Q*#F56X>"(%$:)FPEPZJ&78NPD@F4FOV9(/WJ9>(:&<!2$75A[[23&5P2
MWC(RAB"9MJ#LW5&R"@JJ($A4AYM%$+[J%;X6X24S*.CZ,T/RS^>WCED10EMK
M$XP7JH6E9`9G5L^,\X35C.TT29)8=9V<G;SB*`@2=>+B!*$KLFI#+\9J/K4(
M+1A)/B0]&VO90Q@2M1*;XP^9!1<S8RBLE7BAVE].5E`KGG![_"&KL'PXO+]Z
M%4-R1+5>ZU^-*/G[D++%NX2J!S.$NUY04?KX0V9X%Z2ULC*/K:"O>BMS^&&K
MH-`8"@0P0U='K-CJZH@U6S4C2OX^))/ACJ+ACR!HA[S64C(+^DMFH=Q"!4/!
MT8<AO_E5%JH%)!-$.=J[Y20D7GW1K@F21Q_]I#%E*\]"9J'<0@5#X95WDPBT
M3,56/GPM()DR:K[^*3N%&.[$"4'8MMHZCA=J!TS)3+8&\\".K/!PVL:R6Y*/
MQ554,!06@YO8]1&K7B/6'-Z>EA-4B?WY<YI2\$<0GK+:G..%/@(UX\`M*7_I
M,X9"QPZR7/R@0`IR#'<JCN7#5PQ=#5^3E0LO*PL%8W]FG+P4S!"$XBE@1FW%
M:>+,Q)[6T6W)"HJBC=5!EK,*FE%!X<5NU6?$BN=U=<2:K-R(DC](.^3O+SU-
M3S"($@$.4CW*[&'.ZA</V"G\]<?=.5F)$G3A10GV&;'J-6(M1I2L*KVM6>WW
M0#VQ.IP@>&#+32FU4&:AW$*%A4H+51:J!23S1BD:K$;,^R_]8A]>3S,5Y2!\
M5MVNK5CW]I0<`X(R"^46*BQ46JBR$+Y)AU-U(SHVW)MQ[GVEP^[TM$MW+R_G
MP?;X%=]Z@S5Q?]O"[I6\=;*`=_*:?<5\L^2W]=0W\!K?I^81B,+7\'I?TV$U
M/EG!VS10-QJ/5_#ZB<4_):M/D)S]8IW`C+KPZ0K>8^BPGZW@E_T=^'P%OW;O
MP(&++BK2Y0I^<&WMTVB\RN"WQ_8;^!7S"G^H;+^!I_0K?&[>]4V\RN`1LOT&
M'D:#3]<WZP@N$ORHQ/JL)V-@O6L&ZPE<)Z@%\!FU5P1>@WS;/.W^L3D][5_/
M@Y?=(Q3,N/EQT\F]2.G^N-`O<CX?+_#^([1>>`4.7GC=P0_@Q_A:Q./Q>.$_
M<(#V%=K[_P$``/__`P!02P,$%``&``@````A`'`:FZ\V`P``6PD``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&ULG%9=;YLP%'V?M/^`>"]?(02B)%6;
MJMND39JF?3P[8()5P,AVFO;?[]HW(9BT:;>7!.QS#^>>>_%E<?W4U,XC%9+Q
M=NF&7N`ZM,UYP=KMTOWU\_XJ=1VI2%N0FK=TZ3Y3Z5ZO/GY8[+EXD!6ER@&&
M5B[=2JEN[OLRKVA#I,<[VL).R45#%-R*K2\[04EA@IK:CX(@\1O"6A<9YN(]
M'+PL64[O>+YK:*N01-":*-`O*];)(UN3OX>N(>)AUUWEO.F`8L-JIIX-J>LT
M^?S+MN6";&K(^RF,27[D-C=G]`W+!9>\5![0^2CT/.?,SWQ@6BT*!AEHVQU!
MRZ5[$\[78>#ZJX4QZ#>C>SFX=F3%]Y\$*[ZREH+;4"==@0WG#QKZI=!+$.R?
M1=^;"GP73D%+LJO5#[[_3-FV4E#N*62D$YL7SW=4YN`HT'C15#/EO`8!\.LT
M3+<&.$*>S/^>%:I:NI/$F\Z"20AP9T.ENF>:TG7RG52\^8.@\$"%)-&!9`+J
M#_N1%Z73<)J\S>*C(I/@'5%DM1!\[T#7P#-E1W0/AG-@/F:&.OI<7TL5<M0D
M-YK%<$$6$NKSN(KC<.$_@J?Y`7.+&'@E>LP(L3XB="E`7J\1,A]KG$`-7W;_
M*$D'V9*2R4C1.22R$>L7$&D/L32"=T.-E[5I,/3`T(IT].A;Q,2F!;3'Z\&"
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MU]+)^4[/KQ"(^U6<K;=ZMIKIV&_`:.O(EGXC8LM:Z=2TA-#`FT$%!`Y'O%&\
M,R?PABL8:N:R@H\8"J=9X`&XY%P=;_29WW\6K?X"``#__P,`4$L#!!0`!@`(
M````(0`NGLAG<P<``#PD```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;)R:6V_B2!"%WU?:_X!X'\`V=X6,QO1MI%UIM=K+LP,F6`,8V<YDYM]OM=LV
MU579`)F',/ERNO#IZP'[X?./XZ'W/2W*+#^M^L%@U.^EITV^S4[/J_[??ZE/
M\WZOK)+3-CGDIW35_YF6_<^/O_[R\)H7W\I]FE8]J'`J5_U]59V7PV&YV:?'
MI!SDY_0$?]GEQ3&IX-?B>5B>BS39UHV.AV$X&DV'QR0[]5V%97%+C7RWRS:I
MR#<OQ_14N2)%>D@JN/YRGYW+MMIQ<TNY8U)\>SE_VN3',Y1XR@Y9];,NVN\=
M-\NOSZ>\2)X.X/M',$XV;>WZ%U;^F&V*O,QWU0#*#=V%<L^+X6((E1X?MADX
ML-W>*]+=JO\E6)IHW!\^/M0=]$^6OI;H_[URG[_J(MO^EIU2Z&T8)SL"3WG^
MS4J_;BV"QD/66M4C\$?1VZ:[Y.50_9F_FC1[WE<PW!-P9(TMMS]%6FZ@1Z',
M()S82IO\`!<`/WO'S$X-Z)'D1_WZFFVK_:H?30>3V2@*0-Y[2LM*9;9DO[=Y
M*:O\^*\3!4TI5R1LBL!K4R28#V;!:!'-;B\2-47@]>-7,FZ*3+LB03@(YY-@
M,KW#SZRI`J^MGV`PGTS&T_D=AF")U5T+KVV5R6`<3F;S&_IVZ,:I'G:15,GC
M0Y&_]F`MP4B4Y\2NS&`)E=OQ=J/3S8#_FP`P\K;(%UMEU8?V,+8ES-KOC^-@
M]##\#C-MTVABIX&?2!/XFC6O0Q2B5=BI9]]:MN"=LJK5M(TT!<8!^(DN+NPN
M;@B=U?48S$K<8V^OC+9CK-AV3/O.<0OP&T7=&]66UDZ#+^9R*;5"\"KAW"\B
MN60<3'R->DLS]37Z+<W,UYBW-)?K\7H/EN/MO6?%7N]1L'8`=]4X&/M7)V@C
M28&B0%-@$/#LP`:![=CE$\&F^_ZDL(U`YTVVA7_1L=/4.[V;%!0("B0%B@)-
M@4'`LP7;[/VV;*-5'^;"90V%=!-P&F3+@4F]9T2+^9@T$+2!I$!1H"DP"'@N
M85?'+M\?-"NF[LCF%#L-<N?`M'9'G5&QI$!1H"DP"'C.X*3!SFZ;EK81=4@V
MGMAID$,*A`.SVG*PB$;VGS^W)6VC*-`4&`0\HW#DW&_4-O*-!@%=?TZ#C#K@
M?"U&T9S9$E@1S.``9,9I446!IL`@X!E?<./A[.K.8UOYSL<A.7UBIT'.6X#7
M-=UC6TU[SDD*%`6:`H.`9S4`6WB0WU^GM9IZ)`=?W(A@^T-[%3GYUIVH-248
MD8PH1C0C!A/?JLTA*(Y=L6K5U"HYF^/`B=!X=L3F-+(V1??'UK1D1#&B&3&8
M^!9M6+C=HHL6_J%RB1;UT1@'3H0MML1:)+NT8'+)B&)$,V(P\2W:M'"[19<M
M?(MT.PJ<"%ND1#"-9$0QHADQF/B^;%Q`OFX[5@(7,N!R+VN-;;>-"/M#V<2%
M7J:1C"A&-",&$]^?#0KW^W/QPAN_B"RKV'Z&AJ6*_5$BF$8VQ.4',HT5DVM&
M#":^59L<B-4Q7-&5#<?E#=\JN:XX0*'$15=&!".R(VB61"1]J$[4;DZ:$8.)
M;]EF"&3YBE67.+#5<,KV5A1+&JN4B(`2R8AB1#-B,/%]V8B`?-VX*EVPN+(J
M4?IH_%$B`DHD(XH1S8C!Q/=G<\']_ER:P./'0UZ`(D?CCQ+!-)(1U1"W3N<S
M&WG)!J`]R:R.Q7XJ-KYBX1?Q>B0D@>BV$:];D;00T?#7B-`^Q8A@1#*B&-&,
M&$Q\?R0%W>C/!9WW9W3(TA`C@A')B&)$,V(P\?W!K,0S^OV=*+1J.FXD?\>-
M"(^;:^8^L,!'`Q*:!&LA&5&,:$8,)KY+&U#N7K>A;47=TOC>B+!;U^Q"!--(
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M8`EWH#F/PV7\5AT1+N$F)M?+<`GW,CE7X1)N:7*NPR7<V00^[`S`LQOGY#G]
M/2F>LU/9.Z0[L#X:V,<2"O?TA_NERL_ULP)/>05/;=3_W<-3.BG<@1\-0+S+
M\ZK]Q;Y!]]S/XW\```#__P,`4$L#!!0`!@`(````(0#T)RO49P(``'P%```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(Q474_<,!!\K]3_8/F=.%]`
MB2Z'CB):I%:JJGX\^YQ-8A''D>WCX-]W;=^%.Z"(ERAVQC.[L^,L+A_40.[!
M6*G'FF9)2@F,0C=R[&KZ^]?-R2=*K.-CPP<]0DT?P=++Y<</BZTV=[8'<`09
M1EO3WKFI8LR*'A2WB9Y@Q"^M-HH[7)J.V<D`;\(A-;`\3<^8XG*DD:$R[^'0
M;2L%7&NQ43"Z2&)@X`[KM[V<[)Y-B??0*6[N-M.)T&I"BK4<I'L,I)0H4=UV
MHS9\/6#?#UG)Q9X[+%[0*RF,MKIU"=*Q6.C+GB_8!4.FY:*1V(&WG1AH:[K*
MJJM3RI:+X,\?"5M[\$YLK[=?C&R^R1'0;!R3'\!:ZSL/O6W\%AYF+T[?A`'\
M,*2!EF\&]U-OOX+L>H?3/L6&?%]5\W@-5J"A2)/DH0RA!RP`GT1)GPPTA#_4
M-$=AV;B^IL59<GJ>%AG"R1JLNY&>DA*QL4ZKOQ&4A:(B5RCMFCN^7!B])3AN
M1-N)^_!D%1*_7@L6X;$K#ZXIQA%E+/IWORS*;,'NL6FQPUQ%##YGS!."H>BL
MC&KO5_9@KXS^AE*NXL:A3#X7<B13',MXTPL<W=N-^D.(.VBB*)_X8P414P9W
M#_LJCP7?%O)@M/[L2.G)L*BT`V'5LZ=%6;S>+B;AT-60L31/SO^;L_UL_<%0
MR6SQ;@>=/I`MG\G&M,=(*3`=?(9AL$3HC4]RCB&9=^=+MLJ]:<_WRVH54L_F
M#QC^B7?PG9M.CI8,T")E&GHQ\?K$A=-3"/):.XQ]>.WQ+P<8V33!+EJMW7[A
M+^C\WUS^`P``__\#`%!+`P04``8`"````"$`AM?["VP@``""H@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6RLG5MSVSBRQ]]/U?D.+K^O;=U\8279
MDD52)'67=;']YG&<Q#5QG+(].[O?_C0(-!O`OZ-86V<>)LD/C<:E&P#9@,`/
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MCP]_OWI_/WC]]OSW\.7Q\_CQQP-U-QG*F."/Y^<_C6CYV2#*?`RY\]H$\Y>#
MSP]?[O[Z_K9\_KMX>/SZ[8WLW:,FF98EG_^3/KS>4Y>2FJ-VSVBZ?_Y.%:#_
M'SP]&M^@+KG[]\?#-A7\^/GMV\?#SNE1[^RDTR+Q@S\>7M_R1Z/R\.#^K]>W
MYZ>M%6HY559)QRFA/YV2\Z/S7J][>GY&2G9D[+J,]*?+>+I3GK35M:4_G7RK
M<]3JGIR:RNXHA[36^>A/EZ][=-8ZN>C\IGYG+A_]Z?)1$W>40\.J+H?^?%=[
M+IP\_<GM(3N=]UJ]W[6H19Y2%V7^TK3I?5G9YBTQ>JMWU&WWSLYKJ^]H8(M-
M;?["57Z7"5IL:_,7E[,MGK:K3+:Z\6LN\[WU9<NWQ/2FQW85QT9OB=7;%^^K
M*=N_Y1GTG35MLT'-7UPKJ0([*MIF.YJ_<(^>O*NB;;)\[3UM,<9[7<`,-9O7
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M`!G?>H&#T:H/#F8F-_UQD^<PDXL>+(,Y+)JA+JT,+?%<K0&0%$@&)`<R!%(`
M*8%40$9`QD`F0*9`9D#F0!9`ED"N@*R`K(%L@&R!7`.Y`7(+I-]'A%;MHUG[
M@5T#=Z.GD\#==KN9D:;5EAXVO+4RFJ@NK9!YR&J$VN<7T6S6"+$SID`R(#F0
M(9`"2`FD`C(",@8R`3(%,@,R![(`L@1R!60%9`UD`V0+Y!K(#9!;(/T^(C$T
MV[`_0*G`KH'KT</M'JYGI&O7X\(N+2$_8S(`D@+)@.1`AD`*("60"L@(R!C(
M!,@4R`S(',@"R!+(%9`5D#60#9`MD&L@-T!N@?3[B-"J?31K/[!KX%0T->WA
M5$8Z="I+VC;Z8I[C!T!22[KTJ-E,<*WSTW""RQHA]LX<R!!(`:0$4EE"+YBD
M.6@[O;3MT78C';;=$K_M0%)+NNWZ/:E]TNI&S6[2FV8['75UZS>CH9.Y:`9N
MT>0R;U^DM1-J+9MTUEKY6H-.H/>X/3K!2(>=8,DIO=@VQFU?1*^#`RM$[\M<
MG]22,UJ@O6S1$UC6"'&VW"F2KA@Z&9G5BB:7KSI:=,M&B%57ONJ@AZAI>_20
MD0Y[R)(SW_W;%Y'%!E;(\Z74D3I26_M!9DGOHO:EB\B3\D;>;W8D-+1"9^)<
M19.-.Z(,BXG&:=7(Z\4$/6?B6GMT72T>]IU#D7OU0G<?."G?OQB)IV0.T<N!
M&36MHUYD@USRZ&VSH]%)G7D>)QF;3HP+.XT<L)(\>F%A1YK7=#]TL_NQLV7?
MZNFYD^MSZ5#DA9%Q!T[*=T-&GA\ZY!PQ&NNY9-`;YGK15M'W1,G(M2YWEE1)
M!KVDL`O-*Z7?A2;ZU>X=T9+ZF\ZT[Z)!9UH4>>59[)56*O!*AV@0-=->Z_P\
MS)B9*#C-(8VC=B+-N1.@:"+WU)"13+$%HYV%E7%A)]'@JD0-%19VJ7F]\KOT
M-QWIWL9\KW3(:\G`Q/'-#.JQ5&&9PG*%#156**Q46*6PD<+&"ILH;*JPF<+F
M"ELH;*FP*X6M%+96V$9A6X5=*^Q&8;<*HP`C&IABC`K47($BC8%DZ)#F=6H/
MA[1O7\'(=LASOH'9'@*'1)8I<KG"A@HK%%8JK%+82&%CA4T4-E783&%SA2T4
MME38E<)6"ELK;*.PK<*N%7:CL%N%D4.B,<DA%:BY`CED(!DZI'EAV\,A[?M=
M%"^*'E,NS:8C^6,8,+J(%I&!2/$:D2+*$.6(AH@*1"6B"M$(T1C1!-$4T0S1
M'-$"T1+1%:(5HC6B#:(MHFM$-XAN$9%W-N9F0Y)S(E,,3J[IRX6>:=Z*]_!,
M^Q(=3)4.R8/AP#BNF2D%I8@R1#FB(:("48FH0C1"-$8T031%-$,T1[1`M$1T
MA6B%:(UH@VB+Z!K1#:);1.1S8$CR.62*P<GG?+G0YTP08@^?LS$+TL>.?VD.
M0)BISPLW.=03J=2AWP2<1(K5YXB&B`I$):(*T0C1&-$$T131#-$<T0+1TB$E
M'-8R$9`]S&,#)H%Y7%2EVUAL4"O]>'@F*'7HUS$Q$1#+6,V4A]$0I0I$):+*
M(=L#]=OHB*7DA6K,J(G<1<OP1`2X2E-$,T1S1`M$2X<T.YD0S!YVLA&;P$X6
MG8I1!N9\$(TL#Z4.G=/C3?.RVKZ(-J8RD>)NR!G)D!PRDI6A8.2K[YQ$(<!2
MI%A]Y="I;,R.&'4:]QA+QAVUGX@4JY\RDMK/&$GMYXQVUGXA4JQ^Z9"M?3`]
MF@>Z/>Q:BX?1,H<\(PX0I8SH/:JQ:R<^P9.)%%<]9R0=/W3HW`L[L%2H/@I_
ME2+%ZBM&HG[$R+.KH!VUGX@4JY\R$O4SA[S:SUEJ9^T7(L7JEXQJ]:%=]PO>
MT>)6/T2)_UTZ%-C52GDH=5+GTL`,4<ZZ1&K(4KX1K?I@">V<1%-@Z3*2%'=#
MA>I'C'PC6O5>52=<":G7E#,*FK&45'7NT.ZJ+D2*J[H,U(<6,P&X]\^P-$>#
MQ5R@CY8M;XQ%T?B!RW@NRT[JT(5$ES-&=B4Z[W:ZW6@TY2PB$_H0=1<LY9\T
M@.ACR5*].DS>.3J+@L05"TAA(RQLS%+2D`DCVY!6MWO2BE:3*8N([AGJGK/4
MSH8L6,HVI'5.QYC#0.N2)>K20@\P0:8]/,"(1W.Q113]]3T@"JX.VE8J\`"+
M+F1094[J0D90SD@Z:HBZ"I82724CF5XJ1J)KA+K&+"6Z)HRD7E-&HFN&NN8L
M);H6C*1>2T:*>4S(90_S&/'(/!:9.<`;H)&K#\QAY/!](V4DSP*90YUSN\E+
M1][/(K_.,=>0D?1!P4ATEPZYO9;6T7GT@%1AGA$CT3QF))HG#KE:GW5;O4[D
MG5/,-6,DNN>,1/?"H:;6'1AYKF/K/.'(,R&+/4QK(QS^TZTY#FZ,%HZ\:`]E
M(%*\(*2,9#K.'#('"ALW:<6;MSEF'#*2A:I@).K+=ZFO,..(D:@?,Q+UDW>I
MGV+&&2-1/V<DZA?O4K\,,H:F-I&"/4SM`@LR0UR:8_QV?(IY.B>1LPU$2DQM
M,W;$C3,GU:&5NS%UYP0&LBN1`A&-5"L^[S#$$@M6+R66C'@]/#DZ/;WP_@M7
MJXJ5RC@;,1*E8U8J:,(H:%DKVK>=LJZ=+9NQE*B?LWI!"T:N9:VC>/M[R7J4
M"<#$>'ROL#]3.#(_C'K[]GC_Y^4S]3S-V\IN8X=FX/J-OF]^UQ%/^1:%\T(K
MFD\'+J._:^M01UP_<ZC7M6<)3D[-+Z1">^6L2;(-&<FX*D2YYU#QEG#II+KV
M[$+[*#X?6K%F*6S$2`H;2V$\$B8.N99H3Y=35B2Z9XQ$]UQT[VC(PDFYAN#3
MY9(UUX6%TX6)`8%CT&\#G5^LGG_6?K&'DQB-T7.!1>%S02MZWAX8'[+S#O=C
MZM"9S$X9H[/:2;H7W?9%Y&TY*Y(Q/60DPZE@133WR*2#/F(K=68?0[I'\:);
ML68I;,1("AM+8=RV"2/;D-9%M]>#V</UB.B>H>XY*]K9D`5+V8:T6O1[RG!H
M+5FU,GO$P;%X]F`O468/6JF:Z0.#9K0E;&Q^1G\T1NC$)^\&3HHJR+V7.G0N
M;T(9HQ9/'Z=GL8_E+..%/!VB*K#R@J6"!Q1T#5OW<S,_TH%!9?IP`E+8"`L;
M2V%<_@31E)'HFJ&N.4M)KRP0+1G5NH+9P#R2!;/!;H/6XN%0=X@"-]R:`:(4
M488H1S1$5"`J$56(1HC&B":(IHAFB.:(%HB6B*X0K1"M$6T0;1%=([I!=(N(
M?OAAO*/>(V?;]B\5IAB<?OOAYPU]SH2M_!7H-SYGHUST;B(S1O<DFLLNZ1G4
M556D.O'#Q$"DN$$IH@Q1CFB(J$!4(JH0C1"-$4T031'-$,T1+1`M$5TA6B%:
M(]H@VB*Z1G2#Z!81>69C;C8D>28RQ>#DF;Y<Z)DFWKB'9]KPI/_6;-Y[S+.0
M+.`#1"FB#%&.:(BH0%0BJA"-$(T131!-$<T0S1$M$"T172%:(5HCVB#:(KI&
M=(/H%A'Y'-B6?`Z98G#R.5\N]#D3J-S#YVQ<,_`Y%^KT?0Y0V@&4(<H1#1$5
MB$I$%:(1(WFN&SL4;CRTHA#B1*1XO$\1S1#-$2T0+1%=(5HA6B/:.$11<:[J
MEI&\'UQ+1G^]BL)K-R+%NFX1D6=:VWH[2.29R`8*8[^PU0T]TT07]_!,&XP,
M/-.B4ZJ*][`?!Y8ZC10W,D64(<H1#1$5B$I$%2/9)1LYU**3B5RQL6/!;GXG
MWG^9B!1GG#*2%]M9HU_*G+,8=8GT6#MZ35R(%.M?,A+]5XU^F1A6+!;JCU[,
MUR+%^C<.><<%MHU^Z9]KR>G7/]KQO!$IUG_+2.I/;FT=HT7G[UB._-K"T`+M
MJ`7T:^1&K,G:>%6M+G1U$^S>P]5M;#QP=8N\(3CH`$H198AR1$-$!:(24>60
M9[>10Z%?0UTGJ&R*RF:-,C'<7'+Z3A`%;18BQ19:HOZK1K\L&2O,N4:T067;
M1IGOL=#R&U1VB\K(/6W.EN<&Y)Z@CGP1&7N"<H"E8V+C>_BB$8]>R1TZV1G.
M&-0%4<X3&S\Y.>I$JV[J),YE*<L<ZLE2EC.B1YQFSH+=G:&3HE`$F[MPJ+6[
MGF4CYN(\1YUH/JF<A%?/D4->D&?<Z)%0Q:1A-L9.![-BY5-4/D/E\T:1*%\T
MS%;\@H+O400.=5^A[E6C9Z<]UXT8]U/\(Z0-%K?%XJX;/=*4FX99W6?Q^_<M
MJJ8!8OW0LP&-CW?Y)HT9EFL:$STVT#.U%;%6#Z?S>//C-Q$&W.7H6'0A2^?`
MH=:)#?^U(#*<8J;,(0K'L]?G#M&N[L[AXK99)&.!ZDN'?EVG"C.-&,F,.F8D
MI4T:U79SYJQ]=GX:;>--,=N,D2B?,Q+EBT:Y[<OSH^[9B?]?-!$M4<45(REH
MQ4@*6D<%H=$VF&G+2%1?,Q+5-XUJVT$=VI:(]Y-N,1N-"N=:HIU&!;@;C0#+
M?FU;&@%^MG`$F(V$/181N^_@K627=*+!K"O>G#IPJ'7BS@(=14&X%/-D#GG3
M?NZ0"1#N6B_<5HB_7D"52JC2133%5EBGD4/>O#1&J4FC^M2&^UOM;JQ\BMEF
MJ'R.4HM&N>W*BZ-X!W6)F:Y0]0JEUI%J.NP2#=L-9MJBZFN4NFE4VRZA52#>
M_[[%7.3QUFY>?Y/'@RW)XRT3_SJ/'(P\WL\6>KS9>]G#X^U63>#Q%@5SOI-J
MYOR+:&9*:3O;#!,O4^90,.=;J=_-^5;*RUB@^M(AGA?:[:/X5VL5YAHQDEEG
MS$CFM$FCV\YIYVTXT3S%7#-&HGO.2'0O&MUVSN\>T<E%_[_(UDM4<<5("EHQ
MDH+644%TD^QI].RPP5Q;1J+[FI'HOFETNU7Q_.0L>CF_Q5PT`IR7B'(:`>`Y
M-`(L8]M2U7O1?$9#P,\7#`$Z#K#/$*C%PS<'A_Q)GZ7<I&_<+9I/4LR5.>1/
M^P[]9MK'C`6J+QWBF:+3H5MNPT?K"G.-'/+FH7&C2&P\:9C;.>_1PAXJGZ+R
M&2J?-XI$^:)A]OX1.KH1^SWJOD+=JT:/Z%XWS.FF'>K@)%047=Q@25LLZ;K1
M*B7=-.R7772+RNDV+^.@]>8_/PWW+QM5HIXN]+*"=)-SO?9V?M.2?NB"X:`P
MNSW^NA`?97C702@3GH[>LAG1%23<FH'"4H5E"LL5-E18H;!2897"1HY=R$/5
MN!&3-_I)P]S),^U@UI1UB=UFC&2:FS>J1/VB8?STWXXFN24K$MU7C$3WJM%#
MQI$GR?C8QKH1L\7AN8T-ZY;BMHRDN.M&CS3EIF&VI[332;>L2K332+#^="'J
M:20X'S,7LORZ.30X6(X7TOB($@T'I[XN,AP.9B-JUW!XW\D>^@DAC`=_BZL^
M/CA@*6EYBBA#E",:(BH0E8@J1"-$8T031%-$,T1S1`M$2T17B%:(UH@VB+:(
MKA'=(+I%1.X*MB5W1:88G'S1EPM]T6Q1^;ZX.TS3M3M:],@NPZ,;Q[@NG93Y
M(5DSB#KMZ+%](%(\=Z>(,D0YHB&B`E&)J$(T0C1&-$$T131#-$>T0+1$=(5H
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M^6\-38GZW:D3SB-5FB*:(9HC6B!:.J39R<3$]["3B[+[=K+(^U'XH`LH=2@X
MAX#W.H@46R9G)"4.&<EB43"BZ:(9I9WXI[>E2+'ZRB%_P]^A%OT2E,7&DE/T
M0_4G(L49IXRD^C-&4OTYHYW57X@4JU\ZI.R+=TWH=P_#NF"RU/.RUA#<SC%`
ME#*BAP.OYZ/822927/6<D9Q6&3KD78U0L%2H/@JIE2+%ZBM&HG[D4&A8V^[P
MS%4[JOZ$E8E'3!F)_IE#7O7G++6S^@N1XNHO&>'AFZX):.YA6!<C]0UK43!B
M`:5U.13O]*:V3&&Y8]X(&CKD=43!4D%'=*)@<"E2W!$5(^GGD4.A'5TSO=I.
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MC5%JXI"K=5>97Z:8:\9(:CUG)+5>.-34.IY,ED&><.B9",`>0\\%#,1M+NE7
MYL;:T="+WA,'(B6F=1GE12YS4L&N;">^PB1G7?2LX4UPD0\,64H6L8*1E%A*
MB;4S'<5=5V&>D4,MNO:-&S-&L8FH]JL9S4E3S#AC)#6?.]3R(HN+A@6QD_@B
MDV4C5B\1H?%-/&8/X]OPC7]*I6=1-*ZC#>J!2'%_I0[57X+UC!CU3N:)<=:<
MM<D`&#*285)X.7=T?^F)<0$5:Y,"1@X%8]SUAKD+Y=<MF"@%3+&`&2-IP=S+
MN:.`A2?&+5BRMKH%H<E-J&0/D]O(2F!RBZ+Q#@]=5LI;A5*ZSM5,%,%#ET/N
MH8L^EMR.GH-RSB4KW-`A3W?!4CN?4TJ6XH>N^`:3B@6DL)%#X=H,+9EPSE\_
M/DY91)3/'/):,F>IG2U9L!2W))ZVEBR@+.9Q2.J_.H+0PTB50Y%CP!IO,WI-
M3ED7W1_#'IPU3`9A[MB%=.#0(4];T>04;67#9$JM4-NH$9,2Q@T3=9.&2>6F
MJ&[FD%>Y>9-3M"T:)I5;!MK"`1P'GFKSX8TINW<O>QB/<HBF#C;"`%&**$.4
M(QHB*A"5B"I$(T1C1!-$4T0S1'-$"T1+1%>(5HC6B#:(MHBN$=T@ND5$WYBS
MYO9LV[]4F&)P^LR<GS=T11/LV6,M<3$DFCR;];(;OP-<FE.IYG'2G_\Z\?0V
M$"EVUA11ABA'-$14("H158A&B,:()HBFB&:(YH@6B):(KA"M$*T1;1!M$5TC
MND%TBX@\LS$W&Y(\$YEB</),7R[PS%/RGCT\LQ8/7U@9R0P_0)0BRA#EB(:(
M"D0EH@K1"-$8T031%-$,T1S1`M$2T16B%:(UH@VB+:)K1#>(;A'U^PJ[5)AB
M\'YH\=#G]@MGGMK8I?]D[1`]NO%8&#@4A%W;[>CE.A4ISI@ARA$-$16(2H>4
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M914NHRNK?1X%C,J@K+`GS4O[KIY\WUGC4_ON'\S;#GD-'+"8QU*%90K+%394
M6*&P4F&5PD8*&RMLHK"IPF8*FRMLH;"EPJX4ME+86F$;A6T5=JVP&X7=*HP>
M(M#H_4L-:JY`SQ%!]M!1XP#-[E?Y4XS$,/*<;Z"P5&&9PG*%#156**Q46*6P
MD<+&"ILH;*JPF<+F"ELH;*FP*X6M%+96V$9A6X5=*^Q&8;<*(X=T?N`9G1Q2
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M$A/5QA3:Q$A,<!M3QI1B0MR80CL:B0ET8PIM9"0FW(TI`TH9J"FT^9.8.#_F
MR2C%1/LQA;9^$A/SQQ3:`4I,Z!]3:",H,3L`F$*G6\C:6H_2(1>RMI9"!UO(
MVEH*'68A:VLIM+-)[=&\E+8DR7):RIA2S$8AUIHV`:D&6DI)-3#'2S`/'1TB
M/]!2Z`01^8&6,J:4L9I"QXFH;EH>.D)$?J"ET)$K\@,M):44<^8&:YU12J:F
MT+DK\@,M#QV_(C_04N@4%OF!ED+G@\D/M/F:C@DGYA`PUHW.F5**MJC1449*
MT18:.C%'EM/*H5/%Y#M:RHA2S$D^K`&=D$[,^6<MY9Q2M+J-J6[FD*:2A^IF
MC@)B"AVH)IMJ*70LG/I:2Z'3X8DY^XW:Z'@QI6AUHP.KE*+5C4Y%DE]KY=!A
M<O)K+27MTBBA'TM@#=(NS99T/!]3QI1BSO)CRB65<ZF60R?OR:_U&IPEF=H'
M=(*;4K0^H"/`E*+U`9TRI;&@E4/G]6DL:"ET`6)BKI3#]M`UB(FY10Y3Z)[#
MQ%PFARET202MF^92.26-;CU,Z'8(-8VN-33KO99&UTDFYK)(U$AW]%&*EH=N
MDDS,17R8ARZ43,Q]?)A"UTHFY@H^3*%[(Q-S$Q^FF":9"PLQA>[B3,R]A9A"
M5W(FYOI"3*&+.1-S8R&FT,V;B;FX$%/H`L[$W%^HI+3;B?G@%J;01],2\]TM
M3*$/I24+-84^D):8KW!A'KK\EOI-2Z'[88W!M23ZM%QBOC^&ZNB;<HGY#!FF
MT*?E$O,U,DRA+\PEYJ-DF$(?FDO,M\DPA;XOEYA/E&$*?8LO,5]CPQ3Z)%^2
MJBGT9;[$?)L-\]`'^1+SB39,H>_R)>9+;9A"G^=+S`?;,(4^24JUUAX*Z<ND
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M/U%<X?#@V\/=YX<7(T!!X2_/SV_\#^KTX[^?7_ZL`Q.?_D\`````__\#`%!+
M`P04``8`"````"$`*1AS(>(+``#,-@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6RL6UMOX\H-?B_0_V#X_<26Y#N2'*QUL02T0%&<ML]>1TF,C:W`
M]E[.OR^I(35#TNM5BKZL-Y])SO`;#N>39-W__N/P-OA6G\[[YO@PC.[&PT%]
MW#5/^^/+P_!??Q2_+8:#\V5[?-J^-<?Z8?AG?1[^_OC7O]Q_;TY?SJ]U?1E`
MA./Y8?AZN;RO1J/S[K4^;,]WS7M]A&^>F]-A>X$_3R^C\_NIWCZU3H>W43P>
MST:'[?XX=!%6ISXQFN?G_:[.FMW70WV\N""G^FU[@?F?7_?O9XYVV/4)=]B>
MOGQ]_VW7'-XAQ.?]V_[R9QMT.#CL5M7+L3EM/[]!WC^BR7;'L=L_3/C#?G=J
MSLWSY0["C=Q$;<[+T7($D1[OG_:0`=(^.-7/#\-/T:J:3(>CQ_N6H'_OZ^_G
MX/^#\VOS?7/:/_UM?ZR!;5@G7('/3?,%3:LGA,!Y9+R+=@7^<1H\U<_;KV^7
M?S;?RWK_\GJ!Y9Y"1IC8ZNG/K#[O@%$(<Q>WT]@U;S`!^'=PV&-I`"/;'P_#
M&`;>/UU>'X;)[&XZ'R<1F`\^U^=+L<>0P\'NZ_G2'/[CC"*<5!<DH2#P24'F
M=_-HO$SF$..&WX3\X)/\XMG=))[.%^WH-SPA;CMM^"3/GHXS<H1/<@SSO3'B
MG!SA\T,YPD9K9PJ?'\QQ29[PV2O'D5O:ME*R[67[>']JO@]@^\'BG=^WN)FC
M%03C$G')=D7SLYJ!=<8@GS#*PQ#2@'(X0Z%_>YR,Y_>C;U"<.[)96YM(6J1L
M@>6#83,-Y!HH-+#10*F!*@!&0$+'!%3Y_X$)C(),<`YK!CPUL4J;+=@ETT"N
M@4(#&PV4&J@"0*0-^S),^WIOX'5&8^@"P3HGDZE,9^ULH,]P/JE!,H/D!BD,
MLC%(:9`J1$2>T$?"/+'0X^E=UX-ZESK&@<T"/2*H]87BP!G%T+$[HV2RE$9I
M9\1$90;)#5(89&.0TB!5B`A:@("0EMO+C\9M[CSC-2%SO]@&R0R2&Z0PR,8@
MI4&J$!%9P>KTSPJ-958.B=U!AITH=<@$>H=?T.E8+FC6&3$]N4$*@VP,4AJD
M<D@<(\TB43AQ^B>*QC)1AX2).F02MTT\'D<3E6/W?9<CQ6CGUK;MPB%1TJJ3
M%MIT;G@V0-A$ABV[[SEL%885*:,Z52<6*`-4)+>+%_UD]@Z)PV,KF>I#R1E-
MPY6/%FJ_9V0$/38H#]7G<QH.3MG.*%JJ&BK(R!\@FSX3**].0)%<_6("@F68
M9<CR;6K16%+K$"@LGVLR5;64DI%O'IE#IO#1491,U0&3=V[>R/)(1GX+;SHW
M+K'2(6JTF:S,JG.[/IH@+8*&WY^UUEK21I`J2:6D4K9:=ETW(PBVG)]F,E5E
MFGM';V6I8ZN@!AGR(Y;71U1G7.4=KX\HZ4-I%FSMVT47H;6BST&R[&9JBZ7D
M&`=U1U"R:-M>-)ZH+I!;GX*AH,08\I%+@D2114N],X6CY`1U6W].G,H#=<)%
MOHX<)$MJIO)+V<HO<$;0-'%'P5(+^MSZ%`R%I4/C^\@E68EBO<))Z"@Y09'7
MGQ.2A"$G#A)U$D6J7Z<16?G5S`B"U<1S+)J;#69<"HX2EHFQ*E7@A6J5%4=I
MYR+)0&G7GPPG!$6!D#:$T\$WW9DAPUDEGL4L(@A.ZL!1E79.5C'TT<[J2L_I
M)L&%N^'P?L22H"B)7$U.%ZHU5GXTB"-Y0K$8\.2N=._P+L3E=;_[LFY@>M`_
MKC0=W`%TG4N*T\]IC3=4H`U!+?',4X)F$,VG;#0#6T&9>RO=&7(.[XNP8,B/
MN.%8-T<LV>KFB!6'OU)J*$-O4/A'\_XS"D&>=1PZ,2M*D/2M%XPI7F`AK1[*
M+)1;J+#0QD*EA2H!R=)!+:KR3A:MY/SH?1*G:G&H;LTG8W5HKB/2ON(PGRD9
ME'HK+KS,0KF%"@MM+%1:J!*09`BE9<#0E4T45H`3HL`"SWP=$>3+/+509J'<
M0H6%-A8J+50)2.:'*K!_?DXSBOQ(1OH]FT8.^L4UI;=BKG(+%1;:6*BT4$70
ME2M+O'G1/^766HHQ@L+&2-#/KRZ]09<MAPFN+]G*2XH-0]UUJSJ&2F_`D2L1
M62PW"H,/Y([6*G<'*=&E+BW2=IB'(5Q;\IPR"^4$P0'*5@5#@<RRCJ6%*G9L
M8\F446WUKG"H%Y,R04EXNB0S=4"GY!F*;POE%BH8\F1M&/)-H[10)2"9,^JP
M_CD[U1;NZIB@!#Z[?I[,E"I,R0RTD[>R]Q#8:D[:1EZ'YO2U*`,W/%095\:&
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M'2@<>Q\;6`&:#H)D<>C;H2EYBN)PGE0<D7E$85T*@D1QN"A!X)*L*/!$/VRJ
M1&#)!DJ\_FPX01@>HBA`D"!5'*IUI606K'1&$!6'DE.Y=2@($J41*M3V-F4I
MPZJ&78FPD@E4I/V9(/WJ9>(Z(0C)[HY;>V>=S$))RQ#H!>]HU!=9!>M>$"2J
MP\TB"%_V"E^)\)(9%'3]F2'Y%S+#BA!6JTLP6:@6EN(U(I02"&G?3AT$<VM_
M5S69)*KKY.SDY45!D*@3$[HDJR[T8JSF4XG0DA%4=OT9<3I0[!J"1*TDYO('
ME"DR`A/QC!`$'P&5YIAQ5E`KWLH^>*#PHGS,B"5/0HZH]FM%5C\=4?*',K$_
M?TY4"OX(PNT<T*`O?[`IN8KR5O;JAZV@1KI8YI%<SE9AH5'X0`"S%>Q"'TL+
MRY*M;HY8L54[HN0/!65__D@3^RI:)P3!JG%EI80%_26S4&ZA@J'@5@Q#7AF5
M%JH$)!*<?$C/MM92SQ(D+WWTD\64K3P+F85R"Q4,!2O/D(]56J@2D$SY0Z(5
M[YSCL1NL*4/(:E=[R4*=@"F9R8VJ*S0C*]3872R[)WPLKJ*"H:`8&`KG979A
MV6O$RL>"$25_J!)[[PFX#6_X(PBE8Y=SLM"70.0)>IMSSA@*':^0Y>('$J@@
MQ_"DXE@^?,G0S?`56;GPDAD4C/V9<?)25!9!V.,#9M11G$Z<F3C3S#IG;!5V
M[BMDN5A!,RK(,3RM.!88=_,R(Y9L=7/$BJS<B)(_<`SY^Y^>GD\PB-JP#E(]
M2I]AY/B+!^IL=;-&<K(2)>@F(4K00;='+'N-6(D1):LH5(.JU*SV>Z`.KY`8
M6AT$3[AX@Z9D%4"9A7(+%1;:6*BT$+[:@O-R([J\W:LJ[@6$0WUZJ=/Z[>T\
MV#5?\344>/[Z>-_!_([,?/4)(D$>ZAMX3+["1]+7OEG`-VWWU3Z3*;]RH[Z!
M=W$^M0\*%+Z&=W3:/J3Q>`4_J;\R=K*"WZ!;_--D]<GU$QUH`C.ZXK"&F5Y/
M>P8S:L\\%2F=K>"GPW;H=+[*KM&TF:_@=[=7[*/E"I\57_DF'J\RMYYJ;'@`
MN\)GK.`SZKZ"=XG>MR_UW[>GE_WQ/'BKGV&1Q^U/;D[N;23WQX5^-_*YN<!;
M1%`'\!X*O#56PP^OQ_@+_>>FN?`?.$#W'MKC?P$``/__`P!02P,$%``&``@`
M```A`(P<*.%?!@``TQ@``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
MK%E=CZ)(%'W?9/\#X7U$0%")]J0%^=Q--IO9W6<:44F+&*"[I__]W*(^J`_;
M:+(OPWBX]U35X535K>K5]Y_U27LOVZYJSFO=G$QUK3P7S:XZ'];Z/S_";PM=
MZ_K\O,M/S;E<ZY]EIW]_^OVWU4?3OG;'LNPU8#AW:_W8]Q?/,+KB6-9Y-VDN
MY1G>[)NVSGOXV1Z,[M*6^6Y(JD^&-9VZ1IU79QTS>.T]',U^7Q5ET!1O=7GN
M,4E;GO(>^M\=JTM'V>KB'KHZ;U_?+M^*IKX`Q4MUJOK/@537ZL)+#N>FS5].
M,.Z?YBPO*/?P0Z&OJZ)MNF;?3X#.P!U5Q[PTE@8P/:UV%8P`R:ZUY7ZM/YM>
M9CJZ\;0:!/JW*C\Z[O]:=VP^HK;:_5&=2U`;OA/Z`B]-\XI"DQV"(-E0LL/A
M"_S5:KMRG[^=^K^;C[BL#L<>/K<#(T(#\W:?0=D5H"C03*RA&T5S@@[`OUI=
M(6N`(OG/X?E1[?KC6K?=B3.?VB:$:R]EUX<5HM2UXJWKF_H_'&2B3C$2BY#`
MDY+,)@O'F;F+^?TL-F&!)V693F:6,U\\TA=H;Q@0/"G+.)X;8W!)'CQ)WIP;
MPHW$.4F$)TDTQP;O%'!)..#Y4*=-\`O^?,@X^-/<V6V3?7GXSZ,=-["+!E,&
M>9\_K=KF0X.9#ES=)4?KANFA%J@=L7[,H%_Y$SR%6)X1S5J'-0JLU\&D>G^R
ME\[*>(>)4)"8C1ICBA$^C4!61;2!#&QE()2!2`9B&4AD()6!C`,,T(F)!=/E
M_Q`+T2"QZ#`W%!C5LR1E:`1-"61@*P.A#$0R$,M`(@.I#&0<("@#2X"BC`T6
MO[ZJ4=>@+%B_.-=8UE0<^0;'X!5Y,(6O((&";!4D5)!(06(%210D59",1P11
M9I(HM\5`T3`+83GCYI`KJ8&#+%"6!5F6;!86Q-RB(%L%"14D4I!801(%214D
MXQ%!(%CR!=?<%@A%#P+186TP,AMGDH\1%SX)IX\MBAB0H!F;@-NK:3,Q+61!
MM/V(('B;1@M6K%`G+(OOD42=LB!*G?'4@F;@CP<T0]&B9ACA-2,(KA"&91<C
M+B<0BT%+NS4UI0&$[#T=0$0X.&T4UH1E$5;I0Z7L/67->%9!%MC,'Y`%18NR
M8,3B=S#+DG8P'P<Y\.#<)4W1@#'13F])&NPJ+,U<+"1WD2!KV#R7<_%M1$B7
MS+*QTDQR3S.IV,Q2;";CFQ'D1:</ODRX/5-1M"@O1BQ>`LN2!NGC(`<>3"?+
MDG0*&!.3ER!SIDU(B):#EN9,6A\C)2%62!,E)KU-FO$)@G10(CX@'8H6I<.(
MY$SIP_DXR!7W!5DZQL2D(\AHJQ`CL'6C*;F0FHF4^%CA3)28]"9GQL<+PJ%:
M^0'EAG!1.@*)MK.E"L,G49+OY&D]<C'U*,0YCW)AZRUDYZD9,87&Y3>AT,B;
MBKSF7.I=)J2(*J)B]OZIB\X`D@$))#K05FIWG"A:T)8$"$:N446<:+OC_"51
M]AR[4%RD(LHQNC:FT%@)))1CI$TI=)4VHQP#K2@AJGH?D!`7R5#)T3%N3`R!
M$2GD$PA<1Z%`C=I2:-Q&0PJY@S@S4YKE$7T_NB>FT-A\0J&1.*40)G;D/3ZC
M[P=B42!4`C\@$*F8>8$P)'E,J@=\$T>!QT;-6"*%MB1*,!2.`D-Q6XLM%3$1
M2;1@16(;D+F4EHN81HT?+E%;3"DDMB@5%!GE^JI%46541_,JX[/Z!-W8],>J
M>-TTT&V835<V9QO,0D[JN!H7W$D*=$AEX[85[7&0X%>6-VJ/(9>G4FL=DT3A
M8L>6%K.(O+9X!RM-)93D9E,IC<)-6=*&E@E-B6JC"EQ1&Z[:B-@_FLM78L-%
M'%,;U_&"VAAR1_?[Z/X/%ET."E1HJT*A"D4J%*M0HD*I"J%[T+%?6!U\KXFO
MD.JR/91^>3IU6M&\H3M+$RVM#,87JAO3H3>JTIO8\>)!!0E/'`].1.`I&7<]
M.!*H>`8-7,/A*O?9NA*_05>\UW#+@PL.E7]C>W#(5_'GF?<,$JDO-C,/#KU7
M<,?;7.NH[WC^-3QPO.`:OG4\.(VJ_%O7@Y.8BD>.!^<QP`VF*%PI7_)#^6?>
M'JISIYW*/7R^Z;"6M/A2&O_HB<U?FAXNDP?''^&/!R4<=J=H+NR;IJ<_4`/L
MSQ%/OP```/__`P!02P,$%``&``@````A`#R/6G=0"```LR@``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&ULK%K9CMM&$'P/D'\0]&Y)O'1AM09)PXF!
M&`B"',]<B5H1ED2!Y'KMOT_-00ZGI[V2"+]XK9Z:9K&F63T\'MY_.QU'7_.J
M+LKS9NQ-9N-1?MZ6N^+\O!G_\_?'=\OQJ&ZR\RX[EN=\,_Z>U^/WC[_^\O!:
M5E_J0YXW(V0XUYOQH6DNZ^FTWA[R4U9/RDM^QLB^K$Y9@Y_5\[2^5'FVDY-.
MQZD_F\VGIZPXCU6&=75+CG*_+[;YAW+[<LK/C4I2Y<>L`?_Z4%SJ-MMI>TNZ
M4U9]>;F\VY:G"U(\%<>B^2Z3CD>G[?K3\[FLLJ<CSON;%V;;-K?\X:0_%=NJ
MK,M],T&ZJ2+JGO-JNIHBT^/#KL`9"-E'5;[?C&-OG4;^>/KX(`7ZM\A?Z][_
M1_6A?/VM*G9_%.<<:F.=Q`H\E>47`?VT$R%,GCJS/\H5^+,:[?)]]G)L_BI?
M?\^+YT.#Y8YP1N+$UKOO'_)Z"T619N)'(M.V/((`_AV="E$:4"3[)O^^%KOF
ML!D'\TFTF`4>X*.GO&X^%B+E>+1]J9OR])\">3J52N+K)/BKDWB3912%\^4"
M2=Z8&.B)^'OWT:?J3*0P'[(F>WRHRM<1J@U<ZTLF:M=;(W&KB*+1:?0CB:"-
M2!*++)LQ+A.<?8UU_?H8+%</TZ]8BZW&)"[&LQ%IBQ!+"'H=1RCU$SB*+(*C
M6%9!.FD#AK1/"+4(2@A"]0GQY=-J(\`HE)XVGD^U41B48DLN[4<L,<)[CBW`
M6-EY_^`!D3W1H-5;H+0#42U0LWTM1`'Y\\7$U/+-120R2;*M"(F*^+C.N[KR
M`KI('8@RPUE39MYB.0'^SNH6B6QB*D*(!:1Z.A`EMG")^=']M$0:FY:*$%HA
MH=6!*"W1Y8@5A#,$[U1+I+%IJ0BA%1%:'8C20EU26MX,5^:=M$0:FY:*$%IS
M0JL#45H>JK+/ZVT3D&AY>%/*P6IF'RQI43AHK^`7-BHU*(<3X^:^OQI0\I[R
M8C@'CJ'L4H>(7DM*3DT$RB$GW)345S##17+G0GK*E2UJ*D2H$9--]42.FG!;
M0BW"B=S+3)MV7S05LIF%9-U3KT,YHA&[%_8:+,7NY`>;EK;K>)WUFP74H;#O
MI\&*M(.TG0FT*<+0N*[5C<3NB2IW&S\QT;X>92Z$KO'3,VU^QGQM?L*$R<K>
MQD^YMU5E.G2-7PNS]#,N;/-C>L%M_%SW]W3H&K\69O$S=FSS$[9,]/,C82A7
M_,[M`IX.7:/7PBQZQI9M>L*>A]!3MFZMK@Y=H]?"+'K&HBUZXK*G]&Y:73G1
MOCK:T!5^'<SB9US:YL?TB]OXN>W!UZ%K_%J8Q<]8M<V/:1G^<C:@G_ENT]`A
M(9CQN8A:LT%1:_:9IC%PYRM3D>7N6D*?'?5J/1'GX+`39D^NC&&[7U^WC5Y7
MTR$BG6D1<L.0&I1#CG2-M[U$-#O5*OI2&,/7=W,:A>NSMYP$E;:Y5JY@3*=8
MX.[^[EV`[W8.'2)ZF9:@]5(3N<4D7>**7EUKZ"MA#%[KI5&V7@25^AW*64.F
M,W@1JO;.39/O=@H=(G*9%J#E4A,YN81']VK_BES:T:%^KW",HVNY-,J6BZ!2
MOT-1N0*F%0RYZ9-Y;*O0(2*7L7PEET$YU+@NX"V'W,(';E_0(<+.&+YFIR8R
MBQEP/0!5>6>9R312M]XJSXG;)RW*6F6*2@W*D9+K":$O]^OW$E8-H+]%";B>
M,*<]P:`<=J0GO'U=!)WO]Q4C)I^T*%LQ@DH-RN%$6H%\`#G@]C[HF@2.H"Y9
M';(K;TX[@D$YU)B.H'=']ZZEVQ*"SNS[ZM*68%`..6',-WM<H&W<\K@Y,?ND
M1=EK25"I03F<N)8PCP89B=L5@L[O^XK1KF!0#COAS;<K)M".7Q"_3P*-LA4C
MJ-2@*">Q6>YSDD]/!SP*E'GLKJ!#I/II5S`HAQKI"F^;1=@9?W]QB,LG+<J6
MBZ!2@W(X<;W`FP\IL-"](=`A6[$%:1&I03GLB/E?4:SS]YYB"V+F2:A1EF(4
ME1J4PXE8OBBP`4^VPJX7X`#*776(J$6-WZ`<9L3XKZC5V7M?+>+E2:A1MEH$
ME1J4P^FG.7[H.KX.$<&HXQN40XXXOO2*53!D;Q%V[<`LIPH1=M3[]42@''8_
MS_M#U_MUB+"CWF]0#CM41-]GKQ2;0%/O7Q!73T*-LHN-H%*#HIPBQON7JR'+
M*3/9[J]#1##J_@;ED+O+_86CN((17T]:E"T80:4&Y7!BW'_("RI\8:#9X@C*
MS'3(EFM)K=^@.FKJ4P/U1OV45\]YFA^/]6A;OHC/"*(5WH5W8?V-0[A:QQ`>
M*<@(*FHMZH49B6;X,(*;$T<>LLE/)F@VC`@QN6Q^^YD%F1.'P3J&93-S,"+:
M##<28H2;$X<1LLD7[N0X,&K,D6^[G9$Y1N2C)F=D@9$%RV")$>XX<0"ML<5A
M6&-$[,N8D1!:LW/B$%JC_7-SH#6V+=P(M&;GQ$&XCK&_9^9@1-PQ<2/0#3<L
MW`AT8[/%P0+'X=3!?A]S6$4#*,K.B7THBEMZA@%&Q/,/9B2`HGC\P(U`-S9;
M'/@X#EMO&!%WX%PVU"@[)_91B7@(Q\S!B'@HR(U`479.[$-1/*/BYD!1/#+C
M1J`H/P>R<:K%W@Q'8:L`(^(E,',4#WKB/2TW`M7P`I0;@6IX`<F,^)B#Y]_<
M".;@V3,W@MIE6>/;KIC-)2BSF9"(BXM%9N(Q+B=.QT38$X-/L/#LNF/9V4K!
MTK(KBX65M3#M#`N?C%VRY_QS5CT7YWITS/?H!3-YEU*IC\[4CZ:\H&OCP[&R
MP<=B\K\'?!R8X^,D^8YC7Y9-^P-23[O/#1__!P``__\#`%!+`P04``8`"```
M`"$`8ZH6.Z@(``"W(P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RL
M6EMOHTH2?E]I_X/E]V-#`S:@)$<Q=^D<:;6:W7TF-HG1V,8",IGY]UM]HR]%
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M:'6@$"BOD7;.=N!?_>+0O-;OI_'?W4?9M&_'$;8[`(NH8?'A1]H,>_`HT*Q(
M0)GVW0D6`/\NSBT-#?!(_?UQ26#B]C`>'Y?>9A5L'<\%\<5+,XQY2RF7B_W[
M,';G_W$A5U!Q$D^0P%.0;%8^";8A([FAZ`M%>,K9G548!/XFW,+T-S1AE*T;
MGD(S6)$P<(,-7?<-Q8U0A*><DMRWV*W0A.?/60FYQM8*3Z%(MO=9&0E->-YE
MY9KO+@N6M![KIX>^^UA`!L+^#=>:YK,;`YF,$NZG*6X^"QN(%TKR3%D>EV`&
M1,0`L?[MR8O(P_H;Q.=>R.RPC&M*)%*"!B.E36T@LX'<!@H;*&V@TH`U.&'R
M!`3ZW^`)RD(](6W824"YQG),(B6D2FH#F0WD-E#80&D#E0889D-JZF;/EP>Y
MSU08"H&VSVYHF;/C,E!JI#T)0E*$9`C)$5(@I$1(I2.&G5!)[K>3"D-&0"G0
M`MHSPW7'A0A4YDG(#0-3*)F$I#=2A&0(R1%2(*1$2*4CANU0^'3;>9*O:"&]
MO=U4C[E!+G['D4#;7(2D",D0DB.D0$B)D$I'#`-AHW0#;UM%A4VK.$+XV44K
M3\(1'VJ%MK<;<V_324BZ)T-(CI`"(25"*HX00G/(,!2.F/L-I<*FH1S1#>6(
M3UC1)H[K6S9.XY.-@H.MC97I7"#>E/'%I$6/`F"U4J><QB5KI;,:%M-^U#J@
M"%E!)-S>9*IFVLX1`DFB;>G6-#<10BJ^4X%L)N,R@;#>C3M`("I^"L13(IY*
MYS%,AG-8-_FVH538-)0C!.@G0Z/(LE/(P&.2<</0%$JYD&<6.(LIFV.*'),I
M%T+J6"SFU.P%E',+B*RNH9ICTA9@>-8%6W37TDI(-K0!_HMP8HJFFP4$R:3Y
MT.YZ$B'EJ=A()00GLG)^9*5()NFU,).0XBHDEX)*"9GT5EY7D@OR3EN$VC?3
M;;1GTI+P=D2ZO,."TU-F]TY`1DRZD7U6"BD/SG"U)CLH4BEE)K(=EG)&B`[%
MI84%3UPII06FI+^YB%)*&8N(K`.BDO2?+<)T,NW0-"??'YN\M3/\S2$K-NUB
MYPHIK=H)R`O$>1`X+B%6[&123P_-:4*YYX644NRER1YN/'>SL8I.)=48N>D@
MVMO]DH-$4Z@')(>L@+36DKA<RE.*J83,O$')*^BC*05RH0@S*@\A^G*>W@KN
M2G+=%U>T+?PEMU%%J^9QR(@K>*]C5OO$Y5*^:@A2"=V.*Z&GQY6`=*\A]M)D
M#S<D\D-K4964F8DKVE;^DH-X/VHD'H<L!UE'5D+?PX!G?7^*A51"*M0R">GN
M$(JZ.Q!7*1455R6A&>MIKVE9[P;L<C`>V_W770?U$RKZ3,WWH$BP.OI,;TIV
MJ(@>5F]#B&-=%A.AZ!F1C$L^Y_+U3H0X*.G$C`87+OG3NE0><NCV(DJQ5&L1
M5FVLA!3Y;!%F1:-=[PW??^FNG_D>6I;)^;QWAIFE13N70W`WE5""H11#&89R
M#!48*C%4&9!I-VU]+;M]E[5A/_OBB3?1U.O3,>]%UJ;L7"YE7-6)@]J/24HZ
M+56*$LHPE&.HP%")H<J`3`]!_.@>FLD^/0*HM%6I!:2*1^(B*,50AJ$<0P6&
M2@Q5!F381[?B?ON8M&F?@*#0RIU)!/07EW8E)14S#.48*C!48J@2T,S5G9X)
M/V$R;J(9`=Q7=).YU.?7=Z$#`LI:KL-7R-M@*:7:E4)"TXL!J]J62D`R5P*:
MLYVVAUK"WPYG(+##64"!>0)8_78BI92'4@GI#A"]JK(V%U)Z<R85%5<I(<55
M247&948X;>[N-YFW@GH-)Z*'A.V:2AMQ[!Y>2JD\3P7DA:R'=YT-_?IAMF@9
M5LLEI`PN)*3(2Y,\]#W?M\[TRM`R?4);M_M]PAL]PR<<,MIVXMAM.WW'`^40
MSF`9FJF``MJR?'ORMZY#K*8ZPUJYA+1V2T**N[2XW<BQ.^+*T#)=0MNW^UW"
MFSW#)1RBN:>%B65<0M]P4)>HG4P%),(D\L`G=GN68;5<0GJ8(/+2)`]=?^N'
MUJE<22:V)M,IM"'3G**]L+Z_)R6\JS-\Q2$MS1,A!;V?BA4N%?@B?R+7@>^.
M=@()*J67"RJ-O<#LI8`$>^0[440L\DHR,7+3,W]+QPAA@`HL[AB%%)QHRC5(
M*L-2.88*#)48HM_#693R+]OLXQS_OLT_69Z;_JU)FM-I6.R[=_KM&D+HZ6&"
M^8?U71##AP)8LHV[VYCVI'CDV0WC9Y@;CT#G"#HL_1%;!"-L@^P1`O/,LL$=
M%'3FU@:]2TR[";R"A+AQ"LF-1^"(!IVY$?AIP3,[H^R5P4\.YN1W!!8\,\/.
MB^%[&I[YV8^?9QVY`_O8G=::.-G$\)$#$R7;.)US>[&-X1/!C#PXD%Z>\0B\
M8(CI'1J/9#!"K])X)(>1?':D@)%B=J2$$7J_!K;U9"3\;.):OS5_UOU;>QD6
MI^850M-A5^B>__""_S&*Z]Q+-\(/)MC-[@@_D&G@@Y-#OVB\=MTH_Z`33#^Y
M>?H_````__\#`%!+`P04``8`"````"$`W8Z4TZ@#```%"P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6RL5EUOFS`4?9^T_X!X+]_D`R6IDI!NE39I
MFKKMV0$G6`6,;*=I__VN;:!\9%DF[:64DWN/SSWWVGAQ_UKDQ@MFG-!R:;J6
M8QJX3&A*RN/2_/'T<#<S#2Y0F:*<EGAIOF%NWJ\^?EB<*7OF&<;"`(:2+\U,
MB"JR;9YDN$#<HA4NX9<#9042\,J.-J\81JE**G+;<YR)72!2FIHA8K=PT,.!
M)#BFR:G`I=`D#.=(@'Z>D8HW;$5R"UV!V/.INDMH40'%GN1$O"E2TRB2Z/%8
M4H;V.=3]Z@8H:;C5RXB^(`FCG!Z$!72V%CJN>6[/;6!:+5("%4C;#88/2W/M
M1KNY::\6RI^?!)]YYW^#9_3\B9'T"RDQF`UMD@W84_HL0Q]3"4&R/<I^4`WX
MQHP4']`I%]_I^3,FQTQ`MT,H2-85I6\QY@D8"C26%TJFA.8@`/X:!9&3`8:@
M5_4\DU1D2].?6.'4\5T(-_:8BP<B*4TC.7%!BU\ZR*VI-(E7D\#S`LF51+].
MA&>=&%ANX$SDVE?2@CH-GG7:[)8T(%6UPK-.\QQK%H;!9#:]N*"MS5+>QTB@
MU8+1LP'S#';P"LG=X4:0V9BN);=M^%,7P'Y)LI8L2Q,V(AC,87)>5OY\NK!?
MH-U)';,9Q[C]B&T3(7LK:>,AL.L`-A305@'M^@]52!991;/^I@'>R_(&DIN(
M)B4>`KL.T),,@S*4[,.>N3SMC<\R">:ZX[,7^'U)&QT#.Z?1M!TA\0C9=9&>
M3IC,H4XOM-HANWE$)`\,V:2CW9_/!MIUD`<^=`9IW@_:MD%-@?$(V7617CD@
MO%O.=;MEL-+<K+2ID>F[N2,D'B&[+M)3`V[<KD8&]]5HQ)NI'><Y;CAPJOY]
MWK'3G0T\CW40S)[<MC.G3[%K*<""GO3IOTB7P7WI&O'<1OJDO^Y6_^[KTUD=
M!C7BJ8S)8"/N:C[5F)Y.>3L8'7"6/"5%1I+G#=7?A`N#X,-*^GB3''WY&@'G
MWP?5"P?>;760?]U^'11H^]U@6%>]D/KN]NH"UFMU/=$*%/_M/)$D_<(T`CNP
M&?GM"(E'"%P+)(_.TBKU9UY_:@K,CGB+\YP;"3W)3[B<V!9M;Q=K3ZXZP#=P
MZU!3,,2]",[6"_%^!(?9&%\'T5JY..0)(C@MQO&;,()]>P&?U[<@NR6"6TB%
MCO@K8D=2<B/'!RC143/&]#U&OXBZ)WLJX/ZAVI/!=1/#I\Z1)^J!4M&\P,)V
M>X%=_08``/__`P!02P,$%``&``@````A`,+HFO@S`0``0`(``!$`"`%D;V-0
M<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````)R1T4K#,!2&[P7?H>2^3;LZT=!FH+(K!X(3Q;N8G&W!)@TYT6YO
M;]9U=:)77H;_SY?OG%2SK6F23_"H6UN3(LM)`E:V2MMU39Z6\_2*)!B$5:)I
M+=1D!TAF_/RLDH[)UL.#;QWXH`&32++(I*O))@3'*$6Y`2,PBPT;PU7KC0CQ
MZ-?4"?DNUD`G>7Y)#02A1!!T#TS=2"0#4LD1Z3Y\TP.4I-"``1N0%EE!O[L!
MO,$_+_3)2=/HL'-QID'WE*WD(1S;6]1CL>NZK"M[C>A?T)?%_6,_:JKM?E<2
M"-_OIQ$8%G&5*PWJ9L>W;[Y)$#<5_9U52O9V3'H0`502WV,'NV/R7-[>+>>$
M3_)BFN9E6EPO)SF;3ME%^5K18VNXST>@&03^33P">._]\\_Y%P```/__`P!0
M2P,$%``&``@````A`$-6$<66````J@```!````!X;"]C86QC0VAA:6XN>&UL
M/(Y!"@(Q$`3O@G\(<W=GUX.()%E0\`7Z@)`=32"9+)D@^GOCQ4M#T5#=>G[G
MI%Y4)18V,`TC*&)?ELA/`_?;=7<$)<WQXE)A,O`A@=EN-]J[Y"_!15;=P&(@
MM+:>$,4'RDZ&LA+WYE%J=JUC?:*LE=PB@:CEA/MQ/&#N`K#:JVK@/$V@8C\!
M*OT2K<;_BOT"``#__P,`4$L#!!0`!@`(````(0!&$+:-@`,```D+```0``@!
M9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)Q676^;/!2^?Z7]AXC[E?1#TZN*,%%"UFII$@6Z7EH>'()5
ML)EMHF2_?L>0MF1U6+<[8Y^/YWP\A^-]WE7E:`M2,<$GSOG9V!D!3T7&^&;B
M/"2SC_\[(Z4ISV@I.$R</2CGL__A/V\E10U2,U`C-,'5Q"FTKJ]=5Z4%5%2=
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ML`@C$M]&41*_0X0@-&R4`C36#@OU8LDDKH,1)T$2W4>+)";+&5FNHG60W"T7
M,0D64Q*^0V6UCF;1>AU-29PLPZ_D'2IA$-^2V7SY:(\A*8"$HJHIW[?)B9NJ
MHG)/1$YBMK':7X`F<Z$468$D<8%16\5FC%.>,EIBIK%36A8IJ^2!G1V`Z$?#
M:L,XJ^@:2JHA,[G&$@924KX!(VVWC)%53+?O;72AP-JC!N("NX9QCY8/X/E&
MM7J/U'@ZX:1-@2%,UF82N&JI:\4?574I]@#D!CCD3)-52;D=R1U.M@I(0G<G
MH`Z7[MSJ_VWMT,%W9)95VEZ8(8W!A)]H5]-!;],WY*6?FB&YX0Q=6&/N$>"&
M*I:V]9^RLC%M-[>J6)(Z!4U9J4@"N[]5L1?.RB9R<&-UT0O$4D>KBD4.J37H
MY30AC9K5RW"/G`B_T8T$<L\XJYJ*S`'IAD-@WU';ZF:8R78W)ZA\R(#=C=(,
M=P9LCD=@F\(<`EQ1Z`;(%TFM*KW*Q%JD3V19FW]]-W_M.3NAHLBRT>J/*NOX
M@02I9ELSVKJ>L0);"!Y2571#';O_>*)95>P#;;!ECMC;(XIN3OPVCQ1>/PXS
MU`KK50H4,?S,(`<I,2!-=T=SZ&CG^&W+F#/^I![J1$RQP,]KU/&EU[9,A@O&
M\_OKA7>+&Y0LC9&P,#^J[%GF[8-9^KYUFZU_?G4VOASC/M>[\]P#.?''Y?\"
M``#__P,`4$L!`BT`%``&``@````A`(3FT(<(`@``@AL``!,`````````````
M`````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P
M(_4```!,`@``"P````````````````!!!```7W)E;',O+G)E;'-02P$"+0`4
M``8`"````"$`"GHX!#,"``"I&@``&@````````````````!G!P``>&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`ATK""T4$``"&
M#0``#P````````````````#:"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&
M``@````A`*9(:&7/`P``H0P``!@`````````````````3`\``'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````(0`8$YJ4V`,``*@,```9
M`````````````````%$3``!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M`BT`%``&``@````A`!G#@`X#`P``AP@``!D`````````````````8!<``'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`_8:8I-L'
M```J)0``&0````````````````":&@``>&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;%!+`0(M`!0`!@`(````(0`U/P2D00X``+U2```9````````````````
M`*PB``!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A
M`)[C]7J"`@``'`8``!D`````````````````)#$``'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`1HKBA5X$``#R#P``&0``````
M``````````#=,P``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`
M!@`(````(0#_9&L7F`(``#\&```9`````````````````'(X``!X;"]W;W)K
M<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`!LOE*1V`@``QP4`
M`!D`````````````````03L``'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"+0`4``8`"````"$`D<A'(D`$``"[#@``&`````````````````#N/0``
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`/5FK$H7
M!@``HAP``!D`````````````````9$(``'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"+0`4``8`"````"$`<K2S7F$#``!?"@``&0``````````````
M``"R2```>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+`0(M`!0`!@`(````
M(0#.$#:*"@,``.,(```9`````````````````$I,``!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L!`BT`%``&``@````A`%DJZOF=!```>!$``!@`````
M````````````BT\``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`
M!@`(````(0!":2.F-P,``&(+```8`````````````````%Y4``!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`U(7L]7A>``#R+@$`
M%`````````````````#+5P``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4
M``8`"````"$`XJ8E;!0/``"!FP``#0````````````````!UM@``>&PO<W1Y
M;&5S+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3````````````
M`````+3%``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`)Y!
M-4W;`P``S0T``!D`````````````````><P``'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6Q02P$"+0`4``8`"````"$`G`65>3\#``#3"0``&0``````````
M``````"+T```>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+`0(M`!0`!@`(
M````(0#)*BK`B`0``*41```9``````````````````'4``!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L!`BT`%``&``@````A`.SK5755`P``E@H``!D`
M````````````````P-@``'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M+0`4``8`"````"$`$EB38W4#``"B"P``&0````````````````!,W```>&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0`9TWGR7P0`
M`+81```9`````````````````/C?``!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L!`BT`%``&``@````A`$8\1>B1`@``X`8``!D`````````````````
MCN0``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`
M/RY.16D#``">"@``&0````````````````!6YP``>&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#320)B>@4``),4```9````````
M`````````/;J``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&
M``@````A`+[1&_^+`@``+08``!D`````````````````I_```'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`R#^QU]L&``![&P``
M&0````````````````!I\P``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M`0(M`!0`!@`(````(0"X"49_8@,``-`*```8`````````````````'OZ``!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`\D"G6`,)
M``#C)0``&``````````````````3_@``>&PO=V]R:W-H965T<R]S:&5E=#@N
M>&UL4$L!`BT`%``&``@````A`#I<7VCV!P``F"<``!@`````````````````
M3`<!`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0"2
M*&#3GP4``-P7```8`````````````````'@/`0!X;"]W;W)K<VAE971S+W-H
M965T-BYX;6Q02P$"+0`4``8`"````"$`RL=[7)H&``!7'```&```````````
M``````!-%0$`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@`
M```A`+!6S%V$)```I\$``!D`````````````````'1P!`'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`)\)D%?(#``#6#@``&0``
M``````````````#80`$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M
M`!0`!@`(````(0!@K5BRL`P``(<[```9``````````````````%%`0!X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`'`:FZ\V`P``
M6PD``!D`````````````````Z%$!`'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"+0`4``8`"````"$`+I[(9W,'```\)```&0````````````````!5
M50$`>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0#T
M)RO49P(``'P%```9`````````````````/]<`0!X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L!`BT`%``&``@````A`(;7^PML(```@J(``!D`````````
M````````G5\!`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`
M"````"$`*1AS(>(+``#,-@``&0````````````````!`@`$`>&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0",'"CA7P8``-,8```9
M`````````````````%F,`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M`BT`%``&``@````A`#R/6G=0"```LR@``!D`````````````````[Y(!`'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`8ZH6.Z@(
M``"W(P``&0````````````````!VFP$`>&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+`0(M`!0`!@`(````(0#=CI33J`,```4+```9````````````````
M`%6D`0!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A
M`,+HFO@S`0``0`(``!$`````````````````-*@!`&1O8U!R;W!S+V-O<F4N
M>&UL4$L!`BT`%``&``@````A`$-6$<66````J@```!``````````````````
MGJH!`'AL+V-A;&-#:&%I;BYX;6Q02P$"+0`4``8`"````"$`1A"VC8`#```)
M"P``$`````````````````!BJP$`9&]C4')O<',O87!P+GAM;%!+!08`````
..-0`U`%P.```8L`$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5CHK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Financings and Warrants (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="6">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 04, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 22, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 07, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 03, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 04, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">21,150,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">15,685,562</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">$ 9,038,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">$ 1,741,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding" onclick="toggleNextSibling(this);">9,371,002</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightsExpirationDateEarliest', window );">Class of warrant or rights expiration date earliest</a></td>
        <td class="text">2016-04<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightsExpirationDateLatest', window );">Class of warrant or rights expiration date latest</a></td>
        <td class="text">2020-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 1.60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 116.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember', window );">Weighted Average</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_WeightedAverageMember]" onclick="toggleNextSibling(this);">$ 2.31</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_WeightedAverageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember', window );">Public Offering | Preferred Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockConvertedInToCommonStock', window );">Number of shares of preferred stock converted in to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockConvertedInToCommonStock[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember]" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockConvertedInToCommonStock<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember', window );">Public Offering | Common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares of common stock issued in conversion of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">12,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Preferred Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember;us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember]" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Public Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants available to purchase additional commons shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">6,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant coverage ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price for common stock unit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants were exercisable upon issuance, expiry year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 1.60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NetProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NetProceedsFromIssuanceOfCommonStock[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">17,900,000</a><span style="display:none;white-space:normal;text-align:left;">abio_NetProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockIssuedDuringPeriodSharesNewIssues[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock shares issued upon conversion of each share of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockLiquidationPreference[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockLiquidationPreference<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership', window );">Percentage of total number of shares of common stock then issued and outstanding limit on beneficial ownership</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">9.99%</a><span style="display:none;white-space:normal;text-align:left;">abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature', window );">Intrinsic value of embedded beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=abio_DirectorAndChiefExecutiveOfficerMember', window );">Director and Chief Executive Officer | Public Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants available to purchase additional commons shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_TitleOfIndividualAxis=abio_DirectorAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">39,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_TitleOfIndividualAxis<br>= abio_DirectorAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockPurchasedByOfficer', window );">Preferred Stock Purchased by Officer</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockPurchasedByOfficer[us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember;us-gaap_TitleOfIndividualAxis=abio_DirectorAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">781</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockPurchasedByOfficer<br>/ us-gaap_SecuritiesFinancingTransactionAxis<br>= abio_PublicOfferingMember<br>/ us-gaap_TitleOfIndividualAxis<br>= abio_DirectorAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">PIPE Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">356,430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants available to purchase additional commons shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">249,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of private placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NetProceedsFromIssuanceOfPrivatePlacement[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">805,000</a><span style="display:none;white-space:normal;text-align:left;">abio_NetProceedsFromIssuanceOfPrivatePlacement<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuanceDates', window );">Public Equity Offering Close Date</a></td>
        <td class="text">Jan. 25,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PrivatePlacementSubscriptionDate', window );">Subscription agreement date</a></td>
        <td class="text">Jan. 22,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant coverage ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">0.70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price for common stock unit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 2.81</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants were exercisable upon issuance, expiry year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 2.28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares', window );">Closing bid price of the common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClosingBidPriceDate', window );">Closing bid price date</a></td>
        <td class="text">Jan. 22,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">5,116,228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">164,636</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants available to purchase additional commons shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">1,279,057</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">65,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuanceDates', window );">Public Equity Offering Close Date</a></td>
        <td class="text">Feb.  07,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Feb.  04,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant coverage ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">0.25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">0.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price for common stock unit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 1.70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 4.43</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants were exercisable upon issuance, expiry year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 2.125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 4.13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares', window );">Closing bid price of the common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">125.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClosingBidPriceDate', window );">Closing bid price date</a></td>
        <td class="text">Feb.  03,  2014<span></span></td>
        <td class="text">Jan. 31,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">8,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">730,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">7,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NetProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NetProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 7,900,000</a><span style="display:none;white-space:normal;text-align:left;">abio_NetProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NetProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 616,000</a><span style="display:none;white-space:normal;text-align:left;">abio_NetProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RegisteredDirectSubscriptionDate', window );">Subscription agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or right exercisable expiration period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClassOfWarrantOrRightExercisableExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or right exercise price of share percentage of closing bid price of common shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightsExpirationDateEarliest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or rights expiration date earliest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClassOfWarrantOrRightsExpirationDateEarliest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightsExpirationDateLatest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or rights expiration date latest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClassOfWarrantOrRightsExpirationDateLatest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClosingBidPriceDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date of closing bid price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClosingBidPriceDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsAndWarrantsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_EquityFinancingsAndWarrantsTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Intrinsic value of embedded beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_IntrinsicValueOfEmbeddedBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NetProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via registered direct offering, net of related financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_NetProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NetProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement, net of related financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_NetProceedsFromIssuanceOfPrivatePlacement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total number of shares of common stock then issued and outstanding limit on beneficial ownership.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PercentageOfSharesOfCommonStockThenIssuedAndOutstandingLimitOnBeneficialOwnership</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PreferredStockConvertedInToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock converted in to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PreferredStockConvertedInToCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PreferredStockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock issued during period value new issues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PreferredStockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PreferredStockPurchasedByOfficer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock purchased by officer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PreferredStockPurchasedByOfficer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PrivatePlacementSubscriptionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date of private placement subscription agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PrivatePlacementSubscriptionDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RegisteredDirectSubscriptionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date of registered direct offering subscription agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_RegisteredDirectSubscriptionDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for each share of convertible preferred stock that is converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuanceDates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date of issuance for equity securities of development stage entities, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityIssuanceDates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=abio_PublicOfferingMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=abio_DirectorAndChiefExecutiveOfficerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=abio_DirectorAndChiefExecutiveOfficerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SecuritiesInMoney', window );">Securities in-the-money</a></td>
        <td class="nump"><a title="abio_SecuritiesInMoney[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">abio_SecuritiesInMoney<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SecuritiesInMoney', window );">Securities in-the-money</a></td>
        <td class="nump"><a title="abio_SecuritiesInMoney[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">abio_SecuritiesInMoney<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SecuritiesInMoney">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the number of securities that are "in-the-money" as of the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_SecuritiesInMoney</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001564590-15-001840-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-15-001840-xbrl.zip
M4$L#!!0````(`+>&<T;&P7=7%/4``!:X$@`1`!P`86)I;RTR,#$T,3(S,2YX
M;6Q55`D``UHW"U5:-PM5=7@+``$$)0X```0Y`0``[%U;<Z-(EG[?B/T/6C]L
MS,2N+"X2DARNGI`EJ\?15;9#=G5-/U5@2$FYC4"=@&W-K]],T"5!W)*+`(F*
MB>DJ`<EWSOGRG),G+]S^XW.EM=X!,J&A?[GBK[FK%M`50X7ZXLN5;;9E4X'P
MJF5:LJ[*FJ&#+U<;8%[]XY?__(_;_VJW6[/9I#52+/@.)M!4-,.T$?C;R[>_
MM_YU-_O:>M#)@PIH30S%7@'=:K5;2\M:WW0Z'Q\?UW.HXZM0UJX14J\58]5I
MM=N[EL<(R!9&U9K(%F@Y?VY:`L?WVIS8YH>O?/^F-[CI#J[[W>YPV!W\#\?=
M<!S5P.^N5"WJ#V[@FKL6KWO4;<^R\J>\`*V'"77;7;<O]0>#.U[DQ-%T=,>/
M>7$Z$/L#41K=29-QF\-_AEQ?ZG7Q7_D>Q]/(C?4&P<72:OU-^;L#N36[)O^;
M&+H.-`UL6O_=>C%T$]^Y6LOZYKHUTK36C#QBMF;`!.@=J-?;%C_?D-;"5M+-
M&]M"7ZXH_9%+UP9:=`0,IH.O7FUOA*;1%?A^Z,UB9WO']H&H&[<FW#4MOT'#
M<[N,%/+;>BFCE>P8$4O<Y061WSU"&M0B7J%!_<\WV=R_XI/\X+G_0W3NYH?#
M8<>YNKM5QQJU5\%MJQ;J6)LUZ.";VO@N@*"R?R[^(>\#Y`;5VC]#"]#KN!=W
MM^)>0UHX*'4NFV_.S;LKCH;:'-\^Z`A?6LCR.O`9<B'@$15`+QX3*-<+X[V#
M+P3<KABV;J%-\"/;B^0QT?>8C1#V"&'/;:\&O`]\*LO@A\B5@`>@_@Y,*_@1
M]UH`/--:H^!'R!7R`.][`"HA]T,EX'9=AHH9_(!SB7X$]]96R^FOVHVI+,%*
MGH%YR^'K#;'[ERL3KM8:X;GS&^XYR-!`LI[A/+%$8/[EBG2W]JZ377^::HJ.
MD[Q/=ERQ;!U:+:A^N?K^<^L[OK],7)'QU160B>?_97OI!E^[[>Q^=)[OD`:.
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M=6[X!E9O`)V.`\1?N>Z?CF[@<ZU!!5HNFI8*\0WN4'*+_294.O_0@\X_)#>E
MAE>_[)L)UP&VG@<%%5J]B$NB<4YF/DU7N"PSY]F;27.[_*(:;LN37XC)\@LQ
MQ_S"3_S[OVR,EM0\#)TDI33Y\:\K0_=17J@'Y8/D8J/]D?1%D%THT*=%F7:D
MJI`4\F3M68;J@SZ6U]"2M0LT<Z0FSLKDBF*O;`W?J4[`G,@TL1'4%Q/P#C1C
M31['[2S`)7*`2355)\7)+%<#T@>&L!.G!!4@>'&QK$[Y3&S0NSQBG";Z58TD
M8:.]L:&_`V3!-PT$COA8R!8Z9*P9Q[*-'6,T&LJP4_>#0@>W5:-_OEEBW0A=
MVW2Q3C0*SKLNA2`G*1T46?7.ED5=BIE/7CHHS>3L0>%B.%!ZZ:`L4@2Z^!//
MYE>``"<:6I>P%"'7H'!YQ"AA:%UUDC"'D0MD307&%A6G47#@N12"G&1L4>12
MBVQAY%+,?/*Q16DF9P\*%\.!TL<699'B7(KG36$Z"27N;!/JP#1'"E:7Z;@]
MAPQD??L3@@NHUW`D$2)4,NL[*_N]HI];JA=E]!$61R4B7:#5?;*?C=F)<&,-
MZE"1M5<$9<V\VSPO91/LK>[\ZW6)`/@GP*BF,M1LM(O[6P7C*YJU',L(O"+;
MM*:VKNZ?OP.FY;1<&]8X!@]5"@-IHE27;8XU1.$,V'QFN3A"?QAWZ?C\Z_WC
M_>O#>#2]:%('JJ]L3@>9YN*(G=Y3-\RNKKL^:VKOQJ#VFPE5**/-BZP!>B$8
M4<$,+*!I`3SFFD`$%.MICD=@>-A-\U38\I03A$'E>+H?AH:)R4"':&441@PA
M$3'P;<(@;V*`OVPR<G_'__>Z60//;C#OY0,A>IS`#_9_J30A`L1CW`X6I(1B
MB-`C%N8'<438WY;/_FN1$[G#7TI?1>\OTN#_=>.+--O;\NL:(PQ2Q7&*'"OT
M`A0;X<$M,.\_%<U6@3I%QHJ4N6S+.1_H:7XO(QV["?,9H!=RRL+=)K@!3_<B
M_NEI31JH34ZPK]46IQ[&[NE7XKD%[Q,0\8>,D%S#ZE-E2.A18$/`?#QA328_
M*D/"$WG"\N9-3D#$&3`M!!7K^("+QB,RD3%0D8UGS(^0C7>L+"'/VD,>Y8H-
M$2N7*Y9'P*D,T>^R9A-]F29P=U/2]/EFZ&#S349_`J=8:WJ+Z-3C^[_^$]M>
M1LIR\Y4L`Z+;VM_RH&/#F<YU/K3!;^YA?42G4^04=)1-8&O4C>:,&-I7#*TT
MS4,-P$;28#-EJ]4GL`4;R"06RPUR!!]3HCYF;4V6M%U`)Z]V+&LZ>=/)B]X3
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MGT!QUH@_S>=0`:AV->0(+3+ON(C3=;8E&LDMQ%CA"K?CN16]*]YE:K*WI.DR
M)^\R%?@>T*_`6"!YO22G(^T/T_D!3&M%0IJ7Q@.NNNP-%8CAV)PCL8M)&;B!
M8_,"3N=-;LR:A/%J6[4BX2_\8*S]:`*^XU?A)%L!OGD"CA>$ZEH_VU%8AT%&
MD/@%]6V^+0BY]NULQN4;*Q<5MX4$<7M+ATKT];JX_/K1H8JN/]F9B"(9E)PK
M%4YY%*(_".3\^84<S,PU]BXT'(A<HG!0M?XO[$Y-%$YP:N(%$D-(=O"CD//!
MCSEXC#K4K&I,C+(*/_M#7Z90EW4%"TJ5T`Z'A=MO6&@?+_SE!O]7Y@_+3"._
M'^_R2^*$W5\J['ABM<5R@'B`3K,50D,MP;H8-M)>A74!"?N]!+Y1RMLW5J<+
M-,R_#.9[AP<NH7,<'F0G]"NT2/Q\T%7X#E6;*A^[0=%`(UV-G>=J")V:T($&
M8$"4S$R70^B+^&)AM2G=?%"QDJ0/_!)SP_B*,;ZX+T97A>XY?,Y'K"Y1ZU.8
M\*QD)84HL4JE:V)FH;%WL5]MBAV%[XE1K?XO[?[2;XA1"#&D9,3H5XL8ES#/
M728Q2IKLGLGZPK/UX1O4X<I>U66?RQX_XP&WM)0UV;]R;"KY\Q),14M95U/]
M`'"QM(`Z>@=(7H`S-UF@M#4Q'=DU]2BO#I_X??TP7I>&;<JZ.M+5UR5$%@`Z
MN8T>Z0_YZJ9+M$@,@3!.\(+JGL,VWR_=H-7NEC4RZ$GBX%'*4H]LM5*Y2V7S
MT:,DY[R-6TBV4Q'CCCYDI.[W6A.?]*`K!/D[./[.8]/;&7I[(@0>]3/$C7`C
M-02-)6CJ#;#/".H*7,O:TX=>PUUF%T7W9!HI:(=M$%'.K6/&)/%3PT:4M2XN
MEP^5OR8I_9%YGZPEN#"+AHM<5R,F&FC7(YI5?<1=#S<=5CRKQ3*96E&@Q`\-
M>U+H[8_WJ[5F;$!`$EWYGI\BB]P]&BIU31QZ"E/6PYM7VJ85<>7NMZUE$ZAD
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MIZ]QU8<8E?APUL63I29+,^M/EO+6:R8@RZ]`!TC6L%)&Z@JG^MCORF1_S,7[
MED2*N4#ODI@PE^9?2B1,>1YF`N90)[4R'>=K;_:N%N;9)S"%R+2<LOLS0&3[
MW;.\H1^HG8^)$9JAWI=,->?F99*0YA$W\/IA-(SQ,2:!7LZ-+J_RYQ@!%5IC
M&:'-W$!D7!F4\-:EZ!$J4+J$ME85#RS[L_.P9]^)C#2(A_SXXA]8I-IU;X]0
MC'M.@D0_PQY\;/2ON.V+-'F`X&=H<&:771N[5]AW5\3\^]'4"TY29-S*/JW[
M`:VE85N3[=<)L#:_0OR[AF5ZTA]6:QGB7Q_T9V0HP#2#2S:UXTR@.E@^R)V;
MTNI&-!7`FWL'B'MR+\))"$F:'>9-'>9QW%5K^\P,S'U\#.#(:#8>M>Z@L5[*
M:"7_;PN/_Z]O.V$O\L,88[7@0?Z#KH+/W\"&QL&SX:"9%MK^X?430[&)?<A\
M"OU6@>VM/-?^S7T?W>#A-2/\DTI^GFKR@GZ/R/:>N:R9P'V1I\EC@=PH>N]2
M@GYCE^V--,%"VS]^_12:BJRY-TWQ;R8-H<<&8?J']]5';8>]GB0"1R^7V.4/
M>OV^[</+QS9V(_3U`.WWV=[>IE4?UKZ_,_T`FO:;;GSH+T`V#3P^?C!-&[M0
M"L:`#<:C07>FD/;],'XW-%O'GFLSA1I`'AL,L[S>U^Z1*W&U-`-K`UE07Y`H
MX6$`S^C9_@"FQY4$MN]'X6`;8^,L#$2[,Y[1G;VL9`VWU-J_KD76S\GZAH;D
M>9D?B?MUF:EFR!:-(];!22+6DPH4B!'@<(K_8>O0O?G[3V@:78'O?W^97/TB
M$C<V[/9H1-1+C^QS^*",N_SOR;;(*%@EPE$`8SQCCQ/Y/@WPX7'J@6@ZC>,.
MS//#09?G/3:,P.#BW>488]DD$9_\AWQ+YUW6`/F,CINFXKM_ES6;[N!\G'MU
MS$K!;HNABN5[8J^+G[[M,*')*$",<Q99!)#Z/2FK`,X93R/3!):Y[7HTVCAO
MSH)6]"K[^,4LP&(</9L:ATS`0C'%>7TF;G8'`P^J-(!BX@"CDH1>4D`XI<?)
M,793&LY',1\)%YUT_A'0^(2X2,&`3_1VA"@$Z;#&!!8670K#E%@I9CX:NG)D
M<"$NZC"`E+A!6*\XO)L17DS,8>(C"8ML\-RK-)X\@XG$BT)`_XB#D&<XZ'.#
M;CP$13%P?F<^RQOY30/'7D/(T>?WASZ?$?AR5H`Y^O[>L,\,<'?>TO:(U%U1
M`X(`%RSD&!-$G]^(Q9$!=HZ1H]O+!-OIV)%@Q1S#B"`%)"DY0,PQ>G2[$CO$
M:'0YA@U>].4MV9#E&3%ZG,"$;%>XG.$K;O$\,*J).481T0,P"D`ZJ'E&FY10
M*:W3R'(=:`SY,$,GPI+GV`*/HY-A(6-F:*V<\9KN++G`XS6@*SYL.)Y\FO!&
MA]J7*PO9()':@L&YE?P;W)QG8N%#W-7S^<Z_OGU](5,/<MN=2E?P^SJI<`^9
M<(O%X_9^:MH_3.]R5=-S#%Z^:OJE:D!'8'.,-X*WJ_O?FAQ3GI%&8L`T4K&S
MA(8N:\\R5!_TL;R&EJQ1#]$H<XPUPZ'8]8U88J%D@9YC[!ERW>$@$_09L&2R
MM.U>1CKV5R;.^^V5[22D9-&;`NFPV<TQ.+4'74GPJCT>2Q;L.0:S=K\[%,5,
MV!U3+`U-!<AT/YY.8\VS@-;M=[VNX?C5+-#R+*7U>@,V:%32@&-L)-!>CH.A
MXYI&')#TL',<(!W70=A@>R/MLXR>D+,40G6\]S-`SIP&#9XUGOGG4@[HG=4F
MNZD5[IHCRQ/8<&65A34.EB6+_VP+6@;6*!DVMT6*5YRW5!L%(2U<ULAX,KC.
MQ+,'*FLD#(,:`])]<1J`K.&N8(#!DZ\]UD"7$F7HM"L#5-;`5RS4!!Y,BHJ`
M_I5^8TTV3?K;\[L;`"+!POMR_T+]"GC!)/J("JTYZ:,.44&*BM*GXL5.<%[L
MY>JI@R6.BN6GLGQ1$A^Y?BDJZI_:OD7%-RDJ5SBU20N-D5)4JE$Q<^809Z6H
MQ*5BA@U?S74HMR0)3%FSH&1!)0&H3%)D39"*ER(B1/19RP6A[IWC_*./"`2I
MH+*6"$X"]<A#][,6`ZB%E3VN.Y`B4`9YV`0(LP[Q]XKL28->3Q*R(@SVB/V\
M1O$)%)G$HT5BS6L(GT"EH5@C3XJAP;(MT4^XD$;R+0^,1),2>-S@WGMT1]+%
M>,(@+?"8LS-HZ&P[`A*N!,$AU`,]!D]J\'$A+HW>L<1">O!CPW3FF[<7Z:GF
M`=O^@X0S3M+0._'A!Y`<7EP82Z-,:=CU![0H>$]K0'2K+]Q39+X:I@<AV^:L
MA'-'1QH,`,&$,BZ*I=%C^TB1L2@?,`3LE<G"76<EEGL?#91M1UC"A94>D,$8
M6''&Q;`T"NVEQGGLA@9%Q"TQ$&"@SXE`5D1@ZB9']@BLX#Y21-3!/7G@7='I
M>7U"9$6$%-Q[Q<3(O`/;"7PG^Z95<T?-D?I_MNDN:Z)@#V-B2[H,A!/\FQ>2
M0HM0]NA=AAI9P_QJ4"GD=MKS3C:A0LO%MFTN%Z+$`\Q-NIB`EHYL@Z'4RT^Z
MW0**W6#>N86DH%"S+<_P;<BVIYF21DA2=VASU]T^M5H[&E=J(6*"8KA)D@G!
M7W/=E$+\`'"QQ+^.WG'D7X!'FY3/GN;.@]38*T(VMOW7H9M`]^-7KH=S98&2
M)QW$O,6,"<?A)@P6<R`)PVY_F*^448/V(4O)U5TH0C8'&[JSUI4JNU(=_%!L
M%1*7)R2)$_D>M1HH>I@?N8YF&!7Q\Y<I<6*5:?'5,"I98!$J9)5@.@'[.(D9
MY"8D'WD@").01TOP)C;"+***&;B=!4@G=5OJ#X?=',6.R3Q8L`GX,79D;HG2
MU9%[Z(7;`1_!AW/)I-&RS"$S=Z]PCQFZXD?@.4GR"1PK4"(E.%,+@3I@F57.
MU!M3Y65\5PA87!DG7T:5I,YFRA'$Y<,,.P1D`K>TO-:@Y1&)9:+Y!$R7N@E9
M?BR5JQ+G2"KR$-FM\#2G8'W'J'=?L'J:_Y`1.47)G!J('*/@-DHKAF5>^@2*
MZ0KD:)!,TF52D&\C!1]Y!$\%W(-;=,XB;+[JBBG15$!(;SF"*5RR)&YABQK&
MAHY[M`7Q6#IP80,+IT)71C!W.WX[W95&0PRZ#0TYD:<L5:";]8=\/[F"@F)8
M1OT4,<V2EU03@,VB[@I[=T!W\G2R78E0G9S"Z&V:EBNO#+08N^]KF:GDS$E%
M1<P,Y2%8EM(S'WGR584,G[6('>E"#_HEX6P?%UZ`@F_U;N/F(T_:JG?P:?.^
MQ1;9E%:4`2J6*;M*.[':G!C`I+5"JY+IPEY`+2^MI`4I+:^R9S'.L2U67X.%
M3,@*B?I;&KFI^/%JA%C-Z<=O_H]BSP"VOPDMW#1ZAPIP,<R`8BQTIQ7_$"WR
MF+KRR24,O.0J6C/EV:&(E+Y<[84LC^`C#_(K=C*@^)47$7-R?.01@=FC7_IE
MN!DFY?C(<P;S%RKYR2299FXBCR[,URUF.AHDFY!YY;`I.F*VDSERG_N*/'8Q
M,XO#%T6$SGWA`88@#$X[^15YGF.!2DB\Q/($LUV1AT/FVO'3+8T=2">?`(P]
M@C*E(`'NFJ',F,-L5^3!E25T>@&_6ZC4?%?DX9GE]P91'%1KPBON2,^2I4PX
MQVQ:""K6MI0W(A_3P@GOTQRW-P?0LGV=J-#\C[T3\>)0ZO.)Y]/C94WN/%DU
M=[(<,]T*9R&Q?RY7C47LG"A4^!.6%2*/>RV?8U+7=T+YN99WQ"(VJY2KO;#R
MCIA;!LT\JBQ^RT]4>:>;5RDU.!*FWQ&>I;S3+39'3G\8;J;*1^0AO?FZQ4R'
MUF83,K>UK.P=,=NAL7%B3\`:X:8=UT6V5*_(Y\W^[?R3EK^(O:F^?=T12%)!
M+F*;JF_M0F+(])6G^>X0_#%V)@M/`A9[@G"JV.8+;5%8`ESTG3_"T7C9OJ.8
M+A8'HV!%6L3Z2?^D4!*D.!PB@&^9`/>_#[JSSF7[90G_AW_XN`.%4Z;DO'_7
M<#RH3&+$'3><;C;)_W&GW,38[^8_%J2(';"]KG__>Q)4624I9+=K,F(Q2N+[
MVA(M1!%5(MXW,Q0+*`/^(G:$]'RG<6?&'_XI)EJ4U-M9LW7Q<'#YB)5Z^VI4
M'=+W/<X\I<*V1;;GB=U:RGVO"Y&TB&#>Y@<)R,@`N#CQB\@01"'.L^<K_7&\
MPZU1SWL^5LG''=J<1[TO%<9\Q8P\Z3GU8L=$(9M%3/P#F61X1@99`ZW>;;[C
M1!*WLX^5B@7?W<^0.5]/LO%OVXN&3C,Y\B3G]+6=+N=U6MGP%B5[(5E-3_!]
MK2Y/V7$0WA4:%3Q"1R#T0Z^TG,4D/AXADP/+0Z`B,B%?(I16H!!K/^COP&1C
M9S$YTE'--0/:HB0O(HUJ^^R;I^2X$04`U9PB8W68*?;NS<",<7\`^*)_>U'D
M2<WIM\^X?^C],VEP!G?8[<:673/.X8"T1'DM:F+?X1*I$E\5)DJ:)#8._"X9
M'W=^<[KC(CEQD,":H9\G8Q$@[@CGE#L=?5_/8A4@&?,BSW0N9SG=P/\E^>2L
M2RAS26>(1(;304J99V!]N'=I(.L5H-4$O%G?Y/]O[UV;VS:2_>'W6[7?8<J;
MG+*K*(;@G5:2*EFV<WR>)/9?4C:UK[9`8"AB#0(,+I*YG_[IGAG<2(($*4H<
MD+VUNZ9(7&;Z-WWOZ8E$`N23]YL?\+NIZ=U-`\Y_@XE/"]1X%GMG4-2<^XWR
MT#-]EB8A@^[!9UJB;3\Z'BR"76R#;5VQ]^//5KNH%IXVW.>:^G.81<;(Z%5R
MU?::.SX(3_"%?U#J/)@N+B-9YK#L!>=G^CS1I>[28=V[C.XP\WJ6QAR=9?5R
MZ'E=P8((@@7@O%Q?LZV+]VZ=MI9V]E4:S/IVNE@5D!OFL[3O7M_E%]]<;4S/
ML?.LZI@^!_>FI_*ZP,6A[SIVDID&@SL$0JN<KV)[TTW-A_"]$UJN'\8!QX,O
MG7O/F3@6^L0R48!E>O`\/*S[#B;WSBV:ECMV`O_Y?]SHTG8>_N<^NOS[W_"/
M.0NCA<M_>C4S@WO'NQC[4>3/WK;FT:7Z)O+GXD]\QX7CV3#HMZWO+R?PUHO0
M^2]_:^"OK_"1_V/.YI?>.)Q?XJ-_F!_J-8^BS^3;L>_:R^\5?T[,F>,NWMXY
M,QZRW_DCN_%GIJ<NQ?>^]?P`X)8/CP+3"R?P!7SK<7G5@QDX0/2W3%THIO/:
M>,/NIIRA<6=Z"V9Z-KN-9S#@!?,G+`<6R]!B"5QL/QKT*]-`3`P+=1QK%ZKL
M1H/W/+0"9RYR^C#G=W'H>#P\].1VP%/108WQJ1!?W5Q?L;'CSZ<F?-E@(-";
M#>8'+,KA#G_B=0UFLO?<-1_Q>"'+#^:^U-(-YH1LRDW[K]@,4$:`8/+8GR`J
M9GCV.@\:\"07+K;])OOLL?\S/;AP(9CE'T:_==D>-!A(ZU&C\%8+_G4Y=G0U
MV3@A.WPY!ADB7ZN&^1L/[O$ECTXT%0--7X?C,&%E!C8Z!_("O`/&-`L1SFAJ
MPMJ]#[B016*!8T`.?Y)/%5_=<#\GX1K,QKP8N^7S2#@UN8ETQ42&#7&;"<\$
MDX?!ROEL17[QRF%R)0SQ<>I84YCEX]1WW<6%_^C!76$\#AW;4;SV>XQ56A(?
M]EK^]8;-<(RVG!>^T?$BOTB!M52Q4DN+F1.@18Z*S`S%7R"/'\`N@RMR0,M9
M;1]FDWV:S3A\&7%WP29PM?^(C\J#54`:;'V<!_;W\X!J;`(N?''*R;R6EJH0
M3^L6!WO$B8!-(M9/"*,.9-<]2;,`1A6(I:&$UCR&688\E,@5R?6H:)*[W)1!
MW$!>CC_"\L'"/>0Y'L"LOWI`'WQS81K9H\3]MECD0(+FB8B3O+9PD.HI7A:/
M(U`5;C)C-@=?SW+FIBN6B!6'DE-L68Z(1+[G'A?WP&*+L$8,L<34ECE']8((
M6F9@._Z#&5JQ:P;,=D*T0L-F7FU)IAN"47,9,A?$%+S:MV,K@KL]&RT5WF"_
M<`^>Y:MKN\/V)7L]CL%!L6$5N&RZL`/?FL*"`"?F34/.34T,+KB7HT0[ZB^P
M:,<\,B_&:*DH`0+DMQF,TK<=UXR$V$*Y@ZL,GL3!%HU%[D;(*V:YCB=(%0&%
M73%/(;1P-0LQ!8QFJM^<<>"X;B8/KSX*B3*';T1W)L']()N#B$U,QP4K2PS(
MY9.(/<`5@:,HMP@GL6>ES_G?CS<?/A;(R*8FNH^XSB>.7+DSP$N!Q,1R4#ZF
M!\QF@73T`_$'#GX)J'`!>F$FR>!$0##7`=SQ:A!')D`CQET$10*8([HT2&8F
MKB60-G"7FC:\/IS[>``&B`U\NQW$]\T]5;;1UIS)(IEA@(FB&E[,?9AQZ(1R
M+7V9HL_8?O=#9WE9P2)2]&UDPNJ7#[]_N/MT?7&EL+_Z"(\!TDJ9BBM1W2,D
MF34%D>DQL1$!>1=8&GDR>0]PEBE%.6(`&#TX?ARZJ-D]Y#^X20ZOL[1"7__O
MQS<KH\3YM!N#UA#69KJ^4QO@W8?;.WE+0ZG3,+Z_!\H(D0&K+'D*+I<QZC?+
M`I4QB5VY7&WD]7M\&HZ32RF/5,@H(IE^%KN1<V%Q3]@U`)GMS_`0/K`*_'CL
M<N![H-@RL6U`Y![59>1+`0BS%&K6G/!(KF,^05/:6N2G#%>;:,'@(5/J/B$^
M8,B"09?X'$2'3/KC/)`%X1,L"KA#/!7N]K\M0EA'[#5,A\_!UX.!,=>4"V@`
MB"U"O-<%TKP1Q,!^-T!$M/`_BF%.36$5F%+(&:PS'#'!+*""V=2?^?]=W`/*
M*!?\:#'G4M,G?Q74?LKUDEWMD,W\$%?!`^C=,:P3F+ZBA%R-L+Z$[P%FU=QW
MI"`LXA,!]^%M`4\H$2YF((AF)LJHJX\_)'+3C2,T?(`.OXJ)@OB^L,P8[0,_
M0)<B6IR.P!"*!L6WE1A$L*AL<RZ6E5R:DK<S[L]YLNFG);D3<OY5R!T?``G`
MR&/F'#3K-\!(V'U@WBZO4J4,$J'$YE@/+ATKP0U1;"\DU#E8WZ,8N96,\IOO
M.;"<\;7O?%`I[/7[V]_>O8'ECZ_W3'?Q7V`4#@C"JXKRI^RE<D'@TH9%`SH-
M%E<FT4S%=<`I7J),0$!<R)M"#&N$TJPQPS">"3<Q1`G$T4[)/3^<^K$K+`_,
M4>&C$M$G>%_1#V%)MJ*P;KN54DX2!><JISHSOPI><H)LU%)&9T-':J`>@'DF
M%%'"".DB#7_$*$4'6)OGO*YVEST"Q.(!TH:_B.>2G><B^"?6S`P,+A&VSR9;
MU-<9SUX(IFUF3E`V*:'WG5DV:#%+81:*N21'U<BQ!_P>S0GUSA6QT$!&!\9F
M0I"#C([0KH>5-(X#8$AILTO)FQO,K40H*AT2:"W+C6TIP\0XY)>)@$R]RZT+
M1/EJ0J\"[X/&1H6C3#W3FH)4Q,GE[P[36`OXL8E%F"RA;.+IZ%'-9>M9:,"4
MP]:LPMSZPCM--_1SMTO_+$P80#Y$R8TQA]'P;`YN^G@E&]0;A*8&4V_CP$!)
ME`Y.21YAWB+500\K3R_UZE<6'[N-.!>+$S.1#HA\GCIL.-E&D9O`G/:$LL;X
M0.)(^E[)P^ULXQ0,G\^+7D>FW0K"1W)Z8L47V,\2ZV^<9\'Q0OF6MKS:Z#>R
MZ:Y?I1,\EW*J?`DYIP"4ZM1T)^H9@R8[&<UVYZ?48C#F*;H'>)BEDNTY+;)D
MD`D1$(]A30AN^OC^2FJO!S0@\T:*6"">6I"!"0YF7D9;<J=@DWV:%.X"(&)/
M""RXRQ\+X9N[#5PM6YF;A2O3N9A,G"W*P;%D@ABF<LT4!PE1#3>`PZN".;RP
M'LTTJX;K-S$G_:!P`X9;_#35MK>Y,]0K8/LKN.".[2BK^A=?<C^(S<`[P2`+
M@.ZC#L$P7&0F$AC^#UD``0:W`NP=E-W8TB!4BQ&)`EHT%M&(1;KTI1D$BUP$
M_N3:AL6/GA(J6%APN'*7%H[49I$P">/Q?SCXX>BW,$^<AH7C`/,)S`A0@#[N
M6$P"EBE'!NHX8_&@W"I&48\:%P=C\SD&4U'[P8+^RA="?SXX=@RZ2G)L?OUC
MA$18=*M31',(M4]@25H].(+[5$Q(/6N9X?E?L1D5.'^2)+#7T&=Y-#B4[)W)
MAE$%4/9B==F<1XYTM]%T=4T1KI11,V<IM"6,>E2:]^)D8B2M\%YC*1S$D(7/
MAJ:W\(CL_$IAKA^BM,1K/+"II)MIAE/PC_S'4`X@!S0L"TN*#?P@;)FMC@*^
M6_J@*D:&%.(K:RB:!GY\/X5%)`MYP@0G%76>)W5[P+*^]?5T?#.Y"1OU<J>H
M>,32LY=\JN^,4;.#X417:`./BZ7N3R;2RK&P_*F1$C,T74E(1Y@7:<?:96JF
M"Q2(G7WQJ#H0K87XD\<^\G&`>1P<>[<\=3./QR#O&9<;V].A)E)F:7Z#YBB9
M'AHP.$%E$`KS<R[+2)9U:;AD$HMX5T[Y9SH_-\J",>=[]T)3Y/3ANFDO^2XY
M=2\-.Y%*J.CM+H^OL3Q`AER*(?)(6)$B5!JF(1[!IP(X_,"SD@8F;181Y,*8
MDHB(KA?=\,HH$4(HN$58-T1S-@"1%`<\6TM%.[0'-N3_^H^84A$&N8LLD;KQ
MN;QP["G?4]@BF>.6!0ES<A*C-RZF<M2"Q*I$!#:7$\!(+NH9U!9A%L#,4XU_
MF\-4Q'+99K<)L@A!+NU_M6X52#F`#K!T5BU$F[OF0B9+DQ=OM`E7[4<8U@_H
M,I99B_D7HMFX;/V5F8S!(>Q"[41M:4XHL1@;RI2!]2>V2BTVKAT_R&$#!"[!
M0%HN,HR1LXDF\+L?A#D;I\'&<22TN>N`7R)6KH0PS:"^7<$";""P]H#A?GJ%
M.9U7V2^16$!C/[!Y(`XTM;CKAG,3;9;T[SG.2_VM0)5W7%CP3G,>\K?)ATL0
M*W8T?3OJ-;O][Q.D\:5ON\U>]_O+_+N#W&?,?,D1PK)(7R,?UFEV.M]?/DYA
MNA<X-D3V,3#GK_8QTO/+Z7_,N1]>+BTJ^65YY0XLB'8_5[HC/D5VQ;F,^LW^
MH$"&'8=^-,9`\7\?8`:](/7R]G<N;B&*`-#UP!"84$LRIX*]EK)(W25;2T?Y
M,<@^XK7I7X7*+%K:V?JH\]H^\N*6>AU-":'$0;3"<D[,Q;EK>IB6*P\4@7(6
MJP95P3V&<8#,H3"B\S&C?&IT/9%IX9-,?^EE#P/Z*APH!\,FDU(+-O/Y1&V2
M%.'2`$H,<1%1R6P@Y<TI4XAD/2UY39;\NN6=-^:YS(/"E:XCJQ[2\$@N_*%R
M/K^;H6W^Q50[0/:;8"=:[+38-5CL,N(+DA@<>G\&3J?**<?@ALH**T=%YR<3
M;D5)LKQ4N),HI]6MS^JN(,HQD`4^:6+;+R67BG%.6M6TJC59U7*Y8@#0<470
M#QS(D%MQ)/ZP^82GH5W&/7BJ)?]:8%Y!Q/U=TYE)9]871698`N*Z(.-C4`=S
MU5:&!3AP6/AX'2U^6OQ:+'ZY[TJ:':F!LL$QY=^4D2[6QUAL0WI0.QC`I_5D
M!C'9OE5(5>RWTNN<VL!L[WHW760JLNROS<<1"[,C5A]%X9GK?,4,;,"QL@[#
M7OE"@=PS;<>-189,50.6!A14Z^^5VBB14`E74[CY3*.J5O!DW`*I/`;5CIN\
M9$;$'P.#J-*!0/:IQ/&(O&#^:C4WS(5R#S<GH`\H)",^5XUPTPI,DCWY/#D^
M$:T/4R3N'KB'67(9"9>O"]1A(N4IPUQVK;#!%NLN+=.3=9!R3\LC/E>4F=KJ
M)C83V=9Q+MK>8`Y6O"P:2ZC(HLLB($D%I<>MK'ZR-('59*HP-OO5=(&//<&*
M(E>X)C>&$\B/;VE8HAATY1I?;-;D<ZE4A*Q836'"'5EN-.!83L-17L9JUZ`C
MC4&NXKV8\13]Q<4/;K[]IO3Q)1<AJK@Y$%9"NIM0;B.!=S:8.?,Q4B#4;7[V
M#2;W#.0'*3+M@;A4)'@;2[598J\)7Z[%2U<$,EN6B95V;LB#!SD!D>N'Y06C
MM?B)I6;+RP9"D`6^2GD+&ZIJ\4`2TERJ`RB\"K"-O;P+G`BHO/S#O3UPZ=B/
MRYEZR3<1L(J=I[(\P)(UB++&&U=NZ,MUK(KI40C!%,H*JD*>E)RING*I\F0E
MZ)ASW'W%<5^1G54(9R7G6:%UH:YUTSA%"9`J)%GFM\,QF;C=%[+`4>7U0A!F
MA^#(]TY<KN1IFG^9Q%BA@@6.HMQ#Q>RPMAPT72'$X<)8!=Q)98<:NTH"R140
MEER;GTZ:[51:,MU<`LBH%Q9UR9;%4)3^^.!$*"8$%PLV5\>3%A^LDY6XLB(L
M_FP4WKM4&)FK!L;B9)14C_B655D4IALLEX;%OZ''LJ'L8<_]S/H)IL^Y.C=#
M[-DW>@WV*-89!Q5@(VFR]2(WKE_=OK_Z?V+'7;JS`U1!%F\&-F#RH)]L!:F;
MBK%FS*JG"@:[I.`#QHZ=I73P4870]=040V(S+MEE!J)R%L_6W_V=T<0="%P-
MA]G93AX\7D3NX>BTQ+[`M8))C3J(L=!0%>?9+,:%;@Q;L%I=W)@4X`/8?0"N
M5[IU*)FW*%)53/,[D-)2@N;>3,JB'%&>-0;^X#R-8R:+U4[C^.)8)#.P)4^5
M_YZ9A$@B9RT)Q4;/380#-G-!@D<K%)32/;D7KC1:4H.CA_^0ZU4@MEKFZ+V1
M7/NRDV:E^3>J!8/L#WD+T$;[E^2CKK^8RHD8AH9RXS>L:<\*1D5KD.4BWWRA
MK'$!#[[HIXTJ0J3/NO14DUT)W2V_D7)$U$CSH/!MJMC2G4!K[`>\<>+[D2>V
M$636A-3`HJ`\"GRY!=E=+"OC5/E.Y/;SQ&=XPGJMA.N1%O`[4VVHS'>U>D(K
M(+W7\)WJ>2*6JJB:J6B`KNFZ\T?SMJEV*8@-*L)VP66?:\$B&X*@)GDM+O_E
MZNK+&Y774J8A;I+-F8;9UHNDH&=B.F(+?X:.4I+9V,&`=&1IIK3B!*!+-D]^
M$T12*B0D<9@\G-MK%>)G>!7`8=[+AD)PD^@(([9<)WT^LD'E/;U<]"/1B3)$
MG#+7E>=AB/>&8R$Y6H`?X=&@8"[^OV3OB"13MJT294"`YK=P9OA?,8Y)[(H%
M:Y%_0PS2^7E2^>8M&%NV9I.(@G(&+:4<^1)O9/^=A;IS_HWLII!O<Q;XGH]^
MJER*V^:=L/PJ&=;-LF3,H"K`U+]0`?:W%ZVF41+7/:PD^.2Q_XL]GMOI\?'J
M]IW8K`.+0WS.4>9665HA^V,NEO+K-/#=NKRZ_2/]R[A\`\NJ*1Y[8;0:@H@X
MBH1VJP"KGFR90R/.+&0?L/L2LM'K.W\.KLC(Z+UYRSY@(;67<MRUV@6?-B%4
MK(1C%F>G!A)+T:M)U;T"VU[A3N69VD3Q3R0/>D%)-\3LU;_$CA1X\`HYBB'.
MJ=`04:P2G)4HNY41)GBKCY&T=.29<5Q.V6O?SKP.N=5-/D7<BY(S,9,%DZ/)
MNK1A&<FFFE:9+H:W\F&#))?J8']/O"';\28V["5D"W)DRV_56'X';ES+3*'L
M$ZH86!%B`XVL4WB0-O0$1`^\:<'-(`3M`BSC9>W*W@,SBCIZ],7DFA2#AXM1
MM]B^C'F,N5`KN)<[PLD(VUS*4#](=TXG<AU_E8"4JSGI!H.JDRN_=$II/!>'
M(N0Q3/`^61^FT#B"H3HM.0%95"W;E*%.:B@\$5?5/%\$0N24-D$IM:7<G`="
MYT(P8*+HDH55)KY?1(@]O[@"YF17\3V8"0>26#DIU<M+K\H2Z\N219*)H*P1
M*DNCB<9E<=\R>WT;CR,A'MJMWD6W!;(M:YN*S_NC$"^5<4H074(V%:.45UF4
M\KH0F%K=*9W(J>US%/#8W%)]`M_B%L\`U;F<?;/XN#5,LT3C-/"X02BH?H<%
M'DYRYVNE1']G*;'N%?N("2'BDJDID9D&$U-;49F''(,+W!3;H5=&D4E>%4?)
M=9J!E2`Z5)7%K=$"75T/%:/62#DLA0>9A>1/(C:"6=+8\GH'4XQKH[BDR/^F
MR'^VU]_G<K>WW.&X-!L'+K*B)`Q>W=U1B2@I2T(6S]&@2)@C<3T2W;5^4^SS
M^K]'LOASZN%#&(D-RMF67N'I;I'F)QP5F!?GOY;O99(9GXBL(9/,:YW]-5$!
M1>8_/-P&F6O1%`D0X(U@DV,_@4R8YN1HY,N&/CQ%31I76?LE(;!D7:S*&:%4
M12==!<RR%)$L-<DR0$FZ*U.]DN/OQ<ZXDGNBE4AW:2BN;#C(\A[*IES(>%D9
M+/4?$HUP,B(`5(@G]N9;I47`DWY%MC0S\V)*:',I?IW`BF<H&ZWE3A1INZ.\
M3/I/;-\+3!Y%!XH'WWV0Z*IAK8AUM5$?#Z84?3VD[LM?KI+P\NC*/)D;,CAZ
M(1N@6;E3L)/'B`V*D?D-A_Y;MEYD%R^4VF(1YKJQXFTQ&H1JG&%N425[A?'V
M-"69:,+\A2K3*EIHI9%8F;I,&L&:LG8OD<]RIS8V2L@;[.D#3S:ZBD<SL-S9
M#"<K0J^7.S9D(E#UDT.6G\%#%LD>+EDB)1OD+%5OH62=B;-SY.;]"1NU"IT\
M$P$DFF-B5C(.+.Q)461@1QQ5%\JF0=\LT4\;QXF58$MO"Z/`%RT\D#'"M,4,
MW`[RP@FGP']H,"BC3-1G.4F_*LQM%",7:NR++`#ABRY">`N2`6U!U;)(M4O%
M.23=HY6T53OXGU01H_>BR6.55"F@<D'ALKR>T/A,RJI$5DG4!F8P-M)^E^CS
M2N25#HID"%U45)UN.%>XN5Z4VL`3=HWE=A&[<<*O)RMW,CL5SV4(8E5?@RHH
MW[\Q[>)5K&/)*W9KA7Z6I!^V^DJ%F&S,"9.3/E9)OYIU':VP3Q!H<A<-C0L0
M*'S+*QMI2QCL1HE]*4&$294K]HF8HL&6<FKRWP3I#:K@%$;`[7NA_;']T7V2
MV"@6ZDB1%)9.BJFQ9[E73-5@X9/I?041/I.27/AFJLIF6=HGUK*2N9,"=DX4
MY\RWG/&;FF'BC`Y!H$<P$J<@&6^10NFX1)M/Z3M+>2][Z^/3XR"U/4_6UDB.
MWQ6TSPX%WF^V+>TYOS!=GDX7%XEP0&PFBHS#2!D,%ICYL2RKAE4*BL+)'0""
M';)5$[LFPQ,7D_QL*-T46',BE(#QCO1=#5$PP[$&&4,5@?^0)%O`C7%-*_E+
M*B://X+]CV8Z1KYD@R;YRQRTDUK=HN30EO5HPCMBN3YW3?;G%,L8E$N&$X57
MX]LB/'A#L'Y6^P8NW5PD.OU)@R7;=.1L2TD1\#1(GR9L4IY-FJ1(FUZ<9F&*
M5A*BYQXZ#:J,0OI#RP7AR:[,^7K<1/,H-191;Y4X4EB,A^OF`I<C%CA-,;[T
MH-RWQ(7`.SBVOG=E"?=$N9.N.BT%2=9DOZ[%BZG"$EP"//?L$(]RY&E@T'4F
MJ;,K@$^*+=>,(;LR>779<DU.35%"51U9\\@#KHP9N9"+[\GL&95Y67;&DR-I
M!&:X4-)<N;MX(IUA@2C3M0K%]Y2UU4\->ZG`F?#-/R0AB_W-*:UDZ%6()RBD
M7>Y$6T+9,DF&PT3/Y2A<&]LI5GT)[E=+&:676BYI5",)]J`L<,+T32J`DI["
M(FIR<&^`8R7IA&CJ!+88II-4<V4E*"HTO"Z"/>:B0;1@MV)HQL5`.TY2O:A0
MTF(OYXLMI0UDJU%56H*U;,DH,PY4E@B3UAWR8Q.6C#F;JYZ5&1,MDR4M!TH,
MN71L$R[B0(DIR+$HU5QDG?34Y;!`8NR_!EHJ2`*5A=TP"E_LRZI"G#@2C$T5
MMAN541.;%";W-U3[4G\"$,K]'>M':P(3!&`#XJ82U=X\58BKK7+S!Y(M6:<J
M-5*(_17+V*4<P[6:!NADU$P$_V49E944Q.=#?LE!,5D\X52Z1M_R^Z>&[;42
M5OD%(8T+Z8M@`B^4<RT$06/1-5WH,C.);..B!;KG=E*D&2CU"+&&TI+F25)5
MX>5K1$YEA=SDNU3G*Y!.9,7<E'3A3A*JN-5&"F"[:&?+S4EK??X09'P@XDW+
MHEH)MC">SUWGE':RB1/H\TIBS<$#0C]D2D@>*)A6@HID3":."U)<V)Z)+DVW
MH$C/2+XQKR2E%AXO,NJOUQ_"&;J^^8PX):.5!W*$CDAU+`U8;"+-;<G&H[_`
MY/#$]^I+/\4]4V5YEZO);M2(TW`,YJ<6^3"3NQ"]A;EW'TV3$E>U=T/FTB?.
MMS14@:>3/B35>2JUGQV&(S,L<BDGE,'=F_.Y=!G,](P<T7PUB0S)`X#&N2)"
ME8QQD[B0.K]\(0TEB=Y,GE(D(BJRJA?+\F-/1;W#S,AX`&^YV`463Q\Q'5<X
M.0^^M)G0SC)%7"UM3XR'J?''1N&4GQ1Z$WU-X,4Q:'>>2R0FM@B_R'?#ST[@
M%!HBM$!?K*PUF11,;;]F6DR9CPJJV61'R*3MNK-E+%.F>1C2MK=JPNK@)9G3
M="P$T0F;F3NQ;(#!NBT:2;AT99`;*,VQ9#S,.&#=4D;,,KF5.\Y.=46=F3@'
M1=1P#NZ@.`$11`K,RO?D+FAY0J4@H:C>27*RIR+8/JT6]2<L4W:`0ZXU@]@S
MAW16._<E?B)/GSPEGD\"K#(#BUV:8E+\B:V&N;;IZ3.;[,_$[5=<N?($,Y2^
MF6.7CS'AFN3<0%&OE!32P[`^BX1STG4]VSDJOU=_JX!$8;?$.^7@W**#$ZKX
M:S:T?,Q"[*K9/#Z<2^9%!05>!#JDQ6."=]1!S'(QXVE:JDI,EOZOL>N%I^A;
MBB'3;:[)&56BN,@)DAVD652C,G5/9`>;V+EV\4Y(B.M<B<&I&(%W)1YM66F%
M=/AQ'8,6P'@@QC92`5J,A=WC:1(R\)9/,>8]E?1!X>I;E'^!S2QP<YL:C*E.
MM?%4$_PL*"=7?AJ3$P$7-&?R@8SD$#LQ4`\#P_*!0G6D.^!$'%N4W,D_)EP&
MN)^6'M5H57^2I3%W6!IS2BLY$=IC[O&).NDK7P:$3JHLS`X3"Q&AS@)/JOXJ
MB2&)4U4Q-Y>T*X&G8$(A#CP,^Z'1)C?5HX$J_A26`!;,-L%E5$>NX$UEE6)*
M*2AFFJS$S%7A$#Y"["K&*+50"!%X%V!'):$N63XD?QOSZ!&+D4OJSO!HYD`H
MK$*YF=HUO:$,+E+'3Z)!).L[8%2RZDPT)Y,I#7B&R'A((_9;DK05+X7Y"?:5
M0D#6>LLSP+>32NQHR555(1(RR!'F2:@4L^)U>8A*DJR27`_`"S+(""0.1/2/
M*-1L51E0<9]@$D>1;RG<GRATN#Z_,+-[Y2C4`Q*=NVX(JA^.["@C'#V397L,
M33PT0NZ=3P1R$NZ3QU&":9L>EI4VX>%HL(M=3/A.CG'>&1[PJ-I#`04]8:P+
M4H;(2O+TW#2QLF:<\@P]V4)"M1"Q5[/^609G[202^SMWMMF:=PG)G<N'3\WL
MX,X$?Y$_*Y^4+!N/UCQ][412'R_C34%(*6@:BOBYL$AY%#YW5G.1>\J._2IL
M+_V4A-YNU!%@USZX+;<RKIT5T7:&;>GC2@*K,W??BU-*1(&E')\?1T)08A1'
M1*CEE>HXYT"P=%H_+\ZA6AIQRH6*&GG9E6RF2-UY=>+)2@,WU9SMQQ_B\.+>
M-.=O/^?B%H6==5>>G=]D\WF2%KMD-=G9GAFX^C9S7+-2[R_P/`NX^0YTS3L7
M;)Z?__XWQGY,WO[!#-#L#;_PX!:-D/0RYM@_O?KX[U:K90P[KX2W"3_=\,E/
MKZ[QV]:H->CWNO_&32`MHV6(#T:[8[SZ6358W*?FH)H)45T#/T'=OFZ_@:=%
M[%=<&$`>)NAS2L9$6GMGNI:H!Q"&+IYLIA9%K@O(&`MX09!FVF])/^?;.21=
MZ-1AKW+DR-*HAD0!4[[1`_"EZ&0B0D6Y=BV"H\2F;A5'*K0TR1W,B+5^TG7S
M'YQ0IH_>8T\_8:ZL3,61IGBLCJ,]W+2RHY!VF*#<D"HD*KQ.:7+1_$ZV)7Q0
MY\UG#\\WIRN\)]>O+VMAD'^YH_*\:0^?XOW8:*>PR:O,=\J7UB6C3!Z29#)5
MV_GD_/"D@6!Z0%_L)75BR:E\PF8H=@4YE4C3E5`=(+M=)Q]V15"YB"RK*`/V
M/??$WW&8F7H)?ZH;)8_*;1MRD8N5F^_8@R9&N'JTUM/DL*1>^^6IE]MDMS2A
M@I;9N7.O:DF+-9@\J-[(MU6E9Z\D[2LVOH?[?1C//SZ*_Z2O40.1G8"1Y,D7
M-X)TK>:@E_OR#G&17\E1](;?7ZJY)C`*RX')JV3G,NQ=XD6[M];-_9D.K[@D
M\`LQL;?_J*"$GW-G]+I->^L:$,-H@1Z`3/_5"X"4?/4NHZ_$K6MLQNT?+?&?
MM9@)PHBAOY5K=LVN]9U17#&Q]H7U"1C^2VQ__B!.T4WW.'>,1K66TL_-:EL0
MRW/::D?NYV(^'6"KQ'H_%`0D"<MZ"<OV486E,<IP0U*OE90D39=`1D><)*?6
M$%7EPR,`M1>?O8``K1-L)#YK##*V--6.*TE\ULSP+&5*M$6/`HT@__"Y@^:?
M,&3EQZ'IV5E#SJ6.OJHSMQF9;X[-:.6RLX+H?#FFJY?W<$S8!H?#+:?AQ`$[
MAU!P!&1U_B/VTA$5@N#H$)!BJB%LI)A.!$A23`=TMZX_?FQ]O*ZGNZ4'.%BB
MA/G_?1GFV1$X0X;Y3E\P!I71.%TM\WK4Z`]'^F)T?@RS=QSH)<`X:<H_W>(B
M?B`%<FX*I-\8=4B!:(3()@5"%4@:`?4K#\.WZXY<N.787H-=X4D$:I>2/%13
M;=D29?K<LW4.#%3)I9\;9]8AI#,X*'2GJ_?232#MHX.I<86$1EAIP7<[0T6X
MD"8CY$B3/:<'UVZTVOUCXTA*[,7=ND,YW^36K<U"Y=INY#9/8[V?VCRM<]#D
M(+72Y\:B>H<J7Q+2$]:66B3,2%OJGD4C3Z]^J352>J3T2.FM4WK#QJC?.S;0
MI/1JF_D[WYK$/Y<[8R6-L";%'EZYWE3'#L50O?WI1D*IWKX,R':KT6L9C7;[
MZ`TCJ)BE7NQUXAJL'A"08JHA;*28*@`Y;/0[1J/?'^J+(^DE2LOICIBHMF2)
M.W:QZH[%'C9/ED>@I'[9L6,>5)AR>H%F*DQYL1)+"CV>'=]1XDU/7$B3G1YR
MI,DJEU@:P[W]-U)B9Y\_(U^N>&*/CX></9;X<LEY(?)D&Z`DGF"507NJ1%FW
MDW#Y.)3D2!]U>/GJ@3XZQYBH/.>,P\!D9]0JATFV1FWXDAQF/7$A57B&T)(J
M/%S6M#UJ=(>M8V--FO"$4ZFV'^/^OG;SK'3DNRVG;AX[T'5(S5E`^%PUYVGM
M\7@*I*>K,%^WFMW!L7$N4Y:E<O;<.%';?8WGJ0GKD*0CG4<ZCW3>>IUG-%M[
MATI)YVF@\PI^X0_BV/OT.MMYV(<L!2I\GY]?.YG?)E(\1PV<T6_E%,SA)M1Z
M^0F]XY89AYP]<A;PN1^(K9&8H)4^)#R"15/.%N(8=+YR##K#$WV%ZXEG4S:8
MZ;IL[D<P-0<^+J1#ZCR4;K.<FO#;F',/S^-S8WS\)/!GXITR7VQ&#EP-]^%7
MZ>/2`6:Y5!RJ>#T/'-^&7^!]>/JGW5R7B;T28UF92H,AO9+7Y3:!LD<S`)I&
M(5`*7H9P3OD%3(0OQ/0]G\W,"%YMNH7;U&[2.<YBS;V7^)Z`P]AY`S\NV*,?
MNW8I7?PX6,VS)UX_8.3!._-$L4S7BEU!PR:N4EP(R4)=XJ32I+58Z7@Q7G`;
M6].=$+9@WDX8)22=^*[K/\(HWSX7`Y4:@O(U!2DD!)22\S^]:KUB%G?Q?%P+
M!IC^K72$^%MI'WFL;*IKE*(`\>R:\Y"_33Y<,JE,!JW"GC0J5ZF'EV`E9R7W
MCWI6<K=B1>866_&TCD+^EU!('U84$J47M(:M!L<CD["D@^7/39JBZ4N24VN(
M]*F6.$S5"PE0$J`G)4`[VO$E"=":U;64,N4SMF73`9HO:^-)W(H#)W)XV$B#
M8&_WY3$MTGKGEBBH0S:66MZ<")#4\T9/5`B"HT-`BJF&L)%B.A$@23%I&.0_
MAJ>E!SB?RXH3CAV^(`[2,=B[44&=O?XQ&JW^L-$S]CZ+@9CG/)GGQ)5,/2`@
MQM`/%=(JT>6PVVETNVU]02+6H>211N#\D72*#N"?P+'PHW1M8L^)M#[7E?A(
M/U1(!467W0&X-NVCGZM*K%,OUCEQ15,/"(@Q]$.%=`KH%&/4:+7V;@!%K%,K
MMX8R-4\%Y\]DQVGDLWD<6%,SY`<Y#(<"!#HJ(8JMO01.HT8'79L61=<T`J4.
MS'/BRJ8>$!!CZ(<*:17L;FMT!XWN\.B;*(EY:I6SH4:VM8OD4/N^DX66^O@=
MJBRNU1C!_WK=_K'!IF9^M>%+ZF2K)RZD"L\06E*%!XLW=ENCQJA-FE!WI'9W
M%Y^OOVTU(FP>MAK.CS_$X<6]:<[??E#M0;_PX!9[==[!B]^YOO7UY[__C;$?
MD\L^FD[P3].-^7LGM%P_C`,>II<RQ_[IU<=_`VL;P^XK;.Z)P[_ADY]>7>.W
MK5%KT.]U_XT-I5I&RQ`?C';'>/4S#NJ`),JWK%BW.#:2</]5\KKSAGUT/-.S
ML-/K)R^,@GC&,4N7D7^7Z?5+IG>TAL`(/XJCF#,G9#:?.!ZV!`Y%]]9YX%@<
M/IF1ZE,[QK;!%G<>Y`FF(7==9GIP><@CY@=L;CKB!_EZ'C"3N8XY=EPG6N"9
ML'"MD$;N0EYB6J+=[YA'C]C\%@CU%1X$$BER+&<NLJ'P;AS*C)NX-)'VS#8C
MSE[S;TXD1_BF"<C,XTB=/0OO5U>S238[T1[7A9$Z$T<<4(O#S'>H95.'!V9@
M31=O5\"%A9ST@D7!EF_NNFM+6;5*MO60'?6:W?[W!6G:;?:Z51K+PCI+7R,?
MUFEV.NL"@CL+^/[2`OT?<^Z'ETO+5'Y9+KW^,6RW^Q6-H=6YC/K-_F"/[$PZ
M]*.QVJ_\@;O,2&A@M"__\$S[/[&H9?XK]O$?L9Y#P2J6:(LC64)VYG909#@6
M""+!<"%R7,)>#L^+I!Q)<VILFQ*C54ZK_$"KO+W_*@\=&*H9K%_CERPN>UJ1
M0[8]"%^>O%4H.-0/GA^I$5WBY8Y4*C[V;,>+O*4WIO?YXY`'#X)'D@[ZJ4K,
M]!^Q)[&G)NS9*;!G;OFJ)?^,J[@:H<01!5H9RG=`CFM_!D;I(B7>X!)(E7H'
M2LXXGFA>Q[XS>LT.@^&Y:.*"I$CZEF>'BA1.U/C.Z#=[E:[O-(3T$H=1*)-Y
M$GMVV,@;N&#"6V8X9?ROV(&%C#Y+@P'W65,ALI2%;..+<E;RV$0+&MZOC)54
M!L*(T/2/@P!-9;C,"9LL1Q,V53Y#LD[`O'8=>+<PUN&'$!<7;MR2[M.C$TW]
M.$KW<(D3*]:<1I%_A<TC'LS`00GS0U9K%9Z_2A%!6*0`#"AK,"A>OCS#:!KX
M\?TT$?&)*R(D_=J1_<GEL1V>7Z)AI-_$\\2.0Z3>JMY:4E4XZOR3Q!7W'@!K
MP;H$%;C*L:^5WA7W*B8O>5P#B3[G0L^YBS>X4M:=C5(&1\#EI+S,S0M3#PYA
MRF&3NE3,Q2$)K2L6/,P(%W)S3S?:&%8.$PB.=R(0Y=8N$F0/+UI$49"4GX7!
M<-)A`V1+RPR"!:YG<^;'GCCR19I*F4ATLIDWE&#$&U`P-<2R-"T+[PW!YU_@
M<H9OY_/`_^;@Z3IV?BG9\#_ILCMXVHT?1'@"C^+H)BL>\%,B8J7LC/(BQ;&%
MU2<X6<J8<90_T:>YK/!6XFP;`VC%6-N7P)_S(%I\<8&@5Y[]`233'*F3W;HV
M]-8[R]!;]PU+"";02ZEU*DQ4F!U/9U=VA!)[#=(3M68(UX=O5DY4.L911T,M
MCCKJ]IN=/AW@49L:TE&3SCA:1>Y#&"FU]ZLSV?L4]\-R5JLY:A^=L70`IV['
M.O2:76*Q%137'QUV+K/7Y]@?$"M;EB<=7'%\!4XJ@%3`R0G!LU<!FAQ<1"K@
MD+5I^K2?4[[X2?O8U^*H<I`A:=#FV.6>%7WMTN+>%U,!>@#8D2?<:XN:M+E.
MFH?J4!;?['3I.)45Y+[3%[!NL]6G@U0J;%,8:(NAM`O/C:=J(`U))^F``NDD
MTDDGJI/T;3],.JENW2+/(0KQJSE^>@#BA9+]9Q9?Z#TMOO#LH)`MIP,*TI8C
MM:(?,-)F.WN3S-#X5"*RR?0%AG3+T5$@W:(K,*1;2+=HB0A5'>B-S\<X\)P(
MVYK@?I&)\PT_ZYO#)L=?0U#(.-,!!3+.=`6&C#/9X)YR,7H!4@/>(=6B`PJD
M6G0%AE0+J18=`:$TO][XI)L-0G\2/9K!T7>&D\=_P*T$E([10?M3.N9L@2&S
M3)IEE(W1"Y`:\`ZI%AU0(-6B*S"D6F2F?[#W:3BD6^KF\A_V_")J[)<K]^=F
MR*>^:S-G-@_\!W$6RM$SS54[^FV#Z80C!+_R,.0!MO.,0SZ)7>8Z$RZ;14]X
MTN73173U`%.+AD]Z0%>'O$)A0^@ZM,YU3V@=P"MN#CT`>J=K1@Z/C:+>?:OT
M`$D?GB-=IBTTI,M.$CS29:3+SH[GJ#!";WRH(H)PH<R5GBA0+ZO:(D=-K:IA
MV37V-O4H]W6NW$7:20<42#O5%CG23A5W*Q__/"#23E2947?0KBPKGL6N.+K/
MYO.`6XX9B4.\\83;F1]$SG_%%WI$_:A8HQ:!=DI@:0L-);!.$CQ*8%4_G+NS
M_X81RF&]'$YOM`&)M%A]!"%IL1J#1UJLNA;K#GO'!I*TV-.TV'$+,#8%0VP_
M'KN<M9MGI=^^!/Z<!]%"!#_2XRD:S.-'/Z-B0_AC)ZPH_''<P\?/D['T@>:I
M*;--<)ZK9;GW`6;:9-,.B.KI6IR=HV^%WF!OELK5<V-&?40M:4%MH2$M2%J0
MM.!>,+?W[@%*6E`S45L(O_P0F4"Z]#K;>=B'/@5R?)^?:'L>E0_M<*])Z;F)
M]`<^V\,/1!L(T4N2<1B5S=YSB\_&/!"3_8?1;UUVC`9KMXRNB*W`ATYC<[T)
MX]_FW`LY>S1#]IW1;H#T$1=]U^Z+SPT6\'#.K<AYX.ZBR9:`5@#^^$,<7MR;
MYOQM$MSYXL(,KCS[0Q+?>>^$ENN'<<#O8-[O7-_Z^O/?_\;8C\F=-US4QWPQ
MX>X[I(IIX0C#-3<RQ_[IU<=_P_B,8?\5LX!H\-,-G_STZAJ_;8U:@WZO^V^D
M1,MH&>*#T>X8KW[&41]PU2F,Q[YK[[P^GA*6[KUABEY,$(Q=!7#OO>SXPO9;
M\OVR)2_&Z40@<JTG,L%NL\RO`O;H1%/!`-CMUO06<LT/V\;@,F1?8)$Z.&BQ
M=J^G#I^P#]^X%>.R99\G$\?BP:')<BQ)<)<1@4U-E`41#V`A.%[DL]@#4D2!
M8^'2@(\@+:PINX=G1XJ&3E217@4*FY9I\YEC9<]T3="*9N0'"V9&`ID_/+@[
M"!U8COX$A@@JRK3]!E.2ZU=SW&0?8P\U+5Z`X]\X7"<4K`V7XTCC.8BKL@4P
M<3S3`R'GXAVV@TNF(>9FF1X;<Q""$QX@D7`L/)C!Y?A&-?!U3[1![`0<']1D
M=SXL_E14P@RXF!%\-O-L-]E/1$O9V^FU<L)W-!!_%&4OVRI]=Y"A1>$+%)@Y
MD9@&".WKA.J6P[?)W\%9RM_^&Y8CF>2B/-%.5=;`"@>N#./Q?V!9,I`WN-XG
MONOZC\C5UA)-K#Q-WNY)%&-8&?P]-=5N-/DPF[O^`B?)KNX#_CPZ5P?`9R:H
M%/@?R+)LRF8V9:%.0@XR'Z3C5[X`"9FH$'D#YR$(3WAB[J:9N4"!7!3"^+8(
M)L?&B[Q`EF^`-8?_^G$$TCQ&`8R:X#%PHHA[,/@(E%6R%)/W2N$/+W0B\-3R
MO^"5C^8]T-'QF.OP&%61>@@*<+!>'=\.\2N8C\6Y5%<>AY>[(-/-0,AW-@G\
M&;-A`J(_FYH-6M3%L<(3U9S2`>!;[GT?]9T9HGJY!H,9R*P:O84%<IENZ#-L
MY@?J6H[/7,A?8!Y`QQFH9:61+/685`.&\`9I(\*U)K.FJ*J8O"(*?#?I+*>H
MW3P1_OP,$)HH=IAHB,A.A36OXOLXC)@T'SH%/BF8@*9L%9BM(K%NS#FLHF_.
M#-:#NV"]1@?,B_"OV`Q@67$>X5KPA=W')J;EN+"`)(O\"?89K.T07M!(;3KV
M.'7`3D.-$/+@`9DX++6DY@&\%:S$<1PZ'@_#Y#WP%_S_9ROR"_:1FI\4''(F
M^!X3G@_SD<R'_"8Y_-O<`2,)^)/=\GDD3"W6:8E'])NY($#ZZ1T'785*S`0U
M-A,#4VPPB<71F3!99Q;/U*M3=I.J#9DI,?/6VJ&2=HMRRJ$2G6PR"U\[:.;Z
M<0CS"]^\W9,GVUM7[Y8P2<%($U$;%07[Z54+3#[NNACG`BY+_U9!-/&W"L_)
MXH<T&*?":!;8"^8\Y&^3#Y=,1MMZK<*F5GT.CQV6].@XF4@>K+RCU[F51];/
M;Y??WFF.YP>#&I9'E\.6OOB<'[/4H`U7ID9HBX-4-T<O<]G$0;2SH9YU%;2M
MH1J6_:.?Y52)U2BW7H,^#VN4VGD6GLDLT<8H@LY6(Y6CG9R?1K5HA\#8Z&JR
MD7T'0?MR?+@#-D>K&:L0#7WA6/X-AN77%10(??'$4H+!,*LDZ'?P<[&*BYU*
MIN=]_+50=7(BB9Y/'OL=3^_"7(:LX=N0Z[%<L#0L,#S2ZIDL[R/2I\M$>HU?
MO,&4H$C=))F;U>?XP;WI)76"FY(>OWSX_</=I^N+JX_94\(HMA=K$S!_)*L]
M-]#\_)Q0+%;?"QV4;3!.L)[D+-0@G(`]^L%7!N0W[T79@<I\FF*-ATE"I\I@
M,)5LP9M=4>JS_L[&TF@?'=?-$MAKGUM(>B=%2+F<-U#8=7BPG.\6B3KX5V:&
M)7ZC%K/-1;@FX8TT6?OV3[)0BC_@RT6EE7CA(I^G+BXJE!6"Q(]^[&+=!J@9
M,53&)S`H5=P$SQ'JQ\7,O&=?V/YC2C)%*7Q0(8,OG@>3WX@IIOY%.D^\#):V
M%8MJK6@:^/&]K/M;EVN7;\NNR48ET_AKJ7,:LF^IV`Y(YGA(E1,2@E?SP'%1
M`AH;)2"06:C1);FWIB(Q(Q+<F-S&OUEN'&+1"@@5UW[$0@MAP8:R;&(.*W("
MQK./C_BC>=L4J\[!,<A5"&)B#FL3W+N&RHO#>]S8!@HE@JGD-MLQ[ST_!'Y.
MG@"<!P-&F7;//8X_`$9?80J"3ZYNKJ\*DA>L!9O907R/(L9VD$4:[!?N66;@
MBP2Z\#WEDY,B$J3+V`P=^<AUL[=!<+B^VI6/12RRE&LVXP&66"8J03%^,M"(
MAY&:/];XP#H""0HL:^((''A6<>3.5[1$E%00(D&-F\ED/XC`*"U>L(#'02"S
M__W88%<?I93QX>5!\AJL=FFR3+6@D$CU0+HP&H*"\F\[D4(;UXGI>;'IIFME
MPKDL;`/J^6.P^I/JFM3K=X$*6"R4U@T((IM`%'@'7GP;P3VA0@6>$\;P91B/
M0_Y7+%2A7Y1V^?$O%5/)XJ``6RA@#43@+TP79I"^&C`":%AHNFA18KU2'BM<
M9"`ED1>Y**2`9X3N(M7T\SB8^Z$8!/YD!<X8;QG'0!L;_!NW>1J"]-H$5><_
MF*$5NV;`ODQ-^`T=N'NI%C]X,'(NF?(:EEGL1J;@]5]_O1:US==?/ER?BM05
M_('E-FK%VVN%HN+4AA)T2!D33"+<9Y(83D)D)'_`8C;E`CP(L5',^L51JK&!
MJ$VDB'C=N]]`[@I\1,&/O!R?C0SG@/B5U3^?@/H/<9@,A\<1#CN$[ZTF>VWB
MZUS@#+`K%*]FMWX`7EB^[TV#X2F\HFX0;@G"J3//42^MTTO($P5.0B1X8B*^
M-]O.J8##<OX2#2AI5:RG!)B$=94354CW1'8HH2:*!].">]\2YAA6:\$+D^$+
MZQ*$+OLDI=3']U=)X;[064+`B*JS!PR+`G;ILA''V:Z,.922,9H6J_+EH/U'
M+H$T5X4LCNJ[8;.%O[A)"2:,,'2^L1DL]2E@/P&"B2$F(U+U91M'4?*N>(XP
M?M?+O='QE*2&YZ!28.$4.6*,]SFV)"7\@BV`<</$&@+!$S[$N'E*X/%_)DR]
M;(A"[)=0JZ!D5U%E8KN"T@9&N]G['J?2AG]@7@%"&G/Y(SXS*1^%(=JQ%:'9
M@%LHP.ZVI@Z7YTOCC>AV.1,G=Z74.2X:$F%!3#!X53(L,?:$.POJ%/6RC(K@
M\O:!=QPOIX:+E8UY>Z?"<IHJAU<PI*BBC1=,^`SB6S$VK'T4QI\@%TXQI94Q
M^!Z]MIGY5<XG61?PDYC*ZMH3E$VAS];??BJCBO;<+?"VLHMDM\T@<B.).7;\
MM[C9+UI\E'MQO'N\^T^Q0R;:MHMD>):[2`9OF"09RV@FV#^AVKYQNK)XYY%,
M+!&:7)WI86VF(\WM2^`\H,#_Y#U@O:\PZCWV)09Q9B5S?OWETY</;UAA/^.)
M&(R?/=!5X",%BRPLW6XWML<M;\&,`I]B+K12NH^&O<9;$B76;EVJA\OH]I<X
ML*:83TVO3Z\T+M](HP='Z<>X8=&"MPF7RQ'0^(%RW8"MRG:(RKT1'K?2G1PH
MX17"<Q=,O$3E.:HD'"Z#1X,PPT<_*K9MXDC#V,S<N2W3*%(JA"6,L;;,FH`7
M=GK]1K?30L-"%+QO&8+0HLE[I,'2[HX:O9;!,+VD`A`;'B;B?>D`[@,_%"$$
MW!`C;BCN)_C.2$RA!A@]<"]&$=`20"6)SN9,J'9_,I&VO4I]H!^\D+7EA4"H
MU.7HO*:O5(1,C4)82\MC&+9Z,MF1!"%7D4,=)$V8U57;2S8>/%O)_0OS)M*P
M?($("HJE!JL^]N0"`.](1@9P.XC'Y0(15O_R<\SD2865UFH.\DLT?Y?$-+T2
ML%$[KD1T!`<@LU?MYM"0UQ:'RK]A^"D4JT78TQ@[`57"&VH7B-B*YJF466K#
M)H&4[&H<_=3$S(>7/#09#CH2[69[B($1.8T&=JA$'PTLOU;K^RQ!X`L_<NS8
MV:TKX;D"T90S];L9VN9?X`C/43.QWX0GL'Y!MD]Q0::I#O"L<!6!@($E%TCO
M1-CLJ6$O71!T)=(D@UQ9PC5P%P@`?BL7;[*4US(^+BCP`TI>ANO.YI9KHG[B
M(*-$HC212;>@)0*Y'TJ$*+ZIC73"3`Y#$0KUV$<^#HKX&=U3P^_3JGH$9R>4
ME0?2L%E**ZE(*]"^D=\UG,80OEE<6`#H)$8J6>3YD0BDJXV;J100DBB.`#;1
M0J"AD,*HD+`ME&7AY?.*?G*1S"Q*$;`BS^`)808R3/$!QB<R5?C(1D'TX,*4
M<7.Q"M+O"@_$7&3>BA'4Q"L#7)5Y<N4,F"1XSN%7$0%/K\+GR1^+B=(PYJ$<
MO.N&8HKYL>>FQ!T1+']]]29;GB*^(:\7:UB(L<:*1,RF*@>/TQ</D[\+]QJ6
M@`P-"+D,\/P`5^&<>:YO!\Q'A`#$?:@=1#SOK]B/5+P)J-C(<_F*ULGM$Y;Q
M'+S8`>;'\%D>W#`&4JTGA7CIZW<Y.B@K+Z-$C@;YV1?GFUO,8X[3PK1YA&,,
M_5FZEU`HG\UC%=ID/6KP]I(8G*!2&G01JR_MDR'C<LP&C6A%&+6421+U5VY'
ML!\'N3V9<H0R,"47>1PLZ>_3B/??"!T@7)'W@BIH_4NK](1],E4JM-DG"_,^
MV5(P.1'9N*'5B6+E0&2NU;+C]BGYI>"BK7&P4'>O8C*7#G3B,#361</G.2=K
M53RN]:*,?K?1[_2?X$7U>XUAKU?1B5).2TJ+7;VJ0:<E/9H5GRIS:4S!]6EF
M4@KGEW*Y^D:_Z'*EK\L\K57+Z.0,HZ-X6MVG>EK=9K>SGZ<U0?/XJ8Y6MVET
MUCI:+^5@==)6`X((J1I`XDBS438V`%O,_,KSQ4[KDBTW>=_B-O4MD`%@I;#;
M"Y"]^+"9J.9,2D7&W()O<DZ'K^I>EKD%QIJ7=QB6\D6Y6XS&R'SN*K])N%6I
MT;6W[Z(H4U;;EBZ8?&L2RPRG+AH3*=CX3C"+(C4XL?R#3-:KY>L(HL*R<K#M
M2HX6)>Y:\@3A!"35"ADUT!8"327\#G@JZBS9SL5\,!TW,=BE(ERVQ$I,SR6'
M,W-)9&I)F*1P3S+OYKX]1W2SE508.^&,PU73:6DSQ1Y?T5%K(K-%?7_+A9MS
MA>4*J1'_)4CZS=V*]?-ZZ8LWY5;&JA^Y9`IMM2&^:[>RS+24[P67T69&6P1*
M<S-9'O`V(ZC15NWJ-OAJRQH(AP:4S43^FA>O6B$-Y3]5-GVJ&CR-M0:-,6B.
M,MJM*!QIG8I2V/(^DW,3EH'ES$V9?"C818V$*CC"P=#8!X/.J-'JE2O_4S&J
M/J"U4K90A))>CM1@B#9'EC)-71Y5D.+<G^?K&[&4AP=K->'F$4Y-6]0<_15C
M8:8,L>`5B1/_7;/5,C)ND$N_?#G@XSP_?88()-@.*E_/%OX[7,IG<NBRV$A:
M8'#/@R\81Y4@R:`;VB*J=-!&SG#-QR9['PO.D8(/"U@22;&B'O&O%4B0GQ0F
MB5-IM!N]UK*H$%5FA45[P#IM/==QPKS!LD`0"UG)Y?66?F_G-9W:^J5K,WFX
MO63_;S#7C69>=C=D69;R!Y3IG;H%6#<K*FIS[;76^P<K#H<SFW';D=)XR?E0
MMJ:=U?1(WI1#&0LC<.J,1<Y7N"7JN2MFFS.1IC@&[6(W2D.&R:P;N8?#9_^>
M"\V2ABM,$/0NCA$KOM4&!X^#\`>>E'6";(;N.HS38Z/F:)3FC2*Q1]B+Q=X>
M?.UZ]0F7>NFB0,V6A;U/1[X+<9?Y)YF7O.3GY-1]6@&7>)9CSCV6\RC2K71Y
MS^?*$A`;HTZG\.R]/3DC[\FQU[_[S4ZG<V$,![W6\$WBV1TBJ?2;F<\'CA*3
M-`FVK+,8_BRX\D+*J$6TCK:9UV0+:Z7P0M5'[X3B-&L36*MTG"0U2D7K'TP_
MW/Z$<AK><X'N;JJ!UP3OVKGZT,@7=]][,'.5"HA`^H=@US^8;ISZG[CIS\97
M9`(EGZ.9<!/S"B"T%W,L'787#2FY3%AJ'.OXT_'D-EYA^3Y&>NU$Z`E+6J:5
M3+'[;:5PE"L/&F2YEU:EF7B'%8B.!GAK%@(51:X8VU5!%\=+IINWI.#..>ZF
M@:^2,II$ZJ$85,)<TD.QYSQ%)BSHK2!LLO_U'['W;$,UDDQ+US'F:UGQ+):9
M#EO04978+%-);#94N`@SR%PWR@TS%7IF=1:R?+3\-KFIHF1JB00QA3DU&PLD
MG/+FYUED!#4*/DP-(G>5.&@SVK_'JWX5A=V5BL+3*"@LST^53N^=:7V]#WQ0
M?A>J98)LT[.Y!\.:>1<:+APS%K,:D>S(K>[KZPM\D0+/5Q;D:_Z**:!>PS#Z
MC79[N+.G6.:/KR29&NT!NNB#?7S1M5$3K*HJA$VNY6U"735VS2H-FX,-U7I5
MPRM))CD)LTA/HE+^9Y!@F1@RNZ:=\D&:4W8==\@K244A;=9#9)?:O8W9I:-D
MC-I-`X:UMC9/;6%YIM11LH29DD)+:WUCPNA,,D;=/&4H/;0Q/70:R:$G;E+1
M+@5TM:4S>V.]]A\U.@.CT6JURU:'=,2S"`XNBZ)P"\4^,Y';0=DH0VVXQ1`L
ME>9PU$AV(LCYHHS!,S?N^;*,+)@(("T[1M($(!EY&IS`,8G=FE)B8<H";TIV
M3Z0>L.#1M$HL.Y@B%>PPF>2F2&`TYM$C1F72[@U]M:,QV0'1;C67HA2I8[WJ
M55[DG";)3DZ^NF5BPI^J:$TZCHKG$MTBYLCB4&[6>P>VS=>+6PO\(P1*!,LO
MD';X\\RWN5M^PMT>.]R*9RQE%WR>H#H`JTF(+G5HT[4?1N$MHO<.`[-?U"[^
MM=OE1F>Y76[XA@GZ7,ABTSP-3\/UD]$G/#KQ9(3J78GM(\,1&$_"5-:#*-4'
M;P1GB@]+)KM*?/%4Y/#\IL)/Z6.0>))V>*M8-GBQN@Y_?=.H^)+B8]#&DWMW
M9:`H'V<I'C]B#+84S\S,;Z(WZ$H:0)@;PH9686RP3)`N:*&TEU+NZ_V>$_>%
M<C`FIF76*T^(>N7S*+->[BW`(U62#>@XFV_HE\J?WHC.>,D!A(DUYZ!^4R[2
M/'=Z:I)67;DE-09*KQC[7AQBODBU7!%6I42R^)VL#T2-:1?C@^*'?(^;'#'`
M3P`-;Z>G:R6:'?<_)"=Q-51)>+(/TLK::R0.4B/)#4]$T7C"4P5B-G(]?G)O
M\CUL+^;G#_[:;D\E^`@_5$X`WVPTNIU!HSM(XR<K%E1<0@1X3G_0;@Q[[<*M
M&/\6IQ3ATU5IOGS?2:4VL+M/8+J-9<(P,XZF?@`C"S-&6>42D57%J!G:4(%H
MGH!;&E3"ZIT/]!*`IJLHUQ(PU</7ZI@D+KTK?]+$_@PX+)&K*+PP63OP!A&\
MSU!=JQW0M+1P<T4^V@#CA']5YSS5]4UZ:X$\ZVV"^QA*`@^2$%G0(97,XGPI
MT6M.[2>4;NVRU;Y"PBTS2!""\<[PS"V1,\\.3P2W&\9OOI4/6`E_E#`DF^&I
M8&-A^6+WT*BP47'50%:Q#CEWN4%%'*2U_+IEE$1YS??L-9Y>A\VY>/"FJ`17
MQV'L-(ZU&NV4^!,D[G]B;RGW:-K%<J."0,O'0?%`6K'+!XL"5*.=K$<*:*D'
MX83-TQLKFCE7*HV-J^"&BS"*+?D1')ZYZ&S4D)V0VJU6M[+%)2Z6]E8N9+/&
M2A*<E5ZMW$KA"J*2N&33),V7+,CUBD`\03"9J`9)2(7+5LHTRQ(]+>^3^'+:
M529MI21*9@1EUR[%ZOJL4+TS:@P&Z8:3BHZ\"/KWFD8^ZE^J!)61V&2?18!>
M621"8`J1+@/H8%K.<K)6I1-_X\&]N`=I)H3@.BK+QSR=K`TVCB.,X7G`:<F+
M5'/41,SDFR&+2322#K5R2F*0:I%4@(EM1J<+9O7(V`>=07,PW&"8)*/?,]97
MYGI+\=7>(KZV'.U7;0C:2=!\(7-J=JZW(+OM%N;@Q-=&`YBTT>N4Y3,25MBQ
MU7:QI;:48D+)">V6YOQFYG^`(V1?R?0$V/5FT'[C4`F8-"*V(?XES+A"!$R$
MO#)=E-DB0ESD:(O%I\4KLC>NL$O.M,@HDDFR/8^T+&.))_:>/]YIEX,]3[M\
M]F.4^JT3/^VRM!6:/D=9M0D"`0&,%C@/,.B_.B8<G4&UD\6VG(PB)<0ACD99
M"5/O"^L3,/R7T%0?"IH*[2UMF>I%S\;4`:%*7';<DS%)"Y$6TAZ"5`NUCZJ%
MC,'N9WJ1FD)W25L.(Y6D'R:="EQ&8I'$8KT9$8-'VK(@B<5]+768]HN>,WH0
M,[W?'/8TEH<?OLUE;3?F-/;EF6='@HSU7;32\Q_`6T4KG==)NKWF2*8WM.6A
M%]4[>H#R=(/\V5'IK)=LI\LH).KJCF"O.211IQLHSV5DUR,67A<C^\%WS<AQ
MG6BAK7M*IO;1(2#QI24JO<JPG*[N'U&Z02,TOM<6#')K],/D#!FD#JB06@&U
MTM<7G_/CFDUJA?(TQ\'DQ@F_7DQPXY\C#K8)Y3Y&;4,PY$8>'8(SE%QU0(7T
M?71I-'M[%V@0WVCD2%)^[!Q%V/DQ2!U0(<6"BJ7?UA>A\^.;`[N2E(T\9#8R
M;16_<+AK:QN!(5?RZ!"<H>2J`RJD\:/+EK[PG!_34$)2&RCJ(+_.CT'J@`II
M%=(J6H%!^4C],/E3=<:ZJ-@92]N@#'F71X?@#$7:=_J"0>H?P\B=@;X(G1^[
MU$"(E3B8!`$Q!NF1\]4CK9Z^")T?N^R^2_('T3$WO>Z`1TV)B>*A1@=I::W!
M6XYRL!T+X]D,#U];=Q!FOAFU/)%1'GR#W;29B?VMY6F0R3$[._?)QD_)8;&.
M)PZZD>_:VD_?"?$BV7,Z/'#;:&H-O4$<RE%T.YN;WHH%.#<#F-NSMF;26Q*^
M(""&'GC4H556OCF&T3UJ>[I>EWI'UZ9W],Z,1FWJ]DHWG('N6@?/-4Q_'#BD
MNPB/;5KKN`<>M/O44W5WD'5H-4T:K*YR<2\^.Y+@U-<9(P%:8^[4H2DU"5!R
M`<X-+ST9BU#1YHB%-FFSW4'^/1:9C;*\Q<G.VY^PS_+PT-J)'-+EF@"EJS-4
M)]A(>=08Y*1XG%W)XO'S4R,?U+'KYS?S+WC.O'8BF71G373G/JKQ9'F)E.49
M@$R>5NV$$&D+38`B3XN4QUDK#_*TR-/22R23[GRAC..S[Q_JGOJ61V5^,C^.
MPLCTD`H--N8P=@\^,G^R_[:-NI`@MS[33]C4P?'W[A?X$OO:3GI9UF,G[E9;
MC?8>Z@=;ZW"XG>ZFWF&WT^AVJ<VP1I#4@;=(*VD``6FE^C20(&54`;].<[#W
MV6FDB<Y5#!($1X>`-%$-82.55`%(H]MMM(R1OBB25M(3%8+@Z!"05B+_Z+24
MT;#9'NJ+(:FB`V8\G[T&Y>0SGK]@$W>N[U%@9"3H``&)+/U0:5&WW<MV>]CH
M#?9V/(EUSI-U2*=H``$QAGZHD$[!#NY#0U^$B&_T1(4@.#H$Q!CZH4(*);H<
M=(U&K[/WJ2#$.N?).J13-("`&$,_5$BGB.,*]\YQ$=_4*L=%N_J>"DZR(9@V
ML&G-'D>'@(26?JB0LE<XX0EW;8V!(O;1$Q6"X.@0$&/HAPKI%=(K.L.B.?N0
M7M$``F(,_5`AO4)Z16=8-&<?TBL:0$",H1\JI%=(K^@,B][[N[0Y0T\/Q#[Z
MP80[V"38]&QFF9[%7??XF\!T.5)/#Y#J4(JQ&:ISW4%>!^1:!X7N=&V.UYU&
MK[5WOZTSZ*FM!TQO:H?02<-1!PE(NJNNR)'NJMJ6J]7L#XZ-(^FNVK`<*3$]
M<2$E=GK(D1*KZ(!UVPW#V+OW/FDQ\L!(>>DI`DEYU14Y4EX5/3"CV2?5I3M*
M-=B\5YK`M/UX['+6;IZ5=EM[3A_W;.9/-#FKKHSISA.O.E38['[8<`%+,E?T
MA;9*W^P#8GO"]DRCU1\V>L;>S6R.)EZ)+6L#%>%"FK".T-;\X`A2@!4P;C>'
M1S_FB'1?;60LZ3X]<2'==X;0DA(\$-B:'(=.>K`V3$EZ4$]<2`^2#TCJ;T>,
M=3B`G73?"6]*/4^MF.1TN>S6:@()#I33?>Y"BO/$JPYU2D65MU:=D1533VA;
M+XOMZ9HSW5&WT1X=_<@KLFAJPY2D!_7$A?2@+MX\J;_:8-S5X"05TGVUD;&D
M^_3$A73?&4)+2O!0=;W@`_9ZK6,C37JP-DQ)>E!/7$@/D@](ZF_W;;I&]]@X
MD_)[J90N3)P.V'R.U.T##Y.FPOS;G%OX1^2+KX]=,+%)+YXT-KN:)B_-'%7L
M$I)TFF%6Q?(@JZ+1ZO<;@ZJ]JX[`>,17VD%"]"==I!5F%?U?4D$Z@E=]NRII
M'Y)^I'V.37_2/G7#[(!JB$`CW7/&D!#]2?<09J1[3APTTCW;\W8_1+C[+[W.
M=AYVI8_1AK\+]/A^[4PW$>6P5+B;<A;YD>DRQXL"QPL="Q=AS'%_HU_<^\AM
M!H]D$=RRX&80XC9(^.X]M_ALS`-Y#J[1;UUVC`9KMXRN2+G!APY[-$/V74O\
M_5VKP0(>8A[.>>#NHLFN0GQ9^6,:XI6Q%W#+O_>`4C:S_-F<>Z&)XQ-)/2_D
M\%375+F]V%-)/S6%!EQDN3$N?@8_.#-QX40>.!K#<!IRB/U.IP'RB0$S6%/F
MA(6$X1A?D0[!?^`!,YF$`].+\+=YS]6F4)Q1N]F6A&HR)/,UC-GT%MDSPN(T
M+#^,0D%A!_X-IV;`+\8F4MU\-`,;B.3!^T*`%M]XX3H>9_`[#%(,!6D4\+]B
M)P0^9B$/'APK'4V"&ZPY)^#R@0T&,S;M_\2AHD4VV1QAFBQCC_HO]8GONOXC
MK@+!RRR,9S!F@87CX4,D%.;8CR.8IF]]39D@U]19I9+3#<%(R(TK^.U^-&QM
M)6&I)).O*8@H.6.IF7]ZU7K%\'A=E/<PH_1OI2'$WTH76?!J'J3*1ZEV$.*N
M.0_YV^3#)9.J9-`J&,W5BAVHJ;Q.6N^E<!H23K7`B?B)<"*<#H=3CW"J!4[$
M3X03X43VWKGA1/QT<C@1*!%&#3'>`:@8K5?'W"*UIKG>VKZ76ZK"9&#F$&5A
M>4S&OFOOC>L!=FM\SN)L^^[..`-IJ`-B^FPO)7'X)''8/ZHT;&\Q"\]:&G[(
ML@RU8S*2AIOSR4NID90=A\=EQRZQXPJX-Z9W+U+BBA\Y^Q(X%@^))[6&C;RU
M4S!/VD>5AT:G6,]6Y80"$IB_QU@)0<Y<;0#3553NQ7(D2TF6GHXL_3,I,;Q2
M)88W?&8Z'A:B7<--@6E%L>FR.Q[,2NO,3I8XKQU/%EF^(06C-5"D8$X7,U(O
M-09Y1;T48QPD5K5&3U>Q2F8YR<W3EILJQ$$9FKH`IJNHU-4")5E*LI1L4!*L
MI]L"N8H0/K<*5TT[ZPT/!]7I-M9K-3L5SP"G!A/:&"['[3).\J]^L/5(%E;$
M\1_#MM'6%TB2BCHJ*A*)9!*>#'9&L]/1$SX2?CI"0O0GY4.8[8+9`4$[7374
M'C5&I(BT@4-[IB)%=&SZDR*J&V:DB"J@.`)Z:(H?J2$-(2'ZDQK2"C--@W&D
M?:I%XUJD?70!HP;2C^A/VH<P(S5T8!0'K:ZF\)$6TA`2HC]I(:TP(Q^HQN"!
M#S34%#_2/H<JW7_^?3:$U8[L\^R0#"M#<LK"K;.?<".&.3[#'&.[(*&B(2H]
MDF2'J)\G[CD^]Y":.7M(R"XCNTPK,'1G&`IY'IW^Q!*:05(=D]-5(H/VH#'L
MCS1%B)A&0TB(_L02!`GID0)(PV9WH"D\Q#$:0D+T)Y8@2$B)4$1+5S"TYQA2
M(L>F/[&$9I"0$HDN.^U1PQA21$L7/+1G&M(CQZ8_L81FD)`>(6=$*S#JW(Z=
ML-)K2P35#J%PZ[;T1(<8AKHZ$RI4TTT]T>L/B\9&`$&B'21DEZ%=-J)F2KJ`
MH3O#4.3RZ/0GEM`,$HI<1I=@"S>ZI$>TP4-[IB$]<FSZ$TMH!@GI$>PK;AB:
MPD,<HR$D1']B"8*$E,A21&O/6CSBF#/D&%(BQZ8_L81FD)`2P>;>C:Y!!2NZ
MP*$]SY`:.3;]B24T@X34B/!%Z)`(7<"@-MTGAA6U@SQVZ5!?3W2(8:C1,*%"
M)=W4IKO^L&AL!!`DVD%"=EETV6XW1[216!<T=.<8"ET>G?[$$II!0J'+Z'+8
M;G1:^V7`B&?.D&=(C1R;_L02FD%":B2Z[#:[^V7`B&/.D&-(B1R;_L02FD%"
M2B2Z-#K-/D6T=$%#>Y8A+7)L^A-+:`8):9'H<C!LM`84T=(%#NUYAM3(L>E/
M+*$9)*1&A#/2VZ_5#;',D5CFB'VZ4V#8V`]L'B0D#WW7L9F\B(G9SLT`:$L`
M'F>C1%H^=&"<3E<.8IG1<3?:$V_5IJ,T054SJ'HD">O8$9SXK$[F!N%4#YS(
M+-SA-,1.L]O6`#/BK7KPU@XX$2C';1BP":=_M,1_B)=T@^VPN)VNWC)ZC9&Q
M7Y$)*:[S8C927!J"0HKKQ&`CQ571X6H.CMMCBM16/5B-U):&H)#:.C'82&U5
M5%OMYG!0+WE(O%8/G`@4TEL$&^DMBA.2XJH53@0**2Z"C107.5RDMW3L4%\&
MH.W'8Y>S=O-X`.;1&/NNO3>B]=^^55:S1BCIAQ+Q$J%$*#W7E@5"23^4B)<(
M)4*);+SS08EXZ<10(DB.V>$B00D)NS;2MPE&BN)JBNL+`WNZ85ZCT>H/&SWC
MN"UJ--9\>L"D"4/JHOL(%-)^9XPK:;\#(3ULMDGQ:8V0)KQ(BD]#4$CQ'1C7
M[S2%D_3=@0!N-X?[]>`C?7=>HI7TG8:@D+X[-UQ)\1T(Z>ZHVVB/C'K)5&+'
M>N!$H)#NJQVNY.N=NLIK=HY[")[&^FX'9/;<:?%#9,(DT^MLYV'7F1AM^+LP
M\N\KCVU7BJU[3;ZT)+<6G0A6C;4+!7=;MC<\C`+'BKC-;B/?^LK^\)PHW&]J
M_:T4W#J-P_+DW92S:W\V-[T%&_-[TV/W<&L$C,.";-ZAF'>,\V:O;V[_"-^P
MR&=\-G?]!8<AVG&`=[1;1H<Y'K-\[S^Q9T6.[[%')YJR"-YBVOY<?.-/&#Y'
M7/SAK]B)%NR39P$UG`?.OKBFU\PMH/03#G1B.@'*B)CC0V`<S'PT`SMD3BA>
M8;E^B..8P[#%)5$VN[3'^>`RA`'.9C`2.2WX@-?99B3N$?-GIF?C4P-N^?<>
M@&,S4]PVYUYHBFGP;_B9X^TF/"DP$98+U_$X&YLAW.L_\$`\&0@YYY:8W@/0
M5(R0!XYO-QG.2HY"S42\'=XV->%J$VX%`H4@A%C(@P><E;Q33B[@\/J`3?PX
M8`MN!J&DMNEYL>FF[U+S2^;EP3B"T`P68L;-_=:Q$`4XUXNI7(Z&H=O*OF)A
M/)OA/).U@A#@:H.[!44DR3B,UV;ON<5G8P"L8S1P:7;%"I`+.H0%Q4,N<!ES
MUW]\N[]<VY%F6^1I08@+^:XTVT^O6J^8Q5T7=1<L@O1OI17%WTK9(NOQ(-6N
M2C6"[G7-><C?)A\NF:K9;17.E2O9P"<I\'Q*O+/#^0['5]D:>$'/#8B>70*N
M8?;CP-$(#Q@ET`$`,;JO7@"<4K>FWZZV[7R+BR*%QR%\%!VJA_\E-,*'%8U0
M.Q:C.OS-SM#Y:JUZ2$D-6>JL\4BU5O^H2JO3VCT61UH-W9G:L1MI,$V`VHO/
M*!E%`O2D!&A'.[XD`4HNP(GCI2=C$2J9-FL?59L97=)FNX/\>XQAK=(4QLG.
MVY^PVRFP<%@[B4.J7!.@=/6%Z@0;Z8X:@_RG>#VWST][7#WPP+SGYS?Q7T3=
MR'LS.L.Y?\2"HW]BP9%VJHALAIK8#!J%1S7.*Y$Q4#^F(T>R;K*&E((F0)$C
M2;KCK'4'.9)G-W%R),F1U!ZH9\PC/_M)8IA:/NEBFYOU.]+\.`HCTT.B-$I%
MR\D08=WF.-RZYWB>V.TU45O$]A4T+W%.X4FOTJ>['2]Y5&2IR7IN[0?J`%O[
M<+B=<)L!8]0`0NB+XO?$6UJB0A`<'0+22OLUQ2%EI"E^1K-3L;\I:2(2@T?0
M1/KEA$D#$<>0*GHF(+$#4EMC)$DCZ8D*07!T"$@SD6]$"HD4DA;2\+A;:<\W
M!?J+[`]Y["H",A6.7E-((JM>J+0KPW*Z&M\8&8W!_JDY8IWS9!W2*1I`0(RA
M'RJD4S##-JIX8B[Q#?$-9=B.3GIB"/U0(47RY+I!8IWS9!UR3C2`@!A#/U1(
MISRM_(_XIE:Y+=K>]U1P_LE#W-J'!V\%W.5FN'^>BTIBCJY@*#5_GJB0VH\N
M7QN=4:,_J'BZ._'.2V#R1F<P3IKR=9!:Y\</=4"%=`GM(-,-CSKP#>6WB"&(
M(4B14+E]36#1G'W(0=D&P?6':XK5GQ\JI%<.HU>(?>J4ZCJY$Q'U0.RC'TRX
MDZ3`+-.SN.L>?Z^7SB=::,I6>G8G7X=;Q>;CI+*TX2[28[6!BG`A05@#$$D0
MU@<K$H2URT:0`-2=J4@`U@<K$H"UQ84$H>X@DB"L#U9Z[V(H#>W:?CQV.6LW
MSTI$TLE%Q66;G5S$/5N?,XO*),]Y+MIZ5";L>O9F`<MS;9U:!VBK]%`](+:G
M:]IU!T:CU3YZ$?'.PI68LC90$2ZD!^L(;<U;B)/ZJ[2!IM\^-LRD^VHC8W76
M??HEMTCG$:N1\M,7;$T.PR7]5QNFU%G_G3,NI`?)]R/U5\/F":3[#I[._B$R
M@73I=;;SL`]]"N3X/C_1=C+1$IJ4#GO7(;B.QR^FDIJ&L7%,K2UC>@9@KD),
MS;[G%I^-><`Z1H.U6T:WP:(I9Y$?F2Z+O8!;_KT'0\0"G]F<>Z$9.;X'?X01
M]O$S,>D=^7#E@^SO)Q/@YJ,9V"%[-$-FSN>!_\V9P97N@GW7;PN3M;DN77PW
M=4+YY$?'==F8L]SKX:4F/#TPD0872%HV-D.XP7^`T>.8/9@^,%R7+;@9A&*;
M5?(<T_Y/+(8'A&$P4#$<\1?NR8H#'JX=T'[0&\.JV"M`Q[YKY^%T@/:.M<OR
MV`WYWWWOPC+#*;M%L"[&V(N17>?AW6_B?>W7_$=?+A6Y0CB,RDXY0-9(&?W6
M9<(*8@G!AX[D":20Z2WRBQ*_GOBNZS^"6H`W2;HV6#@%8:\(6^`;_@T_<_;:
M\>!F/P[A%>&;MR\F8[;(MH*L%6)8J;6?7K5>,=RQB(H+YIK^K52B^%LI6PM>
MS8-4M2J]"-K(-><A?YM\N&12=_9:A08$1]JGVNL?O=YS123LJ\!?LMJS?]1J
MSV[G(-6><L4>PC#6`<.\2J=J3ZVAJLTV?A*/=2R&;[=V#S60_$33C^2FUA#I
MMEEHCY#>3N+S9'F-!.H9@(PNM!Y\2@*UOIN.2ID2;=.3#J'?\)";@345\2B;
M/W#7G\]@C,?.?3PI:7EN>1"-$Y+#P\%UPLG&WE!?!*D!HH:HM->KI=-ED1I@
M0IJ)--.IL=U@H"^`I)@HI*\[8K]PCP>F*[PKTYXYGH-E)I'SP(\=M*BBQC9%
MF<Z-]_;69,\/V/"@B)VN,NL.CWZDLL:A0CTPTCC[\L3DRHDQDSY`D28C379F
MS-=N]8\-(FFR^J>]2IVU\]RR=X<;$W2.=]!NO?,+0=)NO0H8][M'CU/29KW:
M9'#*/+N=M-[I,I,^0)$N)%U(NG!7WW"X=T'D&>C"';#1<XMY?]/(]'R+WOMV
M\QN5U^ZGS6U%QUVX?#9W_07G<@NZQ^^!FQQ<UHY7W-G;9%<WUU?,!CGF^5&V
MM9?A1M_(_,;&W.,3I[#7/7FXW.N^;E1B#SON?8?;PMB-<*.]V"H<NRZR=BPO
M,W'C,!X$BIO;L6.\QR-F\PD/`GP3O-T,0QZ%3;:TKM5Z_?&'.+RX-\WYV_=.
M:+E^&`?\\R2_D?M&COH:QA/>XI[D=SC8+^8"RT?#.\#@G0MS^/GO?V/LQ^1A
M7^!NN/?*LS_#H(,O<'/`(R?@>-,[28\P>V/Z%.;8/[WZ^&\0\,8(=P<#FO#3
M#9_\].H:OVV-6H-^K_MO!*!EM`SQP6AWC%<_XZSV9,(]-]I77\E/6+:O1V_8
MAV2U*,JQ+R[<?;([[.]R&^6G@@4`Z]=?W[`Y3%NPW<S\RO'[F1E94]PVCPLE
M<,:Q9.B_8M-%+C-:K>\3ODDX+CW&9'`9LHD3`)=U-E^4?[9L"=';\EC914)<
M4[BYR?)3,VU_'JD&`&)F0K"T^O)PW^0^N.`[HS7$AA?BA^\&+?%YLF\;`A`G
M<VYA:8*[8-O%PKZ<7)0'GSP0;OS._+:%YXT7XWFM5OQK'#O^G`Q_1>+(^N'6
M&R8IR8"47$D`O#;%;R]QH!4M/DPF<GFR_XL]GBUEL9);O6(?#6MJ>O?8A27P
M9[#&V>W%M1_,_4`J1Q`!)KO.?P6Z.ERYKJ%:OX".G7/\"@0*K%'@?#,(%C!F
MU8F&!QRT?)CR)3P^-Y:"!!!J?0K`\2"\9&&,&R]F?@P*4SX&#840K'-GXEA`
M@2:[=5"'XXS%+.'!@1_?3S>P=$.(@`FW1>&1(Y<%*OQY##,+>5BDU-0,MT\1
M!-92KQT#[)L!`^Q=02A1WU2\8C0RA$"">X.232;,`F,$C9-H:D8@M!?83R<.
M)0G]R00,%+!KL(<.3L"41A;.1PK,[<A@BQXPXT`JP9-A97MX8;O5SNC8;G6Z
M3?9'Y+C.?^7B@/&N/IA+`8]D5&-NX%#<&%T?[+8"=J)I_14[:%VML<Y^X\$]
M#QIITZ`P'O\'5K-8B:BZ/-1,KC-S(CD(.^:"!H\>+)2I,U<+.G=)R(#:#PZ*
M]_&"?;JY9K?('KZ76Q'#MB34ZO.1UFJ$HEL,EV1**;!^X2LJ)*B-.5`:`,N(
M)]@(5S6L"`9LE'_<.G;8BJ!:$V+DW&[N:=J(MEQ:";-/GK"_PU`N'W0R3"3B
M&$@9+9!D:VSU!I##,^^Y9!U8`@Z*$?8XY:B!P<IG#E`,(7&=K\B#P%:>$"F"
MOT(4!"DH`;H("39K7B:7*MX\3D:'`.!R@E4CN#P9=(+RNJ?`B&P^YX+L+)[[
M<K'=B[+(Y+ZU+`XL$"3$D6<\X4I]G#H@1B2_16!C@:0.%B!\03<$'"0E+DIY
M-[=C8`=X7I/]MHYJ^-S0FL)E+HPX`*$4A*:[,@W7D9@X*#>!XY!K4:^L'7(B
M(M!J$Z)&%'N"X(%Q.<AT7^6,@"@2?1Q3D[T'9I\'0-+`0=#*M0?<&/F!6![+
MC%E8&_#\V!,#@X?!E%%.<;D(MBV2O&H0*T!!+WY0#FNHEDV8)W,>!*4/+,L/
M4#ZZ4LND\LI<ZZ>:]Z;CA7($,`F4V>M]UC7:J-MM]A)EQ&`6F[1CP"<N2DH@
MG0E/!V$&?NN:9[::798^4]@1I4_M2+Y8M_[!+\YABYY\X*""6ZMEEH0?$K&@
M.C$B`<\"ZJA8@!#$Q;N$",XUWUMC\Z^H?P`?'HQR"]'QP):,>.`!-]P`6W@Q
M7@WK9YU^R>N4,(KM!:QFP>XX)<7L?AP)[H!!28-'7BG-D/L`YRUMH%+5FX1.
M%*_EN$^)!G3&8M<NJ(JK_-B4DELR#\0]Z1)(+Q!+(QW1NE%6L0M1V4<X6^`"
M]*U\293T=6I(ZU@!YQL(3LEX(DQ&L26(4W>]F)JK273,C*1AG<@S/PXDM05/
M*@30'E+F2&;QPF"E4%+7(KD3:QLY41CK8#P!X[N+1-?\T;QMIM9S",LG%B(W
M9T>C2,=%T.E^+TSMU(_N]-(OP)]>%Z-+V_D=I$=?!?@T[,DWU*(G7W?U@-'S
MW*%2LZY\%6MZSZH'RK_`0EB*]%%_/NU1J\UF/A*5]6PHM4>1#,E2:M"G/43Z
M[#PZ#)\=I4$?2522J-2ACR1J7;8JE?(D6J<G;746`E+.NOA8+DR%L:GPV.6?
MU"'I-$JR>]0AJ4*)3J?1'NWM,E"7I,,C\D9G,$Z:\B>R<^C<&(944+WQ>]UN
M=-M'/ZV25%`U%73<D/[Y^E&W$>;M5QVHAJSDF*0^EOK^V#$+XB<=0[X;515I
MHO;HZ(V)B&\.X`J]!!@G3?DZ2*SSXX<ZH$)Z!/5(Z^BM6HEOGM.?H;S04S&Y
MV;XS0.M,T+GQ4!V"HZ1[0/<8`T-?A,Z/;RB=0Q*+^*%>J)`>03W2.7HC-N(;
MRLGHC,FU[&J!FR'5QDKR^O5!AZ)E]<#):+2Z>[LLQ#CGR3@GKEGJ`0$QAGZH
MD$91.&'7H;;&0!'[4#Y&(W#>KS:J,NW_Q&&$61D*!.@#%`70ZH%3NS%J'?U8
M'V*<>C'.B2N9>D!`C*$?*J11#N+6$/O4RJVA%,U3P1&G.U`00!]`*(96#YR,
MP5!?@(AM]$2%(#@Z!,08^J%"^@3TR?#HC2F);6J5BZ'VO27%9FO.7-`Y'E"E
MI22QGW[(;6$\ZE^3ME#K]XZ-HL8=0O4`Z>C;<'9&Z*3AJ(/\(\U55^1(<U4M
M4>@-CUZB0*JK_OFE4E?-]F,\E:O=).VF7<ACU[,`"EB>J_K;N]GHBT097Q+2
MTU6+&I6/ERG'4KEZ;ORHCZC=&2K"A51@':$E%4@J4&>Y>F[\N+M_^(,X*SF]
MKG",<EV/WO[3P0.I(Q;P>S.P\:3M:/E,>]<QQX[K1(OD:'=G-C<=_/73EQM!
M1?S?^\;*"?-3TX9WL7G@/S@AYMWPF.S"0=VA@P>?X__-16+.CL5AWTX4LML+
MRP_F?I"<,F]&<2B:WN&/83P.^5\Q4'#MT?&G<S)ZNKVL0+:`3UQN1>F!](@2
MGTS@JU`<.LYG2+A@H0Y"YT!?/"@]>N3<6W?@O;A+'BHO2)P@[L!MB-G$\4S/
M<DP7W@Q/%I3&Z_)'J\<AC+((,)O'@"#@(8Y%?^2NB_\6P9+/@6ME[T(Y,GC,
M(ZQ&P/%N6FC>OG62^+3"(V",9L3NG0?.`B<4JRL$R>M,'`N(S<1L\!AY=5:[
M6KZI'!]<AH+"]LHV/SQ,W@N=$$^3IX/>=3OHO3>BC-%.#H6EQT'OW1:=]$XG
MO9\$:K7)/Y"LK.FYQ$,ZF'B/Y"T=]:X[1/H$0250[6<^ZIT$*`G0^G`GG>RN
M/40UV*50RI1HC9ZTD%SM&!6^W9>?Z.!<C;7<,6'K$VZUQ(UVU&F(2OO$-5(-
M("`]5$_82`_5$S?20QJ&ZY_79^HWASV-\;F.`_3DUV7B]W:?J$."CM+M^5'I
M$RPZPD*H:(@*.3]'AX`80TM42(MH"0NAHF&ZYPB51D:G.=`8M'^:EFI&95E!
M;+HZQP*HH<<!MW.]:-"-^GALJF2@_E.Z0Z1/K'2E%(PJO;3`A?06Z:USTUO4
M?$IWB,X^F]1N-77.)MWYD>DRJSRGI'-\@S+J-0Q+';`2XH0UV]X>&<45SY*M
M2K)3I\LA-<"$-%0]82,-]:R^%VFH6KE9E/EZOLP7G<-R#GQ'T<1:8/F:TF#:
M8Z3),2Q/S'Z=+@_501Z2)JLK<J3)JFHR2HSICM$F379VS=`T3Y+]SJ.339&1
M+JQ5A_HJL4G2D57M';T[U).NU"YI0.Y?38`BG4@ZD70BZ<23Y<<:9/S.NK"R
M#O$TJD^I)6S42ZJ>N%%9BH:H4%N/HT-`>JB>L)$>JB=NI(<TS+H]K[.D,SB_
M^]Z&Y!KU--0(JCK$=ZD;E9:P$"H:HD+.S]$A(,;0$A72(EK"0JB<79Y'\TU<
M6!NX=))[X=QU"@/H@Y7>+9_.OOR@VVX8G:/OP2*&J54TDQI?Z(?)&7(*J1:M
MX>F,&H/12%^,SH]ASCXEH[E?<SV%;R-S[')FP46!,XY%JXJ#.#<4*-#1+M`I
MJG:ZJJAKM/0%B-A&0U3(Q=$/$^(4+5$A!0.^SL#0%R!B&TK@Z(7/#0^Y&5A3
M9GHVX]_F/(`A>)%LS&<%W';V[_!`@0,=U1"%W%X"I]%H;S5$;'.6;$-^CGZ8
M$*=HB0HIF.ARV-X[D$9L4RL_AQ(ZATCHF',G`A+_E]O,`?_&NW?&+J<4CD80
M482M'C@-NA1ATPB.&K`-N3;Z84*<HB4JI&"BRTZCTR,5HQ$@E,31V[FYC7SK
M*QN;(3@WEC^;<R\4"1P*$.B#$<75ZH&3T1OJ"Q"QC8:HD'>C'R;$*5JB0@HF
MNNSVNOH"1&Q#B1N]\'G/YP&W''52K&<S<^8'D?/?)SDX%"304?]0=.U%CB[7
M%QYB&@U1(?=&/TR(4[1$A=1+=+EW!QMBFEHY-X<]*O=%SUO5W./Y'$UYH'.(
M@`Z(JVWTC0Z"JXKETPZ"HX/$SX[OZ'#4F@!%JNWTD"/51JKM+/GNE#-3FI]Q
M>N='I@O?;#J_1^=@")U>5L\0XZ%P.UTMU^TVNIV!OB!2(%)#5"C/I1\FI*7J
M"1MIJ6I::MBB;J@:(4+ILAJFR_YINK&J#G1=_]'T+'[LT`9%&"G">*Y:[?73
MG"^*+KX03F_T0(CR9366B:3-ZHH<:;/JVNP)3AII,PVT&:7(CGH\+"7(3H;+
M]C[FCR*.6N!W@.H/"COJ:#`>*SE&$)!"(H5$"HD4TDFQ50WR8&?M5M4APD1<
MHR,JU7<H$RS$+.>-"OD\1X>`&$-+5$B+:`D+H7)V^1^=P7F?S_:XCCEV7"=R
M>/B67'U]0*I#X)/4C9:P$"H:HD).R]$A(,;0$A72(EK"0JB<77:EWQSJG%VY
M7E>MEO-?*`"@#U9[%P#H%"2C_#YQC7X:B)(O9P[!&3(&J1.MX2%UHB\L>F=A
MCM`V07,OY_>2;3D'<'1>LA2:-I[6*]Q#&T]K5QE-FT]KPW?44Z$F0)%J.SWD
M2+61:CM+OCN[CGB:;P_"K@MU3%YMW2])FK%N(<N7A)0T)G4BT@0K+1([Y`S6
M!"C2B:0322>23CQ9?JQS@M#VX['+6;MY<"]29\1.O''?)HQ):6J'Z!Y*\RF0
MDM(\8NBU5-Z>&S_JD_(H<R1W4HTGSE1:`$4ZD70BZ432B2?+C[L[DC]$)I`N
MO<YV'O:A3X$<W^]"A-)A[S($HUTRAB5B;QK288&X=3R+LVC*V;4_FYO>@CDA
M<SQF,M</0V:90;"`YSR:@<WF?NC@^5R-Y>OON<<#TW47+(S'_^$6K&V?_=&\
M;;()M_$79GHV$,B,.#S;\F=<^)_\&TS3$T=^A6R\D#YI'$W]0&0X&;P7CP)C
M"VX&\B]@$VNZ=FPP"O/!=%Q<)$UV-XW#PBA3V3"X#)D_YYYXF7PPT(O#\,:F
M]17'W6ZU1OB$;(9C[CK\`0843<V(.5$H;IXX+G!]2I10S-'F=FS)/P/NPGQM
M?"1>/N>!X]MAGD*Y^;-'!R8ZYO`SD,GQX+YXCB>AQ;83R2?[,`#/QS\BQW+F
M2$L<G&G_!VZ9H7,OGA'P,'8C">$,+@+,@?SV`P]"SOAD@N^&!Y?19@(#\BR\
MQ_(]6\&MGNE/D'2!!*S!``_+#*=LXOJ/3?81_L2'*IK"\K;9>V[QV9@'\@U&
MOW79,1I`8*,KI@0?.L6U-#5QCO@^'CQP`7D,ZS-`DD@J)M0N(I02AW^;"^(B
M4/C@2!SM;<[\V`/88`*Q%W#+O_>`WV009`QK=X*8"NJ%H!B<B6,!D6$UPUH-
MN`ET@W'87'U^=**I(PD(6(;\KQAI'SUR%T8\`T:;PN`^R0M@U7A1889`5<N-
M;1@NX.H4EH/C`5H\C/!ML$)-5S`!,&V(ZVP2^+,R8A2)J):!Y2-;),]$>N<>
M"O^%H<Q@B>$`$5AX0I`P)UZ,E/1"X*7?_=PZR@BY?K2/\!W+45@1*EM50@C@
M:I4,O<>*:;(EE:%4P8\_Q.'%O6G.WWX2L[@SO[UW0@M$11SP.V#R=ZYO??WY
M[W]C[,?DRG<QT):'X7L>6H$S1V)>>?:59>$T@>I?P!BS8%[I[<RQ?WKU\=]@
M;QFC]BM$$\7M#9_\].H:OVV-6H-^K_MO'''+:!GB@]'N&*]^QK'NH;7Z)1I#
MJ8&Q[]IY)>#`>G>L793*KKV@4DKA*D@(R/;3AV63.YHZO+JYOF)CQY]/3?BR
M`7QL-86DRS,8_(G7-8"'WH.0!_W#824$<U^*Q@;R]92;]E^Q&2"3"#;X$W@%
MI'T(7S3@26"$F;;?9)\]]G^F!Q<NLB7?'C2$%FHL28[9W.6H44PV3L@.7XZ5
M"DF'^1L/[O$E**C$0-/7":U@H6#`PS7E!4)*\F`FF%K(S:O[@`L6%2SWQ34%
MTO*IXJL;[@?W)C"X>J\M]-PMGT=+O-ONBHD,&^(V<R9Y'%;.9RORBU<.DRMA
MB(F6?YSZ8%-<^(^H#E'6.K8#A,+1_!X_<->7^+#7\J\W;(9CM.6\\(T@H_PB
M!=92!;G8\6*4LN8$:)&C(DI**>F#!^<!K\@!+6>U?9B@#F8S#E]&')3*Q,?3
M3?%1>;`*2$]-#^>!6LD#JDG97YAR,J^EI2J4XKK%P1YQ(J#`Q/I!Z1]P:1+,
MY#R%K97*/3:/898A#R5R17(]*IKD+C>MOV(GP'G@Y4+SP0\13C:`%\"LOX)7
MX^&;"]/('B7NM\4B!Q(T3T2<W!7M9#/#R^(QF''"S)(_SP-0OF#6N6*)6'$H
M.<7F2*XY$AFM;'$/++8()BUD`:IM<YY8RV`2VX[_8(96[)I@LS@AFBQ%8ZE@
M[KD@IN#5/EJM<#=8?,C,#?8+]^!9OKJV.VQ?LM?CV`*ZPBIPV71A![XUA07A
MV/Q-0\Y-30PNN)>C!'/%`>L(3*S(O!BC^E0"!,B/7GCHVV"P1T)LH=S!509/
MX@_R(&"8LK!B+;"S!:DB88,D9H-8S3-EOICJ-V<<@/63R<.KCT*B@+7L")M#
M<#_(YB!B$_`6P#(0`T)_F:&M%CB*<HMP`L96^IS__7CSX6/1YD1;U<%E!O:B
M7+E@_"4@,;$<I",`[P>+"*2C'X2)0;0$5+@`O3!+_(O,X1!&EFE%<MQ%4"2`
M.:(O)&U-7$L@;>`N-6VTI\'2"[GP1>#M=A#?-_=4V?JYL$M,%H&BE=(5U?!B
MCI9MF#BU7Z9HPK??_=!97E:PB!1]&YFP^N7#[Q_N/EU?7"GLKS["8X"T4J;B
M2E3W"$EF34%D>N!(*MX%ED:>3-X#G&5*48X8`$8/CA^'KO`)D/_@)CF\SM(*
M??V_']^LC!+GTVX,6D-8F^GZ3FV`=Q]N[^0M#:5.P_C^'B@C1`:LLN0IN%R$
MVVE9H#(FL2N7JXV\?B]L^T`X,?@74B&CB&3Z&3B&SH7%/6'7`&2V/T/+'ZP"
M$>L"O@>*+1,;_!]PM*1S+`1@(&,0H3GAD5S'X*K"#=8B/V6XVD0+)G(>N+I/
MB`\8LF#0)3X'T:'2WG`-LB!\@D4!=XBGPMW^MT4(ZXB]ANGPN0,""1:K:\H%
M-`#$%B'>ZP)IWDA')X"E%.&#X`X<YM045H$IA9S!.L,1$\P"*IA-_9G_W\4]
MH(QRP8\6<RXU??)70>VG7"_9U0[!FPQQ%3R`WAW#.H'I*TK(U0CK:X:&!IA5
M<]^1@K"(3^3,!-/#Y!4EPL4,!!$X=""CKC[^D,A--X[0\`$Z_"HF"N+[PC)C
MM`_\`%V*:'$Z`D,H&A3?5F(0P:*RS;E85G)I2M[.N#\7^$L_+<F=D/.O0N[X
M`$@`1AXSYZ!9OSDS:?>!>;N\2I4R2(02./1!XE@);HAB>R&ASL'Z'L7(K624
MWWS/@>6,KWWG8QCL]?O;W]Z]D2$`$YSRQ7^!453(H"A_REXJ%P0N;73C9S,9
M&E,2S51<!YSB)<H$!,2%O`E]>^`.P>=F&,:SN8I./$ZY""]DSP^G?NP*R\/B
M4@PDHD_POJ(?PB)C4'!+M]U**2>)@G.54YV97P4O.4$V:BFCLZ$C-5`/P#S3
M((H41D@7:?@C1BDZP-H\YW6UN^P1(!8/D#;\13R7["QC>V+-S,#@BH/$NA<O
M*.KKC&<O!-,V,R<HFY30^\XL&[28I3`+Q5R22*<<>\#OT9Q0[UP1"PUD=&!L
M%8T"D8EV/:RD<1P`0TJ;74K>W&!N)4)1Z9"22):T*'`<\LM$0*;>Y=8%HGPU
MH5>!]T%CH\)1IIYI34$JXN3R=V=Q.HNG%F&RA+*)IZ-'-9>MYS0\*#ALS2K,
MK2^\TW1#/W>[],_"A`'D0Y3<&',8#<_FX*:/5[)!O4%H:C#U-@X,(YIE@U.2
M1YBW2'70PTDD.?'J5Q8?NXTX%XL3[IXY(/)YZK#A9!M%;A)A.U36&!]('$D5
M.UY]N/)4A$4.*V`>E@;1<\)'<GIBQ1?8SQ+K;YQG0<P1"-_2EE<;_48VW?6K
M%*;@A%/E2\@Y!:!4IZ8[4<\8--G):+8[/Z46@S%/T3T`_R^1[3DMLF20"1$0
MCV%-"&[Z^/Y*:J\'-"!7@LN>6I"!"0YF7D9;X(J"M=!DGR;+.:+8$P(+[O+'
M0OCF;@-7RU;F9N'*="XFX(%R"QQ+F38UE6NF.$B(:K@!'%X5S.&%]2A,1IE4
M@O6;F)-^4+@!PRU9?F-[F'GGX'$Q]OPK^,8.D&"Q)DJ=#S-W7B3,;`SUBC.G
MU!%+\Q=?"BU,?W@G&!N"M>JCZL/H860FB@-SGYAI@74)WA"8::AR,-L9*AY"
MHH#RCT4099%RK+3>3)DW4BP)/(L.'MH%P"?(<$OK72KAY9R4R;P88[HX#K#Z
MOF+J*/0M1YC-0O2F@@23=F9@354>-&4^U%!H*.!@;#['&#`J;>##KWPAU/Z#
M8\>@8J6@R;,M!G:$(;HZ1;3B4&D&EJ35@R.$A@IEJ6<MRRG^5RS2ICG)(Q-3
M,+15^BR/!H>2O5-%OQ.`LA>KR^8\<F24`"UNUQ115AGL<Y8B<BKM&:D\.I)6
M.-VQE&DRTVO+@).LY+;S*T5DP[D$T`-34'K'268VE`/(`1V*E+\C_`\,2\&7
M6_T;?+=TG55H#RG$5]90-`W\^'X*BRB,T30+$YQ4L!Q,055_#H^ROIZ.2_E>
MVORK&6VQ].PE5_`[8]3L8!34%4K,XS(%.YE(X\P"MU^L8$G,T'0E(1UA%7D/
MX+TX<K$7J)DN4"!V]@7("Y@$N$SK(/[DL8]\'&#Z2219RS-.\W@,\IX!!Z%,
M3H>:2)FE^0V:HV1Z:'?A!)4=*ZQFY&''YLLF0+ADR8LP7<YFR4R5TLH.[UYH
MBIP:7S?M)9<K9Z5(>U1D0"HZZ<OC:RP/,%>PD:L@2>(Q@D\%</@!R0O23;PW
M5Q*"H3`1R%TONN&542*$4'"+:'2(5G@`(@GLBFPM%<WG'IB^_^L_8B9(^!$N
MLD0:?<A*(;*Z`V%"9?YF%MO,R4D,.KEH&:D%&:I<?RZ5@0%HU#.H+<(L[IJG
MFJSD$,MEF[DIR"($N71;U+I5(.4`.L#2635L;>Z:"YGC35Z\T91=-7MA6#^@
MIUMFY.9?B-;NLM%:9ND&)>9LO45M:2HKL1@;RI2!]2>:92PVKAT_R&$#!"[!
M0%HN,OJ2LXDF\+L?A#D;I\'&<22TN>N`.R56KH0P3?R^7<$";""FBE(Q%94K
M_115CZJ*]*=7+?`%N.MBG2@\)_U;5:"*OQ6HJN[4@G>:\Y"_33Y<,EF;.NHU
MN_WO"_6BW6:O6VC67+)W#Y9%^AKYL$ZSTUG7+77G$M;^TG+Z'W/NAY>WBQFX
M'_)S>5GF/XQAIV+A[^H,1OUF?[!'I^ITP$=C!Q3Z]P&F^PNR+F]UYX(LHF(!
M'0Z,UPEE)!-`LNPK"2M>+ON^DHZYFMQM%;FTH+/U4;\5?>0E+74XF@U"88,8
MQ?I'91K.7=/#S&%Y+`L4L5@K*/;O,=($5`Z%P9P/:^6SM^N)3,N=Y/?++'88
MT%?A(CD8&)F4VJB95R>*IJ2XEB9.8FJ+F$EFY2A_31D[)-=IH1]UH:];U'DC
MG<NT+%SI.K(((PU[Y,(:*@7UNQG:YE_L6AGROPDFHB5.2_QH2USM@V)@3GO^
M#%Q(E=B.P:E<9!MJ8,V+?3A)QKY4D)/8IC5][#5=06QC,`H\S,1F7TH0%6.5
MM)9I+6O@6&+H3NS?;&#\).16'(D_L#]2&I1EW(.G6O*O!68$1,3>-9V9=$V3
M37,1K"N0YS&(?G@:K'7@"[&Y'I8[7D=+GI;\$9>\W-XE#8O4!-G@9O)ORO@6
MJV(L=CL]J(T2X*%Z,N.7[!);K939>7W7.16!V=GU3K?(+&396IN/(X:21NUN
M?Q3U;:[S%3.FV:[M?&(_]TS;<6.1T5)%AZ7A@:GO`F>'*R58(@$2KJ9<\YE!
M55W@R2@$4GD,:AQKG&0&PQ\#@Y@KV]M%'B]_M9H;YBZYAWL@T+<3\A"?JT:X
M:04FR9E\7AN?B):&*1)M#]S#K+:,8<O7X6[DP+&B\A1?+AN6S_N*\D[+]&2Y
MI=PZ\XC/%=6LMKJ)S41V=)R+DS>8@Q4JB\82*K*VLPA(4JCI<2LKTRQ-.#69
MJK_-?C5=X&-/L*+([:W)9>$$\N-;&I:H.5VYQA=[0OE<JA(A*U93CG!'ELL,
M.):_<)27L=J<Z$C#CZN8+68HIUCR(G[(=:U/LNF2BQ!5W(,(*R'=M"AWJ\`[
M&[C;'",`0LGF9]]@<FM"?I`B,QZ(2T5"MK%42R6VM/#EDK]T12"S99E3:=/*
M'@0B^H"Y>5A>,%J+GU@JM3S-'X(L\%6*6EA.59/]28!R*6]?>)7L))!S<A,!
ME9=_N(4(+AW[<3E3+_DA`E:QP56F\RU9,RA+R7'EAKY<QZIF'X403*&L`"HL
MZ5T@"D['G.,F+X[;E^RL$#FK;,_JN0OELYO&*4IV5.'',K\=CLED0Q$A"QQ5
MQ5_L)1+*]TY<KN1IFD.9Q%A1HCJ)A$DL#DO80=,5@A@NC%7`G51BJ+&K1$[2
M2V+]M?GII'E*I273/2R`C'IA49=L60Q%Z8\/3H1B0G"Q8'-U-VFQP#I9B2LK
MPF+-1N&]2X6,N:)CK(%&2?6(;UF516&ZCW-I6/P;^BD;RA3VW#:MGV#ZG*M+
M,T1K`*/78(]BG7%0`3:2)ELO<G_\U>W[J_\G-O:E&TA`%61Q9&`#%@+#\#!;
M0>JF8@P9\^&I@L'2;'S`V+&S!`T^JA"2GIIB2&S&);O,0%3.XMGZN[\SFKC1
M@:OA,#O;,#3'"0J)VVF)[8=K!9,:=1!C8:`JIK-9C`O=&+9@M;JX_RG`![#[
M`!RN=(=2,F]15*J8YG<@I:4$S;V9E#$YHIQJ#/S!>1JI3!:KG<;G45;#JVS)
M4^6_9R8ADLA92T*QGW03X8#-7)#@T0H%I71/[H4KC9;4X.C7/^1:(H@=G3EZ
M;R17<\FO6=D!L*F$7Q;[@WSRW][(5@NW.,U;H&PD=@8LUE;[=\^RVE]1B`D2
M,4&C_:O\T1RYF,J)&(:&HNTW+)//:E!%DY3ENN%\[:UQ`0^^Z*<M.T*DS[K,
M6)-="?-"?B-%G6S\%!2^377OIO9,>./$]R-/[$S(#!YI)(@:]2CPY69L=[%L
M+Z3VP41NQ$_<FC*6JL0H2\V;S-`)/T^6-MPL-C!7[^68J](B/!*W"<(A,E]P
MSX:G]@V>*L/=J58U@J]$)5%%@WY-LR31TS#K=BAM0>317.<<V<<%-?-K<?DO
M5U=?WJA,H#*U<6]SSM3.MIXD14X3TQ&=%S)TE-&1C3UKQBBMXK#8GB^K*5>;
M0)+R*=6&4#V<VVL-C,_P*H##O)=]H.`FT<A'[)1/VK-D@\I[SKEH4F)CJ$:)
MB22X\CP,E-]P+*1'B_HC/!H4]L7_E^R=D63*=L.BP`K0G<DWW!.;F<'ZYM\0
M@W1^GC1F\A:A+96S1!2,'=#Z*C!2XMT5-H2NU_S59$]17L$JSUT?^)Z/_K9X
MXU;)U2?))>T$T<0C(R,KTG&K$$M$UBH9=N@,"WH97+\+E69Y>]%J&B5Q_L-*
MLD\>^[_8X[F=.A^O;M^)S5:PN,7G'&5NE>4=LC_F@A5?)W&3=NORZO:/]"_C
M\@VP15,\]L)H-001<10)[58!5JT`,P<77G;/V0=L^H5BX/6=/P?7=&3TWKQE
M'[`0WDLEQK5JOO`QY3PI"G#,-UST`9M)UOZ45C"#V+G"#?(SM0GFGT@>](H_
M)5THTU?_`A:Y$-CP"CF*(<[I&F0B=M86PQ"K!&<E"JAEQ!'>ZF-D-1UYYBR5
M4_;:MS,O5&Y5E$\1]Z+D3]PF(:30A5G:)X]D4[W23!?#G?DP4I)'%WU(\89L
MQZ+8<)F0+<B1+;_59OD=N/$PLSNS3Z@B846(#5"R,D4U7YV`Z#23!KQC#BSC
M95WRDEZ=#'USN2;%X.%BU(VV+V-@8R[4(K80B'`RPE>3.L`/T@W[B5[*NOR6
MJVD9%@%5+5=^Z932^#X.1>@3[%6<K`]3:$S!4)U6KL>HZHZ'.K6A\$1<)UPD
M1D1@3$YI$Y12V\O-E2!T+@0#)HHZ65AEZN=%A-CSBRML@GL5WX.9<R")E9-2
MO;STJBRQOBQ95)D(NLV66!I=-BZ+^\[9Z]MX'`GQT&[U+KHMD&V9XX_/^Z,0
M/Y=Q:Q!=0C85H]976=3ZNA"H7-WIGLBI[7,4\-C8^%?,\"UNT0U0G<O9-XN/
M6\,T2S1.`]$;A()JLUG@X:2"8JV4Z.\L)=:]8A\Q(41<,C4E,M/@<FKK*O.6
M8[")FV([^\HH,LFKXFJY!D>P$D1CM+(\!EK0J^NA8A9#]9X&OA/D3R)X@EG2
M7,-Z;UZ,:Z.XI$S0IDQ0::_QXFP<N"CKL%[=75.)22E+0M7\/6&.Q'5*=-?Z
M3<U;7)9=W8^B\_)'R#]//H21V.(=YEV3P8NUP=;9,\FIL1R5U-9Q$5'8HG5.
M./HR+\Y_K7R2Q1'X1&1A61RQ-JBR)OJBR/R'A]MM<QW,(@$"O!%\!^Q;D0G]
MG+R/?-GOBJ>H22,PZTXF!*NLV%:Y3I3^&`S)NN'GTK+YS&62ILU,!"F9[L5>
MS))[HI4,36E\MFPXJGE_(=6QK+26VG.)/E$9$0`JQ!-;5Z[2(N!).R];FL-Y
M<2JL#JDFG,"*9RC#K>6.)VDWL+SL_$]LW\N#+$2GDP???9#HJF&MJ!_5$,*R
M`MD_1NKH_.6J>`2OX`4R-V3$_$+V!Q3]6KQ0]0U6UKLZI@2'_ENV7F23.]0N
M8A'FFA7C;3$:KFJ<86Y1)7O2\?8TE9YH[/R%JD)`=)A+P_,RY9[T239EI6FB
M1V1'`&S(D7<LT@=N[V-5%.U%L7]MAM,KS\9_/F2]*38$JH84J,+)(,%8CF(G
M*]^OE]N69/)9]8)$>32#ARR2;8ZR[E!VB5HJB42Q#ZLP^1ON'+4*77@3Z2@:
MVV*J/PXL;,Q2E"X@.SB:GZ)SUC=+],+'<6)YY=+;PBCP11\;Y-HP[;,$MX,P
M<\(I"`>TNI1E*XH>G:37'":KBN$?-?9%%L7Q12LMO`7)@`:UZMNE6AWC')+.
M[TH5J)SRD\K,]%XT>:R2TA_4?"CYEM>3F3O82>1!1<%M!F,C[56+@0.)O%*0
MD<RCB#+%"C']2K)N23RB3^%%TK:Y<<*OUU@^&N&GO%`<D5`4LB)/+<'=DEQ,
MT.M4)61F[N/I+T&LRNM0D^>[Q*9-]XIE;'G[R%JAGR7IAYWY4G$KV__"Y*1+
M7=)>:ET#.FSK!0:1B_;:!8@^ON65C;2#$_:\Q>ZW(&REY2*VA)FB'Y[R8?/?
M!.D-JMX<1L#M>V%$8;>R^R0/5ZS3D\(S+)T44V//ZAHPLXAUCZ;W%93-3.H<
MX8JK(KMEO90X'4H[3`K8.5&<LX)S/D1JS8J3@`2!'L'6GH(,OT4*I>,2S81E
MJ$1J)GF"!SX]#E(3?KO)MD'N%`74%[4="4_QB4"XH6`3X9I2$Z[=:I&TDL%B
MM9,+%TI*MSW%5$M[,568+D^GBRM:.)TV$QLBPDC981:X=K'<`@(L!?K7R9V)
MA(<&J`:936#@,"TS#J5K"FM5A+DP%I>^JR&*^SCNE\`P6N`_)(E`<%U=TTK^
MDOK>XX_@\Z%KAE%9V?Q-_C('I:]8491'V[)V5GC$+-=#L\G^G&(]DW+#<:+P
M:GQ;A&<1"3F5U>F"&S\7103^I,&2C81RMJ6D$&?AR012FDQ,!4S2BDGZ<>*`
M'U.TKI&G6SIA4D\E?>#ES2O)'O'Y>MQ$8SHU%E$;FCC/6#B,Z^8"ER,68TXQ
M]OF@7/;$;<0[.)X&XLKM)A,50G#5`5)(LB;[=2U>3%68X1+@N6>'4XQ3I$%K
MUYFD`0XW.66Q9`S9E<FKRY9K<I"4T@#J%*_T6,+`E@NY^)[,3%19P>4`3')*
ME\`LR!_\Z"Z>2&=8(,HCJ$+Q;8JAJKS/5:=>R>#(!Q4RVJ`8C)=1#&6)S.-%
M=D7P*"'0R1QU&.().&F[3]&?57:1D_%:T3,_"M<&'U=.`%:152EJU=I.PVY)
M-!(%EQ.F;U(1OO04+5&<AYNN'"O)RT53!\\=AF$Z20UJ5HNVX13;,1<-_H5L
M*,8.7<Q8X235BPJU;?9RX86E5)?LN:QJS+`"-QEE)BZ4C<>DW8S"HPE+QIS-
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M71NI"D%_!B*>NZP&E=((X_G<=4YI^_6UH%9.`:\YE$?HWDS!R\-VTW)[D8G-
M5%U!0PHG)+%3TGV3TD66;\P;(-+"&2\RZJ_7S<(KOK[YC#@EHY6'586.R',N
M#5AT/LCU$<%C,<&<\\3WZDL_Q3TS$_*^=Y/=J!&G041,3B_RP5%W(1K8<^\^
MFB;["-2&0UGP,W&^I0$V/+G[(2DA5O5'V4%Q,KTJEW)"&6PY,)]+W]%,SX\3
M';Z3>*8\'&^<JW16F5@WB69>2>`6T@B5Z,WD"7XB#BBW3N!&K=A36:4P,^`>
MN&<76XWCR5RFXPIO]\&7]BC:L*:(!J<]\/&@4?[8*)R`ET)O8M`!>'$,EA//
M51$D=AZ_R!^YDIU.+71::(&&6UEKLB(@M:N;:<5W/I:M9I,=KY:>"9$M8UDO
MD8<A[:VN)JP.)90%#8Z%(#IA,W/5EHU;6+=%`Q27KDPB`:4Y[LL),PY8MY01
MLTQNY8YZ54VX9R;.01$UG'-+G@X,(@5FY7NR=8<\O5F04)08)@49IR+8/JWN
MG$I8INR4H%P_(;'1&^FLVLU(_$213O*4>#X)L!06O"%I/$KQ)_;'Y\[F2)_9
M9'\F\1_%E2M/,$/I]SIV^1@3KDG.U!5%E<EN)1C69U%MDASMD;4[D-^KOU5D
MJK`E[9UR'F_1>0Q5UB`;6CYX)?99;AX?SB7S4(,"+P(=T@I7P3M_Q29&Y>1B
MQI,F52FKW%^UQF<27KAO*89,>S,DYS>*"D@G2-H>9.&MRM3=NNVZ@@VZY(KA
MIM=WR*O7N4*?S\F1;9]$,@74(T;-PE4C]CSW9(M=N!>":BQ/ME,Q8N]*HAUE
M=6$R&(1\"%H,`]L8]TH50#&H>X]'+LD(<KX$(>\;I@\*5]^B/#KL((4K5PW&
M5$>_>>JDF"RZ+#DW#2Z+8!R:8_D@5W)`K1BHAQD.^4"A^M(]W2(A(^J:Y1\3
M+C,U%<HG]F"R(I=^$B5W=^:W#3&2%]S!K1$K2LJP.RQ&/"7V2S3EF'M\HHX>
MS1=>8BQ#;MD)$[,<UV<62545KTE05!SSCFG\I+$9/`73>7'@81P;+679?@>]
M`O&G,+]P*T43_'1UF!K>5%:;JS2QD@"3E8R5*M7$1XC^(Y@C$EHX`I<.C-<D
M=BL+-N5O8QX]XC:5DDI?\#R"0%@)A0)?U5]E0^%QI,[#1BM4%JW!J&2=KVA>
M*A.*\`R1;Y2>P[>DOD.\%.8G9(Z47'(7$)+5KD`JL=<Q5\>*2,A86)@GH;*&
ME("2QZ,EJ6(IJ@!X00894L>!B$Y3A2K9*@,J[H!/PFWR+87[$RL*KL\OS.Q>
M.0KU@,3063<$U3E/]IX3WK7)LMWS)AX');OL)%HDB5_+\['!GTB/P4S;]7'T
MDL3^5GPGQ\3%#$^<5HTD@8*>\)`$*4-D)71-Y4FB*U-5XY2'^LIF4ZK9F+U:
M()3E3]=.(G%Z<J>6KGF74#>YTIFIF9TDGN`OLM?EDY(;BJ(U3U\[D=2QSGA3
M$%(*FH8B?BX659Y6DB=@+G);=Q3WE!WH66B<\"F)T-ZHPSVO??`5;V6B)MNV
MT!FV96!!$E@$5U`ZS=6V.C4^/XZ$H,30F4BYR"ME9NX^$"R=[JP2)TPNC3CE
M0D6-O.Q*MMFE,11UEMGVD'*9$E\RR*TI\(2+=>=F@-Y!^(4'B0'A6&C88[]3
M;M_AX-9:`B_4$4$[W_I*X`8ZPG7R@28\DXZ+6)KRJ_```D_\'8>9G+5,U\)2
M%74C&HZ6VJ4BZ"UU0;ZQ%O)WN'IB7?6RIW+JM5^>>KF]CTL3*BR.G=MJJ\[1
M:.+RH'J7[5:5AMJ2M*_8^![N]V$\__@H_I.^1@U$MNE&DB=?W`C2M9J#7N[+
M.\1%?B5'T1M^?ZGFFL`H6B4P>95L,(@M<;QH]P[8N3_3X167!'XA)O;V'T?>
ML%ZZEW*I3SB,%N@!R(`,>GZ0DJ_>9?25N'6-S;C]HR7^LQ8S01@Q]+=RS:YI
M)K`SBBLNTKZP/@'#?XE=Z1_$X=3IUO..T:C6^?VY66T+8GE.6VV7_US,IP-L
ME5COAX*`)&%9+V'9/JJP-$89;DCJM9*2I.D2R&@_D^34&J*J?'@$H/;BLQ<0
MH'6"C<1GC4'&MK[:<26)SYH9GJ5,B;;H4:`1Y!]6B=X\`9G7GS!DY<>AZ=E9
MG]>EKM:J@;X9F6^.S6CELK."Z'PYIJN7]W!,V`:'PRVGX<0Y6(=0<`1D=?XC
M]M(1%8+@Z!"08JHA;*283@1(4DP'=+>N/WYL?;RNI[NE!SB_\TCD__=EF&='
MX`P9YCM]P1A41N-TM<SK4:,_'.F+T?DQS-YQH)<`XZ0I_W2+B_B!%,BY*9!^
M8]0A!:(1(IL4"%4@:034KSP,WZX[">.68T,!=H4'+Z@M`O)@6;5?PG;$'@I;
MY\!`E5SZN7%F'4(Z@X-"=[IZ+]U7TSXZF!I72&B$E19\MS-4A`MI,D*.--ES
M>G#M1JO=/S:.I,1>W*T[E/--;MW:+%1NS[MH=CN;X6YHK/?#CN,\T#I-=9!:
MZ7-C4;U#E2\)Z0EK2RT29J0M=<^BD:=7O]0:*3U2>J3TUBF]86/4[QT;:%)Z
MM<W\G6]-XI_B:=A`"YN^W?-D`YAH#2U=0I':\^,(&]0BE8X=BJ%Z^].-A%*]
M?1F0[5:CUS(:[?;1&T90,4N]V.O$-5@]("#%5$/82#%5`'+8Z'>,1K\_U!='
MTDN4EM,=,5%MR1)W[&+5'8N]!Q[*0YHRO^S8,0\J3#F]0#,5IKQ8B26%'L^.
M[RCQIB<NI,E.#SG29)5++(WAWOX;*;&SSY^1+U<\>\O'$X8>2WRYY+P0/)8N
M%@?&>#S*H#U5HJS;2;A\'$IRC)<ZKCGGZ#ZQ)E6+$"^9$:<;!B8[HU8Y3+(U
M:L.7Y##KB0NIPC.$EE3AX;*F[5&C.VP=&VO2A"><2K7]&/?WM9MGI2/?;3EU
M\]B!KD-JS@+"YZHY3VN/QU,@/5V%^;K5[`Z.C7.9LBR5L^?&B=KN:SQ/35B'
M)!WI/-)YI//6ZSRCV=H[5$HZ3P.=5_`+?Q#'WJ?7V<[#/F0I4.'[7>:^626H
MX?SX0QQ>W)OF_.VM->5V[/+/DP]FX,&J"+_PX!8=*.%@77GV>^E>W>&T[F!8
M[US?^OKSW__&V(^K#[GR(D?X8\X#O^56'#B1P\,/WRPWMKG],?!GUR(A:D:.
M[ZV^,WT^<^R?7GW\-PB(=FOPBEDP1_CIAD]^>G6-W[9&K4&_U_TWGJW;,EJ&
M^&"T.\:KGW&>!Z3ZTJK:!,*!'5QNF7'(V2-G`9_[@=B_B5EDZ>C"(U@TY6PA
MSFKG*V>U,Z2(\(_Q`,T&,UV7S?T(IN;`QP5+4"K;"SHUX;<QYQX>&BC08Q.`
M3[S3RC#$^_"K]''I`+.$+PY5O)X'CF_#+_`^/*+4;JY+%U^)L:Q,I<&07LGK
M<CM5V:,9`$VC$"@%+T,XI_P")L(78OJ>SV9F!*\VW<)M:LOK'&>QYMY+?$_`
M8>R\@1\7[-&/7;N4+GX<K!8#)*$)KM9YCBB6Z5JQ*VC8Q%6*"R%9J+F%UU[#
MTD7FQHOQ@MO8FNZ$,#!5Z(110M*)[[K^(XSR[?YE"IL9J%0TR=<4F%9(4:6,
M?GK5`A'`73S$UX(!IG\K12;^5BI2GGV;*D2ES4"'N.8\Y&^3#Y=,:KQ!J[!Q
MCFIJZN'*6,F!SOVC'NC<K5@VNL6@/:WSFO\E%-*'%85$.1"M8:O!&<XD+)\F
M+-M'%9;&Z$!IY;.2IFCZDN34&B)]2CH.4YI#`I0$Z$D)T(YV?$D"M&;%-Z5,
M^8R]XW2`YLO:>%(:V&VD0;"W^_*8%KG'<\MFU"%E3'UY3@1(:LRC)RH$P=$A
M(,540]A(,9T(D*28-`SR'\/3T@.<SV7%"<<.7Q`'Z1CLW:B@SE[_&(U6?]CH
M&7L?&$',<Y[,<^)*IAX0$&/HAPIIE>ARV.TTNMVVOB`1ZU#R2"-P_DC:60?P
M3^!8^%&Z-K'G1%H?/DM\I!\JI(*BR^X`7)OVT0]_)=:I%^N<N**I!P3$&/JA
M0CH%=(HQ:K1:>W>I(M:IE5M#F9JG@O-GLN,T\MD\#JRI&?*#G-A#`0(=E1#%
MUEX"IU&C@ZY-BZ)K&H%2!^8Y<653#PB(,?1#A;0*MN`UNH-&=WCT393$/+7*
MV5"WW=I%<JC'X,E"2\T&#U46UVJ,X'^];O_88%/'P=KP);7;U1,74H5G""VI
MPH/%&[NM46/4)DVH.U*[NXNU;<)[J/ZYQ?Z\7P)_SH-H\<4%VEYY]H>_8F<^
M@VFM[;<[?)%^N_T2`A^MWVY")-$TEB<4*NV2REX['GSCQR%<'[Y9:9IZC&ZF
M0RVZF7;[S4Z?>O35)DP\:E(;TU7D/H21@WVC;?:K,]G[-*G#<E:K.6H?G;%T
M`*=NG=MZS2ZQV`J*Z[L#G\OL]>GL"6)ER_*DWG3'5^"D`D@%G)P0/'L5H$EO
M4E(!M:Y6*!4[RA<_:1];1L1`AJ1!FV-'="OZVJ7Q^Q=3`7H`V)&'6&F+FK2Y
M3IJ'ZI#Y:G:ZU#&Q3D>$=INM/O5*K)")//J1UYM$7Y?J4_4$AG32T5$@G40Z
MZ41UDKX=1D@GU6U#^#E$(7XUQT\/0+Q0LO_,X@N]I\47GAT4LN5T0$':<J16
M]`-&VFQG;Y(9&C<>)9M,7V!(MQP=!=(MN@)#NH5TBY:(4-6!WOA\C`//B>*`
MB_TB$^<;?M8WATV.OX:@D'&F`PIDG.D*#!EGLH<5Y6+T`J0&O$.J10<42+7H
M"@RI%E(M.@)":7Z]\4DW&X3^)'HT@Z/O#">/_X!;"2@=HX/VIW3,V0)#9IDT
MRR@;HQ<@->`=4BTZH$"J15=@2+7(3/]@[X:7I%OJYO(?MD4I-?;+E?MS,^13
MW[69,YL'_@/'LO^C9YJK=O3;!M,)1PA^Y6'(`VSG&8=\$KO,=2:<^8'Z5W;Y
M=!%=/<#4HN&3'M#5(:]0V!"Z#JUSW1-:!_"*FT,/@-[IFI'#8Z.H=]\J/4#2
MA^=(EVD+#>FRDP2/=!GILK/C.2J,T!L?JH@@7"ASI2<*U,NJMLA14ZMJ6':-
MO4T]RGV=*W>1=M(!!=).M46.M%/%W<K'/P^(M!-59M0=M"O+BF>Q*X[NL_D\
MX)8C3DL5?1K,F1]$SG_%%WI$_:A8HQ:!=DI@:0L-);!.$CQ*8%6&\W5G_PTC
ME,-Z.9S>:`,2:;'Z"$+28C4&C[18=2W6'?:.#21IL:=IL>,68&P*AMA^/'8Y
M:S?/2K]]"?PY#Z*%"'ZDQU,TF,>/?D;%AO#'3EA1^..XAX^?)V/I`\U34V:;
MX#Q7RW+O`\RTR:8=$-73M3@[1]\*O<'>+)6KY\:,^HA:TH+:0D-:D+0@:<&]
M8&[OW0.4M*!FHK80?ODA,H%TZ76V\[`/?0KD^#X_T?8\VC(T]<H??XC#BWO3
MG+]-PA%?7)C?E6=_2"(2=_"6=ZYO??WY[W]C[,?D^EMKRNW8Y9\G'V,\7^,W
MQW-F\>P&[C#=+^9"--WXZ`>?X:EF!*M*M.4([W#BZ2.98__TZN._@=?;K=$K
M9L$,X*<;/OGIU35^VQJU!OU>]]_MEM%M&2U#?##:'>/5SSB+/>C6WTBW=(%L
M6DN'73SON.L_,B=D)@OC&8QTD72ZF`BZLIDDK&Q\P>:*LD"KV<R)L)(&WB*N
MQ_ZGIK<0D/]CV#8&ER&;F);C.M&".1[[DX<1/"R,>-"`BX%S3-MG9HCO>\\M
M/AOS0-YL]%N7':/!D-KL-=P:3?TX-#T[?/-V_3K:$PVQ4#?#4;J,Y7L*+Q5<
MI:343Z]:L*"XZZ(<@N67_JV$G/A;B4\9G$J%I1)S(%Q<<Q[RM\F'2R:E8:]5
M*#K6YW"?8<D>JI.1M+`@CYZ'*+=\SJ\*4^/3Y*FA7'0Y;.F+S_DQ2PVV26=J
MA$I0I+HY>AAR$P=1Y4D]XUY4=E(-R_[1>VU78C6*?=1@'\X:I7:>B8$[/S+=
MS<$%G:U&2A><G)]&N8)#8/R$<\(/O&U.QTS!#MAH%],_Q+!7XOT'B=^7I01N
MIX#O.[C>5D^Z>C0#^S:"6S[/<8-G^$_3C<56SZLPC&?RN]+<@-%ZD=S`]F#T
M"^<&[K*H/KN'FS#:[TM:R2VS2-50)`"Z[5:C/1B)KXV&T6\U>IT>"Q$'$>#'
M=('O`1D$93V1,!#G<3$.D[4W)0#PD?"ATV#PK#FW(N>!NXLFP]%-3"=`P1++
MM^!39^9__`!3#O`WG\U=?\&Y>F\R]F0N^XV#/7*P7'@8.3.QD]B,Q%-L^`/?
M*1[.XA"6K/C^G6M:7R]@;?HN#'+FV]QECTXTE3D6WW7]1[S4S-:A>-/4M)>N
MR-XH4<97/P!SW'/U3C&"C")LCF?1(0*YI(D&\N!XB9/!GHF39_?(^ZT33YS4
M("I"G7PD!#!:X#S`H/_JF'!T!M6"5"]6]Y^'9.R[]MZP/@'#?PE-]:&@J1@H
M*&V9ZD73+#H@5(,D"VDATD+:0Y!JH?91M9`QV#T\1&H*W25M.8Q4DGZ8="IP
M&8E%$HOU9D0,'FG+@B06][748=HOFK(ZB)G>;PY[&LO##]\PT`M>+K#_[-AI
M)3+6#Z*5GC^76T4KG5=2MM<<R?2&MCQ$A;@ZHM+9>AC.B3$*B;JZ(]AK#DG4
MZ0;*<QG9]8B%U\7(?O!=,Q+[-+5U3\G4/CH$)+ZT1*5'&PTO1Y1NT`B-[[4%
M@]P:_3`Y0P:I`RJD5D"M:+W[]MRX9I-:H3S-<3"Y<<*O%Y.`<^9@II:'$0O,
MB&L;@B$W\N@0G*'DJ@,JI.^C2Z/9V[M`@_A&(T>2\F/G*,+.CT'J@`HI%E0L
M^[>2(;[1WI6D;.0ALY&V\^#`X&RV<+AK:QN!(5?RZ!"<H>2J`RJD\:/+O3N?
M$M-HY$=20O(<Y=?Y,4@=4"&M0EI%*S`H'ZD?)G^JSE@7%3MC:1N4(>_RZ!"<
MH4C3N$\KJ7\,(W<&^B)T?NQ2`R%6XF`2!,08I$?.5X^TZ!@SC?#0J=FWF"B>
M4KFE?^]SOR4_KW5=PP_1XGM[^W#L?LV]4#X&.T\[T:*\3;CQ(FW"-]+T&&W"
MK_(GAU[=7%\5C@#-M]X6G:WE%Z)W.#,E31T>IL>([MP5'#\%W#5E1V\<L"G?
MM>5DT88X]314';;#`S?)ID;86P]JZ':.?LY;#>2^GN=,G7MCL'PK$*-[U&9\
MO=6CT:G7GJZ=LC4^T$T'V&K0/EL;W;4.GFN8_CAP2'<1'MNTUG&/=VCO<>X:
M:34=&FN3!JNK7-R+S\[F7%(2H.<A0(_>@IL$*+D`YX:7GHQ%J&ASH$2;M-GN
M(/\>B\Q&6=[B9.?M3YC*\=5.Y)`NUP0H79VA.L%&RJ/&(">E\NQ*ELJ?GQKY
M\(T'EA.>X<R_!(ZU]]X'TIU:"6$-@3HK.4K*\@Q`)D^K=D*(M(4F0)&G1<KC
MK)4'>5KD:>DEDDEWOE#&\=EW2W5/?8.G,C^9'T=A9'I(A08;<QB[!Q^9/]E_
MVT9=2)!;G^DG;&'A^'MW1WR)77PGO2SKL>]XJZU&.RWU@ZUU.-Q.=POSL-MI
M=+O45%DC2.K`6Z25-("`M%)]VF60,JJ`7Z<YV/ND.-)$YRH&"8*C0T":J(:P
MD4JJ`*31[39:QDA?%$DKZ8D*07!T"$@KD7]T6LIHV&P/]<605-$!,Y[/7H-R
M\AG/7[!E/=?WX#,R$G2`@$26?JBTJ+?P9;L];/0&>SN>Q#KGR3JD4S2`@!A#
M/U1(IV"_^J&A+T+$-WJB0A`<'0)B#/U0(84270ZZ1J/7V?L,%&*=\V0=TBD:
M0$",H1\JI%/$X8Q[Y[B(;VJ5XZ)=?4\%)]D03!O8M&:/HT-`0DL_5$C9*YSP
MA+NVQD`1^^B)"D%P=`B(,?1#A?0*Z16=8=&<?4BO:``!,89^J)!>(;VB,RR:
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M8^]F-D<3K\26M8&*<"%-6$=H:WYP!"G`"ABWF\.C'W-$NJ\V,I9TGYZXD.X[
M0VA)"1X(;$V.0R<]6!NF)#VH)RZD!\D')/6W(\8Z',!.NN^$-Z6>IU9,<KI<
M=FLU@00'RND^=R'%>>)5ASJEHLI;J\[(BJDGM*V7Q?9TS9GNJ-MHCXY^Y!59
M-+5A2M*#>N)">E`7;Y[47VTP[FIPD@KIOMK(6-)]>N)"NN\,H24E>*BZ7O`!
M>[W6L9$F/5@;IB0]J"<NI`?)!R3UM_LV7:-[;)Q)^;U42A<F3@=L/D?J]H&'
M25-A_FW.+?PC\L77QRZ8V*073QJ;74V3EV:.*G8)23K-,*MB>9!5T6CU^XU!
MU=Y51V`\XBOM("'ZDR[2"K.*_B^I(!W!J[Y=E;0/23_2/L>F/VF?NF%V0#5$
MH)'N.6-(B/ZD>P@STCTG#AKIGNUYNQ\BW/V77F<[#_O0IT".[W<APN9AJ^'\
M^$,<7MR;YOSMK37E=NSRSY/;J1GP=V;([6M_-N=>:&)B[,J*G`<G6MSAK.Y@
M5.]<W_KZ\]__QMB/59\AO@VOXFCJ!S!.^P^85W`;P7-D\NV+"VB\6WR0FR?Y
ME\"Q^(WIW6?O8X[]TZN/_P:AT#;:KY@%4X:?;OCDIU?7^&UKU!KT>]U_MUM&
MMV6T#/'!:'>,5S_CM/<`P6B7H+"TW#:!<MBE>#?E;.*[KO\(S,G$*F-A/(,Q
MPXA"YGCX$$%O9H[].()I(N7\U7;#*LF9;E5E9H@;5=]SB\_&/)!'%1O]UF7'
M:#"DY-ML%1UB(5=8K/(U!=SDC*7.^.E5"U8!=UV41#"C]&\EN\3?2DI:\&H>
MI&)1*1T0+ZXY#_G;Y,,EDT)NT"J8<]72\-3N7"=Y_%(X#0FG6N!$_$0X$4Z'
MPZE'.-4")^(GPHEP(GOOW'`B?CHYG`@4``5&"_0`5(S6JV-NWEG3]FUM1\8M
M]4HR,'.(@J4\)F/?M??&]0#["#YG<;9]]PV<@334`3%]-CZ2.'R2..P?51JV
MMYB%9RT-/V19AMHQ&4G#S9G.I=1(RH[#X[)CE]AQ!5R13<4<7Y)C92+)&A)/
M:@T;>6NG8)ZTCRH/C4ZQTJI*[WP2F+_'6`E!SEQM`--55.[%<B1+29:>CBS]
M4[R>V^SJ@0<FV*$W?&8Z'A:B7<--@6E%L>FR.Q[,2NO,3I8XKQV/+;@9A&](
MP6@-%"F8T\6,U$N-05Y1+\48!XE5K='35:R264YR\[3EI@IQ4(:F+H#I*BIU
MM4!)EI(L)1N4!.OI-N>M(H3/K<)5TYYOP\-!=;HMWUK-3L73J:GU@3:&RW'[
M7Y/\JQ]L/9*%%7'\Q[!MM/4%DJ2BCHJ*1"*9A">#G='L=/2$CX2?CI`0_4GY
M$&:[8'9`T$Y7#;5'C1$I(FW@T)ZI2!$=F_ZDB.J&&2FB"BB.@!Z:XD=J2$-(
MB/ZDAK3"3--@'&F?:M&X%FD?7<"H@?0C^I/V(<Q(#1T8Q4&KJRE\I(4TA(3H
M3UI(*\S(!ZHQ>.`##37%C[3/H4KWGW^?#6&U(_L\.R3#RI"<LG#K["?<B&&.
MSS#'V"Y(J&B(2H\DV2'JYXE[CL\]I&;.'A*RR\@NTPH,W1F&0IY'IS^QA&:0
M5,?D=)7(H#UH#/LC31$BIM$0$J(_L01!0GJD`-*PV1UH"@]QC(:0$/V))0@2
M4B(4T=(5#.TYAI3(L>E/+*$9)*1$HLM.>]0PAA31T@4/[9F&],BQZ4\LH1DD
MI$?(&=$*C#JW8R>L]-H20;5#*-RZ+3W1(8:AKLZ$"M5T4T_T^L.BL1%`D&@'
M"=EE:)>-J)F2+F#HSC`4N3PZ_8DE-(.$(I?1)=C"C2[I$6WPT)YI2(\<F_[$
M$II!0GH$^XH;AJ;P$,=H"`G1GUB"("$ELA31VK,6CSCF##F&E,BQZ4\LH1DD
MI$2PN7>C:U#!BBYP:,\SI$:.37]B"<T@(34B?!$Z)$(7,*A-]XEA1>T@CUTZ
MU-<3'6(8:C1,J%!)-[7IKC\L&AL!!(EVD)!=%EVVV\T1;236!0W=.89"ET>G
M/[&$9I!0Z#*Z'+8;G=9^&3#BF3/D&5(CQZ8_L81FD)`:B2Z[S>Y^&3#BF#/D
M&%(BQZ8_L81FD)`2B2Z-3K-/$2U=T-">94B+')O^Q!*:04):)+H<#!NM`46T
M=(%#>YXA-7)L^A-+:`8)J1'AC/3V:W5#+',DECEBG^X4&#;V`YL'"<E#WW5L
M)B]B8K9S,P#:$H#'V2B1E@\=&*?3E8-89G3<C?;$6[7I*$U0U0RJ'DG".G8$
M)SZKD[E!.-4#)S(+=S@-L=/LMC7`C'BK'KRU`TX$RG$;!FS"Z1\M\1_B)=U@
M.RQNIZNWC%YC9.Q79$**Z[R8C127AJ"0XCHQV$AQ572XFH/C]I@BM54/5B.U
MI2$HI+9.##926Q755KLY'-1+'A*OU0,G`H7T%L%&>HOBA*2X:H43@4**BV`C
MQ44.%^DM'3O4EP%H^_'8Y:S=/!Z`>33&OFOOC6C]MV^5U:P12OJA1+Q$*!%*
MS[5E@5#2#R7B)4*)4"(;[WQ0(EXZ,90(DF-VN$A00L*NC?1M@I&BN)KB^L+`
MGFZ8UVBT^L-&SSANBQJ--9\>,&G"D+KH/@*%M-\9XTK:[T!(#YMM4GQ:(Z0)
M+Y+BTQ`44GP'QO4[3>$D?7<@@-O-X7X]^$C?G9=H)7VG(2BD[\X-5U)\!T*Z
M.^HVVB.C7C*5V+$>.!$HI/MJAROY>J>N\IJ=XQZ"I[&^VP&9/7=:_!"9,,GT
M.MMYV'4F1AO^+HS\^]W&IM[YXP]Q>'%OFO.WM]:4V['+/T]NIT#Q=V;([6M_
M-N=>:$:.[XEOPZLXFOH!O,/^`]X;W$:^]?7S''__X@)6[Q8?OO'`<D+^)7`L
M?F-Z]_P.1OG.A>M^_OO?&/NQY'WCY??=\#""9T3<%B^Y\NRE;_[PG"B\LB+G
MP8D6=TC0]$W,L7]Z]?'?P.EMH_.*64`8^.F&3WYZ=8W?MD:M0;_7_7>[971;
M1LL0'XQVQWCU,Q)G7SQ<Q^,74\FGAK$5H*WK[+`L?\7">`9#7C!_PFYN_V"F
MHAV#NUDTY6S!S2!D',9KL_?<XK,Q#UC':#`D#S,]&S]TF!.R.2P%F!1<-^:N
M__@V6UR[LN..-"M=U/*]!>0$DRGQ\M.K%JP#[KHH0$`4I7\KT23^5A+/PID%
MJ8A3\@D$H&O.0_XV^7#)5.%DJW"X5\DN*DF!YY.DG1V:[!]?;FI@BCXW('IN
MU;Z&V8\#1R,\8)1`!P#$Z+YZ`7!*;<M^N]K>WRUVHA0>AS`4=2CA_)?0"!]6
M-$+M6(R*H3=;I.>KM>HA)35DJ;/&(]5:_:,JK4YK]X`(:35T9VK';J3!-`%J
M+SZCC``)T),2H!WM^)($*+D`)XZ7GHQ%J&3:K'U4;69T29OM#O+O,8:U2E,8
M)SMO?\)D4J]V$H=4N29`Z>H+U0DVTATU!OE/\7INGY_VN'K@@7G/SV_BO\"%
M$7MO1F<X]X^F$[!_FF[,M5-%9#/4Q&;0*#RJ<5Z)C('Z,1TYDG63-:04-`&*
M'$G2'6>M.\B1/+N)DR-)CJ3V0#UC'OG9CW/"U/))%]MD.Z)@:KCO*<8]4<R/
MHS`R/21*HU2TG`P1<BLT_<3&',;N`0%PL].<!XYO[RMH7N*PN)->I4]W.U[R
MO+Y2D_7<]H#7`;;VX7`[X;W>QJ@!A-`7Q>^)M[1$A2`X.@2DE?;K3$+*2%/\
MC&:G8I-)TD0D!H^@B?3+"9,&(HXA5?1,0/YCV#;:&B-)&DE/5`B"HT-`FHE\
M(U)(I)"TD(;'W4I[OBE0443!]T[NO40'XI.FOSXUA22RZH5*NS(LIZOQC9'1
M&.R?FB/6.4_6(9VB`03$&/JA0CH%,VRCBL>6$M\0WU"&[>BD)X;0#Q52)$^N
M&R36.4_6(>=$`PB(,?1#A73*T\K_B&]JE=NB[7U/!>>?/,2M?7CP5L!=CB>D
MZ9P7/FDLZE$20^)+/U1([4>7KXW.J-$?5#QBFWCG)3!YHS,8)TWY.DBM\^.'
M.J!"NH1VD.F&1QWXAO);Q!#$$*1(J-R^)K!HSC[DH&R#X/K#-<7JSP\5TBN'
MT2O$/G5*=9W<B8AZ(/;1#R;<25)@ENE9W'6/O]=+YQ,M-&4K/;N3K\.M8O-Q
M4EG:<!?IL=I`1;B0(*P!B"0(ZX,5"<+:92-(`.K.5"0`ZX,5"<#:XD*"4'<0
M21#6!RN]=S&4AG9M/QZ[G+6;9R4BZ>2BXK+-3B[BGJW/F45EDN<\%VT]*A-V
M/7NS@.6YMDZM`[15>J@>$-O3->VZ`Z/1:A^]B'AGX4I,61NH"!?2@W6$MN8M
MQ$G]5=I`TV\?&V;2?;61L3KK/OV26Z3SB-5(^>D+MB:'X9+^JPU3ZJS_SAD7
MTH/D^Y'ZJV'S!-)]!T]G_Q"90+KT.MMYV(<^!7)\GY]H.YEH"4TV#UL-Y\<?
MXO#BWC3G;V^M*;=CEW^>W$X!XC%VMKOV9W/NA6;D^%Z6';[%Y/"59R]]\P=F
MBZ^LR'EPHL4=SOT.QO[.A9]^_OO?&/MQ]4T?9G/77W!^RX,'Q^+BQ>^67WSE
MPB/$I\^3&V[Y]QY,W_XB<K'7?AB%Z6N88__TZN._0:BTC>XK9@%QX*<;/OGI
MU35^VQJU!OU>]]_MEM%M&2U#?##:'>/5STB3/1#JPY^NX_&+J5QLAK$1LM86
MR)YAW7[T`Q9-.5MP,P@QD<UM]IY;?#;F@2RG,?JMRX[18$@,L:D+/G0:XB:$
MP?06+$C)+KZ>^`#)(T@0>)-W89GAM,%"Q.Y"K!H@?(8>X]_P,V>O'0]N]N,0
M7A&^>;M_)<&.]"YE`_G>`NB"8Y4$_.E5"Y80=[$<S(*YIG\KZ2G^5G+9@E?S
M()7"2H2"X'+-><C?)A\NF12SO59AK_J1MC3V^D<O#<RO]['OVGO+^I<L#.P?
MM3"PVSE(8:!<L8>PH73`,!%H#.08%09J#55M=GR3>*QCW72[M;M72O(333^2
MFUI#I-N^DCVB/SN)SY/E-1*H9P`RNM!Z\"D)U/KN3REE2K1-3SK:>L-#;@;6
M5,2C;/[`77\^@S$>.TS^I/S6N87,-<Y=#0\'UPGGI7I#?1&D7GD:HM)>KY9.
MET5J@`EI)M),I\9V@X&^`))BHI"^[HC]PCT>F*[PKDQ[YGA."/=&S@,_=M"B
MBAK;%&4Z-][;6Y,]/V##@R)VNLJL.SSZZ;L:APKUP$CC[,L3DRLGQDSZ`$6:
MC#39F3%?N]4_-HBDR>J?]BIUULYS=]>='YFNSO$.VMAU?B%(VMA5`>-^]^AQ
M2MK759L,3IEGMY/6.UUFT@<HTH6D"TD7[NH;#O<NB#P#7;@#-GKN1NYO&MG+
MO"4_KW7;F@^\V;AT3_-DPG$3-/_D6?Z,WYG?;LR(X[,\RW$=\>SB[NC\MN7>
MBVQ;%GO'M=JF+(G%(O,;&W./3YR(F5$4..-8[LF-?.;'`7/],&23P)\Q?\X#
M0<L0;H`W<.:DCX#!V@[`$*AK<<^R.?-C+PK%WN086YR/%\R<S]T%;F/&"_YH
MWC;9A-LB,1I&9A1'?K#(/97!^SBV`>]TOV?PQFS#=*>7?M%I,#-D)@MX&+L1
M7EW<,'V07=`5X--PU_-0BUW/73K(M9;[GBMF3<YJE\F_N!DLM72@'=#:HU:;
M<BD2E?7<LK='&()D*6V!UAXB?6H[#L-G1]D"31*5)"KM@2:)6I=BD%*>1.OT
MI*W.0D#*61<?RX6I,#85'CO`3GO03B/IU:,]:-OQ>]UIM$=[NPRT#^WPB+S1
M&8R3IOR)U&:<&\.0"JHW?J_;C>[QC\PD%51-!1TWI'^^?M1MA'G[50>JP3PN
M,O2)CZ6^/W;,@OA)QY#O1E5%FJ@].OK6+^*;`[A"+P'&25.^#A+K_/BA#JB0
M'D$]TCIZ,PSBF^?T9R@O]%1,"KUQ\72EP,'6N/*T)2O@MA-IG0DZ-QZJ0W"4
M=`_H'F-@Z(O0^?$-I7-(8A$_U`L5TB.H1SI'W^I*?$,Y&9TQN9Z:WCTF9=*-
ME>3UZX,.1<OJ@9/1:'7W=EF(<<Z3<4Y<L]0#`F(,_5`AC:)P^L>P;;0U!HK8
MA_(Q&H'SGD]X$'!;N#)F&/*(F?9_XC#2_<!"XB+]4"$E%%VV&Z/6T1NG$N/4
MBW%.7,G4`P)B#/U0(8UR$+>&V*=6;@VE:)X*SN=HR@,*`N@#",70ZH&3,=C[
MV'1BF_-DFQ-7)?6`@!A#/U1(GX`^&1Z],26Q3:UR,=2^MZ38#$@?RWTR)C;D
M-SUK[[JSEVQ8LPZ]<^U94Y.0&YT76Z52NM/O'1M%C3N$Z@'2T;?A[(S02<-1
M!_E'FJNNR)'FJEJBT!L>O42!5%?]\TNEKMIYGG5>AY@4'?*Z%[1[-QM]D2@C
M'?*J29W%<Y_\H,%AKQIAI86HW1DJPH548!VA)15(*E!GN7IN_*C3*>J'./Q]
MT^'G.Y]*7G:^>;+="1YQA9N=PBO/_M4QQ_"4R.%A^='F_3,]VCS='U8XH#S@
M$Q<0$<>#8Q]RW#S&!4BA.#6<S^9^8`8+=9(Y]RR.)YU'CYQ[XB;+#`)Q>'ER
MLCG<)7:?A:(QH)M!(LXFGSB>"5";+KP9GAR).^&Z_-GH<0BCQ(MSS=+G<3#W
M0QZ*<\T?N>OBO^KP=7B$.)!=/`>NE<T'Y<C@,8]F8(=-=C<M=%_?.DE\6N$1
M,$8S8O>P>%G@A.(L^!!$IS-Q+"`V$[/!<^#58>O7_FQN>HM4$`\N0T%A>V6?
M'IX&[X5.B,?!TTGMNIW4WAM1RF<GC\#2XZ3V;HN.:J>CVD\"M=HD$$A6UO1@
MX2&=++Q']I7.:M<=(GVBF!*H]C.?U4X"E`1H?;B3CF;7'J(:;#,H94JT1D]:
M2*ZV?`K?[LM/=/*MQEKNF+#U";=:XD9;XC1$I7WB&JD&$)`>JB=LI(?JB1OI
M(0W#]<_K,_6;PY[&^%S'`7KRZS+Q>[M/U.)`1^GV_*CT"18=82%4-$2%G)^C
M0T",H24JI$6TA(50T3#=<X1*(Z/3'&@,VC]-2W63LJP@-EV=8P'4D>.`^[%>
M-.A&C3@V53)0`RG=(=(G5KI2"D:57EK@0GJ+]-:YZ2WJ'J4[1&>?36JWFCIG
MD^[\R'2959Y3TCF^01GU&H:E#E@)<<*:;6^/C.**9\E6)=FIT^60&F!"&JJ>
ML)&&>E;?BS14K=PLRGP]7^:+#E(Y![ZC:&(ML'Q-:3#M,=+D')4G9K].EX?J
M(`])D]45.=)D5349)<9TQVB3)CN[9FB:)\E^Y]')ILA(%]:JQ7R5V"3IR*KV
MCMXMYDE7:I<T(/>O)D"13B2=2#J1=.+)\F,-,GYG75A9AW@:U:?4$C;J)55/
MW*@L14-4J*W'T2$@/51/V$@/U1,WTD,:9MV>UUG2&9S??6]#<HUZ&FH$51WB
MN]2-2DM8"!4-42'GY^@0$&-HB0II$2UA(53.+L^C^28NK`U<.LF]<.XZA0'T
MP4KOED]G7W[0;3>,SM'W8!'#U"J:28TO],/D##F%5(O6\'1&C<%HI"]&Y\<P
M9Y^2T=RON9["MY$Y=CFSX*+`&<>B5<5!G!L*%.AH%^@453M=5=0U6OH"1&RC
M(2KDXNB'"7&*EJB0@@%?9V#H"Q"Q#25P],+GAH?<#*PI,SV;\6]S'L`0O$@V
MYK,";CO[=WB@P(&.:HA";B^!TVBTMQHBMCE+MB$_1S],B%.T1(443'0Y;.\=
M2".VJ96?0PF=0R1TS+D3`8G_RVWF@'_CW3MCEU,*1R.(*,)6#YP&78JP:01'
M#=B&7!O],"%.T1(54C#19:?1Z9&*T0@02N+H[=S<1K[UE8W-$)P;RY_-N1>*
M!`X%"/3!B.)J]<#)Z`WU!8C81D-4R+O1#Q/B%"U1(043779[77T!(K:AQ(U>
M^+SG\X!;CCHIUK.9.?.#R/GODQP<"A+HJ'\HNO8B1Y?K"P\QC8:HD'NC'R;$
M*5JB0NHENMR[@PTQ3:V<F\,>E?NBYZUJ[O%\CJ8\T#E$0`?$U3;Z1@?!5<7R
M:0?!T4'B9\=W=#AJ38`BU79ZR)%J(]5VEGQWRIDIS<\XO?,CTX5O-IW?HW,P
MA$XOJV>(\5"XG:Z6ZW8;W<Y`7Q`I$*DA*I3GT@\3TE+UA(VT5#4M-6Q1-U2-
M$*%T60W39?\TW5A5![JN_VAZ%C]V:(,BC!1A/%>M]OIISA=%%U\(IS=Z($3Y
MLAK+1-)F=46.M%EU;?8$)XVTF0;:C%)D1ST>EA)D)\-E>Q_S1Q%'+?`[0/4'
MA1UU-!B/E1PC"$@AD4(BA40*Z:38J@9YL+-VJ^H082*NT1&5ZCN4"19BEO-&
MA7R>HT-`C*$E*J1%M(2%4#F[_(_.X+S/9WM<QQP[KA,Y/'Q+KKX^(-4A\$GJ
M1DM8"!4-42&GY>@0$&-HB0II$2UA(53.+KO2;PYUSJY<KZM6R_DO%`#0!ZN]
M"P!T"I)1?I^X1C\-1,F7,X?@#!F#U(G6\)`ZT1<6O;,P1VB;H+F7\WO)MIP#
M.#HO60I-&T_K%>ZAC:>UJXRFS:>UX3OJJ5`3H$BUG1YRI-I(M9TEWYU=1SS-
MMP=AUX4Z)J^V[I<DS5BWD.5+0DH:DSH1:8*5%HD=<@9K`A3I1-*)I!-))YXL
M/]8Y06C[\=CEK-T\N!>I,V(GWKAO$\:D-+5#=`^E^11(26D>,?1:*F_/C1_U
M27F4.9([J<839RHM@"*=2#J1="+IQ)/EQ]T=R1\B$TB77F<[#_O0IT".[W<A
MPN9AJ^'\^$,<7MR;YOSMK37E=NSRSY.D>\:=^>U*.%Q7GOUKEL>[PVG=P;#>
MN;[U]>>__XVQ'Y.'O(M#Q^-A>&7]%3NA@V=C?9A,N!4Y#_R]&<'#<[\8S+%_
M>O7QWR`+VL;@%;-@_/#8&S[YZ=4U?ML:M0;]7O??[9;1;1DM0WPPVAWCU<]M
M^/&B95RT!]D,=GOYUH&OW')U'W`^`R`*`Q]N&+AZ^IJ'7WUSPG\#2?W/(-,<
MSW1_X[,Q#TJF.KR`V;:[&Z>Z8;B'FNKH:5.]@@?:^-`M<S5:%^WAT^:*KWO[
M>XRO^3SY8L*R]:(P-Y5V:\-4\.9KU_$<RW3O0!2XX;O%EZD9\G0FXJ^[*;SS
M?[D91!]-QXT#KJ:EQ@V_N-'T&J3E71"'T<?8L]/[W_$P$D\NI02SN>6`\`E_
M>O7I=Y#OL>?(D?XA!Z"F!!0;M(!6:^>[@137_FQN>HLO+DB_._^#%_BNFR>/
M<0#R//KO]J/.+Q]^_W#WZ?KJXZ%(U&J54&@=&9Y`M?91%]6AR=9M[TZVA&=O
M^`/W8EY@N<Y.$CXWS%9AD$[H=T%=_''[_M7/K4Q*)&\LCN-+X%N<V^''P)]]
M"L,8CVC\'-R:J.8^@/2(%OD1=C>/L).,L+,\PHM>Z1"-44=8N]E(MX^IPAPF
M@,',]VXC4,'Y*?2VB^C;>!PZMF,&"_E.\8QT%=WP>R>,.*C_]TX`NO,S:-``
MC,7\>FHKH.!]PXID&(RJ4"$_JQP?7KL^J(#[=X[])7`V3+Y?;?+\KQA6\0=8
M+]'=8BX9</W/V:1[J.G3#YN8*)NUH&<X!68%;C*:J13:-)V\]/$C9P+B`O7;
M1S]XSUT`!NX#Q,0SW_/0"IRY.'\T1X0=#:G/'OO(QT$,RX$9PP;#*3;8(V<`
M/@?#R08K.!L'FP!<[/>KV_=7_X_Y$S;W(R`3B!L@B!H>?NW'`9,3ES=$4Y[<
M=&W.G0BN_\T,OO*(C;EEQB$75UB2+FP,[N0<*9,\RA+T`9,9\9Z:8DAL!G?C
M73.0J;-XMO[N[Y#L;,[5<)@=XUH6]\UQ@N@&L4Z+V>8B;+)DC`&8P2%<X#\X
M-A`@#ID)M&DQ$-U@P9@!7L[N`W!]\-&.;V>SM,$RP1>+&0/AX)+(!UK>FXZ'
M\YB[#JYT-E[`!'B4#`81<T!\V2RA8AB9^"J[R>XV_LX>_=BU@8Z"(,Y:@N'X
M-Y+)C)C+S3!:H1=X1KE[X4JCA6,)N16C5<W&RC83!,Q3=R.YFHE>J;["<WSQ
M"S[IBWC0%P71G?\;$/,Z(=*O\C&W"8ERW%'!6C^0B/CY"]#@O9KISF,NJ@`A
M&J:^"XYY*%4$JKL@Y.*'6UA447Z2F^QTH<<ZK>P#B*8+@/FB#ZM4/).%^+R<
M8[C]Y<71PIPLH$P@<+UQPJ_7H$U`/L*GC^#J>!;(BT]>&`6Q<`;,;[BX/GR;
M^R'8.[EY=#89Z4^W&)XTS.*,$P/I,ZQO4\#([V=++D=GDTV]LYFF7@#@91,J
M'45QL'^*N`BWKP!$\YXG=TF6^QQ'0K*@?C)#Q\I/8)-YNP,<B49LMWHMHYWW
M:G<:V8$FM<4J+;?YUD]JV.\8_?[P^>;T'KP"^&[E_BO[/^`0(-SYV>UMT99`
M9@RW36W[^'8`#@U#;J]@MLG(??Z%F!O4TZ>RR63=:_FU1]UA:]^9"%UU"\H]
M$)&^3]YOOL?S+E)GDW6IWGD%&LW&50`&0O:L#]\L-P:UA_8^^H]Q).0NN#QF
MX,'Z"$$[BE&]6ZQ_0$$'H^;Y+`R#*G[N16<ML1)[?&7"58E1P9AX`6+\:0:!
MN2&HMG71;*%#LI2>.)6KF1\7A5.%<*)^:VE9&:?^7:L_[!F]C/,.0J[G1:"[
MR<`Z,@+EDJ\,@6&WT^VVZP7`)IOPY0"XX6#E.A:J;83B*6S0'1BM]JA>(&RR
M:S4`87=.Z!JC0JRM#B!LLL.UU*5EQ!]U@`5:-9-#F_R$(U)_#R5@=`?=8;=>
MU-_;GRDW1D9&J]?MUXL,>_M"I:S8;8U&[>>EPK493J\\&__!X-@#QCRC\*/I
M!/\TW9B_=T*,N!8#6]T*7E3Z!&`<+,*X=LVPP"S"0I=1=$P#AL5$8>[V]./_
M.N`#!M9T\2M_X&[^6>DEGSR8?2A^-TH?^!LW<4+HRW\,1"C46JQ]6N["\`;)
MO91(VB6-UEM.HU4F_`'PJN#HG0%>.Z4]^[VGX24\TO1768?TCD>/G'M%NH1W
MHH2+!^&J1-D2"-\S@+SWT`XWL]Z6T'C5N-%A9Y:*67'C9I[J57!]GLX4[9<7
M8I5R#Z44*A(R5W6WA9H5?)C3I>9F,NVQ-BLX(T^G9D=3:AY\;59P+DZ7FKNL
MS2^!/^=!)`JK(M"5J"?G.)P_0CZ)W5^=28&N%6I]2I_X;K&<UY:6+P_22\JK
M-+]T_E4HY-DVZ"?-LD)1SPZSK#*[W@O.KH(GL,/L/L;@L$2PKN"RC\XW_!1J
M,M$*)O0.$[WU)]&C*>:9?'R/4L`7UU_[8;1IWL^S?#^$$0B&B-O)G0^%^L=>
MA73'#A3X%805QZJ,3S,L5))2JWS.OW*0Z@%6\,1B=,Q%?/Q`_2L+EK`&B%<@
MS;J95B32+X$?YJG2KY"".)`0VY(5S,OOT6"Y5G'#;/:=>04#^#`S7_7;-LQ\
M]`(SKV"L/E&D[S!CH]M^@2E7L"B?-N5=0'Z9*5<P^PZGVG:8_?`EEOAA;;/-
MD]\%^A>9_&%-MMUT_2ZT>`DN.*R!MQ,M=A()@_X+$..P1N`V$VB7I?`"DW]1
M^V\GF?#\DQ]L*^7=8;A=XR4&O*5:=Q?Z]L`:WW?`5Y85SV(7C>WW'+<L."(W
M!9]=+C8^>O;5S`\BY[_B^])'YZ>VK8YWAZEUEF3HH8;[_$385O>[RX(<]EZ`
M"#=<//&+"9>*Z+MIB1W.W^;<"[G81Y7[.OS3B:;Y6_)SKV"9??(L?\9O([@?
MA_*K+W=I+!6L<(S/P9!S.DB-IQB-*QE[^&Z1_Z7@SDP=/OGP3>TS^3R9.!8/
M=B]Q+*S57C$A]42"/ALZ%4Q'S='9)_O47O*Y#XK.5<#-SY,;;KH?0B1:PG)Y
MLE?9/)@0_!?NWP?F?(J;>=.=DW_R,)HY'FZ>S)-BV-I`@3@*PK\F$>B(3D&"
ME(QW*0*/,1V.A@#6UV/IS+TT`](-(,)(".]X,,--AKC7Q2H(P0K&Z1YSWAAO
MVV_0RQ.'*V`E.'+O#G8#R/<I&%39Y/7T:<&G/O9EZ.2C_6M&5AS[TC0_QNC,
M_28WV'TQ%X(4[V.>G`2=F]6V9/:.%E]NU+N-::_Y?/+N'OU_@43*&UG#`UJ%
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MP[-Y\`DL#=5RZ5=@'>#EE*_RL]J[<JQL5JUD5D\>YI95A@95\F3LUC4UHVO3
M>\??Q8OW_F,>NM'>^ZOW6W1;1K9E#>XPKX/MM$[G-=BP)*M/2\&M?@"-O:(>
M1KLIXY^_]']3(RMY]O+._+312'X':'X`%1)5Y0UDTC"F\X!>BVM:?"E+A1MM
MJY1N=WK];MZP+AGYTO2PYO;S1&TC^!R(IH?IEM>TWOO:=%UNOUNHZT)U8=XR
M'54(D;P$&=K=4:^5V^+_Q!E6:2RT/.H\59[47:@258RUY+GHE]O*B;;>;5;Y
M/CL\VIT2%5L-'9X2FYRZ7F:V5)Y4<4G(_A[)U>B^%KBB2KQ@_UFO<;`[HL=C
M;E?MF@'F38"E9^-@D@XR>&U^+A4[P1QZ+NW$#-@RU"=)M@^F-2U>FY]YA434
M2\BV5G/0VENRK<YPJ6-.3DF(+EO)'IZ,$.#K'9<0)9W"VLUA3N*73J30'VT-
M[3Y\`R/%";%9:Q:06C8X.JT*54B'$V0_?QG\*VV"MMN8*_"#NINKKFK+RL_(
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M%6('D@;N@/$D`^ZY%X'1.:1/L,F0-5[&"LPG9E<E8ZDUJ^(FZG02\5[)#>]%
MWV&Y,"27_,X?Q4]Y/694,>M2&:-:P'KWN2JCK%5_/'8=:VENRY4E"JH50__:
M]QYX$#FPJHN3R=.HWVHG'[J53.9V+OBW(XV>RX[>>*:+?@2O1.=^>ZF*\$4B
M\OE!7WFV_(+#C\L6:I73:#0B^?HUOJ%(L%4UVK^98GN8"56,8'T(NW$MEYU0
MT&_M9FSLZ#UM/'-'/Q*N7YN;6MZD9USLZ(:MD=E?XL#"XV!`8JCJVCPAJQCP
M3R?DG1.A?O_DV<Z#8\>Y\DBIVOT`V_ELJP2N*%<'0V.M\EHEQ'-IJXVG]]24
MJIU1J_=<NJJ4C?*B`ZNCY(5AH6RHL_$T(/V$034;K&`7[$Z>95L@?]>OSE^Q
M8ZO](HDNR].SB@>C*3W+XEH%[=1JMO*%$!6H4RI<U1BY_<F[\TMT515'Z(#D
ME+$MW,/O>UA56$P,E-%QUWZ(&YR$,IJLX_E0-$?,+>;TYKQ/7>DTIA<B86Y"
M3Z??*I=O(,CSA?$V'O2D.<>7$?@)RFI;+/"I(:)*)P?5A-RE1Y3UM]'_0-GG
M+:'(C0<8Z4?KG*?PY(CF2HFP.D@E[S7<3;DG[0<P%7-'K/SJS)SHL_>.>QP,
M1L=T/S]Z()RFSCQ'VXV'*NE'VXWK.*VM'HU&:ZJK#T*Z'"R?O`@F&CJ6:.+V
M>?(!!FK;('S2NS)U\)&;N$DG3_B7\=J.YOZVD]#,OK3:M61AXWE4!PI6XUF7
MG4J:RS#Z[4+QSLO6+&P\Q^JEB6&T!^!X#I[)\:P2KMMX\-5+D:-4S0ZJ!]KV
M*=78>#[6`2??7DN%317*@TK1VX/4:FP\6>N`1.@G'P:[GH2[3Y1P<_JNRNE<
M3Y_S2C%:5U1J=*H6HVVN-JERJ-:SS6%0H=KD.7RY*D=AO9CTECOP#NR&/=4E
MJ')4U8%EFC;5"55.B3J6,FO+/7^U*%FN<M#3L],QJ5M.=TH^5]WR1DARKD^>
M0%OVU.]_!M*V01R882I8?V+;9N%\#KEC=4/_N)<.HQR,'!7LP55RR)VN!R"'
MT6\.1WH1I()MN$*0I9-4-Q"F74UP=K;MZWRJW`R+C6@^F($+FCIO=VP\B*BT
MY4UWD^0J>>F.8_T5[:W"2'=K,P`C;;<N6L8.(Y6O7.-JOL/T,^85N!?*-EM9
MUZ)WB^P2U1'BZM$,[.(YNU=Q-/4#Y[^%\,7&PVF2U(]K>K^;,YXJH+M'_V[J
MQR%(S2O/OILZ0<2YAY?EHS<C8U!%2K>7:YD./MT#45.>#9H_35J^,$?-C0?B
M/(6:U<]<ZW8&W<'@`-0LFVYI@.S:G#N1Z4KJ8^.WX(';'_U`-@I*?)@\M:KT
M'G]6:O4'[6&OO39<5FTV!UI:XO_^"8R?%D?F%4658W4J&!*;^J$=<N0O0Y,*
MD<8*UL0R3;HO1Y/Q]B>/EY^\P37=>+[-NJD:K>6Y'F)$!YIH4G!5]"M$*9;T
M/_(SKV!8BH>FS8M1CGSR\#%X`N/*N<_[LE3%?:+/3YQC@%#!F'T&$)*K=NX=
M"G/R+&>N4FQ/@=1X04B7DHO_Z[NHET$KY>@7%@SV/$05XK*'7_,M0:#=!_Z"
M1EN5?O";S9"/?IR?R9[62&\T&/1?S')[5I+NXU5\Q@YW3Z=BM]T>+7>NJ`45
MEUS[,C:N=%;1(9=KI4""T5L5A,]/EJ-CL8\'L^,ZKT;^07,PK"OY\\GG3ZN6
M;:6#FO9R$W<^T;S;Q@[(!Z#SNBF_$#6KG`&U7\!GYT)6H]_J=7HO1\Y]++/\
M.<3Q+#%49!M6;(&;=THW'C:US@?K_<MH_=;NOC^`!;EUG,>@QY:&OLN;<($>
MH]^,X;'(L<_*V_2>?_K@>^"IJXN;8H7$QJ.I-@JF]EH+>]0]``]5G\E12;<E
M5U`NA4I(=PB#6PO2W3CAUX\!YY\\3`V'T3+A]NZ0W%U?[6KTEKM"/.=,CDBX
M+4V8RU=<&>'Z[=,@7++$W^,>0N[92X3;>MK6CE+N(#FBJO,X(MFVG?FUHX2K
M(]F4&_*+R#0G!MV2)R)^Q)1I.K8\$?<^3J*:N]7L'##%MN,TM:'QWF=?5*1Q
MZQ"N@0XTWA0JVW@,VB[>U+#;Z78/H5F.'S[<>/A8&YNY5LZ&`Z,?PE]_&9H4
M%^G289"=C6>#[17.:+>'O8.$,\K'_Z($VMLW*.T'T34.$Z!X*0)]](,)%V<T
MAWB&8YJ<#==$@C8>4+;7>NKT6@?,7VR=RQ%)M[=/4!Y9-(P#"N\7IMTF8;[S
M\6KEC2WZPYYQ0&Y\9FF>J\Q?)<JNY[25KIM1]Z#IKI5!OR!-MMCLU>/*HVZO
M=\!DU#/3!"N%Q$[@-#[IXU<;>>I0)?+`4_W!(05/U<D<.W.W[02\_7R63O.9
M$O@Z)T&W'=NW8JU7<_^&A5,(]*1E^!2OLY2>!\H.E/K5*P=[O,P4M:#M@=('
MY7&A7=;LT6C[5.NQ*K7W]C"J4;O;:O8/&(=[TK0U16!O1Z4:`D;S(,D,_0#8
M70UN/<=RSPU:P^>)7[T<*7/F<U52[NH=52)E=S?A?)A9'9V4NSI55?G>.$3-
MP3%IN=U3J4KB79VQ(S#^TR;[+(N8IU+]SH],M]BJ*4_>W8JJ*G7P/GQP8.-L
MCDN_W8JP]*??A]G<]1><W_+@`1;G^@'\CGV]Q)K'=X7BH?G?K_TP^MV/_L5A
M>I9_[^$^T?Q>A#P!=][:HKY,![JRN66WU=KOX.%2N:8P+T&`%Z*YQ!P,/_45
M7I<O(:QRV.L>Q%\NQ&S_J_V;T7[_`C1>.^$J`D)\F]O5+`YH7RHC+VZA$9MY
M?O4?>2`_87?!/&FK]#C:?RCO%JN#20N*5W_Z[/%]*K-+^S1WM@;B#D/0XT!7
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M9:DQ=`<L**^R2>,E"#@^T$M77[94*W'#9Z;CP<_70,'`M*+8=+''2#M/8*VB
M()L"6#]_&?UK]-NV%BPO3DOM`=8K5K(AS/7SE^&_>K\9HZUM=@CC98RU"JEL
MCH<A&QN_&2U">6>4]8J];`J<8</JWF_$R;MCK%5<9F-\#1NU#W]K#PCDG4'>
MLOEAC5[LD.%36@7\CM\['H[PG>GBV0>Y,KUN6ZN0R^8XY[[=9S2A>CW6@U91
MG,W1TWUW]FE"]7JL!ZU"0]M"LE7WT2Z'UC6A>SU6A%85/5OBO-461*?9)QGQ
MA!6A58AL2_BX6CN(=G.XO#]9$[K78T5LV;ITL)UUFDS]!;(`N:V6JUF`ME;Q
MK?VJ%0:MK1M3#T["H^.F5<1JOUJ%3GMD;-_Q>GK0:16(VK=688!%%^>'G58E
M0GN6*@R&K<'Y0=?1*EZE<:F"AM"];.O$EZ#?H<S/U9=M,C_SEG9'J_C,8>*W
MS^6+[TAE/?'6*OJB=WSV)/#6*K9RJ/CKLJ='B.<0UZH>Z4#QU=YSY>1.`G&M
MHC>ZQT]/`O$MW4P/UB=/'Z+OTVE*_-\-_RMV0B=*.OK(/CP%:E8(Q:QM-73#
MPPC&&ZD&2G\`A<.;VS^>>)H\UOT<H,W6ILF_,'TKA$L.25_SVQ;Z=FM"WP_P
M\&CQR0,JQ*)ML#A!^&YJ>HJ)TCY4RXWBN]TM34FKGT]AC%H'.4ELU\F\%`V+
MO9;S)-P6;]CYF!1C9`Q>AI;%2;T4*66SR76DW/M4ME)2=D;]P2&.O]AQ4AIP
M]J%V['0'1JM]B%:CNG)V^MH=#K?K=I_E?`BCV7E92K_407<[2J*=D-A6!/#4
MXQ"V;[(]`@&.(ZMWPN6YCZEX&5;9D0!Z"ZUG\0</U./_O(36EI,OGG[.R(LP
MAZ9"J]Q6/_RY?"_F]VRRU9^OXW/Z)'G3\J!RM.U52)GOX;[OV`J[783C:(31
MHSUVMU=AG\6>H*RVR.[^UNYJTB+[RG5]RXSR..6?BJ<<>&%>(/<J)+@_>98_
MX[<1/!<Y]%=\`S)WD6S<#*SIE6>_YP_<]>=XI7I=E199%YW2M6WTAH6U76V.
M3Z5+A43PX>A2+G\WT&4P.`)9*N1+*Y#E%^Z!JG2!*E?VS/$<X#FXYH$?9L%T
MAZ,C4*9"7O&0E-EKR;1;_2-09F^':,-,^MUCK/Z]3\G;A,FP\^29O.>A%3A"
M`W^>O.<3Q\.;\*R0<2S23G`++C3/%OKZ"RB7@$=.():AR$GE9[G;Z70_S\S(
MFCK>O;@I>2/C?\6FRR*?&:W6]\R?,'@QXTHU_L\_AC#]RY!-G"",6*?\@OPS
M0V9Z-NMM>)P'8V9M\7OAQF9&WJ>3:IGTJX^`JY01$/RFB%-\16#!PSY/Q(]Y
MRE?(!)6\[W=SEF6=/R)513&)>A48W/D;]NE9.8\#+LK'6GE:/G'NAR)ECH;]
M"N;X2]&PO8:"K6:K<P@*/M\J[%>PG:M0\'=XP-VC?VCR]5Y\`:(MGEGA>4KM
MG;<I]^2,5M':K32F)TYC2\IDGY.P4#L_RRQVE`85[-4CKN56^_"BX/.<H\GH
MW?_JA^&U&02+B1\()S-/EUUW$%[TRE>LT1%HY^`N'T-QK'?FM^N`VTZ4O^9J
MYL=%$"L4<*U_TAI/;$-X98.1-AH9A0EN&'B%&>9LD/PTMT6IE^RN.["`/!XQ
M/R$V<X':S"I`_NBX+N-X8BQGXV1?)6NWVCVPH`(_OI_"'YUN<\O4<B.6\T.F
MV`!S=D;MOX#J^4E6*":"$<A01^'<,C-P'0XJV?R&CRP/R.#<?OQAI_$]<4H5
MK+:U4_H5K/Q*$^IT]YK0=FX4O<#%7>%G[X^"KS.H8$?MPW1+D_LC<ESGOV((
M:+6OKF<NK?[(_,8L\:ZPP1S/<F/<3`QKV(=1F]9?,2QPFYEP,0MX&+M1XB/\
MQH-['C0D(XPY"^/Q?[@5H6=B>O!?#]T4-Z4#LV..O_F/X(>'4V?.K"F&L'.7
MA&P>^`^.#>\;+]BGFVMV"P_$>SO#=I,A6ZX^=F8NDH$YGG1>4L22H99.7DT<
MA@\TYBS.:-9D5R%,R9HV8.)S/\@_#KU&TUODG*,ML@+'.%8SY785:;Z\?BK(
MODU+KH+A24ON+)9<I:6S8B_R`.Z!6Z]@&E&(J3<97W-=_Q$;">37VC;3?0<#
MJ-OM+=D_%<92'/SJ[\N/N!9KXI.W8AT-MA4\E8?7RJ=TT5V:T:X#7,H#32:X
M7A^XC(#"+3>@^]#R]RQ86/+!T4=N8^P3XZ-QY`>+PL7Y&>]]\O'ZH$:KV<GM
MF#G`6)]U\GL?6UPZ^=XS3C[[J?",]&L5SGS'/7!_HAW(\!Q!Y8M.>]0M+/N#
M#O^%*/,<0>J+=G<IP_SRE!%YDRO/QK2)FU[#\V[M8+?0==6YC_I5IEXVOH--
M;N\BCHV3:U7"]4F32[5YF%AGN6D-MY3B[Y<S'AA59K4ZL`/,9TM=_%XP&4M'
MG1]V/HGJ_N"96/FP*E.&>P<Z-\T)FZ-4F-3ZT>5\]I+[KNS_Q&&$:9L[?]E8
MR<]M?_MI0U(/[A=SVW>`E7`3&:KL*7EA,=S;1MK(5<,J@"T/Z\ESV=ODV327
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M9\HPPL-AUQD-1J.7FS+8N($389^1?!U)295(KW5``T'X^INF66%HAYW<`?5]
M9RG<]`R36YL16Q-_ZK4.J.F7RUYV'-7!IG1`<V#8WK(.GS2E7WS?QK0OF'"?
MO`C\20<@ES_EYW-`&V'0W0+1AB$=9C('-!0ZG=ZSS::RS;V^[AY+%?.S/J"5
ML;S!Z3F&_K+$.:!QT^UUCTV<+P'6,$0++,>,X(&X956$`?)3/J`9U-X\X=+A
M'&`:&X^(WQ&Y+9;<OM,0_MKOOF<MV]2]C4>D[VJN=+N=*HYC-I#]AWU`0Z3;
M15%RP&&ONF;KYW!`HZ,"Z3>-ZD`3.J#)40&4)TP(/+SU,SB@D;'%PWSZ6`]H
M0QQJK$E4V.%X6WZP+Q1@*`Y@[]&^4*!ATVAS46YSYGBFVF=GNGBUM.1XP,/H
MRK*".+\UI;?UJ-(G)R*J#.A0L]EX&NA!TBK/-YN5W;"]C6=9'C:I565D!YO6
M-G5\N"38[M/Z#-_=R0T#^2'O5L*`!F:N34[NF?"R'W_X-@Y<^/#_`U!+`P04
M````"`"WAG-&)L`>4_(+``!SGP``%0`<`&%B:6\M,C`Q-#$R,S%?8V%L+GAM
M;%54"0`#6C<+55HW"U5U>`L``00E#@``!#D!``#M7>MOXS82_WY`_P>="QQ:
M%'[%R>:!S16*[70-.'%@N]O>IX*6Z)A=671)*8G[UQ\I/V0[DDQ2+S-WBZ*;
M5<3A_(;#X7!F2'W^^6WN&"^04(3=VTJSUJ@8T+6PC=SGVXI/JX!:"%5^_O=W
M__C\SVK5&`X[AFEYZ`5V$+4<3'T"?Q@]_&C\?C?L&WWD?IL`"HT.MOPY=#VC
M:LP\;W%3K[^^OM:FR`6NA8!3(\2N67A>-ZK5#>4V@<!C3!@=X$$C^'-CG#6:
M%]5&J]J\'C<O;RZN;LZO:I?GY]?7YU<_-1HWC<8.@:\K$,;.'T:@UJBU:A<[
MKST!ZQMXAD:OL_/:W?GEI\NKJ[MFJ]$R[\V[9KO9NK]J75ZU/IEWGSKM:H/]
MN6Y<?KHX9S\V+QK-7<[Q8DG0\\PS?K!^#%@VAC7^7P>[+G0<N#3^98RP2]F;
M\P5PES7#=!QCR)M08P@I)"_0KJTI.AL9LH%QZ6UE1WYO$^+4,'FNGS4:K?KF
MQ<KJS9LWBO;>?FUMWFW6?W_HCZP9G(,J<JG'!B%LQ<E$M6M>7U_7@]^R5RFZ
MH4'[/K:"41+@RXA]@_^KNGFMRA]5FV?55K/V1NT*DX%A?";8@4,X-0(&;KSE
M`MY6*)HO',YX\&Q&X/2V`B8(,PK-\^;9JOWW8\C>8BK4#SCG='X=]O;8!<3B
MS18S0.8@4,,-@3I_O;Y/H;[/D"1!#[QA%\^7*\HCCY'E\^+.[)N/[>[H2[<[
M'AU#-&1-_TANNB^@-<L6<"S?"8:+0]E[%;YYT+6AO2'`V<L44\`"8\+!UAZ\
M=1>!0DP!G01:P>S,,P"+H(LZ=#RZ>1((HMIHKI7C^_7C/P;>#!*34NC1MD\(
MZWU?$@Y74TPV#QTP@4Y@SF);U_-EN`WHS'1M_E?W+Q^]`(?U2DVO#0A9,EO[
M%3@^E,$@2#!G6#N2?,2NE6HH=@GDS/83P0M(O.63`UR/29%+<,%U^!%*<9],
M)V<0RNI?K.:O>I/GKQC=[2-FY1SD(:AL2*)(Y,QZE]EYO(1L0>+KE)T.A`"Q
MO%7$LK#/K-<36(*)`U54.H9"SHQWX!2RGNPAZXSYKS;RU*Q@,IV<0:33GA+4
M90@]@%QH=P%QV4I'V>#[<S]07B9(9"$I`"+4\M9_FXTX\]*`\P20W7/;8($\
MX+#=PAR[(P];WZ3F@@"UO+V=L"]YQ^9=V]R=@?7L4^,WLGG.+`==S;!CLRTO
M]SF\I0S'4:V+LS&*QJ5(%IDGET["QVEMP>QLTDQB[?7!MF`;^NS'=SNT_3WU
M^HTZ]>?S@%H5L6W9IOV4X+D,>VLV<,Q08,)>OJTT&XUFH]9H5(P%09BPEK>5
MLXKA4\8H7JQL4,5XA3S0$<26&AH"CWHKQ'^F%7XQQ)$6+83<^H"0WR\Z(=[S
M#XA7Q$<()7#Q`24@XO:%$OBDE02B5MMH4[YUV4.HEQ\):O+&*@1]I2OHPQT;
M/KXG#E%??T#4`M&,K0"8"#Z>`&)C4B%LO9RV@P`B/OQ-!$"]O+)X@,GQY1"O
M7BY9/-Z8;$`(5"]?+#I"O^MVBB5Q0OQZ>6)'\4<EXD*PBD[7Y_I!XC./!.YH
M;(Z[#]W'\6AP/WCJ#LUQ;_`X,A\[[<'#T[#[I?LXZGWM]@<CR>RN/-U32/U*
M<)UO$.<7Z$("'#:G3'N.7$0]`GBQ2O=M`5TJ%=<[2BKW*#>%;"2X?>C`%^C@
MP/`K`#E"*/=0,/5XL&7=GU3X[WW;G)GMN1XDD*I(^5W3@EAEX@FL:,]E$U6)
MXT,*>:==F4?#)I+[O.JOCZF43D0V+S1#T$$OR&86E&X$9]I_^M3CDTH*B0S5
MG`$R=U)M-`X:%LFF^0*0PS>V8[P3MEK'?>X`198R$!'2I3I6JH+`L2.G:T0_
M`TG(S$.EP'_UU.04Z8I'V55=@_Y'T<:M?;I&_84!;]T3I>C^*6ARDO^`DWQ'
MI6C^*2".=:&QL).O:WA?!/K1C5KJ,'_A$86V.?IRWQ_\EB)X\([$J<4)0@;S
MWBA9!`(*.W#U=\\-+/XZWK0*/C'=V8F82Q8!*W:0^_[PD"O3LHB_EQ'9K'Y;
MDZI8II.^K\*%$9\F2@<\B6X9([Z;`4P]I/O$"H>SKS_R=>6B%,L!MF<OLK8_
M^5<DLD4`LBT6M/D9-[;N!FN*5%5B#(6\:V_GF'CH[Z"SP713+]!FS#S+V8(C
MA'*O1%\0:*&5=\8\H1UF9$`DDOE_$"H(%X!E$`P88]/ZRT<$QB9II8*!$E1S
M3SPLULP,IJ,94X`Q)/,.G'@/P/-)L/%ZP`2.9\`=LW[A`W:]F=2`J?:0_ZDP
M"T*;WK,M2(]2GQ^3'4P5J_`%B!6DJ$S&O+\-$\&62D4UH^F4,B;[(3LV.U8/
M(/ME1@-UO(?\K2$O"V#<\7BD?;?\E:V,/?=^=82>.2O\$/ZJP(?-#N3Z[-G:
MD\&NK/E,U5,Y@NBY+Y!Z10A"N*=R!!&ZKWD+0KBG4LY2/T&"L'WH#$NEFZ7H
MEAL74Q$!SFZ$=4T7Y20W81.AZ\&1G.0FO,9HG(C*8A7'Z=T5C3-;64LPT9_5
M-B]6E*K%G!'2ZX1,]L)2W=,J):=.6-]D_?*(B2D2`U$ZQ'+"8I/UX@4J>30[
MW9*]8!*#F;J>ALE>3$<"U[J>JLE>4'$9"EW/X60O(;%4E-)QGH]INT53DDHG
M@/Y71/8N,YWZ"-$'%E92@4(H-[VJQ`I2,JF*EE"6>ITM+V=1B*B/"@6HZN'G
M6;87WGX\XD(ER\$T*##G]9?(\?G,8M[X$R2!T]#AETTX6^DD5O.EHEQBD9\:
MW_EF"GX+U`+:Y@M3T&?XZ,\GD*RY"=B@`]_C]R'SZZ[#0G^9I(%R%SDG22+Y
MXJ&)`Y:D3\I($BX3)@]:,1.6*<(]FJ5::FGH6'D0=4WW9"XBD8F=_HQ0P0O7
M)LRV&V%+N6()D#RMI2J)X=POOPTOG@H#5NQG!T9$KC*I-LNNS[(NZOZ%2!8)
M'J/TL6X<+\/8"D$4N=QF/2);.WJE5UA-5@[93<908JJ!M6)6GGO?8_]_0"Z:
M^_,^WQ-N4C]JRXXPO9-8<XYS6]`%#$'?=(^=+2<^VZ:/7_%_("!JUS.($R_J
MOHEDCE1N_Y>D?!I`<T!X*B>"!8%'G7H7'$)=-T+YBVAW1J>N<BMF&5IES<?@
MC>T%-S_>01=.D6=Z'D$3WUM=)C'P"8]=\3J8,-2IME1EVN=)+&?9(,K]R-V*
ML2&TL&LA9^5BM6?`?68`-CEO]L(J',WOW5M-4,?!K^O/I0E;S2QZR_\,8A2+
M::XS$B89"^W]Y.%/X@B'-,?X4*0B?*O3+F=L-NK3=8'E!>P,V98A0[T\)%P.
M3/9@=5$SW5QID0'$**+EP`NN0N#9+@;#V3&=&8",)UT.U.WC]44<VT7A'MK\
MP@[.K\]0+L/VV2BT:L=%B6F?+27`AR1*=2Z/`<.YC9BN[GAZB<5/=EV/F*27
M29255SHX<@J%4^G%$;>NZWH21$`BZCZ=KA\[2:\F29<<ZE4^E]V4$=JBI;Y3
MK?`HQR/TWB%+'<80('IJ<8HDEO.^IN6@6_;#YME::W=KR]D"OU9BNGT,;7-"
M^<$^J3U#QAT7]%W5A/FG$*^7H5HTP"#GF06F?4)%P^#5HQF`V"53-(1@/4S%
M_9I"T8QG4ADB0[5H@,(F*_J@#C_@6XS)3.J_<,."L?V*''X]:L_UF'N#)@Z4
MOV1.CFX)FK':^04?SIEB\@J(K11`E"9=-%1^+@\%&15>?Q^D5[AN[3*7"J\0
M_<)M\C8'R1>W75Y&_N1/:+$M'9N1B*P/Y*6QW7(]E>\'I?O@O"#A4KRAC)"]
MHU6"3Y01E`-*Q0%)^/*@'(XH0J7`2,]_28RG5J486D7/"O7[MH^2*C4()0HT
MXB.U\8.CE.<XA2AV9M+0^-,KPO/XJ!`BRM#T*HT67!NC!1&SG.N:SLA`%LE.
MF[8W60F[@TFRD73D=<UY9"(KH3V?KI^0R41"QZ(`NGY)/A/A)(:"=/W:?%9J
MDSYBJ.N%7IE(4.2TDV8W>&6SO*UR#+I>SB62.#KJ!49\,EQ_=UA&"@GY2VWO
MV!++C&9B=",SVTHW;1VKZOA<YVQ/F'UG__@O4$L#!!0````(`+>&<T8Z7\LJ
M?2@``.:D`@`5`!P`86)I;RTR,#$T,3(S,5]D968N>&UL550)``-:-PM56C<+
M575X"P`!!"4.```$.0$``.T]:V_C.)+?#[C_D.L%#KLXI!/GT2_,W,*.G9G@
MTG'.<4_O?AHH,AWS1A:]>B3Q_/HC)4N4;3U8E$A1[@QV=[*V5:PJL8KUYD]_
M?UTZ1\_(\S%Q?W[7>W_Z[@BY-IEA]^GG=Z%_;/DVQN_^_M___F\__<?Q\=%D
M,CSJVP%^1D/LVP[Q0P_]]>'KWX[^,9C<'MUB]X]'RT='0V*'2^0&1\='BR!8
M?3DY>7EY>3_'KN7:V'+>>][LO4V6)T?'QPGD*P]9`47B:&@%Z"CZY\O1V6GO
M\OCT_+CW>=K[^.7RTY>+3^\_7EQ\_GSQZ;].3[^<GF8`_!83<93YAP)X?_K^
M_/UEYF?WEOV']82.;H:9GPTN/G[X^.G3H'=^>MZ_[@]Z5[WSZT_G'S^=?^@/
M/@ROCD_I/Y]//WZXO*!_]BY/>UG,R6KMX:=%</17^V\1RD>3]^P_0^*ZR''0
M^N@_CQZ(Z]-?+E>6NWY_U'><HPE[Q#^:(!]YSVCV?@/127A(7XSK__PNP[_7
M1\]Y3[RGD[/3T_.3Y(?OXE]^>?7QUJ]?SI/?]D[^\?7VP5Z@I76,73^@+X$_
MQ<#D/=?[_/GS2?1M^E.Z_"Q(?YO%YO(D_I+^U,=?_&BI6V)'+U2`A*/"7[#_
M=YS\[)A]=-P[.S[OO7_U9^\HNXZ.?K(\VR,.FJ#Y483NEV"]0C^_\_%RY3`R
MH\\6'IH7(I)@S^!?,LA_L1SGW=$&\+?)S3[-V`U.9GAYLOG-2?3`B3J$Z%K(
M9=O[>(;F5N@$,/1R'M>#+%E:V)7&=?.T2E2C)8Z7:/F(/"">VX\J1')!07AV
M^(B.4][`4,T%L$%8%%OK$1.*4N^B=Q:+WU^FB/Z**NO;2$?L(L/(HNNSQU8+
MRUM:D<)/`)Q$>&U#V$$("#"P7HE+ENL8\D-`P;(3:-"_[=]=C1Y^'8VF#_>6
M1S]:H`#;EE-%WH3"^1T`9YMU&V*HN&$7,S7(:-SZ)7H-D#M#L^1YAK<Z8B-T
M*$(.L?,V8;1UYI;_&.T?>NX_6=8J6N\$.8&??!)QZ/BTM]'`?]E\_#L]V);$
M?0B(_<<#11?YXS!@YPPS([;YX[!3@7C)AX[UB)S(T!"`<Z*9B!O?#_G[D<(_
M`:$;]7X8+(B'_ZR)?A:,/A+HSAU[T::>_68Y(;I'7H2.)"G%X!23=$]A(<]#
ML_J"40FJ!5+@XE$&I04"Y(2D"I)60IH0%5&(B@E[0!ZFG-S&YNO&NA*GIA2,
M:AWF6+X_GD=+#C?&*T!E[3W]^UGG4%:_31)C)[MV_Q7[H$U2#$07^E/KT0&)
MZ>Z3NA"EABNZH7_*,3CS=(HP-XK[GKT%E)J\"<"-[R+H>L?/S#VR+,=ALQ@I
M9BOQ9LC[^5WO]+1W^O[T]-W1RL-4M0?KG]]1:0Q]BA%9,=PCRS_RU+[8Q`VH
M.3]R(D#4"4!/[`_^O4-\-/OY7>"%2!D?<IV\4KYL;\$\GNR+!V?/135[%%&:
M$\THI;-04Y`JY<NI_6`"M5OZN5%B#2%U.Z221V?)>44$C0!.Z2>3*1537Z+&
M6TIT[^.A$;UO@J?$GET>)K&)TY02>GY^F(1N^;@IM1<"1[/IU`H%*%**/QT6
MQ24B^^GS`5*Z)Z^?#T`+EP=K$U)[I\(Z^*>3[7"YBGS`P[0_'7T=W4T?QM?W
MD]'U:#(9#1^FXZO_Z=_%__YU?#L<31Y&__OM9OK/X>CZYNIF"LL5U%O#@#R"
M)`&J'5*ZT6)!&H8>W6-436(2:\P)\@,/V\'F[.B_6-[L#@7C^37QY@@'(=V=
M,/>U[EK*O?-<!&,YU,0-R&**V4$7O''ISD:WQ`>1MO.@8C3[L_\+_8!)F#\E
M_=D,Q_KOWL*S&_?*6N'`<B*NLFJ'&:L6H9Y?5$0Q0?\*L8\#1#V;9VRC^`U,
MD$V>8K40;4T(Y>IQ:4<$HL6OB+NI:1K/X[\#_.A0A&WZRP`WIPP$%FI3$^C@
M@_!*6A,C0_R,9_1<]/ON;!PLD)?9[_+)D7*HA03N&PSLD]^'B)ZVLP3F`+GT
MD&?E<9R7VZN+X"T)&(KZ]O,%PG&'7J)OA!@N!;9IM..]W#S>>W"AB+/G6-D>
M$Z[4ZOZV(N[H%7DV]ND7WRW/L^@^I.?NE>4OA`^$>O#5$Q+S3B$ER0+MFFQ,
M,%'L3*T<#%-28-`M'LT@X0(";/,--DF7N+IHD+`%<:C'[H^H<1>LP43L/*T:
MX3JU-/JK9_JV'2Y#5NDX&T9'<1"_[2$538>L(I<[L)X0O-H!"EFY@Y/K1TC0
M50Y(7RT:'/6<A[5:OG",6ZF5B34%\RN)2W<IO/8D%X"&BADUB.NKY]A9WI>N
MG<D'I%PT4]^R[K:O!/56>O56>O56>O56>O56>O56C)1+IU@Q4N4Y8T)!DHHM
MG&\@\$JD%FL:@!6$I383$;!).=$M%NK`9+<6S8907"W"Y=9\8772GNCVC*XT
M$Z8RQWGE)!I=F2-,8D5H@=<.'L:^A4:(#JIVLJR(\/ST`.C+";VF!%X>"H$"
M`?*4Z(]&&XRUB-[-=O!BPL.EN3B%E=87]CI<Q5\S8YGRX/S'X\$F_YRRX++K
M+`#7$*2D?^JPHI<J^T@H/SOM.N7P2IV4]K.S[M(N4UV5$G[18OA+RW$G4$N7
M,N/#X3)#M,`RY<6G`["#U)?E)NPZ[W58>2:_VJG?3FD[/P#EV$#9?<*/BT^'
MRP]`4T;"CLM387;H[DFZZC_\>GT[_OZ0<`#><K0'PK".(HZ?VC3JC1L@^MH#
MICLA"=3MYU3G>L/5*LY=4J./NC77#GFY<>>$,C82P$>ZKRT[@.`O#%)U?0-=
MFUIR[%\L-O5L.5$:(;BBCMR:BB^X94408"MDQ;J(GD4>H@?S$,7_KD]=$5SU
M#54,D7N/,)-\-EA_H];&C7L=3_!UGZ(9P)']18VR`+LA_6R\0EZTPZ`=6+56
M4LR("5I9Z\@<&\\?%L0+ILA;#M%C\-4*HD/HQOU*/#1=6.Z4KHN^4B07(`;(
MKJ"\J)#8",W\:WI2YT9G8!6&E<!4D\-YG)@1#(DKX@/[@4KAM/).MIUHJD+B
M#Q#]LJ$75;V"T>I(YA!M:L5V&'-#'64_T*&GA5?2)-_4:;;IZ>DABBA=/5C?
M.Y8;T"W+SM35IC0,+.TB4(U^TPV*`'C%=ABSP42#"`BOI)@1NT8BQ8P%4:]"
MCPV"[OL^"EAD]193W\V)T*0$P1PCJ06TD]VW;2]$63R2@'+ZJC+?U>,`="WM
MS!A1KY^L$9J@J`:D,<++X+;QQDG(O"5K#:WM%@#6CMQRM1()5@."N@?1`(74
MM/YI@ZB$K9OPO,Q9"X&JH[=RL)M=``6@"B"H;CY<4N<9_QDM-IX/-R[+%47F
M":;L*@`I)F.(5AZR<1RK<V=99"!$E(+1.>>&9:"HR^2@K5S-E`B:4C+2I&;]
MMQE&]8W@!OT0\(IO3<-O3<-OO;=O#90_0`/EF4!IQZ$W4%9TG[79WM%.(Y;9
M#1U--6*=&3U9MY%&K#.C&[&$"[<:,>IX.X_1%4X-6\W5%7"G%T97]ZGCAQK?
MC[/5Z'I;I8XW$0PN\`8THT52%Z\JHDDIMSX8+;"ZN%44.^1L,KK(6YU>@T2(
M>3>DT=I*(I1>SI"<;`"_5\)H9:2$%7OY'MXQ:K2N:9H9>PD]S@>CFP:;YD-9
MRI9?UV&T?E6P-4#I>]YU_(-KUIPZCY0W9G<F*G7%:M4'\79NH]5S+0<?7#W6
MD1[WALOSLO$N0`UBRJP+H[6X.F;5K5+EXP2,UN^U1!!<PYPRY4,7%;MLD?A6
MR%FN*CYEW$>C%;I"QI5V2W#V=%%;*=M76VTQ?,C'#RI[LNU1*>/,]O'4,:YN
M8QT?LF*T=`K>50EJKDQ)-]O+JT/Z7M?L0<V5$6Z!3JDV.WT([1+?<N:SW>Q\
MB(ZP1:)P`L(0^ZR\)&3J&[%XO^6NZ59]")=+RUM3?8^?7#S'-O-SXA@>F_I`
M'&Q3K35$@86=]/67SDEH<J'VIBDT0H7BZM"0;>+Q/(UY/,3E1+""UF(@ZF^7
ML.E"\1DXP?X?5]2\QP'[:W-N6LZ-2X4M9/A\M5[Q,ER.7E?12X'5>]9:2/M]
M4'L3&&$%=0+@H!?)_4(5WF;&46+B3,E71(V>V)IA0=W(Y7]@HU\M3V@$B"QD
M*/)W)(@$E;W]:^(-D1-#9"8NF^XS1+[MX95HS3\<)A3A*ZIW**P!IBS!$H,`
M!("\S3.H38[W0(V[\1Q^A9L(-.6#-IZ1"[P^CS\#%L#-$7-/Q86=+)O3E(54
M_2D9N?2\=<0E3PA8712ET5'^Z@8A%6OD^U%\VH^LH"&UTL?SS`?])P]%!FP/
M\H*AD/43.IK/$7.DT1Y>=0DMA0S6W_&6'%@^]J/(I<]\"09L2NW3$-:T"(6H
M?(36HX_^%;)*Z6=F+(%;60H`Z$5[2A&%][,4`M%P$9Y:`MI`']R.4P0"*IX3
M]$2-->JGSX;8HU(_IK+/8IOB>UD(C&J.1O9"9/_<64OZY]2C)R!5`4QMPW=&
M)30=>UPS25IV/9YARUMGD)'9]P5`H#O_?F'Y:/I"!K\BRPNN+>Q0!Q>X[4MA
M@/W*T=UH>G/5OYYZ&')S;<G#4!0&R`]D5M][3O%>HNQV@L45=2ZG7N@'UZ$[
M8]L:+A>E@#1(N1Y"VB`#*MF%(.3DFB7D:@MV$1!X#`.[V+:<2$3\P3J"+OZ.
MJV"4[M-V4&H((=%-5`4!BDR?>G6S)<BDSW\.NO#8PT_8!>O?W<?T>Z.;"C$)
MS54)3(,:UDM0*^0`U7$A"$G_7SA;)-SA7P>Z%B)N(2,`&EE&UZR`)GE"ZKW)
MP[VYN0'I(0+R;-C=SF67XE:IM0IR]PX5(^YZ%IK(T"3EAM!=77HB?BB3`C/(
MA.NME1"Z9V?RJW+;J_?5I-&J;/T.W/(MZ/"4$MNE&[Z;H]<0:HME6MBY3F\@
M+(TTF'#+MV9+I3`0Q'EAQ'%=9JE4Q</*R=V.0'*R6SS$A*R4IJ@VA.;J@ULL
M>IM(^EZ0'#0TK2M4YB<B#!\%)JFU"Q(_)DR&TJRT2_)RG!LMOGHQM5V=HB30
M+#&GOL7I<&)3_YHEWA#2!3H<Q!/MB?1753MPRMN;E]>"`L@M2#%B+)RX^)?5
MY923FR/S%RVV]@C+?%V*#:%7I)6IJFJLF-P]R39S&I_"P+Q(N27GCI%S0B7K
M4<N#JZ7%LGP@H<'!BH894EHFS1EBI$T@SY""^G<^#\](U=@PO?GM!WP0WH$*
M`6\&,7R\6WU21=IU^*2R`WW?D.$9O0,["07:Z?@H*"/#6G5U'J39D;/BP/2!
M;+LJGW)E9.JYOFX0ZCCFXX=:3%&JY$+-)G/#1P_5YT_)G`$^/4CX]-0R)^,.
M!6S4-A7W2,]MACIL:$UH%!R%(03+A&D7Y8@"BP@?D!UZT=@C-CC*14)]TD5/
M*JX@_6YYGB73T;CSH(YQ$>-('"2:+_<?5GT[(3T69]@)6;B`OU.YAH\J6!JJ
MIG62TQ(QHU?;":E28:8^T_AAL+E-861Y+M7;J6H8K/,!0.NNE:*A6AKM!9J%
MS!6L207\EK>&5S9[K^W':M5OK-OV;J1KG%M$W<8YW')TQ4).-*G`#I6[ZSB1
M*ME>4(MF?,6\8<PSA'4"MRV)VG2[,8]M0[HCE?<RU.YX."94WDM36N\0+?)-
M)4JT6PQAI-.2:@4O=F8NF1BVZ"F>P%ESB_67K"Y!HTF;+/@62HF3F'[@83N0
MOI:]`,!;!.@M9/(6,JD.F>RA9?G8'JSCS.J58_GBG?$U@"LF-Q</J7!&%23=
M00I!RG)##\)OYT>*+D#EX0<-(+RYP$8XA3^6"UQ@ZG7:%99T^HTL4)`_E!IR
MJ23:EK5$`'**3R1O\Q"`9$(DH`Q-M:9>YH[6:PM[T5T_'"^(J5<%2;67$]TZ
M6Y.&$B#0650ID!CF``4O"+F_8N31_;%8WZ)GY/A1#]L<>;YX5*4&<&D2.!_\
M_FR&8XT@.Q<<"%7UA2ZYEU_5W$8`H.!WDJ,II-^$""S%_(]BT5\M[P\4=:S[
M\.A0$03%B.^(X%=DL1<Z&[L3=AZS-M.HYO";2QY]Y#TS)^C&I4<R_9I0ICLX
M.INI]<X>CQPE>&A)%0X:BI(.F7WZF)==&QJ/*P&B"_V(FWYT6IW#!;\43`LD
MG#5#PEF+)/2:(:&GFX2-Z"ZWCMG4'*JA&40`Z]26K1*J4Z_MXQ#MK!I*KA1B
M&^\O/65J"%TIO!:(NO:B;GR[H:VX`ZXE25-+E$ZIRL.BAD@5@]-K/5)?*Q-]
MR+'CZ`_NB.MMF77@/%V#BW:`/5+IOH87UIT=5,,WHF0+'7Z2L7DASWL395K,
ML"1B614R1,GGL:'\T#4B)2B4357'!T.X4)U.@I@P%2S8MRE-2)<:IT%*70N>
M9#-BM*"@$A'QOZHV3YG#S+G2XN0-J$91R11#6"*G7JIC$7ELR8L8\0FT1LY<
M4,J$LWTF&#F:1RD3SO>9T)[>-.ZDV8W4\Q&FQH_MK$Y:%#M*C6:V3)C[##YZ
MVF.9(0P#J"-5*<4,LXN2SIQ51@X>51[H$*\K,'SL-+C8(CM62;S\P_#)HYKV
M"ZPB*.79!W,O*9`KG=IC"*B\BP_P--)TKL<7@0H]/M732%EJAOZJ*LMT+MFI
M64V]Z8SK>X]0FSI@<Z^9<EPQI2I7VPL!:4*1KQ"^:A-#R<IL]&^07?X.@5IZ
MR^&HKO2U[7`9.E:`9D.THH=,;+C1OQT4R;$[HRK1"_"?T>>%N((*@QM;4S%S
M"E?^Q2,^*)=7!:DM0D9^@)?L17SST3QT;O$S:H:N?,!MD9D@,0?EJ(7`*2;I
MEMJ#B,U6O5FN//(<AX7@-2ZE8%3W^Y)Y\,(:9=Q9\N>0&5TDXN45\64(`@!5
M71\0>O3<"R-4KO$K^TN"GC(HJAN4DVT-QWKO4=4-!E$C%O)JH%P(HBW=E',G
M2QW=M'TMS\$1U1Y)@_7>54%U2,J"TS9PH9C!\G,6JF"V];[V0R1U7M=M>X54
M``IS1RU4O:##+WX""P`!"G"':IL@^DV$#077P!E?VZ2.#X9PH3H0#3F]B8`%
M94(YDSJRB\DU>_2#)+EE#DE'1D%(4@YP+3DCC,Y02C*B-&C0D0(K.>-)*/)C
MQ"7/VCF0']CC:<1N"H(<+S;!6YXK/$!1:"Y8GV;3S"Q24+1'HB0.OQ/-K-E`
M$Q2]V'N+)=#8M*<G5&,^D"`T$]*'5:BJGCO+5\_<O#YZ75''!45W+&8^]K_C
M8)%]!!+0J+V4^A&\B-5A4)')&%D;]*0&\E:#4TS2C4NW('H(*!,CM4'BBQ/A
MX=!20!JBNWH(:8L,:"2W%(SJO,<"H_GH%=G1D+KQ?(YMY$GD/LK`*!=TKE7@
M.VC_:0W[OVF4M2*<U>J#]=9Y!]SX$*C:,AEB2-5(:X`6:.>]2F4XJF'ISF\(
M4Y>;W0"]IQ\IU2$C(41.ZCN4_I!0D05,Z6+2HVGJ#:&]VJDO.<J)H'UD0G9#
MOQHHM7HY2XSH.RZ3>Q$GH)KLO);K%OL#A&2^2<H-H;M:WL5<5P(,'$A<\M6V
MLA,UJ&K'B3AOA`\"+2%.=GD&#J+@'FLCH\8<=I^0:V/DU[K/'0S7A+"G.-+`
M2<H3LK:<8#T(Z>GZX@Y#=(_HZY]MTUXR/;GP>>A(YZ_6*UZ&2_JX3:FTGM@)
MR**[]%_1$I32Z<(*KBQW@#:K"2,I!1M,`-T/R@B0@0TE8`MZ_%K'CPY^8KIB
M2NZM]3>ZJ[V;P!][^`E3=7!+K2RJ8_I/'D*BK21-K=3$]MI:.6.12>VG?6!-
M;"!Y%(6`05'LNR18((\=+NQ"E:_807Y`7$1?6:2;OJWH6;EB-0>[ZK,$51A0
M*,K-XJH(R71C3Y&WI!N>O9T[$M!=#U3'U8`41[S&U,^QV.$4U:#X$VZ+`9OK
M*@#IZ-ZAZV$O-C^I9NI!L,]_7CG2OH\06YHUGV>2HSN\9'MC/&=&A.A%"757
M4-T+Z2&+.<R6,_*9YY#D]"&D%<.`"G.)K29[1P4$)!3=[U21457A!Y#$5-&3
MJM,(<0CW%T2>/&NUP+;EP/,[A4`T9*;4$J#A`MN-7YY=&YJ6*@'2I*B)9I`$
M`36(&BC]`P"F*_\#IX\(L_EP$SVP#4N$Y*5#^9MJU4$$5;01F0NA"&XS-!M"
M<77XLOIP(\66@PE9FJJY-8WKO,*A3FU.R95G@LCDHD(SV_"9IPW0+NL]<<X8
MV:_0"&?RW&5.MY'E^5(J03"\P5M4C-3X-5ZY8)B*CP0\-&T`B2/R[APC^_5J
M;P-0Y)<SXR!E0BQBGS+AHY&]J[69()19X4PPLFFM+A,:2(]Q#G72FI:1E<I\
M*._V.TAE*I7DYCPY2)U:6)W`IZ0*JU$M12^L^S!8;R8NNT^,X.\6\Q2">D4O
M8+@F%+V((PV-S;*QYN/Y!MC8F^"G1>!O^Q^W]+\^($,#``D.)0O`'EF>@YM&
MF`-5W2:5A\PX#/S`<F?TU4/2"]6PH/R_H8XX=GUL1W.&Q_,1550SNM<'R*4"
MP2:C4Z7TC#P6#[Q&5A"-(!9\#5*PZU3V/%`!1#X++RR7Q'T(B/W'=('<&]\/
MT8Q*6(93MYCJW;'+41F_N!23!5Y)5?HTM++R284)NRG&#,<8[?AC:H"!R@`$
M@('?)?T2>1Z:1?!22#?NE&08*_Z"!,$I'P:71>,64\T_VXPE8%_0TQXX`%8`
MG):-%.!'!VVC$^^!>-LS#Y=O$OC6`H*OM]GN0\]>6#Y53NM-BX7D-LL#I'[:
MH(W0+*J'9KRA)D4T52Z+%M5!?'\(BU'=%>J]D_@]#T-VP41LW,;O_PZ]1%^)
MYYC!<*&(3]`39AD?"A9[R`X>PD??]O`JL3;$:XXK`4%1NT-!_NN34:EBP%K9
M[T!R`,#@-BUA69`!I@)!%0#H_><^VXA1/7JE]@KV401W8[%D39B=E5,>1*)1
MS_2NN70;!OH.RHEOEO@2,$M);H$FWSJKO^#^#[#P%@Y8=:E6Q@R(^$?7C3X#
ME6H5`VECP]V%+$1$A8-=J13=_G)E.0XS(T:6O=C^;>W-!UL,?HKC9Y;^=BP[
M"ME*'X;5@#1,H0_6R;'`E@15`^8^WMCYO<N=^H?X/L26+%<X85"(9HGXKO97
M*.#[2ZF_'B$QI;(J%^8/%H``-\P41UUER]<A(!5S^CMB;Q3-^M0GIG85?!13
M`0#%:&^2.W!T=QY4C6:<EY-`<_M!U6-Y6%Y,8D8=?TS'$*O:2.I!$3R5BC^D
M3ZM*73>S^[#6&"@<X_SGM5A_;+(\<:G1`&]F*0"@JY%E9WE?NIDE'Q#8+0@?
M'6R/Y_1%TH,2V(^5_[#RCJ;$>DK/]\R\B9PYY4(-3F(PM31LM4=>R\2!14$`
M6ELY%QG]7P%*CW<4+0G?8GE/ZU*IV;6EU>D^$*@JC7,#Q&,U0_6FL(+`*>;R
M%`=L.-B-.\//>$8]IW2@#YONL\"K*1FY`9:9>PH$K4'YFD.L?E*ADE,`H&Z2
M3M(4J0*CW)3>CF7)&-/Y$%0K48N]Q$CKW5E+^F?F!)4P-`2@J28H?/3Q#%O>
M.H,,^%0H!J)M;G&TYF`=G4LUIA/G@-%H2-S*#!XN`*![VG`Y';DCAG.8?;C]
MY9`M2X1DR[#N\K)&ZTHM0V!:L2L=U^+'!:D^VPQOP98C6L@<X7W7G1H1+"3@
M!88A;ZXU0KC+1D>4V\9EI%9[,)P-I@^34,4%0WA0+?>RWB`!>O"<'8>G#$KB
M*[SEW/3!V-61)E(>">.D&CT.NB0$2`"!2A.NNU2VGP5BSBG]%T:H^-(A2>(!
M>6$F;*=+.#-:M/'$I%PI+PSAA,A0)6`"BI1F`_E<C?;F!R@_W/)SL4:,3H`=
M<*79Z9TKSG.2Z)QB(SO>Q6H(MAS7TO/-S&D08"IS*D\XB>T=8:JD-E,/E-ZV
M>]GB?A6\CFJO]&F7)%XHQLDRPM4NNV9*D"I#:!*X426GB"Y#TD[9(2?*:$>X
MBJCMDD].E-%V3@51!66W*7$?C!R'))R[`)=)<\*-=&%E*\GSC\'M@O:4](_F
MCH:K27K==@7.(G/GB-9CD6@/2\J)3X<F)]`V)<X)<Z=IUML3N:UD*=F?S1V>
M6F,#5+?_)0PX$\EX=XH!DNHRKWTS95*+"4"U3"IIY4V);S,5J$Y$X*W9*4/.
MC;0J58E,=;L]9XR1#I+*G2([F"%EV861,;CZ+,N9Q<%I/E1M*C`1)67"P=G@
M@"DW*1,.T_RNGD24,N!0S4_@T*B$'^>7A[8AJCS3JCE@*6<^_``[)6\"7,J`
M@],5E:4:93/[$K9<F%F*VHC$"$QK3-G0.T@[2G0.)V?#H9I6`C-34R8<IL.J
M8&ANRK'+0PO^R4]13GEB9G6$*B]_:Q1VPH/+CP=I=,"&G*?,^'R00@(949^P
MXL.I\+[0<C]"I`X'S'!DA33(]6/,ZUR-``%IPJT(0O@J'OI"Z2=KA!Z0]TQM
M]WR,[IC&]5G*_L7R9OZ4!$P+\^^OB!_<D>"?*)@@FSRY^$\TXY#BA\;L>JCI
MPG+'T6:##19L#TD=HSWW2,E<*#A8\Y]L[M**4(W^9X*H"O%QD#`F=M1!PUH5
M(:!Z5)&J#1$3<$V\S4?L=R!^ZL:LJXR.S%^C5,$60J:*_0;!))'AWVP271&)
MVZ:S%BT`PL=4IF9#-C>`:=&*%C:539MWG7$Z=BKYMM)K.K>?,$KRM^W\2AP&
MGNK?K*(`4RP#5<=^>*QF_N,N\Y/`[W:N-`H)QP2"MX`B+$QEH,R$>@6+FJIO
MHO_YC9[C:0I*HV6[NZZ^^:97U@K3PS,^&R;(IX8.8G;?=<AB74D:"L()">"F
M[HE]A1\7A[5TVB2+F\JNM'(N>M_],%@0CQF[6MA5O+CJ6<94=NEI$&R,^F_4
M6?(G#]\D!C"7`]+E>W'3`$Y""1"H,10%1S)P[AT+@%`E""@ZTQ<R79#0IY+8
M=ZD."VOB)@Q/_<`[U\:K3<Y':MQ=SO/*1<YA5UK?6Y[,!,>\IS4BG&G"]@?K
M[#?@@>@`J/"K2YDUBY_E]$$EB+:/,+_4'&/-\:S2AHHA&Q0E,3]1P?HZ9E8?
M(-N4,XTO#13?G0??+@+)::P%H-FQBT"Z>\>&D(4T76`O0*B^:90'2+5-)*W`
MM&OLIE#5ABAT0VX_IV]HK_1)5&?$;]U%VS8/BM"[E9D>W,1JND<--\BA_+G$
M=7?(#S7%N"$9)D7:R+`QQV539W+5;PYA.?/>VJP>%YH]`Z/-$,JJ1W\4'.U$
MV$HR82JS&6*;,RGJM&?ZMH:/5&IS"+6RD4JG9T:V4HL2E3]2Z?2LO<IQ,T1R
M)_C!&=-B!;7849H?[]D=F*`@^->=.<NML,@0!@D,9E49924"P7<3IEB;H84@
M&13.->,M!WBVJ8`G^Y)EMH51G!?<OL4D)V7)ISH;;6^`O(*2M#(GU\C^+4%R
MRS+\G$(CQVCH.@T$2C/X:.\W3E77X:3<^F!D#['B4&3SY5DI/S]UVVK3R\_B
MZL"4GY^-/LC4\%.B^)3SZTV>:Y8MIR,SS9P8J8&5S=3(<SX:V4]N*!\%>C-2
MQO:,G!2DAK$R74`IH\Y^5$G6T2"6<MG,J9B&<CF_CS'E9<?=O59VK%A';4<N
MA%##8DVMX/QZAA]0)>@>9\!O.S!RD).A.J-\%@>_+>`'M!Q:'!W#KRL0WLMZ
M!B^%RZ7EK3<C^?8MI+X[RXQ4WTPC2G@K.HFISAI&C&:2(J"-1O/=^-TWRHK=
M"/RV,Q%52&2PWU!79AG#.Z];P[.5DEM)XI(8[#Z1]>MR%:#4RB`%23HRLBJP
M;P;H";LNFWYO.2P(V=Y^KXWW0;VD"6)V`_WZBKC1*,30<J;(6YZ9^WY*4.ZB
M:MJGMW75E(=2EUC[;;5"7O17-.>W-7[NX=$E)MZ2%R.8N(<'M$MO'^0U?@9T
M,@H`:0`E$@)&$0@`J8_2E/Z^/INVH#2`U`NICQ*'41^AL5N?1QD87=(0376[
MUUJ^M1D!76::R2P;K/>QAK;0*EF^Y4Y<:>P;;\^MBXFY>R_'^FBNC[<^!F;T
M]C;&24"_;]TM]]8$W)#ZJ,RFU%2R'6HP5GG&-</F,IO)B)9@H=Z.[O+9$"[+
MI@:;L7")B-MC0N.VL7S*^*N\[[F#E<[*^90--7!.=;#0036GLH$BSJ@.%H,K
M9U0FR&?$'`7-C)(HIVDJS,O9W<&*<./9O9>:Z$AW9$?979992SG_L8/E8\HX
M;T(ZF?=)O:D@`PLQ>,=&!^O?.Z.R\NJ4>%G\VV%A0$4>+T`6[O'24@A[1]PK
MRU_DOX;1*_M3LOQ5`K()1:\0M!6/\':B%$:VS#H'%TC20Q2BXNS/+\BE,N+T
MW5E_MJ3OEEWPRX8";=:'#[`6!*C^RA5$-]R"HC%$S\@A*Y:+D"9*")QBDFY<
M*C/H(:![ABU^RQ"F&P6>(*\`U`X9T)1U*9BW(="EBYIP1^M&_=&_QO/=+BS6
MWN)+99(;7UIW"ED5[]YF11LX6ZY4AQF6V2U).(IH]&JJ.Y8"%#N-"="$Z$A>
M#TR\H%'8D72=!B4MZAUPCIGERB8L&M`7/\=!Y+G+N:X"D$QP5<O05&MN#1FA
M;'NP60R/81(H87N,[SN($24(4+$568#%AL_>5RNP%TD4.OD>?LUSG56,9<!X
M'GVIAP_I8LK9X=L>7L4*-0_=V%*A1TS4^7Y/=ZN'`NQ%)U0DCC!^U%\-VBQQ
M1_72](5L^$HMR.R"P*8)(5A0!*^QYP=1U4@C.(J":T?.Y.[,J@2FH?]"+T%M
MD@,-&E6":H<4<"RH'$X[1'!32"IR`X&J.R@C03$1?5F''T(1VO35_.KDI5JB
MNDN,_"Y6HZO@@"'T5P<*Q$]B`K2).A(H@C-`R'#M2+%RW7.CO@O"&65TR8^2
M`Q;BN_++I8R>^ML6GPRY?:LE!NT&OGCIKW`!JI:8:QR5GUJO*(D\3JDR#:W4
MJA6,N%;",2'>6HRD6N]GO$+4='W])[)`!21;CVFIL*"KC5ZM)78W<^/I;@PP
M\NEQ<4.]!P_Y@431$ABT(:3V;9OZ0J`H.!BT/E(CWFX2#9(D;8-071`RGR.;
MI?M2!"96@)A*=6WLX#A=%ERC&<L1LJQB2&E8;_T85`32Q'**6<+F9:=IPA=6
MH$T/'^1Y:$8QZ/L^"JX6K+#@QNTO20C+:<!AJX\8;2WO[V,(#!55@U-,$EW[
MBJ*`@RO+\]9SXL6#?Y<XB!#QQ^XWF&85!*B8+'I,L<2\^W1+?#^+B5^'-@A4
M:$ZB&#:_-$7TL`8";&.+99S"VKMK"U8;Q,!56RF8UF2C&5F`[_V,#;PQ?ON/
M?M23);S;RT!`T?F.@P4)@XQZOL7T"X=Z1F/W9KFRL!==Q^$1&_E^?CT4,(78
MY)+*BX:I\4@=Q6^NOT(VGF,TDYAM5@1$QU@WI02H1S^I5DM0``])RP>@J9%!
MOF=!T_[.5<UR.><*4!KVNCYB6CIY@7N_!(AB]&^IT/G!)G0"%X+<QU6[NY;G
MX#I(%P!0OU'BZE2I/9Y]5(^`-H2L/E0EA"[[8&OF+;@\I1)4BUZL1&F*$#C=
M-2D0&@G@U1Q^/8KH1B>%DMBA`I1\Y9-'6A>+2Z#4&4);=1ZSZ'@CE49"1PI#
M!`C,-=U,Z!!2K&F*#&U.>HMSCX2U3H7/445R0;E;FY<RBVJDQB@WA&XA81;R
MEG.Z(??ENKT).2KENB!XQ,MJ6FQX%!S?7!H_V^HO+XE1<H);K-P3&Z-<FUY#
MJ!68^U09V24*XNV<.48/4@4Z6I59%4ZVD269HHDE(9\R0^VYD<,:):@M34%R
M<HT<]-84N5N98TZSD:6A`)J!^7]>!VJD==:H).\7:J347QZT9)<1?B@R+E10
MQ<?N&CF;0X)L>)T<YX&1T2,)'C12*\GG_AZ*(BRLE$U'AYH97JM'JEB=<\J"
M@S'IP%7M*0L.Z>3G_0D2XXIS&EQ^.F&KL"&_]/_\/U!+`P04````"`"WAG-&
MO%+.P\1I```U<`8`%0`<`&%B:6\M,C`Q-#$R,S%?;&%B+GAM;%54"0`#6C<+
M55HW"U5U>`L``00E#@``!#D!``#M?7MSY#:2Y_\7<=\!Y]W;F(E3MUO=ML?V
M[,Q%Z>55K+JED]3CFW!<3%`D2N(:191)EKIK/OWAP0?(X@,``0)4>^-NK):J
M,A/YRTPD@$3BW__WYPT"SS#-8IS\Y:OCUV^^`C`)<10GCW_Y:I>]"K(PCK\"
M61XD48!P`O_RU1YF7_WOO_[W__;O_^/5*W![>P9681X_P[,X"Q'.=BG\P]W[
M/X+_>W)[!:[BY->'((/@#(>[#4QR\`H\Y?GVQZ^__O3IT^MUG`1)&`?H=9I&
MKT.\^1J\>E52/DUAD!.IP%F00\#^[T?P]LWQMZ_>O'MU_,/]\9]^_/;['[_Y
M_O6?OOGFAQ^^^?Y_O7GSXYLW`H&_\5$!X?\(@==O7K][_:WPL9L@_#5XA.#R
M3/C8R3=_^NY/WW]_<OSNS;O5Q>KD^/3XW<7W[_[T_;OO5B??G9V^>D/^[X<W
M?_KNVV_(C\??OCD6)<?;?1H_/N7@#^$?F<C@]C7]?V<X22!"<`_^#=SA)".?
MW&R#9/\:K!`"M_0K&;B%&4R?8?2ZH(A*'1*DDNPO7PGZ^_R0HM<X??SZ[9LW
M[[XN/_@5_^2/]-\*'_]\\/E/[]BGCW_XX8>OV5^KCV9QUP<)V>.O_^_[J[OP
M"6Z"5W%"K2:D#++XQXS]\@J'#%0)N4#O)^B_7I4?>T5_]>KX[:MWQZ\_9]%7
M1&4`_'N*$;R%:T#_^_'VLI?=#U_33WR=P$=B9-%5\``1$9?2_O$IA>ON[Z$T
M;7R-BO`#%>'X.RK"OW11R_=;XCI9O-DBHI"OITCY`>9F!6T3-"CK#4QC')TG
MAE7;3=:XW'=YD!K6=1]A@[+?D[@'S4I]2-*DO#@/D&%Y#TB:D5?#&/)#$260
M1_03=/8L/D2)#<1,QJN(T`)1^#F'202+H$C)XK!+=D8L@^'K1_S\=01C0O3X
M&_K#*_K#JS?'17#]%_*K?YPG>9SO3\EDG@;HDI#__)]PW^2+:)3':?E+-IB_
M?#7PY:\K`>E'Z2Q#OD0S$)B\^G@G2^<?Z*&EU11F>)>R*4A:C7EMZW_E;$#!
M!S!&@'#Z]Z^9+`VI5VG8X!VD8<F6_#C"N?C$UR$F$^8V?X5$"UFG>#.HOH(M
M'M7-UWV&$#S$F(%]_+:`FO[F'V7:MDHB3O4R6>-TPZ;PU4-&&(2Y#/0*Q)1,
M09JN&=.("DZ,]%=_K9):DAN3K)F92ESS?NW"2M1AP\IJ]!DBKI(:&L(1%%XL
M\`2_E%S_7QLD8Q'R%C[&E$>2?P@V4"U`MK^K&1^;9*R%QYH-H'S<!L<>M>,Q
MO7BD8J2J7;<3)E*;*PTX6.G=]T1F6<=J?D<9;?'KYAVI"E>4O"O_Z=0J[AN^
M!QILQ_HNY1FPMA4A'E$&%RAXE#6WUI>4M=7XOGF#J\@#2M^5Q75K%O=JP`<M
M(AD%&HQQU58'W095#7:M+VO[;(..Q?#'^9"$+6*[OJXC8;?N\:AN?-)S.TB.
MJ-B@Y5[$61@@SN^"_"Y3M=X.`MJ:/:!ET8HYKU+3C)MK2^['`DOIR3>]MZU:
M0N7&+?OO,$@GV+7P]8G:K2C9MVG*RB>+/L2@TYY;&O)+WSVVW*]J`Y9\NDO3
MQG@4$XS^[ROKMH^4>6,N.#44[#K5&`4"RVC),Z4C=7T;VW;[&2+TGPG^E-S!
M(,,)C"ZS;`=36<,>(:*Y2]1#S]J.'.7WZE?*$)0<`6?I=G-N#!PLK30?@4`'
M&(#_E,'`F.W_#:-=D@?I_B)&Q"C4;/[@RYHJ;M&Q9N,5'\`9N;7L/M7C4=7X
MI&:DI&%SA\E\HKB%6YSF<?)XEP>Y?%H]3$/W:+F3G+T3YF*JK/@!SM#Q0?,P
M+EA681YB@+34;\SBF4.=DCSH$:>*Q1.MKVKJMD'%FEDS+J!DX]:8NU6.1Y3B
MCWJ1@F:-V>G-[@'%X07"@52=1\\7-94HT+!FH9P'8$S<VF>7JO&@.GQ1*Y+6
MJ+F,`6\V.+G+<?CKW5-`A+[>Y:Q&G<1NQ;QAD)+NS#5`U%X.P9@"QO4(<+Y`
M8.PXEY!!#*LIT5MT4"\P$K@,.,DZR!X8JUWVZC$(MMQ3(,JS\C=MERE^_0^:
MST"ZO7B]OBAO7=S@+%:MY%.CIP20"FFC,%4,P?4:5"Q!R7.@6&P.%])"$.NH
ML[<ZU(P)KK(,YEF1:NO87`\!+2/KI&5ORSE@['YT:3_#ZL=2JO%-U64Q!N-0
MK>*TBCOU[?HTR)Y6243_<_[;+GX.$!$B6^6G09KN27S_6X!V4@<KB@2UP)"B
M;<$/"#]6)AW2'V#-V:5'J`&'M93H.TA(P(?62K,?!*9@E8.2+6!\9_&IZ_P)
MIHW`H>)`7=_6`N*0D'G78#Q`V)@H7'K%@.KQN&:\4C,2-=R<)&:Q8FT#-F&[
M-LRVOE;W5W;%SB.S';584\9JSTX=6.A-BK<PS?<W9-SL=@Z)_%NZ6/@`E0QV
MF(Z6GH=(FH_")3=^EZMD=002Z&1;4`D?K*(T3[%`+1@8)WY[J^0%/AQB83OY
M^$`@FI1_B`2FSHTU+5M9B/LP/JS[[@2DK1??]-R5AM0\9LQ$U%.027.DK:3#
MO96VU'F094Q.+RSD%;/8V54</,0HSF,X9:-OB(J64OL)VMOR0S5/I_M^$I!@
M>4UYJ?["S@4VKO8"5V&(=TF>W03[X`%!G:5?#P6]8-))S,)UPH(/V')&3F/S
M,`183CO>J1NU-%WPF'6U>+[9(KR'\!8BUN#JP*U5#%V"F!8(HW2MF'^Z@Q$(
M\68+DXRWF&`+R4(6\``3N([=)BWRZ&%E;?J,5'D87V)1L`,=T\5\R\MIOM-+
M0G_I,Z>?P,_438C:J8]@MBP2LB7GRT\YSQC4FG\X-!:AKDQ_FM4;,WAKMMZ[
M/^Z)><M9ME&CMFS/KBSY#*XAX1;=$H:GY+]QKK=5.$Q'2^-#)"W<$"ZX@;3<
M+P=X7=D]*Z?'B4N;ET(*JZC/4U10"Q#*"7!6<V\W"EZI&>"G1QM;(=V_4#X2
MP\T$;UM1>YX2+;S9Q/F&5=$DT2E.Z!T?F(2*]CE(1J_2IY^BA9W)FAFOQ1+9
M.2W$DH`'*RC-3RC0(0JLXFH(!4NUX#C\]0FCB-@&/5W-]WH5X/U4-.N^^PB:
M=P61U[_]R_=OC__T9W;JG^^=[M5+((/E%>8E"N@0`,#YS+U7?Y,6F1*31;E*
MM_/KFM45!Y1L%+B4>6'&+PC]ZYO7;]X<@VV0@F?*\L_@6[")$:)[EQF_I!+L
M\B><QO^$T9]!@LO?QK2)001P"G!]B>4UN(,I782MZ+3R#$G:3W>GM^-<C]]]
M>_3FS9N2>@2S^#%A&W34-P09VL1&90)!#LY@"#</,`7OCH_H4QS?L)F/_/#.
M;5E/O^EA"</PR\Q0V\+X3:?YJH6%"UWJQ?8'W]7.'D0R=K(WZIJ]?D1\J-=_
MAUWAS^#M\='QMV^.OOG^._;+XV^/OOO^VZ-OOWO;<C"V82OK84>`?',+V>M`
MR,GM[U$#P6,(>F0,J&$'<_O8*HK8E;$`W01Q=)F<!MN8+(>%H2J=<DM0TSN"
M'25LX5BCXDG\,8Y>Q0D(.5NGY^#R@&%U_7D-#CK`A?(#EPDH.#:NY,[B/K<P
M#^($1N=!FI#`F:W"<+?9L8/(,[B.PUAI[25#30NA<<)63@5+'B3[8TQ<^HT"
M4EA=<5ZC4OA-R0Z4_(`(T5DW1#/M5$S;H3"V)K:UN9SU[DOXM2TAMQUA=!O"
M]O;#W`<CJR2:9M[CM*;N^7>2G>%<A:T@_'0%:0"[SV(&-.HQ6!UG[73GVI43
M51TM[FD%I-J,T/SFM/XDC(B-O>FR'<DOC(,?74>:NN[J+R*HPQN](DF5VK73
M4Q1DV?6:^<OJ<ZQTYCA`9)J6V_0L[%A1#K0:I'.9Y<2*>Y'H,NAN#?FH]0,S
MYZJ_+E0/?J&L9NJ&(@SP#&_(0D)I-[;CVWI;<`>$7K)]#R@=C^O$*P4C4;>U
M`7,6,\5M=I*U:IZ7O&>;W$J1>XB,7A3IIV@A#2G/\UKG.D[CN`0R6$%??J*`
MA@$`OW!F,R<Q5W$"+\F/>MF+\.UI$VA%R&KB3;D`QL:/[/M0^5T)2TLW7BGZ
M,!,?T/$,]1XW07J=,FDB=HAV`U/6FE._!*2?HH'C^C[B,Q2*5&?,_E1,C(+7
M6T0QK$?O@>HIM2!,P74*.%M^*$S?0N/-9ATX%V]RNZK*#_2=ZI"2`8S:1&=P
MHH.*#'^<J1>L7B?JUI^WP/0X3=&)>=4+R6R.PIX%FNPD)15C.'"",S@'+R[R
MS2-:J(QX@Z@L+Q$8]H++3@AF\P#%]OW2I(PA8;6!_X%#8+==^U61&G&-:7W[
M9T5EV$GF;MHO%$:96*Y(D9M:\#C?0J59$.O%*D4%L.[24POKD]G`00U<?%F9
M'+SVH;<L&20S%1?["Y*FLWBU&I$!J-M9#*Y#K(/1Y1QN5B`'0U5??O22,*-[
M6PN/3B=PO_@8`V3(^"<O.ZPJ?\#H9UQP3'TL3(Z.&>U;76=TVK\G:PW9]\'D
M-><I(`,^,??ZXC()\0961S(ZM\![26AIOX>:4<5S'D`XB/+B>:\Q++"DEBP_
MXG6*,]8?X;QHX:9C,_TT-%VVFYR-^)D5K3/*#G9.NP6,8H%EE>2AWI&H<O8.
M0-DT<.8V`;<P@P04^B#3&7R&"+/'"`II5,Q^A)#FS:`!FN8=H&3'?""J&;J]
MKR6##U;2F:]8H!8,U"\$7J6/S.(7/\$$I@$B(JRB39S$U"?I36\-SQ@EI87'
M"%7SWE$P9,X1-%BZ]`]9G+"BYOS%!#7AH$[2Y#:KG[2GR2F9DJ&9VEJWTX/\
MR*?T2"8M,I@.64Z#YFE5O8748Y)'ON2XPIF2^79^7:\U\B$E\T9,J?*F0YBS
MPXG;9M0#VL<2NO%+TX4E5_1!L1"G'&;:[2"3-<SH^V6L"S;GK[;9T4U!<Z^C
MBYCYK*3D(S1;CQDKM[L=@UA@.35YIW?44CD-V+SC^F6GRJW:N48B?O#521HV
MD]3]P%6;P$?V2$1+P[`[DW-ARP,)=:=&/-!MC]G.F1Y_@+E><M'ZHI8V&S3,
M)Q2$/$`TJ>#==C?;%#X1Q=(5".J8]>8TVFZUXT'5^*)B5&MW[ARB681V%C_'
M$4RBK)Q+5M%_[3+>VU?%E%6H&JB=&V)@(UA?P2S[$9Q!N#ELX@FB0AA_ZARE
M4.TM>1Q7KM\(#A="5HR%U$;@/?^,L7H.8D1;.MQCX>BV:$IR$F1QJ#VGR)">
M'A+'N=B<ETKF(,=T@JJJ`PK^WLQ0"C#WS6&RBEX.I-WS(*C8@WO<:'18MNIA
M(LSS8&#10*ZL,]4Y+>ZGH??H7`\Y\PMO:2\#6Q)%636.T^/D4;"PK!8]!*;P
ME:JC856#//=Q<GN8S!GID6&,=KE:%>8H*2,XM*B:]Q/&@)\H<Q8^.4$?/`.^
MT*DP?Z'H]PP.##MC[@;&A8.PG/,LSD(26G>I7@&2-@L;*/9Q,^]H/\/X\8E>
MPPB>81H\PHX*4*\F(%7DY7UR6.?+0UG!AXM%FR#*W#-@:88K;H4?=K29S?6:
MR2M4P$Z8&'4Y:`&OQ^R%3Z,3,<9FU+LX/%$K4!<R`"X$:X?&O%J00WF6#AYB
MS%SS^&WAF/0W_Z#W,0*"Z_5:6+-^W.+D_#-,PS@C?_@Y2-,@R;,+G)X&V1,O
M6I?QRXD,E&"<Q,L,BA$.=W0[C%40?/774ACV+JJP^@,[(A"`A43TKY\*F<`:
MIR`D4I67-%Z[\&4S9H&-0-);U6[,FJ4?#II&?PY;-OCFC$E39K>SEV3)!T\%
M3<=#U8Z;V_[\SMS9+B5QGZ1X,8ZXCWR`G]B?Y(.Q,EUUNU5D8<5>6XTURE>L
M(B8&W78C<G"[!`G\Q/_L,-CJHHVGJ-RT23)K-V^1;;+F#;+)P;$]'BW"('NP
MEK7'+HVKFB,_5B[/)4]@PIZGH8]*T5<H,Z+VIA32!JE.6-TD57E8,<KB8+X\
MB`</E1C%4YY4CO:YO3N;U`8<3U*ZY7N5U6W.HJ6V@>>9I0A.ZQ$[1-M2V]BR
M);CTV\%S;GNHH=C5PG=<H]8O^%:O]TYM@#Y*2O.>Q2!5BXW0!<YN[[7((805
M=>8O&D40$'AYTA.=^R=9!Y+E'ZU_TG[<I9O0M.#<1=.\=Q3QMV;C1?P=!*8K
M[O8KRU<0#F;&`R3F?/:E-4[UEU]Z".B=Q771LF_Z3L].!_6/I73CFZY1MYKG
M?0QF:A)D,/.9)]WQZ+D7V?3&<$YC/9%QFKP(N]8Z*?W!EZ>VV;)EQV*S,T\:
MFPTEZ)WZ\$FWJ*%6!X;;\WJ\NA&/$#+YM+TMXVX];?\JKIZV=VGJ<@AA):WY
MB@;J!`)<5D#,[!P'3\+SC7:A.Q!9*3Q"#6]1I*P'F!(3"_XT_L#]K(ZDAR:>
MIM#%((=Z00.<>:,I%F,_\P;1E#:SIGK+6NI?RD\IB5+3O*P\A(]QDO!:-$1+
M(\JR):=;03)-9$UVCK7;+G:\0ZS2[E3[B&%&T^A\I,'2-JVIFAE5BII[AO/5
MR30:Q/05==6E6PG,Z5_QFBQ;*9BLT9<77JY<**.C;>_AK/:"*6R<9SD3<JYE
MAVG"E_]]GJO:QDJ$%`F:!,Q&69`)]_/0[?K+@31T[#N&XS['7[OQP^6X_]]"
M6N$">7O[+8K5VI0HDS8?-P^YV&A84G>T8$ZXIL47?(WO^8PW@*_LU->GX05@
MJ3H9%@*4;S`P$32R:@]NG$C-)_+739:I!-0:__6ZT?T"4$%`*0G]:RD+(,(`
M*DUA&/,-W^!-#6,FT/N(GO<J,&``?YLR>"<W'OIPKZK60J%JJE7$J[&P\U8/
M/4>K>HLA4R.=<^TP`?`E#5\%Y[$$7':<;LKT1:!'FN>Q\-U=M[^&0;X[?&K3
M[Z&CQJA+[J!F#VK^[5)0]ZNL6C8Z#5;.>`=#\M$\-KCE*,')?-X^RM1&+4>%
M-@E>!T'-\U69O#W(+M(D(5@L]M)+.,$P6+97SWRU2,YW.N>(![*,C.^J^18-
M/(P"BD8@N5WJ(`;,";CL]JHW$4!H@WN/>PJ06-1Z"#(8T6IFF&3L"N8M_&T7
M9W%.=)@^QR'DX[N%(7Y,&!7IWA3SR:)9EF57+`MWOZ@TKY@XK(%[*8_;*KN9
M#`W/C=P+-JJR9*D6EG;G':@>K$4&HLR@$AH44I?A4)!;>QNKU*F-=Q$Z.N-.
M*6&Q6=QTGI0G0>=ECZW1NB8O2F_Z!?>DZN869GD:AWFQ6[#Z%*01L8;K]05.
MUS"F.Q4FCR1EF-DXV!KG._>F_S.1B1H$^6,M7K%WQ@3TOYQ'R7;DCSMEL5JR
MG2@<B7;9!J`!FV37@ES.%]4S11(%7L976DN-([TGB#ZLPPU'$46@%FPCL@MR
MWT)(U5B%'O!>(/Q)JV7X,)VI770.2-IKGL..N1DO_WKF]"/4W2JG1VV6.^00
M2Z:,;U),CZ6BD_U'LDB[3*J'35=A'C^S?:=3G)!?[,COKJL'976,SQ1'W:=M
M##"WL`M,#7G-#%E\LY>$HZ"2R&D[>\-V@NU`LGB;0/6>`C.)4BAPL@=4++JI
M4C\Z7$L&:M%`+=O<S?`;NU=T"R<)8P0;^R_W6%+7.J'%#O_I&WF&1+%Q\[K>
MP<LQ2$LY664->^Z)_);^3*OIP(X:8)SX%YRLVEW?QK%14%^8C75O$%<B@O8K
M;_1M-Z5P-W-@.X-;XALQBZJK)%IM<)K'_^0M1Q7BTR`9+1,8H&BC;JMFYM+=
M9=#`"CKR4_/H4.GL80R1TSRSNL#P>GU6%"B</@7IH]JNU`@AO1@X1-/"A"FP
MH]M&45FN$7*.3F=!*9RPDNY\Q01UP'&]!B4O<-H-A[W^""?M\UBE_9@>"OI7
M]P^(?1G5!"-0M)LE]&C).[4C0>/@Y.`8?18K)^E:"@GK,\C_*V21Q2F_SHI-
MA:H6+/(,+&SJ/!'Q8&O%E&609,/T93,4!P\Q<K]ZTD`6ZRMX$2@6#E>R!27?
MYGJDZHTU[V*D0QGT%<33'9GYDGS%#&RB#W;0,X7;`6D;=Y[YLY`A9U/XG&<N
MU@_9L'/UZ,]7>&0<BH%5,`6K3K#F=*1Z=\24*QU0-(E6B[@]=_+6C?H`&W>D
M3MWY"XZT,PE[9B[=:16&>)?DV4VP#QZ04M&W!#%#.+7H6FG'R!B`+>?@EP?U
M833H/)TZ\QF/(9>I\+GIQF<F9SG?;!'>0W@+61/(JWIU,,UOAN@:@JR?A15O
M2G>M+0>VG(*%$,758=]F*@EX!UUN3,<+@7+($4O>H&`.!.[N9C!J;8(@JR1J
MSNS&'%65E[EXJ\#6GD/#S]2?(=\;P2R-0?WX.Y\T=<QB;$Y5QF'!)C`R(S.3
M$)BRHZ]V<NL^/ARNEXF<@E@?X-3M4!D&UA;_![RLK2[]\F\56!6W:WI4NA@(
M-3=TF/^*_DPDF<5GIU7WJ3CO5$X.BA<-S>8X#]!57;DX6BRVW$+6+J\W`<%B
ML4<U[`8*5EU&A,NDN`XT6\F[,D>35J+(W'[)>UP*Y$M5J6$[&8\86I`LWB9D
M(D@EF'<E[S?!ONS6$/ZVBU-(Q"?"Y/L;@D).DAYZ+YX]W:(2,%2HZKT**,W`
M1L9_0[[^%/"FK=N",=_#*[DZ?:A1'5*LKUF_X6OUJ2S8LFX?G#$H.0/&FJ7Y
MYWTH>CB=SS>-.PG5,R3X7?/V<J=M\].ULVG:Q^G9942XB),@">=,\)4YFK02
M1>;V$_QU*9#G";ZNG8Q'#"U(%F\3,A&D$LR_!#_%(811=D%,IWX0H-DGFB0]
M_!>0_)']1BG9U^2@^1RX#C,;#[-S.7AHR)\@B(56+1ZU09V(/S:C^L5AC5HP
M4QF`^)A%N^<]73C4DLS8_;Q<U%ROJ]8T5,93^I:`SIJ]F\ZD95X722LG<=Z\
MR28%2L>JNU]3O@'0L[(FGE$W)6*^<MJ%Q8Q3G?#VS?19K4',8%`3Z,X]5XEM
MQ?R;J+K0&YV3#K3I,U*C,XWX;-(L?G0+MW7<>,)I?@_3S1E\R-_3UTM(?+U,
MWN,4WC\%R3WA"]^3//=)::[1Y:"%HQXS&_-3)0G/$6.R8M@&"+!.?DE$'S=D
MRP@(@L<40M?[R!/-`)M!8#F0-_VY%H'-B50(0*4`5`Q0RD'7CE020$4!3!;`
MA5G`3M-\.TQ.=A$L[CUORRV$AWWGMM)R=Y7,[R8YVT7R<?=HEJA`Y23+6?H?
M>A3V'"`:QGA?T7;)GDH,4*.KA;@*"SO^_8>H(/]'$)?%A7'"W9X>$;,?8"V;
M2U?7`AI/T?9"0$7""0#=V&$_"+S+)KL'Y:,3'B/H'N6*1+`TW9,H8/#]"_X^
MP5T>I+EXUM%EGD?@`3[&21+S-M/\FTL:9?T*P\`8Z7N&O:.STW1GM]TBEN('
MJ.R<>YFL<;KA';ETNB++DM3K#R-'W4*?'H$QAXZ>R9&86O%V>@BG"B365*G_
MH*$.O*H&UT!@.W_#$6)/,,OIJSXJ#M7\GN8-AYJ$A=<!"NI@2\B[O8'2H6$\
MI`9/M(E:BKSI4*2=IH3\TC:9\6XPBD/=AL$#5/1:W_42--OWKF(#2CZ>-,"7
MP`7+J\MR\_OK]#%(BO:!9+F8$1FBLJ'G#8&'QF#>Q+!880:H:MB?G<59B'"V
M2R'Y]%W\F,3K.*35EP=CNH>?\Q.D>'XROVQ:!C^WF.8G@?LGR+KI!0FO0;[;
M;39!NF>OT-<B@0Z7<^EGSDP7N\;^"S+3(MJ+PH.&]&751"4_>Y6F'`&HAP#J
M,;#OC%@V^(6.!+"AS)-CG@<I72/370G6YE(K9@X0T;*:7GIV7I%DK=`)+_Y^
MF<OH,HX&EM:2CYHO'*OD4BM=Q?"#AQ@S<SY^6Q@S_<T_*O>[3$@JLV/NIY*;
M2A!14NDH/3,JC7#(R/*.NW^M@U!<<WSMPJ;E0<'2RO(1@,*F:\4+G.;>,;@(
MXI3M1-;3CEX6/$)(*[8,TC0?V3L!<1G<Y<#!2@KS%8C2*0BGXD4_@=?\64[O
M-3V=S0L)8KIU6\-T3==M]=X?]&1/0QXUK*Q%RSL<O5+4;J`5E]7HFC7##A96
M:C[K:\F]%UJ]L,(A*&4,LE>?"X%-)I`(R]_9@W[1S?`F(,+=IT&2T3HES8N&
MX[0TZ_V&R1JN[./='1DW(++S)-Y+`X95-6@YVO<),3'8*Y$U:G^SA/JF/:[2
ME+[:X3Q+U\%2PA[-!OO9<1L/(2XC/;UI$//W#FF-#BM`?(0)W5$5]I`UPKXB
M8;TJ,14>9LO$:LZ\6DSDW0#4B^E!#V4\2=.6)PXIB;3F#E7*]DS7X@PB&G#0
M-F#O375P'M%1[6(P5(X_DP\'Z(HDWU?UZG2H/P<TX\AU'4V+K/K^M1H'*T<*
M7(3ZO@?WM4^%%.[.%C0QQ1,T:WDZX"+I)"KM;^H=_C6(F#WQXS;D1R+1HV8\
MK(EE^*XX/19*OV@Z;BF"1C&\LU&AO@&MA`$Y78)4`];QWHXO:SGP`1VCVJ]5
MZHD?]^L<C^K$<B2O39'=O*]>S"D6T*RW1/UR;=564B?3G\Q*[QGV:5SM/HL\
M]$COG`9JR@JP8;TO%_$B%`F1GC>:J)^D*K>HF#Q`?+JYZO7B8G^J$I#,6+<P
MCU/8/)O1W)V2)ZN[.)3E8'IE6"-*Y_B:LY?[4LKHX@DZMGUT383AHK#W1&Z(
M'Z653"?%&V]3C[&U>>B=C6JRLY"2ET^M%5S9H:G;CE]3X<:F]+Q`:,LC<"Z$
M\%964XX2;;=+E,LDQ!MX'WR>-NL,DM%]3JF/HNE'DP@?0!CY-XG(@(,55&9Y
MDNC@KS41#-,Q94T6`WIM4\[?2AP'9-B`3(1C^\H?]N6Y8^K)+HL3F&5G,`O3
M>%OD<(:N(FH0UP)-F8]Y-Q)8TPN`I40N/4H?6CQ9M4N"L7#(DCL0H:0)D1?7
MW*[BWW9Q%.?[B?/5,!TMV(9(6BBZBK-?LR-0,65'`C]ABLXI]8G4Z8:9%$Q8
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MZ,YW;)``2W?#:4<S!-O,2G(>*.FFUVD*HSBG/ZF5V`R0T2RIZ:5HXX*,P(PM
MAC@W0-FYK9D9AP<K*,U/*%`'"DSU0S#,VX]BPO0B3]-L0P/KD\R">E!(S#9J
M>EP`5*B%4E??"?5IIV<KG:3BZ0Y&YY]IC1[4R<:DR*COW0Y3M+*)+IQ1D)DD
MJ!<I6Z[M-4X!Y"ES]9@E?4QDQYX;S9^"'#P%SQ`D.`=[F(,'"!/P$",$(W>;
M\9(`8P6U^PEF:X%)^8&2H>X>_!QRHVZ1G666=_"1^L0MW.+4R.Z[)$&]AQ1D
M:%NXC,'9.EV>J>&$M73F.R:H`0>H6+K>O[N%&210TE7J&7R&"+-9NW!M+I2*
M!TF1TVRT,DK9QA8Z9\KR3X&MV[8X\HAA#?WYC0YJ`;-J`E-.2H4_S3,-55>M
MQ`LDUV79UR5;<L;/D%TP4'<I+?)ZX5"=DX4)BY[KOSKQZO;@%(2Q`?TN"\UR
MJA,N_#5ND5W7%8F5$/SVS9Q>6]5'3\@7^VE,*]FVGA5Z5RLOD0P.:\=#A:.V
MKMTME,(G&.T0/:1KO2I`:S]".FG':)?#Z#YX0'KEN-HL]&*;'C<;3PM63^4P
MSCQ1Y+P]>LUBJ@%@0ZI?'MCE9%;(P,ZB#]_,X-BO!.R9+"X]?47FU8@*0V;7
M.QCN4O8F]/GG$.TB&%T0\Z"3\JY\],?(ZS,VN$\T&5."V`L=Q*)N<$[3H`"A
M/3<@FA$Q_EG156%#$B:6&?L118P;5V>`,8O=BS*DCK`D"@AJ"4$I(J`R`D'(
MGECFSY,09L]"K9V"SI->+.@H5.\0U.KQIX.#3X=S_\4NWZ7P?9S$F]WFEAX;
MHK+ES@5.KXG,[%SPBKXWGYG(^2<QG!B8)_"V\-01$P84T@#&M&IWY,?<;<(X
M.J?KR4`LW1`Z)N66/7"IZOY71"Y0"<:M)7.U=)#N*O8@=A73Z5LRE9/=IFF=
M3!WV3'MHM4SSHDF*(6/1::<W@(_E5BMUJ#GHKK?Z%*016Z#QW>V,/K7&&XEE
MV6[#?V=BIC7#>6*D-2&$A8Y>Q1V!"/P,X\<G^L/JF<361PA^HFUIP1GY(Q`>
MPMOZM35GU*@Z9VASN+T8`^J8LSLZ50(F7W'GN)`05"("04;W&W_=YWZK,(^?
MXWQO-@;)<#!F*N/,K"[`1?#9(IS_@EM&(8_CQRXF&L%(S)#5_^(`'XD!S1:H
MA1R^^CG?-5[M\B><QO^$T<<D@JD06-DY^\G^_#-,PSB#-VD<PEOZW)>5F&!"
M&BOF-%VPV6)-!JYW>9:3B$/7B&SWCTM%#=#G:&/0%!4BDRED7[39J42\XARJ
M%AHPJ9OS(2_?.=F7MDEO1Q/9`1/>>91\:.-P"\FR,0[)$H&-@C5[;OSF8Q*3
MQ:7IG,FP'"9,U*A(5F/B[=U'$!1L/0I[=FRK/^!9`.R%VE%?D#M\F0+4HI59
M/>MTW_HED]BC#+!L87X'TV<2;'L29\1"%#N4OH4A?DQH#+^!:8SYIMK4<B_3
M0DRM$3(KC_F0]@$GK^CE_"-NC1VESF41NQ]1SI:5==>4V4#O)5I45UU:^:)!
M(>C`(K82EGZO%A=P>8O3!Y>1;;V&-,S"JD+W-L@A%30)8Q0ST8W4JFKPF6I-
MRBQMEG^#\O6+54[FNH==SN:T'),U9\KK5VE8*,\HL=L',HS81W?8T01EH;;0
M%3Q*48!@'%0:T!3'?=9S!M>07F,G`JZR#++'<J_BX(%(2/=?380%1183K4")
MFX5\!.:@%(&ASH7PP]'UP.[T<0TU+P_8#L_NP)8M;P1)U)VZIT<'S3*"9%\T
M,17;O5+2NP"IE(NH4E1O]B!-W$H3CX([>"C;XVX%`=RUX5#'$.NIL[=:8]BX
MB.T6NT+7Z[N8)*[K.*35GH>O*U"COHH3>)G#C51K2B-LM,U0DZ-5VZ3'#5F]
M!Y?58AUTG2&".3?:J;:!#2(RBWG;M>K9C/EW&YYL`)-,5[=;DD.PF\T5.=(T
MK1&N50FB]+Q]0\7IK*/T?/#(QKBM/LNU"G_;Q5G,MLH^QTJ-HGM)3'J;J47-
MPJL'Y3-,`B<?7M'J0Z+CK:Q.'?FG==2O</`+9>/.U.F/*81G>!/$R52C;Q$S
M!D2#[CR.<`1*KKZY1#=B(\[1H4&?T1ERF)(?^(5SU-P)N$[CQS@)T'NX>8"I
MC.5W?DT])6E2L))8EBS<I8H]VL4#.O!#DV)<*.GKYE\VY$--T<`OG+ANRUIB
M-!$U'$4O./B>1A_3)@DK?E#Q<-@SMD?#>$@-GFBST0:V9*#=_]6&A*@EW$1W
M."4?(:L2=)_&`<I.]C=/009E5P-C%#06KWW$[.Q&%-Q`SMB!ASU@#!WN-XS"
M@>4TY9WJ&WL#I=XY+UJCRKAIK_KMBHZ&I99;SZCXG_S29)R&(4,PF>HNTPL/
M5Q]RVO(0@-E]T<)"J=\;)ZV1&(U[\A'X'S!(\XL@1K2!@5JN.$Q$W2"&Z%EQ
M2:[)G'($3Y0E6'.>[GQ2"A@LK3`?06B\LL(0>-?4/OC#?US\D8=)>FKR$TS"
M(,6ZGFI_0$@<"^,$&"M0\)+-7<WL!1+6*'\ZI8V_TEV67^R22'7;NY>$ULY2
M#S7SQL09`<H),%:`\G*YRS>&!9;4DG]Z1T,JGW/KNV.4'X*-QK;W""%3$-0T
MYW*`(T!Y>N8&'1@-.T-;;[[B,>P8E-O$U.T$9CE+!A6SM8/OJ><&+1)6<C+*
M@\_][I*P/A7C(3UXHL[&\=?YW3U?..@F3U9$+,^`*-*,^,3-O9_./YS?7YZN
M+G3<HOO+ZF!VT;'B(`6C5ZL+UVXRJ'<\JA>?="QZC:#@2;YC3]K"@7X"Y^`#
M^?_WX!*<@A6X,.)-?+WT"9],WAGHH:&[)NTD9W-?X!,&#W[M"PRC@F75Y2$"
MAYL"A!LX:2ZDIVT!6)0>C0@^[P[`W>XABZ,X2/=W`;LESV[!*^X!#!#1NYO2
M1\]"YP;"H&IEX_0RT2@06%I!/BJ],/N:"V"JORZ[",VX#2",CZZQKM?W:9!D
MM&D'3M3W`F2HZ0$R2O@ENX,\1EA=95[C@00H*O=@FP'D7P+/B7L#M_`QS@CV
M,#J+4QCFU^LU3./D43%]&R.CGC\,4[22Q-4L0<1X$A_@3-UE<9+X8`6M^8E%
M\R73"@C.$)0<=?.Y.4:`QH2?/Z>#O^WHRZ;/]%$),BZ=C*Z3A'9JT4'-1A^N
MDA%@G`!EY3JK&X("2RK)/[6C`8W/FLP=#E(CA^LG8DKSUC*V!9C\0,(VK"@?
ME3]L^'(IF173ET_<1@B8T+JM!*&M=H\L_3`QD]"-;[KNL^Z^!$8V#?.A>8"!
MN[A%!Q(J&&"2+5HAR"]=S-7@I,L.3LKN)B)W\(>"_Q]'WK/Q<)"H:WS7K?$5
MG`=&-]<5U*JQ%WW]Y'HM_.589493I6SJ^N,`$_,VRQZ((:8:$FP19$"2?SV4
MUR3)KQ_BA`/\*<Z?P(?=,T2=-9$.;[#*`#Y\G754YXL!MRQRZ+KH6G>\8[#3
M%U0%_J[<]4`3J\<40KJC-M5=!RF;0G2`B<6+Y3V.>02BPJ&#4@K/?%4&[6%?
M'57X8I`=\M4.#P4U?[UM^@\[FG>3A('8#7U*3GIC_O"+ZMN_;1I6-M\Y$]99
MKF#C;M.]5]MX4".^:+;1,/-`K;J9JQU944-,FIGVB*GG)T7BRU[\N,?G">&)
MM'VGF]ATU+OHSN1C+'ND*X,M>Q,EQP`R]O[XWB""??[8KU&?T1KVVSZH3/FS
MO7'U^C@HUZ7\19Y[#,X[AV0EG[V%SS#90:4#L?H[6IE*^74;)Z:<LLN4\4"A
MN&_D'B@/#>O-BL7=I#B$,,HNB-HNLVP7$)5>I[R@Y)SDBOE>Q19EJ&DI>IRP
M&0B>8?J`A<?HDPBD04S??\B?4KQ[?`)948=$C(]\.(_I3N,V+5M$TU:9)"9N
M2'J=N2Y44H`6JVO::Q@+3RK9`<H/E`S!=5I5^'&FNMT@,%EI/9[$$7NJC;VZ
M38!G55'2^=PP$9UV!/WT+#6$8`S!0QP1/Z"OIO#]O\H%7':&D``(2RM.M1_Q
M!YRS0PJJIPN<GD$49_2<HGCP*SN#69C&[/D_^?1?A:9&7BE/WLYB0.`/UC@%
M42D!:SS,'U*,:B$<+@DTP,6Z6E:UO)_2((3\*2(2`I_C"$;W^#V$^2FF)V4[
M&%UQCG?T5=0@C:3M3X.RQ@4I529V;JA1*>@3]_1!IVTA!UWB;(@D=/KGHH#2
M0+-"&(<WV;1AQ],T[^,T):Y$WL=)O-EM0#@V5^GWT;$]G/+0M!@!X50\$$N2
M&,ZLOS+>R\C??-%O/.PO9F"H8TR$,:@X5^]H9D!@KGT_TTVP[-X7>F0Q,PKV
M61TQ'_;@P^KN;/5_)&+GPI100,UGBN+IOY(_W3FB$H!*!%#(`.YZ1FNG%(]&
MA2>,(@(87^W0_04"'OO#W1;%4F\)*9'3*QT;IVQGCXK\BT=_D%$F3NOV%,#"
M&JKS&YC"G41^Q0(=E#CQ*T=W73A9\9Y3BEF2\[<;;^/LU],41G%.?[J(DR`)
MXP!=)EF>LLSQ??"9YAGGG[<XVZ52;\L88J0%["2>-@K>!'%8Q5O(Y`$I$<BE
M5YHQ`FQ4\4L%''5@#:@`@,O"?ZZD`;4XH)`'E`+-$@#*$ZGB`5>20<#'C6RU
M@P01+1Q[Z=G,[;*"ATM/'$<#2VO)1\T?G$I6?,!=C_JM6/W/,'Y\RF&T(K-N
M\`C+4?-5R_4N9_DZ7?`&61RJ>((B82V,E'B8]YB2/0@X_W+;LK75`'`MB4N7
MTH,:3U+W4F!%+40+UJ#VSV(=+[!G]>RA.R\]B]&._.Y`+:OHOW993D/(9'^5
M86$.XG%N$\'^@8.=P,>`\"F\^`IFV8^@%.C5H2_ODF>84:/PY;AWJC6,N;0L
M#@M"7L[-"S&Z?+V6Q/VT3(^W861V1F[0-!^U!?*&YF&<!ZCPX'OZ,_C4X\$[
M6M,1)ZR`;<<2K`3F`.$LHT<^_%,@R/,T?F#@Y[CAZ,7VA'?^/F0,LG/V`2H+
M`%YZIN:<NR=IA=&=!VE"C":[@2DCS.BMDJB(%3:*D1@+5F`4%0&I::UZ12QW
M,-RE[`W[R^0]3J!4N5??-]7/`0^(6#G*O7^*,Y#"XGGX#.1/$"3"PK:4@?PA
MR`'U_*_BY!7YU*L-'UC`IGSZ-4CT7_Q(".*4/WW,MO[='?SV@XB']=Q;6&#H
M["%\@M&.%G>MDCQF9AL_PUJ6\\\AVD4PHN59IRP0,\"NUVWWDGZJVQ9GO8US
MHT)8Z%A0R,<N!@D2@EI$4,K(2^@$*5GU7"$G/?OB`7;H2>C9#E'L6!VV"^R+
ML3`TNW%9B5T3%7JR[R:@VN[*JAA:-F=1(@O/0G9;GLOP-(=AX1GA>IE&A`;M
M1SERG>Q[@^",'<FZE:;WT,PX+8.&8?.YF1Y<W+\W(XW6J+<;>75F'F1&_$[E
MY1F#]5/7K$1/HXW9X9?U2W!$.N;=H"BTN>XM1IRU!JI3X>V*IT.%^*1<L9JI
M4.N\S59_#M(TT&F^U_JBWO:?2,/"(2LG[W3_M5.]>%`%OJ@2-;0XKUE.3/VN
MRD9S,ZZB!)XNLMTK>\T&C:W,KX9[[2UD<75H7.964BT47X`A&5XCF>C7:.D\
MH7D2(XQ1/";P3&9T(.QE`MYW"6IY[[_SK.QDSV\MG:(@RR9L[TL3G[B_*LG'
M[B9]U\8".Q4\V9>7P)@H?NW"J^+?N=&NI/\E8=VQ73X59DNM:;(\C4-:CT-7
M-.JKBAX"FGU7.FB9][V/98U76O$KBC=W2>RV$GH8#BRE*M]47[A"S:%\@&O.
MY4FG\VLM.L8H::E_F*B%;:&^6.1+QB^)%U93H;?8H`FP^+B<7VUH]_89U_(E
M0Q?K+\[;P2I^W5Z!X:XLXPAP`1>\@&^9D[G5NPC=TDW'\+J]VVCDR@\[KAUF
MK4<'I`L2I6BIERA*D+52M%C?@8QKQNYJ#%60PJJJ4VUP=!'$Z=\"M(-G<4:;
MNNR(OE=1Q/I:!TC;@-2H:IB2"@,[1D4D`$P$(,@`_E!+`20?%IG'Z+1PQOKJ
MUC;$59;!/#N!^2<(D_^(84J&^+2_@L\09>QEU#69K^63G0G$)YBE`A][UOG,
MK#-@HH`'+@MX*H4!B$D#\E(<$#!Y'`;&*29P8*K*$%@NX6X)MDJBJYA(C%BJ
M\!X&U*FBZ^26I@_T/5'R@0\X2<M_LL=]E+=W#3+5RM6,\3>?Z@L!G`O'WL82
MQ`.E?.`Z`96$[%.BC,6S2QYL%)NW,&P-R9=@36A.0[(;DT[VA8QT#KE(V;.`
MX5ZUQ%J*W#3D^RE;:'98<P(5*R\<7`*N+M<=4Y[?T!RZV\D>=&(T9R5P-?RN
MP:L7`TN1FX93/V6;D^Q1-U1>N),$=%WN-*9(OV$Z=*<>7YJS1KAK]%DU9:H?
ME<K1,P94F[35K%7D>U3G%;YY5"]\(R[5K4O/H1ITJDQ(_F8]B16FZ.K'YHIX
M0J8W2'%J1C%`W.YD5?'SPIWD<.M.^495Z#U&G8F?\*^*+V",76=_V:%"S.2!
M`X3-A<4^'E:G,K^\30G+L5EL6)]+P6UD7NMT1C>)XV6RW>49"P3'$_+%+C+3
MP#JD:-ZE>/P[>(76B1<-`-'E,WWJ\5/IA_[`.?$9Z-A1>B>,]JT9VW]KW/;?
MVE\9'15@'!7YP%O?_*$-SH@_O+7B#T:!&/:'M^[]X9T9?WAGW!_>S>\/[WSS
MAS8X(_[PSHH_&`5BV!_>.5O^LP,J=N5APHJ_363J`K))ST)1)Z7/+WIX8?F]
M,'0OX+O4XZ/*.Y?I@NZ=K,OYB6S'V3`[;/V8X(<,IL_TQ)4Y*/DS`3)&,:NC
M$?4T80EO7`83A^?&Q'GY_FK+AOJK*PR#\P+MI;?VHKO6@I=6B++R"1DTI3V(
M6'-N8;`;Q>^#]%>8T^>R,_6,M8^"%O[=Q"Q465`^@#,"C)-+IQ\!`<OIQSN%
MHSY=.\I$)Q1P7>G<(#3,V%GUVI6]^XFFR]BN_+C5:,?D#!=&7AFX,^FA>?5.
MTE8MRZNK2`T/ZWB++0-_D+PFXM6PT-"("HX#X['SPF20/1&3H?^A+?B>`]0X
M%ZNOKJA,'`I$]1X2E*5OX95(PA/`FBE]33BK'XMFG7C`AN<*:]=YF3JX6%O)
M2P`2"1C2.,E^$!B+1[(U;^VX,O]U.XG`J7[5SM.Q'LZ3XI7"PV&:'.7L-]5$
M8"L&-."T+JJMZRML[3MKRQMT;R94R-"N82*3:*4:J5OAAEI0,*$F3ID#1/3N
M^_?1L[0&XC97&:33'@ZC>&!I/?FH>R1L^$I.65;L7EB+3#3^,4I:*`P3M>H&
MJ&;MTA$D`<)J.O,6C,(OQ"6R.^>HV_G=I'@+TWQ_0[24DZR3YIM;FHQ-:#LY
M1G-B!\)A\G:;3):\`6/.TO2*O0_WA96![>PG*:/A!8"(S.!GQ0-[QW^ROR<#
M5BWED"*G!9D$9?,N5S(]*G`*1)R.`&7LTLM4P,,:JO0;*-3$J-.53O8,I#GK
M0_HC"A%$O=1#BIQ9H&K*OWO4`'@R'M56I=]`R7@4=Z<YBQ=X<SN85C*H5R_T
MDM#;C^VF9F$;O6!4J]_I/OD(#EA20_[I'/6I>^:NQOH&;L:PK1LT^8\?MBQA
MP^9LUZ;-.C+5BUV:Q/DNA61RN(@_TY\TBLJ&J.@5*O02M+"35?)B.4S)S6D]
MRC@H6%Y77@*`VKI?";J?UP7N\#K_%+"1EC^>T?,5S-SQ%&>YAD<H$-7;^)"E
M;S&9*1D[W9]2!@]K*W$)0)5;5`4KYE;5/P3&@'&>U]&N8)#!)XRBR\TVQ<_\
M7KBZ:PV2T=NN[Z=HX_YUP0R(W)P>G$C@@A6TY2<&:$C]\SI"[S[`E4[=L@PU
ML]L55_8JC(?WTZ_\J!=6P$]F;^G*0&7O7%C)["S-_BI*[^`_9G"]0U?Q6NG@
M48J<691JRA8>%<KR>!/0!YXH?2_]I@,G&<=I:\UO3&1<A_/L!&I>SZF,IM3"
M,S0S*743-HM<%X\OTJ\&493QL'Y-+@4Q&:^KD:S\[_EP!VA>!_PIQ9D9CRLH
MF06,$;68_K6.$QD[+UVLB9.,3PFJ\Q83&:_IQ,1.R7$8[C8[1#WT#&Y3&/*;
MV.1G!.D/1*[5!J=Y_$_V^UX%J;B3.9YZ1;6&V$\TAQ^X.23PD4I2.*D@&X@$
MX9C3!H)43LNB3=L,M@7.DNVC5:,M&(8H%:C$8B%$%&RP@$[C#L=HD/P`3=U1
MP7F`NJ8M6$];"9PR!E&%+3S-#.$9I@^XFGO/AEP9P,];F&1S5Q/?0F9--P%1
M+KOM$H14FNQDW_B+?FFQ$H.)):H*O.P6'1?L`.,'1%%HG5WSKU[5(.N80V=!
MLC(42X,>64'=TEOW,KI1+6!6H:KY-+LL`_/.W`#+I6MJ8(?U5;@(G%`'1&/>
M-E]1LSAF]1KFKF]/!L56A;*73M)?>MRG$J_TVVG<\Q81/\5P??X9ANPE[>OU
M.@YAJE%(/$1&K["UGZ*%&AS*#%3<0,'.:56Q!#!805U^@H`&]3]O&<%E$N(-
MO,N)*[*37FKP=*FHF"D-DM%"88"B>5?@S$#%#93L7#J###1806%^PH!&$)@S
ML>D9K'J.,T+()!*V,I\EN41_0B2A-%_!&'>,.5.F6YA!VC=FE41"!>@YW]!3
M3YVDR&EFK:.4;2P3.%/P$UFCN2W$5`$*:ZC-;U!0"P]Z%"!6+!<LY\VQ>G8/
MKG0*-<=IF=S@N+)7I-F[M^%-A:8T;..[45<&JC/G@6ALYVG^PLR><1>>G%T0
MS,2=L9_C_$G\B@'GDF=E$EA9KA:ZY=%3R;[#.@\\4!GZ<0=54_9R81YU[U(<
M0.5I;CE3B<#@AFC+_VDO1.;5QV\+GV;=$4_Q9A/G[,H$;62*$]H)%B9A#-L]
MA&5\5YFD$GB*U,V`%.&0M1YE:3Z[*U>R9T?JH2C`:Q?^J0LCUE3HU^8L3"GI
M4B!FU*H,S^F+MZ?.E$M1B09M2+I41)*0V8AD[OQ_\79S4,2AH#Q?06G=HJX0
M8<VY19Y#53?^#`=-&(F=NK%RH^TGB!_38/L4AP%2/0X9(*)7!-1'S[Q-B1R<
M%FR-XH"E]>.CSLOBJFI?5V0SYZ'''7QLCU+]P&.`B)[R^^B]8(,?Q0%+Z\='
MG9<&S[FTS%WN**,G5?L99ODF3K)<I8BC[YOJ\_X!$2O9E\#%7:[5KVD\K`QO
MM"IZOL#BB&0<"*=!A'73)4ORH@-1>\\N_%MX*N2J(WO^?HU++FFU.R3KC^&T
MEWO-T9E\36SN44K!Y^AQL54*`UKJ'Z#SC*:&Y:T@E62LGX;>-;$><A8>9":<
MZ(,HF%7"@740EJ\2Y,&O,`$X`8BVWG%Z)W`,("RK.0_!0`(.[+8'<0#.I[IC
M-U.7KRR#D+99H@](IBE1"^^Q=$UD"*B7LA9,)#RDF^LU=5S9XX*I'#3[4NDP
ML]0V#)#?;-RV"IL$+C:CU\4!B4H,J0B@D`&(0H!*"L#%`%0.ZLBE)/.UZ#O_
MO(U37A-'HL>QFFMV?5^_(5R+E"VW@I3-'D2$A_-&?'W:;W?@ZU2-9YI&HI)K
M#H"QF,6@6\Y]L:,-9M_'2;S9;6Z"/?.]LQT\W:6I8H,(5<I:T*@Q,>\>1*O?
MNO0(3?CP-`TN!JK"OP[F#LX<%-Q!R1X0_J`0P"?ONTSN/^&_PR!5.JC1(&X3
MV)J/%3?\;@%NV(&CNB>V];@DS'3\\3(!1`C`I/#)*2VXHETPS;=UX<64:P[>
MI@"/[6*`;<%W`5XYP1?M>Z`SOW/A:K?UQ8D/<$JRV29D`J$F31N7!I+<A\)D
M.4SZ?:5+3[[JO\\O;L7[-!\.FU3)G=VN'E/(=B_H5D6<L*7=!YS'(;R!:8PC
MZ:/<<4+J9Y!C-*T<]%9,V49=P14DC"W8,K[N#H"EX<)**O05FL9Y&/D6*U9(
MR\ME0874)UH:?[;[%8*/2?Q,OA331PU[\=,]*)MGT.4A0#4Z@1O@[,!-YSCD
M7)[&C#"'T?L8P2S'"2RGU(];G*RV]$&%`$G[O20U=0N3(FPE`I2<2;I8L*Y2
M11"1;'^WI<WU"@G<Q0(U'+&Z6E5+ME?$R9Y@:M:^U(AJ!#(%^G;F&RX`2ZNZ
MK<XGH]/"&&OK6M4$R\4)))@0#3_2MGUX'Z!\?_V`XD>N<EG3DR.F;G(R=*V8
M6KF&VE:<Z6E_RGD#7#%W9UY*^&%E?2J;4_#9H#E)$=,P)PFZ=LR),_;9G%3P
MP\KZ5#6G?I(PNL<D"GY,(IA>YMEU&C^2C`]=D5R/+.^J5%#:U@QP4C?$R4RM
M6.G-D'62Z3;'=)X%.RH;B$F*APOI`.+BU>L,=X9LSG*P6;!,3-"T@*(4@M8<
M/@7Y:9"<P)/=_@Q_FC9?C](V,WV/L)ES-J>BU);.BO>(-"`,$O``P0/>/3Z1
MC)((Y=<L+VL$0Y.^%`HF<@!C%JM#VTR&X,1BNQ.&)5CL!",8RBNL6&P1S@L:
M9SO5K=S>[ZM;7@\I*]95\`(/NSVS%K9L=KUA.X8%EE&4UYMGC>?45';.='=A
M9QP;:@VK8ED?0U*F8#5Q2/-O0C7*_D=WH`RB-_]047.4UL&<;WM'!%%V;\?_
M4:'F@(3U&[T240SH>OJ`9MLV:<`DN6?B_ZA0<T"V8/)D4Z'UP&&T"W.0!22`
M`$3;6V8EA`L?9@'J()@D=-YC&C,!DPE<TIL/Y9Y)(1:HY#(9;V99LT@$5>D%
MR^(&/QQ[V;@K@V"W-.FXB1C@!`(B"#B;,FA7JU2)^&P?<5>#'P[C=A&WNCIL
MU*WU+PV]E!TUQ2[US&J-)Y5^_+:+\_T%B=1)&">/]+KWST'*>F;KMGY4(:FQ
MCI6F;J<2A+$'ZXH_NXG_J9#`8>F'.HY84Z.JFT\?8$[RHQ#"B+54O<RR'>%$
MXMA-&C_3"],H"-7.LA0HJAN8-'$K]G7_!,D<DCV!.%DC_`D$68;IZYTDQ6(E
M;63!2E_PW"4Y2&$(XV?R!VH&@)`@*/Y;L,79GTGN&<3L,BJ9H,)@&]."]^<X
M`%L^!/)GMO`E,U8"MCN2Q(5@6PZ+O6_*9K:BL6QEZR#$F4L;5S<DK(>I\BEN
MB\K=[B$+TWA;WKN4/Z0=):1Q!CM"TXH94\+4ADJ#JZP+9`)[+\Y19;'#2OKL
M-2%#+>*J-TCO<AS^>K(_12123'@QMX/,Q,=1#RC:??V6L:./,#*&?CUPVX]1
MYS.V/9KS$P^D"X45OV@[I_H[.'T4M+3?3<S"_M/ES;G8&MZEV8]`@.6TXYVZ
MRWVP8D*K>,S[<,U]G%-?ODRB^#F.=NI]<'L(:*F[DY:%QR\H&YI,U(Q<VO<P
M!%A*/;ZI&XF:OA8U/6??VX,!5B]NT-<NGN+M/3YGJQSU;KC*I,T@-,S%TA-.
M!2]:QLBY>>4MDI@.^9&,5I>#WX#OU>^[E)C>EYA.;-![%J<P).Y"NSM.>WI9
MB9SZZE6.LITU;,&:/ZW`G@:&U=/`O"&BP\:_B@AB#7WZC988]QI0*;RB[=N8
M4&LXJ_[A3&DZ7,:[4YP\PS2/R?+LAD0+F*8P8HLWDV,B'!YPO62'*3TS6@&!
M-ZB8\Z7C3$WVPUW*6IE6.]_"`DKY>0D):IHMX,<(6]A6J7B"BJDOJTL%V+"Z
M%KV&",FA,^]+%4-#OR=#U7FX0I:F!;1J\K^[U2"0TL[5UN@"0)-U-,IW8AY^
MPP[?R)1.IL7D43'K[OZRQ@E1!QT[%^_X42,N.#D\]!E2.QY5BT\J;FP#<_V6
M;+0K#ZT)BSKEG/GM;UK!I)K?"5_2>VJV_+Z%/1]*VNF;P`<*Q;T#]T%Y2-#;
MG,D28ZA^(-7XFK[^;,4</\RO_Y#I8/!^J+!IA'/&OZ*25]T06U_4TF.#AK7J
M;)?FV*U>/*@"7U2)&EJ<V2QYN;&&63:_J*=+D8:U$G*G9MFI7CRH`E]4B1I:
MG-<L?X;QXU,.H]4S3`.=Z;N'@)9N.VG9>(6/LP$%'Y=V.ZQ_+*4;WW2-NM4\
MKV&SVJRB*NSJX#5W"</N(:"E[$Y:-AJ&TGJTJD)M[#W`N6Q\&`HLI2;?U(ZT
M-.[C!9!&-X/!VQ]&GV"<>YBH,<*:+SN#+#F[>H.Q,-1"C.OTED;.#SL:+8GY
M5ONTIP%",#K9E^(6']0):_JLIGBB+E<+.4")>/`<Q(@6\+*V:(3D$WTH(8BB
MF.[I$E,(\6:#DPQD3P%AZD$<G6PEAQ%W&B[+M8AV%"^X@.L4,#:`"\0"?'U:
MPF6B!>"5%95?F.<M%'/7S50I:I8MSW?=K-'EY?$QA?3Z/GA,,0%X6\CAMGI<
M]8*7CA:]AZD\*"E8`LH3E$RINQW4H>OF&3-?=Q3MC["N;(Y?8HS+$79='5O(
M"%$]N`GP68F+/+DKY:"7U912H\ZO:[E2!R5KIZ%%1EL=-IXB3!*8,\>/@@Y!
M@244Y9?:FXN'RM`9!^U3Z%GNK38*=#JOIO:^'^O/(*K9HGTWJ3&B+I.7JU+I
MS$7//\,TC#.Z-*C?@%7L*ZE.6+WT0I6'E<H7GD&36:W8*P`X!2G+H&$M"7^P
MF+_JXKI+I3;D>)+:56_>#W&!Q!_H-']'%Z9B&QTZ`Y"9X"2.BD^<LB4L^YS4
MA&B-M5GKUI/"C?U#FN_QQ(]M)+3:+85<8O`01_4'^<Y#L?'@IZM,M$$99YJ"
MLKJ[-4@J];;H_*Z.P1^0L=K!XL#R7!I:O_;QF'HL-Z10W*XZ#\*GYF<M[M%V
M,9MC3^Z0K[5]6A(+BT-$-J<N:!=VP!+T]V'[-+]DU*?NQ5*Y#KXTSRT1-N/0
M52'D48G,4NQW*CX_0$3O2D$?/1L;$<6I"<]<UB3W*5,7=BJZ2^+.S:W9+G^,
MXH.E]>8C%H7G<"Z`LP&,#VV="-CO=1?X;E:7G2=UGV`*&\M)UIV]W%(]XJO+
M/=C#0/LNK)O1CD8^00)0BR#7%]-B^M-*T-M'=,>34YYQ!N8FO#%>]E(;'C7)
M>I"O]+S+;:1A'LMGY%2\-$AEO1<6(;G^B'!L?&PC8KG<'VF6I75L;M!&GV*6
M\-(4H&$6C'VK'W6I.R)J_4$N+?^\]OF#M8V&8>BGG#98$QDUI:V5K7^FT'LJ
M6Y@:M7GIO24Y8@9[`0MT%]@&.(6/<4;,D'PI8JU&JBNY"VS^VV4OHWU_#_!3
M?E&M4B%OUJ+=\G><D,8;:R,TK6Z8]AN7=[U_I4'$2HKU.<ZT7JT1:F]H2!'K
M;TPD'_.-2ZKJILP+I@QI'M^R7)8PSR`*3&IF@',S59;0[%E5[K)%)_NB199T
M#!XGI--V?9BFG08;52,MOK-8UFM'X&'OOF6=-%Y828>^8M,,M8T.9^!&!&9B
M@[IY1H/&!G+2.Q`=;R[:P\'H,KG'.DL"67)3K:>/\BS^'9;,R3J!WL\0YVQ?
M_'P4R6YO']:K[=/LOL:(XDD%?1J4?S"CX*ALYNJ0U]OW4^=D89-#/.SBU3HL
MTR1FRXXHPHHWS3LA/:?D-4`L"ZW;1&Z;UN]T(WB"@6`#\"S+&,KMH_Z6GZ!Y
M.,=>W:VEF.G2D*B2J_BW71SQHRSV!YB$2N?54N0T[Z&,4K:9P'`W1C7;PB\I
M7S].:520Q!IZ]1NUGD1-X`AJEF9R3KLY4./*$*]Q*:M$,WY12#XI6L)X>P"L
MF(++A/:!']K,L)@4T7A<M`S@,;N22^T\>YS8A#EN@.X\-MFH[RERG;B=Z7B7
MS\A@>Y"]C.K:9QP;F0G#I>I5460D-4?-9:UPK,I)-G8_[Y]@PI.>51)=[_(L
M#Y(H3AZOXDV<7R<G,(%D31T'Z/I30B1\BK?R*V#SG#46RZ:%L+.N;EPVR#$]
M*$O&W#HGLI>^3=N`X%I\DAX1^0&F;T&7(P"X'(+#E;DU8\1V\7XQAM?(J6>U
M.NW4QT]%H@,=EA4B6?NH!U`9RZ4E;6<CB`F8G.`Z`;6DX+I/9W(A_S+)TSC)
MXO!O`=H1K9T32*,(1C6'>KZY@$&^DZN$UJ>M[CT:;*P$YDH.\$P%8?M#A2BB
MD0MYU9I+XR[&3D$?3U7_@I`6(Z$VS+I!S=FH47O`3``:L4H1Q$`DY*47W0.>
M<$TVJTNEZ1GL>9"B&&;RK["K$35TM;6'_KR75C/QIC8]AP>PD,.S6ZAC$`_>
M+QU4M9&+VBT.5[1=A%G[*TG:L3Y.W;7M(2:%WY;7@E;%[D0EN[C$*B2+2AM<
MH[3,%?(+9&UN;U5]+H4UAW>W,;K@&KMX<:`_CZ$I=ZQZZ^:OA\'Q<^8][-*K
M-.TN9Z!C\&7B!3964GL^PQA-3F2:4/)9;"F#5(?QJG-\=NY;AT\PVJ%RO^:$
MEF>=XLT6)AD3:$5E?615I-G)OO[,3;"GOUL1L*)[>IE29;XSR%3O#K$I_A8*
M>`O1ZCM,C#,0Q0.B?+263OQ@(2-@0H)?F)A..Y:;MS!L#<F78$UH3D.R4UU#
M=/XAV"@_O-;\GE[EA4#"PB8^H0XH>:<5+UW:Q4,J\$23J*7$.=]C*T>C_D1M
M^YN3E&GKN5FO#+/_]=@N-7BCST/SG/3:Z_TG?/^$=QE9G:V2Z/XI3G,($TI=
M\>77<4+J&UYC-.W<<_V$05YP9<>9><&7MGUV\B*R&E!827F^@B*&#6*U[V@'
MV4[E^R-RX9G4?DIN[&BWY,>&,.^+2CSI(R-2S7%:7]2*?@T:%IX*8`DCI>]R
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M8*>"\CX$S,RNB^5Q]6V^=`]IHO]?YT]PHLL/D5`WH7YJ5AR;L6LDDVQOU)UG
M2P"")57EG_)%E^6:-^:BMD5'@U+/FU.>;[8([Z'>(E""B-[S=WWT+.S?%*Q&
MUR*SO3<X"@B65I2/RD<#>I_7]&]AEJ=QF!>]`CXF<9[=WGU4-_\10EHH#-(T
M[P8UNP(0QA#\@;#,_NC2'>1`PDJ*\Q40-(C%+;@#'^?UD-'=U;[-U:LX@9<Y
MW"B=KIG@9F<3>92QA:T/B7WCD:(Q*AU@XKDM031G1"KG$)*8+=I@%,X8]&W%
MK\A2/>?%+I"O=OD33N-_0JF7;"TRG]>,^N2P%(8R0/X_3%GK>IR"]:[O0J_W
M(674>DQ$F&%T7I*E&(L_PHMXW.!J2?T.1WS=D@E7N?A09@E'_<SG-;(^.>;H
MX"4T"-DE$?E;49#AJBK1OD69"%'#B+TDZS$6H@HQ&RUIN*`S]?2K&OF<\@=B
M>*2\+6;F"YQ>L'FY?$9!)0)I$-?L%:?(YTM):/31Q9.UNR0D"V]N](PJ^)>9
M0RD!("(`+D/UM,C4QH#_@1'U>T)9V!S-&F^T21]U*5*=TE=-@H&5`['W<1)O
M=INZLQGM.EPV`:..=WS\YG^"=1"G8!.DO\*\;"J4L#=N'ME%77KGV(<^?"K8
M'_;8DX;`<N,,[5F:_<_?8):34?#G6I6ZR)KE.V^"TB&"I5*GXM@X`P%E>02>
M.5/J-AWOXRXBG1VR&Q.9;"\X+\1&C.6O_'\+$8L7E\<ZY1J,.0_C2GUH*[7]
M2+5RP#'#5-^23/"?*=3473Z<AQFCIM*.,>8@>0EF(4:7![G@\M`16]P\Y:ZM
MR_(IK.:3R>Q-+IZPS1)H)*28U\1&!;+=6!F6#TE7;VN+Q72+C$ORIF8B4$DB
M^"+-RE`H*Z4]?*.<OZ+'19[>HGNV-7F/NSUQ_FP9GC42@J87+FBDZ&"0!6NV
M%236F66M-^N7=L;T,Z2MRV"T>H8I&:?R!M3L(KD^41B2SKR;E=Q`P:YVJ9MR
M8NLX37`^O\UHFW;.L,91?OEV:/6\Z\"PEQ1&^?D`?USB4G='P1SC>4VQ2P8+
M]S#*/07:(XBRS?@F_F$5QR*"VZ#%F`AA_:B\%.LP%HZ*T[WB;9C+^3<:=/1Z
M$<0I>S9B1<3><.=8)=%[F#_A""/\N%\]9'D:A.H[#K;%F=<`Y26S<`,HR^--
M0&>U3^7T%A336WT"R4\I^?&D%T^GSFF3)D*=*L(OV_Z,A44J>/$RC2`ZN^,K
M"`]^*<6?L;I;9Z^H"X?SSUM(+\/<PW2C?N9L28IYM]!&!;(0%0OR@/QRXSS0
MV;4E$UNODA"]2+LQM/7:$\LJ2V02+R_A*^7_&T:$#(KS_2U)*)PE?'WBN)]P
MNR6S&-J>*T;.`]Q,QF8KDQN"[F4;ENU,KC+66GA`I5]>'+R-LU\O4@@O$^*,
M,,N=1L%N8=R;:I=<%F[[$RZOUH0-B`L^(.VPJ<5&P4%3LQ4#^Z%[R69E._Y1
MR0$5'92R+S3\E8'\+'Z.(YA$7B2!36'<VVF77!83P*A@`_8Q1,L\HU`V-=LI
MX"%T+]FL9DO_2M$7$/V*4\"?Z.9Y5AXGM4Z^V1_I<WL57'/6K2B+YJ1N0%%*
M>W4LKU[R><A$:S58R:*%]Y=CF<8K6_@HZK/DP_(6]@G^*F@=GS4J(CV_(\^O
ME]WE09JW"CG$]@H/\#%.$OH37O?<2%O`//13BK-YNI(-L??`:YDD-CMT%%R/
MN!<MM`1(PH:LS0`"0B_+7NQ'<B;L/-&)EI7SJJ2S75K=_N3E2ET%[VHUAQK4
M]6Q%F=$LH:/BYC1XZ$.,IVMX47"6GLWN6A2U>ER`TC.+.K[NVQC+2"@N<+J&
M,6TL0FN$ZKN/V:Q5Q?+".)D\1N6::'`_<(-+X",MW>N/((4<D#]:&M(N,`@M
M.QF1MS^#J8DDGB_2UFRE+8+<K&)/D+R_POFE+#?/D])KNQ:;=*>3N#%M`[2@
MI68QCP4/",[?!K*#N1-O/)##WCT36+,Z*DV&F\L1.)@+EASR^PW+8(CO`>XE
M&9'Q$"[(.6<WR*GJI6V`8,0G2UX-BNFOG+:QE9?)B47*BF<OVCTS"5@>"ZOJ
M;,Q^_<+"G;)Y&HR":CA_`:9H/&9R\<N,MZCMQNS7$MUUW>2_]B]N'Q["C+01
M..JZHGT$3GP]INE]B5OF4-%>BPN38LW\A+FRA!9;701M&]UR&UW"X8\%RU29
MD$SC^V58H<*TE)FJ!_"QW<48+J7,_D561<G<F+62D`[BJQ\G9&Z,U&20U<#Y
MBS%(\Z&V&L32HNW4DPA?.K=-%-3/8Q[/0O.7>/0X=_<W`S;QI=JRF^-,U3#_
MLK=[ZD-0O<V>QIG7(F9(X<#$E[E06B37)V&>S6_CI[!+GNI4#=7.0:RGT]>L
M1FGUT/8EK#K&SX-\";53)?7TN,VK]M)U8!X\,'XQ@=J0]<]ZA.QI6/?!TIT=
M-[^$F>!@<_`>YP&Z3/(T3K(XG/VBM9P\+E.80=',QV[&A';=X5S*!R_7!Z]O
M+#HD*YFA^<19`M,7;G*V4N;&ACVWY4K\[MO15L+D^6:+\![".Y@^D]#<C<L'
MG/`$B(TD8]**?S_%6?X!YW^'^2T,\6,2_Q-&XM4HE3@YDT!:5CN+;.8CY<<D
MK3B!4#1>FLLF9%I.(0J*E'972%^&49?!<U[CQ$Z`?NF&6,3/4F)0B`QZ`VHE
M-H^;61$<&Y^AHI,/YH`(#VKIFW<AEQT_^<QP@=/B5_1S2CV[YY;,+T/N%-)\
M:'T?Y+N4-A+EBW^:?AX\?5#_J2OVOLP`.VR]<T3:`0/X8BQUUMA;I++T@4!Q
M)/,L]L,G&.T0O%YWX\)^FZUV^1-.J;`?DPB*;RC>$/RSDWUC#^:6IO7W=&=;
M:9EO61*]U995H2P\JUW(2]\,[;55+C2HI09,[$8.`)CD=%W6W($"3'KP"Y/_
MX"&/6?<'YK%</*\QO%@K15X8Z(P;IMI*7WV.#30'F\C>X-[4)$EL--X]-!?_
M]CG-6,_HMJ8!;%Z6I8QM6IH(351:[R/3H9+/\":(DYDB4S_[N>VM3Q(+R1L5
MY]7#@=$==5C=KL?JCCIM;J'Q;=0&S<2W881?EKT9C&_=P8T+.Q;>@H<8LZ!U
M_+8(6?0W_S@<^W4"WT/9+A#C-)3`'"-G!I$(ASMZV,7TWYV>`,+RM0L?E@8%
MRVK+0P#$$/RO;UZ_^^[5OQZ_?O=.HPA\'GE1?QY+#07\PID9<\'[3WBR"PHT
M3%A`16X^%R0L?7+!0U#Z7;"E+0\!:+@@<;[OF0M^;\X%#<L[Y(*$E7D7))^?
M/@\VJ!BQ@IK@C(Y(F7KEBAW@##AC6V=>`M%RR&_>4(?\X5N##FE:XD&7I,R,
M.^4%D7&R3XI$3%A"36\^CZ0\?7+(#F#Z_;&M,!]!:'GC#R1#??OV]0\&YT?3
M$@]Y(^5EWAGCY^D3I$C$B!U4]&9T1L+3*V<\!&;`&5L*\Q&$AC-2-_SAU;^^
M>_?ZF[<&O=&PR(/>2'C)>J.'F])7<0(O<[B9Z\1L4`+W6X65,)9VIZUL&5*A
M`9/:;4&!7;NTM5?=@OS%V:#U'>L!\UM`_,.?8%JH?1/G[J)@6PX/[+`IDOF(
M*%C1$7@?)_%FMWDY`:S'L*R%L2ZT7J@1V0YI3.CR9RKV\N+:Q^W6B[AV((=[
MDVR)9#NN!9]?5%SK,RQ;<:T3K1=J1+;C&A-ZV7&-]Y._7@N7_C6N>LXFDGM#
M[9?.PB,70B>&Q/^W+.R9H*U@.`;FRS<WVR&R>(+E>MUH*S+GO4XV@@=#<!S"
MT&K^<@MIN1GY\RE.\C0(\UV`[F&Z>:L<3GT06=_^W4MO-QR7_7"NXK7[:E;W
MRNZ-U.Y%FQK)?1F!R4A_6-,].=!WA/?#[E'5$($P1L`&^0+G@L97JB>(3@)$
MNUXK=0#P2^X%^-+P$.:9&H9;I;W<24+2[)W-%#*V\;N)>S-GM+Y9/^56#G6Y
MFR[%7^C-8%\V7;I$\F<5?"B=M?NXK!'RR]]T&3!!VYLN?6"^?'.;;]-%-.;%
M;KH<PC`T%;I+K)7E=)]E*(IL-=H>Z3R#LL@46M>@;:7,6E;PA1JOY92X(V"/
MN87+!%BBSR_[GUOXVR[.XKQLNL9;C*F':O,"S-OT>$@6\\'U%F8YL9"\ZJ?Y
M,8GS#`14B".0EF*`K.@FM^!W#Z2LS$17[7$$7YI%C66KTGVS^?]6LE9-#`MI
M_0YCYT3J?'^9$(]B=UZRZ_P)IO=/05*$Z:KCXBU&Z`*G]$NSQ#=-R>8U4RTA
M9XB(O#OF4;EDPD47.`\7^M9MU$1TG`#S%V./QN(I'P,0!@'8*``=1I4]UIU@
MZ4A`,927$FRYWWH69TNA?#5I+I_)-SOO\B#-#V-LQF+LCF6=6'RC\Z':Q5_V
M<UO:ACIOL!4!_Q*,TEF(Y8-8>'#]B9#(J_=X_(BM;9D\L^*F>.;S5D9_H>]?
MZ=K;+"&R"[@OP+9F#I!\"/4S60L/D/SU1+\"9%LFSXRX*=Y$(_Z!&W$"'^E;
M5T6(_%O]L&L*$:02OLQPV6-]LX3++AA?LJ6Y"9>%*;^4<'F!TS6,O8N8'6)Y
M9LH'$II/+"L6+'"&M*`.H9<:.?L-<9;@V0/GEV%T,X?0VJY[HZ@7VK:X)W>>
ME*F1S(X<3*+^O;B%33B54EOU(&P9<D9RQHL@3MG+O/Z>U:F)[ED,T1K%C*=]
M!Q4U3#!`)0-4M.YGFU_&)#C-.>;=MU8WG]\=P?D>N)QSO<C3R%&4ES;)+-BA
M?C_>]`H.7V>0A4\;7\1<L?#IH7F`LY`Y0EEHSUQ(4?[?CVQG,6D'9[K+G`&<
MF*_C4^$O8S9HGD\M9#90%MHS=U*4W_QL\(6>3GLV,VB9P>^F[/P`_,N8&8HS
MJQT!:"'3@IK$GCF2BO"_'[S/;]ESGLDK&,$7;\5N3O+I`"><VSG'R<W&M>\U
M`.>;+<)[6-Y;[E9_I3I^?'N/\P")?S_%6?X!YW^'^2T,\6-"VR[4E/B7VG"H
MS)\.A=0*-L[D-3]+?DS2BCL(Q2@3$OGH4HI6`(,<$W,NMI2Y=;,>!TYO\;HW
M;>R!,!/FS(6;<3%-EJ,`9;>#WGFS/A7A8@$VF.9GZ'#(!W-`!@3J$36(%M\^
MG$HGS(MD]H#$]I]6270&GR'"6SK)G7^FDAE]&I),B@]8+.!A;%F.'-6,9YF;
M?H()F:$1&?(JVL1)3.9/`L(S;(Q:91Z1)*CE+%*T+1QR<+8,GZ#!V&7H54,.
M:VG1=Y10$R#"$C1Y@H+IO(^M2@7U%6*.1'ZZ7M=!CF\%T0B87>F\LFJ<M;U9
M35X*"QWYI">L6DK::E*8C8I-.R:I-\^IVK(\U2Q+%=N78V7*&=%T`[,2PPJQ
MQ$12%+N(JRJA29:BEBW($3<?2'CZ"CEYITLQ1<"PGNZ\!Z?POXIEO^,5;&?Q
MIC.X)OX;L0=!XH<=Y4_[8][3%I@J/C1,1PN<(9+F_:7@!D1VK%4H^(5Q=#I[
M2J&$553G*2)($XPY?>-#L(&KS[%2]CM*RB0>)=4YG83R]-!##K`:=Y*F]OS%
M9=15*#OP"V7HW%W.,'UYRI##E,1,0\/I_NXT78C)N8VH09_1D70=SG+,>8*'
M&#.7.'Y;.`3]S3\NXC3+[\E':#O@$";Y3;`7&<EO8"J14U*[`F4SBH]PR,YG
M69[[U5\9:Y!3WO38DS('VV`/0H']:Q<.HH,@UM"GWV@U"F885._^)SNA%B'J
M+IKQ;2A('`7C"0JFM"JB&0$D=V1[_/X#_)S??\)&G%Z*EKH-29"UXNZ4+\@_
M80]]704UK*I&CQ$279S!\]:DA\\V#"2,@#"<[-M6$^*S.`L1SG8IU#I(4:%J
M,@GK8#!GKERS]^9,0P/?\3RZ5\V+P'(TLY:$T9(_9F$:;_F12Y=F8)+1@YDD
M8M4;-SC+4YC'*2L]9*\&J?GI=&Z:F$]E;-ZOWP=Y^$1OY(O3O5O?-68+V+SJ
M%XU[%0,J<>CY87=(X"*Q^@A>,=64BK_5Y7*R+HY+T]*`FPIE6<;UFOW1P!RN
MPLSD="#/UWQD.($)$8HC?50F;K2XG*2AC*6',[R&48Q/_*H@+-D`1M.$4B!0
M31RMN,'S^^L>&_$L0LP3&F8W"6O53RG8=.4+Y;X!B0[+#`IFHX&3,."5_[MT
M>UK]5-=$&?#P-D&3P#9IF_=;6KX2)/M_"[8X^W/F49*O`MVX4W:IT7>81EV-
M76JHN>KM>E\F(=[`^^`SS.[AYWP7H-4#+74.I>:^41+J.ZC]U*QL;7-V@/$#
M?R@X_A'\4C)ULD\EBPR6U-G7BD9Q3>9KHI_D\0IGV6F0IOLU;SB9G7_>QBE3
MW=]A('\>(D]0W6!D:5LQGXHY0(0["$7VM(:SX`_V1`!WAR3*>&(MW?::F9GY
MO%\8Y:+'45):D\,(5?.S=VU]E"-HL/2A^E$6,:RH0W_10?K`6/$9,B?PHG_5
MNL?6%[4TWJ!AH5`^^#SP1,%<-MZM83RH!5^TB=J*G+/JL!J/>HWAP5>G*=16
M_:!G!MI?&=BI"7]TVF&F<A5^ANY>!BF*8983_C374;_`W$-`[X9:%RT+^WD%
M&[HP`I21TRN(@P!@*>7XIFS4H^=Y"UVN@GR*87=^74O3'93,&S5GXH5)#RD>
M2ZC%+R6C3OW.:\J$ZVD*HS@7DVV-K+>/B.YTV$W/3K+!>366&XXSCQ%(L+2J
M?%0_&M3\S+GTX4#U[N^,DC*'A,V[.SV@'#F_NB,+U9AK&+FV,PLL(VZB<F7'
MC+>4[9'4$Y[V-[64WB1BY?DVWOW)PRFA1_5X6#O>J!FU-#QKAG.7D_R*GCW<
MA3`)R#I8-;OI(:#7F;6+EGE;+JD[[>\[J'<LI1/?=%P8<L4!E"SFS%I*GA^3
M;`O#>!U#C;W``2)Z2N^C9\^XCX#`S*FECP*"I17EH_)14^^BVB=>&OXYSI_P
M+C^#:YB2&9?,O%<Q^0.*\_UU<KG9!G'*'A](<0BSK+LMI.(=0Y,LU4_=S7&W
M<BY?B`>B0CZ0DUP(E1("G("XD!'$"=AR*4':TS?3W<F]!;O"EA!<O@V)L;DT
MH%(XEDQ7XH'K!)0"LN<V"@.J$D-Z+^*LO_'J4C6$;"AGWBRZOPS@2N=2IQ0Y
MP_4*%>6Y*TJN_+B^J0*A5&E)2Z%^PR558C*"E`^%F*+9:55A^C`(U"%_P6A`
M^ID#FYEX9MPO;#1"R`$>J,CT,VBIQ2HK(6JVR.3P*'"#=VH7N@;)&#R/8A0M
M;@/3Q0QM)YO&U0()A$P,IPXA@]+H^:"@.S\1&3G\X*S<>85PUWNR:S1HF4-#
M(#OC,:'`U3LGZ0)MS%,.M.@Q0",^,P*-?W=&NA=8XQ=&EC$ZF?5(S;>S\FKV
MA?XFYO-@=IU\5&LYKT+5^#JRR6!>XSP"J.9/-U!WAXW._<BG>^&5W`OHTO(B
MH)3Q1($SW:?[.%.W^LZ)8XH?2A(T-\O9]SXZW_&\O.%YOCF>&I1C>8E!=YL1
MMI$,Q9&3"<<$JRR#>4;?1:V>K/E$WTI6<3$I<KJWZ,<HFW>OB@<(2B:.6QQ(
M@X4U5.<W,(4#-0Z0.$=0X[3JP\F*]QP.M:V-TR?ZG/%EHKZ5I$Y;"SY5-A.Q
M_(%CF<!'^BS.50DIF<."#(($MH[?`RJ`2Y?31AA/5?$2T&QZ9H<7@D-O!5P"
M>LH[XT[6^7H-0_H68W6Z<TL,D'9"2<(8Q5QG^06,Z!..M,1M1SQSW_BPBO,:
M8:=W_VPZ9PL-Y3D[D)7\0,Q/OZB/DX6'TUG5I&E@"T`LVPR*V%#)`^IS3T"Y
M@*9,8)6#TEHJL=K?F=BVJ*6%Z+]V64Z/.>YQ.UA*%]9IT9[0Z$B>C952N9HA
M[=R9/T&^^J3[!\]D$F#]/`_G\0Q$NY1^AG[!;7>;*;9PT$%)%0S+/6\JN8JG
M!8NFJ[096)SLB/Z+S1ZRTNP;@D([+QM<M2*>.0$L7(V7C'Y'14KDN)>814O"
M]@![$59S4!Q4O1U>]DZN10.U;`V[:DZH,Y<4]6BI1\\&4V[#C*=9DPD9S(>A
MCZ_O7H-UD5T)&?A#85I!+F3H-"UW6NQAQY*Z`I`YM%Z*U1R&H594&0A0!C)X
MJZ&(76!;)=$5"2=(*/8T$&SZ29LTC#XN%FZ;44X=D>*([=21)+\,)L7O/0P7
MHVB/!X1A?2\'V5&GYG#3JQ9,`,%I#V>".3VV.J6KKJL8\-4NHB:Q/*1O8^O<
M]XI-=43'_;%/LUZC)^N#]?EP??O)I>^5YP7G"5E"L)T,0XEY'V&3*';SL-`2
MGQ]IQ(D7&]IZ2([[W9`VEX+:J/_5IU,%^]Z<U?M-V]9;BZW=6!!4`BQN9*,H
M"AO4][CC$-)E1&5OG]4"FEAW')(TZ8]MZA:*2"D'#T-F+U3CP;);:?[#,NI:
M_.D^@:\/V8GA,C83W&S,B$Z*X.KDYMFO<CB#-B&?_-@MIO,%?X4TR:=ZO)XM
M4P/GF&:/EPPY*<X#5#CI/?W9"V?L4?WXP9_Y4[R9CN0TTN=Y[$,(XC<I?H[9
M\[MKG`H[NC-M[!T$K@\P/T5D'1*OXU"[YD"%JIG:YEX&<ZS8LA^]*CX?AW"H
M!GU$DXN`"[60$F9`VE:BR7KN@_A.9>S(;Q);GC=,W!RB0WPLI+^<75<]FW_^
M*(7OF%N.ZW=)6(XY:0&O9\Y*?BA_5Z0&]-E5\E^NH20J,H6L^C6,B,B0F(W2
MAI)AQF8,8XH,-BZ!%381A&&Z<YMEV[&3H8`P'8N78A,#@83^6/V^7!V(\K%#
M]5)"((@(2AG=A)F?4GK-G(?`26&C2<@,Y")-2RMF$/;/[E[Y>2=00WY[J#Q?
M01GP*\:LG*)]N0]MPET&J-JZA&L&L\XBE.5=DU;QI!%5^HV7UMUIMQY7+PL,
MK4C-KU?,ST9T*;*4N:@#(+DEI9W%XYS+1&<>\8'@9'/S9IR^,=C&6%GH\5IQ
M7,0NCC36(UXGI^B%X3KBIP+4GNWH]'?VNML]_!<,\WM<M[R;Y,Z*G,P8@!+3
M+ZN-LR%3&/)V#>TO%O:!"##8QJX0B!8$UB*YB06G3T$:Y\$#@O0V9QH_[%B5
MAVX#=CWZ9@Q`@I65DJ2"*0@%KAZ[O`KB0XXNK>Z%H3O@U`+8HA`.FL1W;4H?
MM@^L;HQ,/8<9)&UL5WV`RY?78%X7X9$3E%$=+P?-D5.0CM:6,]]C.MRQQCCZ
M%".T2J)+8FK)8TQ""?_3M"./(;J&-MO[65B85(,M";,H_B=[X*[DYI<[RF`Y
M>"HRIM"%X#9T9E+P9D>.-??BSYY7,]R1N1Z>!!F,Q`^<XFS:!I<1_C.?8_>+
M8N.>/PY_!0^4&4FH:VY>^;Y)(S)2\3"&T`LS&'/U#TQ2P$1M?HH*ZR9"W:1T
M]RC?WQ"$<B+L^6^[F+TT.2GN#%`U8QR]#&S4(V]3&!;7/VCZ'FQPFL?_]"]0
MC&,YY/XC*ET$;@.N6G(&C#7SRXJYHXUQ>J%PVH8WIV!H1Y,2>X%77$?T/KB[
M7*O$.QT/[09WJ7S&NKKZ+&IZ:9U(RV`A5TW65H%=,GCVZI5#]($V6F;7UJ+'
M`(T6V]4,?:FW,^1&PX1M57$9P^^%%-XINM>X0KT'3J\"S[4;-NHYS!4762DW
ML5.-MZ")JQLLZ>H@:W5`,U?\S.(I=+\")[3OR?5:&/U5'#S$*,YCF.F4Y*E0
MU0)*GH'EF\RHYNBT\$X#1ZROSD5@5CA:S19<KYOM/036#NOI!"FF%8IW$9H:
M!@]ISG0E67`L3R:G`9RZYZ8^W?F*2=?,)+J(HZ)Q083).5P/+8.(6,WC>G(X
MKWU%.I4;4*+'^(PYC;N5CR#%=&\QBH&=>NGEN(2\(Q@W_UF,WLT:7W1RN;?.
MI$F964PVJ7[QR_P>O(;6^5T:]!>;@95^8X:8NW_O^>=@$R=LB^X&)@%B2R]6
MV@7),/,5[0L"(Q4'4B8]M2V>#!<[Y;[I,V0]YW;$X-,\*'JD;W$64W'\>)Q`
M$>#N7H;R*EX.F(5'-GH?5MQ!Q;ZL-60"@$("KWRT*$JRX:,5::NP%ES,^V@%
M&_'1;05H"D/\F-!:X"4X:!M=#0=MZ'<Y2&HY:"'!+`YZ35@1L?X.`Z4:G\;7
MM.`0*%BHYB'$V3Q&G[%UZ2%=ZL4#2O!#E4C0(K79O[>T6/Q\1>B1?Y-_D1]H
M=3+YQ_\'4$L#!!0````(`+>&<T8.JGZ[\CL``-6-!``5`!P`86)I;RTR,#$T
M,3(S,5]P<F4N>&UL550)``-:-PM56C<+575X"P`!!"4.```$.0$``.U]ZW/C
M.)+G]XNX_\'7&W&Q&Q=5Y5>].J9O0[;E;L>Z+)^LZM[YU$%+L(UIBM"0E%V:
MO_X`4"(HB0\D"(`4R(G=J1J7F4C\`"3RA<R__>>/N7_TBL((D^"7GT[>'_]T
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M??YR]FEP\>GJ\MTQ_<_7X\^?/I[3OYY\/#[)<DX6JQ`_O\1'_S[]#\[RT?@]
M^[\K$@3(]]'JZ'\?/9`@HK\Y7WC!ZOW1P/>/QNR3Z&B,(A2^HMG[-45_@R%=
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M`E*IN`V+S_8S"3<_]+U'Y/_RDRRE#_I9OU\^^GAZ[1,OAG&Z]:$!QJZQC\)+
M>E2>2;B"L;;SJ0'F+I=A2+?7&"U(&-.E>:`[>QD!E[J`A@%V?R?^DAZ^,$$&
MR.?>QP88_(/><O\5D+?@`7D151IF-U&T1"&,T4(B6AE>+]LUU5X\_^_("X?!
MC&D<LKP6?Z^5S8T$%.-<TY](+WWAYP:9O$<A)K,:;&X1,,)H,@)PQ0L^ULK@
M@`XPXTCXGO25L_.1$<0FE`<H4,DW)L0V)1YZ_@U5-G[\%P+>*GL?&V!PC)YQ
M1$<)XCMO+HU;_K>%[.WK>.PG?Y;I3(-'1GDJI2(`B*4L9M7#03C=&H4J?YL1
MZ%_W=,-M57_]&Q\6'A.R[Z8OV$_5RJ>0S$'LK;D@92B3<(9":@A34^;X_3&U
MAA?TD(?T%W_YZ?2GHV5$F24+1M;SV;^A)T3%_^PV@:IP&GP.,;UM$?_-@T1J
M[[P(J+[V4)$\D9<B=/*Y1XCD7E(I1*<?>XA(J8*10G5VUD-%*A7&%*[S7I+G
MPY4Q`P18O2S?@%5LV:5H?>SE^K:24&BSIY!]ZN7\-F1[_I@4JL^]G-]100M<
M;"EB7WI1OXW8CNM4`-6+^6V@MMS?*4Q?>_F^<P)+XQD;W.C%:!ZWOWW8#4)I
MC+0QR8(81!>#V\'=Y?#AM^%P\B`56RO_M,EH6@%G,FZO)R]ZY"NRC-X]>]XB
M\7TA/XXV/]EU@JU__.<MILSY.,8HHMN-[YP7XM-]$@W_N:1;0\8%)4]+RH>G
M/IEZ[#?`\!C%'J9JV-`+`WI$H\&4GOPEBUC/KM`3GF(I%R"$FN$)#68SG$B0
M>P_/;H)+;X%CS\_()<B$9*@9GE!FK-\]?RGE)"[^UC"S]QN9K<9O[N?6CRS$
M^2U#Q<(&P3$3VTSH79*`:;XHF%(A"-TKA60,3R$CMQ7%O7$6K]8[<TP!NJ1_
MXOB.!-/$WH#P7$[''LZ7<-;SOC;,\"A^06$]K@M)&&9]2#4XLD)4U>3W7[U)
M2!`S?:].IV1)9<.]M_(>?:0PAR(*UO>\BGPOHV(:^2A",4@N;KZP<3B3L=1D
M80$!XSH*6:"06O2^EUBX]+I>L'OO#H&X+Z=C95.HG,+M#^UM$571;9?A2R]Z
M8>H/_8.MYZOG<X4HOO3"<$45(K@*+D?0YG91D7\%!(SKYFN'Q.CI>O,4X)Y$
M&)JB`J/7A-M-:<:D<GT<3C"0V]H$?!(=3C@`0Y8G@!W.,@#C4P2-@8P"$GM^
M"Z!1E4_ERI+#V05U@2O0D1W.,-!S%9K-*#CPTUAFS3J<70!P"9!JOX7#205J
M0$DXJ1S.+U##K-`[Z7"*@1I292"9R"<X<!%?'F=(@3MQ5LAKN!LS.)WV&OVN
M.5T6+Q2X.2OG57$KBQ2GL)TY*_0EPNU;9F-.0D"*TKFS'AH82OMI'BE$'QV6
M[Q"(9!)Y4M`^.:O0PT"32><2H#DLZ2&@Y27QI2!]UB_7#UR-J$[93,'[8D')
M;R!I^)YC^X)B/&4SR$;10!G$N73:ETZ\S::UW$FE.CUR=.PE@":#\R=3LUK\
M;TC89GVPC%_HV?U73?:S9.Q-@>[<4<@W]8RK6?<HY.PH3J68G-4DW5H'HY)4
M`U.!'X\R*@U,0.V05%&R.A$=1T66HJT<%'I3HAOZ5U`J7M[7IAE&(5.FMN'[
MAN:/<O6UI,B8%KJ^%T6C)S[D%9E3(P0D8W.^MK5)LF,/?F"UO;)/Q!;[$Q;A
M4N)Y_66?$-82NVIW840QGE-W[?3<79P'ROX)$_@X[#&K$E*D7(@*C)QUO);<
M/$3R;A0H.>S$ESYI&;U')*,ZNWU*E,7"J$:Q9BL`^]0#5F;;B)S=\QZH(DM6
M).ZZKP&`0<HM4W%\?MQMI*2\52*GJT>KV$TI4/K2HY3KBQ89;QV_[61KZ%BX
MZ^R$PQXF@\GPV_!N\C"Z'MT/QX/)S>CN87!W=3GZ=C\>_C:\>[CY?7@[>@`6
MV('3;46X#,"V66_+'XAUG$&SP2L*O6=TMV0&#C6.V*;,[,D++\+303"[POXR
MACFM54<P_79_G?"PN>1VQN=)NZ*=4:3B>5(>HMFI:YRB]:GH6"9KZW"'XIN`
M2@MT2Z)H\.IAGYG:$Y*Y'-9Y$AQ6R)S`I*V&CJ[P*YY1D<K209+'3[-_+*,D
MT50]?%1.U>9:*J^4<39O`JH`H"@>_EB@(`*%`?8^M<3J9C43E%0XWJ5@NB#"
M@EYT+%-:;4/D?FX\`R+B*=[KM046E=K]UC"SOZ*`(N33(0>S.0YXZP;6?%!A
M3U>2,EZ:+T)4>61OUJ_0*_()?R^K,)$*0I:WC\HM7$S#N)QAQRS5S%5X+R31
MI"%:-2\B@[W#_3VD-R^1/F8=*,4!0:M2NG:@#@<$K_V;U&0ACI8DE0/$5*YF
MU(&"'`"(BE3>#E3?4$!I7Q!I++7Q-8$G0,_\I?Q!`;1CE':@S`8`'(C7P42E
M#6<VEHQ?2@"H7W`=WM8K=E6*V*.SJF>EK[<$J#V_M(A$.JMZUMA7TI$*$:ET
M-J6R;J`H`[-J*$R4\K#P:ME^//A^/+P>CL?#JX?)Z/*_!G?)G[^-;J^&XX?A
M__M^,_G[U?#ZYO)FHAX;AH_1NC@Q8`H6VBDD*1U7RY!NV*3G(L\9&E.U.L33
M>*T=#=Z\<$8O_='3-0F?$([9$8%E[]<=RT9OB7T&DZP.2VA`!CNP[CA_^OC8
M/S7/=IT7DGL?6V+Z0&*.&8-H0@J*='`('[T(S:@EP(QR+F''B.Z!",?H`86O
M>(J2W3Y&4_(<<"K@4MWF>6E&W/#!+TE`%8N(\C)Z2OX>8VI=/:`I_4UHXY6:
M`S4I=6W@(#U2=Q,K]M6SI/$@HIK-;$/S`@6\S`RKT[/!<GMT&;X5"4-9W_Z^
MX'#<H3?^+U*`*Y'5S7:RE_7SO4<7RCC[S@NFB!VNU#_T?4&"X0\43G%$_^$/
M+PP]N@^ICL.JODM?"/7HFY](@IW!F6P&:%8]9@<3)6G0"Q_#A!28=(-7,^AP
M`0DVN8(ZYR4O+MIIJAR8D=)7U<CI?[93^R[9GIE4#\K5,X(7VH!2;J:!JL*\
MR@G9J]L$9SWG8ZNJ.ISC1LJT)**-&<(DH+L47JFE@(`MV;,S?*1<L"6?D/$=
MGMJ4=7=/):F^WD]?[R?W2WOU?G3U:98BV(I'HE)S[DO^]"5_^I(_YDO^5%Z1
M?=F?:HUH^\2=.HU1J7))*G5@\5S`6>%=;CX4)E7N';@39XO^2".48[`*>)PM
M."(-3X4K0CPUZ<\:U!O5I=);:M7N3IT]?W+E;,H*;.EO#[5(P@6Q%\:'@U!)
MUPL#CW(.%B*)L)!X$N"LO5(+L-WX8`=2W35LL+R`L<B[=OA96#EV-;,+.M'M
MS@!^>SW>N@P?.,](].)R]K6K!MB*[HF3KUU&#9Y%N,'MU$`#V8/`325K-`7M
MW.&'L1K4$HD,XQ3*3^['.)3U80B.!IH0'A2.YA]);*`^<[>LD!S4!846SLXZ
M?I44/JE*$?JH':'$9S(,#NSFR'TNE\+TN8=)QZO)#9[G7[I^,&N_Q]U`^?'8
MR<?LEX.'WZYO1W_4J&.^1Z)U3]$%AW9JP#+5`Y("MOV=Z02VY8*N"X.(6HE>
M]'+MD[>;X(E08/GQ54EADR5I.FF3CDW--_8'NU]>/9^G.<277ABNZ.$'O[^5
M(FCI^70SDVMH6HF8IKIFB*C2?H62/^O/KHBN^:?OC)'[D#`GP^QB]9U:(C?!
MNGUB\#R8QOB5VW74V(MQL*0_6Y</)`'TK7RMD8Q7$%YX*VZJL3HR)(PG*)Q?
MH<?XFQ?S^_DF^$9"-'GQ@@D=%WVC3+Z``%`=P?AK"C)%:!9=4R4FU[\.>UI1
M2<ST=`3&&PV+,<%+@H)F4DJGD379=@M2$9+\`-%_U+10U2.T6ARI:`BZ1FP&
MF)O@E6IG-N2T]$B6SO>$#*;T]@P1992.'J_N?2]@Y5K9G<I3KU1.NPS55J^T
MQB,`'K$98-)BQL:/@/1(Y@OM;RF)E#,6%KI<ALPU,8@BQ*M?WV)JF/J<33HA
MF-6G-(#U:0^FTW")LGQL0F3I4F7^K1X"T+&L@S&<+WRR0FB,>$*JMHF7T6UB
MQ<F264O>"OH:3X)8,^=6B!5^L#0<U#V*+1!(NN5/$Y/:P+H.W2EV.)&F:J,*
MQL5NY!'D72N@8+KJPIP:S_A??+#1T]7:9+FDS#S#A%T%(</3N$*+$$UQXH@,
M9EEF(),H)6.S(B&+3E.3R4=;L=@)D52E5$Z3F?'[:I/UE6"-=@AXQ+X<3U_>
MI2_OTJ7R+H=8HV,3CE02E>5T6I']4#9#F4(<'4@"KET:P-TWN-I+`[C[Y%97
M:8#33YU'J*PT0`>>)JN]V3X[=AZ8?4V?Z#=;!*#.WGR:;4J)1GMGSN;%F\/2
MC%=%/-)W]G6-47<8D73YB1:<SHH16SA7^(<%TLX*&5M(%T423#9,;0G$YN0X
M)-9DHK]JRX!6".B5@YD3DQ3=0_4)W]:]QC4"Y%[,6D"I3[HZ#^5>2H.H6>-L
MX0O=&)8EO(@VK<[>1P:V)"AQ2M0*ZF\BY9LH)SLOQ56C8[UU\M2H@Z%63JB`
MW]G^Z[7<9>!LXPY4Q-*<"IX-!0#RW5.@S_7=>8<B.#1`7?<]A2A=IO\^=$%P
M@%_JI(!^<M9!IOD9U58,4>W=F`#=65^90=!+WR**(GW=D\_&=O36D]4487>+
MEIC#5_79LZBBZ'#-6'.PUWUNGQ9Q,^#I."BU`U:N(87-@/?"`=CV:G@8K/EY
MB*7;065=!';:+>`#K$TF6^DG1<W=-!MH(:4MYV*VX)/`RH+6;K3$V!6.ICZ)
MEDS10"S&[`4K>M`>EO.Y%ZZH9H*?`_R$I\S[D<106$DVXN-IY@%M:04R+2,T
M6:"LW@3,YLV/PF<O6&=B4'TEHJ/.-NDO]QEX1D]K!<?S4[$1B8FQZ93-8D+1
MO/"!I53L\V:^???.V$IO\TJH-)K24CT[TN3BBKY_AU[644R?&B,L58@JS3S1
M!RA/"[YNAZS<9<[P,S,O#.BV28=3$E@E1$R_DML9646N%--H](E!U<R(%/XN
M'OY4,-X$%)/ENF\!2`*4D6B'&,CET.QANO9PR.U!P86:`E-!J%`F["\;;_R1
M!P7DH$L0:>*DR\^-2$/KXG'?1)+S2K%)'O<R$NTX[KD<&J\)F1^AS]AM*J<?
M1M=\X<M\9E0T!0EB3:H,\G,EJJOEHGQ9IV7>>^SXL5YOSTA%I:@BTPXY4\BE
MZ6+(8M@)'36BNY&%A6J*&A!9X_6>\WE1$335M)J4,](S)8HKY:*48?%_G#Q\
M8O$8'B)]1H&"-UB"4CMD31FCY@L4%8Q<4^)`*5NHQ%3)CHH$`A)N4ARI84#4
MU]1%\914M$B3.1@0F\:W0/$D0:D=XJF,4:"'HH24HKQ1(FNE))F2BW7GR^9K
MM^3)`R7,710&Y85<)>6`3#78ID5``8^&R[2FP_.LT$R+3JXB\R1<P5CZL$)%
M6ZD]E&&)DHZD(E1R/FY2KA3/A6A<$!?%S>9];-+2.V:>*+#244*B':(FET/#
MOD^ZNY+$`OZ>\YYNKA#%..0>GS4?=>TA]3',6T;IZ:+<C5.F:MM%\F0;MHK`
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M&<;\%M-32*7)JJ816$['],991CA`472%HFF(-QJ1IE=?"L3[9UO6GFTIK(Y5
M*_@0,"P_NP(N9\LTRL$E*;`%7LY6#@4>4<E+6`#G;)T_&'!P!4U`Z&SQ+1B$
MN^IZ"M!)+_LA]IC`K>.7@)11+M#JKP"@2T9`U_%+0,H[)]#JY3W$V=J!WI,P
MW*0\[P*U_A)0#\D(%/O+H2)@)Z"R<!DT4R&%=V*$1J)+:;0CQIS/HN'0W?0%
MS98^U?@'=//-L+]DA^\!39<AKW\Y_#'UEW2>K``L.[#+344?+<563(QN.M:9
MLKS+`[/9I^PR8--`,[Y\-5$!#M$7J+%0H$9Y=3K@0U7#4=_9M^IW;;!DB-(-
M6$VH'==@"9\-)5;H3:EH0:9(7S!$?HU<3``M>26L)%JDZ;5#PE2S:TN'O%[&
ME)]O.,#SY7S,0/`W#Z6N2:8''*N?'NG0*&L-V!<`,"[&:A<`T+34+DJ]?->3
MDL"3(=4.65?*J353>?U@\`&%KWA:P-/`YZ>8Z_BLF_9S@/^%9DDO"?Z8M*XQ
MK9L):YX&SNKC+JMC1*4`GL:BL=3.3[X'F$J1I)7)2L?E88(/NR#NK3?_:318
MQB]4NM&5_D[/7\BY3ES2W`U]L1K^0.$41]0VH3MGS"J-Z8#2"#<-`ZI]OTF/
MT,#$U_?IX,T+9YEEBEA5TX37*%K.DY_I!:3.R(:!DJX+\)BM"Z"BU]4=J4E%
M3Q-*N9J?GFW2`7^EG460$5X=R!BU#[:.Z[0#J:G&%T:SRMB!I%>32Z+=#K*:
M06N_2H:2@Z#P^W9X!?;9LZ4\7ZV7GXY-=0_$W5RWF/+O\ZB?#BT9.(2]A(&G
M)\1$FD!_3`\S.UW!E/(F'#-U'1T*X_0E1VR6'*FW5AU0S)7Q!)Y]%Q,&%$J5
M7*'8P[Z%XBX[`[7C,JPQ#\,OV9?S1Q2.GM)8S3I5&_3ZOH1(<[4<<EH%??-^
ML$#5\,>"+PHLOE=K(-,*`#-H7HA/)4V45.3=>Q`)NN=ER$$?Y_]*)2M*M/M-
M4_0)^890O.Y_3F4>COCFB;U@YH4S&8Y5*4.9OR,Q/ZAL]:])>(7\A.+:^LR^
M<Y9F&T03RO`EE3N4U@6><9<#-_'F).`+*,UA.1'SF453A&812\Z[B:(E/6/P
M:0"(-3&=\,'C&AH_8[7GLT/->)&I5T3/%NBB$-^`#^#ZBKFGQX7=+.O;E+O7
M)F08T/O6ES]Y4L3JLJC,CK7"'(,IW2H19A+FBIH$[#%X^H/!<XCXH^83R`)#
M*=N?:&H-[?%5=Z*EE,'R.]F2ZT?ZV4['S+18>CZXHR.`HB*STJHM-Y&HWHUN
M8C27/R=UAS&MA"T?(_3/)7N@]\IT0,1.-4CMRB=@E^T)9?2*S#TLI<A($+'/
M_N`'!MU*A23@]:>>J0J'J&5PA4,J"T94(H1T0\IO!2DRIA'E6@37BNZ\.?UK
MI@&9PLZ0H&9AB^`9I@(CPXS*)BD@`MTF]R]>A"9OY.(WY(7Q-;7R61(E;(^4
MT@";9L.[X>3F<G`]":D9"^0D_V,H"Q<HBE5&W_O.\%ZB</OQRR5[$Q0NH_AZ
M&<S8MH:?BPI"]J<!/1"%)-2.`_T55/L\%!&!6\\XH$J%SW=6=+'BU.77N)J&
M%H9D5ZR*`KC&+57>9W.0BI/_'73@48B?<0"6$;N?V3<Z^%_IWH2+"0EB#4P'
M*"H*25@Q-,S:%WU925M5=Q271\3?3ET+96HX$SDU._=.:0<2!ZN$7`5,.Q*Y
M`PE]\I<<*;B%.Y!B!P=I3T5RN'2D'NE5I=QN"Z]3]P"LM`Q*0=H362>.WI(2
M%AV1LB4%4N=N(J5+GRAT$&P?R7.7$)3UKY3#E'4$=:#RIIQ/;7,Z]SQ^':BV
M"4,HWR,KJO8Y*K?`$K[`>YX"=>9<[JM>`5\2$MD6\9]<PE`^JD1@43"Q[SZY
MMN\40HNBLT-Y,%2@]L4UU/2?UMPH]_99_>(2@K))`N4P[1W0<^<N!OEDD&*H
M]D[DN7/N0ITNBYK)3`)EY^P"G3EE.W#+9+\)9)V^40"IA>7>[]*\QQ3,CX[Z
ME32#69HM*\!T3D-4![,@A3K%ZK-SE[5FK/*SWU/\OO0'=^_@BG<,*4Q?G;Z&
MU6"2>:6R`?!$?^#A%86/Q$4(MQ\N"01[?64WXE7V?BW%[<PYOW'=&P+R,C&%
MT6U#1`%&A7>I*9@?G<L<J2\+I9XEIPA^/NX1W$6PYBOV%-LOO4Z]AVU)$804
MMZ\6=&E;E:XW7IF=EC39]E)J-3\4*+>CR`>$<;MME'88@B0.5Y(RG/[\!\+/
M+W2@`97TWC/:G+)$$6$:,9IQEB!SDJ?9Q.36R";<C)9QQ+0#N@2#V3^6$:_;
M7WNN,D,TN:X9EO0N[CYAP].\0W%2:(H)@<$K/?N\/!3)6")KC08\43!IXQ4N
MUA<7'_H*,X4WF+'J6*/X!85B;X'>CD"HVEQ+Y97J>^A9Z?VV@WD'WC!`T(&<
M*A.)^E\3Z`+TS&K-'AAX8,$K,A3UVTTD]OP#PP]X0POTG/.):$-/1J$ST2?\
MH,^QO!D@H-/O*C[``UQI$XJD/.T^X;R@3C,]PM>F_-HU!'1R2-%JAUNCG%7@
M"V[1?/<F^$8")%7UKNA+TR^OZS4-WD]&DGFGK6U,T_:[%X:>2I6KG0]M5$9-
M6G$H%.3:_[B1+:=68:::5KO/S\4JGP"T^H11-JQ5]J_;P5RV$H:ID7NGAP7%
M3/>B.5P[P_`)(Y;D3P?\6C:ND<KERGV2ZVYY#VD]9#<]8UM;ZD"-#Q6D=E1@
MAVM\'(R4O<UY66/`6]N2Y=!NV9)B(]U@99'6^8+2$N*UO$`[A<C;Z?\Y,9S"
M4G.+#N;L?9A%,W$SH&4[A[M>E3Q-591Z_U'RTF.K:2B<W0("O=NK=WOU;B^)
MAI9Y4NIBE83:+WTODJ_Q6H-X[[RRZKR27I=.^:>@1Z%W0;7%7NI=4+T+JF5(
M%:BE'7!%Z738N>LATG+M5)F8`D=G;PY)>UW?7;WQ0U@M4VO)Z9;S1E&QK[0$
MI78XW\H8-6N49%J:7WLX_-WSETCP!3%-JBB9ML=YD_::<R@A`FUBDA)):%Z@
M^`VAX#>,0KH_7E:WZ!7Y$2^,2,]D)._(K$%<>0H"AV@PF^%$GJAVJ`12-=U:
MW(M>!L&,_<$>F[]Z/CM[-;<1@"AX37(DA?)*R-`RC/_.3J:H9>3(-^0QE&:C
M8,RN2%80E/["'0G"S?_DC[B5'..:!S8,$X^R??/"OQ`O"QW!W;U%%.RN;PZP
M',GO`7F,4/C*=,R;@.H]])\)W9L^YI<P-:W9YUP/A?N*S?%@"[SLV%`/<0D1
M6^QS-"-^*YW!=VXIF0:F<*IG"J<-3N%$SQ1.;$]A?73G6]=IJO;4D`QRA.T=
M]WT>..`USGXIQ2;6+Q6^-?9B*;T&)G4=\DK)4TU;<8^<O0V8QT6-W5=,[@#T
M2W#L4>.@.NP#+89!LY%&^;D1(\O0@1"D_I.2MQ1EHJ`#(4:(A,V#K^QRZ$"T
M$'+G5L"WKR]T((9HZXR7*IL.]VI4U.2KMFJQ12+B/\Y5!:YG_.5!FF>YBIH/
MSA42-0K@Z3Z`[FM&.@$\VP?0N78/MJ^=7?]F!UJ05KN(BPTBC8YPA[LI6HMD
M9!:J*%@C8';?0C(J*_0$_<1RN&]Q:8W/$D@$VN&.F>"0?K;*NWR2@</MN2SM
M4UC.2HKW)S>;,*LE!NV!"4I>$IVJG#/4ZF$JD;LFVE<Y=_[U8%>5NYBV=K#A
M_K?=VN$^)`L4QJP))[M(%NP"JMG308)D.Q)OI3@V75`]&9EUYHNSP]\AT-/`
M<CJFLV^GT^5\Z;/RL%>(KN(TL7;HWWW$I4`PHX(\C/&_^,\+>04EZVH;TWC)
M_(*1?PV!)>:K*#4UD6$4XSE;B.\1>EKZM_@5Z9E7/N&FIKEAX@F4#2!%KJDI
M[>N\=69T:RTA]I:J](C57[^9+T+RFOADX9E$I61,/W\G3_$;>\L3S#9_O6*Z
M+^%07I)(94(`HJ8S;Y9A@.,E9^4:_V!_4YA/&173[_4WNQK.]=ZGIE\Q\+=B
M**S!<B&)IB33A#(-3Z.3(M?4E"Y6C`MH&IT4.6NE.HH!5J_0446SJ?52J=`A
M0:Q)/YG\7'-K=E2M5`?RY,!'@0"/<@?2X"`24@:^K'#O0!H<Y,XD$E=\!S+?
M%"$K@<K9TAF*4)5IZATHI:&(&L!>ZT`=#4402ZWX#J1(&E%)<O,<NK?S<H/"
M(->>0,^Y:+`A]/*]OB*JWN]".1S740$1.G=6`JH!IR^"E`:(->8HM:[KHN;=
MR>.2*7#G^H7C7L]%2Y'UDEBR6AM!>8+MB*I+\&O6HY<]S3N'&.++*R73.R6;
M=4J6+HXPT[4;G`VVHQ@C?E?=>^QLL5J5SZA&=3Q):NT0*57,FNX/($;GF8ET
M3]*9#W\L4!"AB)5KS/PX^@/'+]E/($>U]E#&6R7D\J>41U!-RWS?!\223EE7
M8^%U66.MU`6BFISA*24]ZQ_HT>0'Y)8QS'1:<"2U@E`STX#&3DO)F`[*OV#T
M-/R!IKS(Z^CI"4]1J!"8+R-C\;##=U#>U\U(I^ABM76!`'<1A*JU0+P<4S6B
M\J`!&EI7%66XFE:3NK#T3'/C\Z`UZU2P7N6X$#41T($`OH*<+0"S0V'[DMN4
M2-[W'8C4:SNRI;I?!XK0R*C0U7#M5YIQ[OT=S'0B0'O/8&?4M@!G^I;-"T7;
M:'C1_#51ZF&I!D[>:R1PM7#]6G*7LN8U.$[*1`:S2Q+$.'A&P12CJ%8X!DRW
M'2Y4>;:!-4?'9.7Y\>IB2;6:M^!JB>X1W3PS&9NL_'MH\=-OW@\\7\[IYU.&
M[#,32,Q33/_@0]"93EZ\^-(++M!Z-&DFE6B#)X`#<Q-0H0V=P!;U9%E'CS[F
M$>P)N?=6W^FN#F_B:!3B9TR%R2W5;JF$&CR'",D^`-4UDH[MM36R9'@10$S'
M!E)G48H8E,5!0.(7%+*KB36F^X9]%,4D0'3)N&SZOJ`W[8+E\>T*T!)6842A
M+.OEU1"3Z<:>H'!.-SQ;G3L2TUT/%,?5A`P[^T8+%'KL<N)YG=%8Z-3`)_$5
MA&P\4:7CX3`Q(ZAD.H%PG_^]<::C""$V-"N2DPFT[F#)]L;HB2D14/>KZ@BF
M*QB$R&/VB^</(V8!;G(2(%,KI@$]S"6ZFFJW)PA)C>R"`L,`8E`6_Z"REDJS
M*(;$X(J^-!WD0<\\?1.1Y]!;O."IY\.C;R5$3+._\:!DQX;&W$J(Z#Q,LN$Q
M24+FWWD7FG"IG:<2$P,2;M(]HH8!D5Y"AZ-BL--`I`YC!X)=U?*,2(G=#H2X
MJF\N4GRK.AS<`I\\@"9DU77;+MAR?>)@;5<`Z&:!605C@L@8-0[W3M"`FZJ=
M*U!U+L*E!=4\IXC`S+D7;DHB4-(!YG#]\AI;3=()*HIJ]])O!SQ)#[=XT.M<
M58C:VP\4SQ!`]N=X!TBY&)8`T+FJ+K4!E(I3I@!^=LX+4!=`#8%J@6[W#&.%
M\UV9U2`*(O07C\1Q!^#9WS\[>!;F-@G,+%PYEA+NKI>LZM?Z2'*38Z.OJ+U0
MEJ;7C@2[:G:MYDULL9-RL@2]!I,F:3<EI(B/FV#R1OZ.O!`4:E0@WH[I7B[#
M4#)G3I5R']!L;T!3=4T[$+*SA6E6)C@<OK(-J]F*H4W5A6)E;>+5NMU?\,P@
M_,-C@8&XWGL$,-UVJ$OR;$/S?5ASU='3FM@H'./GESC:#AK<TO^/`,ES`)+@
M]"0)VD,O]+%NA@51T[=\'C.C91S%7C"C2P^ZV"MI0?&_">(0!Q&>\K9OHZ?A
M_!'-Z%Z_0`%ZPJPQ)Q5TKU0"4]BND1?SCG"2RZ!$N\ZCBP=Z`%'$XHGS.0D>
M8C+]:_*"@ILH6J(9/6$9I&XQE>6C0+`R>@LH)R]XH?0(0]/(QA7.#=R48\9C
MPG;RXQC-0!G:$L3`:[FYRCB]E!+5,T@&6/D%DB1GO)A=EHU;3"7_;%U2D_T#
MU2"`';4DR%G92#%^]-$V.\D>2+8]"].(30+?6D#R]3;;_3*<OE"M;':Q6E<=
M4-QF>83,5TN<(C3C#UT9-E2EX-6PLVQ1&23VA_0QJCM"O35)UOEJR7H4)Y[#
M9/WOT!O_)_FL>C!=*.-C](Q9-A\EBT,TC1^6C]$TQ(N-MB'-:34A*&MW*,Y?
M/A61*D>LD?T.G`Z`&%RG)2SMZ0+3`T$%`&C]<[_5HE0/?U!]!4>(TUUK+%D5
M9F?D%`-^-.JIWC6';D)!WV%Y8YMM;`F8IJ0V@,Y59QFVPOX!OHF$$S;]QB:C
M!G#\Z+C\9Z`W-L5$FMAP=TN6!TX/!YK2BXF%&B\]WV=JQ-";OFS_;NW-!QL,
M?HOC5Y8KZWM3'L-7O@RK"5GH@AFO-M<"&Q(46\G]7-O]O8M._4M\GV)#FBM\
M8E"*[3KBN]+?X`'?'\I"E&NM2F5%+C2>E4L"7,N@V.NJ^K(80M+.IEO[!11*
M4A<0,,SV'XAM1#0;4%.>JH/P(L$%!`RSO4X6@K.[\Z%I-I/XD@*;VQ^:KG'+
M\JP4BHYG/[/!(KAZLOC(GIQ5:H"]^[%5KRB<X_SOK>B#K)4H":@:`:]+4$#`
M5DV"G>$CY;H$^83`AL+RT<?3T1-=2'IU`BM3Y']LO#C%1I]*;_Q,:<&<1HU2
MM2ID:38Z.?!>D:#65)A"14!6D+*HV\&W6-[7MF1.=FQE>;-/!"IK$G<Z"5GJ
M3KW>%"!RAE&>X)A5GKT)9O@5SZBQD18W995.7_!B0H9!C%4:6(!)VYXJ=#,5
M$*@;ZE&\OJK(&%>_MCTB*@I8/@73<L5CB\@%P9TWIW_-7"H*=Z\$-=,36CY&
M>(:]<)5A!BPHBXE8Z\G"Q[Q8<5%=H_-*#ADK6KU*HO7NETVFIQ;,(K=32@[&
M#E=^@FQ5(G6F.I!$7BV6"$R,=J$`E/S=1*HOT@ZDU,,`D]*;1.Z\NZC!Y%B!
MWMN!)C#E)D,91%6VCJBYXZPP4S4M"=!"%E#V![;2Z[%]:,^=!*O2<43*'5NB
ML).SFFR)-Y``?)8"*>W5UO(:A1_&X9-P6V^?PD\N[C!`+$`:O&PH(X7PW%VI
M#XT5D=+(ED#,N3)-=>_)_&CD]BG]XB1@4H%=LNLDVHL_BQI+SM4$D@O=;YGC
MI5>E>S6^P`CE)(L(>)RUAX#"*9/XLR6(3IP$9S\W:A>*W9UR\M'9@Y27RY:!
M8R>Q3@#B[-&I`F0[(5(`XJQJ6`%(04*K`*;7`/?MX-O]I@`G[M76K9CYCB4!
M24X7H#GG-E'-_<_7>;:?(*2P?7:S$G9-V.H^3A'PNMF>HAZ\LJ^=4A2_]&=[
M1T0"'L,)%-ULM%!O+^8^=DPA^^IF/X\:&Z_Z<>L&/,I0#U[=JR7O87,*L'NY
M`AH`+GD@GP)WZIP17_=8PXLE"#"=,^M,'?/JXADIJ(YV]S&T0U5+M*1PGSMG
M<=>'.Z>BC\"KOWEDS9JMFDPI@+U=*&W1Y`/8FX2[`%;78$O!Z\V:?;,&6&IO
M@^79QWXCRGMXJBHOIJA^ZG=HZ0[-J]>9@M?+QEQ7N$)UU@VDY^Z]_M!RRB5J
M^J80&N@*<+@0@BH]"PA[M;OH8)=6]$X![!T_>WM0?SGX%.V/?<!A!VVEW@(I
MGNZE.9KRM&TUE]C@]_%SKU3*.-4*6XZD0'[M#[8"D)MF,QL8/QU;V(^6^B3Q
MJ^."&20L$Q<%43+K.BV2("3;T1U)BF/#12$H`F2%T`,*7ZE5F,_1';MC(I:I
M]^:%LVC"FFME__V21/$=B?^.XC&:DN<`_PO-!*7DHQ'K=3YY\8(1WZJP`L/-
M,6FCQ/?>5`9,*#SS</G%2OS*NGD:9Y7_UQA1`13A>`-,XGH"%6TWQ(#I4B:F
M-D0R@6L2KG_$?@^$IVW.#A5H;BRT2A1L,=368[]F<!/&C&[6X74^Q6UCP8H4
M`/'35E"S#KT;0-<(0P.W%:;U6F=,I9T$_JW@NLWM)\V2>M>]WXC/R%/YFQ44
MX!FK4+6Q'QZKP7_<!7\34MC.E.#!AF2"X"U@B(NV`JC2J<;`H&V5-_R_?J?W
M>!I4M:C9[HYKKZKYI;?`]/),[H8QM4C#5\3TOJ2/\B8X"D%"@7A;]\2^P$]2
M81NZ;3:#MQ6N-$^8K_=@&;^0D"F[5N`J'KRM<-VJ=!/1,9KIE@Y4F-'K,5Y;
M.=^I]1B-'[XK]*$H)V3+&!6Z$GP*)42@VB'W%F7HW/L>@*%*$E!V)F]D\D*6
M$15-@X`*]65-WJ3IF:_A'$SQ8ATR5*K@G/.]\2/G>S$[[Z%*4?*\KRTRG*G?
M$UVLLO\"[@L#H`KOZ<[4>_RJ)@\J231]246E^BFKJ\02XN@Q9"5%%4J"&QG?
M,&AB:.`^W/FP[YF54Z$#P&;?,\M2SRRIJW[R@L,8H?IW?!XATY>[L@"S+'HV
MPT%7>?L[>UT*E,5[G9X&=0<U#(^(O'-'8<KA6A=A8:%HSVL6J71,J#M2DS57
M-*&4WY&A[@[I5O\&38>8%(FC#C1XR)7;.8!TJ']#P9U+I'6"+K1L,'D(BXHF
MNMF>`%XTT>&F%FI%$X]/G*N9(`M(?M'$XU/G4MNM2)X=/T@'^BSDNXQVZ[]H
M=X2)G@/.%36RXL$D$A[:#G3`,*N&`)SS'>@%H1`!*0!S7PBXJ\\4Q[FV>[_E
MA.`$/,YJ-R!3JR3$*KIB./<D31*JLDBY0,>Y*CFV+EN)](@4Y8\]RC51KLBC
M29'^Y*Q;SJABHR,E2[3Z</9RTI@GIP/\XGS!="V^=->8LKL6Q:FN8BWZ<P%:
M"X4L[!3KK^[>`^W:][FY_VEU;_<*5%M8!CV/5,0:.%=*HJ5K(/&P*EV4$W<=
M<%H71>7Y7PKR:2]]FE)^RE^5IBOD7A'NEJY0_L/I=!TZ[`9JY*3(/?_O0,,[
M,\MCJ>:%Z(S6B[%VK$]!S1?1+,S=)(AVR;GR8D>B85:OH;7CX`A*176]1,<N
M"V?(4DV]813C.8O&[JBKO[(2@ZR@X+6'0WX9;UH<K4O-;=9&LM!>[7':47U/
M?1HM?;Z^WMR<_U05JYR<UD>#NEEK^A%FT7Q2%@?4!IEOM.`%8B&]*_R*9W2W
MCGD/#0O@RC-S2'".<?37=8@0-2,0%0UQHW#F,W-(<&XVQ._$IV1\>M.U8G_N
MLM/66DUE<YB@<`XO362(BT/:DX-@]@W%+V1&?/*\4GEG9X6=_E6BFZ\2;>P=
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M*^I6JU0J\W`RXSO)=;]:ANG#M"0'/N_A"`P?!>HMWS_;:L*O(8GL-/0H&[[E
MD+5+3O4A]S[D#GZ/KC_`OD@D8>R%<0OB#NU;C5Q!UX'0N8&54+B$.Q#D;M^6
ME]`&390H_9JL2X">V;S[E8$8.V(]M`NDY((8!OV*2%KK(CW`V=R.]JV#O.])
MA/R=S=YHW_*`RPP<GQL29!W6='5&'D2=Q%XQL[="P`B<*+'8WT3MT9YEUZPW
M+=MV/>UIVY^U"[]>V]:2S"0*./9*7HMT<,E%<ZA<05ZN:5;<<+323:TO'U=Z
MC/:FY%9/H8EGM(F[4A3N_4ZAV"W9OEW=CC?_R7"_GEW96=#PT-86GXW$_!0G
MMRF^O#_)^I%``RPU\DQ<<1Z9LRJQ;R[0,PX"^KL7GL^J`#>WWVOS[=0BC1$K
MYD__^9($7$U8>CY[+7K:WO4I8?D01=/^?!L737DL'1*TWQ?4J.)_N\5SK*'R
M@BX^#@G$6_+6"A#W^#@H$/?JQ%F'3W!0"-R^O<$K.N\3N\:ONTTM2^8C040#
M2V09UF<I0Z0^2Q/Z^_5AVJ*B@:DW4I\E0:,^0Z.@/D89&H<D%78Z*-D6"9OA
MVPO9Q6J?ZZT.A68A*Q[>-&05[:.4N=_N*26#GF%.^DQ8-S-A#6\;D8;I;FL.
M.S*@,@I04U)N=]9U<Z4,7G!ZEJ?X[A?+XVRB@$F5C<BHI`)C9S-FFL$X8X=T
M("^_(8RSYJ=(RN]8N4?3*&<=#P+D_L;4"W+&X21`=O?>.R0%LM1AV8&W0(:]
MS<86:=<I+Y:J8XTL6[]4>T$HD7!_WB]5JY:J+/XJ,E`[UHW)V*JU(6%!)$#V
M8O/`5K4J34@TN.U8V\Z#$;-Y&7BBFV=_.;;K0(+S5$7_0@NQ`MO)Y>.'[^N:
MQ:N:*>3%E%J6*)[#:$NK#PW_N:1,W@11'"YYR&RW46/:_+$=;>PT\MOV6FR5
M4\T\YCN0Q8%Q?+`+D[PU:E?_1_U,'^SRM+$]IWZF#W9YW+UQ.K$H5'GSJ9QG
M5`]M?;98/_RELEA'$LJ4*[J7N##;`7,.6P<+\;9"T@Y\=WDZ6'"WU8EV@+O+
MT\&">P@2V`5XVZMJV-0D^@3R`ZM(HKB-^D;&IF2&W47=K_7H>-ULEU=U5V<1
M%=(ZEAGIQG+NZO>B5)>^',S6E9)V>4%S#.(TV-JUMPYNK&B!)TGDL/1E#]NF
MQL(<K^E*ZJ^RW*'SJ>2G;]FVR";&.%YQNPUPMT2)!FR+TZX]\NK(A@#G(J0;
MXJPWNUS<$+#$H70W?'3WY5R7=P,\QR_=$9^U[XA\Z\!2DBU%XM*+7O*A9I6N
M@TBQ;K,"Y78DX4(8-QN8&?@\G()FI;Q``C"R%`U'G(9TA<D*H0<4ON(I*CCH
M":_T;Z.G,9J2YX!ET"<W.C=3]_/Q)1#0/K1AJ'Y%`15-_B"8#69S'&!FA\?X
M%:V72KZL')"@X6F-Z:&F9_.%LG&%7I%/%DQ0*T]*BISA*=T$5+P@:@_&_'*Z
M7>\@>`&\"D+-3`-:DJZ43,.EY61Z$FFO(@<8M(_WNQGOU[=#^MIP"H>82$JG
M#I1SDQ'RU7!UJ,":W.5.@!J)P:IIU*!])(<)G:2&VH5R:"9EH'9+J`.5TTP9
MK@1NH@NTW7GRO8'W@DJ`)QSSU_%JWB<)2NWP-I4Q:M@,H.,%;',%<8@?EVS&
M;'2V0\6N!6G[<@1-6S?Y7*QQ#K]Y,3W?Z_HTFW]'X90NNH:Y2HW26@!&3_P?
M[>"0#F8<CF@:XD4BCO/8I>*4">U@QJ,$]W2WABC&(;]5^7&$X5%_M&;VAQ!)
M2GY5"%5H0XT[*G@G;V2]<:ARDQT%V%A#BA:4P6L<1C&O(JN%1UERS6R4.V^N
MT-5#@EASTX$Z-RM)-3,5L,^RG([A26RIS,%LG(I!(3-4?(X@LDW:$BKS)[)K
MUP$'H=0AJ`9,'-H.^/UD9:`<;!WR_\G?A01XB7>@<P(</"DMK0/^)DTR+E<+
M[T!Y>`53A^BUY03(SE9&K0MR;0="BO%IUW0=XQAGP76V:K,1<'>]GN*QMH6:
MYI;<]4ED;^+]0!N7]83>VTLV`Y"SOI)..USUQ6R:-91'U$RDH_X=>:"<N*W/
MK"2-T=&&/[PY#KSU]>CY,481O2!O`KI)410KI*R"2;=DJH/I-%S"`BA@TO:F
MRK%=QZ@4I[1-PG2&\=,38@64Q:$=>S%B`CF88A\GUTM\C68LTX#E)BSI'%9;
MOPS**M8QG&%(V'N&-#[]QBKW7ZUO&<K!((I0?/G"L@EN@L&<+&'A,#AM\Q[2
MK>&C?0Z!CM)J<H:G1,>^I"S@^-(+P]53\FZ&][GAC$2CX#M,LDH2-#PM>DVQ
M])[@^99$49:3J,[<(%2AT9YBVE3(X9#3EKVL@02;V&(9,[CV[MJBU<1DX**M
ME$QC9T//68#O_8P.O%9^(3&:2A(-RAJ%F+<4.2C"?^#XA2SCS(USB^D_^-14
M'`4W\X6'0_ZR.213%$7Y::;`>+/.(8T_[:#Z,+6<OP?1`DWQ$T8S>"RZA(AI
M]C=9L!L6H)'G`@*67FNI/\RRM#URA;5:PD(EJ4:N+^!V*2%BF/U;ND^C>.U_
M@.^;W,]-VXQ>Z.,Z3!<0,+]1DMQBI3V^_:DM5A7V<?;#QM0$<(9-)2E;+IQZ
M236E9)I_7%(^/P)8C@[DS<CN;E)X_#J0*),OJ?(@Z5`23-%-0RJOP`XDN4B`
MDZO4=.`9FYK$*5)<MZ7/J8N`5>O^55#EIN?9>"G6(L#R\\N*+%.!DK/=<!7.
M88&_8?L,GKL(5KFKADAYDT3RC+,9BM4..6+`RRB`=58#53BL4OYH`9VS>BK$
MS4\DHA(",N>2.&6#.E*[+(/4F84LM]8C51HZ%%`YIV_H@FHK6BSP<BX1%8`7
M,%]`9)TZI_IKE5S[22$I<A][22:=*B1`ZV6:9-*8Z/?DG/M'`3)X'F&*G\;"
MS*UIL*2`H)9,U!34K_VU49+#['`CJ'HPR66OI_#UQH+*.P?1YJ@_I#NO75)H
M;.@A]A];I7]=2Z)!G#P]8WZA"1DM0Z;?7E,DUPHO4:VBIG7,UCWBJC&E_MU-
M%>O;&L=&:]/\+$/':,T`PE^,#V;_6$8QK]ZI8=;[))63NW?4Q93FA.Q""L_Z
MAM!N=K,.`WK7<':@S\&`A)N99FK3I[$6#5/,(]K,]'C\CNI-K-ZPGY'Z&B99
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MS`3[%);RMV8E*].!E`B%[5\%9OEQ[D#2@[H$+8.VWJ5A(O^A$[!OJR@FDQKV
M`F,NP5BBO0I,]04;6Y>:8TS.9G,1]-]2+=F3&N[X:DM7!+T[=3-)NQC*``9Z
M4L1;]$[=1EJ@EO+9I0!_<38UQAC`54Y@@:VSB>O&L"T-)(AB"ITRMW1MVOKA
M*E&FH;\!H0M0$CI-876WK*PYQ2()KZ<0GO;WF9(%FTVR$&#J/^8M,1B,@5F>
MBR,*M3C\RL08MCOY6Z)LB[.^%J!="TGC$^@YJZ4JY$KF;[^\/$]1&<=99=0$
M?KD'V,#[C)8<8!,09H%S5@^OZ]';S?$7D#7U8N5O'QC7C]2RHO_C_P-02P,$
M%`````@`MX9S1O,Y8Q^I$```TZD``!$`'`!A8FEO+3(P,30Q,C,Q+GAS9%54
M"0`#6C<+55HW"U5U>`L``00E#@``!#D!``#M76USVS82_GXS]Q]P^M!)YRI+
MBNTD]L6]T6NB.=G224K3?NK`)"3A2I$J`-K6O[\%2$JD^`)2EF/FCIDVH<C=
MQ2Z>Q6*Q@*B/_WQ:6^B!,$X=^Z;6.FO6$+$-QZ3V\J;F\CKF!J6U?_[\U[]\
M_%N]CJ;3'FH;@CZ0'N6&Y7"7D3>SVQ_1KYWI",V,%5ECU',,=TUL@>IH)<3F
MNM%X?'P\6U`;VP;%UAECYIGAK!NH7@_D=AG!`E1`/2P(4G^NT=MFZ[+>/*^W
MKN:M]]>7'ZXO/IR]O[BXNKKX\/=F\[K9#`GXQ3,!A?Z`@+/FV?G998AL@HT_
M\)*@82]$UKEX_^[]AP^=UGGSO#UH=UK=UOG@P_G[#^?OVIUWO6Z]"7^NFN_?
M75[`9>NRV0IK[FRVC"Y7`KTQ?E0JH^F9_*_GV#:Q++)%/Z"98W.@7&^PO3U#
M;<M"4\G"T91PPAZ(>>9+Y%X/`B@VO[9!@KN^J84Z\>F>66<.6S9,P1IBNR$-
M(*H#%6'4J/E\U'X@7.SX%`\GQMG2>6AXSQJ@YWF]V:J?MP(FP%K*XSNV!>;W
MJJG@B62ZB#)QL6')[<@GDJ%UP$"-%'IJ))!+$O/`$JG2VV;SLN$]#$CQ/74B
M7869(>]M5IBML?(WJ7_K;<3D)<:;1(OE@P2#34*3]8<'">22A"8#"":<`QI<
MP*`@`;WAN+9@V^0F_(<)V%G4_B.C%?GX'O-=*T\Q^L=S1=VZNKIJJ*<!J8VI
MP9/548\2,#-<QB"$I!GA/TWH+/)DK)*9Y),$AAR#(Q@86`A&[UU!!@Y;]\@"
MNQ:XE6O_Z6*++B@Q(>Q91`:M"$'HL<!L2<0=7A.^P08IYFI)G0W0M!J_WHZ\
MH%F#T8_01[K>.$P@+PR,'$,%Q0QHY:=ZX$5U>:O>>@M==/;$06<[4=LT%VP\
M0X7`Q8Y28>^?1ZD01`+9]F5:J\FAHWA[AZXE&[V2!K?>Y3(X[IK/T<&Q[YZK
M1GCZR*6*DI$8*AO$$GPW7=3W`S9-I>PIYE3:R#L%E8E%__RZ'$X(\B)'ZYF3
M2?'6PW-%\*&^GSAR:9$TWQRA23C@[SX5[9'$::.X,KN)1%T552(V#157()1^
M^==%44E(X(JKL9^[O<OZ?AK/I41\[B^N0Y#QR8NB[1]FBT>T'N2GZJIP^X?9
MK:\`MFU'J%;59WEGLZ'VPO$_P@TYV5TSQR)S"'B(FC>U.5EO+%CVC%3>)1]]
MF0YSYA<-2=Z(2BB6$^XT"W0S":S4J+)!KGM@D15>T`5-(=G6Q\8AQZ$PEQ-S
M;/^LKC<,%CNVUSTA;I\DB]/`EN%:1S#N-4OG\^\&D!P@%?33E"R0RHRO`0Q)
MFYT_-S;,V1`F*,QIH?1;"5@QLKBI24#K`8R_@X5G@%M`$FL@"IX"_:!3?"4#
M"8(**:*[)U*(\9\0MG;-R#GWIL9AV%CD)=<2C=?I5$"_:*=&'2:Y3WL[&FV7
MOI+A%KXO:CBP$"O=YI%\7%9S(;`4-?<P%B5;/0E1%39^%^,+1G2!GQS;66\]
M18/0&_S;MLV^#>IMAS"K`*]4K::FD2F0_YZ+/"ODMQ)B_NX2VR;RQ*&0O&*S
MP-&Q_/CIX_FSP&FPG('RJL;0:8_:=]W^['._/Y^%T$LAT.'5DGCM>.':9T<>
M?X7/L_"98%AYB!41%+I&"U:46H?<VVSDT)N(N!\K)(LB.9NWY_W;_MU\-AZ,
M)_UI>SX<W\W:=[WN^'8R[7_NW\V&O_1'XUGB,"S`K4/Z_!#IO6PT'J"]=`3B
M440^D@U4T#\'>NC,07\Z[?=F\W'W7]##ZM_/XU&O/YWU__UE./^MUQ\,N\.Y
MS@T*2-*YQ$6V2^Q:0JH)Y1?AQG[`&X?_`WEMHC=^JU6,>):C=-NSSX/1^*LV
M'.P)=3!?9L,L!2$EJ4(N;TZ\VWJ>KXB_JPJ)[LQ=KS';CA<SNK3I`F9,R'\-
M5<6D]G+B6-2`%44X67Z6'!WN[U06O6M"UDY6)-@$5JFTWQ!R%BC4%-JWA8+&
M*M<H[!IW1(P<SB>$S8"+),)^2*.#]'T,4I"`I`@$,I`24D%5&*I!<#)D:'/!
MU%(S>9@F$NI`^Q`#;2<&A>14N!7&;>*5:63,[/_ITHWLQT3<$@EUN%W%<`O$
M>'6(0%`%7&'@ID26\$U87`(FC&%[2=('72JQ!L!6,P:@+PHI62@LK`*Q,(B0
M2:RI4+T'XZKKJ(R!V*DY3A:]#LI6#,J0-#4<(_(J-`NC*<.9V/HSD[V4$'W%
M<H"DC,HL>AV:;V-H>M+07IS"-!!8P5D83I4*=C"H(!-^8O-8H5Y'J@/Q/`:B
M$E27.QDF"HNJX"L^&M<;R]D2TB$VZ"8F%K93AF$2H0ZZB_CX\\4@7PY2@BK@
M"@,WM(&,S/%3RB08?JZ#Z3(&D\>-%'L%SK>HUIRZ:I.W>M,Z9?4&O0FNJNKL
MLPLY<WQOI?A#,J4.Z3Q%'?3&$U;A=YHJ00:(&>0Z)..5GN2*087FBZPZ,T#5
M<^FPC5>#,E>@%<2G7KMDH)O)H`'V;;Q*E+:.J3`]25Z<`62<2H=>O#`4SI$K
MQ+YILMPC`E/K9+ER($[G`_%RTG-29;_5RF6."-P!K!"+J0$X]ZCE"F*&D^(L
M'RG"KW.*A/+4W@F4?.49?@NQ=+OR@E.ME_R>G),GX4;.+^;ET"$=KV8EK9]\
MH<B76@%[*F!;!2!M:<&,U[RRP&Q5,)[FM$-65,ZBU\$9KV(EGGVHXNTI9MVD
MRD6NZ3:+48=PO'H5FF?3RA\5VB>M9N688G.PZ9#.7]VJYMH7.R&3-9YU/#J`
MXR6N]/,RU1A^F1IFCJ&<GUL#^'F\]*6I:58#^_G9ERO@[UO0:NVN1P1S,L%;
M?0ZFY=)A'2^4>3*1+Q0IJ2@06XWOESE+E6-\Y^?685[TG%4UP%]L]R('[KD8
M=9#G/Y55@7V*D<X%7<L4Z2N1[U,D9ON!,+PDG^1XDJ^2'&#*?L&62_+4/X^7
MIG.+A!-?05LH:`SYK2'5G/<B3-D@4BU6Q='3+M9GPC'^&&^D;G)#1'YJ/V)F
MJI>;4J'933E"C,Y%XI6W\*Z)%(R\=KP=%75#-87V;56N<6+7X&-7R-<CRM?A
MRJ7[$V$&Y7)/LZAWZ"7I'"1>RTMQ$(Y";7FU@7UKE8N<PD6FLR_^J-OF<H0$
M>AW<F84]D!<,^VV%Z'/V5!R[B_DJ.??K/\G+S*%>A%^'>+S`!]+K4OQ/?A;9
MB6>1?AN5$YSXM']FGIA!KP,Y7N1+/OM?`7J:TTXY%G[IU!HP+^(%O.CIIVJ%
M=THH=Y?^0&G[[_26:<W<&;M,;E,/F+,>;V`AI3*AK%%\&LDZ%]$<D`M_W`6`
M</-(.)#.,6\+?@$JH+T.58PXC6/=$=$C"\(8,>%SFW.270W.R:ISC7AY\,`U
MY-$+TY>.P`Z$E?S_"]@_-L)OSH5/T3?K?O3?UJ_@D=#_GO7&P_8]%PP;PGNO
M[TTM'ZWW>D?U$P[7<`\64T-!UE+'&N(ND%'A2HY/S'$W`2$%DAKRKF&@4L><
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MSC86+,,=BQK;F*UZNC):US8,8##]Z@Y/L4U'54;+_.^%R*\`<'GT<9]:^JOD
MP_%8@*%D@[/H%V[4EZ4@4292:WY@_]%2_A<ZY5E]<507F.)Z!<^9X=ZKCGR9
MSA@SNH0H;-V2]3UA@96'=R/#V'36F-JO"F$;/IKR5E3MV.VRZ=V%A:9\C_:<
MP>S..]O)"G/2?J+[H99.<)P+F10TD`G3R[E0HLX]U=F99@4D90-)*3=?,4(^
M$\S$`%-+'KV+>%HV3=DLZA`N5-='C8C=+IO>G_IW_?FPVQXD*)_\K&P6>'[R
MZ'1TKI1"4C9[IF1)N2!,+LX8,<1X`:LP"$51DW149;/JSI5Z06H'<KRW4'IV
MQ.^'@S"U!5D2]KK)[*&*?GZB=O#F3M]FCORUF&1SDFE+9V(75H/@/!UJ3A@]
M*)KM)Y@L&M_?P-DV_K&Y5P;-$2IAE&(&#NL1"X8+J`^YI*IA]0@W&-WXK7C8
M%6'YY@FWQMY/0$6\4M:$.;*H8\Z=6T*$]^T"6$"./&MF\LP09N8NR!=G#-L>
MJ/ZZUL^(X3)U.FYHWSHVV0;6)3PH6STSJ125LDK.15JRI>#N..V^Z,3;IJGV
MBR!;33&T&%-93?:V"CM$/!)B?Z:$86:LMB/R0"P^9S`EP)S-VVNYGHU97HBW
M-*597;4ZZQU1J96AW!PE\X,,U9,*0#EHOQ\##RLZ&KK2%F^^P@)N+7\^G;!H
M`I[PH&PY=WO)B+HU)PQ45=)DDA/,][N:CI:N?#.^+(<;@IBWU`(@(.0%7ZJ3
M>[SMS092&;S+RG,2GSB*2N?`*K*?.(BV;4>L""O4!<5XOI>>\+]7"6YJR/V"
M):Q*ILX66V([OK?H,G`RU0/Y:"/K&$GXNFY^BY_R&YB+MF0&IFLKUR'@G5]L
M4ZZ.>5`O'T%8LCG9Q:Q=C>?Y@DK6-4D.*]\-$-@G9\\5%EUL=TC'W?:<QTQ?
MU[*6S?P$=\YK_C&L)3/?]V%?O9Y[,&>G/B[A5)U^$"$EYR_"4;*4^(Z("7,,
M0DQUEGA_#&W"Z`/$HHF%C4C<*L!0FE6>Y@#.H>8ST"RHG,EOO.[/9.GH(LX,
M=U[7D;U*N\/D&F9%R:+_1`Q0X`'`6L!D<K!`R$M=ME7#Q(5ITTC>=4A^5C8+
MNA;F?'>^<\RF\KO7H:]'0A),O3:B,;4X7_F";98-Q"_<JW)V>'),*^U'CA:_
MA.13SKGY%QDY=T'"H2KQ4;FB4^I$DK"7DX_V>YEO#O="T^8;/5VY$(T>P)VX
MS)#[V&9GZ\\@R6>;D^A.NN?Q_($65=@[<0S+M*$]=Q*<-2]UV39VPG'0"WB1
M\35?$=L[APX90NC+_".ZIF)L[T]DCQ]MPOB*;I*6NB<27*Y`/+1E(L^IH79"
MQHL^Y!FF21)/J0\(EJ_8VGWOXQC6[R70)4[!?)^6R"#6QR"1<)$Y;:?RA'MB
M^1O![-:QQ:J$*<V!!2/XOYC-`4<9+9X_.O.5XW(8MS"$YRL*\8[8\A!)-!W7
MTY4M-1_:,KC`(BCTUI2H35D49;,FVO\#QV4AI75P99"7S<ZQW#K(-"V+HFS6
M[*?/SXXE)\:!$U:=1]8T\3DW%U/)BHD1[;Q2J'UP1C*3I&P0QI6%L:6S)T3R
M'=@C#SYK+0H3E=\F&?%T)H5IO@.+8)[26A2B*9M%`\JX4%[DQ[<)WLKC&>K-
M%+&I.2]UV:R\(T\"!G\>$W.1ELV^\"]Z)6^H9%&4;`/%?_,)+%<=SKN0P6\7
M#I.O0`SE[S)-WV4>N>ECF?[KSLE?J8!D,/QFD1&%!Q85V[$]7&\P9;+(H>IT
MG$\))_($H/S!)GD&T-G$OYMU2HFE]?$I,1S;`*.\%WF8_W&Y.EDV=P[?T1)S
M_B*L92P)?&QP8T76&"[_"U!+`0(>`Q0````(`+>&<T;&P7=7%/4``!:X$@`1
M`!@```````$```"D@0````!A8FEO+3(P,30Q,C,Q+GAM;%54!0`#6C<+575X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`+>&<T8FP!Y3\@L``'.?```5`!@`
M``````$```"D@5_U``!A8FEO+3(P,30Q,C,Q7V-A;"YX;6Q55`4``UHW"U5U
M>`L``00E#@``!#D!``!02P$"'@,4````"`"WAG-&.E_+*GTH``#FI`(`%0`8
M```````!````I(&@`0$`86)I;RTR,#$T,3(S,5]D968N>&UL550%``-:-PM5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`MX9S1KQ2SL/$:0``-7`&`!4`
M&````````0```*2!;"H!`&%B:6\M,C`Q-#$R,S%?;&%B+GAM;%54!0`#6C<+
M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+>&<T8.JGZ[\CL``-6-!``5
M`!@```````$```"D@7^4`0!A8FEO+3(P,30Q,C,Q7W!R92YX;6Q55`4``UHW
M"U5U>`L``00E#@``!#D!``!02P$"'@,4````"`"WAG-&\SEC'ZD0``#3J0``
M$0`8```````!````I('`T`$`86)I;RTR,#$T,3(S,2YX<V155`4``UHW"U5U
D>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``M.$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EINAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Income Tax Benefit Attributable to Our Loss from Operations (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax benefit at statutory rates</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (3,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (2,429)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(296)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(209)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(171)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(133)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" onclick="toggleNextSibling(this);">1,041</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset', window );">Deferred tax asset adjustment</a></td>
        <td class="nump"><a title="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" onclick="toggleNextSibling(this);">2,907</a><span style="display:none;white-space:normal;text-align:left;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">178</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherAdjustments</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">184</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(365)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">2,587</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment of the carrying value of deferred tax assets during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32059-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUIBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Stock Options Outstanding and Exercisable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" onclick="toggleNextSibling(this);">1,068,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">8 years 3 months<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" onclick="toggleNextSibling(this);">$ 2.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" onclick="toggleNextSibling(this);">494,291</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" onclick="toggleNextSibling(this);">$ 4.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember', window );">$0.36-$1.33</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">$ 0.36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">$ 1.33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">29,933</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">9 years 9 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">$ 1.05</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">704</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">$ 1.08</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember', window );">$1.38-$1.38</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">$ 1.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">$ 1.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">727,869</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">8 years 5 months 19 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">$ 1.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">329,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">$ 1.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember', window );">$1.40-$1.95</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">$ 1.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">$ 1.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">212,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">9 years 1 month 10 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">$ 1.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">70,410</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember]" onclick="toggleNextSibling(this);">$ 1.84</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeThreeMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember', window );">$1.96-$22.98</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">$ 1.96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">$ 22.98</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">82,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">4 years 5 months 9 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">$ 13.68</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">78,070</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember]" onclick="toggleNextSibling(this);">$ 13.55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFourMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember', window );">$22.99-$33.42</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">$ 22.99</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">$ 33.42</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">15,918</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Average Life</a></td>
        <td class="text">3 years 8 months 27 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">$ 32.87</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">15,918</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember]" onclick="toggleNextSibling(this);">$ 32.87</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= abio_ExercisePriceRangeFiveMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFiveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeFourMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeThreeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abio_ExercisePriceRangeTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Financial Instruments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs for the asset or liability </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets include $15.3 million at December&#160;31, 2014 and $16.5 million at December&#160;31, 2013, in money market funds, classified as cash equivalents, which are measured at fair value based on Level 1 inputs on a recurring basis. The Company has the ability to liquidate these investments without restriction.&nbsp;&nbsp;The Company determines fair value for these money market funds and equity securities with Level 1 inputs through quoted market prices.&nbsp;&nbsp;We have no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December 31, 2014.&nbsp;&nbsp;There were no transfers between any fair value hierarchy levels in 2014 or 2013. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Other Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of other financial instruments, including cash, and accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2014 and 2013, the Company did not have any debt outstanding. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FinancialInstrumentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_FinancialInstrumentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y
M,#<Y,SAE,#$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U
M8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V
M-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0D%,04Y#15]32$5%
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"04Q!
M3D-%7U-(14544U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]/4$52051)3TY37T%.
M1%]#/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1!
M5$5-14Y44U]/1E]04D5&15)2141?4U1/0TM?/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]#05-(7T9,3U=3
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O
M;7!A;GE?86YD7U-U;6UA<GE?;V9?4VEG/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3F5T7TQO<W-?4&5R7U-H87)E/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1FEN86YC:6%L7TEN<W1R
M=6UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4')O<&5R='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?07)R86YG96UE;G1S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N
M='-?86YD7T-O;G1I;F=E;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y%<75I='E?1FEN86YC:6YG<U]A;F1?5V%R<F%N=',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R96)A
M<V5D7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D5M<&QO>65E7T)E;F5F:71?4&QA;G,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y4:&5?0V]M<&%N>5]A
M;F1?4W5M;6%R>5]O9E]3:6<Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3F5T7TQO<W-?4&5R7U-H87)E7U1A8FQE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%
M<75I<&UE;G1?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5B87-E9%]#
M;VUP96YS871I;VY?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E1H95]#;VUP86YY7V%N9%]3=6UM
M87)Y7V]F7U-I9S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=6UM87)Y7V]F7T)A<VEC7V%N9%]$:6QU=&5D7TP\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?3&]S<U]097)?4VAA
M<F5?1&5T86EL<U]497@\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y.971?3&]S<U]097)?4VAA<F5?1&5T86EL<U\Q/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1FEN86YC:6%L7TEN<W1R
M=6UE;G1S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=6UM87)Y7V]F7U!R;W!E<G1Y7V%N9%]%<75I<&T\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?
M17%U:7!M96YT7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7T%R<F%N9V5M96YT<U]$970\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT
M<U]A;F1?0V]N=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1G5T=7)E7TUI;FEM=6U?3&5A<V5?4&%Y;65N='-?
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:71Y
M7T9I;F%N8VEN9W-?86YD7U=A<G)A;G1S,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-H87)E8F%S961?0V]M<&5N<V%T:6]N7T1E
M=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5S
M=&EM871E9%]796EG:'1E9%]!=F5R86=E7T=R83PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4W1O8VM?3W!T:6]N
M7V%N9%]3=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4W1O8VM?3W!T:6]N<U]/=71S=#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4E-57T%C=&EV
M:71Y7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DYO;D-A<VA?4VAA<F5"87-E9%]#;VUP96YS871I;SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5M<&QO>65E7T)E;F5F:71?
M4&QA;G-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DEN8V]M95]487AE<U]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?26YC
M;VUE7U1A>%]"96YE9FD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#(N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?3F5T7V1E9F5R<F5D7W1A>%\\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\
M+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B
M5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\
M+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\
M+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L
M<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\
M+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4
M:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E
M;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y
M,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?
M9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970P
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P1413044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,3<L(#(P,34\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U
M;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E
M9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M05)#02!":6]P:&%R;6$L($EN8RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,#DP-S8U-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`M2SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I
M<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A
M=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L;&5R
M(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B;&EC($9L;V%T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P+#`P,RPY-#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,3DX+#0Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P
M7V$P9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K
M<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5064%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D)!3$%.0T4@4TA%1513("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PS-30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#<U-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H
M97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PT.#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPY,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V+#$S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`X-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M<&5N<V%T:6]N(&%N
M9"!E;7!L;WEE92!B96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PS.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N="P@;F5T
M(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PS.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD(&-O
M;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G/B
M@)D@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#4@
M;6EL;&EO;B!S:&%R97,@875T:&]R:7IE9#L@;F\@<VAA<F5S(&ES<W5E9"!O
M<B!O=71S=&%N9&EN9RX@4V5R:65S($$@8V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E.R`Q,S4L,#`P('-H87)E<R!D97-I
M9VYA=&5D(&9R;VT@875T:&]R:7IE9"!P<F5F97)R960@<W1O8VL[(&YO('-H
M87)E<R!I<W-U960@;W(@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P
M,30@86YD(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,#$@
M<&%R('9A;'5E.R`Q,#`@;6EL;&EO;B!S:&%R97,@875T:&]R:7IE9"!A="!$
M96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,SL@,C$L,34P+#0X-B!A;F0@,34L
M-C@U+#4V,B!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!$96-E
M;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M
M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DL
M,S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`L-#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X-"PV,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S0L.3,S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K
M:&]L9&5R<^*`F2!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T+#<T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U+#4X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S(&%N9"!S=&]C
M:VAO;&1E<G/B@)D@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$V+#$S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3<L,#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y
M,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ
M,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE
M970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15%-044^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0D%,04Y#12!32$5%5%,@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q+#$U,"PT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-2PV.#4L-38R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$L,34P+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+#8X-2PU-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!(%!R969E<G)E9"!3
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R
M960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T
M.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T
M.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I)
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1!5$5-14Y44R!/1B!/4$52
M051)3TY3($%.1"!#3TU04D5(14Y3259%($Q/4U,@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V]S=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PV
M,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O
M<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PV.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#DT,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#8Y,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#DT,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M(&%N9"!O=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@86YD(&-O;7!R96AE;G-I=F4@
M;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PV.#DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPY
M,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,97-S.B!$965M960@<')E9F5R<F5D('-T;V-K(&1I=FED96YD/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`R-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<R!A=F%I;&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Y+#8X.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@L.38U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY.970@;&]S<R!A=F%I;&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R<R!P
M97(@<VAA<F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N-#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q+C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!A
M=F5R86=E('-H87)E<R!O=71S=&%N9&EN9SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4P,2PR,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#8R.2PT
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4X
M-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U
M8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M-4="23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY35$%414U%3E13($]&(%!2
M149%4E)%1"!35$]#2R!!3D0@4U1/0TM(3TQ$15)3)R!%455)5%D@*$1%1DE#
M250I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T
M83PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O=&%L
M/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M0V]M;6]N('-T;V-K/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED+6EN($-A<&ET86P\8G(^55-$
M("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!8V-U;75L
M871E9"!$969I8VET/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5R:65S($$@0V]N=F5R=&EB;&4\8G(^4')E9F5R<F5D
M(%-T;V-K/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M96=I;FYI;F<@0F%L86YC92P@=F%L=64@870@1&5C+B`S,2P@,C`Q,CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#DP-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S`L.#DX
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@V-RPY.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92P@<VAA<F5S(&%T($1E8RX@
M,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C8P
M+#,Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!C87-H+"!N970@
M;V8@;V9F97)I;F<@8V]S=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3(Q+#`V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M(&9O<B!C87-H+"!N970@;V8@;V9F97)I;F<@8V]S=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D:G5S=&UE;G0@9F]R
M(&9R86-T:6]N86P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C
M:7-E(&]F('=A<G)A;G1S(&9O<B!C87-H+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L,C0U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<R!F;W(@8V%S:"P@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(%-E<FEE<R!!(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@
M;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(%-E<FEE<R!!
M(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPY,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPY,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E96UE9"!P<F5F97)R960@<W1O8VL@9&EV:61E;F0@9F]R(&)E
M;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#`R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!$965M960@<')E9F5R
M<F5D('-T;V-K(&1I=FED96YD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R+#`R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#`R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@<')E9F5R<F5D('-T
M;V-K+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,C4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!P<F5F97)R960@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#8L.3,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#8L.3,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('9A
M;'5E(&%T($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U+#4X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3`L-#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-S0L.3,S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L
M('-H87)E<R!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-2PV.#4L-38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C;W-T<RP@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$Q-BPR,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#@V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@
M;V8@=V%R<F%N=',@9F]R(&-A<V@L('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`Y+#`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',@9F]R(&-A<V@L('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.2PV.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.2PV.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@=7!O;B!V97-T:6YG(&]F(%)E<W1R:6-T960@4W1O8VL@07=A<F1S+"!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S.2PV-S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N('9E<W1I;F<@;V8@4F5S
M=')I8W1E9"!3=&]C:R!!=V%R9',L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@=F%L=64@870@
M1&5C+B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-"PW-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Y.2PS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#@T+#8R,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E
M+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$L,34P+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T
M.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y
M,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H
M965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$535$%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-4051%345.5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S
M:"!F;&]W<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Y+#8X.2PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#DS
M.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@
M;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&-H87)G97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C@S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V4@:6X@;W!E<F%T
M:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,30L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U-#4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DX+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S,BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@
M8V]M<&5N<V%T:6]N(&%N9"!E;7!L;WEE92!B96YE9FET<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3,P+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-38L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&5X<&5N<V5S(&%N9"!O=&AE<B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3@R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C4L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH.2PT,#8L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,C@X+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C
M:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S(L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S
M960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$Y+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO
M=W,@9G)O;2!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@
M:7-S=6%N8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!I
M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDL,#,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-S0Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F('!R
M:6YC:7!A;"!O;B!V96YD;W(@9FEN86YC92!A9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$W.2PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<T+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP,C,L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,34V+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="`H9&5C<F5A<V4I(&EN8W)E87-E(&EN(&-A<V@@86YD(&-A<V@@97%U
M:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#`R
M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,RPX,S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!B
M96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-BPW-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPY,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PS-30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38L-S4V+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M
M96YT86P@8V%S:"!F;&]W(&EN9F]R;6%T:6]N.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!P86ED/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R
M960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9F5R
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`X
M,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C
M=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#@S-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@S,C@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P
M9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE
M971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY4:&4@0V]M<&%N>2!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4:&4@0V]M<&%N>2!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#L^
M)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$97-C<FEP
M=&EO;B!O9B!"=7-I;F5S<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M9&\N($]N($IA;G5A<GDF(S$V,#LR-RP@,C`P.2P@=&AE($-O;7!A;GD@8V]M
M<&QE=&5D(&$@8G5S:6YE<W,@8V]M8FEN871I;VXL(&]R('1H92!-97)G97(L
M('=I=&@@05)#02!#;VQO<F%D;R!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('1E
M<FUS(&]F('1H870@06=R965M96YT(&%N9"!0;&%N(&]F($UE<F=E<B!A;F0@
M4F5O<F=A;FEZ871I;VXL(&1A=&5D(%-E<'1E;6)E<B8C,38P.S(T+"`R,#`X
M+"!A;F0@86UE;F1E9"!O;B!/8W1O8F5R)B,Q-C`[,C@L(#(P,#@L(&EN('=H
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M(&%C<75I<F5D(&-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M:&4@9')U9RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T
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M<V4@,R!H96%R="!F86EL=7)E("A(1BD@=')I86P@;V8@1V5N8V%R;R!I;B`R
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY!4D-!(&AA<R!C<F5A=&5D(&%N(&%D87!T:79E(&1E<VEG;B!F;W(@1T5.
M151)0RU!1BXF;F)S<#LF;F)S<#M4:&4@0V]M<&%N>2!I<R!S965K:6YG('1O
M(&5N<F]L;"!A<'!R;WAI;6%T96QY(#(P,"!(1E)%1B!P871I96YT<R!I;B!T
M:&4@4&AA<V4@,D(@<&]R=&EO;B!O9B!T:&4@<W1U9'DN(%1H92!'14Y%5$E#
M+4%&($1A=&$@4V%F971Y($UO;FET;W)I;F<@0F]A<F0@*$1334(I('=I;&P@
M86YA;'EZ92!C97)T86EN(&1A=&$@9G)O;2!T:&4@4&AA<V4@,D(@<&]R=&EO
M;B!O9B!T:&4@=')I86P@86YD(')E8V]M;65N9"!B87-E9"!O;B!A(&-O;7!A
M<FES;VX@=&\@=&AE('!R92UT<FEA;"!S=&%T:7-T:6-A;"!A<W-U;7!T:6]N
M<RP@=VAE=&AE<B!T:&4@=')I86P@<VAO=6QD('!R;V-E960@=&\@4&AA<V4@
M,R!A;F0@96YR;VQL(&%N(&%D9&ET:6]N86P@-#(P('!A=&EE;G1S+B!4:&4@
M1%--0B!W:6QL(&UA:V4@=&AE:7(@<F5C;VUM96YD871I;VX@8F%S960@;VX@
M86YA;'ES:7,@;V8@8V5R=&%I;B!T<FEA;"!D871A(&%F=&5R(#(P,"!P871I
M96YT<R!H879E(&-O;7!L971E9"`R-"!W965K<R!O9B!F;VQL;W<M=7`L('1H
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M='5D>2!N;W0@<')O8V5E9"!T;R!0:&%S92`S+B!4:&4@0V]M<&%N>2P@:6X@
M8V]N<W5L=&%T:6]N('=I=&@@=&AE('1R:6%L)B,X,C$W.W,@(%-T965R:6YG
M($-O;6UI='1E92!A;F0@=&AE($1334(L('=I;&P@;6%K92!T:&4@9FEN86P@
M9&5T97)M:6YA=&EO;B!O;B!T:&4@=')I86PF(S@R,3<[<R!D979E;&]P;65N
M="!S=&5P<RX@5&AE($-O;7!A;GD@8F5L:65V97,@=&AE(%!H87-E(#)"(&5N
M<F]L;&UE;G0@;V8@,C`P('!A=&EE;G1S(&-O=6QD(&)E(&-O;7!L971E9"!B
M>2!T:&4@96YD(&]F(#(P,38L('=I=&@@=&AE($1334(@:6YT97)I;2!A;F%L
M>7-I<R!F:6YI<VAI;F<@:6X@=&AE(&9I<G-T(&AA;&8@;V8@,C`Q-RX@(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<V-O;G1I;G5E(&ET<R!O<&5R871I;VYS+B`\+W`^#0H\<"!S='EL93TS1"=M
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M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ
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M;VXN)FYB<W`[)FYB<W`[5&AE($-O;7!A;GD@:&%S(&AI<W1O<FEC86QL>2!F
M=6YD960@:71S(&]P97)A=&EO;G,@=&AR;W5G:"!I<W-U86YC97,@;V8@8V]M
M;6]N(&%N9"!P<F5F97)R960@<W1O8VLN(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$=7)I;F<@,C`Q
M,RP@=&AE($-O;7!A;GD@<F%I<V5D(&%P<')O>&EM871E;'D@)#$Y+C,@;6EL
M;&EO;BP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!T:')O=6=H('-A;&5S(&]F
M(&ET<R!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@86YD(&-O;6UO;B!S
M=&]C:R!A;F0@=V%R<F%N=',N)FYB<W`[)FYB<W`[26X@1F5B<G5A<GD@,C`Q
M-"P@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@<'5B;&EC(&5Q=6ET>2!O9F9E
M<FEN9R!R86ES:6YG(&%P<')O>&EM871E;'D@)#<N.2!M:6QL:6]N(&EN(&YE
M="!P<F]C965D<R!T;R!P<F]V:61E(&%D9&ET:6]N86P@9G5N9',@9F]R('1H
M92!0:&%S92`R0B\S($=%3D5424,M048@=')I86P@86YD('1H92!#;VUP86YY
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M=6-T=7)E+"!T:')O=6=H('1H92!E;F0@;V8@,C`Q-2X@($AO=V5V97(L(&EN
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I
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M9RP@8G5T(&YO="!L:6UI=&5D('1O+"!T:&4@9F]L;&]W:6YG.B`\+W`^#0H\
M9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE9G0Z-"XU-"4[
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S
M)3MW:&ET92US<&%C93IN;W=R87`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SMF;VYT+7-I>F4Z,3!P=#LG/B8C.#(R-CL\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^('!R;V=R97-S(&]F($=%3D54
M24,M048L(&EN8VQU9&EN9R!E;G)O;&QM96YT(&%N9"!A;GD@9&%T82!T:&%T
M(&UA>2!B96-O;64@879A:6QA8FQE.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE
M9G0Z-"XU-"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HS+C,S)3MW:&ET92US<&%C93IN;W=R87`^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#L[9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[9F]N="US:7IE.C$P<'0[)SXF(S@R,C8[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;W9A;"!F;W(@1V5N8V%R;SL\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^
M#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE9G0Z-"XU
M-"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS
M+C,S)3MW:&ET92US<&%C93IN;W=R87`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SMF;VYT+7-I>F4Z,3!P=#LG/B8C.#(R-CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HY-BXV-R4[/@T*/'`@
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M969T/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[
M('=I9'1H.CDU+C0V)3MM87)G:6XM;&5F=#HT+C4T)3LG/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C,N,S,E.W=H:71E+7-P86-E
M.FYO=W)A<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.V9O;G0M
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M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.34N-#8E.VUA<F=I;BUL
M969T.C0N-30E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[9F]N="US:7IE.C$P<'0[)SXF(S@R,C8[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.34N
M-#8E.VUA<F=I;BUL969T.C0N-30E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[9F]N="US:7IE.C$P<'0[
M)SXF(S@R,C8[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z-G!T.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
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M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.34N
M-#8E.VUA<F=I;BUL969T.C0N-30E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[9F]N="US:7IE.C$P<'0[
M)SXF(S@R,C8[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z-G!T.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
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M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.CDU+C0V
M)3MM87)G:6XM;&5F=#HT+C4T)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!S='EL93TS1'=I9'1H.C,N,S,E.W=H:71E+7-P86-E.FYO=W)A<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O
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M965M96YT<RX@/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M(')E<V]U<F-E<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ
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M<&5R:6]D(&]F('1I;64N)FYB<W`[)FYB<W`[5&AE<V4@9FEN86YC:6%L('-T
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ
M,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D]N($9E8G)U87)Y(#$X+"`R,#$U+"!W92!R96-E:79E9"!N;W1I
M9FEC871I;VX@9G)O;2!.05-$05$@;V8@<&]T96YT:6%L(&1E;&ES=&EN9R!O
M9B!O=7(@<VAA<F5S(&9R;VT@=&AE($Y!4T1!42!#87!I=&%L($UA<FME="!B
M96-A=7-E('1H92!C;&]S:6YG(&)I9"!P<FEC92!O9B!O=7(@8V]M;6]N('-T
M;V-K(&AA9"!N;W0@;65T('1H92!M:6YI;75M(&-L;W-I;F<@8FED('!R:6-E
M(&]F("0Q+C`P('!E<B!S:&%R92!D=7)I;F<@=&AE('!R96-E9&EN9R`S,"!D
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M<W0@)#$N,#`@<&5R('-H87)E(&9O<B!A(&UI;FEM=6T@;V8@,3`@8V]N<V5C
M=71I=F4@8G5S:6YE<W,@9&%Y<R!D=7)I;F<@=&AE(#$X,"!C86QE;F1A<B!D
M87D@9W)A8V4@<&5R:6]D+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5V97)S92!3=&]C:R!3<&QI=#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M-G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3VX@36%R8V@F(S$V,#LT+"`R,#$S
M+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82`Q+69O<BTV(')E=F5R<V4@<W!L
M:70@;V8@:71S(&-O;6UO;B!S=&]C:RX@06QL(&-O;6UO;B!S:&%R97,@86YD
M('!E<B!C;VUM;VX@<VAA<F4@86UO=6YT<R!I;B!T:&4@9FEN86YC:6%L('-T
M871E;65N=',@86YD(&9O;W1N;W1E<R!H879E(&)E96X@861J=7-T960@<F5T
M<F]A8W1I=F5L>2!T;R!R969L96-T('1H92!E9F9E8W1S(&]F('1H:7,@86-T
M:6]N+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M<F=I;BUT;W`Z-G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[
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M8V]U;G1I;F<@<')I;F-I<&QE<R`H52Y3+B!'04%0*2!A;F0@:6YC;'5D92!A
M;&P@861J=7-T;65N=',@;F5C97-S87)Y(&9O<B!T:&4@9F%I<B!P<F5S96YT
M871I;VX@;V8@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;BP@<F5S=6QT<R!O9B!O
M<&5R871I;VYS(&%N9"!C87-H(&9L;W=S(&9O<B!T:&4@<&5R:6]D<R!P<F5S
M96YT960N)FYB<W`[)FYB<W`[3W5R(&UA;F%G96UE;G0@<&5R9F]R;65D(&%N
M(&5V86QU871I;VX@;V8@;W5R(&%C=&EV:71I97,@=&AR;W5G:"!T:&4@9&%T
M92!O9B!F:6QI;F<@;V8@=&AI<R!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M
M2RP@86YD(&-O;F-L=61E9"!T:&%T('1H97)E(&%R92!N;R!S=6)S97%U96YT
M(&5V96YT<RP@97AC97!T(&9O<B!T:&4@;F]T:6-E(&9R;VT@3D%31$%1(&1I
M<V-L;W-E9"!I;B!.;W1E(#$@=&\@=&AE<V4@9FEN86YC:6%L('-T871E;65N
M=',N("`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C$X<'0[;&EN92UH96EG:'0Z,3%P=#MT97AT+6EN9&5N=#HP)3MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5C96YT($%C8V]U;G1I
M;F<@4')O;F]U;F-E;65N=',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'0[;6%R9VEN+6)O='1O;3HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.VQE='1E<BUS<&%C:6YG.BTP+C%P=#MF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DEN($IU;F4@,C`Q-"P@=&AE($9!4T(@:7-S=65D($9!4T(@06-C;W5N
M=&EN9R!3=&%N9&%R9',@57!D871E("@F(S@R,C`[05-5)B,X,C(Q.RD@3F\N
M(#(P,30M,3`L(#QF;VYT('-T>6QE/3-$9F]N="US='EL93II=&%L:6,[/D1E
M=F5L;W!M96YT(%-T86=E($5N=&ET:65S("A4;W!I8R`Y,34I.B!%;&EM:6YA
M=&EO;B!O9B!#97)T86EN($9I;F%N8VEA;"!297!O<G1I;F<@4F5Q=6ER96UE
M;G1S+"!);F-L=61I;F<@86X@06UE;F1M96YT('1O(%9A<FEA8FQE($EN=&5R
M97-T($5N=&ET:65S($=U:61A;F-E(&EN(%1O<&EC(#@Q,"P@0V]N<V]L:61A
M=&EO;CPO9F]N=#X@=VAI8V@@<F5M;W9E<R!4;W!I8R`Y,34@9G)O;2!T:&4@
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M($1E8V5M8F5R(#$U+"`R,#$T+"!W:71H(&5A<FQY(&%D;W!T:6]N(&)E:6YG
M('!E<FUI='1E9"!F;W(@86YN=6%L(&]R(&EN=&5R:6T@<&5R:6]D<R!F;W(@
M=VAI8V@@9FEN86YC:6%L('-T871E;65N=',@:&%V92!N;W0@8F5E;B!I<W-U
M960N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@861O<'1E9"!T:&ES(&=U:61A
M;F-E(&%S(&]F($IU;F4@,S`L(#(P,30@86YD(&%S(&$@<F5S=6QT+"!R96UO
M=F5D(')E9F5R96YC97,@=&\@8F5I;F<@82!D979E;&]P;65N="!S=&%G92!E
M;G1I='D@86YD(&EN8V5P=&EO;BUT;RUD871E(')E<W5L=',@9G)O;2!T:&5S
M92!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H\<"!S='EL93TS1"=M87)G
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M(%5P9&%T92`H)B,X,C(P.T%352!.;RX@,C`Q-"TQ-28C.#(R,3LI+"`\9F]N
M="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SY0<F5S96YT871I;VX@;V8@
M1FEN86YC:6%L(%-T871E;65N=',@)B,X,C$Q.R!';VEN9R!#;VYC97)N("A3
M=6)T;W!I8R`R,#4M-#`I.B!$:7-C;&]S=7)E(&]F(%5N8V5R=&%I;G1I97,@
M86)O=70@86X@16YT:71Y)B,X,C$W.W,@06)I;&ET>2!T;R!#;VYT:6YU92!A
M<R!A($=O:6YG($-O;F-E<FX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+7-T
M>6QE.FET86QI8SMT97AT+61E8V]R871I;VXZ=6YD97)L:6YE.SXN/"]F;VYT
M/B8C,38P.R8C,38P.T%352!.;RX@,C`Q-"TQ-2!W:6QL(&)E(&5F9F5C=&EV
M92!F;W(@9FES8V%L('EE87)S(&%N9"!I;G1E<FEM('!E<FEO9',@96YD:6YG
M(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+"!W:71H(&5A<FQY(&%D;W!T:6]N
M(&)E:6YG('!E<FUI='1E9"!F;W(@86YN=6%L(&%N9"!I;G1E<FEM('!E<FEO
M9',@9F]R('=H:6-H(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@;F]T(&)E
M96X@:7-S=65D+B!!4U4@,C`Q-"TQ-2!R97%U:7)E<R!T:&%T(&UA;F%G96UE
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M)B,Q-C`[)B,Q-C`[5&AE('-I9VYI9FEC86YT('5N8V5R=&%I;G1I97,@<W5R
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M861O<'1I;VX@;V8@=&AI<R!G=6ED86YC92XF;F)S<#LF;F)S<#L\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#ML
M:6YE+6AE:6=H=#HQ,7!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY!8V-O=6YT:6YG($5S=&EM871E<R!I;B!T:&4@
M4')E<&%R871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@/"]P/@T*/'`@
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M(&5S=&EM871E<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ.'!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-A<V@@17%U
M:79A;&5N=',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M<R!A;F0@9&5B="!S96-U<FET:65S('=I=&@@;6%T=7)I=&EE<R!O9B`Y,"!D
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M:6YC:7!A;"!A;F0@;&EQ=6ED:71Y+B`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[;&EN92UH96EG:'0Z,3%P
M=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY4:&4@0V]M<&%N>2!C;&%S<VEF:65S(&%L;"!C87-H(&5Q=6EV86QE
M;G1S(&%S(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S+"!A;F0@<F5C
M;W)D<R!I;G9E<W1M96YT<R!A="!F86ER('9A;'5E+B`@/"]P/@T*/'`@<W1Y
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M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M-G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1FEN86YC:6%L(&EN<W1R=6UE;G1S
M('1H870@<&]T96YT:6%L;'D@<W5B:F5C="!T:&4@0V]M<&%N>2!T;R!S:6=N
M:69I8V%N="!C;VYC96YT<F%T:6]N<R!O9B!C<F5D:70@<FES:R!C;VYS:7-T
M('!R:6UA<FEL>2!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+B!4:&4@
M0V]M<&%N>2!H87,@;F\@;V9F+6)A;&%N8V4M<VAE970@8V]N8V5N=')A=&EO
M;G,@;V8@8W)E9&ET(')I<VLL('-U8V@@87,@9F]R96EG;B!E>&-H86YG92!C
M;VYT<F%C=',L(&]P=&EO;B!C;VYT<F%C=',L(&]R(&9O<F5I9VX@8W5R<F5N
M8WD@:&5D9VEN9R!A<G)A;F=E;65N=',N(%1H92!#;VUP86YY(&UA:6YT86EN
M<R!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G0@8F%L86YC97,@:6X@=&AE(&9O
M<FT@;V8@8F%N:R!D96UA;F0@9&5P;W-I=',@86YD(&UO;F5Y(&UA<FME="!F
M=6YD(&%C8V]U;G1S('=I=&@@9FEN86YC:6%L(&EN<W1I='5T:6]N<R!T:&%T
M(&UA;F%G96UE;G0@8F5L:65V97,@87)E(&-R961I='=O<G1H>2X@4W5C:"!B
M86QA;F-E<R!M87D@870@=&EM97,@97AC965D('1H92!I;G-U<F5D(&%M;W5N
M="X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ.'!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M('1H92!R96QA=&5D(&%S<V5T<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY!8V-R=65D($5X<&5N<V5S
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4V5G;65N=',@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M86P@<F5P;W)T:6YG+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N
M="`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D-O<W1S(')E;&%T960@=&\@8VQI;FEC86P@=')I86P@
M86YD(&1R=6<@;6%N=69A8W1U<FEN9R!A8W1I=FET:65S(&%R92!B87-E9"!U
M<&]N(&5S=&EM871E<R!O9B!T:&4@<V5R=FEC97,@<F5C96EV960@86YD(')E
M;&%T960@97AP96YS97,@:6YC=7)R960@8GD@8V]N=')A8W0@<F5S96%R8V@@
M;W)G86YI>F%T:6]N<RP@;W(@0U)/<RP@8VQI;FEC86P@<W1U9'D@<VET97,L
M(&1R=6<@;6%N=69A8W1U<F5R<RP@8V]L;&%B;W)A=&EO;B!P87)T;F5R<RP@
M;&%B;W)A=&]R:65S+"!C;VYS=6QT86YT<RP@;W(@;W1H97)W:7-E+B!296QA
M=&5D(&-O;G1R86-T<R!V87)Y('-I9VYI9FEC86YT;'D@:6X@;&5N9W1H+"!A
M;F0@8V]U;&0@8F4@9F]R(&$@9FEX960@86UO=6YT+"!A('9A<FEA8FQE(&%M
M;W5N="!B87-E9"!O;B!A8W1U86P@8V]S=',@:6YC=7)R960L(&-A<'!E9"!A
M="!A(&-E<G1A:6X@;&EM:70L(&]R(&9O<B!A(&-O;6)I;F%T:6]N(&]F('1H
M97-E(&5L96UE;G1S+B!!8W1I=FET>2!L979E;',@87)E(&UO;FET;W)E9"!T
M:')O=6=H(&-O;6UU;FEC871I;VYS('=I=&@@=&AE('9E;F1O<G,L(&EN8VQU
M9&EN9R!D971A:6QE9"!I;G9O:6-E<R!A;F0@=&%S:R!C;VUP;&5T:6]N(')E
M=FEE=RP@86YA;'ES:7,@;V8@97AP96YS97,@86=A:6YS="!B=61G971E9"!A
M;6]U;G1S+"!A;F0@<')E+6%P<')O=F%L(&]F(&%N>2!C:&%N9V5S(&EN('-C
M;W!E(&]F('1H92!S97)V:6-E<R!T;R!B92!P97)F;W)M960N($-E<G1A:6X@
M<VEG;FEF:6-A;G0@=F5N9&]R<R!M87D@86QS;R!P<F]V:61E(&%N(&5S=&EM
M871E(&]F(&-O<W1S(&EN8W5R<F5D(&)U="!N;W0@:6YV;VEC960@;VX@82!P
M97)I;V1I8R!B87-I<RX@17AP96YS97,@<F5L871E9"!T;R!T:&4@0U)/<R!A
M;F0@8VQI;FEC86P@<W1U9&EE<RP@87,@=V5L;"!A<R!C;VYT<F%C="!D<G5G
M(&UA;G5F86-T=7)E<G,L(&%R92!P<FEM87)I;'D@8F%S960@;VX@<')O9W)E
M<W,@;6%D92!A9V%I;G-T('-P96-I9FEE9"!M:6QE<W1O;F5S(&]R('1A<F=E
M=',@:6X@96%C:"!P97)I;V0N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF;VYT
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4W1O8VLM0F%S960@0V]M<&5N
M<V%T:6]N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/E1H92!#;VUP86YY)B,X,C$W.W,@<W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&-O<W0@<F5C;V=N:7IE9"`@:7,@8F%S960@;VX@
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M;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^26YC;VUE(%1A>&5S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O
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M(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P
M-#!?83!F-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO<W,@
M4&5R(%-H87)E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,
M;W-S(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXH,BD@3F5T($QO<W,@4&5R(%-H87)E(#PO<#X-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
M.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D$@<F5C;VYC:6QI871I;VX@;V8@=&AE(&YU;65R871O<B!A;F0@9&5N
M;VUI;F%T;W(@=7-E9"!I;B!T:&4@8V%L8W5L871I;VX@;V8@8F%S:6,@86YD
M(&1I;'5T960@;&]S<R!P97(@<VAA<F4@9F]L;&]W<SH@/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY,"4[)SX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY996%R<R!%;F1E9"!$
M96-E;6)E<B`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M<'0@<VAA<F5S(&%N9"!P97(@<VAA<F4@9&%T82D\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C4X)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY.970@;&]S<SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^*#8L.3,Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU."4[(&)O<F1E<BUB;W1T
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M969E<G)E9"!3=&]C:R!D965M960@9&EV:61E;F0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M,BPP,C8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3F5T(&QO<W,@879A:6QA
M8FQE('1O(&-O;6UO;B!S:&%R96AO;&1E<G,\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH.2PV.#D\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU."4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M,2PV-C@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4X)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.R9N8G-P.R!L;W-S('!E<B!S:&%R
M92!A='1R:6)U=&5D('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(P+#4P,2PR,C0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXX+#8R.2PT.#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D)E8V%U<V4@=V4@<F5P
M;W)T960@82!N970@;&]S<R!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M(#,Q+"`R,#$T(&%N9"`R,#$S+"!A;&P@<&]T96YT:6%L;'D@9&EL=71I=F4@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!H879E(&)E96X@97AC;'5D960@9G)O
M;2!T:&4@8V]M<'5T871I;VX@;V8@=&AE(&1I;'5T:79E(&YE="!L;W-S('!E
M<B!S:&%R92!F;W(@86QL('!E<FEO9',@<')E<V5N=&5D+B9N8G-P.R9N8G-P
M.T%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!N;VYE(&]F('1H92!O=71S=&%N
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M9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z-S`E.R<^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4X)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C4X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3DE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
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M;6%L.R<^,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ.24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU."4[/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ+#`V."PU,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU."4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C0Q.2PP,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXY+#,W,2PP,#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4X)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3`L.3$P+#4T-CPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/CDL-#`Y+#DR-CPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U,#%?
M-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,#DN:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&:6YA;F-I
M86P@26YS=')U;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L($EN<W1R=6UE;G1S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1FEN86YC:6%L($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B@S*2!&:6YA;F-I86P@26YS=')U;65N=',@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M<W5R96UE;G0@9&%T92`H97AI="!P<FEC92DN($EN<'5T<R!U<V5D('1O(&UE
M87-U<F4@9F%I<B!V86QU92!A<F4@8VQA<W-I9FEE9"!I;G1O('1H92!F;VQL
M;W=I;F<@:&EE<F%R8VAY.B`\+W`^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY
M-2XT-B4[;6%R9VEN+6QE9G0Z-"XU-"4[)SX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S)3MW:&ET92US<&%C93IN;W=R87`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P
M=#MF;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SMF;VYT+7-I>F4Z,3!P
M=#LG/B8C.#(R-CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93L@=VED=&@Z.34N-#8E.VUA<F=I;BUL969T.C0N-30E.R<^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,RXS,R4[=VAI
M=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HV<'0[9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[9F]N="US:7IE.C$P<'0[)SXF(S@R,C8[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M<VEZ93HQ
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M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.34N-#8E.VUA
M<F=I;BUL969T.C0N-30E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[9F]N="US:7IE.C$P<'0[)SXF(S@R
M,C8[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M.38N-C<E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z-G!T.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE
M=F5L(#,F(S@R,3([56YO8G-E<G9A8FQE(&EN<'5T<R!F;W(@=&AE(&%S<V5T
M(&]R(&QI86)I;&ET>2`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\
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M9&4@)#$U+C,@;6EL;&EO;B!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&%N
M9"`D,38N-2!M:6QL:6]N(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,L(&EN
M(&UO;F5Y(&UA<FME="!F=6YD<RP@8VQA<W-I9FEE9"!A<R!C87-H(&5Q=6EV
M86QE;G1S+"!W:&EC:"!A<F4@;65A<W5R960@870@9F%I<B!V86QU92!B87-E
M9"!O;B!,979E;"`Q(&EN<'5T<R!O;B!A(')E8W5R<FEN9R!B87-I<RX@5&AE
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M<W`[)FYB<W`[5V4@:&%V92!N;R!A<W-E=',@;W(@;&EA8FEL:71I97,@=&AA
M="!W97)E(&UE87-U<F5D('5S:6YG('%U;W1E9"!P<FEC97,@9F]R('-I;6EL
M87(@87-S971S(&%N9"!L:6%B:6QI=&EE<R!O<B!S:6=N:69I8V%N="!U;F]B
M<V5R=F%B;&4@:6YP=71S("A,979E;"`R(&%N9"!,979E;"`S(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,L(')E<W!E8W1I=F5L>2D@87,@;V8@1&5C96UB97(@
M,S$L(#(P,30N)FYB<W`[)FYB<W`[5&AE<F4@=V5R92!N;R!T<F%N<V9E<G,@
M8F5T=V5E;B!A;GD@9F%I<B!V86QU92!H:65R87)C:'D@;&5V96QS(&EN(#(P
M,30@;W(@,C`Q,RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY&86ER(%9A;'5E(&]F($]T:&5R($9I;F%N
M8VEA;"!);G-T<G5M96YT<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY4:&4@8V%R<GEI;F<@86UO=6YT
M(&]F(&]T:&5R(&9I;F%N8VEA;"!I;G-T<G5M96YT<RP@:6YC;'5D:6YG(&-A
M<V@L(&%N9"!A8V-O=6YT<R!P87EA8FQE+"!A<'!R;WAI;6%T960@9F%I<B!V
M86QU92!D=64@=&\@=&AE:7(@<VAO<G0@;6%T=7)I=&EE<RX@07,@;V8@1&5C
M96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@9&ED
M(&YO="!H879E(&%N>2!D96)T(&]U='-T86YD:6YG+B`\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R
M8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W
M.3,X93`Q+U=O<FMS:&5E=',O4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E
M<G1Y(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[
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M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W
M:61T:#HX,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#8N,S8E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ.2XQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C`N
M.3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,34N-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY$96-E;6)E<B`S,2P\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-#PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDT)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34N-"4[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$96-E;6)E<B`S,2P\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,C`Q,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDT
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT-BXS-B4[/@T*/'`@<W1Y;&4]
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M.2XQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$N,S0E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HP+CDT)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"XP
M-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.30E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Y+C$E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4@>65A<G,\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,"XY,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HP+CDT)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C`N.3(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ+C,T)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXQ-#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY-"4[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-#8N,S8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D9U<FYI='5R92!A;F0@9FEX='5R97,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3DN,24[/@T*/'`@
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HP+CDR)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,2XS-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"XP-B4[
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.#D\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY-"4[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,2XS-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"XP-B4[=VAI
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^.#D\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY-"4[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-#8N,S8E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Y+C$E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C,@>65A<G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,"XY,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.30E.W=H:71E+7-P
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,"XY,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HP+CDT)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$Y+C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^3&5S<V5R(&]F('5S969U;"!L:69E(&]R(&QI9F4@;V8@=&AE
M(&QE87-E/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.3(E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.30E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDR)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^.#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HP+CDT)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3DN,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C`N.30E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY,B4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M+C,T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXU,30\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY-"4[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-#8N,S8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$N,S0E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-"XP-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@S.#(\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HP+CDR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^*#0X-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDT
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M97)T>2!A;F0@97%U:7!M96YT+"!N970\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,"XY,B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$N,S0E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$N,S0E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#L^)FYB
M<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^1F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P
M.S,Q+"`R,#$T(&%N9"`R,#$S+"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA
M=&EO;B!E>'!E;G-E('=A<R`D,3(L,#`P(&%N9"`D,C8L,#`P("P@<F5S<&5C
M=&EV96QY+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y
M,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?
M9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970Q
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E
M;&%T960@4&%R='D@07)R86YG96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A
M;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!087)T>2!!<G)A;F=E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1R86YS86-T:6]N
M<R!W:71H('1H92!#;VUP86YY)B,X,C$W.W,@4')E<VED96YT(&%N9"!#:&EE
M9B!%>&5C=71I=F4@3V9F:6-E<B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M;6)E<B8C,38P.S,Q+"`R,#$T(&%N9"`R,#$S('=A<R`D,S4P+#`P,"!A;F0@
M)#(Y-RPP,#`@<F5S<&5C=&EV96QY+B`@(#PO<#X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?
M-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[
M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@V*2!#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9"!C;VYT:6YG96YC:65S.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5M<&QO>6UE;G0@06=R965M96YT
M<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3W!E<F%T:6YG($QE
M87-E("`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY!=6=U<W0@,2P@,C`Q,R!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!L96%S92!A9W)E96UE;G0@9F]R(&%P<')O>&EM871E;'D@
M-2PS,#`@<W%U87)E(&9E970@;V8@;V9F:6-E(&9A8VEL:71I97,@:6X@5V5S
M=&UI;G-T97(L($-O;&]R861O('=H:6-H(&AA<R!S97)V960@87,@=&AE($-O
M;7!A;GDF(S@R,3<[<R!P<FEM87)Y(&)U<VEN97-S(&]F9FEC92!S:6YC92!/
M8W1O8F5R)B,Q-C`[,2P@,C`Q,RX@5&AE(&QE87-E(&AA<R!A('1H<F5E('EE
M87(@=&5R;2!A;F0@97AP:7)E<R!O;B!397!T96UB97(@,S`L(#(P,38N)FYB
M<W`[)FYB<W`[0F5L;W<@:7,@82!S=6UM87)Y(&]F('1H92!F=71U<F4@;6EN
M:6UU;2!L96%S92!P87EM96YT<R!C;VUM:71T960@9F]R('1H92!#;VUP86YY
M)B,X,C$W.W,@9F%C:6QI='D@:6X@5V5S=&UI;G-T97(L($-O;&]R861O(&%S
M(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30@*&EN('1H;W5S86YD<RDZ/"]P
M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[/B9N8G-P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z-3`E.R<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@Q)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXR,#$U/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C@Q)3L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/E)E;G0@97AP96YS92!U;F1E<B!T:&5S92!L
M96%S97,@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$T(&%N9"`R,#$S('=A<R`D-S@L,#`P(&%N9"`D-C,L,#`P+"!R97-P96-T
M:79E;'D@+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/D1U:V4@56YI=F5R<VET>2`\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN
M9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY);B!.
M;W9E;6)E<B`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN
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M;FEC86P@<W1U9'DN)FYB<W`[)FYB<W`[57!O;B!C;VUP;&5T:6]N(&]F('1H
M92!C;&EN:6-A;"!S='5D>2P@=&AE(&%G<F5E;65N="!W:6QL('1E<FUI;F%T
M92XF;F)S<#LF;F)S<#M4:&4@86=R965M96YT(&-A;B!B92!T97)M:6YA=&5D
M(&5A<FQI97(@8GD@=&AE($-O;7!A;GD@9F]R(&%N>2!R96%S;VX@=VET:"`Y
M,"!D87ES('=R:71T96X@;F]T:6-E('1O($1U:V4N)FYB<W`[)FYB<W`[26X@
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M;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E5N:79E<G-I='D@;V8@0VEN8VEN;F%T:2`\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY);B!!<')I;"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!L
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP
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M,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ
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M(&]F($=E;F-A<F\N)FYB<W`[)FYB<W`[56YD97(@=&AE('1E<FUS(&]F(&ET
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M>6UE;G0@;V8@=7`@=&\@)#4N,"!M:6QL:6]N(&EN('1H92!A9V=R96=A=&4@
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M;"X@/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.CAP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.SMF;VYT
M+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P
M9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE
M971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY%<75I='D@1FEN86YC:6YG<R!A;F0@5V%R<F%N=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U
M:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17%U:71Y($9I;F%N8VEN9W,@86YD(%=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@W*2!%<75I
M='D@1FEN86YC:6YG<R!A;F0@5V%R<F%N=',@/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT
M.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,#$S($5Q=6ET
M>2!&:6YA;F-I;F=S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY0<FEV871E($EN=F5S=&UE;G0@:6X@4'5B
M;&EC($5Q=6ET>2`H4$E012D@5')A;G-A8W1I;VYS(#PO<#X-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D]N($IA
M;G5A<GDF(S$V,#LR,BP@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O
M(&$@4W5B<V-R:7!T:6]N($%G<F5E;65N="`H=&AE("8C.#(R,#M*86YU87)Y
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M0V]M<&%N>2!S;VQD(&%N(&%G9W)E9V%T92!O9B`S-38L-#,P('-H87)E<R!O
M9B!I=',@8V]M;6]N('-T;V-K(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92!U
M<"!T;R`R-#DL-3`Q(&%D9&ET:6]N86P@<VAA<F5S(&]F(&ET<R!C;VUM;VX@
M<W1O8VL@9F]R(&%G9W)E9V%T92!G<F]S<R!P<F]C965D<R!O9B!A<'!R;WAI
M;6%T96QY("0Q(&UI;&QI;VXL(&)E9F]R92!D961U8W1I;F<@97-T:6UA=&5D
M(&]F9F5R:6YG(&5X<&5N<V5S('!A>6%B;&4@8GD@=&AE($-O;7!A;GDN(%1H
M92!N970@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@=V5R92!A<'!R;WAI;6%T
M96QY("0X,#4L,#`P+"!A;F0@=&AE('!R:79A=&4@<&QA8V5M96YT(&-L;W-E
M9"!O;B!*86YU87)Y)B,Q-C`[,C4L(#(P,3,N(#PO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N
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M+"!A;F0@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXR."!P97(@<VAA
M<F4L(&5Q=6%L('1O(#$P,"4@;V8@=&AE(&-L;W-I;F<@8FED('!R:6-E(&]F
M($%20T$F(S@R,3<[<R!C;VUM;VX@<W1O8VL@;VX@=&AE($YA<V1A<2!#87!I
M=&%L($UA<FME="!O;B!*86YU87)Y)B,Q-C`[,C(L(#(P,3,N(#PO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M<G5A<GDF(S$V,#LQ-"P@,C`Q,RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O
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M;&4@<V5C=7)I=&EE<R!E:71H97(@*$$I)B,Q-C`[870@82!C;VYV97)S:6]N
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M<FET:65S+"!O<B`H0BDF(S$V,#MW:71H(&$@8V]N=F5R<VEO;BP@97AE<F-I
M<V4@;W(@97AC:&%N9V4@<')I8V4@=&AA="!I<R!S=6)J96-T('1O(&)E:6YG
M(')E<V5T(&%T('-O;64@9G5T=7)E(&1A=&4@869T97(@=&AE(&EN:71I86P@
M:7-S=6%N8V4@;V8@=&AE(&-O;G9E<G1I8FQE('-E8W5R:71I97,@;W(@=7!O
M;B!T:&4@;V-C=7)R96YC92!O9B!T:&4@<W!E8VEF:65D(&]R(&-O;G1I;F=E
M;G0@979E;G1S(&1I<F5C=&QY(&]R(&EN9&ER96-T;'D@<F5L871E9"!T;R!O
M=7(@8G5S:6YE<W,@;W(@=&AE(&UA<FME="!F;W(@;W5R(&-O;6UO;B!S=&]C
M:RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY296=I<W1E<F5D($1I<F5C="!/9F9E<FEN9R`\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY/;B!*86YU87)Y)B,Q-C`[,S$L(#(P,3,L('1H92!#;VUP86YY(&5N=&5R
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M92!G<F]S<R!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0W,S`L,#`P+"!B
M969O<F4@9&5D=6-T:6YG('!L86-E;65N="!A9V5N="!F965S(&%N9"!O=&AE
M<B!E<W1I;6%T960@;V9F97)I;F<@97AP96YS97,@<&%Y86)L92!B>2!T:&4@
M0V]M<&%N>2X@5&AE(&YE="!P<F]C965D<R!T;R!T:&4@0V]M<&%N>2!W97)E
M(&%P<')O>&EM871E;'D@)#8Q-BPP,#`L(&%N9"!T:&4@;V9F97)I;F<@8VQO
M<V5D(&]N($9E8G)U87)Y)B,Q-C`[-"P@,C`Q,RX@/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H92!C
M;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('=E<F4@<V]L9"!I;B!U;FET<R!C
M;VYS:7-T:6YG(&]F(&]N92!S:&%R92!O9B!C;VUM;VX@<W1O8VL@86YD(&$@
M=V%R<F%N="!T;R!P=7)C:&%S92`P+C0P('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VLN(%1H92!P=7)C:&%S92!P<FEC92!F;W(@96%C:"!U;FET('=A<R`D-"XT
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M:V5T(&]N($IA;G5A<GDF(S$V,#LS,2P@,C`Q,RX@(%1H92!/9F9E<FEN9R!W
M87,@969F96-T960@87,@82!T86ME9&]W;B!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(%)E9VES=')A=&EO;B!3=&%T96UE;G0@;VX@1F]R;2!3+3,L(&%S(&%M
M96YD960L('=H:6-H(&)E8V%M92!E9F9E8W1I=F4@;VX@07!R:6PF(S$V,#LT
M+"`R,#$Q+"!P=7)S=6%N="!T;R!A('!R;W-P96-T=7,@<W5P<&QE;65N="!F
M:6QE9"!W:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S
M:6]N(&]N($9E8G)U87)Y)B,Q-C`[,2P@,C`Q,RXF;F)S<#LF;F)S<#M4:&4@
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4'5B;&EC($]F9F5R:6YG)FYB
M<W`[)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;&QI;VXN(%1H92!#;VUP86YY(&ES<W5E9"`Q,C4L,#`P('-H87)E<R!O9B!0
M<F5F97)R960@4W1O8VL@86YD('=A<G)A;G1S('1O('!U<F-H87-E('5P('1O
M(#8L,C4P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&$@<'5R8VAA
M<V4@<')I8V4@;V8@)#$V,"!P97(@<VAA<F4@;V8@4')E9F5R<F5D(%-T;V-K
M+B!4:&4@;F5T('!R;V-E961S+"!A9G1E<B!D961U8W1I;F<@<&QA8V5M96YT
M(&%G96YT(&9E97,@86YD(&]T:&5R(&]F9F5R:6YG(&5X<&5N<V5S('!A>6%B
M;&4@8GD@=&AE($-O;7!A;GDL('=E<F4@87!P<F]X:6UA=&5L>2`D,3<N.2!M
M:6QL:6]N+B!!4D-!)B,X,C$W.W,@1&ER96-T;W(@86YD($-H:65F($5X96-U
M=&EV92!/9F9I8V5R('!A<G1I8VEP871E9"!I;B!T:&4@;V9F97)I;F<L('!U
M<F-H87-I;F<@-S@Q('-H87)E<R!O9B!0<F5F97)R960@4W1O8VL@86YD('=A
M<G)A;G1S('1O('!U<F-H87-E(#,Y+#`U,"!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^16%C:"!S:&%R92!O9B!0<F5F97)R960@4W1O8VL@
M=V%S(&-O;G9E<G1I8FQE(&EN=&\@,3`P('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;GD@=&EM92!A="!T:&4@;W!T
M:6]N(&]F('1H92!H;VQD97(N)FYB<W`[)FYB<W`[16%C:"!S:&%R92!O9B!0
M<F5F97)R960@4W1O8VL@:&%D(&$@;&EQ=6ED871I;VX@<')E9F5R96YC92!O
M9B`D+C`P,2!P97(@<VAA<F4N(%1H92!S:&%R97,@;V8@4')E9F5R<F5D(%-T
M;V-K(&AA9"!N;R!P<F5F97)E;G1I86P@9&EV:61E;F1S(&]R(')E9&5M<'1I
M;VX@<FEG:'1S+"!A;F0@;F\@=F]T:6YG(')I9VAT<R!E>&-E<'0@87,@<F5Q
M=6ER960@8GD@;&%W+B!$=7)I;F<@,C`Q,RP@86QL(#$R-2PP,#`@;V8@=&AE
M('-H87)E<R!O9B!T:&4@4')E9F5R<F5D(%-T;V-K('=E<F4@8V]N=F5R=&5D
M(&EN=&\@,3(L-3`P+#`P,"!S:&%R97,@;V8@05)#02!C;VUM;VX@<W1O8VLN
M)FYB<W`[)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5A8V@@<'5R8VAA<V5R(&EN('1H92!O
M9F9E<FEN9R!W87,@:7-S=65D(&$@=V%R<F%N="!T;R!P=7)C:&%S92`U,"!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@9F]R
M(&5A8V@@<VAA<F4@;V8@4')E9F5R<F5D(%-T;V-K('!U<F-H87-E9"X@5&AE
M('=A<G)A;G1S(&AA=F4@86X@97AE<F-I<V4@<')I8V4@;V8@)#$N-C`@<&5R
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP
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M:6]N(&]N($UA>28C,38P.S(Y+"`R,#$S+"!A;F0@=&AE(%!R969E<G)E9"!3
M=&]C:R!A;F0@5V%R<F%N=',@=V5R92!O9F9E<F5D(&%N9"!S;VQD('!U<G-U
M86YT('1O(&$@<')O<W!E8W1U<R!D871E9"!-87DF(S$V,#LS,"P@,C`Q,RX@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@4')E9F5R<F5D(%-T
M;V-K(&9I;F%N8VEN9RP@=&AE($-O;7!A;GD@<F5C;W)D960@82!N;VXM8V%S
M:"!D:79I9&5N9"!O9B!A<'!R;WAI;6%T96QY("0R+C`@;6EL;&EO;B!T;R!R
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M;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,C`Q-"!%<75I='D@1FEN86YC:6YG(#PO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[
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M+79A<FEA;G0Z(&YO<FUA;#LG/D]N($9E8G)U87)Y)B,Q-C`[,RP@,C`Q-"P@
M=&AE($-O;7!A;GD@86=R965D('1O('-E;&P@=&\@8V5R=&%I;B!I;G9E<W1O
M<G,@86X@86=G<F5G871E(&]F(#4L,3$V+#(R."!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('1O('!U
M<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q+#(W.2PP-3<@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%T(&$@<'5R8VAA<V4@
M<')I8V4@;V8@)#$N-S`@<&5R('-H87)E(&]F($-O;6UO;B!3=&]C:RP@9F]R
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M:6UA=&5L>2`D-RXY(&UI;&QI;VXN)FYB<W`[)FYB<W`[/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H
M92!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('=E<F4@<V]L9"!I;B!C;VUB
M:6YA=&EO;B!C;VYS:7-T:6YG(&]F(&]N92!S:&%R92!O9B!C;VUM;VX@<W1O
M8VL@86YD(&$@=V%R<F%N="!T;R!P=7)C:&%S92`P+C(U('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VLN(%1H92!W87)R86YT<R!W97)E(&5X97)C:7-A8FQE('5P
M;VX@:7-S=6%N8V4L(&5X<&ER92!F:79E('EE87)S(&9R;VT@=&AE(&1A=&4@
M;V8@:7-S=6%N8V4L(&%N9"!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F("0R
M+C$R-2!P97(@<VAA<F4L(&5Q=6%L('1O(#$R-24@;V8@=&AE(&-L;W-I;F<@
M8FED('!R:6-E(&]F($%20T$F(S@R,3<[<R!C;VUM;VX@<W1O8VL@;VX@=&AE
M($YA<V1A<2!#87!I=&%L($UA<FME="!O;B!&96)R=6%R>2`S+"`R,#$T+B!4
M:&4@;V9F97)I;F<@=V%S(&5F9F5C=&5D(&%S(&$@=&%K961O=VX@;V9F('1H
M92!#;VUP86YY)B,X,C$W.W,@4F5G:7-T<F%T:6]N(%-T871E;65N="!O;B!&
M;W)M(%,M,RP@87,@86UE;F1E9"P@=VAI8V@@8F5C86UE(&5F9F5C=&EV92!O
M;B!!<')I;"8C,38P.S0L(#(P,3$L('!U<G-U86YT('1O(&$@<')O<W!E8W1U
M<R!S=7!P;&5M96YT(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I97,@86YD($5X
M8VAA;F=E($-O;6UI<W-I;VX@;VX@1F5B<G5A<GDF(S$V,#LT+"`R,#$T+B!4
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M:&4@=&EM92!O9B!E>&5R8VES92X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E=A<G)A;G1S(#PO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E
M>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/D%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L('=A<G)A;G1S('1O('!U
M<F-H87-E(#DL,S<Q+#`P,B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@
M;W5T<W1A;F1I;F<@870@97AE<F-I<V4@<')I8V5S(')A;F=I;F<@9G)O;2`D
M,2XV,"!T;R`D,3$V+C@Y+"!W:71H(&$@=V5I9VAT960@879E<F%G92!E>&5R
M8VES92!P<FEC92!P97(@<VAA<F4@;V8@)#(N,S$N(%1H97-E('=A<G)A;G1S
M+"!W:&EC:"!W97)E(&=R86YT960@87,@<&%R="!O9B!V87)I;W5S(&9I;F%N
M8VEN9R!A;F0@8G5S:6YE<W,@86=R965M96YT<RP@97AP:7)E(&%T('9A<FEO
M=7,@=&EM97,@8F5T=V5E;B!!<')I;"`R,#$V(&%N9"!*86YU87)Y(#(P,C`N
M(%=A<G)A;G1S('=E<F4@<F5C;W)D960@:6X@861D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86P@870@=&AE:7(@97-T:6UA=&5D(&9A:7(@;6%R:V5T('9A;'5E
M(&%T('1H92!D871E(&]F(&=R86YT('5S:6YG(&$@0FQA8VLM4V-H;VQE<R!O
M<'1I;VXM<')I8VEN9R!M;V1E;"X@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P
M7V$P9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K
M<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!"
M;&]C:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH."D@4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY3=&]C:R!0;&%N<R`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY4
M:&4@0V]M<&%N>28C.#(Q-SMS(&5Q=6ET>2!I;F-E;G1I=F4@<&QA;BP@/&9O
M;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SL^=&AE(#(P,3,@17%U:71Y
M($EN8V5N=&EV92!0;&%N(#PO9F]N=#XH=&AE($5Q=6ET>2!0;&%N*2P\9F]N
M="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SX@/"]F;VYT/G=A<R!A<'!R
M;W9E9"!B>2!S=&]C:VAO;&1E<G,@;VX@4V5P=&5M8F5R(#$W+"`R,#$S+B9N
M8G-P.R9N8G-P.U1H92!M87AI;75M(&YU;6)E<B!O9B!S:&%R97,@:7-S=6%B
M;&4@=6YD97(@=&AI<R!P;&%N(&ES(#(L,C4P+#`P,"!S:&%R97,N)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M
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M96UP;&]Y965S+B!!<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$T+"!O<'1I
M;VYS(&%N9"!A=V%R9',@9F]R(#$L-#,W+#0W-R!S:&%R97,@=V5R92!O=71S
M=&%N9&EN9R!U;F1E<B!T:&4@17%U:71Y(%!L86XL(&%N9"`V-S(L.#4R('-H
M87)E<R!W97)E(')E<V5R=F5D(&9O<B!F=71U<F4@87=A<F1S+B`\+W`^#0H\
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M92!P<FEC92!O9B!O<'1I;VYS(&=R86YT960@=&\@,3`E("AO<B!G<F5A=&5R
M*2!S=&]C:VAO;&1E<G,@;75S="!B92!A="!L96%S="`Q,3`E(&]F('1H92!F
M86ER(&UA<FME="!V86QU92!O;B!T:&4@9W)A;G0@9&%T92XF;F)S<#LF;F)S
M<#L@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
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M97(@,3<L(#(P,3,N(%1H92`R,#`T(%!L86X@97AP:7)E9"!I;B`R,#$T.R!H
M;W=E=F5R+"!O<'1I;VYS(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`T('!L
M86X@=VEL;"!C;VYT:6YU92!T;R!V97-T(&%C8V]R9&EN9R!T;R!T:&4@;W)I
M9VEN86P@=&5R;7,@;V8@96%C:"!G<F%N="XF;F)S<#LF;F)S<#M!<R!O9B!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$T+"!O<'1I;VYS('1O('!U<F-H87-E(#4Y
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M<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@;W!T:6]N<R!T;R!P=7)C:&%S92`T
M,BPR.3$@<VAA<F5S('=I=&@@82!W96EG:'1E9"!A=F5R86=E(&5X97)C:7-E
M('!R:6-E(&]F("0Q-RXW."!W97)E(&]U='-T86YD:6YG('5N9&5R('1H97-E
M('!L86YS+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,G!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H
M92!#;VUP86YY(&=R86YT960@;W!T:6]N<R!A;F0@87=A<F1S(&9O<B`T,C`L
M,C<Y(&%N9"`Q+#$V,"PU,S4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!T
M:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q
M,RP@<F5S<&5C=&EV96QY+B!4:&4@9F%I<B!V86QU97,@;V8@=&AE(&UA:F]R
M:71Y(&]F(&5M<&QO>65E('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!I;B!T:&4@
M>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,R!W
M97)E(&5S=&EM871E9"!A="!T:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4@
M0FQA8VLM4V-H;VQE<R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP
M=&EO;G,@86YD(&AA9"!T:&4@9F]L;&]W:6YG(&5S=&EM871E9"!W96EG:'1E
M9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92!P97(@<VAA<F4Z/"]P
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!W:61T:#HW,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-C`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,W)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M-C`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3,\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4N.2!Y96%R
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HS)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)3PO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-C`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C8N.#5P=#L[=&5X="UI
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N-C(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B4\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV,"4[/@T*/'`@<W1Y
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C,E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="US:7IE.C9P=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I
M>F4Z-G!T.SXF;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30@86YD
M(#(P,3,L(&%N9"!R96QA=&5D(&EN9F]R;6%T:6]N(&%S(&]F($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,30L(&ES(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L
M92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!W:61T:#HW,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU-"4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY996%R<R!%;F1E9"!$96-E;6)E
M<B`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C(V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C8E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q,SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HT,R4[(&)O<F1E<BUB;W1T;VTZ<V]L
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M8F5R/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/F]F($]P=&EO;G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M9V4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^17AE<F-I<V4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4')I8V4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY796EG:'1E9"!!=F5R86=E/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5X97)C:7-E
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;F<@;V8\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C,N-S8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$T-"PP,3D\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT,R4[/@T*/'`@<W1Y
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C<T,2PU,S4\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,2XS.#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HT,R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3`E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH,RPU,#8\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C0S)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D]P=&EO;G,@;W5T
M<W1A;F1I;F<L(&5N9"!O9B!P97)I;V0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-#,E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3`E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@
M8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ,2XQ
M-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(N.#D\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E
M<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M97)C:7-E9"!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,30@86YD(#(P,3,@=V%S("0P(&%N9"`D,"P@<F5S<&5C=&EV96QY+B!!
M<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$T+"!T:&4@=6YR96-O9VYI>F5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=6YV97-T960@;W!T
M:6]N<RP@97AC;'5D:6YG(&5S=&EM871E9"!F;W)F96ET=7)E<RP@=V%S("0V
M,S,L,#`P('=H:6-H(&ES(&5X<&5C=&5D('1O(&)E(')E8V]G;FEZ960@;W9E
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M<F5S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M86YD(&5X97)C:7-A8FQE(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30Z
M/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P
M/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HW,"4[)SX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,3`@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT,R4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(X)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M<F-I<V%B;&4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!C;VQS<&%N/3-$."!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(T)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ,R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.=6UB97(@3W5T
M<W1A;F1I;F<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3,E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
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M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$S)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXR.2PY,S,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/CDN-S4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXQ+C`U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXW,#0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXQ+C`X/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-24[=VAI=&4M
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C@N
M-#<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,2XS.#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C$N,S@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HX)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HU)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HX)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(Q,BPT.34\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C<P+#0Q,#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z."4[=VAI=&4M
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M."4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C(N.3@\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
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M.R<^.#(L,S`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C0N-#0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M,3,N-C@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[=VAI
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$S
M+C4U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HX)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z-24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z."4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C,N-S0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HX)3L@8F]R9&5R+6)O
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HX)3L@8F]R9&5R
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXQ+#`V."PU,34\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(N.#D\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C0N,S@\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1&UA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[
M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<W1R:6-T960@4W1O
M8VL@56YI=',\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
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M9W)A;G0@86YN:79E<G-A<GD@9&%T92X\+W`^#0H\<"!S='EL93TS1"=M87)G
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M;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W
M:61T:#HX,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,S4E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HV,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY996%R<R!%;F1E9"!$96-E;6)E<B`S,2P\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,S4E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C,P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S`E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,C`Q,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HS-24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3G5M8F5R/"]P/@T*/'`@
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^5V5I9VAT960\+W`^#0H\<"!S='EL93TS1"=T
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M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY'<F%N="!$871E/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
M97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D9A:7(@5F%L=64\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SYO9B!3:&%R97,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D%V97)A9V4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^1W)A;G0@1&%T93PO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M;6%L.R<^-#$Y+#`P,#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C$N,SD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I#86QI8G)I.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS-24[/@T*/'`@<W1Y;&4]
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXT,3DL,#`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N,SD\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S4E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9E<W1E9"!A;F0@<F5L96%S
M960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T-%0T9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#0T5#1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#0T5#1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,S4E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,30E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q
M,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X
M,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C,U)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<W1R:6-T960@
M<W1O8VL@=6YI=',@;W5T<W1A;F1I;F<L/"]P/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[)FYB<W`[(&5N9"!O9B!P97)I;V0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C0W,2PP,CD\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXT,3DL,#`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$N,SD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E
M>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X
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M:R!A=V%R9',@=V%S(&%P<')O>&EM871E;'D@)#8R.2PP,#`N)FYB<W`[)FYB
M<W`[5&AI<R!C;W-T('=I;&P@8F4@<F5C;V=N:7IE9"!O;B!A('-T<F%I9VAT
M+6QI;F4@8F%S:7,@;W9E<B!T:&4@;F5X="`R+C0@>65A<G,@86YD('=I;&P@
M8F4@861J=7-T960@9F]R(&5S=&EM871E9"!F;W)F96ET=7)E<RXF;F)S<#LF
M;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X
M="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M1F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&%N
M9"`R,#$S+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D('1H92!F;VQL;W=I;F<@
M;F]N+6-A<V@L('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E("AI
M;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;&EN92UH96EG:'0Z,3%P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L
M92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!W:61T:#HU,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C4V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(P,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$X)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-S<\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3@E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXT.#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3@E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXR,#8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ."4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I
M=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C9P=#L^)FYB<W`[/"]P/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z-G!T.SXF;F)S<#L\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#ML:6YE
M+6AE:6=H=#HQ,7!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E(')E;&%T960@=&\@;F]N+65M<&QO>65E<R!W87,@;F5G;&EG:6)L92!I
M;B`R,#$T(&%N9"`R,#$S+B!!4D-!(&1I9"!N;W0@<F5C;V=N:7IE(&%N>2!T
M87@@8F5N969I="!R96QA=&5D('1O(&5M<&QO>65E('-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B!C;W-T(&%S(&$@<F5S=6QT(&]F('1H92!F=6QL('9A;'5A
M=&EO;B!A;&QO=V%N8V4@;VX@:71S(&YE="!D969E<G)E9"!T87@@87-S971S
M+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T
M,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5M<&QO>65E
M($)E;F5F:70@4&QA;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0V]M<&5N<V%T:6]N($%N9"!2971I<F5M96YT
M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!"96YE9FET(%!L86YS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;&EN92UH96EG
M:'0Z,3%P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^*#DI($5M<&QO>65E($)E;F5F:70@4&QA;G,@/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[;&EN
M92UH96EG:'0Z,3%P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY4:&4@0V]M<&%N>2!H87,@82`T,#$H:RD@<&QA
M;B!A;F0@;6%K97,@82!M871C:&EN9R!C;VYT<FEB=71I;VX@97%U86P@=&\@
M,3`P)2!O9B!T:&4@96UP;&]Y964F(S@R,3<[<R!F:7)S="`S)2!O9B!T:&4@
M96UP;&]Y964F(S@R,3<[<R!C;VYT<FEB=71I;VYS(&%N9"`U,"4@;V8@=&AE
M(&5M<&QO>65E)B,X,C$W.W,@;F5X="`R)2!O9B!C;VYT<FEB=71I;VYS+B!4
M:&4@0V]M<&%N>2!A9&]P=&5D('1H92!P;&%N(&EN(#(P,#8@86YD(&-O;G1R
M:6)U=&5D("0Q,#@L,#`P(&%N9"`D-S`L,#`P(&9O<B!T:&4@>65A<G,@96YD
M960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV
M96QY("X@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X
M93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U
M,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,38N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O
M;64@5&%X97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^*#QF;VYT('-T>6QE/3-$9F]N="UW96EG:'0Z8F]L9#L^,3`I($EN
M8V]M92!487AE<R`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^169F96-T:79E($IU;F4F(S$V
M,#LQ+"`R,#`U+"!T:&4@0V]M<&%N>2!C:&%N9V5D(&9R;VT@86X@4RU#;W)P
M;W)A=&EO;B!T;R!A($,M0V]R<&]R871I;VXN($%S(&%N(%,M0V]R<&]R871I
M;VXL('1H92!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!W97)E
M(&1I<W1R:6)U=&5D('1O('1H92!#;VUP86YY)B,X,C$W.W,@<W1O8VMH;VQD
M97)S.R!S=6-H(&%M;W5N=',@=V5R92!N;W0@<VEG;FEF:6-A;G0N(%-I;F-E
M($IU;F4@,C`P-2!T:')O=6=H($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L(&9O
M<B!F961E<F%L(&EN8V]M92!T87@@<'5R<&]S97,L('1H92!#;VUP86YY(&AA
M<R!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!O9B!A<'!R;WAI
M;6%T96QY("0Q,3,N-R!M:6QL:6]N+"!A;F0@87!P<F]X:6UA=&5L>2`D.3DQ
M+#`P,"!O9B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8W)E9&ET<R!T:&%T
M(&UA>2!B92!U<V5D('1O(&]F9G-E="!F=71U<F4@=&%X86)L92!I;F-O;64N
M(%1H92!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!W:6QL(&5X
M<&ER92!B96=I;FYI;F<@,C`R-2!T:')O=6=H(#(P,S0N(%5T:6QI>F%T:6]N
M(&]F(&YE="!O<&5R871I;F<@;&]S<V5S(&%N9"!T87@@8W)E9&ET<RP@:6YC
M;'5D:6YG('1H;W-E(&%C<75I<F5D(&%S(&$@<F5S=6QT(&]F('1H92!-97)G
M97(L('=I;&P@8F4@<W5B:F5C="!T;R!A;B!A;FYU86P@;&EM:71A=&EO;B!D
M=64@=&\@;W=N97)S:&EP(&-H86YG92!L:6UI=&%T:6]N<R!P<F]V:61E9"!B
M>2!)4D,@4V5C=&EO;B8C,38P.S,X,BX@5&AE(&%N;G5A;"!L:6UI=&%T:6]N
M(&UA>2!R97-U;'0@:6X@=&AE(&5X<&ER871I;VX@;V8@=&AE(&YE="!O<&5R
M871I;F<@;&]S<V5S(&%N9"!C<F5D:71S(&)E9F]R92!U=&EL:7IA=&EO;BX@
M07,@<W5C:"P@82!P;W)T:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;F5T
M(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;6%Y(&)E(&QI;6ET960N
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
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M-"XU(&UI;&QI;VX@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"P@<F5F;&5C
M=&EN9R!A(&1E8W)E87-E(&]F(&%P<')O>&EM871E;'D@)#`N-"`@;6EL;&EO
M;B!F<F]M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,N(%1H92!D969E<G)E9"!T
M87@@87-S971S(&%R92!P<FEM87)I;'D@8V]M<')I<V5D(&]F(&YE="!O<&5R
M871I;F<@;&]S<R!C87)R>69O<G=A<F1S(&%N9"!R97-E87)C:"!A;F0@97AP
M97)I;65N=&%T:6]N(&-R961I="!C87)R>69O<G=A<F1S+B!!<R!O9B!$96-E
M;6)E<B8C,38P.S,Q+"`R,#$T('1H92!#;VUP86YY(&AA<R!N;W0@<&5R9F]R
M;65D(&%N($EN=&5R;F%L(%)E=F5N=64@0V]D92!396-T:6]N)B,Q-C`[,S@R
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M:&5S92!G<F]S<R!D969E<G)E9"!T87@@87-S971S+B`\+W`^#0H\<"!S='EL
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M97)A;"!S=&%T=71O<GD@:6YC;VUE('1A>"!R871E(&]F(#,T)2!F;W(@,C`Q
M-"!A;F0@,S4E(&9O<B`R,#$S+"!A<R!A(')E<W5L="!O9B!T:&4@9F]L;&]W
M:6YG("AI;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M
M<VEZ93HQ,'!T.SXF;F)S<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H
M.C@P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HT-24[(&)O<F1E
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
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M665A<B!E;F1E9"!$96-E;6)E<B`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z-#4E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXH,BPT,CD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;64@=&%X(&)E;F5F:70L(&YE="!O9B!F961E<F%L(&)E;F5F:70\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-#4E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/E)E<V5A<F-H(&%N9"!E>'!E<FEM96YT871I;VX@8W)E9&ET
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT-24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^0VAA;F=E(&EN('1A>"!R871E/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#4E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(L.3`W/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M-#4E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D]T:&5R/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ.#0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-#4E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M0VAA;F=E(&EN('9A;'5A=&EO;B!A;&QO=V%N8V4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@S-C4\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$U)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BPU.#<\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HT-24[(&)O
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY7:71H;W5T(')E9V%R
M9"!T;R!T:&4@9&5F97)R960@=&%X(&QI86)I;&ET>2!O;B!T:&4@:6UP86ER
M960@25!2)F%M<#M$+"!T:&4@0V]M<&%N>2!H87,@:&%D(&YO('!R;W9I<VEO
M;B!F;W(@:6YC;VUE('1A>&5S('-I;F-E(&EN8V5P=&EO;B!D=64@=&\@:71S
M(%,M8V]R<&]R871I;VX@<W1A='5S(&%N9"!I=',@<W5B<V5Q=65N="!N970@
M;W!E<F%T:6YG(&QO<W-E<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M
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M.C`E.V9O;G0M<VEZ93HQ,'!T.SXF;F)S<#L\+W`^#0H\9&EV/@T*/'1A8FQE
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P
M<V4[('=I9'1H.C@P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU
M.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C0P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Y)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3@E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z-3DE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C<\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-3DE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Y)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(P
M+C5P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/DYE="!C=7)R96YT(&1E9F5R<F5D('1A>"!A
M<W-E=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S@R,3([/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C4Y)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HR,"XU<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DYO;F-U<G)E;G0@9&5F97)R960@=&%X(&%S<V5T<SH\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-B4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C,Y+#<Y.3PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*/'`@<W1Y;&4],T0G;6%R
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXT,3`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXS-S$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXY.3$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXX,C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/D-A<&ET86QI>F5D(&EN=&%N9VEB;&5S/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,38E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,38E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M871I;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HU.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M>"!A<W-E=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT-"PX,#`\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3DE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@T
M-"PX,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(P+C5P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/DYE="!N;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E=',\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,C`N-7!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1&5F97)R960@=&%X
M(&QI86)I;&ET:65S.CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C8N.#5P=#L[
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4Y)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C8N.#5P=#L[=&5X="UI;F1E
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S@R,3([/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,C`N-7!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^#0H\
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M=&\@,C`P.2X@5&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!I=',@=&%X(&9I
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M:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q
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M,#LS,2P@,C`Q-"!A;F0@,C`Q,RX@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P
M7V$P9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K
M<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$514$%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E1H92!#;VUP86YY(&%N9"!3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O
M=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@0G5S:6YE
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1&5S
M8W)I<'1I;VX@;V8@0G5S:6YE<W,@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M;&]R861O+B!/;B!*86YU87)Y)B,Q-C`[,C<L(#(P,#DL('1H92!#;VUP86YY
M(&-O;7!L971E9"!A(&)U<VEN97-S(&-O;6)I;F%T:6]N+"!O<B!T:&4@365R
M9V5R+"!W:71H($%20T$@0V]L;W)A9&\@:6X@86-C;W)D86YC92!W:71H('1H
M92!T97)M<R!O9B!T:&%T($%G<F5E;65N="!A;F0@4&QA;B!O9B!-97)G97(@
M86YD(%)E;W)G86YI>F%T:6]N+"!D871E9"!397!T96UB97(F(S$V,#LR-"P@
M,C`P."P@86YD(&%M96YD960@;VX@3V-T;V)E<B8C,38P.S(X+"`R,#`X+"!I
M;B!W:&EC:"!A('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y(&]F($YU=F5L;RP@
M26YC+B`H3G5V96QO*2!M97)G960@=VET:"!A;F0@:6YT;R!!4D-!($-O;&]R
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O
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M.R`H8G5C:6YD;VQO;"!H>61R;V-H;&]R:61E*2P@:7,@82!P:&%R;6%C;VQO
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M,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z
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M(%!H87-E(#,@:&5A<G0@9F%I;'5R92`H2$8I('1R:6%L(&]F($=E;F-A<F\@
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M<GD@;V8@<&%R;WAY<VUA;"`H048@97!I<V]D97,@;&%S=&EN9R`W(&1A>7,@
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M86P@9FQU='1E<B`H049,*2!O<B!A;&PM8V%U<V4@;6]R=&%L:71Y+B`\+W`^
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M($=%3D5424,M048N)FYB<W`[)FYB<W`[5&AE($-O;7!A;GD@:7,@<V5E:VEN
M9R!T;R!E;G)O;&P@87!P<F]X:6UA=&5L>2`R,#`@2$92148@<&%T:65N=',@
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M(&]N(&%N86QY<VES(&]F(&-E<G1A:6X@=')I86P@9&%T82!A9G1E<B`R,#`@
M<&%T:65N=',@:&%V92!C;VUP;&5T960@,C0@=V5E:W,@;V8@9F]L;&]W+75P
M+"!T:&4@<&5R:6]D(&9O<B!M96%S=7)I;F<@=&AE('1R:6%L)B,X,C$W.W,@
M<')I;6%R>2!E;F0M<&]I;G0N)B,Q-C`[(%1H92!$4TU"(&EN=&5R:6T@86YA
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M;R!0:&%S92`S+B!4:&4@1%--0B!M87D@86QS;R!R96-O;6UE;F0@8VAA;F=E
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M<&UE;G0@<W1E<',N(%1H92!#;VUP86YY(&)E;&EE=F5S('1H92!0:&%S92`R
M0B!E;G)O;&QM96YT(&]F(#(P,"!P871I96YT<R!C;W5L9"!B92!C;VUP;&5T
M960@8GD@=&AE(&5N9"!O9B`R,#$V+"!W:71H('1H92!$4TU"(&EN=&5R:6T@
M86YA;'ES:7,@9FEN:7-H:6YG(&EN('1H92!F:7)S="!H86QF(&]F(#(P,3<N
M("`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES
M:W,L($QI<75I9&ET>2!A;F0@1V]I;F<@0V]N8V5R;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3&EQ=6ED:71Y(&%N9"!';VEN
M9R!#;VYC97)N/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M('!R969E<G)E9"!S=&]C:RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D1U<FEN9R`R,#$S+"!T:&4@
M0V]M<&%N>2!R86ES960@87!P<F]X:6UA=&5L>2`D,3DN,R!M:6QL:6]N+"!N
M970@;V8@;V9F97)I;F<@8V]S=',L('1H<F]U9V@@<V%L97,@;V8@:71S(&-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!A;F0@8V]M;6]N('-T;V-K(&%N
M9"!W87)R86YT<RXF;F)S<#LF;F)S<#M);B!&96)R=6%R>2`R,#$T+"!T:&4@
M0V]M<&%N>2!C;VUP;&5T960@82!P=6)L:6,@97%U:71Y(&]F9F5R:6YG(')A
M:7-I;F<@87!P<F]X:6UA=&5L>2`D-RXY(&UI;&QI;VX@:6X@;F5T('!R;V-E
M961S('1O('!R;W9I9&4@861D:71I;VYA;"!F=6YD<R!F;W(@=&AE(%!H87-E
M(#)"+S,@1T5.151)0RU!1B!T<FEA;"!A;F0@=&AE($-O;7!A;GDF(S@R,3<[
M<R!O;F=O:6YG(&]P97)A=&EO;G,N)FYB<W`[)FYB<W`[)B,Q-C`[(%1H92!#
M;VUP86YY(&ES(&5N<F]L;&EN9R!P871I96YT<R!I;B!T:&4@4&AA<V4@,D(@
M<&]R=&EO;B!O9B!T:&4@1T5.151)0RU!1B!T<FEA;"P@86YD('1H92!#;VUP
M86YY(&%N=&EC:7!A=&5S('1H870@:71S(&-U<G)E;G0@8V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<R`@=VEL;"!B92!S=69F:6-I96YT('1O(&9U;F0@:71S
M(&]P97)A=&EO;G,L(&%T(&ET<R!P<F]J96-T960@8V]S="!S=')U8W1U<F4L
M('1H<F]U9V@@=&AE(&5N9"!O9B`R,#$U+B`@2&]W979E<BP@:6X@;&EG:'0@
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M($-O;7!A;GDF(S@R,3<[<R!O;F=O:6YG(&]P97)A=&EO;G,N)FYB<W`[)FYB
M<W`[268@=&AE($-O;7!A;GD@:7,@9&5L87EE9"!I;B!C;VUP;&5T:6YG(&]R
M(&ES('5N86)L92!T;R!C;VUP;&5T92!A9&1I=&EO;F%L(&9U;F1I;F<@86YD
M+V]R(&$@<W1R871E9VEC('1R86YS86-T:6]N+"!T:&4@0V]M<&%N>2!M87D@
M9&ES8V]N=&EN=64@:71S(&1E=F5L;W!M96YT(&%C=&EV:71I97,@;W(@;W!E
M<F%T:6]N<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T
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M9VX],T1L969T/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
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M,T1L969T/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
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M,'!T.SXF(S$X,SL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL
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M1&QE9G0^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S
M93L@=VED=&@Z.34N-#8E.VUA<F=I;BUL969T.C0N-30E.R<^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A
M8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C9P=#MF;VYT+69A;6EL>3HG4WEM8F]L)SMF;VYT+7-I>F4Z,3!P
M=#L^)B,Q.#,[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z-G!T.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/G1H92!#;VUP86YY)B,X,C$W.W,@86)I;&ET>2!T;R!R971A:6X@=&AE
M(&QI<W1I;F<@;V8@:71S(&-O;6UO;B!S=&]C:R!O;B!T:&4@3F%S9&%Q($-A
M<&ET86P@36%R:V5T.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\
M9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE9G0Z-"XU-"4[
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S
M)3MW:&ET92US<&%C93IN;W=R87`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.B=3>6UB;VPG.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$X,SL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M="!O9B!C87!I=&%L.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\
M9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE9G0Z-"XU-"4[
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S
M)3MW:&ET92US<&%C93IN;W=R87`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.B=3>6UB;VPG.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$X,SL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!W:61T:#HY-2XT-B4[;6%R9VEN+6QE9G0Z-"XU-"4[)SX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S)3MW:&ET92US<&%C
M93IN;W=R87`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.B=3>6UB;VPG.V9O;G0M<VEZ93HQ,'!T
M.SXF(S$X,SL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.34N-#8E
M.VUA<F=I;BUL969T.C0N-30E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT
M+69A;6EL>3HG4WEM8F]L)SMF;VYT+7-I>F4Z,3!P=#L^)B,Q.#,[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/G1H92!T97)M<R!A
M;F0@8V]N9&ET:6]N<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&5X:7-T:6YG
M(&-O;&QA8F]R871I=F4@86YD(&QI8V5N<VEN9R!A9W)E96UE;G1S+B`\+W`^
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M(&%C=&EV:71I97,@=&\@8V]N<V5R=F4@:71S(&-A<V@@<F5S;W5R8V5S+B`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
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M=&4@86YY('-T<F%T96=I8R!T<F%N<V%C=&EO;BX\+W`^#0H\<"!S='EL93TS
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M970@=&AE(&UI;FEM=6T@8VQO<VEN9R!B:60@<')I8V4@;V8@)#$N,#`@<&5R
M('-H87)E(&1U<FEN9R!T:&4@<')E8V5D:6YG(#,P(&1A>7,N)FYB<W`[)FYB
M<W`[3D%31$%1(')U;&5S('!R;W9I9&5D('5S(&$@,3@P(&-A;&5N9&%R(&1A
M>2!G<F%C92!P97)I;V0@9G)O;2!T:&4@9&%T92!O9B!T:&4@3F]T:6-E('1O
M(')E9V%I;B!C;VUP;&EA;F-E(&)Y(&UE971I;F<@=&AE(&-O;G1I;G5E9"!L
M:7-T:6YG('-T86YD87)D+B!4:&4@8V]N=&EN=65D(&QI<W1I;F<@<W1A;F1A
M<F0@=V]U;&0@8F4@;65T(&EF(&]U<B!C;VUM;VX@<W1O8VL@:&%S(&$@;6EN
M:6UU;2!C;&]S:6YG(&)I9"!P<FEC92!O9B!A="!L96%S="`D,2XP,"!P97(@
M<VAA<F4@9F]R(&$@;6EN:6UU;2!O9B`Q,"!C;VYS96-U=&EV92!B=7-I;F5S
M<R!D87ES(&1U<FEN9R!T:&4@,3@P(&-A;&5N9&%R(&1A>2!G<F%C92!P97)I
M;V0N/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V97)S92!3=&]C:R!3<&QI=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5V97)S92!3=&]C:R!3
M<&QI=#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z-G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3VX@36%R8V@F(S$V,#LT
M+"`R,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82`Q+69O<BTV(')E=F5R
M<V4@<W!L:70@;V8@:71S(&-O;6UO;B!S=&]C:RX@06QL(&-O;6UO;B!S:&%R
M97,@86YD('!E<B!C;VUM;VX@<VAA<F4@86UO=6YT<R!I;B!T:&4@9FEN86YC
M:6%L('-T871E;65N=',@86YD(&9O;W1N;W1E<R!H879E(&)E96X@861J=7-T
M960@<F5T<F]A8W1I=F5L>2!T;R!R969L96-T('1H92!E9F9E8W1S(&]F('1H
M:7,@86-T:6]N+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.VQI;F4M
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M<R`H52Y3+B!'04%0*2!A;F0@:6YC;'5D92!A;&P@861J=7-T;65N=',@;F5C
M97-S87)Y(&9O<B!T:&4@9F%I<B!P<F5S96YT871I;VX@;V8@;W5R(&9I;F%N
M8VEA;"!P;W-I=&EO;BP@<F5S=6QT<R!O9B!O<&5R871I;VYS(&%N9"!C87-H
M(&9L;W=S(&9O<B!T:&4@<&5R:6]D<R!P<F5S96YT960N)FYB<W`[)FYB<W`[
M3W5R(&UA;F%G96UE;G0@<&5R9F]R;65D(&%N(&5V86QU871I;VX@;V8@;W5R
M(&%C=&EV:71I97,@=&AR;W5G:"!T:&4@9&%T92!O9B!F:6QI;F<@;V8@=&AI
M<R!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2RP@86YD(&-O;F-L=61E9"!T
M:&%T('1H97)E(&%R92!N;R!S=6)S97%U96YT(&5V96YT<RP@97AC97!T(&9O
M<B!T:&4@;F]T:6-E(&9R;VT@3D%31$%1(&1I<V-L;W-E9"!I;B!.;W1E(#$@
M=&\@=&AE<V4@9FEN86YC:6%L('-T871E;65N=',N("`\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M96-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#ML:6YE+6AE:6=H=#HQ,7!T.W1E
M>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L
M:6,[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY2
M96-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C9P=#MM87)G:6XM8F]T=&]M.C!P=#MT97AT+6EN
M9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[;&5T=&5R+7-P
M86-I;F<Z+3`N,7!T.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^26X@2G5N92`R,#$T+"!T:&4@1D%30B!I<W-U
M960@1D%30B!!8V-O=6YT:6YG(%-T86YD87)D<R!5<&1A=&4@*"8C.#(R,#M!
M4U4F(S@R,C$[*2!.;RX@,C`Q-"TQ,"P@/&9O;G0@<W1Y;&4],T1F;VYT+7-T
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M:6-A=&EO;B!A;F0@<F5M;W9E<R!F<F]M($=!05`@=&AE(&-O;F-E<'0@;V8@
M82!D979E;&]P;65N="!S=&%G92!E;G1I='D@86QO;F<@=VET:"!T:&4@87-S
M;V-I871E9"!I;F-R96UE;G1A;"!F:6YA;F-I86P@<F5P;W)T:6YG(')E<75I
M<F5M96YT<R!F;W(@9&5V96QO<&UE;G0@<W1A9V4@96YT:71I97,N)B,Q-C`[
M)B,Q-C`[5&AE($%352!I<R!E9F9E8W1I=F4@9F]R(&9I<V-A;"!Y96%R<R!B
M96=I;FYI;F<@869T97(@1&5C96UB97(@,34L(#(P,30L('=I=&@@96%R;'D@
M861O<'1I;VX@8F5I;F<@<&5R;6ET=&5D(&9O<B!A;FYU86P@;W(@:6YT97)I
M;2!P97)I;V1S(&9O<B!W:&EC:"!F:6YA;F-I86P@<W1A=&5M96YT<R!H879E
M(&YO="!B965N(&ES<W5E9"XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!A9&]P
M=&5D('1H:7,@9W5I9&%N8V4@87,@;V8@2G5N92`S,"P@,C`Q-"!A;F0@87,@
M82!R97-U;'0L(')E;6]V960@<F5F97)E;F-E<R!T;R!B96EN9R!A(&1E=F5L
M;W!M96YT('-T86=E(&5N=&ET>2!A;F0@:6YC97!T:6]N+71O+61A=&4@<F5S
M=6QT<R!F<F]M('1H97-E(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.VUA<F=I;BUB;W1T;VTZ,'!T.W1E
M>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B!);B!!=6=U<W0@,C`Q-"P@=&AE($9!4T(@:7-S=65D($9!4T(@06-C;W5N
M=&EN9R!3=&%N9&%R9',@57!D871E("@F(S@R,C`[05-5($YO+B`R,#$T+3$U
M)B,X,C(Q.RDL(#QF;VYT('-T>6QE/3-$9F]N="US='EL93II=&%L:6,[/E!R
M97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R`F(S@R,3$[($=O
M:6YG($-O;F-E<FX@*%-U8G1O<&EC(#(P-2TT,"DZ($1I<V-L;W-U<F4@;V8@
M56YC97)T86EN=&EE<R!A8F]U="!A;B!%;G1I='DF(S@R,3<[<R!!8FEL:71Y
M('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N8V5R;CPO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.W1E>'0M9&5C;W)A=&EO;CIU;F1E
M<FQI;F4[/BX\+V9O;G0^)B,Q-C`[)B,Q-C`[05-5($YO+B`R,#$T+3$U('=I
M;&P@8F4@969F96-T:79E(&9O<B!F:7-C86P@>65A<G,@86YD(&EN=&5R:6T@
M<&5R:6]D<R!E;F1I;F<@869T97(@1&5C96UB97(@,34L(#(P,38L('=I=&@@
M96%R;'D@861O<'1I;VX@8F5I;F<@<&5R;6ET=&5D(&9O<B!A;FYU86P@86YD
M(&EN=&5R:6T@<&5R:6]D<R!F;W(@=VAI8V@@9FEN86YC:6%L('-T871E;65N
M=',@:&%V92!N;W0@8F5E;B!I<W-U960N($%352`R,#$T+3$U(')E<75I<F5S
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M.R9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1I;F<@17-T:6UA=&5S(&EN('1H
M92!0<F5P87)A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.VQI;F4M:&5I9VAT.C$Q
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE
M.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D%C8V]U;G1I;F<@17-T:6UA=&5S(&EN('1H92!0<F5P87)A=&EO;B!O
M9B!&:6YA;F-I86P@4W1A=&5M96YT<R`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#ML:6YE+6AE:6=H=#HQ,7!T
M.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/E1H92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M96YT<R!I
M;B!C;VYF;W)M:71Y('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R
M86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D)B,Q-C`[4W1A=&5S(&]F($%M
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M86P@<F5S=6QT<R!M87D@9&EF9F5R(&9R;VT@=&AE<V4@97-T:6UA=&5S+B`\
M+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HQ.'!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-A<V@@
M17%U:79A;&5N=',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M=6YD<R!A;F0@9&5B="!S96-U<FET:65S('=I=&@@;6%T=7)I=&EE<R!O9B`Y
M,"!D87ES(&]R(&QE<W,@870@=&AE('1I;64@;V8@<'5R8VAA<V4N(%1H92!#
M;VUP86YY(&EN=F5S=',@:71S(&5X8V5S<R!C87-H(&EN('-E8W5R:71I97,@
M=VET:"!S=')O;F<@<F%T:6YG<R!A;F0@:&%S(&5S=&%B;&ES:&5D(&=U:61E
M;&EN97,@<F5L871I=F4@=&\@9&EV97)S:69I8V%T:6]N(&%N9"!M871U<FET
M>2!W:71H('1H92!O8FIE8W1I=F4@;V8@;6%I;G1A:6YI;F<@<V%F971Y(&]F
M('!R:6YC:7!A;"!A;F0@;&EQ=6ED:71Y+B`\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[;&EN92UH96EG:'0Z
M,3%P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY4:&4@0V]M<&%N>2!C;&%S<VEF:65S(&%L;"!C87-H(&5Q=6EV
M86QE;G1S(&%S(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S+"!A;F0@
M<F5C;W)D<R!I;G9E<W1M96YT<R!A="!F86ER('9A;'5E+B`@/"]P/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N8V5N=')A=&EO;G,@;V8@0W)E9&ET(%)I<VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[;&EN92UH96EG:'0Z,3%P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A
M;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M0V]N8V5N=')A=&EO;G,@;V8@0W)E9&ET(%)I<VL@/"]P/@T*/'`@<W1Y;&4]
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M="!T:6UE<R!E>&-E960@=&AE(&EN<W5R960@86UO=6YT+B`\+W`^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ.'!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E!R;W!E<G1Y
M(&%N9"!%<75I<&UE;G0@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^06-C<G5E9"!%>'!E;G-E<R`\+W`^#0H\<"!S='EL93TS1"=M
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M92!T:6UE+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y396=M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4V5G;65N=',@/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&AE
M($-O;7!A;GD@;W!E<F%T97,@:6X@;VYE('-E9VUE;G0N($UA;F%G96UE;G0@
M=7-E<R!O;F4@;65A<W5R92!O9B!P<F]F:71A8FEL:71Y(&%N9"!D;V5S(&YO
M="!S96=M96YT(&ET<R!B=7-I;F5S<R!F;W(@:6YT97)N86P@<F5P;W)T:6YG
M+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z
M,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<V5A<F-H(&%N
M9"!$979E;&]P;65N="`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY297-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',@87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+B!4:&5S92!C;VYS
M:7-T('!R:6UA<FEL>2!O9B!S86QA<FEE<RP@8V]N=')A8W0@<V5R=FEC97,L
M(&%N9"!S=7!P;&EE<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB
M;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/E1H92!#;VUP86YY)B,X,C$W.W,@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&-O<W0@<F5C;V=N:7IE9"`@:7,@8F%S960@;VX@=&AE(&5S=&EM
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M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^26YC;VUE(%1A>&5S(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E
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M960N(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P
M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F-3`Q
M7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#$X+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO
M<W,@4&5R(%-H87)E("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U;6UA<GD@;V8@0F%S:6,@86YD($1I;'5T960@3&]S<R!097(@
M4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\
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M9&EL=71E9"!L;W-S('!E<B!S:&%R92!F;VQL;W=S.B`\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN
M9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V
M,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.CDP)3LG/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HU."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C0Q)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Y)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Y)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
M97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3@E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3@E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$W)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH.2PV.#D\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXH-BPY,SD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4X)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE<W,Z)FYB<W`[)FYB<W`[4V5R:65S($$@4')E
M9F5R<F5D(%-T;V-K(&1E96UE9"!D:79I9&5N9#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$W)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@R
M+#`R-CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU."4[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@Y+#8X.3PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P+#4P,2PR,C0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU."4[(&)O<F1E<BUB;W1T;VTZ<V]L
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M;G9E<W1E9"!C;VUM;VX@<W1O8VL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH,BPQ.#@\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M:&%R97,@=7-E9"!I;B!C;VUP=71I;F<@;F5T/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[)FYB<W`[(&QO<W,@<&5R('-H87)E
M(&%T=')I8G5T960@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^,C`L-3`Q+#(R-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C4X)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#`N-#<\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@Q+C`T/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!/9B!0;W1E;G1I86QL>2!$:6QU=&EV92!3:&%R97,@3V8@0V]M
M;6]N(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M<F5S96YT960N)FYB<W`[)FYB<W`[07,@;V8@1&5C96UB97(@,S$L(#(P,30L
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M<W1Y;&4],T1F;VYT+7-I>F4Z,3)P=#L^)FYB<W`[)FYB<W`[/"]F;VYT/E-U
M8V@@<&]T96YT:6%L;'D@9&EL=71I=F4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*/'`@<W1Y;&4],T1M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!W:61T:#HW,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HT,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY996%R<R!%;F1E9"!$96-E;6)E<B`S,2P\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Y)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
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M,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY0;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S+"!E>&-L=61E
M9#H\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C4X)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY5;G9E<W1E9"!R97-T<FEC=&5D('-T;V-K('5N:71S/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3<E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C0W,2PP,CD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-#$Y+#`P,#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU."4[/@T*/'`@
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/CDL,S<Q+#`P,CPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXX+#$T-RPT.#0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3@E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ,"PY,3`L-30V/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$W
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P
M-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O
M<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO
M<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.#`E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C0V+C,V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3DN,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY%<W1I;6%T960@3&EF93PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDR)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U+C0E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY
M-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDR
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$U+C0E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^1&5C96UB97(@,S$L/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z-#8N,S8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3DN,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C,@>65A<G,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY,B4[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$T+C`V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^.3<\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY-"4[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$N,S0E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HP
M+CDT)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HT-BXS-B4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$T+C`V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-#(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,"XY-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,2XS-"4[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Y+C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4@>65A<G,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY,B4[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,30N,#8E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C`N.30E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,"XY,B4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$N,S0E.W=H:71E
M+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,30N,#8E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C@Y
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C`N.30E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C0V+C,V
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY#;VUP=71E<B!S
M;V9T=V%R93PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ.2XQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E
M;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXS('EE87)S/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HP+CDT)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$T+C`V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M-S8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,"XY-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#8N,S8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ.2XQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.C`N-S5P=#MW:61T:#HP+CDR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HP+CDT
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$N
M,S0E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-"XP-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C@\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HT-BXS-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Y+C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HP+CDR)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$N
M,S0E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ-"XP-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HP+CDT)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C`N.3(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,2XS-"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C`N.30E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C0V+C,V)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$Y+C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C`N.3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ+C,T)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30N,#8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.30E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY,B4[(&)O<F1E
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$N,S0E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ-"XP-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@T.#4\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#8N,S8E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$Y+C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.3(E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S8\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C`N.3(E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ+C,T)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T+C`V)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,"XY-"4[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z
M,"4[9F]N="US:7IE.C$R<'0[/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?
M-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O
M5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9U='5R92!-:6YI;75M($QE87-E(%!A>6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y
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M)B,Q-C`[,S$L(#(P,30@*&EN('1H;W5S86YD<RDZ/"]P/CPO9&EV/CQD:78^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P
M=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/@T*
M/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HU,"4[)SX-"CQT<CX-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.#$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,38E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C@Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,38\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C8R/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z.#$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M<V4@<&%Y;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXQ-#(\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T
M.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T
M.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14I#
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@3V8@0V]M<&5N<V%T:6]N
M(%)E;&%T960@0V]S=',@4VAA<F5B87-E9"!087EM96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S
M=&EM871E9"!796EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!686QU
M92!P97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
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M<R!F;W(@-#(P+#(W.2!A;F0@,2PQ-C`L-3,U('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@:6X@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2X@5&AE(&9A:7(@=F%L=65S(&]F
M('1H92!M86IO<FET>2!O9B!E;7!L;WEE92!S=&]C:R!O<'1I;VYS(&=R86YT
M960@:6X@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30@
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M<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X-"CQD:78^
M#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93IC;VQL87!S93L@=VED=&@Z-S`E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS-R4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY996%R
M<R!%;F1E9"!$96-E;6)E<B`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-R4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV,"4[/@T*/'`@<W1Y;&4],T0G;6%R
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$W)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXU+CD@>65A<G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HV,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.30\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.38\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B4\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV,"4[/@T*/'`@
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M;F0@>6EE;&0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B4\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,R4[/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C`E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N
M,S<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N,#4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL
M93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M<VEZ93HV<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z
M,"4[9F]N="US:7IE.C9P=#L^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O
M9B!3=&]C:R!/<'1I;VX@86YD(%-T;V-K($%W87)D($%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS
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M-C`[,S$L(#(P,30@86YD(#(P,3,L(&%N9"!R96QA=&5D(&EN9F]R;6%T:6]N
M(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L(&ES(&%S(&9O;&QO=W,Z
M/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P
M/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HW,"4[)SX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,30@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU-"4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY996%R
M<R!%;F1E9"!$96-E;6)E<B`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A
M;&EB<FD[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(V)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,C8E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q,SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HT,R4[(&)O
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^3G5M8F5R/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/F]F($]P=&EO;G,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E=E:6=H=&5D($%V97)A9V4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^17AE<F-I<V4\+W`^#0H\<"!S='EL
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY796EG:'1E9"!!=F5R86=E
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D5X97)C:7-E/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86YD:6YG+"!B96=I;FYI;F<@;V8\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C,N-S8\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$T-"PP
M,3D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HT,R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3`E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C<T,2PU,S4\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[=VAI
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HT,R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXH,RPU,#8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D]P=&EO;G,@;W5T<W1A;F1I;F<L(&5N9"!O9B!P97)I;V0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,3DT+#4U,#PO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(N.#D\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=6UM87)Y(&]F(%-T;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<@86YD
M($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!I;F9O
M<FUA=&EO;B!A8F]U="!S=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E
M>&5R8VES86)L92!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$T.CPO<#X-
M"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[/B9N8G-P.SPO<#X-"CQD
M:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=VED=&@Z-S`E.R<^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HX)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HX)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$P('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR."4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@8V]L<W!A;CTS1#@@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR-"4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY286YG92!O9B!%>&5R8VES
M92!0<FEC97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3,E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$S)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
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M86-T=6%L(%1E<FT\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3,E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,R4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.
M=6UB97(@17AE<F-I<V%B;&4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3,E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HX)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HX)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^-S`T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C@E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N,S@\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C4E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C@E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N,S@\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C$N,S@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/CDN,3$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXW,"PT,3`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C$N.38\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C4E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q
M,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$S+C8X
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C<X+#`W,#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M-#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ-2PY,3@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S(N.#<\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-2PY,3@\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z."4[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z."4[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR+C@Y/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="US:7IE.C$P<'0[/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@4E-5
M(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ
M,G!T.VQI;F4M:&5I9VAT.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^02!S=6UM87)Y(&]F(%)352!A8W1I
M=FET>2!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N
M9"`R,#$S(&ES('!R97-E;G1E9"!B96QO=SH\+W`^#0H\<"!S='EL93TS1&UA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VQI;F4M:&5I9VAT.C$Q
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[/B9N8G-P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z.#`E.R<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C,U)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$T('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C(E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C,U)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I#86QI8G)I.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS,"4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXR,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,P
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,S4E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SYO9B!3:&%R97,\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
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M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D%V97)A9V4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E
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M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY.=6UB97(\+W`^#0H\<"!S='EL93TS1"=T
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY796EG:'1E9#PO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY!=F5R86=E/"]P/@T*/'`@<W1Y;&4]
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M=&4\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS-24[/@T*/'`@<W1Y
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M<R!O=71S=&%N9&EN9RP\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C0Q.2PP,#`\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,S4E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D=R86YT
M960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/C$Y,2PW,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A
M;&EB<FD[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-#$Y+#`P,#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T-%0T9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C,U)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$T)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF(S@R,3([/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D-A;&EB<FD[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$T)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HS-24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
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M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C$N-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-#$Y+#`P,#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+C,Y/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;VXM0V%S:"P@4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#ML:6YE
M+6AE:6=H=#HQ,7!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/D9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;V=N:7IE
M9"!T:&4@9F]L;&]W:6YG(&YO;BUC87-H+"!S:&%R92UB87-E9"!C;VUP96YS
M871I;VX@97AP96YS92`H:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VQI;F4M:&5I9VAT
M.C$Q<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[/B9N8G-P.SPO
M<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z-3`E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C4V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU-B4[(&)O<F1E<BUB
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M<&UE;G0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3@E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-3@\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ."4[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4V)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$X
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,C`V/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3@E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXV-#<\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3@E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR.#,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HV
M<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C9P=#L^
M)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X
M93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U
M,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,C(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O
M;64@5&%X97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>"!"96YE9FET($%T=')I8G5T86)L92!T;R!/=7(@
M3&]S<R!F<F]M($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
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M>"!R871E(&]F(#,T)2!F;W(@,C`Q-"!A;F0@,S4E(&9O<B`R,#$S+"!A<R!A
M(')E<W5L="!O9B!T:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO<#X-
M"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
M.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.SXF;F)S<#L\+W`^#0H\
M9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C@P)3LG/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E
M;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^665A<B!E;F1E9"!$96-E;6)E<B`S,2P\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#4E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ-24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,34E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH,BPT,CD\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M961E<F%L(&)E;F5F:70\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-24[=VAI
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^*#(P.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#4E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$U)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXH,3,S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXI/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HT-24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E
M+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-#4E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,34E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(L.3`W/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z-#4E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D]T:&5R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ.#0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#4E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M=V%N8V4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@S
M-C4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,BPU.#<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HT-24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,34E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!$969E
M<G)E9"!487@@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D1E9F5R<F5D(&EN8V]M92!T87AE<R!R969L96-T('1H
M92!N970@=&%X(&5F9F5C=',@;V8@=&5M<&]R87)Y(&1I9F9E<F5N8V5S(&)E
M='=E96X@=&AE(&-A<G)Y:6YG(&%M;W5N=',@;V8@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!F;W(@9FEN86YC:6%L(')E<&]R=&EN9R!A;F0@=&AE(&%M;W5N
M=',@=7-E9"!F;W(@:6YC;VUE('1A>"!P=7)P;W-E<RP@87,@=V5L;"!A<R!O
M<&5R871I;F<@;&]S<R!A;F0@=&%X(&-R961I="!C87)R>69O<G=A<F1S+B!4
M:&4@:6YC;VUE('1A>"!E9F9E8W1S(&]F('1E;7!O<F%R>2!D:69F97)E;F-E
M<R!A;F0@8V%R<GEF;W)W87)D<R!T:&%T(&=I=F4@<FES92!T;R!S:6=N:69I
M8V%N="!P;W)T:6]N<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&YE="!D969E
M<G)E9"!T87@@87-S971S(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG("AI
M;B!T:&]U<V%N9',I.CPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ
M,'!T.SXF;F)S<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C@P)3LG
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU.24[(&)O<F1E<BUB;W1T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C0P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4Y)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3@E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ."4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*/'`@<W1Y;&4],T0G;6%R
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(P+C5P=#L[=&5X="UI
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HR)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,C<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4Y)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(P+C5P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DYE="!C=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E=',\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3DE
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYO;F-U<G)E;G0@
M9&5F97)R960@=&%X(&%S<V5T<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-B4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HU.24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXT,3`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXS-S$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXY.3$\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXX,C`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3DE.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.W=H:71E
M+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M.B!N;W)M86P[)SY3=&]C:R!B87-E9"!C;VUP96YS871I;VX\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M)SY4;W1A;"!N;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E=',\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ-B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXT-"PX,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#0T+#0S
M-SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@T-"PX,#`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C(P+C5P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYE="!N
M;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E=',\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$V)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,C`N-7!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ-B4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU.24[/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z-3DE.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C8N.#5P=#L[=&5X="UI;F1E;G0Z,'!T
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$V)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Y
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,C`N-7!T.SMT97AT+6EN
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3DE.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-B4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,38E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P
M-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O
M<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E:0DD^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^5&AE($-O;7!A;GD@86YD(%-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`P-"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E-E
M9VUE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N
M(#$X+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E
M8BX@,#,L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2F%N+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y&96(N(#(X+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;7!A;GD@0F%S:7,@;V8@4')E<V5N=&%T:6]N
M("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1A=&4@;V8@8V]M<&QE=&EO;B!O9B!B=7-I
M;F5S<R!C;VUB:6YA=&EO;B!W:71H($YU=F5L;SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^2F%N(#(W+`T*"0DR,#`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=6YD(')A:7-E9"!T
M:')O=6=H('-A;&4@;V8@8V]N=F5R=&EB;&4@<')E9F5R<F5D(&%N9"!C;VUM
M;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#,P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,S@L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW-#$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;W1I9FEC871I;VX@9F]R(&1E;&ES=&EN9R!O9B!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D]N($9E8G)U87)Y
M(#$X+"`R,#$U+"!W92!R96-E:79E9"!N;W1I9FEC871I;VX@9G)O;2!.05-$
M05$@;V8@<&]T96YT:6%L(&1E;&ES=&EN9R!O9B!O=7(@<VAA<F5S(&9R;VT@
M=&AE($Y!4T1!42!#87!I=&%L($UA<FME="!B96-A=7-E('1H92!C;&]S:6YG
M(&)I9"!P<FEC92!O9B!O=7(@8V]M;6]N('-T;V-K(&AA9"!N;W0@;65T('1H
M92!M:6YI;75M(&-L;W-I;F<@8FED('!R:6-E(&]F("0Q+C`P('!E<B!S:&%R
M92!D=7)I;F<@=&AE('!R96-E9&EN9R`S,"!D87ES+B`@3D%31$%1(')U;&5S
M('!R;W9I9&5D('5S(&$@,3@P(&-A;&5N9&%R(&1A>2!G<F%C92!P97)I;V0@
M9G)O;2!T:&4@9&%T92!O9B!T:&4@3F]T:6-E('1O(')E9V%I;B!C;VUP;&EA
M;F-E(&)Y(&UE971I;F<@=&AE(&-O;G1I;G5E9"!L:7-T:6YG('-T86YD87)D
M+B!4:&4@8V]N=&EN=65D(&QI<W1I;F<@<W1A;F1A<F0@=V]U;&0@8F4@;65T
M(&EF(&]U<B!C;VUM;VX@<W1O8VL@:&%S(&$@;6EN:6UU;2!C;&]S:6YG(&)I
M9"!P<FEC92!O9B!A="!L96%S="`D,2XP,"!P97(@<VAA<F4@9F]R(&$@;6EN
M:6UU;2!O9B`Q,"!C;VYS96-U=&EV92!B=7-I;F5S<R!D87ES(&1U<FEN9R!T
M:&4@,3@P(&-A;&5N9&%R(&1A>2!G<F%C92!P97)I;V0N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E<G-E('-T
M;V-K('-P;&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ+69O
M<BTV(')E=F5R<V4@<W!L:70\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;F-E;G1R871I;VYS(&]F(&-R961I="!R
M:7-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@<V5G;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U8G-E<75E;G0@179E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUP86YY($)A<VES(&]F(%!R97-E;G1A=&EO;B`H
M5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(&-L;W-I;F<@8FED('!R:6-E(&]F
M(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@9W)A8V4@9&%Y<R!P<F]V:61E9"!B>2!.05-$05$@
M=&\@;65E="!C;VYT:6YU960@;&ES=&EN9R!S=&%N9&%R9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,3@P(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9VES=&5R960@1&ER
M96-T($]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M<&%N>2!"87-I<R!O9B!0<F5S96YT871I;VX@*%1E>'1U
M86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@:7-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L
M-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-S,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-RPY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0:&%S92`S(&AE87)T(&9A
M:6QU<F4@*$A&*2!T<FEA;"!O9B!'96YC87)O('P@0D535"!4<FEA;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;7!A;GD@
M0F%S:7,@;V8@4')E<V5N=&%T:6]N("A497AT=6%L*2!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!P871I96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!H87-E(#,@:&5A<G0@9F%I;'5R92`H2$8I('1R:6%L(&]F($=E
M;F-A<F\@?"!'14Y%5$E#+4%&(%1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M<&%N>2!"87-I<R!O9B!0<F5S96YT
M871I;VX@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('!A=&EE;G1S(&-O
M;7!A;GD@<&QA;G,@=&\@96YR;VQL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!H87-E(%1W;R!"($AE87)T($9A:6QU<F4@?"!'14Y%
M5$E#+4%&(%1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M<&%N>2!"87-I<R!O9B!0<F5S96YT871I;VX@*%1E>'1U
M86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('!A=&EE;G1S(&-O;7!A;GD@<&QA;G,@
M=&\@96YR;VQL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]R:6=I;F%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M<&%N>2!"87-I<R!O9B!0<F5S96YT871I;VX@*%1E>'1U86PI
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0G5S:6YE<W,@8V]M8FEN871I;VX@=VET:"!.=79E;&\L(&1A
M=&4@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y397`@,C0L#0H)"3(P,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;7!A;GD@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)U<VEN97-S(&-O;6)I;F%T
M:6]N('=I=&@@3G5V96QO+"!D871E(&]F(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^3V-T(#(X+`T*"0DR,#`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q
M7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q
M+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)-04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!"87-I8R!A;F0@1&EL=71E
M9"!,;W-S(%!E<B!3:&%R92`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H.2PV.#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#DS
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQE<W,Z($1E96UE9"!P<F5F97)R960@<W1O8VL@9&EV:61E;F0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,#(V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M(&%V86EL86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#DL-C@Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PY-C4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!A=F5R86=E('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4P,2PR,C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#8S
M,2PV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQE<W,Z(%=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(&]F('5N=F5S
M=&5D(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPQ.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@=V5I9VAT960M879E<F%G92!S:&%R97,@=7-E
M9"!I;B!C;VUP=71I;F<@;F5T(&QO<W,@<&5R('-H87)E(&%T=')I8G5T960@
M=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`L-3`Q+#(R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L-C(Y+#0X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T
M960@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XT-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y
M,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?
M9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970R
M-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15!)04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M3F5T($QO<W,@4&5R(%-H87)E("A$971A:6QS(%1E>'1U86PI/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@3W!T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT
M:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@1G)O;2!#;VUP=71A=&EO
M;B!/9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E8W5R:71I97,@
M:6XM=&AE+6UO;F5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@1G)O;2!#
M;VUP=71A=&EO;B!/9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E
M8W5R:71I97,@:6XM=&AE+6UO;F5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P
M7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970R-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Q+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO<W,@
M4&5R(%-H87)E("A$971A:6QS(#$I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E
M($)A<VEC(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L
M=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92P@
M06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,3`L
M-30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PT,#DL.3(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<75I='D@3W!T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E($)A
M<VEC(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E
M9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92P@06UO
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`V."PU,34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M-#,L-#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G9E<W1E9"!R97-T<FEC=&5D('-T;V-K('5N:71S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@
M4&5R(%-H87)E($)A<VEC(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I
M=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E
M<B!3:&%R92P@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-S$L,#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!"87-I
M8R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@
M9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4L($%M;W5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PS-S$L,#`R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ
M-#<L-#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P
M9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15!1044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1FEN86YC:6%L($EN
M<W1R=6UE;G1S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L($EN
M<W1R=6UE;G1S("A!9&1I=&EO;F%L(%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-F
M97)S(&]F(&%S<V5T<R!B971W965N(&9A:7(@=F%L=64@:&EE<F%R8VAY(&QE
M=F5L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER(%9A;'5E($UE87-U<F5M96YT<RP@4F5C=7)R:6YG('P@3&5V96P@,2!\
M($UO;F5Y($UA<FME="!&=6YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEA;"!);G-T<G5M96YT<R`H5&5X='5A
M;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&5Q=6EV86QE;G1S(&-O;G-I<W1I;F<@;V8@;6]N
M97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N
M=',L(%)E8W5R<FEN9R!\($9A:7(@5F%L=64L($EN<'5T<RP@3&5V96P@,CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;F%N
M8VEA;"!);G-T<G5M96YT<R`H061D:71I;VYA;"!497AT=6%L*2!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9A:7(@=F%L=64@;V8@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&86ER('9A;'5E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT
M<RP@4F5C=7)R:6YG('P@1F%I<B!686QU92P@26YP=71S+"!,979E;"`S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC
M:6%L($EN<W1R=6UE;G1S("A!9&1I=&EO;F%L(%1E>'1U86PI(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F%I<B!V86QU92!O9B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T
M.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y
M,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H
M965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5)2D%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U;6UA<GD@;V8@4')O<&5R='D@86YD($5Q=6EP;65N="`H1&5T86EL
M<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY0<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5P
M<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N
M="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUP=71E<B!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%<W1I;6%T960@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N="P@1W)O
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8B!%
M<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<W1I;6%T960@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5R;FET=7)E(&%N
M9"!&:7AT=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE;G0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5S=&EM871E9"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@4V]F
M='=A<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY0<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I
M;6%T960@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S96AO;&0@26UP<F]V
M96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T
M:6UA=&5D($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DQE
M<W-E<B!O9B!U<V5F=6P@;&EF92!O<B!L:69E(&]F('1H92!L96%S93QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W
M.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B
M7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T
M,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5'2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E
M8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F
M-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+U=O<FMS:&5E
M=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P159&04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4F5L871E9"!087)T>2!!<G)A;F=E;65N=',@*$1E=&%I;',I
M("A#:&EE9B!%>&5C=71I=F4@3V9F:6-E<BP@4F5S96%R8V@@1W)A;G1S+"!5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAI968@17AE8W5T:79E($]F9FEC97(@?"!297-E87)C:"!'<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA
M=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y
M-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F
M-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%0S%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A
M;F0@0V]N=&EN9V5N8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`P,2P@,C`Q
M,SQB<CYS<69T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A497AT
M=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-L:6YI8V%L(')E<V5A<F-H(&%G<F5E;65N="!W:71H
M($1U:V4@56YI=F5R<VET>2P@=&5R;6EN871I;VX@;F]T:6-E('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^.3`@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@;6EL97-T;VYE('!A>6UE;G1S(&1U92!U<&]N(&%P<')O=F%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YO=&AE
M<B!E>'!E8W1E9"!M:6QE<W1O;F4@<&%Y;65N=',@9'5E('5P;VX@87!P<F]V
M86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36EN:6UU;2!P97)C96YT86=E(&]F(')O>6%L='D@;V)L:6=A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(N-3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('!E
M<F-E;G1A9V4@;V8@<F]Y86QT>2!O8FQI9V%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@<V%L97,@;&5V96QS
M(')O>6%L='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-:6YI;75M('!E<F-E;G1A9V4@;V8@<F%N9V4@;V8@<F]Y86QT:65S('1H
M870@8V%N(&)E(&)O=6=H="!D;W=N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<&5R8V5N=&%G92!O9B!R86YG92!O
M9B!R;WEA;'1I97,@=&AA="!C86X@8F4@8F]U9VAT(&1O=VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!B=7D@9&]W
M;B!D=64@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#<X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y797-T;6EN<W1E<BP@0V]L;W)A
M9&\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&5X='5A;"D@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!<F5A(&]F(&]F9FEC92!F86-I;&ET:65S('1A:V5N(&]N(&QE87-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A
M<V4@97AP:7)Y(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/E-E<"`S,"P-"@D),C`Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X
M93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U
M,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,S(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$512#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&=71U
M<F4@36EN:6UU;2!,96%S92!087EM96YT<R`H1&5T86EL<RD@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!F=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?-#`T,%]A
M,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H
M965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-4-(2SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY%<75I='D@1FEN86YC:6YG<R!A;F0@5V%R<F%N=',@*$1E
M=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-CXP
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#`T
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@
M,C(L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B
M+B`P-RP@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&
M96(N(#`S+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D9E8BX@,#0L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2F%N+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y&96(N(#(X+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!F:6YA;F-I;F=S(&%N9"!W87)R
M86YT<R`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#$U,"PT
M.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2PV.#4L-38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!I<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M.2PP,S@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#<T,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A
M;F-E(&]F('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G1S(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,W,2PP
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-L87-S(&]F('=A<G)A;G0@;W(@<FEG:'1S(&5X<&ER871I;VX@9&%T
M92!E87)L:65S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q
M-BTP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0VQA<W,@;V8@=V%R<F%N="!O<B!R:6=H=',@97AP:7)A=&EO;B!D
M871E(&QA=&5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`R
M,"TP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D5Q=6ET>2!F:6YA;F-I;F=S(&%N9"!W87)R86YT<R`H5&5X
M='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT('!R:6-E('!E<B!S:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@9FEN
M86YC:6YG<R!A;F0@=V%R<F%N=',@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M="!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3$V+C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(&9I;F%N8VEN9W,@
M86YD('=A<G)A;G1S("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@<')I8V4@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!U8FQI8R!/9F9E<FEN9R!\(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!F:6YA
M;F-I;F=S(&%N9"!W87)R86YT<R`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@<VAA<F5S(&]F('!R969E<G)E9"!S=&]C:R!C;VYV97)T960@:6X@=&\@
M8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0=6)L:6,@3V9F97)I;F<@?"!#;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@9FEN
M86YC:6YG<R!A;F0@=V%R<F%N=',@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D(&EN(&-O;G9E<G-I
M;VX@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@02!#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@?"!0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@9FEN86YC:6YG<R!A
M;F0@=V%R<F%N=',@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@4V5R
M:65S($$@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!N970@;V8@;V9F
M97)I;F<@8V]S=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V5R:65S($$@0V]N=F5R=&EB;&4@4')E9F5R<F5D
M(%-T;V-K('P@4'5B;&EC($]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(&9I;F%N8VEN9W,@86YD('=A
M<G)A;G1S("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&%V86EL86)L92!T
M;R!P=7)C:&%S92!A9&1I=&EO;F%L(&-O;6UO;G,@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(U,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@8V]V
M97)A9V4@<F%T:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S92!P<FEC92!F;W(@8V]M;6]N('-T;V-K('5N:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!W97)E
M(&5X97)C:7-A8FQE('5P;VX@:7-S=6%N8V4L(&5X<&ER>2!Y96%R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT('!R
M:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L.3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@4V5R:65S($$@8V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K+"!N970@;V8@;V9F97)I;F<@8V]S=',L('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!T:&4@:7-S=6%N8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@
M<VAA<F5S(&ES<W5E9"!U<&]N(&-O;G9E<G-I;VX@;V8@96%C:"!S:&%R92!O
M9B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K(&QI<75I9&%T
M:6]N('!R969E<F5N8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F('1O=&%L(&YU;6)E
M<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1H96X@:7-S=65D(&%N9"!O
M=71S=&%N9&EN9R!L:6UI="!O;B!B96YE9FEC:6%L(&]W;F5R<VAI<#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2XY.24\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=')I;G-I8R!V
M86QU92!O9B!E;6)E9&1E9"!B96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M:7)E8W1O<B!A;F0@0VAI968@17AE8W5T:79E($]F9FEC97(@?"!0=6)L:6,@
M3V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY%<75I='D@9FEN86YC:6YG<R!A;F0@=V%R<F%N=',@*%1E>'1U86PI
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V%R<F%N=',@879A:6QA8FQE('1O('!U<F-H87-E(&%D9&ET
M:6]N86P@8V]M;6]N<R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Y+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K(%!U<F-H87-E9"!B>2!/
M9F9I8V5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!)
M4$4@5')A;G-A8W1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%<75I='D@9FEN86YC:6YG<R!A;F0@=V%R<F%N=',@*%1E
M>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-38L-#,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!A=F%I;&%B;&4@=&\@<'5R8VAA<V4@861D:71I;VYA;"!C;VUM;VYS('-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0Y+#4P,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E(&=R;W-S('!R;V-E961S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<R!F<F]M(&ES<W5A
M;F-E(&]F('!R:79A=&4@<&QA8V5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0=6)L:6,@17%U:71Y($]F9F5R:6YG($-L
M;W-E($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIA;B`R
M-2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W5B<V-R:7!T:6]N(&%G<F5E;65N="!D871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,C(L#0H)"3(P,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G0@8V]V97)A9V4@<F%T:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4'5R8VAA<V4@<')I8V4@9F]R(&-O;6UO;B!S=&]C:R!U
M;FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S('=E<F4@97AE<F-I<V%B;&4@=7!O;B!I<W-U86YC92P@97AP:7)Y
M('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(N,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-L;W-I;F<@8FED('!R:6-E(&]F('1H92!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-L;W-I;F<@8FED('!R:6-E(&1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DIA;B`R,BP-"@D),C`Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5G:7-T97)E9"!$
M:7)E8W0@3V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%<75I='D@9FEN86YC:6YG<R!A;F0@=V%R<F%N=',@*%1E
M>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$Q-BPR,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0L-C,V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!A=F%I;&%B;&4@=&\@<'5R8VAA<V4@861D:71I;VYA;"!C
M;VUM;VYS('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR-SDL,#4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C4L.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0=6)L:6,@17%U:71Y($]F9F5R:6YG($-L;W-E
M($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D9E8B`W+`T*
M"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^1F5B(#0L#0H)"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@8V]V97)A9V4@<F%T:6\\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E('!R:6-E(&9O<B!C;VUM;VX@<W1O8VL@=6YI=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('=E<F4@
M97AE<F-I<V%B;&4@=7!O;B!I<W-U86YC92P@97AP:7)Y('EE87(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+C$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"XQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0VQO<VEN9R!B:60@<')I8V4@;V8@=&AE
M(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0VQO<VEN9R!B:60@<')I8V4@9&%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^1F5B(#,L#0H)"3(P,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,S$L#0H)"3(P
M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PW,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@:7-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#<L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-C$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V-R:7!T:6]N(&%G<F5E;65N="!D
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,S$L#0H)
M"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F
M-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#,T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%44%#23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`Q-RP@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R
M92!"87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@0GD@4VAA<F4@0F%S
M960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!O
M=71S=&%N9&EN9R!U;F1E<B!%<75I='D@<&QA;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP-C@L-3$U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0S+#0T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PP,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;G,@87=A<F0L(&5X<&ER871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(&5X97)C
M:7-E(%!R:6-E(&]F($]P=&EO;G,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,BXX.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXW-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&EN=')I;G-I8R!V86QU92!O9B!O<'1I;VYS(&5X97)C:7-E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!3=&]C
M:R!/<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@0GD@
M4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96-O9VYI
M>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=6YV97-T960@
M;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%T=7)I='D@<&5R:6]D(&]F('=E:6=H=&5D(&%V97)A9V4@<&5R:6]D
M(&]F(&-O;7!E;G-A=&EO;B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,B!Y96%R<R`R(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC
M=&5D(%-T;V-K(%5N:71S("A24U5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W87)D(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-871U<FET>2!P97)I;V0@;V8@=V5I9VAT960@879E<F%G92!P97)I
M;V0@;V8@8V]M<&5N<V%T:6]N(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XR('EE87)S(#0@;6]N=&AS(#(T(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C
M;V=N:7IE9"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O('5N=F5S=&5D
M('-T;V-K(&%W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`V,CDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N
M9V5M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K(&]P=&EO;G,@87=A<F0L('9E<W1I;F<@<&5R:6]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&AO
M;&1I;F<@9F]R('-T;V-K(&]P=&EO;G,@97AE<F-I<V4@<')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!\($EN
M8V5N=&EV92!3=&]C:R!/<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R8V5N=&%G92!O9B!E>&5R8VES92!P<FEC92!O9B!S=&]C:R!O<'1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;FEM=6T@?"!);F-E;G1I=F4@4W1O8VL@3W!T:6]N('P@4W1O8VMH;VQD97)S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@97AE
M<F-I<V4@<')I8V4@;V8@<W1O8VL@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M('P@4F5S=')I8W1E9"!3
M=&]C:R!5;FET<R`H4E-5<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!3=&]C:R!5;FET<R!A=V%R9"P@<F5Q=6ES:71E('-E<G9I
M8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;G,@87=A<F0L('9E<W1I;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('P@4F5S=')I8W1E
M9"!3=&]C:R!5;FET<R`H4E-5<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!3=&]C:R!5;FET<R!A=V%R9"P@<F5Q=6ES:71E('-E
M<G9I8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#XR,#$S(%!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F5S(')E<V5R=F5D(&9O<B!F=71U<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!O=71S
M=&%N9&EN9R!U;F1E<B!%<75I='D@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PT,S<L-#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@<F5S97)V960@9F]R(&9U
M='5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<R+#@U,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!A;F0@87=A<F1S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0R,"PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$V,"PU,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1W;R!4:&]U<V%N9"!!
M;F0@1F]U<B!3=&]C:R!/<'1I;VX@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO
M;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W87)D(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&]U='-T86YD:6YG('5N9&5R($5Q
M=6ET>2!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.2PW
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@97AE<F-I<V4@4')I8V4@;V8@3W!T:6]N
M<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-2XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=&AE<B!3=&]C:R!/<'1I;VX@4&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W
M87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&]U='-T86YD:6YG('5N
M9&5R($5Q=6ET>2!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,BPR.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@97AE<F-I<V4@4')I8V4@;V8@
M3W!T:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q-RXW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U,#%?
M-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,S4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5)24%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5S=&EM
M871E9"!796EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!686QU92!0
M97(@4VAA<F4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<W1I;6%T960@=V5I
M9VAT960@879E<F%G92!G<F%N="!D871E(&9A:7(@=F%L=64@<&5R('-H87)E
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@
M>65A<G,@,3`@;6]N=&AS(#(T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#D@;6]N=&AS(#$X(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDT+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDV+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-3,E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV,B4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(&=R86YT
M(&1A=&4@9F%I<B!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XP-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?
M-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X
M-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S
M+U-H965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5)1T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U;6UA<GD@;V8@4W1O8VL@3W!T:6]N(&%N9"!3=&]C:R!!=V%R
M9"!!8W1I=FET:65S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R
M92!/9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<R!3:&%R96)A<V5D(%!A
M>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N9&EN9R!B96=I;FYI;F<@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-#,L
M-#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30T+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,L($=R86YT960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R."PU-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#$L-3,U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@3W!T:6]N<RP@1F]R9F5I=&5D(&%N9"!C86YC96QL960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3`V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0R+#$Q,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@;W5T<W1A;F1I;F<@96YD(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#8X+#4Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T,RPT-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M97AE<F-I<V%B;&4L(&5N9"!O9B!P97)I;V0L($YU;6)E<B!O9B!/<'1I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.30L,CDQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DT+#4U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!V97-T960@86YD(&5X<&5C=&5D('1O('9E<W0L($YU;6)E
M<B!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#`V-BPW,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@97AE<F-I<V4@4')I8V4L($]P
M=&EO;G,@3W5T<W1A;F1I;F<L($)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXW-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D(&%V97)A9V4@97AE<F-I<V4@<')I8V4L($=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M879E<F%G92!E>&5R8VES92!P<FEC92P@1F]R9F5I=&5D(&%N9"!C86YC96QL
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30P+C8W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M,2XV,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@079E<F%G92!E>&5R8VES92!0<FEC92P@3W!T:6]N
M<R!/=71S=&%N9&EN9RP@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C<V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E
M(&5X97)C:7-E('!R:6-E+"!/<'1I;VYS(&5X97)C:7-A8FQE+"!E;F0@;V8@
M<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Q+C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(&5X97)C:7-E(%!R:6-E+"!/<'1I
M;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="P@96YD(&]F('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C@Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F
M-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X
M93`Q+U=O<FMS:&5E=',O4VAE970S-RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P155)0D<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3=&]C:R!/<'1I;VYS
M($]U='-T86YD:6YG(&%N9"!%>&5R8VES86)L92`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@4VAA<F5S($%U=&AO<FEZ
M960@56YD97(@4W1O8VL@3W!T:6]N(%!L86YS($5X97)C:7-E(%!R:6-E(%)A
M;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!N=6UB97(@;V8@3W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-C@L-3$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S
M=&%N9&EN9R!!=F5R86=E($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C@@>65A<G,@,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($%V97)A9V4@
M17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BXX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V%B;&4@;G5M8F5R(&]F($]P=&EO;G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y-"PR.3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE
M+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/B0P+C,V+20Q+C,S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S
M960@0V]M<&5N<V%T:6]N(%-H87)E<R!!=71H;W)I>F5D(%5N9&5R(%-T;V-K
M($]P=&EO;B!0;&%N<R!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I8V4@4F%N9V4L($UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')I8V4@4F%N9V4L($UA>&EM=6T\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@;G5M
M8F5R(&]F($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Y+#DS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W5T<W1A;F1I;F<@079E<F%G92!,:69E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XY('EE87)S(#D@;6]N=&AS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N
M9&EN9R!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&YU;6)E<B!O9B!/
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/B0Q+C,X+20Q
M+C,X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%-H87)E<R!!=71H;W)I>F5D(%5N
M9&5R(%-T;V-K($]P=&EO;B!0;&%N<R!%>&5R8VES92!0<FEC92!286YG92!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')I8V4@4F%N9V4L($UI;FEM=6T\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@4F%N9V4L($UA>&EM=6T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A
M;F1I;F<@;G5M8F5R(&]F($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<R-RPX-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($%V97)A9V4@3&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^."!Y96%R<R`U(&UO;G1H
M<R`Q.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!!=F5R86=E($5X97)C:7-E(%!R:6-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-A8FQE(&YU;6)E<B!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,CDL,3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92P@5V5I9VAT960@079E
M<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XD,2XT,"TD,2XY-3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO
M;B!3:&%R97,@075T:&]R:7IE9"!5;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,@
M17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6-E(%)A;F=E+"!-
M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I8V4@4F%N9V4L($UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XY-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@;G5M8F5R(&]F($]P=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,BPT.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T
M86YD:6YG($%V97)A9V4@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^.2!Y96%R<R`Q(&UO;G1H(#$P(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($%V
M97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V%B;&4@;G5M8F5R(&]F($]P=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#0Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^)#$N.38M)#(R+CDX
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4@0F%S960@0V]M<&5N<V%T:6]N(%-H87)E<R!!=71H;W)I>F5D(%5N9&5R
M(%-T;V-K($]P=&EO;B!0;&%N<R!%>&5R8VES92!0<FEC92!286YG92!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')I8V4@4F%N9V4L($UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@4F%N9V4L($UA>&EM=6T\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(N.3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD
M:6YG(&YU;6)E<B!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX,BPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG($%V97)A9V4@3&EF93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<R`U(&UO;G1H<R`Y
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]U='-T86YD:6YG($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,N-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A
M8FQE(&YU;6)E<B!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW."PP-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$S+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XD,C(N.3DM)#,S+C0R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N
M(%-H87)E<R!!=71H;W)I>F5D(%5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<R!%
M>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@4F%N9V4L($UI
M;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(N.3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R:6-E(%)A;F=E+"!-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,S+C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!N=6UB97(@;V8@3W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L.3$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S
M=&%N9&EN9R!!=F5R86=E($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C,@>65A<G,@."!M;VYT:',@,C<@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@
M079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S,BXX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V%B;&4@;G5M8F5R(&]F($]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#DQ.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(N.#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?
M-#`T,%]A,&8T7S5C-#DP-SDS.&4P,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E.#8T.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O
M5V]R:W-H965T<R]3:&5E=#,X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$%!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%)352!!8W1I=FET>2`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E)E<W1R:6-T960@4W1O8VL@07=A<F1S+"!.
M=6UB97(@;V8@4VAA<F5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@;W5T<W1A;F1I
M;F<L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0Q.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Y,2PW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960@86YD(')E;&5A
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,SDL-C<Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!S=&]C:R!U;FET<R!O=71S=&%N9&EN9RP@96YD(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<Q+#`R.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5S=')I8W1E9"!3=&]C:R!!=V%R9',L(%=E:6=H
M=&5D($%V97)A9V4@1W)A;G0@1&%T92!&86ER(%9A;'5E/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O
M8VL@=6YI=',@;W5T<W1A;F1I;F<L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CDU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6
M97-T960@86YD(')E;&5A<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$N,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@;W5T<W1A;F1I
M;F<L(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XV,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X
M93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4X-C0Y,3)B7V8U
M,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE971S+U-H965T,SDN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R0D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO
M;BU#87-H+"!3:&%R92U"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E($)A<V5D($-O
M;7!E;G-A=&EO;B!!;&QO8V%T:6]N($]F(%)E8V]G;FEZ960@4&5R:6]D($-O
M<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92!"87-E9"!#;VUP96YS871I;VX@
M06QL;V-A=&EO;B!/9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E
M<G9I8V4@4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%L;&]C871I;VX@3V8@
M4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T
M.3$R8E]F-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T
M.3`W.3,X93`Q+U=O<FMS:&5E=',O4VAE970T,"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^16UP;&]Y964@0F5N969I="!0
M;&%N<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9FEN960@0V]N=')I8G5T
M:6]N(%!L86X@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T8VAI;F<@8V]N=')I
M8G5T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YM871C:&EN
M9R!C;VYT<FEB=71I;VX@97%U86P@=&\@,3`P)2!O9B!T:&4@96UP;&]Y967B
M@)ES(&9I<G-T(#,E(&]F('1H92!E;7!L;WEE9>*`F7,@8V]N=')I8G5T:6]N
M<R!A;F0@-3`E(&]F('1H92!E;7!L;WEE9>*`F7,@;F5X="`R)2!O9B!C;VYT
M<FEB=71I;VYS+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M<&%N>2=S(&-O;G1R:6)U=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#@L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I<G-T
M(#,E(&]F('!A>2!C;VYT<FEB=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D1E9FEN960@0V]N=')I8G5T:6]N(%!L86X@
M1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I="!0;&%N+"!097)C96YT86=E
M(&]F($UA=&-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;7!L;WEE<B!M871C:&EN9R!C;VYT<FEB=71I;VX@<&5R8V5N=&%G
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE>'0@
M,B4@;V8@<&%Y(&-O;G1R:6)U=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&5F:6YE9"!#;VYT<FEB=71I;VX@4&QA;B!$
M:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"96YE9FET(%!L86XL(%!E<F-E;G1A9V4@
M;V8@36%T8V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16UP;&]Y97(@;6%T8VAI;F<@8V]N=')I8G5T:6]N('!E<F-E;G1A9V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#8T.3$R8E]F-3`Q
M7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93@V-#DQ,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q
M+U=O<FMS:&5E=',O4VAE970T,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-'04<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS(%1E>'1U
M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@*%1E>'1U86PI(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$S+#<P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A>"!#<F5D
M:70@0V%R<GEF;W)W87)D+"!$97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^5&AE(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O
M<G=A<F1S('=I;&P@97AP:7)E(&)E9VEN;FEN9R`R,#(U('1H<F]U9V@@,C`S
M-"X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E(&YE="!D969E<G)E9"!T
M87@@87-S970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9E9&5R86P@<W1A='5T;W)Y(&EN8V]M92!T87@@<F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I
M;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5R=F4@9F]R('5N8V5R=&%I;B!T87@@<&]S:71I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@
M;W(@<&5N86QT:65S(')E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<&5N('1A>"!Y96%R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XR,#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y7:71H;W5T($1E9F5R<F5D(%1A>"!,:6%B
M:6QI='D@3VX@26UP86ER960@26X@4')O8V5S<R!297-E87)C:"!!;F0@1&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);F-O;64@5&%X97,@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N
M(&9O<B!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<V5A<F-H(%1A>"!#<F5D:70@0V%R<GEF;W)W87)D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A
M>&5S("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!E>'!E<FEM96YT
M871I;VX@8W)E9&ET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Y.3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S+"!L:6UI
M=&%T:6]N<R!O;B!U<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/E5T:6QI>F%T:6]N(&]F(&YE="!O<&5R871I;F<@;&]S<V5S(&%N9"!T87@@
M8W)E9&ET<RP@:6YC;'5D:6YG('1H;W-E(&%C<75I<F5D(&%S(&$@<F5S=6QT
M(&]F('1H92!-97)G97(L('=I;&P@8F4@<W5B:F5C="!T;R!A;B!A;FYU86P@
M;&EM:71A=&EO;B!D=64@=&\@;W=N97)S:&EP(&-H86YG92!L:6UI=&%T:6]N
M<R!P<F]V:61E9"!B>2!)4D,@4V5C=&EO;B`S.#(N(%1H92!A;FYU86P@;&EM
M:71A=&EO;B!M87D@<F5S=6QT(&EN('1H92!E>'!I<F%T:6]N(&]F('1H92!N
M970@;W!E<F%T:6YG(&QO<W-E<R!A;F0@8W)E9&ET<R!B969O<F4@=71I;&EZ
M871I;VXN($%S('-U8V@L(&$@<&]R=&EO;B!O9B!T:&4@0V]M<&%N>>*`F7,@
M;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;6%Y(&)E(&QI;6ET
M960\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1A>"!C<F5D:70@8V%R<GEF;W)W87)D+"!L:6UI=&%T:6]N<R!O;B!U
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E5T:6QI>F%T:6]N
M(&]F(&YE="!O<&5R871I;F<@;&]S<V5S(&%N9"!T87@@8W)E9&ET<RP@:6YC
M;'5D:6YG('1H;W-E(&%C<75I<F5D(&%S(&$@<F5S=6QT(&]F('1H92!-97)G
M97(L('=I;&P@8F4@<W5B:F5C="!T;R!A;B!A;FYU86P@;&EM:71A=&EO;B!D
M=64@=&\@;W=N97)S:&EP(&-H86YG92!L:6UI=&%T:6]N<R!P<F]V:61E9"!B
M>2!)4D,@4V5C=&EO;B`S.#(N(%1H92!A;FYU86P@;&EM:71A=&EO;B!M87D@
M<F5S=6QT(&EN('1H92!E>'!I<F%T:6]N(&]F('1H92!N970@;W!E<F%T:6YG
M(&QO<W-E<R!A;F0@8W)E9&ET<R!B969O<F4@=71I;&EZ871I;VXN($%S('-U
M8V@L(&$@<&]R=&EO;B!O9B!T:&4@0V]M<&%N>>*`F7,@;F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y9F]R=V%R9',@;6%Y(&)E(&QI;6ET960\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FQI97-T
M(%1A>"!996%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^26YC;VUE(%1A>&5S("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN
M9R!L;W-S(&-A<G)Y9F]R=V%R9',@97AP:7)A=&EO;B!Y96%R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,871E<W0@5&%X(%EE87(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O
M;64@5&%X97,@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QO<W,@8V%R
M<GEF;W)W87)D<R!E>'!I<F%T:6]N('EE87(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C(P,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS
M.&4P,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#8T.3$R8E]F
M-3`Q7S0P-#!?83!F-%\U8S0Y,#<Y,SAE,#$O5V]R:W-H965T<R]3:&5E=#0R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%24Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)
M;F-O;64@5&%X97,@+2!);F-O;64@5&%X($)E;F5F:70@071T<FEB=71A8FQE
M('1O($]U<B!,;W-S(&9R;VT@3W!E<F%T:6]N<R`H1&5T86EL<RD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%9F9E8W1I=F4@26YC;VUE(%1A>"!2871E(%)E8V]N8VEL:6%T:6]N+"!!
M;6]U;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5+E,N(&9E9&5R86P@:6YC;VUE('1A>"!B96YE9FET
M(&%T('-T871U=&]R>2!R871E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@S+#(Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(L-#(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A=&4@:6YC;VUE('1A>"!B96YE
M9FET+"!N970@;V8@9F5D97)A;"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&5X<&5R:6UE
M;G1A=&EO;B!C<F5D:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0VAA;F=E(&EN('1A>"!R871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@=&%X(&%S<V5T(&%D
M:G5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T,#0P7V$P
M9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7;W)K<VAE
M971S+U-H965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V2T%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/DEN8V]M92!487AE<R`M($YE="!D969E<G)E9"!T87@@87-S
M971S("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!D969E<G)E
M9"!T87@@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y686-A=&EO;B!A8V-R=6%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@9&5F97)R
M960@=&%X(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-U<G)E;G0@9&5F97)R960@=&%X
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F]N8W5R<F5N="!D969E<G)E9"!T87@@87-S971S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T
M:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#(L,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,SDL-SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%R:71A8FQE(&-O;G1R:6)U=&EO
M;B!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!E>'!E<FEM96YT871I;VX@8W)E9&ET
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I
M=&%L:7IE9"!I;G1A;F=I8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I
M;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!N;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#0S-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#@P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#0L-#,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0T+#@P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;F]N8W5R<F5N="!D969E
M<G)E9"!T87@@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!N;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ,F)?9C4P,5\T
M,#0P7V$P9C1?-6,T.3`W.3,X93`Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4X-C0Y,3)B7V8U,#%?-#`T,%]A,&8T7S5C-#DP-SDS.&4P,2]7
M;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N
M.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-
M86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970T,RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?93@V-#DQ
B,F)?9C4P,5\T,#0P7V$P9C1?-6,T.3`W.3,X93`Q+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Net deferred tax assets (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract', window );"><strong>Current deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation accrual</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" onclick="toggleNextSibling(this);">$ 25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" onclick="toggleNextSibling(this);">$ 27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossCurrent', window );">Total current deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossCurrent" onclick="toggleNextSibling(this);">25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossCurrent" onclick="toggleNextSibling(this);">27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" onclick="toggleNextSibling(this);">(25)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" onclick="toggleNextSibling(this);">(27)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Net current deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNetCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNetCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract', window );"><strong>Noncurrent deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" onclick="toggleNextSibling(this);">42,135</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" onclick="toggleNextSibling(this);">39,799</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" onclick="toggleNextSibling(this);">410</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" onclick="toggleNextSibling(this);">371</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and experimentation credits</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">991</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized intangibles</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" onclick="toggleNextSibling(this);">741</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" onclick="toggleNextSibling(this);">3,351</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">454</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossNoncurrent', window );">Total noncurrent deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossNoncurrent" onclick="toggleNextSibling(this);">44,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossNoncurrent" onclick="toggleNextSibling(this);">44,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" onclick="toggleNextSibling(this);">(44,437)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" onclick="toggleNextSibling(this);">(44,800)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Net noncurrent deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNetNoncurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNetNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNetNoncurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNetNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net noncurrent deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31938-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrentClassificationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">$ 12</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">$ 26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Property and Equipment (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 418</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 514</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(382)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(485)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">29</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">97</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">99</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember]" onclick="toggleNextSibling(this);">82</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember]" onclick="toggleNextSibling(this);">176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
        <td class="text">Lesser of useful life or life of the lease<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6539997&amp;loc=d3e1205-110223<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Arrangements (Details) (Chief Executive Officer, Research Grants, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Chief Executive Officer | Research Grants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total expense</a></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">$ 350,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">$ 297,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EC1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Aug. 01, 2013

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AgreementTerminationNoticePeriod', window );">Clinical research agreement with Duke University, termination notice period</a></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExpectedMilestonePaymentsUponApproval', window );">Expected milestone payments due upon approval</a></td>
        <td class="nump"><a title="abio_ExpectedMilestonePaymentsUponApproval" onclick="toggleNextSibling(this);">$ 8,000,000</a><span style="display:none;white-space:normal;text-align:left;">abio_ExpectedMilestonePaymentsUponApproval</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AnotherExpectedMilestonePaymentsUponApproval', window );">Another expected milestone payments due upon approval</a></td>
        <td class="nump"><a title="abio_AnotherExpectedMilestonePaymentsUponApproval" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">abio_AnotherExpectedMilestonePaymentsUponApproval</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfRoyaltyObligation', window );">Minimum percentage of royalty obligation</a></td>
        <td class="nump"><a title="abio_MinimumPercentageOfRoyaltyObligation" onclick="toggleNextSibling(this);">12.50%</a><span style="display:none;white-space:normal;text-align:left;">abio_MinimumPercentageOfRoyaltyObligation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MaximumPercentageOfRoyaltyObligation', window );">Maximum percentage of royalty obligation</a></td>
        <td class="nump"><a title="abio_MaximumPercentageOfRoyaltyObligation" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_MaximumPercentageOfRoyaltyObligation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement', window );">Product sales levels royalty</a></td>
        <td class="nump"><a title="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown', window );">Minimum percentage of range of royalties that can be bought down</a></td>
        <td class="nump"><a title="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" onclick="toggleNextSibling(this);">12.50%</a><span style="display:none;white-space:normal;text-align:left;">abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown', window );">Maximum percentage of range of royalties that can be bought down</a></td>
        <td class="nump"><a title="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" onclick="toggleNextSibling(this);">17.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RoyaltyBuyDownDuePeriod', window );">Royalty buy down due period</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 78,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 63,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=abio_WestminsterMember', window );">Westminster, Colorado</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office facilities taken on lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfRealEstateProperty[us-gaap_StatementGeographicalAxis=abio_WestminsterMember]" onclick="toggleNextSibling(this);">5,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfRealEstateProperty<br>/ us-gaap_StatementGeographicalAxis<br>= abio_WestminsterMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
        <td class="text">Sep. 30,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AgreementTerminationNoticePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement termination notice period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_AgreementTerminationNoticePeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AnotherExpectedMilestonePaymentsUponApproval">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Another expected milestone payment due upon approval.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_AnotherExpectedMilestonePaymentsUponApproval</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_CommitmentsAndContingenciesTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExpectedMilestonePaymentsUponApproval">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected milestone payments due upon approval.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ExpectedMilestonePaymentsUponApproval</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of range of royalties that can be bought down.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MaximumPercentageOfRoyaltyObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of royalty obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_MaximumPercentageOfRoyaltyObligation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum percentage of range of royalties that can be bought down.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfRoyaltyObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum percentage of royalty obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_MinimumPercentageOfRoyaltyObligation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalty obligated to pay under its original license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RoyaltyBuyDownDuePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty buy down due period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_RoyaltyBuyDownDuePeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of a real estate property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=abio_WestminsterMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=abio_WestminsterMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic earnings per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted earnings per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#8217;s potentially dilutive shares include stock options, restricted stock units and warrants for common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except shares and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp;Series A Preferred Stock deemed dividend</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,631,668</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares of unvested common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total weighted-average shares used in computing net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share attributed to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,629,480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.04</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&nbsp;&nbsp;As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,371,002</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,910,546</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,409,926</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQH">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Future Minimum Lease Payments (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 80</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">62</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2HAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plans (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Matching contribution</a></td>
        <td class="text">matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">$ 108,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">$ 70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanNameAxis=abio_FirstThreePercentPayContributionMember', window );">First 3% of pay contributed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Benefit Plan, Percentage of Match</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch[us-gaap_DefinedContributionPlanNameAxis=abio_FirstThreePercentPayContributionMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch<br>/ us-gaap_DefinedContributionPlanNameAxis<br>= abio_FirstThreePercentPayContributionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution percentage</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent[us-gaap_DefinedContributionPlanNameAxis=abio_FirstThreePercentPayContributionMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent<br>/ us-gaap_DefinedContributionPlanNameAxis<br>= abio_FirstThreePercentPayContributionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanNameAxis=abio_NextTwoPercentPayContributionMember', window );">Next 2% of pay contributed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Benefit Plan, Percentage of Match</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch[us-gaap_DefinedContributionPlanNameAxis=abio_NextTwoPercentPayContributionMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch<br>/ us-gaap_DefinedContributionPlanNameAxis<br>= abio_NextTwoPercentPayContributionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution percentage</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent[us-gaap_DefinedContributionPlanNameAxis=abio_NextTwoPercentPayContributionMember]" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent<br>/ us-gaap_DefinedContributionPlanNameAxis<br>= abio_NextTwoPercentPayContributionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the cost recognized during the period for defined contribution plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage employer matches of the employee's percentage contribution matched.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the terms and benefits provided by the employer's defined contribution plans. A defined contribution plan provides benefits in return for services rendered, provides an individual account for each participant, and has terms that specify how contributions to the individual's account are to be determined rather than the amount of benefits the individual is to receive. Under a defined contribution pension plan, the benefits a participant will receive depend solely on the amount contributed to the participant's account, the returns earned on investments of those contributions, and forfeitures of other participants' benefits that may be allocated to such participant's account. A description of the plan(s) including employee groups covered, the basis for determining contributions, and the nature and effects of significant matters affecting comparability of information for all periods presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Defined Contribution Postretirement Plan<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510416<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanNameAxis=abio_FirstThreePercentPayContributionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanNameAxis=abio_FirstThreePercentPayContributionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanNameAxis=abio_NextTwoPercentPayContributionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanNameAxis=abio_NextTwoPercentPayContributionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 15,354</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 16,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">134</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">169</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">15,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">16,925</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">29</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">608</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">16,132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">17,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">795</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">597</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">329</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">459</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">264</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">446</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">1,388</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">1,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">1,391</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">1,503</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding. Series A convertible preferred stock, $0.001 par value; 135,000 shares designated from authorized preferred stock; no shares issued or outstanding at December 31, 2014 and 2013</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100 million shares authorized at December 31, 2014 and 2013; 21,150,486 and 15,685,562 shares issued and outstanding at December 31, 2014 and 2013, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">99,342</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">90,498</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(84,622)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(74,933)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">14,741</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">15,581</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 16,132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 17,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (9,689,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,939,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">12,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">26,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred charges</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDeferredCharges" onclick="toggleNextSibling(this);">67,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDeferredCharges</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">647,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">283,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssets" onclick="toggleNextSibling(this);">214,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssets" onclick="toggleNextSibling(this);">130,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(545,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">14,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">198,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">532,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(130,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">356,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">(182,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">325,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" onclick="toggleNextSibling(this);">(15,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(9,406,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(5,288,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(19,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(32,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(19,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(32,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">9,038,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">1,741,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths', window );">Repayment of principal on vendor finance agreement</a></td>
        <td class="num"><a title="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" onclick="toggleNextSibling(this);">(179,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" onclick="toggleNextSibling(this);">(174,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">8,023,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">19,156,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(1,402,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">13,836,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">16,756,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">2,920,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">15,354,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">16,756,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">3,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">3,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember]" onclick="toggleNextSibling(this);">(2,083,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_PreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
        <td class="num"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ (836,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ (328,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of amortization of deferred charges applied against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets less other current operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Estimated Weighted Average Grant Date Fair Value Per Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated weighted average grant date fair value per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">5 years 10 months 24 days<span></span></td>
        <td class="text">5 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">94.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">96.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.53%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.62%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.05</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Benefit Attributable to Our Loss from Operations</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal income tax benefit at statutory rates</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,294</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax benefit, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,041</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset adjustment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,907</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(365</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Net Deferred Tax Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company&#8217;s net deferred tax assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacation accrual</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net current deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,799</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contribution carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized intangibles</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Stock Option and Stock Award Activities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">843,442</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">144,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">228,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">741,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(3,506)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(42,112)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,068,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">843,442</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, end of period, Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">494,291</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">194,550</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" onclick="toggleNextSibling(this);">1,066,712</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options Outstanding, Beginning of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 3.76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 18.28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 1.81</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 1.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited and cancelled</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 140.67</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.62</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options Outstanding, end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 2.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 3.76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable, end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 4.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options vested and expected to vest, end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 2.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2MAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Basic and Diluted Loss Per Share (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,939)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Deemed preferred stock dividend</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_PreferredStockDividendsAndOtherAdjustments" onclick="toggleNextSibling(this);">(2,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsAndOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (8,965)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">20,501,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">8,631,668</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Less: Weighted-average shares of unvested common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">(2,188)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Total weighted-average shares used in computing net loss per share attributed to common stockholders</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" onclick="toggleNextSibling(this);">20,501,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" onclick="toggleNextSibling(this);">8,629,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.47)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2646-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) The Company and Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January&#160;27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, and amended on October&#160;28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidate, Gencaro&#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro&#8217;s pharmacology and may predict patient response to the drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA has created an adaptive design for GENETIC-AF.&nbsp;&nbsp;The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&#8217;s primary end-point.&#160; The DSMB interim analysis will focus on available data regarding the  primary endpoint, AF/AFL event rates, AF burden, and safety.&#160;Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&#8217;s  Steering Committee and the DSMB, will make the final determination on the trial&#8217;s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants.&nbsp;&nbsp;In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company&#8217;s ongoing operations.&nbsp;&nbsp;&#160; The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents  will be sufficient to fund its operations, at its projected cost structure, through the end of 2015.  However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company&#8217;s ongoing operations.&nbsp;&nbsp;If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> progress of GENETIC-AF, including enrollment and any data that may become available; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general economic and industry conditions affecting the availability and cost of capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to control costs associated with its operations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&nbsp;&nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented.&nbsp;&nbsp;Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font> which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities.&#160;&#160;The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued.&#160;&#160;The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In August 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU No. 2014-15&#8221;), <font style="font-style:italic;">Presentation of Financial Statements &#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-style:italic;text-decoration:underline;">.</font>&#160;&#160;ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued.&#160;&#160;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Estimates in the Preparation of Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation cost recognized  is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company&#8217;s history of operating losses. The Company has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">21,150,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">15,685,562</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">21,150,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">15,685,562</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">135,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">135,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January&#160;27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&#160;24, 2008, and amended on October&#160;28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidate, Gencaro&#8482; (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro&#8217;s pharmacology and may predict patient response to the drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA has created an adaptive design for GENETIC-AF.&nbsp;&nbsp;The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial&#8217;s primary end-point.&#160; The DSMB interim analysis will focus on available data regarding the  primary endpoint, AF/AFL event rates, AF burden, and safety.&#160;Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial&#8217;s  Steering Committee and the DSMB, will make the final determination on the trial&#8217;s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Risks, Liquidity and Going Concern</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants.&nbsp;&nbsp;In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company&#8217;s ongoing operations.&nbsp;&nbsp;&#160; The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents  will be sufficient to fund its operations, at its projected cost structure, through the end of 2015.  However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company&#8217;s ongoing operations.&nbsp;&nbsp;If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> progress of GENETIC-AF, including enrollment and any data that may become available; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general economic and industry conditions affecting the availability and cost of capital; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to control costs associated with its operations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.&nbsp;&nbsp;NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented.&nbsp;&nbsp;Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.  </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font> which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities.&#160;&#160;The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued.&#160;&#160;The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In August 2014, the FASB issued FASB Accounting Standards Update (&#8220;ASU No. 2014-15&#8221;), <font style="font-style:italic;">Presentation of Financial Statements &#8211; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-style:italic;text-decoration:underline;">.</font>&#160;&#160;ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued.&#160;&#160;The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time.&nbsp;&nbsp;The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.&nbsp;&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates in the Preparation of Financial Statements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Estimates in the Preparation of Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.  </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation cost recognized  is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.  </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company&#8217;s history of operating losses. The Company has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for estimating costs incurred that have not yet been billed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_AccruedExpensesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ReverseStockSplitPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ReverseStockSplitPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiquidityDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 17, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ARCA Biopharma, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000907654<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 30,003,945</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">21,198,411</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Loss Per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except shares and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,939</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp;Series A Preferred Stock deemed dividend</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,026</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,689</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,631,668</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares of unvested common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total weighted-average shares used in computing net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share attributed to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501,224</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,629,480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.04</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary Of Potentially Dilutive Shares Of Common Stock</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&nbsp;&nbsp;As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,371,002</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,910,546</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,409,926</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 5,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 2,928</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">4,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">4,012</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">9,693</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">6,940</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(9,693)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(6,940)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(3)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(4)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(6,939)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Deemed preferred stock dividend</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_PreferredStockDividendsAndOtherAdjustments" onclick="toggleNextSibling(this);">(2,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsAndOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (8,965)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss available to common stockholders per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.47)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">20,501,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">8,629,479</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6) Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has or is subject to the following commitments and contingencies: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which has served as the Company&#8217;s primary business office since October&#160;1, 2013. The lease has a three year term and expires on September 30, 2016.&nbsp;&nbsp;Below is a summary of the future minimum lease payments committed for the Company&#8217;s facility in Westminster, Colorado as of December&#160;31, 2014 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense under these leases for the years ended December&#160;31, 2014 and 2013 was $78,000 and $63,000, respectively . </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Duke University </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2013, the Company entered into a clinical research agreement with Duke University (Duke) to serve as the clinical research organization for the Company&#8217;s GENETIC-AF clinical study.&nbsp;&nbsp;Under the agreement the Company is responsible to pay Duke for their work managing certain aspects of the clinical study.&nbsp;&nbsp;Upon completion of the clinical study, the agreement will terminate.&nbsp;&nbsp;The agreement can be terminated earlier by the Company for any reason with 90 days written notice to Duke.&nbsp;&nbsp;In the event of an early termination, the Company and Duke would coordinate efforts for an orderly wind-down of the study, and the Company would be responsible to pay Duke for time and effort incurred through the date of termination and through the wind-down period.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">University of Cincinnati </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2011, the Company entered into a license agreement with the University of Cincinnati to license exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain U.S. and international diagnostic patents covering genetic markers for ARCA&#8217;s lead drug candidate, Gencaro. These patents provide the basis for exclusive worldwide development, use and commercialization of the genetic test which may indicate a patient&#8217;s likely response to Gencaro as a treatment for chronic HF, AF, and other indications. Under the terms of the agreement, ARCA agreed to pay the University of Cincinnati annual license fees and is obligated to future milestone payments for each United States patent issued subsequent to the date of the agreement. The agreement also requires royalty payments on net sales from genetic testing performed expressly for the purpose of prescribing bucindolol.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA has licensed worldwide rights to Gencaro, including all preclinical and clinical data from Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC, who has licensed rights in Gencaro from BMS. CPEC is a licensing subsidiary of Indevus Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of Gencaro.&nbsp;&nbsp;Under the terms of its license agreement with CPEC, the Company will incur milestone and royalty obligations upon the occurrence of certain events.  If the FDA grants marketing approval for Gencaro, the license agreement states that the Company will owe CPEC a milestone payment of $8.0 million within six months after FDA approval. The license agreement states that a milestone payment of up to $5.0 million in the aggregate shall be paid upon regulatory marketing approval in Europe and Japan. The license agreement also states that the Company&#8217;s royalty obligation ranges from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels, including a 5% royalty that CPEC is obligated to pay under its original license agreement for Gencaro. The agreement states that the Company has the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5) Related Party Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transactions with the Company&#8217;s President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado, or the Lab. Funding of any unrestricted research grants is contingent upon the Company&#8217;s financial condition, and can be deferred or terminated at the Company&#8217;s discretion. Total expense under these arrangements for the years ended December&#160;31, 2014 and 2013 was $350,000 and $297,000 respectively.   </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYZBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 04, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Segment</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 18, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 03, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Date of completion of business combination with Nuvelo</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 27,  2009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Fund raised through sale of convertible preferred and common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">19,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">9,038,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">1,741,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NotificationForDelistingOfSharesDescription', window );">Notification for delisting of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days.  NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
        <td class="text">1-for-6 reverse split<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Concentrations of credit risk</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_NumberOfOperatingSegments" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NumberOfOperatingSegments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClosingBidPriceOfCommonStock', window );">Minimum closing bid price of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_ClosingBidPriceOfCommonStock[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 1.00</a><span style="display:none;white-space:normal;text-align:left;">abio_ClosingBidPriceOfCommonStock<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_GracePeriodProvidedToMeetContinuedListingStandard', window );">Number of grace days provided by NASDAQ to meet continued listing standard</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">180 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 8,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 730,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember]" onclick="toggleNextSibling(this);">$ 7,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= abio_RegisteredDirectOfferingMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember', window );">Phase 3 heart failure (HF) trial of Gencaro | BEST Trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfPatients', window );">Number of patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NumberOfPatients[abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember;us-gaap_HealthCareTrustFundAxis=abio_BestTrialMember]" onclick="toggleNextSibling(this);">2,708</a><span style="display:none;white-space:normal;text-align:left;">abio_NumberOfPatients<br>/ abio_ClinicalTrialsByPhaseAxis<br>= abio_PhaseThreeHeartFailureMember<br>/ us-gaap_HealthCareTrustFundAxis<br>= abio_BestTrialMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember', window );">Phase 3 heart failure (HF) trial of Gencaro | GENETIC-AF Trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfPatientsCompanyPlansToEnroll', window );">Number of patients company plans to enroll</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NumberOfPatientsCompanyPlansToEnroll[abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember;us-gaap_HealthCareTrustFundAxis=abio_GENETICAFTrialMember]" onclick="toggleNextSibling(this);">420</a><span style="display:none;white-space:normal;text-align:left;">abio_NumberOfPatientsCompanyPlansToEnroll<br>/ abio_ClinicalTrialsByPhaseAxis<br>= abio_PhaseThreeHeartFailureMember<br>/ us-gaap_HealthCareTrustFundAxis<br>= abio_GENETICAFTrialMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember', window );">Phase Two B Heart Failure | GENETIC-AF Trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfPatientsCompanyPlansToEnroll', window );">Number of patients company plans to enroll</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_NumberOfPatientsCompanyPlansToEnroll[abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember;us-gaap_HealthCareTrustFundAxis=abio_GENETICAFTrialMember]" onclick="toggleNextSibling(this);">200</a><span style="display:none;white-space:normal;text-align:left;">abio_NumberOfPatientsCompanyPlansToEnroll<br>/ abio_ClinicalTrialsByPhaseAxis<br>= abio_PhaseTwoBHeartFailureMember<br>/ us-gaap_HealthCareTrustFundAxis<br>= abio_GENETICAFTrialMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abio_OriginalMember', window );">Original</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Business combination with Nuvelo, date of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep. 24,  2008<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abio_AmendmentMember', window );">Amendment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyBasisOfPresentationTextualAbstract', window );"><strong>Company Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Business combination with Nuvelo, date of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 28,  2008<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClosingBidPriceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Closing bid price of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClosingBidPriceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CompanyBasisOfPresentationTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_CompanyBasisOfPresentationTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_GracePeriodProvidedToMeetContinuedListingStandard">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grace period provided to meet continued listing standard.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_GracePeriodProvidedToMeetContinuedListingStandard</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NotificationForDelistingOfSharesDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notification for delisting of shares description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_NotificationForDelistingOfSharesDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_NumberOfPatients</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfPatientsCompanyPlansToEnroll">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients company plans to enroll.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_NumberOfPatientsCompanyPlansToEnroll</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the business acquisition agreement was executed, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e845-128460<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Acquisition Date<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6919109<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e848-128460<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abio_AmendmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abio_AmendmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abio_OriginalMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abio_OriginalMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or life of the lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(9) Employee Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. The Company adopted the plan in 2006 and contributed $108,000 and $70,000 for the years ended December&#160;31, 2014 and 2013, respectively . </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 80<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35742057&amp;loc=SL14450702-114947<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Financings and Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock', window );">Equity Financings and Warrants</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(7) Equity Financings and Warrants </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2013 Equity Financings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Private Investment in Public Equity (PIPE) Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;22, 2013, the Company entered into a Subscription Agreement (the &#8220;January 2013 Purchase Agreement&#8221;) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the January 2013 Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January&#160;25, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on January&#160;22, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company filed a registration statement for the resale of the shares underlying the units sold in the private placement. That registration statement was declared effective by the Securities and Exchange Commission on February&#160;14, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#8220;variable rate transaction,&#8221; which means a transaction in which the Company issues or sells any convertible securities either (A)&#160;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)&#160;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Offering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &#8220;Investors&#8221;) in connection with its Registered Direct public offering,&nbsp;&nbsp;pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fees and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the offering closed on February&#160;4, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on January&#160;31, 2013.  The Offering was effected as a takedown of the Company&#8217;s Registration Statement on Form S-3, as amended, which became effective on April&#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;1, 2013.&nbsp;&nbsp;The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offering&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;4, 2013, the Company sold shares of its Series A Convertible Preferred Stock (Preferred Stock) and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20.0 million. The Company issued 125,000 shares of Preferred Stock and warrants to purchase up to 6,250,000 shares of common stock at a purchase price of $160 per share of Preferred Stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by the Company, were approximately $17.9 million. ARCA&#8217;s Director and Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Preferred Stock was convertible into 100 shares of the Company&#8217;s common stock at any time at the option of the holder.&nbsp;&nbsp;Each share of Preferred Stock had a liquidation preference of $.001 per share. The shares of Preferred Stock had no preferential dividends or redemption rights, and no voting rights except as required by law. During 2013, all 125,000 of the shares of the Preferred Stock were converted into 12,500,000 shares of ARCA common stock.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each purchaser in the offering was issued a warrant to purchase 50 shares of the Company&#8217;s common stock for each share of Preferred Stock purchased. The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance, provided that the holder will be prohibited from exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the Company&#8217;s Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May&#160;29, 2013, and the Preferred Stock and Warrants were offered and sold pursuant to a prospectus dated May&#160;30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company&#8217;s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since ARCA has an accumulated deficit, the deemed dividend is recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company&#8217;s statement of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2014 Equity Financing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Offering</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;3, 2014, the Company agreed to sell to certain investors an aggregate of 5,116,228 shares of the Company&#8217;s common stock and warrants to purchase an aggregate of 1,279,057 shares of the Company&#8217;s common stock at a purchase price of $1.70 per share of Common Stock, for aggregate gross proceeds of approximately $8.7 million, before deducting placement agent fees and other offering related expenses. The offering closed on February&#160;7, 2014, and the net proceeds to the Company were approximately $7.9 million.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $2.125 per share, equal to 125% of the closing bid price of ARCA&#8217;s common stock on the Nasdaq Capital Market on February 3, 2014. The offering was effected as a takedown off the Company&#8217;s Registration Statement on Form S-3, as amended, which became effective on April&#160;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&#160;4, 2014. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2014, warrants to purchase 9,371,002 shares of common stock were outstanding at exercise prices ranging from $1.60 to $116.89, with a weighted average exercise price per share of $2.31. These warrants, which were granted as part of various financing and business agreements, expire at various times between April 2016 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity financings and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_EquityFinancingsAndWarrantsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(8) Share-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s equity incentive plan, <font style="font-style:italic;">the 2013 Equity Incentive Plan </font>(the Equity Plan),<font style="font-style:italic;"> </font>was approved by stockholders on September 17, 2013.&nbsp;&nbsp;The maximum number of shares issuable under this plan is 2,250,000 shares.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2014, options and awards for 1,437,477 shares were outstanding under the Equity Plan, and 672,852 shares were reserved for future awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of three to four years from the date of grant and have a maximum term of ten years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the adoption of the Equity Plan, the Company discontinued grants under its previous plan, the <font style="font-style:italic;">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan </font>(the 2004 Plan), effective September 17, 2013. The 2004 Plan expired in 2014; however, options outstanding under the 2004 plan will continue to vest according to the original terms of each grant.&nbsp;&nbsp;As of December&#160;31, 2014, options to purchase 59,776 shares with a weighted average exercise price of $15.10 per share were outstanding under this plan. Other stock plans that were assumed by ARCA in the Merger still have options outstanding that will continue to vest according to the original terms of each grant, but no new options can be granted under these plans, as the plans have expired.&nbsp;&nbsp;As of December 31, 2014, options to purchase 42,291 shares with a weighted average exercise price of $17.78 were outstanding under these plans.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December&#160;31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December&#160;31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of ARCA&#8217;s stock option and stock award activities for the years ended December&#160;31, 2014 and 2013, and related information as of December&#160;31, 2014, is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, beginning of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,579</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.67</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,112</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, end of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable, end of period</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066,712</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised for the years ended December&#160;31, 2014 and 2013 was $0 and $0, respectively. As of December&#160;31, 2014, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $633,000 which is expected to be recognized over a weighted average period of 2.2 years. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding and exercisable as of December&#160;31, 2014:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,933</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727,869</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.47</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329,189</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,495</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.11</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,410</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.98</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,300</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.44</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.68</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,070</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.55</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.99</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.42</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.74</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began granting restricted stock units (RSUs) to employees during 2013 in conjunction with the adoption of its 2013 Equity Incentive Plan.&nbsp;&nbsp;The fair value of RSU awards is the closing price of the Company&#8217;s common stock on the date of grant and is recognized as compensation expense on a straight-line basis over the respective vesting period. The stock awards granted have a requisite service period of three or four years with annual vesting on the grant anniversary date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; beginning of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and released</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; end of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2014, the total unrecognized compensation cost related to unvested stock awards was approximately $629,000.&nbsp;&nbsp;This cost will be recognized on a straight-line basis over the next 2.4 years and will be adjusted for estimated forfeitures.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-cash Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to non-employees was negligible in 2014 and 2013. ARCA did not recognize any tax benefit related to employee stock-based compensation cost as a result of the full valuation allowance on its net deferred tax assets. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-weight:bold;">10) Income Taxes </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective June&#160;1, 2005, the Company changed from an S-Corporation to a C-Corporation. As an S-Corporation, the net operating loss carryforwards were distributed to the Company&#8217;s stockholders; such amounts were not significant. Since June 2005 through December&#160;31, 2014, for federal income tax purposes, the Company has net operating loss carryforwards of approximately $113.7 million, and approximately $991,000 of research and development credits that may be used to offset future taxable income. The net operating loss carryforwards will expire beginning 2025 through 2034. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section&#160;382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#8217;s net operating loss carryforwards may be limited. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to the Company&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that the Company will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax asset of approximately $44.5 million at December&#160;31, 2014, reflecting a decrease of approximately $0.4  million from December&#160;31, 2013. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2014 the Company has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal income tax benefit at statutory rates</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,294</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax benefit, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,041</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax asset adjustment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,907</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(365</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without regard to the deferred tax liability on the impaired IPR&amp;D, the Company has had no provision for income taxes since inception due to its S-corporation status and its subsequent net operating losses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company&#8217;s net deferred tax assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacation accrual</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net current deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,799</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contribution carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and experimentation credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized intangibles</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net noncurrent deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. Thus, the Company&#8217;s open tax years extend back to 2009. The Company believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on the Company&#8217;s financial condition, result of operations, or cash flow. For the years ended December&#160;31, 2014 and 2013, the Company has no reserve for uncertain tax positions. The Company does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve months. In the event the Company concludes it is subject to interest or penalties arising from uncertain tax positions, the Company will record interest and penalties as a component of other income and expense. No material amounts of interest or penalties were recognized in the financial statements for the years ended December&#160;31, 2014 and 2013. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQACI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 17, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding under Equity plan</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,068,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">843,442</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">144,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options award, expiration</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 2.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 3.76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 18.28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">633,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Maturity period of weighted average period of compensation expenses</a></td>
        <td class="text">2 years 2 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Maturity period of weighted average period of compensation expenses</a></td>
        <td class="text">2 years 4 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested stock awards</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 629,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageHoldingForStockOptionsExercisePrice', window );">Percentage holding for stock options exercise price</a></td>
        <td class="nump"><a title="abio_PercentageHoldingForStockOptionsExercisePrice[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">abio_PercentageHoldingForStockOptionsExercisePrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Incentive Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price of stock option</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent[us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent<br>/ us-gaap_AwardTypeAxis<br>= abio_IncentiveStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Incentive Stock Option | Stockholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price of stock option</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent[us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember]" onclick="toggleNextSibling(this);">110.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent<br>/ us-gaap_AwardTypeAxis<br>= abio_IncentiveStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_PrincipalOwnerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Restricted Stock Units award, requisite service period</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Restricted Stock Units award, requisite service period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember', window );">2013 Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for future</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember]" onclick="toggleNextSibling(this);">2,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndThirteenPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding under Equity plan</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember]" onclick="toggleNextSibling(this);">1,437,477</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future</a></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember]" onclick="toggleNextSibling(this);">672,852</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options and awards granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod[us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember]" onclick="toggleNextSibling(this);">420,279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndThirteenPlanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod[us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember]" onclick="toggleNextSibling(this);">1,160,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndFourStockOptionPlanMember', window );">Two Thousand And Four Stock Option Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding under Equity plan</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=abio_TwoThousandAndFourStockOptionPlanMember]" onclick="toggleNextSibling(this);">59,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndFourStockOptionPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_PlanNameAxis=abio_TwoThousandAndFourStockOptionPlanMember]" onclick="toggleNextSibling(this);">$ 15.10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= abio_TwoThousandAndFourStockOptionPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_OtherStockOptionPlanMember', window );">Other Stock Option Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding under Equity plan</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=abio_OtherStockOptionPlanMember]" onclick="toggleNextSibling(this);">42,291</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= abio_OtherStockOptionPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_PlanNameAxis=abio_OtherStockOptionPlanMember]" onclick="toggleNextSibling(this);">$ 17.78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= abio_OtherStockOptionPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageHoldingForStockOptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum ownership percentage for 110% fair market value on the grant date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PercentageHoldingForStockOptionsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase price of common stock expressed as a percentage of its fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share instruments newly issued under a share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_OtherStockOptionPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_OtherStockOptionPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndFourStockOptionPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndFourStockOptionPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Estimated Weighted Average Grant Date Fair Value per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December&#160;31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December&#160;31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Stock Option and Stock Award Activities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of ARCA&#8217;s stock option and stock award activities for the years ended December&#160;31, 2014 and 2013, and related information as of December&#160;31, 2014, is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, beginning of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,579</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.67</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,112</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding, end of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843,442</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable, end of period</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066,712</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Options Outstanding and Exercisable</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding and exercisable as of December&#160;31, 2014:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,933</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727,869</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.47</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329,189</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,495</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.11</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,410</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.98</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,300</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.44</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.68</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,070</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.55</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.99</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.42</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.74</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,918</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.87</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,515</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.89</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494,291</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU activity</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; beginning of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and released</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CCECFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; end of period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Non-Cash, Share-Based Compensation Expense</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">10,910,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">9,409,926</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1,068,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">843,442</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">471,029</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">419,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">9,371,002</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">8,147,484</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 113,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax Credit Carryforward, Description</a></td>
        <td class="text">The net operating loss carryforwards will expire beginning 2025 through 2034.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">44,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease net deferred tax asset</a></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">34.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Reserve for uncertain tax positions</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recognized</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember', window );">Without Deferred Tax Liability On Impaired In Process Research And Development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit[us-gaap_StatementScenarioAxis=abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit<br>/ us-gaap_StatementScenarioAxis<br>= abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and experimentation credits</a></td>
        <td class="nump"><a title="us-gaap_TaxCreditCarryforwardAmount[us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember]" onclick="toggleNextSibling(this);">$ 991,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TaxCreditCarryforwardAmount<br>/ us-gaap_TaxCreditCarryforwardAxis<br>= us-gaap_ResearchMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, limitations on use</a></td>
        <td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#x2019;s net operating loss carryforwards may be limited<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
        <td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company&#x2019;s net operating loss carryforwards may be limited<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
        <td class="text">2025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
        <td class="text">2034<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_IncomeTaxesTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLossCarryforwardsExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_OperatingLossCarryforwardsExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the limitation related to use of the tax credit carryforward.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=abio_WithoutDeferredTaxLiabilityOnImpairedInProcessResearchAndDevelopmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5GBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common stock

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A Convertible

</div>
          <div>Preferred Stock</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, value at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 2,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 70,898</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ (67,994)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,660,315</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">521,066</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of offering costs</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">1,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Adjustment for fractional shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(64)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares', window );">Issuance of common stock upon exercise of warrants for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,245</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue', window );">Issuance of common stock upon exercise of warrants for cash, value</a></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" onclick="toggleNextSibling(this);">12</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">12</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember;us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember]" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_PreferredStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PreferredStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs</a></td>
        <td class="nump"><a title="abio_PreferredStockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">17,917</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_PreferredStockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">17,917</a><span style="display:none;white-space:normal;text-align:left;">abio_PreferredStockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeemedDividendBeneficialConversionPreferredStock', window );">Deemed preferred stock dividend for beneficial conversion feature</a></td>
        <td class="nump"><a title="abio_DeemedDividendBeneficialConversionPreferredStock" onclick="toggleNextSibling(this);">2,026</a><span style="display:none;white-space:normal;text-align:left;">abio_DeemedDividendBeneficialConversionPreferredStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_DeemedDividendBeneficialConversionPreferredStock[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">2,026</a><span style="display:none;white-space:normal;text-align:left;">abio_DeemedDividendBeneficialConversionPreferredStock<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Deemed preferred stock dividend</a></td>
        <td class="num"><a title="us-gaap_PreferredStockDividendsAndOtherAdjustments" onclick="toggleNextSibling(this);">(2,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsAndOtherAdjustments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_PreferredStockDividendsAndOtherAdjustments[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(2,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsAndOtherAdjustments<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">12,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember;us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember]" onclick="toggleNextSibling(this);">(125,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_PreferredStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" onclick="toggleNextSibling(this);">(20)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(33)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">283</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">283</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(6,939)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(6,939)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">15,581</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">90,498</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(74,933)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">15,685,562</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,116,228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of offering costs</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">7,866</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">7,861</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares', window );">Issuance of common stock upon exercise of warrants for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">209,025</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue', window );">Issuance of common stock upon exercise of warrants for cash, value</a></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue" onclick="toggleNextSibling(this);">338</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">338</a><span style="display:none;white-space:normal;text-align:left;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(9,689)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Awards, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">139,671</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Awards, value</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 14,741</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 99,342</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ (84,622)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">21,150,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeemedDividendBeneficialConversionPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deemed dividend beneficial conversion preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_DeemedDividendBeneficialConversionPreferredStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock upon exercise of warrants for cash, shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock upon exercise of warrants for cash, value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PreferredStockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock issued during period value new issues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PreferredStockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PreferredStockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock issued during period value, new issues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_PreferredStockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction in the number of shares during the period as a result of a reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(4) Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or life of the lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:19.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2014 and 2013, depreciation and amortization expense was $12,000 and $26,000 , respectively. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Financial Instruments (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresAdditionalTextualAbstract', window );"><strong>Financial Instruments (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Transfers of assets between fair value hierarchy levels</a></td>
        <td class="nump"><a title="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</span><span></span></td>
        <td class="nump"><a title="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 1 | Money Market Funds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents consisting of money market funds</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">15,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">16,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Fair Value, Inputs, Level 2</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresAdditionalTextualAbstract', window );"><strong>Financial Instruments (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Fair Value, Inputs, Level 3</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresAdditionalTextualAbstract', window );"><strong>Financial Instruments (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assets between hierarchy levels transfers amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresAdditionalTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_FairValueDisclosuresAdditionalTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FinancialInstrumentsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">abio_FinancialInstrumentsTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>264</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETS</Role>
      <ShortName>BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/StatementBALANCESHEETSParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Equity Financings and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrants</Role>
      <ShortName>Equity Financings and Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Basic and Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Basic and Diluted Loss Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetailsTextual</Role>
      <ShortName>Net Loss Per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss Per Share (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNetLossPerShareDetails1</Role>
      <ShortName>Net Loss Per Share (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Related Party Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureRelatedPartyArrangementsDetails</Role>
      <ShortName>Related Party Arrangements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Future Minimum Lease Payments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Equity Financings and Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual</Role>
      <ShortName>Equity Financings and Warrants (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureShareBasedCompensationDetailsTextual</Role>
      <ShortName>Share-based Compensation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Estimated Weighted Average Grant Date Fair Value Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEstimatedWeightedAverageGrantDateFairValuePerShareDetails</Role>
      <ShortName>Estimated Weighted Average Grant Date Fair Value Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Stock Option and Stock Award Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionAndStockAwardActivitiesDetails</Role>
      <ShortName>Summary of Stock Option and Stock Award Activities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Summary of Stock Options Outstanding and Exercisable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureSummaryOfRSUActivityDetails</Role>
      <ShortName>Summary of RSU Activity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Non-Cash, Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureNonCashShareBasedCompensationExpenseDetails</Role>
      <ShortName>Non-Cash, Share-Based Compensation Expense (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Income Taxes - Income Tax Benefit Attributable to Our Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxBenefitAttributableToOurLossFromOperationsDetails</Role>
      <ShortName>Income Taxes - Income Tax Benefit Attributable to Our Loss from Operations (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Income Taxes - Net deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20141231/taxonomy/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net deferred tax assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element abio_SecuritiesInMoney had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_IncomeTaxExpenseBenefit had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -4 -3.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '100050 - Statement - STATEMENTS OF CASH FLOWS' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100300 - Disclosure - Commitments and Contingencies (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100320 - Disclosure - Equity Financings and Warrants (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100400 - Disclosure - Income Taxes (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 100010 - Statement - BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 100020 - Statement - BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 100050 - Statement - STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>abio-20141231.xml</File>
    <File>abio-20141231.xsd</File>
    <File>abio-20141231_cal.xml</File>
    <File>abio-20141231_def.xml</File>
    <File>abio-20141231_lab.xml</File>
    <File>abio-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of RSU Activity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Awards, Number of Shares</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">419,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">191,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">419,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" onclick="toggleNextSibling(this);">(139,671)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">471,029</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">419,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Restricted Stock Awards, Weighted Average Grant Date Fair Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units outstanding, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units outstanding, end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.62</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below is a summary of the future minimum lease payments committed for the Company&#8217;s facility in Westminster, Colorado as of December&#160;31, 2014 (in thousands):</p></div><div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
